
<html lang="en"     class="pb-page"  data-request-id="4d12bb71-44e2-4ca6-8024-716cf8ce91f4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b01237;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="The Druggability of Solute Carriers" /></meta><meta name="dc.Creator" content="Wesley Wei  Wang" /></meta><meta name="dc.Creator" content="Leandro  Gallo" /></meta><meta name="dc.Creator" content="Appaso  Jadhav" /></meta><meta name="dc.Creator" content="Richard  Hawkins" /></meta><meta name="dc.Creator" content="Christopher G.  Parker" /></meta><meta name="dc.Description" content="The transport of materials across membranes is a vital process for all aspects of cellular function, including growth, metabolism, and communication. Protein transporters are the molecular gates th..." /></meta><meta name="Description" content="The transport of materials across membranes is a vital process for all aspects of cellular function, including growth, metabolism, and communication. Protein transporters are the molecular gates th..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 27, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01237" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01237" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01237" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01237" /></link>
        
    
    

<title>The Druggability of Solute Carriers | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01237" /></meta><meta property="og:title" content="The Druggability of Solute Carriers" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0032.jpeg" /></meta><meta property="og:description" content="The transport of materials across membranes is a vital process for all aspects of cellular function, including growth, metabolism, and communication. Protein transporters are the molecular gates that control this movement and serve as key points of regulation for these processes, thus representing an attractive class of therapeutic targets. With more than 400 members, the solute carrier (SLC) membrane transport proteins are the largest family of transporters, yet, they are pharmacologically underexploited relative to other protein families and many of the available chemical tools possess suboptimal selectivity and efficacy. Fortuitously, there is increased interest in elucidating the physiological roles of SLCs as well as growing recognition of their therapeutic potential. This Perspective provides an overview of the SLC superfamily, including their biochemical and functional features, as well as their roles in various human diseases. In particular, we explore efforts and associated challenges toward drugging SLCs, as well as highlight opportunities for future drug discovery." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01237"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01237">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01237&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01237&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01237&amp;href=/doi/10.1021/acs.jmedchem.9b01237" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3834-3867</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01183" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01621" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Druggability of Solute Carriers</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wesley Wei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wesley Wei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wesley+Wei++Wang">Wesley Wei Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Leandro Gallo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leandro Gallo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leandro++Gallo">Leandro Gallo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Appaso Jadhav</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Appaso Jadhav</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Appaso++Jadhav">Appaso Jadhav</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Richard Hawkins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Hawkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Hawkins">Richard Hawkins</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Christopher G. Parker</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher G. Parker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</div><div class="loa-info-affiliations-info">Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: 561-228-2785. E-mail: <a href="/cdn-cgi/l/email-protection#fc9f8c9d8e97998ebc8f9f8e958c8c8fd2999889"><span class="__cf_email__" data-cfemail="8fecffeefde4eafdcffcecfde6fffffca1eaebfa">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+G.++Parker">Christopher G. Parker</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8509-9289" title="Orcid link">http://orcid.org/0000-0001-8509-9289</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01237&amp;href=/doi/10.1021%2Facs.jmedchem.9b01237" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3834â3867</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 27, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 July 2019</li><li><span class="item_label"><b>Published</b> online</span>27 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01237</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3834%26pageCount%3D34%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWesley%2BWei%2BWang%252C%2BLeandro%2BGallo%252C%2BAppaso%2BJadhav%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D8%26contentID%3Dacs.jmedchem.9b01237%26title%3DThe%2BDruggability%2Bof%2BSolute%2BCarriers%26numPages%3D34%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3867%26publicationDate%3DApril%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01237"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4305</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01237" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Druggability of Solute Carriers&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wesley&quot;,&quot;last_name&quot;:&quot;Wei Wang&quot;},{&quot;first_name&quot;:&quot;Leandro&quot;,&quot;last_name&quot;:&quot;Gallo&quot;},{&quot;first_name&quot;:&quot;Appaso&quot;,&quot;last_name&quot;:&quot;Jadhav&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Hawkins&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;G. Parker&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;3834-3867&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01237&quot;},&quot;abstract&quot;:&quot;The transport of materials across membranes is a vital process for all aspects of cellular function, including growth, metabolism, and communication. Protein transporters are the molecular gates that control this movement and serve as key points of regulation for these processes, thus representing an attractive class of therapeutic targets. With more than 400 members, the solute carrier (SLC) membrane transport proteins are the largest family of transporters, yet, they are pharmacologically underexploited relative to other protein families and many of the available chemical tools possess suboptimal selectivity and efficacy. Fortuitously, there is increased interest in elucidating the physiological roles of SLCs as well as growing recognition of their therapeutic potential. This Perspective provides an overview of the SLC superfamily, including their biochemical and functional features, as well as their roles in various human diseases. In particular, we explore efforts and associated challenges toward drugging&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01237" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01237&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01237" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01237&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01237" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01237&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01237&amp;href=/doi/10.1021/acs.jmedchem.9b01237" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01237" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01237" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (12 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01237%26sid%3Dliteratum%253Aachs%26pmid%3D31774679%26genre%3Darticle%26aulast%3DWang%26date%3D2020%26atitle%3DThe%2BDruggability%2Bof%2BSolute%2BCarriers%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D8%26spage%3D3834%26epage%3D3867%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290925" title="Carbohydrates">Carbohydrates</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291691" title="Membranes">Membranes</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/jmcmar.2020.63.issue-8/20200423/jmcmar.2020.63.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The transport of materials across membranes is a vital process for all aspects of cellular function, including growth, metabolism, and communication. Protein transporters are the molecular gates that control this movement and serve as key points of regulation for these processes, thus representing an attractive class of therapeutic targets. With more than 400 members, the solute carrier (SLC) membrane transport proteins are the largest family of transporters, yet, they are pharmacologically underexploited relative to other protein families and many of the available chemical tools possess suboptimal selectivity and efficacy. Fortuitously, there is increased interest in elucidating the physiological roles of SLCs as well as growing recognition of their therapeutic potential. This Perspective provides an overview of the SLC superfamily, including their biochemical and functional features, as well as their roles in various human diseases. In particular, we explore efforts and associated challenges toward drugging SLCs, as well as highlight opportunities for future drug discovery.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cell, the basic unit of life, is partitioned from its environment, and therefore defined by, a lipid membrane. Membranes are essential barrier structures that retain all components within the cell. They protect the cell from extracellular invasion, and perhaps most importantly, allow the cell to respond to its environment. In addition to the extracellular membrane, higher-order eukaryotes possess membrane-bound organelles, providing an additional intracellular level of protection, containment, and functional regulation. Transporters, which include ion channels, ATP-driven pumps, and solute carriers, comprise the largest family of membrane proteins in humans, with roughly 10% of the genome encoding transport-related proteins. These proteins control the import and export of molecules across membranes, thus serving as pivotal regulatory machinery for cellular function.</div><div class="NLM_p">The solute carrier protein (SLC) family is comprised of over 400 members spanning across 65 subfamilies. They are the largest class of transporters and the second largest class of membrane proteins, behind G-protein coupled receptors (GPCRs). SLCs are broadly defined as integral membrane proteins that transport solutes in an ATP-independent fashion. Unlike most other protein âsuperfamilies,â SLCs are evolutionarily diverse and inclusion into the SLC family is primarily based on functional, rather than sequence homology. Although SLC subfamilies are grouped based on sequence similarity, homology between SLC families is very low to nonexistent.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> SLCs shuttle an extraordinarily diverse collection of molecules across both cellular and organellar membranes, including amino acids, sugars, nucleotides, inorganic ions, lipids, peptides, and also small molecule drugs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), typically through facilitative or secondary active transport (symport and antiport/exchanger) mechanisms. SLCs can be found in membranes of most cell types and membrane-bound organelles and possess physiologically diverse roles including in nutrient absorption, metabolism, and energy homeostasis, development, oxidative stress, immune responses, and neurological transmission.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Given their manifold roles, it perhaps is not surprising that SLCs cause or contribute to a wide variety of human diseases, ranging from monogenic disorders to metabolic and immunological disorders to cancer. However, relative to other prominent protein families (e.g., kinases, ion channels, GPCRs), studies on the SLC superfamily are limited, with little structural characterization and relatively few biochemical reagents for functional interrogation.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Examples of Chemically Diverse Endogenous Substrates Transported by SLC Members</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0030.gif" alt="" id="fx1" /></img><div></div></div><div class="NLM_p last">Furthermore, the vast majority of this superfamily lacks chemical probes, with much chemical probe discovery effort focused on a small subset of SLC targets (e.g., monoamine transporters (SLC6A2/3/4), glucose transporters (SLC5A2, SLC2A1), and glycine transporters (SLC6A5/9)). Many of the probes that have been developed and widely utilized are often substrate derived, lack selectivity, and/or have not been rigorously characterized. Technical hurdles are partially responsible for this apparent dearth of SLC inquiry; fortuitously, their increasingly recognized physiological roles and therapeutic potential has garnered increased attention from academic and industrial investigators alike.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Herein, we aim to provide an overview of SLC function and their involvement in various human diseases. Mainly, we discuss efforts to drug SLC members and the associated challenges, as well as provide future prospects of therapeutic discovery for this challenging but high potential protein family.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  the Biochemistry of SLCs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Historically, there have been several systems for classifying proteins into the SLC family. SLCs were originally defined as ATP-independent transporters, and 15 years ago, only 298 human genes were annotated as SLCs.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The HUGO Gene Nomenclature Committee (HGNC), which uses various characteristics, homology, functions, and structures to arrange human genes into families,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> currently lists 423 proteins encoded by an SLC gene root symbol, and recent reports propose an updated number of 430 SLCs.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In the human genome, the solute carrier family is therefore one of the largest protein families, with more members than the ion channels, nuclear hormone receptors, and nonolfactory GPCR families and comparable to that of the kinase and protease families (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Currently, the SLC superfamily is divided into 65 subfamilies (<a href="http://slc.bioparadigms.org/" class="extLink">http://slc.bioparadigms.org/</a>), wherein each subfamily member has 20â25% sequence identity with at least one other subfamily member.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> However, unlike other membrane protein superfamilies, such as GPCRs, voltage-gated ion channels, and receptor tyrosine kinases, the degree of sequence similarity between SLC subfamilies varies significantly. Although some SLC families that cluster based on sequence similarity or structural features may share similar substrate profiles, there are also members with similar substrate profiles but dissimilar sequences or structural motifs. This dichotomy presents challenges when attempting to assess function based solely on sequence homology. Given their essential functions, it is perhaps unsurprising that SLCs are an evolutionarily ancient class of proteins, with many subfamilies being shared across eukaryotes as well as prokaryotes and archaea. However, there are also a large number of SLC genes showing a high rate of divergent evolution, possibly driven by responses to external factors such as chemosensing or toxin extrusion.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Size of the SLC family relative to other protein families. Graph displays number of genes for each protein family, including: SLC (solute carrier family), GPCRs-NO (nonolfactory G-protein coupled receptors), NRs (nuclear receptors), ion channels, and ABC (ATP binding cassette) transporters. See <a class="ref internalNav" href="#sec8" aria-label="Methods section">Methods section</a> for further details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  How SLCs Function</h3><div class="NLM_p">Most SLC members are composed of one continuous domain with 7â14 membrane-spanning regions that have flexible cytoplasmic/extracellular domains, which allow the transmembrane domains to bundle and form substrate passageways through the surrounding membrane. Many SLC members transport their substrates either through secondary active transport or facilitative transport mechanisms.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> A few SLC members have ion-channel like properties and some have no transport function themselves, but rather associate with other SLC members, facilitating their transport activity as heterodimers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> SLCs that operate via secondary active transport couple the movement of one type of ion or molecule against its concentration gradient, to the movement of another ion or molecule down its concentration gradient in a concentrative fashion (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). This mechanism can be further categorized based on whether a molecule or ion and the cotransported molecule or ion are moved in the same direction across a membrane (symporters) or opposite directions (antiporter or exchanger, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) across a membrane. Other SLCs function as uniporters or facilitative transporters, which transport cell membrane-impermeant substrates down a concentration gradient. Unlike other protein transporters, such as ion channels, SLCs typically have a fixed stoichiometry of substrate movement per translocation cycle. Biochemical and crystallographic studies suggest this general cycle consists of an alternating access mechanism wherein SLCs switch between outward and inward open-facing confirmations, often with an intermediate state where the substrate is fully enclosed and occluded from the environment. Studies on small subsets of SLCs and SLC homologues have revealed crucial insights into SLC-mediated transport to provide a framework for a broader exploration of the family. However, for the vast majority of SLCs, molecular details of substrate recognition and scope, as well as their transport mechanics, remain poorly characterized.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General types (A) and conformational mechanisms (B) of SLC mediated transport. (A) In facilitated transport, substrates move down their concentration gradient across biological membranes. In antiport-based transport, multiple substrates are exchanged in opposite directions, whereas in symport-based transport, substrates are transferred in the same direction. SLCs with orphan transport mechanisms are yet to be annotated. (B) SLCs move substances through membranes via multiple conformational mechanisms. In the rocker switch mechanism, the transporter opens outward to capture its substrate, shields it from the membrane environment, followed by its release. The gated-pore mechanism involves the opening of the transporter to the extracellular environment via conformational changes, which then binds the substrate in a fixed stoichiometric fashion. A scaffold domain remains static during this process. The binding site is enclosed on the extracellular side, which then opens on the intracellular side. In the elevator mechanism, the substrate binds to a transport domain, resulting in a piston-like movement to transport the substrate to the other side of the membrane.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6">2.2.  SLC Structural Insights</h3><div class="NLM_p">Structural analysis of SLCs in various conformations can be useful to determine the relative movement of each structural element during the transport cycle. In addition, structural information can aide in pharmacological design. However, due to difficulties in expressing and purifiying human SLCs, structural and mechanistic information has mainly been provided by their prokaryotic homologues, which often have low sequence homology relative to their human counterparts and lack analogous post-translational modifications (PTMs), which could influence structural features. Furthermore, unlike ABC transporters or GPCRs, SLCs exhibit incredible structural and functional diversity both within and across subfamilies. For example, despite sharing â¼25% sequence homology, the 53 members of the mitochondrial SLC25 family transport chemically diverse substrates, including amino acids, nucleotides, cofactors, carboxylates, and acyl carnitines.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Even human SLCs with common functions, such as large neutral amino acid transporters (LATs), do not necessarily share common topology. Thus, functional insights of human SLCs derived from related members or prokaryotic homologous structures may be incomplete. Fortunately, with the development of powerful technologies like cryogenic electron microscopy (cryo-EM), more three-dimensional structures of human SLCs are likely to be resolved, evidenced by the fact that seven out of the 10 human SLC structural studies reported since 2018 were conducted using cryo-EM.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13 ref14 ref15 ref16">(10â16)</a> Nonetheless, structural investigations of SLCs and their prokaryotic homologues have yielded three general architectures and associated transport mechanisms (in italics) which are predicted to occur frequently in human SLCs: (1) major facilitator superfamily (MFS), <i>rocker-switch</i>, (2) leucine transporter (LeuT)-like, <i>gated-pore</i>, and (3) Glt<sub>Ph</sub>, <i>elevator</i> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> We will not extensively detail the structural biology of SLC transporters, as this topic has been the subject of recent reviews,<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17â19)</a> however, we will provide a brief introduction of these basic structural features based on recently reported human SLC structures.</div><div class="NLM_p">The major facilitator superfamily (MFS) represents the largest fold cluster among SLCs. Proteins possessing an MFS fold often operate via a ârocker-switchâ mechanism (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B) of the symmetrical N-terminal and C-terminal domains during which the substrate-binding site is alternatively accessible from either side of the membrane.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Recently, crystal structures of human SLC2A1 (GLUT1) and SLC2A3 (GLUT3) have been resolved in both inward-facing<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and outward-facing conformations.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> These studies revealed that SLC2A1 shares a similar MFS fold with its prokaryotic homologue XylE,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> composed of 12 TMs separated into N-terminal domain (TM1â6) and C-terminal domain (TM7â12). The N- and C- domains are connected by a series of intracellular helices, which form the intracellular helices (ICH) domain together with a C-terminal helix. The ârocker-switchâ domain movement and alternate access of the substrate site were recently revealed by a comparison between inward-facing SLC2A1 and outward-facing SLC2A3 structure (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. âRocker-switchâ conformational mechanism. Conformation changes from outward open SLC2A3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWC">4ZWC</a>, cocrystallized with maltose) to inward open SLC2A1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PYP">4PYP</a>, cocrystallized with Î²-nonylglucoside). The N-domain (TM 1â6) is shown in blue, C-domain (TM 7â12) in light brown, ICH domain in magenta, and ligands as red and gray spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">One of the most well-studied SLC families with LeuT folds is the SLC6 neurotransmitter: sodium symporter family, which mediates Na<sup>+</sup>-dependent translocation of various neurotransmitters, including dopamine, serotonin, norepinephrine, glycine, and Î³-aminobutyric acid (GABA).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Structural information collected from the prokaryotic homologue of LeuT has revealed that it operates through a âgated-poreâ mechanism (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), which is also referred to as the ârocking bundleâ mechanism.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Recently, both the occluded and inward open conformations of human SERT (SLC6A4) have been resolved using cryo-EM, providing additional insights into SERTâs intrinsic structural dynamics during the transport cycle (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Human SERT has 12 transmembrane domains (TM), and the first 10 (TM1â10) are organized into the typical (5 + 5) inverted repeats as the prototype LeuT fold. TM1 and TM6, the first TM of each repeat are separated into two segments as TM1aâTM1b and TM6aâTM6b, in which each half TM can rotate independently around a central kink, thus controlling the access to substrates. Comparison of SERT structure at outward-open and inward-open<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> conformations reveals both local and global changes of helices and loops during the transport process (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. âGated-poreâ conformational mechanism. Conformational changes of SERT revealed by cryo-EM. Outward-open human SERT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZY">6DZY</a>, cocrystallized with Ibogaine, gray) to inward-open human SERT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZZ">6DZZ</a>; TM 1a and TM 1b shown in magenta, TM 6a and TM 6b shown in green, TM2, 5, 7, 8, and EL4 (extracellular loop) are shown in brown, and TM 3, 4, 9, 10, 11, and 12 are shown in blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Details of the distinctive âelevatorâ transport mechanism have primarily been elucidated through studies of the prokaryotic prototype Glt<sub>Ph</sub> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> However, recently structures of two human Glt<sub>Ph</sub> homologues, SLC1A3 and SLC1A5, have been resolved in the outward-facing and inward-facing conformations. SLC1A3 was crystallized as a homotrimer complex, with each unit composed of a static scaffold domain (ScaD) and a mobile transport domain (TranD) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> ScaD includes TM 1, 2, 4, and 5 and forms the homotrimer interface. TranD is composed of TM 3, 6, 7, 8 and re-entrant helical loops HP1/2 and is responsible for carrying substrates and cotransported ions from the extracellular region into cell. The structure of SLC1A5 was resolved in an inward-facing conformation by single particle cryo-EM and resembles the same domain organization as SLC1A3.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The âelevatorâ transport mechanism was visualized through comparison of the outward-facing SLC1A3 structure with the inward-facing SLC1A5 structure (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. âElevatorâ conformational mechanism. The conformational switch from outward open SLC1A3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LLU">5LLU</a>, cocrystallized with aspartic acid) to inward open SLC1A5 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCT">6GCT</a>, cocrystallized with glutamine) is shown. The scaffold domain is depicted in blue, transport domain in brown, helical loop HP1 in green, and the helical loop HP2 in magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">With structural information available only for a limited number of human SLCs and given their overall lack of sequence homology, the development of generalized structural models remains elusive. Many reported SLC structures do not belong to the aforementioned three types of folds but often contain bundles of transmembrane helices, which undergo both local and global conformational changes to facilitate substrate transport. Structural information for all transport conformations (outward-facing, inward-facing, occluded) is necessary to fully depict the transport cycle. Chemical inhibitors can be useful tools for this purpose, as many of them lock SLCs in specific conformations.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">3.  SLCs in Human Physiology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17648" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17648" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.1.  Glucose Transporters</h3><div class="NLM_p">Solute carriers are broadly expressed in all human tissues and carry out myriad essential physiological functions in the body (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). For instance, the SLC2 (glucose transporters or GLUTs) and SLC5 (sodium-glucose transporters or SGLTs) families mediate hexose (principally glucose) uptake in hepatocytes, erythrocytes, and other cell types. There are 14 members of the GLUT family, which are primarily annotated as transporters of glucose and fructose via facilitated diffusion. The GLUT family is further divided into three classes (IâIII) based on sequence homology, class I (SLC2A1â4, 14), class II (SLC2A5, 7, 9, 11), and class III (SLC2A6, 8, 10, 12, 13).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> GLUT1 (SLC2A1), one of the first transporters to be purified<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and cloned,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> is located primarily on cell membranes and is the major glucose transporter in erythrocytes, the brain, and the placenta. The remaining class I GLUTs are also glucose transporters, with GLUT2 functioning primarily as a glucose sensor in the pancreas, liver, and kidneys, GLUT3 in neurons and placenta, and GLUT4 functioning as an insulin-responsive transporter in the heart, adipose tissue, skeletal muscle, and brain.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Class II members are fructose transporters located primarily in the small intestine, testes, and kidney.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Class III members are mainly glucose transporters located in the brain, testes, spleen, skeletal muscle, heart, lung, and kidneys. SGLTs (SLC5A1, 2, 4, 9, 10) are a family of symporters located primarily in the small intestine and kidney that transport glucose in conjunction with sodium ions against an âuphillâ glucose gradient.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> SGLT2 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A) is the main transporter of glucose reabsorption in the kidney and the main target of the gliflozin drug class (e.g., canagliflozin, dapagliflozin) used for the treatment of type II diabetes mellitus (T2DM), which act by blocking glucose uptake. Despite all members of the SLC5 subfamily sharing a common structural core of 5TM Î±-helical domains, the remaining seven members of the SLC5 subfamily are not primarily glucose transporters; rather, they transport other substrates such as iodide (SLC5A5), choline (SLC5A7), biotin (SLC5A6), <i>myo</i>-inositol (SLC5A11), and various monocarboxylates (SLC5A8, A12). In addition to these main sugar transporters, members of the SLC37, SLC45, and SLC50A1 have also been annotated as sugar transporters.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Examples of SLC function in human physiology. (A) In proximal convoluted tubules of kidney nephrons, SLC5A2 (SGLT2) is the main glucose transporter from the apical membrane, glucose is reabsorbed into blood via SLC2A2 (GLUT2). (B) Astrocytes express both SLC1A2 (EAAT2) and SLC1A3 (EAAT1). SLC1A2 is the main glutamate (Glu) transporter to remove Glu from the synaptic cleft to avoid excitotoxicity. Glutamine synthase (GS) converts Glu to glutamine (Gln), which is secreted and transported into neurons by SLC38A2 (SNAT2). In neurons, glutaminase (GLS) converts Gln to Glu, which is transported into storage vesicles by SLC17A6 (vGLUT2). (C) In response to cold temperatures, sympathetic postganglionic neurons release norepinephrine that induces triglyceride breakdown into free fatty acids, which in turn activates SLC25A7 (UCP1) in brown adipose tissue (BAT). SLC25A7 dissipates the proton motive force to generate heat. (D) In islet of Langerhans Î² cells, SLC30A8 is a critical transporter to ensure the crystallization of insulin by mediating the transport of zinc ions to form hexameric insulin in a ratio of two Zn<sup>2+</sup> for every six molecules of insulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2.  Amino Acid Transporters</h3><div class="NLM_p">The SLC1, SLC3, SLC7, SLC36, SLC38, and SLC43 subfamilies are nearly exclusive amino acid transporters, in addition to several members of the SLC6, SLC16, SLC17, and SLC25 subfamilies that also transport amino acids. These transporters mediate the uptake and transport of essential amino acids as well as regulate overall amino acid homeostasis, representing key checkpoints for several essential functions such as protein synthesis, energy production, nucleotide biosynthesis, and neurotransmission.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The glutamate transporters are comprised of two subclasses: the excitatory amino acid transporters (EAAT1â5), which belong to the SLC1 subfamily (SLC1A1â3, â6â7), and the vesicular glutamate transporters (VGLUTs), which belong to the SLC17 subfamily (SLC17A6â8). These transporters are primarily responsible for Glu uptake in the central nervous system (CNS). Glutamate is a major excitatory neurotransmitter and is synthesized in the cytoplasm then stored in synaptic vesicles by the glutamate/proton exchangers VGLUTs. Following its exocytotic release, glutamate activates ionotropic glutamate receptors for excitatory transmission. EAATs, present in cell membranes, remove glutamate from the synaptic cleft into glial cells and neurons to terminate the action of glutamate via a sodium-coupled symport mechanism (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p last">The 14TM SLC7 transporters are divided up into two subclasses: cationic amino acid transporters (CATs, SLC7A1â4), which are glycosylated, and glycoprotein-associated amino acid transporters (gpaATs, SLC7A5â11), also sometimes called heteromeric amino acid transporters (HATs), which are not glycosylated but heterodimerize with single transmembrane glycoproteins SLC3 family members and possess no transport function themselves. CAT members are expressed in a variety of tissues, and they are thought to mainly transport arginine, lysine, ornithine, and histidine via facilitated diffusion, with CAT1â2 playing important roles in the synthesis of nitric oxide (NO) from arginine, whereas the physiology of CAT3â4 is less elucidated.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> HATs, on the other hand, have a much more diverse substrate profile, functioning mostly as obligatory amino acid exchangers. Their substrates range from large (e.g., valine, leucine, phenylalanine, tyrosine) and small neutral amino acids (e.g., glycine, alanine) to negatively charged (e.g., aspartate, glutamate) and cationic amino acids (e.g., arginine, histidine). HATs are broadly expressed throughout various tissues (largely in cellular membranes), with diverse functional roles including the transport of essential amino acids across the bloodâbrain barrier and placenta,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> redox homeostasis, neurotransmission (via glutamate regulation),<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and amino acid reabsorption. Like most SLC members, the full substrate profiles of CATs and HATs are incompletely characterized. For example, SLC7A5 is perhaps most well-studied as a large neutral amino acid transporter, but it has also been shown to transport nonamino acids substrates, such as thyroid hormones, across cell membranes in the placenta.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Given the essential roles of amino acids in numerous physiological processes, amino acid transporters are obvious therapeutic targets in disease areas, such as metabolic disorders, neurological disorders, and cancer.<a onclick="showRef(event, 'ref34 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref34 ref40 ref41">(34,40,41)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.3.  Neurotransmitter Transporters</h3><div class="NLM_p">The SLC6 subfamily, a relatively well-characterized subfamily, is composed of 20 Na<sup>+</sup> and Cl<sup>â</sup> dependent neurotransmitter transporters (NTTs).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In general, SLC6 members have 12 TM domains with structural features shared with the leucine transporter, LeuT.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Members of the SLC6 family are widely expressed in the brain and CNS, playing essential roles in the regulation of neurotransmitter signaling and homeostasis by mediating their uptake and release from the extracellular space into neurons and glial cells. These proteins are primarily located in cell membranes and can be divided into four general subgroups on the basis of sequence similarity and endogenous substrates they transport: (1) monoamines (SLC6A2âA4), (2) neurotransmitter amino acids (SLC6A5, A7, A9, A14), (3), GABA and osmolytes (SLC6A1, A6, A8, A11âA13), and (4) neutral amino acids (SLC6A15-A20). Substrates of the monoamine transporters include noradrenaline, dopamine, and 5-hydroxytryptamine (5-HT or serotonin), therefore these proteins regulate central and sympathetic nervous system functions including learning, mood, attention, movement, appetite, sleep, and reward. In addition to these endogenous substrates, monoamine transporters can also transport amphetamines and neurotoxins including MDMA (ecstasy) and 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>).</div><div class="NLM_p">The two main glycine transporters, GlyT1 and GlyT2, are predominantly located on glia and neurons, respectively. GlyT1 regulates synaptic glycine concentrations influencing <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor-mediated neurotransmission, but it is also important in neonatal development by regulating glycine concentrations at inhibitory glycinergic synapses. ATB<sup>0+</sup> (SLC6A14), which is expressed in various peripheral tissues, has a much broader substrate specificity and is a transporter for numerous dipolar and cationic amino acids.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Likewise, PROT (SLC6A7), which is expressed only in brain in association with a subset of excitatory nerve terminals, does not transport glycine but has high specificity for proline. The activity of GABA-transporters (GAT), which are located predominantly upon neurons (GAT-1), glia (GAT-3), or both (GAT-2, BGT-1), serve to terminate phasic GABAergic transmission, maintain low ambient extracellular concentrations of GABA, and recycle GABA for reuse by neurons.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> GAT1 is a target for antiepileptic drugs, such as tiagabine (<b>2</b>) and nipecotic acid, which likely exert their effects by elevating extracellular GABA levels.</div><div class="NLM_p last">Members of the neutral amino acid transport subfamily are found on the apical surface of epithelial cells, where they absorb amino acids from the duodenum, jejunum, and ileum. They also mediate the reabsorption of neutral amino acids within the proximal tubule of the nephron, as well as in brain tissue. Since the discovery of fluoxetine and other SSRIs, other classes of compounds that affect neurotransmitter reuptake have been developed. We will discuss these efforts in following sections.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.4.  Mitochondrial Transporters</h3><div class="NLM_p">Although members of SLC subfamilies are typically functionally related and are often located on cell membranes, the human SLC25 subfamily, which contains 53 members, making it the largest SLC subfamily, is composed of transporters that are primarily restricted to the mitochondria and can transport a diversity of substrates. Members of the SLC25 subfamily can be found in nearly all tissues and have common structural characteristics that are unique among other transporters, with three tandemly repeated homologous domains about 100 amino acids in length, with each repeat consisting of two hydrophobic stretches separated by a hydrophilic region. Substrates of SLC25 members include amino acids, various nucleotides and cofactors, carboxylates, keto acids, acylcarnitines, and protons.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Not surprisingly, given their diverse substrate profiles, SLC25 members contribute to nearly all the functions of the mitochondria, including oxidative phosphorylation, fatty acid oxidation, Krebs cycle, urea cycle, heme biosynthesis, and branched amino acid catabolism as well as more specialized physiological functions reflective of the tissue in which they are expressed. For example, the carnitineâacylcarnitine transporter CACT (SLC25A20), is the main importer of fatty acids into the mitochondria through the exchange of free carnitine for fatty acid acylcarnitines across the inner mitochondrial membrane, where they then undergo fatty acid oxidation. The mitochondrial oxidation of fatty acids is an important source of energy during prolonged fasting and long-term exercise. Thus, SLC25A20 is present in the mitochondria of all tissues, however, has higher expression levels in skeletal and cardiac muscle.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Similarly, SLC25 members that support oxidative phosphorylation, such as the exchange of cytosolic ADP for newly synthesized ATP (e.g., SLC25A4) and phosphate import (e.g., SLC25A3), are found in all tissues with higher expression levels in muscle.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p last">Other SLC25 members possess more highly specialized functions and thus more restricted expression profiles. For instance, the mitochondrial brown fat uncoupling protein 1, or UCP1 (SLC25A7), is responsible for thermogenic respiration, a specialized function of brown adipose (BAT) that contributes to nonshivering thermogenesis to compensate for temperature and diet variations (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C). UCP1 has restricted expression in BAT and beige fat, whereupon activation by long-chain fatty acid (LCFA) binding, it transports protons across the inner mitochondrial membrane (IMM), thereby dissipating the proton gradient and resulting in the overall conversion of the energy of substrate oxidation into heat rather than ATP synthesis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Considering the essential role of UCP1 in fat metabolism, its restricted expression to BAT, and LCFA-dependent activity, pharmacological modulation of UCP1, or its expression represents an intriguing approach for weight loss and one that would likely be safer than other general mitochondrial uncouplers.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> However, to our knowledge, there are no direct modulators of UCP1.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.5.  Metal Ion Transporters</h3><div class="NLM_p">Although the substrate profile of most SLCs consists of organic molecules, approximately 35 SLCs are dedicated metal transporters. These include the SLC11 and SLC40 subfamilies which transport divalent iron and manganese ions across cell, endosomal, and lysosomal membranes,<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> the SLC30 and SLC39 zinc transporters which regulate zinc accumulation in the cytosol and intracellular compartments,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> the SLC31 subfamily of copper transporters primarily located on cell membranes<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and also less well annotated SLC41, SLC57, and SLC58 subfamilies,<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> which are thought to transport a variety of metals, including magnesium, iron, cobalt, strontium, copper, and barium.</div><div class="NLM_p last">Among these families, perhaps the most well studied are the zinc transporter families ZnT/SLC30 and ZIP/SLC39 subfamilies. Zinc is the second most abundant transition metal in the body, and it is often found in coordination with nitrogen, oxygen, and sulfur ligands present in histidine, glutamate, aspartate, and cysteine. Zinc is essential for structural and enzymatic functions of many proteins, with an estimated 10% of human proteins binding zinc. In addition, zinc is a secondary messenger, with an estimated 2000 transcription factors requiring zinc for their function.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Zinc homeostasis is tightly regulated by 10 ZnT transporters, which function to reduce cytoplasmic zinc concentrations, and 14 ZIP transporters, which increase cytosolic zinc levels. There is no structural information available for human zinc transporters, and their mechanism of transport is unknown. However, on the basis of homology modeling, ZIPs are predicted to have eight transmembrane domains, whereas ZnTs are predicted to have six. Perhaps one of the most highly explored zinc transporters is ZnT8 (SLC30A8). It is expressed almost exclusively on pancreatic beta cells, where it plays a critical, but incompletely understood, role in insulin synthesis, storage, and function (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Despite being relatively underexplored, SLC metal transporters have already established roles in cell function and human physiology, as well as increasingly appreciated roles in human disease, such as cancer, infection, and genetic disorders, some of which will be discussed in the next section.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">4.  SLCs in Human Disease</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34181" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34181" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Given the diverse and essential functions of SLC members, it is not surprising that they can cause and contribute to the pathogenesis of many diseases. Early knowledge of the roles of SLCs in human disease was highly informed by pharmacological tools and drugs. In some instances, these compounds were clinically approved prior to elucidation of their molecular target but later served as useful tools to connect the disease to corresponding SLCs as well as assist in their functional annotation. As we will discuss in later sections, this was the case for several monoamine transporter inhibitors and diuretics. Further compelling evidence has come from the use of knockout mice, which have been useful in deciphering the relative contribution of specific transporters in various tissues.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In addition, there are clear genetic links between SLCs and human disease, with nearly half of the family members found mutated in human disease and genome-wide association studies (GWAS).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Below, we survey several SLCs with well-established disease links, as well as highlight potential therapeutic areas in which SLCs have emerging roles but currently lack pharmacology.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14">4.1.  SLCs and Neurological Disorders</h3><div class="NLM_p">The pathological and clinical roles of SLCs expressed in the CNS have been investigated since the 1950s. Monoamine transporters including SLC6A2, SLC6A3, and SLC6A4 are the primary targets for monoamine reuptake inhibitors (MRIs), the largest group of SLC-targeting drugs, with over 40 FDA-approved molecules.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> MRIs inhibit the reabsorption of neurotransmitters including norepinephrine, dopamine, and serotonin, into presynaptic cells, thereby increasing their synaptic concentrations and subsequent binding to their corresponding postsynaptic receptors. Although the activation of monoaminergic transmission is immediate, the antidepression effects are usually observed after weeks of treatment, implying that secondary neuroplastic changes that are induced after the prolonged activation of receptors, are involved.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> In contrast, overactivation of monoaminergic transmission is the underlying mechanism of other neurological diseases. Tardive dyskinesia, a movement disorder caused by dopamine hypersensitivity, is commonly observed in patients after antipsychotic treatment with DRBAs (dopamine-receptor-blocking agents). Inhibition of the vesicular monoamine transporter 2 (SLC18A2) decreases synaptic dopamine concentration by blocking the uptake of dopamine into synaptic vesicles and facilitating its degradation by cytosolic enzymes.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">Neuro-excitotoxicity mediated by glutamate, the major excitatory neurotransmitter transported by SLCs, is involved in the pathogenesis of neurodegenerative diseases, epilepsy, and stroke.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> SLC1A2 is predominantly expressed in astrocytes and is responsible for over 90% of glutamate reuptake in the CNS.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Functional loss of SLC1A2 has been observed in the early phase of Alzheimerâs Disease (AD) patients. Enhanced extrasynaptic glutamate levels can increase amyloid-Î² formation, which in turn induces more glutamate release through a positive feedback cycle. In mouse models, defective SLC1A2 accelerates cognitive decline associated with AD, whereas transgenic or pharmacological restoration of SLC1A2 function can attenuate AD-like symptoms.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> In addition to glutamate, glycine is also required to bind and coactivate NMDA (<i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate) receptors for glutamatergic neurotransmission. The NMDA antagonists ketamine and phencyclidine produce schizophrenia-like symptoms, supporting the hypothesis that hypofunction of glutamatergic system is involved in the pathophysiology of schizophrenia.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> SLC6A9 controls NMDA activity by mediating the clearance of glycine from excitatory synapses. Inhibition of SLC6A9 leads to NMDA activation and cognition enhancement in mouse schizophrenia models, although clinical development of SLC6A9 inhibitors has been unsatisfactory.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_p last">In addition to directly regulating synaptic neurotransmitter concentration, SLCs can also participate in disease progression or treatment by modulating neuronal ion homeostasis. For example, SLC12A5 extrudes chloride ions into synapses and maintains intracellular chloride concentration below its thermodynamic equilibrium potential, thus enabling the GABA<sub>A</sub> receptor to permeate chloride ions down the electrochemical gradient to induce synaptic inhibition. Loss of SLC12A5 activity has been observed in a number of diseases including neuropathic pain, schizophrenia, and epilepsy.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">4.2.  SLCs and Inherited Disorders</h3><div class="NLM_p">Perhaps the most convincing evidence of the pathophysiological roles of SLCs comes from studies of rare monogenic diseases. It is estimated that over 25% of SLCs are associated with monogenic disorders.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> For instance, mutations in SLC3A1 (1 in 15000 births in the U.S.) and SLC7A9 (1 in 7000 births) result in cystinuria, characterized by impaired transport of cystine, ornithine, lysine, and arginine (COLA) in the renal proximal tubules, excessive excretion of cystine in urine, and the formation of cystine stones in kidneys and bladder.<a onclick="showRef(event, 'ref3 ref67'); return false;" href="javascript:void(0);" class="ref ref3 ref67">(3,67)</a> Mutations in SLC3A1 cause cystinuria type I, whereas mutations in SLC7A9 cause non-type I, in which the clinical symptoms can be further observed in mouse models of cystinuria.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Mutations in mitochondrial SLC25A19 cause the autosomal recessive disorder Amish lethal microcephaly (MCPHA), which is characterized by severely impaired congenital brain development.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Homozygous deletion of <i>SLC25A19</i> in mouse models results in embryonic lethality with remarkable malformation of the CNS, whereas heterozygous <i>SLC25A19</i><sup><i>Â±</i></sup> animals appear normal. Functional studies revealed that loss of SLC25A19 reduces the mitochondrial pool of thiamine pyrophosphate (ThPP), a cofactor required by Î±-ketoglutarate dehydrogenase (KGDH) and pyruvate dehydrogenase (PDH), thereby reducing flux through these complexes, leading to reduction in the Krebs cycle intermediates and oxidative phosphorylation and ultimately to mitochondrial dysfunction during embryogenesis (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Despite the extensive links of SLCs and inherited disorders, to our knowledge, no drugs or chemical probes have been developed specifically and directly targeting mutant SLCs.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. SLC25A19 transports ThPP. SLC25A19 transports thiamine pyrophosphate (ThPP), which is a cofactor for pyruvate dehydrogenase (PDH) and Î±-ketoglutarate dehydrogenase (KGDH). Impaired SLC25A19 function attenuates mitochondrial ThPP, as observed in the disorder Amish lethal microcephaly (MCPHA), leading to mitochondrial dysfunction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">4.3.  SLCs and Metabolic Disease</h3><div class="NLM_p">SLCs are often expressed in a tissue-specific manner and are involved in the uptake of a plethora of metabolites and nutrients, thus intimately linking them to the pathogenesis and treatment of various metabolic disorders. For example, the facilitative glucose transporter SLC2A4 (GLUT4), is an insulin-responsive glucose transporter expressed in muscle and fat cells. Upon insulin stimulation, glucose transport is upregulated several-fold and SLC2A4 translocates from intracellular storage vesicles to the plasma membrane; however, this insulin-responsive SLC2A4 redistribution is impaired in muscle tissues isolated from T2D patients.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Interestingly, several compounds were recently found to induce SLC2A4 membrane translocation, resulting in a significant reduction in blood glucose levels in diabetic mice models, representing a potentially promising approach for T2D treatment.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Another glucose transporter, the sodium-dependent glucose transporter SLC5A2 (SGLT2), reabsorbs glucose at proximal tubules and inhibitors targeting this transporter increase renal excretion of glucose, showing great clinical efficacy for the treatment type 2 diabetes (T2D).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In addition to glucose transporters, it was recently discovered that among people of Latin-decent, several SLC16A11 variants, identified through genome-wide association studies (GWAS), pose higher (â¼20%) risks for T2D.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> SLC16A11 (MCT11) is a proton-coupled monocarboxylate transporter highly expressed in the liver. It was discovered that T2D-risk coding variants decrease SLC16A11 expression and disrupt its interaction with basigin, ultimately reducing the amount of SLC16A11 at the plasma membrane, resulting in T2D-associated metabolic changes, together suggesting that increasing SLC16A11 membrane localization could be therapeutically beneficial for T2D.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a></div><div class="NLM_p last">SLCs also play vital roles in maintaining body-fluid and nutrient homeostasis. Diuretics targeting SLC12A1/2 and SLC12A3 in renal tubules decrease blood pressure through the blockade of salt reabsorption and removal of extra water.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> At the apical membrane of renal tubule cells, SLC22A12 inhibitors alleviate hyperuricemia by decreasing uric acid reabsorption.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> SLC10A2, located on the brush border membrane of the ileum, is responsible for the uptake of bile acids into portal circulation. Downregulation of SLC10A2 results in the accumulation of excess bile acids in intestines, which prompted the clinical development of SLC10A2 inhibitors for idiopathic chronic constipation and liver cholestasis-associated pruritus.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> SLC13A5 is a dicarboxylate transporter expressed in various organs, but with highest levels in the liver. Knockout of its mice homologue reduces hepatic uptake of citrate, produces a calorie restriction phenotype and protects mice from high fat diet (HFD)-induced hepatic steatosis and insulin resistance.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> In another example, several SLC39A12 mutations were discovered in pulmonary hypertension-resistant rat strain. Chronic hypoxia has been shown to activate SLC39A12 transcription, resulting in increases of intracellular zinc uptake and constriction of pulmonary vascular endothelial cells. The resulting vascular remodeling effect is attenuated in SLC39A12â/â mice.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17">4.4.  SLCs and Cancer</h3><div class="NLM_p">Cancer cells rewire their metabolism to support unremitting proliferation and survival, necessitating an increased amount of metabolic building blocks, including sugars, amino acids, inorganic materials, and other nutrients. A hallmark example is the metabolic shift toward increased glycolysis in transformed cells to preferentially produce ATP via glycolysis of glucose to lactate, commonly known as the Warburg effect. As glycolysis is less efficient than oxidative phosphorylation, cancer cells compensate by increasing glucose uptake and the glycolytic rate. Indeed, various tumor cells upregulate glucose transporter (GLUT/SLC2A and SGLT/SLC5A families) expression levels to sustain this increased energetic demand.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Perhaps it is not surprising that as nutrient and metabolite transporters, other SLCs have also been shown to play essential roles in the progression of numerous human cancers.</div><div class="NLM_p">Glutamine is the most abundant free amino acid in the body and plays pleiotropic roles in various cellular functions. Not only is glutamine utilized in protein synthesis but also through catabolic processes, provides nitrogen and carbon for the biosynthesis of nucleotides and amino acids, as well as fuel for the citric acid cycle. Although mammals can produce endogenous glutamine in most tissues, cancer cells require amounts that exceed the supply generated by endogenous synthesis, leading to a dependency on glutamine import.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Glutamine metabolism is upregulated by many oncogenic alterations, including in mutant K-Ras, NRF2-activated, and c-Myc driven cancers.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Glutamine supplies intermediate metabolites for the TCA cycle, amino acid/protein synthesis, and fatty acid synthesis as well as indirectly regulates key signaling pathways (e.g., mTOR) and redox homeostasis through the exchange with other amino acids, all of which heavily contribute to cancer cell proliferation in vitro and in vivo.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> A series of SLC transporters, SLC1A5 (ASCT2),<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> SLC7A5 (LAT1),<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> SLC3A2 (4F2hc),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> SLC7A11 (xCT),<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> SLC6A14 (ATB<sup>o,+</sup>),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> and SLC38A1/A2 (SNAT1/2)<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> control the flux of glutamine and other amino acids involved in glutaminolysis and glutamine-regulated homeostasis (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).<a onclick="showRef(event, 'ref40 ref82'); return false;" href="javascript:void(0);" class="ref ref40 ref82">(40,82)</a> Multiple lines of evidence implicate these transporters as having essential roles in glutamine-dependent cancers,<a onclick="showRef(event, 'ref84 ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref84 ref87 ref88 ref89">(84,87â89)</a> prompting the development of various early stage small molecule inhibitors for a few of these transporters, some of which will be discussed in later sections.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Various roles of glutamine-mediated transport in cancer. SLC1A5 is one of the major glutamine (Gln) transporters in cells. Upon entering the cell, glutaminase (GLS) converts Gln to glutamate (Glu), which participates in nucleic acid, glutathione, and amino acid synthesis. SLC7A11 exchanges Glu for cystine, which is reduced to cysteine by Trx1/TR1 and Grx/GSH/GR. SLC7A5 exchanges Gln for leucine and other amino acids, which can lead to mTOR activation. SLC38A1 and A2 modulate the transport of neutral amino acids, while SLC6A14 is involved in transporting neutral and cationic amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the metabolic shift toward the glycolytic pathway in cancer, there is an increased production of the metabolic monocarboxylate end products, pyruvate, and lactate. Excess lactate production in cancer can cause intracellular acidification, and so to compensate, many cancers upregulate the expression of the bidirectional monocarboxylate transporters MCT1 (SLC16A1) and MCT4 (SLC16A3) to increase lactate export. Indeed, several studies have demonstrated that pharmacological blockade of these transporters has been shown to reduce tumor growth in various cancers through the induced buildup of lactate, as well as pyruvate.<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a> In recent studies, these bidirectional transporters were shown to sustain tumor growth (pancreatic and nonsmall cell lung cancers) through the import of lactate from the blood which is then be converted back to pyruvate to be used in the citric acid cycle (TCA) and subsequent ATP production (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> These compelling studies suggest that certain tumors can utilize circulating lactate as an alternative fuel source, establishing new roles of MCTs in cancer. In addition to roles of MCTs in energy production, it was observed in breast cancer that pyruvate uptake mediated by SLC16A7 (MCT2) induces the production of Î±-ketoglutarate, which in turn activates collagen hydroxylation by increasing the activity of the enzyme collagen prolyl-4-hydroxylase (P4HA), enabling the remodeling of the extracellular compartment in the lung metastatic niche.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Both genetic deletion and pharmacological inhibition with Î±-cyano-4-hydroxycinnamic acid (Î±-CHCA) resulted in reduced deposition of functional collagen I and III as well as substantially reduced metastatic burden in vivo. Î±-CHCA, a substrate mimic and common matrix component for MALDI-MS studies, is commonly used as an MCT2 inhibitor for biological investigations, however, like many other substrate-mimicking inhibitors, its low potency necessitates millimolar concentrations to induce biological effects, potentially resulting in undesirable off-target perturbations. Efforts have been pursued to develop various inhibitors of MCTs, some of which we will discuss in sections below.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SLC16A7 modulates the remodeling of metastatic niches. SLC16A7 transports pyruvate which is metabolized to Î±-ketoglutarate. Î±-Ketoglutarate was shown to metabolically activate prolyl 4-hydroxylase subunit alpha 1 (P4HA). P4HA-mediated modification of procollagen results in triple procollagen molecule formation, which is deposited onto the extracellular space as mature collagen fibrils.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">There is increasing evidence that metal dyshomeostasis contributes to cancer progression. Although the mechanisms are still not thoroughly characterized, changes in zinc levels have been shown to contribute to altered signaling pathways in tumor tissues and cancer cell lines.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> For example, in prostate cancer, downregulated expression of SLC39A1 lowers intracellular zinc, resulting in activation of the Akt-p21 pathway, which supports aberrant proliferation.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> In addition to zinc, copper has recently been demonstrated to promote tumorigenesis. Specifically, copper influx enhances MEK1 phosphorylation of ERK1 and ERK2 through a CuâMEK1 interaction. The BRAF<sup>V600E</sup> mutation drives a wide spectrum of cancers by increasing phosphorylation of MEK1/2, which in turn activates ERK1/2, stimulating the MAPK pathway to promote cancer.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> In <i>BRAF</i><sup><i>V600E</i></sup> dependent tumors, the copper transporter SLC31A1 controls the influx of copper, which in turn binds and allosterically promotes MEK1/2 kinase activity and subsequent phosphorylation of ERK1/2.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Deletion of <i>SLC31A1</i> substantially decreases MAPK signaling and <i>BRAF</i><sup><i>V600E</i></sup>-dependent tumor growth in vivo, promoting this solute carrier transporter as a potential target for <i>BRAF</i>-driven tumors. Thus, SLC metal transporters represent compelling targets for the treatment of various cancers.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">4.5.  SLCs and Immune Disease</h3><div class="NLM_p">Relative to neurological and metabolic disorders and cancer, possible contributive roles of SLCs to immune disorders remain underexplored, representing a relatively untapped therapeutic target class. For instance, germline-encoded immune sensors, known as pattern recognition receptors (PRRs), recognize pathogen-associated molecular patterns (PAMPs), are crucial components of the innate immune response. The detection of microbial pathogens involves the recognition of conserved microbial PAMPs by PRRs like Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs are membrane sensors that scan the extracellular environment for microbial PAMPs while NLRs monitor the cytosolic environment. Upon ligand binding, the production of inflammatory cytokines, such as type I-interferons, is triggered, leading to protective roles against infection. However, these sensors, which are dedicated to the detection of infection, are sometimes usurped, resulting in inappropriate triggering of these pathways, initiating or perpetuating various chronic inflammatory disorders (e.g., lupus, irritable bowel syndrome).<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> Endolysosome-resident SLC15A3 and SLC15A4, 12TM-spanning proton-coupled peptide/histidine transporters that are preferentially expressed in plasmacytoid dendritic cells (pDCs), activated macrophages and B cells, have recently been shown to be essential for TLR7, TLR9, and NOD-mediated signaling in vitro and in vivo (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref100 ref101 ref102">(100â102)</a> Although their roles in TLR-mediated signaling are not fully elucidated, it is thought that SLC15A3/A4 are responsible for the egress of NOD ligands from the endolysosome.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. SLC15A3 and SLC15A4 roles in inflammatory immune response. Immune cells, such as macrophages, engulf invading pathogens that have penetrated through the endothelial barrier. Microbes are digested and endolysosomal SLCs are thought to mediate the transport of oligopeptides derived from pathogens to the cytosol, such as muramyl dipeptide, a component of bacterial cell walls. This event leads to the activation of nucleotide-binding oligomerization domain (NODs), which induces inflammatory NFÎºB-mediated transcription of pro-inflammatory genes. In addition, activation of Toll-like receptors (TLR) 7/9 and subsequent type I IFN production has been shown to be dependent on SLC15A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recent GWAS studies have revealed numerous SLCs to be associated with irritable bowel disease (IBD) and Crohnâs disease, although their potential contributive mechanisms remain unclear. In particular, mutations in the carnitine transporters SLC22A4 and SLC22A5 have been strongly linked to these diseases in human populations.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> Interestingly, Slc22a5-deficient mice have recently been shown to develop spontaneous intestinal ulcers with substantial lymphocytic infiltration.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><div class="NLM_p last">SLCs also play specific metabolic roles which regulate immune cell function. For example, it has been long known that alanine supports T cell activation, however, its specific roles were unknown.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Recently, Ron-Harel et al. discovered that extracellular alanine is required for early activation stages of both naÃ¯ve and memory T cells, likely supportive of protein synthesis and not catabolic processes.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Interestingly, protein expression of the sodium-dependent neutral amino acid transporter SLC38A1 (SNAT1), a major mediator of alanine uptake in T cells,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> was highly induced during activation, together suggesting that blockade of SLC-mediated alanine uptake may provide a therapeutic avenue for modulating T cell function. Given the vital roles of SLCs in various metabolic processes and their function to transport chemicals (e.g., signaling molecules) through membranes, their roles in immune cell function are certain to expand.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">4.6.  SLCs and Bacterial Infections</h3><div class="NLM_p last">Host SLCs have been shown to play essential roles in the pathophysiology of various infectious bacteria. For example, diarrhea-causing pathogenic bacteria induce intestinal fluid accumulation by disrupting the absorption or secretion of electrolytes and nutrients. These processes are mediated by intestinal SLCs, including SLC5A1, SLC9A2/3, SLC12A2, and SLC26A3.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Bacteria can modulate SLC function through two major pathways: injection of effector proteins into enterocytes or toxin release. For instance, enteropathogenic <i>Escherichia coli</i> (EPEC) releases virulence factors through type 3 secretion system (T3ss) which can deactivate SLC5A1 and reduce SLC26A3 expression levels in the apical membrane, thus reducing electrolyte absorption by intestinal epithelial cells (IECs).<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> On the other hand, enterohemorrhagic <i>Escherichia coli</i> (EHEC) releases Shiga toxins 1 and 2, which induce secretion of intracellular galectin-3, causing redistribution of SLC9A2 from apical membrane to basolateral region. Reduced Na<sup>+</sup>/H<sup>+</sup> exchange mediated by SLC9A2 contributes to EHEC induced diarrhea.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Therapeutic agents such as lysophosphatidic acid<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> and probiotic <i>Lactobacillus acidophilus</i><a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> have been shown to alleviate diarrheal phenotype in several preclinical studies by restoring the expression of SLCs including SLC9A3 and SLC26A3 in mouse models. Elucidation of the various roles of SLC transporters can play during infection is an emerging area and additional insight into their mechanistic contributions to infection are likely to yield advances in targeted antibacterial therapies.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">5.  SLC Pharmacology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compared to other protein families of similar stature (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), SLCs are substantially underexplored as therapeutic targets. Among the 667-FDA approved human target genes reported in 2017, 12% are GPCRs, 19% are ion channels, and 10% are kinases, however, SLCs account for less than 3%.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Currently, there are only 13 SLC classes targeted by approved drugs in which the primary mechanism is direct modulation of SLC function, five of which have been shown to function through more than one SLC target (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <b>1</b>â<b>15</b>). In addition, we estimate that there are approximately 10 SLC classes being mechanistically targeted by compounds currently in clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The dearth of chemical tools available to study SLCs can also be exemplified by the number of compounds known to functionally engage SLCs relative to other protein families. Using the ChEMBL Database (<a href="https://www.ebi.ac.uk/chembl/" class="extLink">https://www.ebi.ac.uk/chembl/</a>), we found less than 20% of SLCs are affiliated with compounds possessing SLC bioactivity data. This is in comparison to â¼50% of kinases, ion channels, and nonolfactory GPCRs, â¼30% of proteases and more than 90% of nuclear receptors (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Further, our analysis reveals that a handful of SLC members have received the vast amount of interest from the chemistry and drug development communities. For example, SLC6A4 is associated with more than 6000 unique compounds and SLC5A2 has more than 1400 compounds. On the other hand, of the majority (>90%) of SLCs with associated compounds, each has fewer than 100 chemical entries (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). Similar trends observed by CÃ©sar-Razquin et al.,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> show that published literature pertaining to SLCs is likewise limited to a relatively small subset of SLCs.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SLCs Currently Targeted by Clinically Approved Drugs with Example Chemical Structures</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0031.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SLC Classes Currently Targeted by Compounds Undergoing Clinical Trials</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">gene ID</th><th class="colsep0 rowsep0" align="center">representative compounds (ClinicalTrials.gov identifier)</th><th class="colsep0 rowsep0" align="center">disease</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC5A1/2</td><td class="colsep0 rowsep0" align="left">sotagliflozin, phase III (NCT03315143);</td><td class="colsep0 rowsep0" align="left">type 1/2 diabetes mellitus</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">LIK066; phase II (NCT03205150)</td><td class="colsep0 rowsep0" align="left">nonalcoholic steatohepatitis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC6A5</td><td class="colsep0 rowsep0" align="left">VVZ-149, phase II (NCT03997812)</td><td class="colsep0 rowsep0" align="left">postoperative pain</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC6A9</td><td class="colsep0 rowsep0" align="left">BI 425809, phase II (NCT03859973, NCT02788513);</td><td class="colsep0 rowsep0" align="left">schizophrenia, Alzheimerâs disease</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">PF-03463275; phase II (NCT01911676)</td><td class="colsep0 rowsep0" align="left">schizophrenia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC7A5</td><td class="colsep0 rowsep0" align="left">JPH203, phase II (UMIN000034080)</td><td class="colsep0 rowsep0" align="left">advanced biliary tract cancers</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC9A1</td><td class="colsep0 rowsep0" align="left">rimeporide, phase I (NCT02710591)</td><td class="colsep0 rowsep0" align="left">Duchenne muscular dystrophy</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC10A1</td><td class="colsep0 rowsep0" align="left">bulevirtide, phase II/III (NCT03852719, NCT02888106)</td><td class="colsep0 rowsep0" align="left">hepatitis B/D</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC10A2</td><td class="colsep0 rowsep0" align="left">elobixibat, phase II (NCT04006145);</td><td class="colsep0 rowsep0" align="left">nonalcoholic steatohepatitis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">A4250, phase III (NCT03659916, NCT03566238)</td><td class="colsep0 rowsep0" align="left">intrahepatic cholestasis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC16A1</td><td class="colsep0 rowsep0" align="left">AZD 3965, phase I (NCT01791595)</td><td class="colsep0 rowsep0" align="left">Burkittâs lymphoma</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC22A12</td><td class="colsep0 rowsep0" align="left">verinurad, phase II (NCT03990363, NCT03316131)</td><td class="colsep0 rowsep0" align="left">gout, kidney disorders</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SLC40A1</td><td class="colsep0 rowsep0" align="left">LY 2928057, phaseÂ I;<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></td><td class="colsep0 rowsep0" align="left">anaemia</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">VIT 2763, phaseÂ I<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></td><td class="colsep0 rowsep0" align="left">iron overload</td></tr></tbody></table></div></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Fraction of protein families with individual members associated with 0, 1â100, or more than 100 compounds. See <a class="ref internalNav" href="#sec8" aria-label="Methods">Methods</a>  section for details regarding this analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering that relatively few SLCs have successfully been drugged, it is perhaps not surprising that the range of pathologies targeted is relatively narrow, with diuretics, neurotransmitter-reuptake inhibitors for neuropsychiatric disorders, glucose transport inhibitors for diabetes, and uric acid transporters for gout being the most common drug types. It is interesting to note that many of these drugs were discovered several decades ago and, in many instances, without the knowledge of an SLC being the primary target (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). For example, imipramine (<b>16</b>) was first discovered in the 1950s as an analogue of the antipsychotic drug chlorpromazine, however, it was later discovered to be an effective antidepressant.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> After imipramineâs FDA approval in 1959, the main mechanism of action was revealed to be inhibition of norepinephrine and serotonin reuptake into presynaptic neurons. It would not be until the early 1990s that the SLC transporters SERT (SLC6A4) and NET (SLC6A2) were found to be the primary mechanistic target.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Diuretics like thiazides and furosemide (<b>17</b>) were approved based on their inhibition of salt reabsorption in renal tubules, but once again their molecular targets NCC (SLC12A3)<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and NKCC1/2 (SLC12A2/1)<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> were not established until these genes were cloned and characterized decades later.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Additional drugs and compounds targeting SLCs. Imipramine (<b>16</b>) targets SLC6A2/4. Furosemide (<b>17</b>) targets SLC12A1/2. Elobixibat (<b>18</b>) targets SLC10A2. AZD3965 (<b>19</b>) targets SLC16A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inspection of compounds currently in clinical trials reveals an expanded repertoire of SLCs being pharmacologically targeted for a broader range of pathologies. For example, elobixibat (<b>18</b>), the bile acid transport (SLC10A2) inhibitor under development at Albireo Pharma, is currently in phase III clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> AZD3965(<b>19</b>), an inhibitor of the monocarboxylate transporter SLC16A1 (MCT1) developed by AstraZeneca, is currently in phase I and progressing to phase II clinical trials in the UK for diffuse large B cell and Burkittâs lymphoma.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> MCT1 is overexpressed in numerous cancers, and bidirectional blockade of monocarboxylate transport leads to lactate buildup and inhibition of glycolytic metabolism.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p">In addition to small molecules, monoclonal antibodies (mAbs) targeting SLCs have also entered clinical trials. For example, a humanized IgG4 mAb LY2928057 binds to human ferroportin (SLC40A1), disrupting its interaction with hepcidin, thus preventing ferroportin from internalization and degradation. LY2928057 is currently in phase I clinical trials for the treatment of anemia associated with chronic kidney disease (CKD).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> In addition, ASG-5ME, a humanized monoclonal antibody conjugated to monomethyl auristatin E, a microtubule disrupting agent was recently developed to target SLC44A4, a putative choline transporter overexpressed on prostate cancer cells. However, its clinical development was discontinued earlier this year due to a narrow therapeutic index.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div><div class="NLM_p">Historically, a significant portion of attention that SLC transporters have garnered from the drug discovery community does not relate to SLCs as pharmacological targets themselves but as proteins that influence the absorption, distribution and elimination of drugs. Many SLC members have well-established roles in the transport of pharmaceuticals, ranging from platinum-based drugs and antibiotics to kinase inhibitors. These transporters are expressed in the intestine, bloodâbrain barrier (BBB), liver, and kidneys, which intimately connects them to the bioavailability and sometimes the unwanted toxicity of pharmacological agents. Perhaps the most well-studied SLCs in this context are SLC22A2 (OCT2), SLC22A6 (OAT1), SLC22A8 (OAT3), SLCO1B1 (OATP1B1), and SLCO1B3 (OATP1B3).<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> For example, SLCO1B1 and SLCO1B3 are exclusively expressed in hepatocytes and are responsible for the uptake of anionic drugs, such as statins and sartans,<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> whereas SLC22A6 and SLC22A8 are expressed on the basal side of renal tubular epithelial cells and modulate the excretion of anionic drugs.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a></div><div class="NLM_p">In addition to bioavailability, SLCs also captured the attention of the drug discovery community through their sometimes-common propensity to be unwanted off-targets or their contributions toward undesirable drugâdrug interactions (DDIs). For example, octreotide inhibits SLCO1B1 and SLCO1B3; however, this effect also results in decreased reuptake of bilirubin from portal blood, which has led to hyperbilirubinemia during clinical usage.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Pyrimethamine inhibits SLC47A1 and reduces the efflux of cisplatin from renal cells, thus potentiating cisplatin-induced nephrotoxicity in vivo.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> On the other hand, DDIs mediated by SLCs can have beneficial clinical effects. For example, prolonged treatment of antiviral agents adefovir and cidofovir cause their accumulation in renal cells and subsequent nephrotoxicity. Co-administration with probenecid in healthy subjects inhibits renal uptake through SLC22A6, decreasing the renal clearance and nephrotoxicity of these antivirals.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> As another example, increased oral bioavailability was observed for valacyclovir, the prodrug of acyclovir, due to enhanced uptake mediated by intestinal SLC15A1.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> SLCs expressed in cancer cells can also mediate the intracellular uptake of anticancer drugs. For instance, uptake of the anticancer polyamine bleomycin-A5 has been shown to be mediated by SLC22A16.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> Additionally, leukemia cells have been shown to develop resistance to YM155, an antitumor compound previously under clinical evaluation, through mutagenesis of the transporter SLC35F2.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">5.1.  SLC Screening Strategies</h3><div class="NLM_p">Traditional high-throughput, target-based screening strategies utilizing purified protein or simple in vitro functional assays have, to date, not been broadly implemented for the SLC family. Because of their complex topography and numerous transmembrane domains, SLCs often require conditions that mimic their native environment to remain properly structured and functionally active. In addition, the substrate scope and the physiological roles for the majority of the family have not been detailed, presenting challenges for functional assay development as well as selectivity assessment. Lastly, there are few human SLC structures and even fewer SLC costructures with small molecule ligands, hindering in silico design and screening approaches. Despite these challenges, various strategies for the identification of small molecule SLC modulators have succeeded. We have divided these strategies broadly into four categories: substrate uptake assays (isotope labeled and fluorescence-based), downstream functional/reporter assays, ligand binding, and phenotypic screens/retroactive discovery (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Examples of screening strategies that have been used for the discovery of SLC modulators. (A) Cellular substrate uptake assays with radioactivity or fluorescence detection. (B) Downstream functional assays represented by methods based on detection of pH and membrane potential. (C) Ligand binding assays with detection methods including radioactivity, fluorescence, mass spectrometry, or thermal shift (e.g., CETSA). (D) Phenotypic screening assays with different target identification methods.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The most common strategy to date for the discovery of small molecules targeting SLCs is the direct measurement of substrate uptake (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A). Such assays have been carried out in mammalian cells recombinantly overexpressing the target SLC, on tissues dissected from living organisms bearing target SLCs, or liposomes reconstituted in vitro embedded with the target SLC. To quantitatively monitor the trafficking process, the substrates are most often labeled by radioactive elements or substituted with fluorescent analogues. Radioactive substrates including amino acids (SLC1A1/2/3/5, SLC6A5/9, SLC7A5/11),<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> sugars (SLC5A1/2),<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> neurotransmitters (SLC6A1/2/3/4/12, SLC18A2),<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> metabolites (SLC10A2, SLC13A5, SLC16A1, SLC22A12),<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> and nucleosides (SLC28A1, SLC29A1)<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> have all been prepared and utilized in SLC-mediated cellular uptake screens. However, the broad implementation of these classical uptake screens has been limited by the required protection from radioactive reagents and inconvenient real-time measurement. In addition, not all SLCs have well-defined substrate scopes and some substrates can present synthetic challenges for the incorporation of radioactive isotopes or the identification of suitable fluorescent substrates.</div><div class="NLM_p">The translocation of SLC substrates can have profound influences on the metabolism, physiochemical status, and morphology of cells. Hence, a number of drug screening approaches have taken advantage of these downstream functional changes associated with transport events (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B). Various functional screens have been implemented for the discovery of inhibitors for many SLCs. For example, inhibitors of Na<sup>+</sup>/H<sup>+</sup> exchanger NHE1/3 (SLC9A1/3) were discovered from pH recovery screens in PS120 fibroblast cells overexpressing the corresponding SLCs. Real-time detection of intracellular pH changes was enabled by pH-sensitive fluorescent dye BCECF-AM.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Allosteric inhibitors of the high-affinity choline transporter CHT (SLC5A7) were discovered through a high-throughput fluorescent imaging plate reader (FLIPR) assay, which is based on the electrogenic nature of CHT transport. CHT inhibition blocks the depolarization caused by Na<sup>+</sup> influx and decreases fluorescence as the membrane potential-sensitive dye migrates out of cell.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Similar to other function-based screens, carefully controlled counter-screening should be conducted to ensure that the observed functional changes are the result of SLC perturbation and not modulation of other upstream targets. Further validation of SLC engagement via substrate uptake inhibition or direct binding assays should be carried out to confirm the targeting event.</div><div class="NLM_p">Because of the technical challenges associated with the expression and purification of multipass TM proteins, the implementation of SLC binding assays have remained limited (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C). To avoid issues with SLC reconstitution, membrane components are often extracted from cells or tissues overexpressing targeted SLCs and used directly in screening. Known binders utilized in a competitive format in which binding of screening compounds would block the known binder, and this event could then be detected by either LC-MS<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> or radioactivity measurement.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Emerging new techniques have enabled SLC binding assays to be conducted in living cells. We recently developed a chemical proteomic-based strategy for fragment-based ligand discovery (FBLD) in cells.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Using a library of specialized chemical probes called fully functionalized fragments (FFFs), wherein each member contains: (1) a âconstantâ region consisting of a photoactivatable diazirine group and an alkyne handle for UV light-induced covalent modification and detection, enrichment, and identification of FFF-bound protein targets, respectively, and (2) a âvariableâ recognition region consisting of structurally diverse small-molecule fragments, we identified fragment-based ligands for a wide variety of SLCs in living cells.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> We demonstrated that FFFs can be used to map sites of ligand engagement and that these fragment interactions can be progressed into inhibitors of protein function. Using this FBLD approach, we developed an inhibitor (<b>20</b>) of the acylcarnitine transporter SLC25A20, confirmed its target engagement in live cells, and demonstrated that transport blockade resulted in a buildup of long chain acylcarnitines and inhibition of fatty acid oxidation (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Using quantitative proteomics, we later demonstrated SLC25A20 as a functional target of clinically approved drugs, such as ingenol mebutate (<b>21</b>) (Picato, LEO Pharma) and omeprazole (<b>22</b>).<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> In addition, cellular thermal shift assays (CETSA), which function by monitoring the thermostability changes induced by small molecule binding to a protein, are becoming more widely utilized to measure target engagement. CETSA can be used to study single proteins using specific antibodies or through tagging of target proteins and also in an unbiased fashion through the employment of mass spectrometry, termed thermal proteome profiling (TPP).<a onclick="showRef(event, 'ref143 ref144'); return false;" href="javascript:void(0);" class="ref ref143 ref144">(143,144)</a> Similar to chemical proteomic strategies, CETSA offers the advantage of direct ligand binding in native cellular environments without purification of the protein, however, does not require installation of retrieval tags on bioactive compounds. Recently, CETSA was used to measure ligand engagement of specific SLCs, including known inhibitors and endogenous ligands to SLC16A1 and SLC1A2, highlighting the potential of this technique to screen for ligands of orphan SLCs.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Representative compounds identified as SLC inhibitors using various target deconvolution strategies. Compound <b>20</b>, ingenol mebutate (<b>21</b>), and omeprazole (<b>22</b>) target SLC25A20. NVS-ZP7-4 (<b>23</b>) targets SLC39A7.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to targeted screening methods, many pharmacological modulators of SLCs have also been discovered through the target-agnostic phenotypic screening of compound libraries (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>D). For example, ezetimibe (<b>15</b>) was originally identified in an in vivo intestinal cholesterol absorption screen but its direct target was unknown.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Its elusive mechanisms of action did not stop ezetimibe from being approved by the FDA in 2002 for the reduction of serum low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The authentic target was revealed later to be NiemannâPick C1 like 1 protein (NPC1L1, SLC65A2) by a genomicâbioinformatics approach. Genetic ablation of NPC1L1 significantly decreases intestinal absorption of <sup>14</sup>C-cholesterol in mice models.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Upon binding with cholesterol at its N-terminal domain, NPC1L1 undergoes endocytosis and translocation to the (ERC) endocytic recycling compartment where cholesterol is released. Ezetimibe binds to the second extracellular loop of NPC1L1 and inhibits its internalization.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> This example highlights the major hurdle of phenotypic screening, i.e., the identification of pharmacologically relevant targets of bioactive hits, during this process NPC1L1 gene stood out from â¼16500 cDNAs after extensive analysis, which was a formidable task to achieve in 2004. However, given the advances in genetic editing (e.g., siRNA, CRISPR/Cas9) and sequencing technologies as well as the development of more robust chemical proteomic strategies and synthetic methods for chemical probe derivatization, this hurdle has substantially been eased. A recent example is the discovery of a novel druggable target for the inhibition of Notch signaling, one of the most commonly activated signaling pathways that drive cancer cell proliferation and survival.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Researchers at Novartis performed a phenotypic screen to identify inhibitors of Notch pathway and NVS-ZP7-4 (<b>23</b>) was discovered to block Notch activation with a mechanism distinct from known Notch inhibitors (e.g., Î³-secretase).<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Genome-wide siRNA screen and sequencing of NVS-ZP7-4 resistant cell line identified a V430E mutation on an ER/Golgi Zinc transporter ZIP7 (SLC39A7), which induces resistance to the compoundâs inhibitory effect. Subsequently, direct target engagement of ZIP7 was confirmed with a photo-cross-linking probe analogue. Detailed studies on the molecular mechanism revealed that NVS-ZP7-4 likely alters ER zinc levels, disrupting Notch trafficking and maturation, subsequently leading to apoptosis.</div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">6.  Small Molecule SLC Modulators</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As common in the era of early drug discovery, a significant portion of approved drugs targeting SLCs, including mainstay therapeutics like fluoxetine (<b>3</b>, Eli Lilly), MRIs, thiazides, and loop diuretics, were initially discovered through empirical means, often using isolated tissues or in vivo models intended to mimic clinical conditions. The definitive characterization of their main mechanistic targets often came years, if not decades, after their approval. In the era of modern drug discovery equipped with advanced experimental technologies and a deeper understanding of human biology, approved drugs targeting SLCs, such as SGLT2 (SLC5A2) and URAT1 (SLC22A12), were discovered through target-centric approaches using a variety of screens discussed the previous section. However, unlike other commonly drugged protein classes (e.g., ion channels, kinases, GPCRs), nearly all SLC-targeting compounds have been discovered in the absence of any structural insight. Structural studies conducted with small molecules targeting SLCs (e.g., SLC6A4 and SLC29A1), were rather performed retroactively, to confirm the binding of lead compounds. This is perhaps not surprising considering 13 of the 14 published human SLC structures were published only in the last five years. Although structure-guided computational approaches, such as computer-aided drug discovery (CADD), have been recently been used to guide the development of SLC inhibitors, such approaches are limited due to a general lack of atomic-resolution structures and costructures.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> In the following sections, we survey prevalent examples and diverse chemotypes that have been described to target various SLC members and subfamilies, most of which are at preclinical stages of development. We have organized this discussion into six sections according to specific areas of therapeutic focus: amino acid neurotransmitter transporter inhibitors, monoamine neurotransmitter transporter inhibitors, glutamine transporter inhibitors, metabolite transporter inhibitors, ion exchange inhibitors, and targeting SLCs for viral infections. Most of these efforts were initiated through discovery efforts using one or more of the screening strategies described above, and notably, lead optimization was often pursued with little to no structural information.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25">6.1.  Amino Acid Type Neurotransmitter Transporter Inhibitors</h3><div class="NLM_p">Excitatory amino acid transporters (EAATs) belong to the SLC1 subfamily and include EAAT1 (SLC1A3), EAAT2 (SLC1A2), EAAT3 (SLC1A1), EAAT4 (SLC1A6), and EAAT5 (SLC1A7). Although EAATs have received considerable attention, most often driven by genetic manipulations, such approaches are limited in illuminating the dynamics of glutamate homeostasis in response to the acute disruption of uptake systems. Selective and potent EAAT inhibitors have been useful as tools for the elucidation of the physiological roles of distinct EAATs in glutamate accumulation, synaptic transmission, and animal behavior (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a><span class="smallcaps smallerCapital">dl</span>-<i>threo</i>-Î²-Benzyloxyaspartic acid derivatives with bulkier aryl-substituents, such as L-TFB-TBOA (<b>24</b>), were found to have enhanced potency toward EAAT1â3 (IC<sub>50</sub> value: EAAT1 = 22 nM, EAAT2 = 17 nM, EAAT3 = 300 nM) with relatively weak affinity toward NMDA receptors (IC<sub>50</sub> = 49 Î¼M). The behavior patterns induced by all TBOA analogues on mice were similar, including seizure activity, transient running-jumping, and loss of normal body posture, agreeing with the excitotoxicity effect caused by EAATs defect.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> Inspired by L-TFB-TBOA, more substrate analogues with bulky substituents were synthesized with varying selectivity and potency.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> WAY-213613 (<b>25</b>) was discovered to be a selective EAAT2 inhibitor (59- and 45-fold over EAAT1 and EAAT3).<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> A series of allosteric EAAT1-selective inhibitors with novel scaffolds were discovered by screening a library of 3040 compounds in an [<sup>3</sup>H]-aspartate cellular uptake assay. Optimization yielded UCPH-101 (<b>26</b>) with 0.66 Î¼M IC<sub>50</sub> in uptake assays,<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> which exhibited a noncompetitive and long-lasting EAAT1 inhibition through an allosteric binding mode confirmed later by structural studies.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Although in vivo administration of UCPH-102 (<b>27</b>), an analogue with improved bioavailability, did not cause significant effects in a rodent locomotor model, presumably due to compensatory activities by EAAT2<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. EAATs inhibitors. L-TFB-TBOA (<b>24</b>) targets SLC1A1/2/3, WAY-213613 (<b>25</b>) targets SLC1A2, UCPH-101 (<b>26</b>), and UCPH-102 (<b>27</b>) target SLC1A3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">EAAT1 inhibitors represent one of the few SLC inhibitor classes with structural information to provide insight into ligandâprotein interactions. In 2017, both the competitive SLC1 inhibitor TFB-TBOA (<b>24</b>) and noncompetitive inhibitor UCPH-101 were cocrystallized with human SLC1A3 (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> TFB-TBOA was found to occupy the substrate-binding pocket, precluding substrate loading and disrupting the functional conformation of extracellular gate HP2. Interestingly, UCPH-101 (<b>26</b>) was found to bind at a hydrophobic pocket 15 Ã away from the substrate binding site between the TranD and ScaD interface, resulting in the stabilization of the TranD and ScaD in the outward facing states, effectively blocking the âelevatorâ cross-membrane movement of TranD. Residues lining the allosteric pocket are less conserved between the SLC1 family members as those surrounding the substrate pocket engaged by TFB-TBOA. It was observed that M231 and F235 interact with the methoxy-phenyl ring and naphthalene ring of UCPH-101, which are residues unique to SLC1A3, likely explaining the high selectivity of UCPH-101 over other SLC1 subfamily members.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Human SLC1A3 bound with competitive inhibitor TFB-TBOA (magenta) at substrate pocket, and noncompetitive inhibitor UCPH-101 (yellow) at described allosteric pocket (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MJU">5MJU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Synaptic glycine levels are regulated by two sodium-dependent glycine transporters GlyT1 (SLC6A9) and GlyT2 (SLC6A5), which are related by â¼50% sequence homology. Antagonists of GlyT1 have been shown to elevate synaptic glycine concentrations, enhance NMDA receptor activity, and alleviate schizophrenia symptoms.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Potent GlyT1 inhibitors based on an endogenous GlyT1 inhibitor sarcosine (<b>28</b>) were discovered through a [<sup>3</sup>H]-glycine-based cellular uptake screening assay (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Analogues including ALX-5407<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> (IC<sub>50</sub> = 3 nM, <b>29</b>) and ORG-24598<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> (pIC<sub>50</sub> = 6.9, <b>30</b>) with hydrophobic sarcosine <i>N</i>-substituents exhibit potent GlyT1 inhibition and excellent selectivity over GlyT2. Additional sarcosine analogues targeting GlyT1, ORG-25935<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> (<b>31</b>), and AMG-747 (<b>32</b>),<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> developed by Merck and Amgen, respectively, have progressed to clinical trials for panic disorder, alcoholism, or schizophrenia. However, both compounds were halted at phase II for demonstrating little to no benefit over placebo. Nonsarcosine analogues have also been identified from [<sup>3</sup>H]-glycine-based cellular uptake<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> and competitive binding screens with radiolabeled GlyT1 ligand.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Among them, bitopertin (<b>33</b>), identified by Roche, advanced to phase III clinical trials but failed to provide a significant effect over placebo in patients with suboptimally controlled positive symptoms. Additional trials for other symptoms including Î²-thalassemia and obsessiveâcompulsive disorders were discontinued recently. After completion of phase I studies with validated safety and tolerability, Pfizerâs GlyT1 inhibitor PF-03463275 (<b>34</b>) is currently being examined for the treatment of cognitive impairment associated with schizophrenia based on its neuroplasticity enhancement effect.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Glycine transporter inhibitors. Sarcosine (<b>28</b>), ALX-5407 (<b>29</b>), ORG24598 (<b>30</b>), ORG-25935 (<b>31</b>), AMG-747 (<b>32</b>), Bitopertin (<b>33</b>), and PF-03463275 (<b>34</b>) target SLC6A9. ORG-25543 (<b>35</b>), and ALX-1393 (<b>36</b>) target SLC6A5. VVZ-149 (<b>37</b>) targets both SLC6A5 and 5HT2A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">GlyT2 has emerged as a promising candidate for the development of antichronic pain agents. Antagonists of GlyT2 can reduce uptake of glycine at glycinergic nerve terminals and enhance activation of the glycine receptor, followed by blockade of nociceptive neurotransmission.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Cellular [<sup>3</sup>H]glycine uptake screening assay led to the identification of a class of potent GlyT2 selective inhibitors and extensive optimization led to the development ORG-25543 (<b>35</b>) by Organon (now Merck), with an IC<sub>50</sub> of â¼16 nM and negligible activity on GlyT1.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Intravenous injection of <b>35</b> showed dose-dependent antiallodynic effect without a time lag. However, ORG-25543 did not advance into clinical trials, possibly due to high plasma protein binding and slow off-rates from its target.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> When administered intrathecally, another potent GlyT2 inhibitor ALX-1393 (<b>36</b>) exhibited antinociceptive effect on both the thermal and mechanical pain mice models,<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> however, poor bloodâbrain barrier penetration limited its further development.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><div class="NLM_p last">Despite the continued development of potent and selective GlyT1 inhibitors, they have yielded unsatisfactory clinical efficacy, likely due to their narrow therapeutic windows, complexity of target kinetics, and strong placebo response in schizophrenia patients. In contrast, GlyT2 inhibitors have received much less attention from industry and their ADME profiles need improvement. Despite these setbacks, the dual GlyT2 and 5HT2A inhibitor VVZ-149 (<b>37</b>, developed by Vivozon) has recently been granted fast track status by FDA and entered into phase III trials for the treatment of postoperative pain.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">6.2.  Glutamine Transport Inhibitors</h3><div class="NLM_p">ASCT2 (SLC1A5) is the primary transporter responsible for the uptake of neutral amino acids in many cell types. As mentioned above, many human cancers show dependency on glutamine, suggesting abrogation of glutamine metabolism as a potential therapeutic strategy.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Indeed, the glutamine synthase (GLS1) inhibitor CB-839 blocks the first step of glutamine catabolism (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>), and it is currently in phase II trials for the treatment of multiple cancer types. Although inhibition of glutamine catabolism has shown promise in early clinical trials, a limitation of this strategy is that targeting GLS1 does not fully address the additional roles of glutamine in cancer (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Glutamine-dependent tumors often have elevated ASCT2 levels and demonstrate dependency on glutamine import in in vivo models,<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> prompting the development of ASCT2 inhibitors. One of the most widely utilized investigatory inhibitors used to study ASCT2 biology has been the substrate inspired Î³-glutamyl-<i>p</i>-nitroanilide (GPNA, <b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>),<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> despite its weak potency (â¼1 mM IC<sub>50</sub>), and demonstrated lack of selectivity.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> Additional <i>N</i>-Î³-glutamylanilide analogues have been generated, with (<b>39</b>) showing modest activity (IC<sub>50</sub> = 312 Î¼M) in <sup>3</sup>H-glutamine uptake.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Exchanging the glutamylanilide scaffold to 2,4-diaminobutanoic acid, yielded a new series of 4-<i>N</i>-disubstited compounds with greatly enhanced activity.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> One analogue, V9302 (<b>40</b>, IC<sub>50</sub> = 9.6 Î¼M), demonstrated growth inhibition toward a variety of cancer cell lines, and its in vivo administration reduced glutamine uptake by approximately 50% in tumor xenografts and significantly reduced tumor size with chronic administration. Interestingly, in a recent study, V9302 was found to potentially engage two additional glutamine transporters from two different subfamilies, SNAT2 (SLC38A2) and LAT1 (SLC7A5), suggesting additional contributive or potentially alternative mechanisms responsible for its antitumorigenic effects.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Such studies highlight a cautionary reminder of the challenges associated with utilizing chemotypes structurally related to the endogenous substrates, as they may affect several functionally related SLCs. These investigations also represent the need to robustly characterize the selectivity of a given inhibitor toward functionally related SLC members, however, such characterization is often challenging due to the general lack of SLC substrate and functional assays. Additional ASCT2 inhibitors have been developed using in silico screening with an ASCT2 model constructed based on the structure of Glt<sub>ph</sub>. These studies have yielded mostly amino acid hits,<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> but they lend promise to the potential of using computational approaches for the development of SLC inhibitors.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Glutamine transporter inhibitors. GPNA (<b>38</b>) and compound <b>39</b> target SLC1A5. JPH203 (<b>41</b>) targets SLC7A5. V9302 (<b>40</b>) has been discovered to target multiple glutamine transporters, including SLC1A5, SLC7A5, and SLC38A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">JPH203 (<b>41</b>), an inhibitor of SLC7A5 (LAT1) dependent leucine uptake developed by J-Pharma, arrests thyroid tumor growth in mice and is currently in phase I clinical trials for the treatment of advanced solid tumors in patients with biliary tract cancer and colorectal cancer. Although the precise mechanism is yet elucidated, LAT1 is overexpressed in many human neoplasms and many tumors display a dependency on glutamine for proliferation. JPH203 is hypothesized to suspend tumor growth by blocking the uptake of leucine, a stimulator of the mTOR pathway, resulting in apoptosis.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">6.3.  Monoamine Transporter Inhibitors</h3><div class="NLM_p">Since the approval of imipramine, additional tricyclic antidepressants (TCAs) like clomipramine, nortriptyline, and amitriptyline, have been used clinically for various neurodisorders besides depression. Beyond their effects on SLC6A4 (SERT) and SLC6A2 (NET), TCAs manifest a complex pharmacological profile with antagonist or agonist activity toward a wide range of neuroreceptors and ion channels. These off-target effects make the pharmacological outcome and clinical safety of TCAs unpredictable, hence limiting their use and prompting the search for more selective antidepressants. After the initial discovery of serotoninâs role in depression, efforts led by Eli Lilly resulted in the first widely used serotonin reuptake inhibitor (SSRI) fluoxetine (<b>3</b>).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Compared to TCAs, fluoxetine exhibits high selectivity toward SERT over NET and other postsynaptic receptors.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Additional SSRIs, including paroxetine (<b>42</b>, GlaxoSmithKline), sertraline (<b>43,</b> Pfizer), citalopram (<b>44</b>, Lundbeck), and its (<i>S</i>)-enantiomer escitalopram (<b>45</b>, Lundbeck and Forest Laboratories) were approved as first-in-line treatment of depression due to similar effectiveness to TCAs and fewer adverse effects (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>).<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Representative MRIs. Paroxetine (<b>42</b>), sertraline (<b>43</b>), citalopram (<b>44</b>), and escitalopram (<b>45</b>) are SSRIs targeting SLC6A4. Venlafaxine (<b>46</b>), duloxetine (<b>47</b>), and levomilnacipran (<b>48</b>) are SNRIs targeting SLC6A2 and SLC6A4. Bupropion (<b>49</b>) is an NDRI targeting SLC6A2 and SLC6A3. Atomoxetine (<b>50</b>) is an NRI targeting SLC6A2. Vanoxerine (<b>51</b>) and modafinil (<b>52</b>) are DRIs targeting SLC6A3. Ansofaxine (<b>53</b>), centanafadine (<b>54</b>), and dasotraline (<b>55</b>) are TRIs targeting SLC6A2, SLC6A3, and SLC6A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to selective SSRIs, monoamine reuptake inhibitors with different target profiles including SNRIs (serotoninânorepinephrine reuptake inhibitors), NDRIs (norepinephrineâdopamine reuptake inhibitors), NRIs (norepinephrine reuptake inhibitors), DRIs (dopamine reuptake inhibitors), and TRIs (triple reuptake inhibitors) have been developed. Their transporter selectivity is typically evaluated in vitro by radioligand binding assays using membrane preparations of cells overexpressing either SERT, NET, or DAT (SLC6A3)<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> and in vivo by PET (positron emission tomography) imaging.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> SNRIs, such as venlafaxine (<b>46</b>, Wyeth), duloxetine (<b>47</b>, Eli Lilly), and levomilnacipran (<b>48</b>, Forest Laboratories and Pierre Fabre Group), selectively target NET and SERT with minimal or no interactions with other postsynaptic receptors.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> However, it still remains unclear as to whether SNRIs are more efficacious than SSRIs for major depression disorder (MDD) with only modest increase of response rate observed in clinical trials.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Levomilnacipran shows greater selectivity toward NET over SERT, and patients treated with it displayed functional improvement for work and social activities.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> NDRIs like bupropion (<b>49</b>, Burroughs Wellcome, now GSK) show minimal affinity toward SERT and other pre- and postsynaptic receptors. When used as a treatment for MDD, bupropion causes less sexual dysfunction, weight gain, and sedation compared to other antidepressants active for SERT.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> NRIs like atomoxetine (<b>50</b>, Eli Lilly) are used clinically to treat symptoms associated with ADHD (attention deficit hyperactivity disorder) and narcolepsy through their specific adrenergic neurotransmission activation.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a></div><div class="NLM_p">DRIs like vanoxerine (<b>51</b>, Laguna Pharmaceuticals) and modafinil (<b>52</b>, Cephalon) compete with cocaine for binding with DAT but do not produce the cocaine-like discriminative-stimulus and self-administration effects.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> With such promising activity, they have entered into clinical investigation for the treatment of cocaine dependence, although further mechanistic clarification of their atypical DAT inhibition is still needed.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> With the belief that dopamine may play a positive role in depression treatment, TRIs like ansofaxine (<b>53</b>, Luye Pharma Group), centanafadine (<b>54</b>, Euthymics Bioscience), and dasotraline (<b>55</b>, Sunovion) have entered into late-stage clinical trials for major depression disorder (MDD) and ADHD.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a></div><div class="NLM_p">Neurological disorders are accompanied by the complex and variable dysregulation of several monoamine neurotransmission. Hence patients tend to display distinct responses to antidepressants with different pharmacological profiles. With more than 30 antidepressants on the market displaying inhibitory activity toward the SLC6 monoamine transporter SERT, NET, and DAT, clinicians have tended to adopt a stepwise treatment plan with SSRIs as the first option, then switching to other types of antidepressants like SNRIs, TCAs, or MAOiâs (monoamine oxidase inhibitors) if patientsâ initial responses were not satisfactory. On the basis of recent resolved human SERT structures,<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> most SSRIs bind the central pocket and competitively block the entry of serotonin. Their bulky size leads to the arrest of SERT at the outward-facing conformation and subsequent obstruction of the âgated-poreâ transition required for substrate transport.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition to this central pocket, there is also an allosteric pocket located at the extracellular vestibule above the central substrate pocket (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> Allosteric binding of (<i>S</i>)-citalopram (<b>45</b>) prevents release of the additional inhibitors from central pocket by slowing their off-rate. At the central pocket, three subsites, A, B, and C, were revealed for (<i>S</i>)-citalopram. At subsite A, the tertiary amine forms a hydrogen bond with D98 and cationâÏ interaction with Y95. The fluorophenyl group engages subsite B through hydrophobic interaction with Y176 and I172. At subsite C, F341 and F335 form aromatic interactions with the cyanophthalane group. The conformational flexibility of these residues allows the binding of other SSRIs including paroxetine, sertraline, fluoxetine, and fluvoxamine to the central pocket with varied geometry and affinity.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Crystal structure of human SLC6A4 bound by two molecules of (<i>S</i>)-citalopram at the central (bottom inset) and allosteric (top inset) pockets (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73">5I73</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tetrabenazine (<b>56</b>) was developed in the 1950s by Hoffmann-La Roche as an analogue of reserpine (<b>9</b>), an approved (United Kingdom, 1971; United States, 2008) drug for the treatment of chorea symptoms associated with Huntingtonâs disease (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Despite its usage, the direct target(s) of tetrabenazine were not characterized until the biochemical characterization of VMAT2 (SLC18A2) in the 1990s.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> Tetrabenazine was found to bind VMAT2 at a different site from reserpine, and it noncompetitively inhibited the release of dopamine into the synaptic cleft.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> To increase the metabolic stability of tetrabenazine, the two methoxy groups were replaced with trideuteromethoxy groups to generate deutetrabenazine (<b>57</b>, Teva), which displays a slower oxidative metabolism and a prolonged half-life in vivo. Deutetrabenazine was approved by the FDA for treatment of chorea symptoms of Huntingtonâs disease and tardive dyskinesia (TD) with high tolerability and a wider therapeutic window.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Both tetrabenazine and deutetrabenazine are administered as racemates, and more stereoisomers are generated after reduction of the ketone groups by carbonyl reductase. All four possible stereoisomers were synthesized and (<i>R</i>,<i>R</i>,<i>R</i>)-dihydrotetrabenazine was found to possess the highest affinity (<i>K</i><sub>i</sub> = 4.2 nM) and selectivity toward VMAT2; however, the hydroxy group limits the intestinal absorption of this active metabolite. To mask this hydroxy group, a series of ester-based prodrugs were synthesized and valbenazine (<b>10</b>, Neurocrine Biosciences) was identified with prolonged in vivo half-life and metabolic stability. Valbenazine was approved in 2017 by FDA for the treatment of TD in adults, and its slow-releasing feature allows once-a-day dosing.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Lobeline (<b>58</b>) is an alkaloidal natural product isolated from <i>Lobelia inflata</i>, was found to be a potent VMAT2 inhibitor.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> Lobeline shares the same substrate pocket with reserpine and shows therapeutic potential for the treatment of psychostimulant abuse by inhibiting the dopamine rewarding effect.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. VMAT2 inhibitors. Tetrabenazine (<b>56</b>) and deutetrabenazine (<b>57</b>) target SLC18A2 at the site different from reserpine. Lobeline (<b>58</b>) shares the binding pocket with reserpine at SLC18A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">6.4.  Glucose Transporter Inhibitors</h3><div class="NLM_p">Phlorizin, a natural product isolated from the bark of apple trees, was found in the in 1930s to increase urinary glucose excretion when administered in humans.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> In vivo mouse studies revealed that phlorizin corrects hyperglycemia caused by pancreatectomy through inhibition of SGLT2 (SLC5A2) (IC<sub>50</sub> = 160 nM).<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> Initial attempts to make derivatives of phlorizin focused on the <i>O</i>-glycosidic scaffold (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). Replacement of the dihydrochalcone group with other aromatic building blocks yielded derivatives with potent and selective SGLT2 inhibition, including T1095 (<b>59</b>, Tanabe Seiyaku), sergliflozin (<b>60</b>, Kissei Pharmaceutical), and remogliflozin (<b>61</b>, Kissei Pharmaceutical). These compounds show better in vivo efficacy and metabolic stability than phlorizin, but they are prone to in vivo degradation by Î²-glycosidases.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> Thus, numerous pharmaceutical companies have switched to the development of analogues with the stable <i>C</i>-glycoside scaffold, which has yielded several molecules approved by the FDA or in Japan, for the treatment of type 2 diabetes, such as dapagliflozin (<b>62</b>, Bristol-Myers Squibb), canagliflozin (<b>1</b>, Tanabe Seiyaku), empagliflozin (<b>63</b>, Boehringer Ingelheim), and ipragliflozin (<b>64</b>, Astellas and Kotobuki).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Recently, the SGLT1/2 dual inhibitor sotagliflozin (<b>65</b>, Lexicon Pharmaceuticals) was approved in Europe for the treatment of adult type 1 diabetes.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. SGLT1/2 inhibitors. T1095 (<b>59</b>), sergliflozin (<b>60</b>), and remogliflozin (<b>61</b>) are <i>O</i>-glycosides targeting SLC5A2. Dapagliflozin (<b>62</b>), empagliflozin (<b>63</b>), and ipragliflozin (<b>64</b>) are <i>C</i>-glycosides targeting SLC5A2. Sotagliflozin (<b>65</b>) is a <i>C</i>-glycoside targeting SLC5A1/2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">GLUT1 (SLC2A1) is overexpressed in many types of human cancers to meet the increased demand of glucose for ATP production and central biosynthetic intermediates.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Many GLUT1 inhibitors have been identified through functional screens based on ATP production, a direct consequence of increased glucose import (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>).<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> For example, a recent 3 million compound screen and several rounds of structureâactivity relationship (SAR) studies conducted by Bayer, yielded BAY-876 (<b>66</b>), a compound which displays a 2 nM IC<sub>50</sub> toward GLUT1 and is >100-fold more selective over other GLUT isoforms. When evaluated in ovarian cancer cell lines, BAY-876 suppressed glycolysis and proliferation. Oral administration of BAY-876 inhibits tumor growth in a patient-derived xenograft model.<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a> Using a similar screening assay, additional GLUT1 inhibitors with novel scaffolds were developed by Bayer.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Facilitative glucose transporter inhibitors. BAY-876 (<b>66</b>) and GLUT-i1 (<b>67</b>) both target SLC2A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The glucose transport inhibitor GLUT-i1 (<b>67</b>) was cocrystallized with human SLC2A1 in the inward-facing conformation, and its binding pose overlaps well with the substrate analogue Î²-nonylglucoside (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Interestingly, the geometry of residues surrounding the glucose moiety are nearly unchanged upon binding the 5-fluorophenyl ring of GLUT-i1. Unlike glucose, which is much smaller and only contacts with residues from the C-terminal domain, the bulkier GLUT-i1 makes broader contact with residues across both C-terminal and N-terminal domains, effectively blocking the ârocker-switchâ rotations required for the transport cycle, and locking SLC2A1 in the inward-facing conformation.</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Comparison of SLC2A1 binding poses between substrate analogue Î²-nonylglucoside (tan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PYP">4PYP</a>) and inhibitor GLUTi1 (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EQG">5EQG</a>)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29">6.5.  Ion Exchanger Inhibitors</h3><div class="NLM_p">NHE1 (SLC9A1) is a ubiquitously expressed sodiumâhydrogen exchanger and is responsible for the regulation of cell volume and intracellular pH. NHE1 is the major NHE isoform in myocardial tissue, and it plays a central role in ischemia/reperfusion injury and cardiac hypertrophy.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> The Na<sup>+</sup>/H<sup>+</sup> exchange mediated by NHE1 was found to be sensitive to the compound amiloride (<b>68</b>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Latter analogues also containing the acyl-guanidine group were prepared and evaluated for NHE1 inhibition, which was observed as the prohibition of pH recovery in PS120 fibroblast cells expressing human NHE1.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Additionally, real-time detection of intracellular pH changes was enabled by the pH-sensitive fluorescent dye, BCECF-AM, and radioactive <sup>22</sup>Na<sup>+</sup> uptake assays were usually carried out to confirm inhibition. Using this strategy, several potent NHE1 inhibitors, including sabiporide (<b>69</b>, Boehringer Ingelheim), zoniporide (<b>70</b>, Pfizer), cariporide (<b>71</b>, Aventis), and eniporide (<b>72</b>, Merck), were discovered with significant cardioprotective effects on a variety of animal models.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> However, these drug candidates failed clinical trials due to either lack of efficacy or serious side effects.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> Besides cardioprotective effects, NHE1 inhibitors have also been reported to disrupt the alkaline intracellular pH of breast cancer cells and prevent their metastasis.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Similar screening strategies have been applied to the discovery of inhibitors, for NHE3, which is expressed in the apical region of enterocytes and acts as the major sodium uptake transporter in intestines.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> A potent NHE3 inhibitor tenapanor (<b>6</b>), developed by Ardelyx Inc., strongly inhibits sodium uptake in the gastrointestinal tract and was clinically approved to treat symptoms associated with sodium management (e.g., chronic kidney disease and hypertension).<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. NHE1 inhibitors. Amiloride (<b>68</b>), sabiporide (<b>69</b>), zoniporide (<b>70</b>), cariporide (<b>71</b>), and eniporide (<b>72</b>) target SLC9A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">6.6.  Metabolite Transporter Inhibitors</h3><div class="NLM_p">The ileal bile acid transporter (IBAT, SLC10A2) is a bile acid/Na<sup>+</sup> symporter mainly located in the terminal ileum and mediates the uptake of bile acid into enterohepatic circulation.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Pharmacological inhibition of IBAT first attracted the interest of academia and industry because of its plasma LDL lowering effect. Using 2164U90 (<b>73</b>) as a lead, a series of substituted benzothiazepines were synthesized and evaluated for their IBAT inhibition using [<sup>14</sup>C]taurocholate cellular uptake assays (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). Several analogues were discovered with greatly enhanced in vitro activity (IC<sub>50</sub> < 10 nM), which also significantly decreased fecal bile acid.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> Because inhibition of IBAT took place at the luminal side of the intestine, compound modifications were made to minimize their absorption and systemic exposure. Charged and polar IBAT inhibitors, represented by SC-435 (<b>74</b>), maintained good efficacy both in vitro and in vivo, and were minimally excreted in bile.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> In animal models, SC-435 decreased bile acidâs return to liver and caused compensatory upregulation of bile acid synthesis. SC-435 has also has shown protection against nonalcoholic fatty liver disease in high-fat diet-fed mice through transcriptional regulation of metabolic genes.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> There are several benzothiazepine analogues in clinical trials including GSK2330672 (<b>75</b>), elobixibat (<b>18</b>, Albireo Pharma), and A4250 (<b>76</b>). Elobixibat has advanced to phase III clinical trials for the treatment of chronic idiopathic constipation.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> A4250 has recently been designated as an orphan drug and is now undergoing phase III clinical trials for children with progressive familial intrahepatic cholestasis. GSK2330672 is in phase II clinical trials for the treatment of pruritus in patients with primary biliary cholangitis.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. IBAT inhibitors. 2164U90 (<b>73</b>), SC-435 (<b>74</b>), GSK2330672 (<b>75</b>), and A4250 (<b>76</b>) target SLC10A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Urea transporters UT-A (SLC14A2) and UT-B (SLC14A1) exhibit channel-like properties and facilitate the permeation of urea across the cell membrane. Urea is of equal importance to salt in order to maintain osmolarity during the concentration of urine in renal tubules. Thus, urea transporter inhibitors have been pursued as diuretics (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>).<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> In a recent high-throughput screen with â¼100000 compounds based on cell morphology changes, two new classes of UT-B inhibitors were discovered. A UT-B specific inhibitor UTB<sub>inh</sub>-14 (<b>77</b>) was found with potent activities for both human (IC<sub>50</sub> = 10.3 nM) and rodent (IC<sub>50</sub> = 25.1 nM) UT-B. After follow-up SAR studies, an analogue (<b>78</b>) of UTB<sub>inh</sub>-14 was discovered with similar potency and higher metabolic stability.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Inspired by UT-B inhibitor discovery, Verkman et al. performed a fluorescence-based HTS screening for UT-A1 inhibitors using a compound library of â¼150000 small molecules, and follow-up SAR optimization yielded a potent UT-A1 inhibitor (<b>79</b>, IC<sub>50</sub> = 150 nM) with modest inhibition against UT-B (IC<sub>50</sub> â¼ 2 Î¼M). Administration of a metabolically stable analogue to rats induced significant diuresis effects.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Urea transporter inhibitors. UTB<sub>inh</sub>-14 (<b>77</b>) and its analogue <b>78</b> target SLC14A1. Compound <b>79</b> targets SLC14A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Uric acid is filtered at the glomerulus from blood, and â¼90% is reabsorbed back into blood from the proximal tubule region through URAT1 (SLC22A12), an anion-exchanging uric acid transporter localized to the apical membrane of renal tubular cells.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Several uricosuric agents, including probenecid (<b>11</b>, Pfizer) and benzbromarone (<b>80</b>), have been used prior to the identification of URAT1 (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> However, probenecidâs clinical application was limited due to its low efficacy and significant drugâdrug interaction. Benzbromarone, although more potent toward URAT1 (IC<sub>50</sub> < 0.1 Î¼M), displayed high hepatic toxicity, leading to its withdrawal from Europe in 2003. During the clinical trials of a nonrelated nonnucleoside reverse transcriptase inhibitor REDA806 (Ardea Biosciences, now AstraZeneca), hypouricemic side effects were observed. Subsequently, its metabolite lesinurad (<b>12</b>) was found to be a potent inhibitor for URAT1 (IC<sub>50</sub> = 3.53 Î¼M) as well as OAT4 (IC<sub>50</sub> = 2.03 Î¼M) using a [<sup>14</sup>C]-urate cellular uptake assay.<a onclick="showRef(event, 'ref239'); return false;" href="javascript:void(0);" class="ref ref239">(218)</a> Adverse drugâdrug interactions were greatly reduced for lesinurad compared to probenecid. The combined administration of lesinurad and a xanthine oxidase inhibitor was approved in 2015 by the FDA for the treatment of hyperuricemia associated with gout. Since then, more potent URAT1 inhibitors have been discovered. Verinurad (<b>81</b>, Ardea Biosciences), a lesinurad analogue, demonstrated a significant improvement in potency with an IC<sub>50</sub> of 25 nM in a substrate uptake assay, which is approximately 200-fold stronger than OAT1 and OAT4.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> On the basis of results from phase II clinical trials, verinurad led to the rapid reduction of hyperuricemia when combined with febuxostat.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(219)</a> UR-1102 (<b>82</b> or URC102, Chugai and JW Pharmaceuticals), a benzbromarone analogue now in phase II clinical trials for gout patients, maintains strong inhibition toward URAT1 in vitro as well as decreased uric acid levels in vivo.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. URAT1 inhibitors. Benzbromarone (<b>80</b>) targets SLC22A12 but also potently inhibits CYP2C9. Verinurad (<b>81</b>) and UR-1102 (<b>82</b>) target SLC22A12 selectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31">6.7.  Targeting SLCs for Viral Infection</h3><div class="NLM_p">During a phenotypic screen to identify compounds that block Ebola virus infection, <b>83</b> (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>) was found to prevent the entry of vesicular stomatitis virus particles pseudotyped with EboV Zaire glycoprotein (EboV GP).<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(220)</a> The formation of cholesterol-avid filipin for HeLa cells after treatment with <b>83</b> implied a protein involved in cholesterol metabolism could be a functional target. SiRNA knockdown experiments confirmed that EboV GP-mediated infection is dependent on NiemannâPick C1 (NPC1, SLC65A1), a membrane protein that resides in late endosomes and lysosomes and mediates trafficking of cholesterol liberated from low-density lipoprotein.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(221)</a> Immunoprecipitation using truncated recombinant EboV GPs enriched NPC1, confirming their interaction. A photoaffinity probe (<b>84</b>) analogue further confirmed that NPC1 is the direct target of <b>83</b> and subsequent optimization yielded compounds with increased potency and better pharmacokinetics.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(222)</a> Interestingly, target deconvolution studies of another cholesterol trafficking inhibitor U18666A (<b>85</b>) with its photo-cross-linking analogue (<b>86</b>) also revealed NPC1 as a target.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(223)</a></div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. SLC inhibitors and probes for viral infection. Compound <b>83</b>, and its photo-cross-linking analogue <b>84</b>, targets SLC65A1. U18666A (<b>85</b>), and its photo-cross-linking analogue <b>86</b> target SLC65A1 at a different domain. Cyclic peptide (<b>87</b>) and vanitaracin A (<b>88</b>) target SLC10A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to its physiological role of bile acid uptake on the basolateral membrane of hepatocytes, the sodium taurocholate cotransporting polypeptide (NTCP, SLC10A1) has also been shown to be a receptor for both hepatitis B (HBV) and hepatitis D (HDV) entry via interaction with the virus envelope protein.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(224)</a> Recently, an affinity screen against immobilized NTCP was performed to identify compounds which might block viral entry. Using large libraries (>10<sup>12</sup>) of cyclic peptides, macrocyclic peptide <b>87</b> was found to bind to NTCP and inhibit both HBV and HDV infections without inhibiting NTCP transport function.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(225)</a> In another study, a fungus-derived secondary metabolite-based library was screened for NTCP-mediated inhibition of HBV entry, resulting in the discovery of a novel tricyclic polyketide, vanitaracin A (<b>88</b>), which inhibits both HBV and hepatitis D (HDV) infection.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(226)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">7.  Looking Forward</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02673" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02673" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Solute carrier proteins mediate the transport and supply of vital molecules that regulate nearly all facets of cell function. SLCs can have broad as well as distinct expression profiles, reflecting both their general housekeeping functions and their tissue-specific roles with specialized functions. Given their essential roles in physiology, SLCs are strongly linked to numerous human disorders, and nearly all SLC members have genetic variants or mutations correlated with severe diseases, such as neurodevelopmental and psychiatric disorders, diabetes, and cancer (<a href="http://www.ncbi.nlm.nih.gov/omim" class="extLink">www.ncbi.nlm.nih.gov/omim</a>). However, currently only 13 SLC classes are specifically targeted by approved drugs. In addition to serving as âgatekeepersâ to the molecules of life, SLCs also often play pivotal roles in the absorption, distribution, and toxicity of drugs by mediating their transport across membranes and often representing undesired off-targets for drugs. Despite their importance, our understanding of this protein superfamily remains underdeveloped, having received significantly less attention from the research community compared to other protein families of similar stature.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This is evidenced by the large number, approximately 30%, of SLCs with completely unknown functions or substrates,<a onclick="showRef(event, 'ref2 ref8'); return false;" href="javascript:void(0);" class="ref ref2 ref8">(2,8)</a> relatively few available chemical tools (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>), and the limited number of human SLC three-dimensional structures.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Contributive to this paucity are inherent technical challenges posed by SLCs. One of the most significant obstacles is their complex integral membrane topography, which often requires an intact membrane to maintain native functional characteristics. Difficulties in the expression and purification of SLCs in native state limits the use of traditional HTS approaches and common in vitro biochemical investigations to annotate substrate scope, measure transport rates, and examine the effects of various perturbagens (e.g., mutations, PTMs, allosteric ligands, etc.) on transport. Although proteoliposomes have proven useful for various investigations, the artificial reconstitution of multipass transmembrane proteins do not always yield functional states reflective of their endogenous function. Structural investigations are also hindered, as they are often resolved in detergent solutions, which may not properly mimic native membranes. Prokaryotic homology models have contributed substantially to our understanding of SLC structure; however, their mammalian cousins are often more complex and decorated with PTMs, such as glycosylation, which are not properly mimicked in bacterial structures. In addition, most available structures generally have lower resolution (â¼3.5 A) and few exist in multiple conformations or with substrates or drugs bound.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> These hurdles are only amplified by the genetic and structural diversity of the SLC family, hampering the development of general models that can be used as templates for broader structural and functional characterization. Cell- and animal-based models for SLC investigations can similarly be challenging. Although useful to investigate SLC contributions in more complex systems, genetic perturbations, whether it be gain- or loss-of-function studies, can be complicated by overlapping specificities, compensatory mechanisms, and toxicity, limiting studies to only a subset of SLCs and sometimes obscuring the relative contribution of a transporter to the studied function or phenotype.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Such complexities emphasize the need for high-quality, selective chemical probes against SLC targets to assist in their biochemical and functional characterization. Chemical probes offer the advantage,<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(227)</a> over genetic approaches, the ability to produce reversible and graded gains or losses in protein activity, and in some instances, neofunctional outcomes.<a onclick="showRef(event, 'ref227 ref228'); return false;" href="javascript:void(0);" class="ref ref227 ref228">(228,229)</a> Further, chemical probes can be used in complex, native environments, features particularly useful for SLC investigations. However, as highlighted here and by others,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> there is a deficiency in useful chemical probes targeting SLCs. Additionally, as we note in the above sections, many of the existing chemical probes targeting SLCs require high concentrations and lack selectivity, decreasing their utility to precisely interrogate SLC biology. Many probes commonly used to study SLC function are low molecular weight and possess structurally simple core chemotypes resembling substrates. For example, GPNA (<b>38</b>), a glutamate derivative, has been widely used to study the glutamate transporter SLC1A5 (ASCT2). Because of its low affinity, it is often used at millimolar concentrations, and, perhaps not surprisingly, has been shown to functionally modulate other SLC members.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(230)</a> Given the few chemical tools available for this superfamily, many of which likely are nonselective, we believe a challenge to the drug discovery community is the exploration of more advanced chemotypes as well as the implementation of assays and platforms to better assess SLC selectivity.</div><div class="NLM_p">Ideal screening technologies would not only enable the measurement of target engagement in native settings, but also the assessment of SLC selectivity. In this regard, we believe the recent developments of MS-based ligand discovery platforms will prove enabling.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Chemical proteomic-based methods, in theory, provide assessment of endogenous SLC ligand occupancy, site of ligand engagement, and selectivity directly in lysates or whole cells. For example, our recent integration of FBLD with quantitative proteomics could prove broadly useful for the discovery of initial lead-like molecules for SLC chemical probe development as well as determining druggable sites on SLC proteins.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Further, the incorporation of multiplexed quantitation methods (e.g., tandem mass tagging<a onclick="showRef(event, 'ref230 ref231'); return false;" href="javascript:void(0);" class="ref ref230 ref231">(231,232)</a>) substantially accelerates proteomic ligand screening, which could increase the throughput of MS-based SLC screens.<a onclick="showRef(event, 'ref232 ref233'); return false;" href="javascript:void(0);" class="ref ref232 ref233">(233,234)</a> CETSA has also been used to measure SLC engagement by drugs and substrates in physiological settings<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> and can be integrated with MS-based proteomics for proteome-wide thermal profiling.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> The development and more routine implementation of robust genome-wide loss- and gain-of-function screens will lead to the discovery of new SLC functions and potentially unrealized roles in human disease. For example, recent genome-wide CRISPR screens identified the folate transporter SLC19A1 as a potential importer of cGAMP, a stimulator of the STING pathway.<a onclick="showRef(event, 'ref234 ref235'); return false;" href="javascript:void(0);" class="ref ref234 ref235">(235,236)</a> In another recent example, an SLC-focused CRISPR screen identified sialic acid transporter SLC35A1 and zinc transporter SLC30A1 as host factors that play opposing roles during cytolytic vesicular stomatitis virus (VSV) infection.<a onclick="showRef(event, 'ref236'); return false;" href="javascript:void(0);" class="ref ref236">(237)</a> We also anticipate that advances in MS-based metabolomic profiling technologies will aide in the profiling of endogenous transport substrates and provide global metabolic portraits of SLC regulated processes.<a onclick="showRef(event, 'ref237'); return false;" href="javascript:void(0);" class="ref ref237">(238)</a> Lastly, recent advances in cryo-EM, serial femtosecond crystallography, nanodisc crystallography, and high throughput protocol screening will have substantial impact on the structural elucidation of SLCs. Advances in cryo-EM are already making an impact: of the 10 human SLC structures deposited in the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB) in the last two years, seven were generated by cryo-EM.</div><div class="NLM_p">Parallel to technical advancements, there is also renewed interest in SLCs from both academia and industry. For example, since the beginning of 2018, there have been seven new human SLC structures, prior to which there were only seven. In addition, the multinational consortium RESOLUTE (<a href="https://re-solute.eu" class="extLink">https://re-solute.eu</a>) was established in Europe in 2018, composed of 13 organizations from academia and industry with the overarching goal of broadly characterizing the SLC family and to generate reliable reagents and models to investigate SLCs. Moreover, there is increased recognition of the therapeutic potential of the SLC family from the pharmaceutical industry, evident by the launch of Jnana Therapeutics Inc. (<a href="https://www.jnanatx.com" class="extLink">https://www.jnanatx.com</a>), the first company to focus mainly on drugging SLCs.</div><div class="NLM_p last">This is a thrilling time for SLC research. Members of the SLC family pose unique challenges compared to other commonly drugged protein classes. However, we anticipate that new and enabling technologies, as well as increased recognition of their importance, will bring about significant advances in the ability to develop safe and selective SLC-targeting therapies over the next decades.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">8.  Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Human gene quantitation for solute carrier family (SLCs), nonolfactory G-protein coupled receptors (GPCRs-NOs), nuclear receptor (NRs), ion channels, and ATP binding cassette (ABC) transporters were obtained from HUGO gene nomenclature committee. Human gene quantitation for kinases were obtained from an updated human kinome database produced by Gerard Manningâs lab at Genentech, Inc (<a href="http://kinase.com/web/current/kinbase/browser/SpeciesID/9606" class="extLink">http://kinase.com/web/current/kinbase/browser/SpeciesID/9606</a>).<a onclick="showRef(event, 'ref240'); return false;" href="javascript:void(0);" class="ref ref240">(239)</a> Human protease gene quantitation was obtained from the manually curated and annotated degradome database produced by LopezâOtin laboratory (<a href="http://degradome.uniovi.es/numbers.html" class="extLink">http://degradome.uniovi.es/numbers.html</a>).<a onclick="showRef(event, 'ref241'); return false;" href="javascript:void(0);" class="ref ref241">(240)</a> Compounds associated with SLCs were extracted from the ChEMBL database (<a href="https://www.ebi.ac.uk/chembl/" class="extLink">https://www.ebi.ac.uk/chembl/</a>; 05/15/2019), a manually curated database of bioactive molecules with drug-like properties. Compounds were required to have at least one of the following associated values: IC<sub>50</sub>, inhibition potency, activation potency, AC<sub>50</sub>, EC<sub>50</sub>, AC<sub>50</sub>, <i>K</i><sub>i</sub>, binding <i>K</i><sub>d</sub>, or transporting efficiency. Resultant compounds were filtered to contain only single human proteins with transporter activity and subsequently manually reviewed. Molecular graphics and analyses of PDBs performed with UCSF Chimera, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco, with support from NIH P41-GM103311.<a onclick="showRef(event, 'ref238'); return false;" href="javascript:void(0);" class="ref ref238">(241)</a></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01237" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23236" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23236" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher G. Parker</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8509-9289" title="Orcid link">http://orcid.org/0000-0001-8509-9289</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b3d0c3d2c1d8d6c1f3c0d0c1dac3c3c09dd6d7c6"><span class="__cf_email__" data-cfemail="a6c5d6c7d4cdc3d4e6d5c5d4cfd6d6d588c3c2d3">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wesley Wei Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leandro Gallo</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Appaso Jadhav</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Hawkins</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, The Scripps Research Institute, Jupiter, Florida 33458, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35562" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35562" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Wesley Wei Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=BIO-d7e2527-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wesley Wei Wang</b> received his Bachelorâs and Masterâs degree from Peking University Health Science Center under the supervision of Dr. Runtao Li. He obtained his Ph.D. in Chemistry from Texas A & M University under the supervision of Dr. Wenshe Liu. Currently, he is a postdoctoral research associate under the supervision of Prof. Christopher Parker in the Department of Chemistry at The Scripps Research Institute. His research focuses on designing new chemical probes to modulate cellular post-translational modifications.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Leandro Gallo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=BIO-d7e2532-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Leandro Gallo</b> attended Hunter College in the City University of New York. After earning his Bachelorâs degree in Biological Sciences, he proceeded to pursue a doctoral degree in Chemistry under the mentorship of Dr. Daniel J. Donoghue at the University of California, San Diego. His graduate studies encompassed understanding the function of activation mutations in the kinase domain of IKKbeta. Currently, he is a postdoctoral research associate under the supervision of Prof. Christopher Parker in the Department of Chemistry at The Scripps Research Institute.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Appaso Jadhav</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=BIO-d7e2537-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Appaso Jadhav</b> received his masterâs degree in organic chemistry from the Pune University, India (2006), and Ph.D. in chemistry from National Tsing Hua University, Taiwan (2013), under the mentorship of Prof. Rai-Shung Liu. Subsequently, he held a postdoctoral position at The Ohio State University. Currently, he is working as a postdoctoral research associate at The Scripps Research Institute under the mentorship of Prof. Christopher Parker.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Richard Hawkins</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=BIO-d7e2542-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Richard Hawkins</b> earned his B.Sc. in Animal Science from Purdue University (2007). Since 2009, he has worked as a Research Assistant at The Scripps Research Institute in the departments of Molecular Medicine and Chemistry.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Christopher G. Parker</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=BIO-d7e2547-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher G. Parker</b> is an Assistant Professor in the Department of Chemistry at The Scripps Research Institute. He earned his B.Sc. in Chemistry from Case Western Reserve University (2007) and a Ph.D. in Chemistry from Yale University (2013), under the supervision of David A. Spiegel, and then carried out postdoctoral studies under the supervision of Benjamin F. Cravatt as a fellow of the American Cancer Society. His group works on developing and applying chemical proteomic methods to discover useful chemical probes to investigate SLC members and other protein targets.</p></figure></div><div class="ack" id="ACK-d7e2523-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Andre Leon for useful discussions. Financial support from Scripps Research is gratefully acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">LAT</td><td class="NLM_def"><p class="first last">large neutral amino acid transporter</p></td></tr><tr><td class="NLM_term">MFS</td><td class="NLM_def"><p class="first last">major facilitator superfamily</p></td></tr><tr><td class="NLM_term">XylE</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">d</span>-xylose-proton symporter</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane helix</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">LeuT</td><td class="NLM_def"><p class="first last">bacterial leucine transporter</p></td></tr><tr><td class="NLM_term">GltPh</td><td class="NLM_def"><p class="first last"><i>Pyrococcus horikoshii</i> glutamate transporter</p></td></tr><tr><td class="NLM_term">GLUT</td><td class="NLM_def"><p class="first last">facilitated hexose transporter</p></td></tr><tr><td class="NLM_term">SGLT</td><td class="NLM_def"><p class="first last">sodiumâglucose cotransporter</p></td></tr><tr><td class="NLM_term">EAAT</td><td class="NLM_def"><p class="first last">excitatory amino acid transporter</p></td></tr><tr><td class="NLM_term">vGLUT</td><td class="NLM_def"><p class="first last">vesicular glutamate transporter</p></td></tr><tr><td class="NLM_term">UCP</td><td class="NLM_def"><p class="first last">uncoupling protein</p></td></tr><tr><td class="NLM_term">GS</td><td class="NLM_def"><p class="first last">glutamine synthetase</p></td></tr><tr><td class="NLM_term">SNAT</td><td class="NLM_def"><p class="first last">sodium-coupled neutral amino acid transporter</p></td></tr><tr><td class="NLM_term">GLS</td><td class="NLM_def"><p class="first last">glutaminase</p></td></tr><tr><td class="NLM_term">CAT</td><td class="NLM_def"><p class="first last">cationic amino acid transporter</p></td></tr><tr><td class="NLM_term">gpaAT</td><td class="NLM_def"><p class="first last">glycoprotein-associated amino acid transporters</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">heteromeric amino acid transporter</p></td></tr><tr><td class="NLM_term">NTT</td><td class="NLM_def"><p class="first last">neurotransmitter transporter</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last">Î³-aminobutyric acid</p></td></tr><tr><td class="NLM_term">GlyT</td><td class="NLM_def"><p class="first last">glycine transporter</p></td></tr><tr><td class="NLM_term">MPP<sup>+</sup></td><td class="NLM_def"><p class="first last">1-methyl-4-phenylpyridinium</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartic acid</p></td></tr><tr><td class="NLM_term">ATB<sup>0+</sup></td><td class="NLM_def"><p class="first last">amino acid transporter B0<sup>+</sup></p></td></tr><tr><td class="NLM_term">PROT</td><td class="NLM_def"><p class="first last"><span class="smallcaps smallerCapital">l</span>-proline transporter</p></td></tr><tr><td class="NLM_term">GAT</td><td class="NLM_def"><p class="first last">Î³-aminobutyric acid transporter</p></td></tr><tr><td class="NLM_term">BGT</td><td class="NLM_def"><p class="first last">betaineâGABA transporter</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">LCFA</td><td class="NLM_def"><p class="first last">long chain fatty acids</p></td></tr><tr><td class="NLM_term">IMM</td><td class="NLM_def"><p class="first last">inner mitochondria membrane</p></td></tr><tr><td class="NLM_term">ZnT</td><td class="NLM_def"><p class="first last">zinc transporter protein</p></td></tr><tr><td class="NLM_term">ZIP</td><td class="NLM_def"><p class="first last">zrt/irt-like protein</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">monoamine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">DRBA</td><td class="NLM_def"><p class="first last">dopamine receptor blocking agents</p></td></tr><tr><td class="NLM_term">MCPHA</td><td class="NLM_def"><p class="first last">Amish lethal microcephaly</p></td></tr><tr><td class="NLM_term">KGDH</td><td class="NLM_def"><p class="first last">Î±-ketoglutarate dehydrogenase</p></td></tr><tr><td class="NLM_term">NRF-2</td><td class="NLM_def"><p class="first last">nuclear factor erythroid 2-related factor 2</p></td></tr><tr><td class="NLM_term">ASCT</td><td class="NLM_def"><p class="first last">alanine serine cysteine transporter 2</p></td></tr><tr><td class="NLM_term">4F2hc</td><td class="NLM_def"><p class="first last">4F2 cell-surface antigen heavy chain</p></td></tr><tr><td class="NLM_term">xCT</td><td class="NLM_def"><p class="first last">cysteine/glutamate transporter</p></td></tr><tr><td class="NLM_term">Trx</td><td class="NLM_def"><p class="first last">thioredoxin</p></td></tr><tr><td class="NLM_term">TR</td><td class="NLM_def"><p class="first last">thioredoxin reductase</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">monocarboxylate transporter</p></td></tr><tr><td class="NLM_term">P4HA</td><td class="NLM_def"><p class="first last">prolyl 4-hydroxylase subunit alpha 1</p></td></tr><tr><td class="NLM_term">BRAF</td><td class="NLM_def"><p class="first last">B-raf proto-oncogene, serine/threonine kinase</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">Toll-like receptor</p></td></tr><tr><td class="NLM_term">NOD</td><td class="NLM_def"><p class="first last">nucleotide binding oligomerization domain containing 1</p></td></tr><tr><td class="NLM_term">SNRI</td><td class="NLM_def"><p class="first last">serotoninânorepinephrine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">OAT</td><td class="NLM_def"><p class="first last">organic anion transporter</p></td></tr><tr><td class="NLM_term">URAT</td><td class="NLM_def"><p class="first last">urate anion exchanger</p></td></tr><tr><td class="NLM_term">ENT</td><td class="NLM_def"><p class="first last">equilibrative nucleoside transporter</p></td></tr><tr><td class="NLM_term">ANT</td><td class="NLM_def"><p class="first last">adenine nucleotide translocator</p></td></tr><tr><td class="NLM_term">CETSA</td><td class="NLM_def"><p class="first last">cellular thermal shift assay</p></td></tr><tr><td class="NLM_term">FFF</td><td class="NLM_def"><p class="first last">fully functionalized fragment</p></td></tr><tr><td class="NLM_term">FBLD</td><td class="NLM_def"><p class="first last">fragment-based ligand discovery</p></td></tr><tr><td class="NLM_term">DRI</td><td class="NLM_def"><p class="first last">dopamine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">NACT</td><td class="NLM_def"><p class="first last">sodium-dependent citrate transporter</p></td></tr><tr><td class="NLM_term">CHT</td><td class="NLM_def"><p class="first last">hemicholinium-3-sensitive choline transporter</p></td></tr><tr><td class="NLM_term">VMAT</td><td class="NLM_def"><p class="first last">vesicular amine transporter</p></td></tr><tr><td class="NLM_term">NHE</td><td class="NLM_def"><p class="first last">sodium/hydrogen exchanger</p></td></tr><tr><td class="NLM_term">NCC</td><td class="NLM_def"><p class="first last">NaâCl cotransporter</p></td></tr><tr><td class="NLM_term">cGAS</td><td class="NLM_def"><p class="first last">cyclic GMP-AMP synthase</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 241 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shima, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apeltsin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span> <span> </span><span class="NLM_article-title">Comparison of human solute carriers</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">412</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1002/pro.320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fpro.320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20052679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=412-428&issue=3&author=A.+Schlessingerauthor=P.+Matssonauthor=J.+E.+Shimaauthor=U.+Pieperauthor=S.+W.+Yeeauthor=L.+Kellyauthor=L.+Apeltsinauthor=R.+M.+Stroudauthor=T.+E.+Ferrinauthor=K.+M.+Giacominiauthor=A.+Sali&title=Comparison+of+human+solute+carriers&doi=10.1002%2Fpro.320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of human solute carriers</span></div><div class="casAuthors">Schlessinger, Avner; Matsson, Paer; Shima, James E.; Pieper, Ursula; Yee, Sook Wah; Kelly, Libusha; Apeltsin, Leonard; Stroud, Robert M.; Ferrin, Thomas E.; Giacomini, Kathleen M.; Sali, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-428</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Solute carriers are eukaryotic membrane proteins that control the uptake and efflux of solutes, including essential cellular compds., environmental toxins, and therapeutic drugs.  Solute carriers can share similar structural features despite weak sequence similarities.  Identification of sequence relationships among solute carriers is needed to enhance our ability to model individual carriers and to elucidate the mol. mechanisms of their substrate specificity and transport.  Here, we describe a comprehensive comparison of solute carriers.  We link the proteins using sensitive profile-profile alignments and two classification approaches, including similarity networks.  The clusters are analyzed in view of substrate type, transport mode, organism conservation, and tissue specificity.  Solute carrier families with similar substrates generally cluster together, despite exhibiting relatively weak sequence similarities.  In contrast, some families cluster together with no apparent reason, revealing unexplored relationships.  We demonstrate computationally and exptl. the functional overlap between representative members of these families.  Finally, we identify four putative solute carriers in the human genome.  The solute carriers include a biomedically important group of membrane proteins that is diverse in sequence and structure.  The proposed classification of solute carriers, combined with expt., reveals new relationships among the individual families and identifies new solute carriers.  The classification scheme will inform future attempts directed at modeling the structures of the solute carriers, a prerequisite for describing the substrate specificities of the individual families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDKLcThSY89rVg90H21EOLACvtfcHk0lhngq5Y6-6WyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhurc%253D&md5=3a19c72447ca4f6bfada62c80e5c8fad</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fpro.320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.320%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DShima%26aufirst%3DJ.%2BE.%26aulast%3DPieper%26aufirst%3DU.%26aulast%3DYee%26aufirst%3DS.%2BW.%26aulast%3DKelly%26aufirst%3DL.%26aulast%3DApeltsin%26aufirst%3DL.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DComparison%2520of%2520human%2520solute%2520carriers%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26issue%3D3%26spage%3D412%26epage%3D428%26doi%3D10.1002%2Fpro.320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesar-Razquin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frappier-Brinton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isserlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyimesi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reithmeier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">A call for systematic research on solute carriers</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">478</span>â <span class="NLM_lpage">487</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2015.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2015.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26232220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jsr%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=478-487&issue=3&author=A.+Cesar-Razquinauthor=B.+Snijderauthor=T.+Frappier-Brintonauthor=R.+Isserlinauthor=G.+Gyimesiauthor=X.+Baiauthor=R.+A.+Reithmeierauthor=D.+Hepworthauthor=M.+A.+Hedigerauthor=A.+M.+Edwardsauthor=G.+Superti-Furga&title=A+call+for+systematic+research+on+solute+carriers&doi=10.1016%2Fj.cell.2015.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A Call for Systematic Research on Solute Carriers</span></div><div class="casAuthors">Cesar-Razquin, Adrian; Snijder, Berend; Frappier-Brinton, Tristan; Isserlin, Ruth; Gyimesi, Gergely; Bai, Xiaoyun; Reithmeier, Reinhart A.; Hepworth, David; Hediger, Matthias A.; Edwards, Aled M.; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">478-487</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Solute carrier (SLC) membrane transport proteins control essential physiol. functions, including nutrient uptake, ion transport, and waste removal.  SLCs interact with several important drugs, and a quarter of the more than 400 SLC genes are assocd. with human diseases.  Yet, compared to other gene families of similar stature, SLCs are relatively understudied.  The time is right for a systematic attack on SLC structure, specificity, and function, taking into account kinship and expression, as well as the dependencies that arise from the common metabolic space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowMgFKDGzGgrVg90H21EOLACvtfcHk0lgunGPi4gVCFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jsr%252FP&md5=d159e524e5f2b713a1c512ffe633050e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DCesar-Razquin%26aufirst%3DA.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DFrappier-Brinton%26aufirst%3DT.%26aulast%3DIsserlin%26aufirst%3DR.%26aulast%3DGyimesi%26aufirst%3DG.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DReithmeier%26aufirst%3DR.%2BA.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DA%2520call%2520for%2520systematic%2520research%2520on%2520solute%2520carriers%26jtitle%3DCell%26date%3D2015%26volume%3D162%26issue%3D3%26spage%3D478%26epage%3D487%26doi%3D10.1016%2Fj.cell.2015.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span> <span> </span><span class="NLM_article-title">SLC transporters as therapeutic targets: emerging opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">560</span>, <span class="refDoi">Â DOI: 10.1038/nrd4626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd4626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26111766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=543-560&issue=8&author=L.+Linauthor=S.+W.+Yeeauthor=R.+B.+Kimauthor=K.+M.+Giacomini&title=SLC+transporters+as+therapeutic+targets%3A+emerging+opportunities&doi=10.1038%2Fnrd4626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">SLC transporters as therapeutic targets: emerging opportunities</span></div><div class="casAuthors">Lin, Lawrence; Yee, Sook Wah; Kim, Richard B.; Giacomini, Kathleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">543-560</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Solute carrier (SLC) transporters - a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biol. membranes - have important roles in physiol. processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics.  Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities.  This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx70dg86WE57Vg90H21EOLACvtfcHk0lgunGPi4gVCFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7nJ&md5=559132670a520a0dcccb1d858436599d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd4626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4626%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DYee%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26atitle%3DSLC%2520transporters%2520as%2520therapeutic%2520targets%253A%2520emerging%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D543%26epage%3D560%26doi%3D10.1038%2Fnrd4626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanaga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruford, E. A.</span></span> <span> </span><span class="NLM_article-title">The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins</span>. <i>Pfluegers Arch.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">465</span>â <span class="NLM_lpage">468</span>, <span class="refDoi">Â DOI: 10.1007/s00424-003-1192-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00424-003-1192-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=14624363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVygt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2004&pages=465-468&issue=5&author=M.+A.+Hedigerauthor=M.+F.+Romeroauthor=J.+B.+Pengauthor=A.+Rolfsauthor=H.+Takanagaauthor=E.+A.+Bruford&title=The+ABCs+of+solute+carriers%3A+physiological%2C+pathological+and+therapeutic+implications+of+human+membrane+transport+proteins&doi=10.1007%2Fs00424-003-1192-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins Introduction</span></div><div class="casAuthors">Hediger, Matthias A.; Romero, Michael F.; Peng, Ji-Bin; Rolfs, Andreas; Takanaga, Hitomi; Bruford, Elspeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Pfluegers Archiv</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">465-468</span>CODEN:
                <span class="NLM_cas:coden">PFLABK</span>;
        ISSN:<span class="NLM_cas:issn">0031-6768</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The Human Genome Organization (HUGO) Nomenclature Committee Database provides a list of transporter families of the solute carrier (SLC) gene series.  Currently, it includes 43 families and 298 transporter genes.  This special issue features mini-reviews on each of these SLC families written by the experts in each field.  A WEB site has been established that gives the latest updates for the SLC families and their members as well as relevant links to gene databases and reviews in the literature.  A list of all currently known SLC families, a discussion of addnl. SLC families and family members as well as a brief summary of non-SLC transporter genes is included in this introduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWvcPuX4WTrVg90H21EOLACvtfcHk0lgunGPi4gVCFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVygt70%253D&md5=7d979e32b9216f988ca3e2292078b5f8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs00424-003-1192-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00424-003-1192-y%26sid%3Dliteratum%253Aachs%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DRomero%26aufirst%3DM.%2BF.%26aulast%3DPeng%26aufirst%3DJ.%2BB.%26aulast%3DRolfs%26aufirst%3DA.%26aulast%3DTakanaga%26aufirst%3DH.%26aulast%3DBruford%26aufirst%3DE.%2BA.%26atitle%3DThe%2520ABCs%2520of%2520solute%2520carriers%253A%2520physiological%252C%2520pathological%2520and%2520therapeutic%2520implications%2520of%2520human%2520membrane%2520transport%2520proteins%26jtitle%3DPfluegers%2520Arch.%26date%3D2004%26volume%3D447%26issue%3D5%26spage%3D465%26epage%3D468%26doi%3D10.1007%2Fs00424-003-1192-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruford, E. A.</span></span> <span> </span><span class="NLM_article-title">A review of the new HGNC gene family resource</span>. <i>Hum. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi">Â DOI: 10.1186/s40246-016-0062-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1186%2Fs40246-016-0062-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26842383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslGktbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=6&author=K.+A.+Grayauthor=R.+L.+Sealauthor=S.+Tweedieauthor=M.+W.+Wrightauthor=E.+A.+Bruford&title=A+review+of+the+new+HGNC+gene+family+resource&doi=10.1186%2Fs40246-016-0062-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the new HGNC gene family resource</span></div><div class="casAuthors">Gray, Kristian A.; Seal, Ruth L.; Tweedie, Susan; Wright, Mathew W.; Bruford, Elspeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Genomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6/1-6/9</span>CODEN:
                <span class="NLM_cas:coden">HGUEAT</span>;
        ISSN:<span class="NLM_cas:issn">1479-7364</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The HUGO Gene Nomenclature Committee (HGNC) approves unique gene symbols and names for human loci.  As well as naming genomic loci, we manually curate genes into family sets based on shared characteristics such as function, homol. or phenotype.  Each HGNC gene family has its own dedicated gene family report on our website, www.genenames.org.  We have recently redesigned these reports to support the visualisation and browsing of complex relationships between families and to provide extra curated information such as family descriptions, protein domain graphics and gene family aliases.  Here, we review how our gene families are curated and explain how to view, search and download the gene family data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3ujrY83-hBLVg90H21EOLACvtfcHk0lgunGPi4gVCFg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslGktbY%253D&md5=26da6deb0cb573a9b2c0dadaa676df0d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs40246-016-0062-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40246-016-0062-6%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DK.%2BA.%26aulast%3DSeal%26aufirst%3DR.%2BL.%26aulast%3DTweedie%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DM.%2BW.%26aulast%3DBruford%26aufirst%3DE.%2BA.%26atitle%3DA%2520review%2520of%2520the%2520new%2520HGNC%2520gene%2520family%2520resource%26jtitle%3DHum.%2520Genomics%26date%3D2016%26volume%3D10%26spage%3D6%26doi%3D10.1186%2Fs40246-016-0062-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span> <span> </span><span class="NLM_article-title">Classification systems of secondary active transporters</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">305</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tips.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27939446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOis7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=305-315&issue=3&author=E.+Perlandauthor=R.+Fredriksson&title=Classification+systems+of+secondary+active+transporters&doi=10.1016%2Fj.tips.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Classification Systems of Secondary Active Transporters</span></div><div class="casAuthors">Perland, Emelie; Fredriksson, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-315</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Membrane-bound solute carrier (SLC) transporter proteins are vital to the human body, as they sustain homeostasis by moving sol. mol. as nutrients, drugs, and waste across lipid membranes.  Of the 430 identified secondary active transporters in humans, 30% are still orphans, and systematic research has been requested to elaborate on their possible involvement in diseases and their potential as drug targets.  To enable this, the various classification systems in use must be understood and used correctly.  In this review, we describe how various classification systems for human SLCs are constructed, and how they overlap and differ.  To facilitate communication between researchers and to avoid ambiguities, everyone must clearly state which classification system they are referring to when writing scientific articles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozhvKcW7vAPrVg90H21EOLACvtfcHk0ljWefcXjIbbsQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOis7rP&md5=e77548a64c08700c00b586821bc0e1b9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DPerland%26aufirst%3DE.%26aulast%3DFredriksson%26aufirst%3DR.%26atitle%3DClassification%2520systems%2520of%2520secondary%2520active%2520transporters%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26issue%3D3%26spage%3D305%26epage%3D315%26doi%3D10.1016%2Fj.tips.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordstrom, K. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span> <span> </span><span class="NLM_article-title">The solute carrier families have a remarkably long evolutionary history with the majority of the human families present before divergence of bilaterian species</span>. <i>Mol. Biol. Evol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1531</span>â <span class="NLM_lpage">1541</span>, <span class="refDoi">Â DOI: 10.1093/molbev/msq350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Fmolbev%2Fmsq350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21186191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ntlCksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=1531-1541&issue=4&author=P.+J.+Hoglundauthor=K.+J.+V.+Nordstromauthor=H.+B.+Schiothauthor=R.+Fredriksson&title=The+solute+carrier+families+have+a+remarkably+long+evolutionary+history+with+the+majority+of+the+human+families+present+before+divergence+of+bilaterian+species&doi=10.1093%2Fmolbev%2Fmsq350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The solute carrier families have a remarkably long evolutionary history with the majority of the human families present before divergence of Bilaterian species</span></div><div class="casAuthors">Hoglund Par J; Nordstrom Karl J V; Schioth Helgi B; Fredriksson Robert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology and evolution</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1531-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Solute Carriers (SLCs) are membrane proteins that regulate transport of many types of substances over the cell membrane.  The SLCs are found in at least 46 gene families in the human genome.  Here, we performed the first evolutionary analysis of the entire SLC family based on whole genome sequences.  We systematically mined and analyzed the genomes of 17 species to identify SLC genes.  In all, we identified 4,813 SLC sequences in these genomes, and we delineated the evolutionary history of each of the subgroups.  Moreover, we also identified ten new human sequences not previously classified as SLCs, which most likely belong to the SLC family.  We found that 43 of the 46 SLC families found in Homo sapiens were also found in Caenorhabditis elegans, whereas 42 of them were also found in insects.  Mammals have a higher number of SLC genes in most families, perhaps reflecting important roles for these in central nervous system functions.  This study provides a systematic analysis of the evolutionary history of the SLC families in Eukaryotes showing that the SLC superfamily is ancient with multiple branches that were present before early divergence of Bilateria.  The results provide foundation for overall classification of SLC genes and are valuable for annotation and prediction of substrates for the many SLCs that have not been tested in experimental transport assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiyBhdq98sQT0O18WR3iAofW6udTcc2eatGacAxVCY0rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ntlCksA%253D%253D&md5=7b48e5f85d54d5d23b9dd5c37bc737f9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fmolbev%2Fmsq350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmolbev%252Fmsq350%26sid%3Dliteratum%253Aachs%26aulast%3DHoglund%26aufirst%3DP.%2BJ.%26aulast%3DNordstrom%26aufirst%3DK.%2BJ.%2BV.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26aulast%3DFredriksson%26aufirst%3DR.%26atitle%3DThe%2520solute%2520carrier%2520families%2520have%2520a%2520remarkably%2520long%2520evolutionary%2520history%2520with%2520the%2520majority%2520of%2520the%2520human%2520families%2520present%2520before%2520divergence%2520of%2520bilaterian%2520species%26jtitle%3DMol.%2520Biol.%2520Evol.%26date%3D2011%26volume%3D28%26issue%3D4%26spage%3D1531%26epage%3D1541%26doi%3D10.1093%2Fmolbev%2Fmsq350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemencon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrier, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruford, E. A.</span></span> <span> </span><span class="NLM_article-title">The ABCs of membrane transporters in health and disease (SLC series): introduction</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">95</span>â <span class="NLM_lpage">107</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=95-107&issue=2%E2%80%933&author=M.+A.+Hedigerauthor=B.+Clemenconauthor=R.+E.+Burrierauthor=E.+A.+Bruford&title=The+ABCs+of+membrane+transporters+in+health+and+disease+%28SLC+series%29%3A+introduction&doi=10.1016%2Fj.mam.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ABCs of membrane transporters in health and disease (SLC series): Introduction</span></div><div class="casAuthors">Hediger, Matthias A.; Clemencon, Benjamin; Burrier, Robert E.; Bruford, Elspeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">95-107</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The field of transport biol. has steadily grown over the past decade and is now recognized as playing an important role in manifestation and treatment of disease.  The SLC (solute carrier) gene series has grown to now include 52 families and 395 transporter genes in the human genome.  A list of these genes can be found at the HUGO Gene Nomenclature Committee (HGNC) website (see www.genenames.org/genefamilies/SLC).  This special issue features mini-reviews for each of these SLC families written by the experts in each field.  The existing online resource for solute carriers, the Bioparadigms SLC Tables (www.bioparadigms.org), has been updated and significantly extended with addnl. information and cross-links to other relevant databases, and the nomenclature used in this database has been validated and approved by the HGNC.  In addn., the Bioparadigms SLC Tables functionality has been improved to allow easier access by the scientific community.  This introduction includes: an overview of all known SLC and "non-SLC" transporter genes; a list of transporters of water sol. vitamins; a summary of recent progress in the structure detn. of transporters (including GLUT1/SLC2A1); roles of transporters in human diseases and roles in drug approval and pharmaceutical perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK0fRstQGk7bVg90H21EOLACvtfcHk0lig2hSFEL4oPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyktrk%253D&md5=5d559fd0aba51c721ec45abd5893d1eb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DClemencon%26aufirst%3DB.%26aulast%3DBurrier%26aufirst%3DR.%2BE.%26aulast%3DBruford%26aufirst%3DE.%2BA.%26atitle%3DThe%2520ABCs%2520of%2520membrane%2520transporters%2520in%2520health%2520and%2520disease%2520%2528SLC%2520series%2529%253A%2520introduction%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D95%26epage%3D107%26doi%3D10.1016%2Fj.mam.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial transporters of the SLC25 family and associated diseases: a review</span>. <i>J. Inherited Metab. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">565</span>â <span class="NLM_lpage">575</span>, <span class="refDoi">Â DOI: 10.1007/s10545-014-9708-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs10545-014-9708-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24797559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVamu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=565-575&issue=4&author=F.+Palmieri&title=Mitochondrial+transporters+of+the+SLC25+family+and+associated+diseases%3A+a+review&doi=10.1007%2Fs10545-014-9708-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial transporters of the SLC25 family and associated diseases: a review</span></div><div class="casAuthors">Palmieri, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inherited Metabolic Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">565-575</span>CODEN:
                <span class="NLM_cas:coden">JIMDDP</span>;
        ISSN:<span class="NLM_cas:issn">0141-8955</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  To date, 14 inherited diseases (including phenotypes) assocd. to mitochondrial transporters of the SLC25 family have been well characterized biochem. and genetically.  They are rare metabolic disorders caused by mutations in the SLC25 nuclear genes that encode mitochondrial carriers, a superfamily of 53 proteins in humans that shuttle a variety of solutes across the mitochondrial membrane.  Mitochondrial carriers vary considerably in the nature and size of the substrates they transport, the modes of transport and driving forces.  However, their substrate translocation mechanism at the mol. level is thought to be basically the same.  Herein, the main structural and functional properties of the SLC25 mitochondrial carriers and the known carrier-related diseases are presented.  Two of these disorders, ADP/ATP carrier deficiency and phosphate carrier deficiency, are caused by defects of the two mitochondrial carriers that provide mitochondria with ADP and phosphate, the substrates of oxidative phosphorylation; these disorders therefore are characterized by defective energy prodn. by mitochondria.  The mutations of SLC25 carrier genes involved in other cellular functions cause carnitine/acylcarnitine carrier deficiency, HHH syndrome, aspartate/glutamate isoform 1 and 2 deficiencies, congenital Amish microcephaly, neuropathy with bilateral striatal necrosis, congenital sideroblastic anemia, neonatal epileptic encephalopathy, and citrate carrier deficiency; these disorders are characterized by specific metabolic dysfunctions depending on the role of the defective carrier in intermediary metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXEveYUSt9-rVg90H21EOLACvtfcHk0lig2hSFEL4oPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVamu7w%253D&md5=76c20c20b5ad26c8f1d2de1e626336e7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs10545-014-9708-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10545-014-9708-5%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DF.%26atitle%3DMitochondrial%2520transporters%2520of%2520the%2520SLC25%2520family%2520and%2520associated%2520diseases%253A%2520a%2520review%26jtitle%3DJ.%2520Inherited%2520Metab.%2520Dis.%26date%3D2014%26volume%3D37%26issue%3D4%26spage%3D565%26epage%3D575%26doi%3D10.1007%2Fs10545-014-9708-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Structure of the human LAT1â4F2hc heteromeric amino acid transporter complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>568</i></span> (<span class="NLM_issue">7750</span>),  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-1011-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-1011-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30867591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslKhurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=568&publication_year=2019&pages=127-130&issue=7750&author=R.+Yanauthor=X.+Zhaoauthor=J.+Leiauthor=Q.+Zhou&title=Structure+of+the+human+LAT1%E2%80%934F2hc+heteromeric+amino+acid+transporter+complex&doi=10.1038%2Fs41586-019-1011-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex</span></div><div class="casAuthors">Yan, Renhong; Zhao, Xin; Lei, Jianlin; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">568</span>
        (<span class="NLM_cas:issue">7750</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The L-type amino acid transporter 1 (LAT1; also known as SLC7A5) catalyzes the cross-membrane flux of large neutral amino acids in a sodium- and pH-independent manner.  LAT1, an antiporter of the amino acid-polyamine-organocation superfamily, also catalyzes the permeation of thyroid hormones, pharmaceutical drugs, and hormone precursors such as L-3,4-dihydroxyphenylalanine across membranes.  Overexpression of LAT1 has been obsd. in a wide range of tumor cells, and it is thus a potential target for anti-cancer drugs.  LAT1 forms a heteromeric amino acid transporter complex with 4F2 cell-surface antigen heavy chain (4F2hc; also known as SLC3A2)-a type II membrane glycoprotein that is essential for the stability of LAT1 and for its localization to the plasma membrane.  Despite extensive cell-based characterization of the LAT1-4F2hc complex and structural detn. of its homologs in bacteria, the interactions between LAT1 and 4F2hc and the working mechanism of the complex remain largely unknown.  Here we report the cryo-electron microscopy structures of human LAT1-4F2hc alone and in complex with the inhibitor 2-amino-2-norbornanecarboxylic acid at resolns. of 3.3 Ã and 3.5 Ã, resp.  LAT1 exhibits an inward open conformation.  Besides a disulfide bond assocn., LAT1 also interacts extensively with 4F2hc on the extracellular side, within the membrane, and on the intracellular side.  Biochem. anal. reveals that 4F2hc is essential for the transport activity of the complex.  Together, our characterizations shed light on the architecture of the LAT1-4F2hc complex, and provide insights into its function and the mechanisms through which it might be assocd. with disease.  LAT1 transporter complex 4F2hc human structure drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdBX0ZuozAAbVg90H21EOLACvtfcHk0lig2hSFEL4oPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslKhurc%253D&md5=21f3bbb22441cd49666914a98a3852b3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1011-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1011-z%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLei%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DStructure%2520of%2520the%2520human%2520LAT1%25E2%2580%25934F2hc%2520heteromeric%2520amino%2520acid%2520transporter%2520complex%26jtitle%3DNature%26date%3D2019%26volume%3D568%26issue%3D7750%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fs41586-019-1011-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajkhorshid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>569</i></span> (<span class="NLM_issue">7754</span>),  <span class="NLM_fpage">141</span>â <span class="NLM_lpage">145</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-1135-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-1135-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31019304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVSkurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=569&publication_year=2019&pages=141-145&issue=7754&author=J.+A.+Colemanauthor=D.+Yangauthor=Z.+Zhaoauthor=P.+C.+Wenauthor=C.+Yoshiokaauthor=E.+Tajkhorshidauthor=E.+Gouaux&title=Serotonin+transporter-ibogaine+complexes+illuminate+mechanisms+of+inhibition+and+transport&doi=10.1038%2Fs41586-019-1135-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport</span></div><div class="casAuthors">Coleman, Jonathan A.; Yang, Dongxue; Zhao, Zhiyu; Wen, Po-Chao; Yoshioka, Craig; Tajkhorshid, Emad; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">569</span>
        (<span class="NLM_cas:issue">7754</span>),
    <span class="NLM_cas:pages">141-145</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) regulates neurotransmitter homeostasis through the sodium- and chloride-dependent recycling of serotonin into presynaptic neurons1-3.  Major depression and anxiety disorders are treated using selective serotonin reuptake inhibitors-small mols. that competitively block substrate binding and thereby prolong neurotransmitter action2,4.  The dopamine and noradrenaline transporters, together with SERT, are members of the neurotransmitter sodium symporter (NSS) family.  The transport activities of NSSs can be inhibited or modulated by cocaine and amphetamines2,3, and genetic variants of NSSs are assocd. with several neuropsychiatric disorders including attention deficit hyperactivity disorder, autism and bipolar disorder2,5.  Studies of bacterial NSS homologues-including LeuT-have shown how their transmembrane helixes (TMs) undergo conformational changes during the transport cycle, exposing a central binding site to either side of the membrane1,6-12.  However, the conformational changes assocd. with transport in NSSs remain unknown.  To elucidate structure-based mechanisms for transport in SERT we investigated its complexes with ibogaine, a hallucinogenic natural product with psychoactive and anti-addictive properties13,14.  Notably, ibogaine is a non-competitive inhibitor of transport but displays competitive binding towards selective serotonin reuptake inhibitors15,16.  Here we report cryo-electron microscopy structures of SERT-ibogaine complexes captured in outward-open, occluded and inward-open conformations.  Ibogaine binds to the central binding site, and closure of the extracellular gate largely involves movements of TMs 1b and 6a.  Opening of the intracellular gate involves a hinge-like movement of TM1a and the partial unwinding of TM5, which together create a permeation pathway that enables substrate and ion diffusion to the cytoplasm.  These structures define the structural rearrangements that occur from the outward-open to inward-open conformations, and provide insight into the mechanism of neurotransmitter transport and ibogaine inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGl4bcGBU7V7Vg90H21EOLACvtfcHk0lig2hSFEL4oPg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVSkurw%253D&md5=c149b8cf3358fdbb655f9cd260d54a6a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1135-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1135-1%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWen%26aufirst%3DP.%2BC.%26aulast%3DYoshioka%26aufirst%3DC.%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DSerotonin%2520transporter-ibogaine%2520complexes%2520illuminate%2520mechanisms%2520of%2520inhibition%2520and%2520transport%26jtitle%3DNature%26date%3D2019%26volume%3D569%26issue%3D7754%26spage%3D141%26epage%3D145%26doi%3D10.1038%2Fs41586-019-1135-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garaeva, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oostergetel, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guskov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slotboom, D. J.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human neutral amino acid transporter ASCT2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">515</span>â <span class="NLM_lpage">521</span>, <span class="refDoi">Â DOI: 10.1038/s41594-018-0076-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-018-0076-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29872227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=515-521&issue=6&author=A.+A.+Garaevaauthor=G.+T.+Oostergetelauthor=C.+Gatiauthor=A.+Guskovauthor=C.+Paulinoauthor=D.+J.+Slotboom&title=Cryo-EM+structure+of+the+human+neutral+amino+acid+transporter+ASCT2&doi=10.1038%2Fs41594-018-0076-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the human neutral amino acid transporter ASCT2</span></div><div class="casAuthors">Garaeva, Alisa A.; Oostergetel, Gert T.; Gati, Cornelius; Guskov, Albert; Paulino, Cristina; Slotboom, Dirk J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">515-521</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Human ASCT2 belongs to the SLC1 family of secondary transporters and is specific for the transport of small neutral amino acids.  ASCT2 is upregulated in cancer cells and serves as the receptor for many retroviruses; hence, it has importance as a potential drug target.  Here we used single-particle cryo-EM to det. a structure of the functional and unmodified human ASCT2 at 3.85-Ã resoln.  ASCT2 forms a homotrimeric complex in which each subunit contains a transport and a scaffold domain.  Prominent extracellular extensions on the scaffold domain form the predicted docking site for retroviruses.  Relative to structures of other SLC1 members, ASCT2 is in the most extreme inward-oriented state, with the transport domain largely detached from the central scaffold domain on the cytoplasmic side.  This domain detachment may be required for substrate binding and release on the intracellular side of the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeHykepTMB2rVg90H21EOLACvtfcHk0lg0VbhJQR5OuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fN&md5=c175f3ea45ca21f1b31e930497c4e7e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0076-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0076-y%26sid%3Dliteratum%253Aachs%26aulast%3DGaraeva%26aufirst%3DA.%2BA.%26aulast%3DOostergetel%26aufirst%3DG.%2BT.%26aulast%3DGati%26aufirst%3DC.%26aulast%3DGuskov%26aufirst%3DA.%26aulast%3DPaulino%26aufirst%3DC.%26aulast%3DSlotboom%26aufirst%3DD.%2BJ.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520neutral%2520amino%2520acid%2520transporter%2520ASCT2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D6%26spage%3D515%26epage%3D521%26doi%3D10.1038%2Fs41594-018-0076-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abuladze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsirulnikov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pushkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, I.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human SLC4A4 sodium-coupled acid-base transporter NBCe1</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">900</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-03271-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41467-018-03271-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29500354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrnt1Kjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=900&author=K.+W.+Huynhauthor=J.+Jiangauthor=N.+Abuladzeauthor=K.+Tsirulnikovauthor=L.+Kaoauthor=X.+Shaoauthor=D.+Newmanauthor=R.+Azimovauthor=A.+Pushkinauthor=Z.+H.+Zhouauthor=I.+Kurtz&title=Cryo-EM+structure+of+the+human+SLC4A4+sodium-coupled+acid-base+transporter+NBCe1&doi=10.1038%2Fs41467-018-03271-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CryoEM structure of the human SLC4A4 sodium-coupled acid-base transporter NBCe1</span></div><div class="casAuthors">Huynh Kevin W; Abuladze Natalia; Tsirulnikov Kirill; Kao Liyo; Newman Debra; Azimov Rustam; Pushkin Alexander; Kurtz Ira; Huynh Kevin W; Jiang Jiansen; Zhou Z Hong; Jiang Jiansen; Zhou Z Hong; Shao Xuesi; Kurtz Ira</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">900</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Na(+)-coupled acid-base transporters play essential roles in human biology.  Their dysfunction has been linked to cancer, heart, and brain disease.  High-resolution structures of mammalian Na(+)-coupled acid-base transporters are not available.  The sodium-bicarbonate cotransporter NBCe1 functions in multiple organs and its mutations cause blindness, abnormal growth and blood chemistry, migraines, and impaired cognitive function.  Here, we have determined the structure of the membrane domain dimer of human NBCe1 at 3.9 ÃA resolution by cryo electron microscopy.  Our atomic model and functional mutagenesis revealed the ion accessibility pathway and the ion coordination site, the latter containing residues involved in human disease-causing mutations.  We identified a small number of residues within the ion coordination site whose modification transformed NBCe1 into an anion exchanger.  Our data suggest that symporters and exchangers utilize comparable transport machinery and that subtle differences in their substrate-binding regions have very significant effects on their transport mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPzHSE9LOK2cRAV4D_Ins_fW6udTcc2ebYBv68_ZIkn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrnt1Kjtg%253D%253D&md5=0f48a91d16682563ab6692f503ea5f7f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03271-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03271-3%26sid%3Dliteratum%253Aachs%26aulast%3DHuynh%26aufirst%3DK.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DAbuladze%26aufirst%3DN.%26aulast%3DTsirulnikov%26aufirst%3DK.%26aulast%3DKao%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DNewman%26aufirst%3DD.%26aulast%3DAzimov%26aufirst%3DR.%26aulast%3DPushkin%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DZ.%2BH.%26aulast%3DKurtz%26aufirst%3DI.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520SLC4A4%2520sodium-coupled%2520acid-base%2520transporter%2520NBCe1%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D900%26doi%3D10.1038%2Fs41467-018-03271-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garaeva, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guskov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slotboom, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulino, C.</span></span> <span> </span><span class="NLM_article-title">A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3427</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-11363-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41467-019-11363-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31366933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3MvjsVensg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=3427&author=A.+A.+Garaevaauthor=A.+Guskovauthor=D.+J.+Slotboomauthor=C.+Paulino&title=A+one-gate+elevator+mechanism+for+the+human+neutral+amino+acid+transporter+ASCT2&doi=10.1038%2Fs41467-019-11363-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2</span></div><div class="casAuthors">Garaeva Alisa A; Slotboom Dirk J; Paulino Cristina; Guskov Albert; Paulino Cristina; Slotboom Dirk J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3427</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human Alanine Serine Cysteine Transporter 2 (ASCT2) is a neutral amino acid exchanger that belongs to the solute carrier family 1 (SLC1A).  SLC1A structures have revealed an elevator-type mechanism, in which the substrate is translocated across the cell membrane by a large displacement of the transport domain, whereas a small movement of hairpin 2 (HP2) gates the extracellular access to the substrate-binding site.  However, it has remained unclear how substrate binding and release is gated on the cytoplasmic side.  Here, we present an inward-open structure of the human ASCT2, revealing a hitherto elusive SLC1A conformation.  Strikingly, the same structural element (HP2) serves as a gate in the inward-facing as in the outward-facing state.  The structures reveal that SLC1A transporters work as one-gate elevators.  Unassigned densities near the gate and surrounding the scaffold domain, may represent potential allosteric binding sites, which could guide the design of lipidic-inhibitors for anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPdPrOAUoabGbPKh4T9eAfW6udTcc2ebYBv68_ZIkn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvjsVensg%253D%253D&md5=bdb8e27fd66ac8d3a59fc28b3740d9d1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-11363-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-11363-x%26sid%3Dliteratum%253Aachs%26aulast%3DGaraeva%26aufirst%3DA.%2BA.%26aulast%3DGuskov%26aufirst%3DA.%26aulast%3DSlotboom%26aufirst%3DD.%2BJ.%26aulast%3DPaulino%26aufirst%3DC.%26atitle%3DA%2520one-gate%2520elevator%2520mechanism%2520for%2520the%2520human%2520neutral%2520amino%2520acid%2520transporter%2520ASCT2%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D3427%26doi%3D10.1038%2Fs41467-019-11363-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiriyasermkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakizako, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishitani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nureki, O.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">510</span>â <span class="NLM_lpage">517</span>, <span class="refDoi">Â DOI: 10.1038/s41594-019-0237-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-019-0237-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31160781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=510-517&issue=6&author=Y.+Leeauthor=P.+Wiriyasermkulauthor=C.+Jinauthor=L.+Quanauthor=R.+Ohgakiauthor=S.+Okudaauthor=T.+Kusakizakoauthor=T.+Nishizawaauthor=K.+Odaauthor=R.+Ishitaniauthor=T.+Yokoyamaauthor=T.+Nakaneauthor=M.+Shirouzuauthor=H.+Endouauthor=S.+Nagamoriauthor=Y.+Kanaiauthor=O.+Nureki&title=Cryo-EM+structure+of+the+human+L-type+amino+acid+transporter+1+in+complex+with+glycoprotein+CD98hc&doi=10.1038%2Fs41594-019-0237-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc</span></div><div class="casAuthors">Lee, Yongchan; Wiriyasermkul, Pattama; Jin, Chunhuan; Quan, Lili; Ohgaki, Ryuichi; Okuda, Suguru; Kusakizako, Tsukasa; Nishizawa, Tomohiro; Oda, Kazumasa; Ishitani, Ryuichiro; Yokoyama, Takeshi; Nakane, Takanori; Shirouzu, Mikako; Endou, Hitoshi; Nagamori, Shushi; Kanai, Yoshikatsu; Nureki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">510-517</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The L-type amino acid transporter 1 (LAT1 or SLC7A5) transports large neutral amino acids across the membrane and is crucial for brain drug delivery and tumor growth.  LAT1 forms a disulfide-linked heterodimer with CD98 heavy chain (CD98hc, 4F2hc or SLC3A2), but the mechanism of assembly and amino acid transport are poorly understood.  Here we report the cryo-EM structure of the human LAT1-CD98hc heterodimer at 3.3-Ã resoln.  LAT1 features a canonical Leu T-fold and exhibits an unusual loop structure on transmembrane helix 6, creating an extended cavity that might accommodate bulky amino acids and drugs.  CD98hc engages with LAT1 through the extracellular, transmembrane and putative cholesterol-mediated interactions.  We also show that two anti-CD98 antibodies recognize distinct, multiple epitopes on CD98hc but not its glycans, explaining their robust reactivities.  These results reveal the principles of glycoprotein-solute carrier assembly and provide templates for improving preclin. drugs and antibodies targeting LAT1 or CD98hc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dNxEDKM31rVg90H21EOLACvtfcHk0lilshy-117Fjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7nP&md5=76486ba3a84bf0b54eea6a43502cea2a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41594-019-0237-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-019-0237-7%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DWiriyasermkul%26aufirst%3DP.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DQuan%26aufirst%3DL.%26aulast%3DOhgaki%26aufirst%3DR.%26aulast%3DOkuda%26aufirst%3DS.%26aulast%3DKusakizako%26aufirst%3DT.%26aulast%3DNishizawa%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DIshitani%26aufirst%3DR.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DNakane%26aufirst%3DT.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DEndou%26aufirst%3DH.%26aulast%3DNagamori%26aufirst%3DS.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DNureki%26aufirst%3DO.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520L-type%2520amino%2520acid%2520transporter%25201%2520in%2520complex%2520with%2520glycoprotein%2520CD98hc%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D510%26epage%3D517%26doi%3D10.1038%2Fs41594-019-0237-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structures of the human cation-chloride cotransporter KCC1</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">6464</span>),  <span class="NLM_fpage">505</span>â <span class="NLM_lpage">508</span>, <span class="refDoi">Â DOI: 10.1126/science.aay3129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.aay3129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31649201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVemtrzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=505-508&issue=6464&author=S.+Liuauthor=S.+Changauthor=B.+Hanauthor=L.+Xuauthor=M.+Zhangauthor=C.+Zhaoauthor=W.+Yangauthor=F.+Wangauthor=J.+Liauthor=E.+Delpireauthor=S.+Yeauthor=X.+C.+Baiauthor=J.+Guo&title=Cryo-EM+structures+of+the+human+cation-chloride+cotransporter+KCC1&doi=10.1126%2Fscience.aay3129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structures of the human cation-chloride cotransporter KCC1</span></div><div class="casAuthors">Liu, Si; Chang, Shenghai; Han, Binming; Xu, Lingyi; Zhang, Mingfeng; Zhao, Cheng; Yang, Wei; Wang, Feng; Li, Jingyuan; Delpire, Eric; Ye, Sheng; Bai, Xiao-chen; Guo, Jiangtao</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">6464</span>),
    <span class="NLM_cas:pages">505-508</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cation-chloride cotransporters move chloride and cations across the cell membrane and are important in regulating cell vol. and setting the chloride concn. inside the cell.  Mutations lead to serious diseases, such as epilepsy.  Liu et al. present the structure of the human potassium-chloride cotransporter KCC1, as detd. by Cryo-electron microscopy.  Based on the structure, functional studies, and mol. dynamics simulations, they propose an ion transport model.  The structure provides a framework for interpreting disease-related mutations in potassium-chloride cotransporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeP9poU5b_S7Vg90H21EOLACvtfcHk0lilshy-117Fjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVemtrzI&md5=34f810dba287470ec4913a8ab9e0b2f6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.aay3129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aay3129%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDelpire%26aufirst%3DE.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DX.%2BC.%26aulast%3DGuo%26aufirst%3DJ.%26atitle%3DCryo-EM%2520structures%2520of%2520the%2520human%2520cation-chloride%2520cotransporter%2520KCC1%26jtitle%3DScience%26date%3D2019%26volume%3D366%26issue%3D6464%26spage%3D505%26epage%3D508%26doi%3D10.1126%2Fscience.aay3129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reithmeier, R. A. F.</span></span> <span> </span><span class="NLM_article-title">Structural biology of solute carrier (SLC) membrane transport proteins</span>. <i>Mol. Membr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1â2</span>),  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">32</span>, <span class="refDoi">Â DOI: 10.1080/09687688.2018.1448123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1080%2F09687688.2018.1448123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29651895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1Omsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1-32&issue=1%E2%80%932&author=X.+Baiauthor=T.+F.+Moraesauthor=R.+A.+F.+Reithmeier&title=Structural+biology+of+solute+carrier+%28SLC%29+membrane+transport+proteins&doi=10.1080%2F09687688.2018.1448123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology of solute carrier (SLC) membrane transport proteins</span></div><div class="casAuthors">Bai, Xiaoyun; Moraes, Trevor F.; Reithmeier, Reinhart A. F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Membrane Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-32</span>CODEN:
                <span class="NLM_cas:coden">MMEBE7</span>;
        ISSN:<span class="NLM_cas:issn">0968-7688</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The human solute carriers (SLCs) comprise over 400 different transporters, organized into 65 families (http://slc.bioparadigms.org/) based on their sequence homol. and transport function.  SLCs are responsible for transporting extraordinarily diverse solutes across biol. membranes, including inorg. ions, amino acids, lipids, sugars, neurotransmitters and drugs.  Most of these membrane proteins function as coupled symporters (co-transporters) utilizing downhill ion (H+ or Na+) gradients as the driving force for the transport of substrate against its concn. gradient into cells.  Other members work as antiporters (exchangers) that typically contain a single substrate-binding site with an alternating access mode of transport, while a few members exhibit channel-like properties.  Dysfunction of SLCs is correlated with numerous human diseases and therefore they are potential therapeutic drug targets.  In this review, we identified all of the SLC crystal structures that have been detd., most of which are from prokaryotic species.  We further sorted all the SLC structures into four main groups with different protein folds and further discuss the well-characterized MFS (major facilitator superfamily) and LeuT (leucine transporter) folds.  This review provides a systematic anal. of the structure, mol. basis of substrate recognition and mechanism of action in different SLC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAsFzTpIxkmbVg90H21EOLACvtfcHk0lilshy-117Fjw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1Omsr8%253D&md5=070a749c134430cd9edfe09d22c65112</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F09687688.2018.1448123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09687688.2018.1448123%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DX.%26aulast%3DMoraes%26aufirst%3DT.%2BF.%26aulast%3DReithmeier%26aufirst%3DR.%2BA.%2BF.%26atitle%3DStructural%2520biology%2520of%2520solute%2520carrier%2520%2528SLC%2529%2520membrane%2520transport%2520proteins%26jtitle%3DMol.%2520Membr.%2520Biol.%26date%3D2017%26volume%3D34%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D32%26doi%3D10.1080%2F09687688.2018.1448123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">SLC transporters: structure, function, and drug discovery</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1069</span>â <span class="NLM_lpage">1081</span>, <span class="refDoi">Â DOI: 10.1039/C6MD00005C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1039%2FC6MD00005C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27672436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGhtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1069-1081&issue=6&author=C.+Colasauthor=P.+M.+Ungauthor=A.+Schlessinger&title=SLC+transporters%3A+structure%2C+function%2C+and+drug+discovery&doi=10.1039%2FC6MD00005C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">SLC transporters: structure, function, and drug discovery</span></div><div class="casAuthors">Colas, Claire; Ung, Peter Man-Un; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1069-1081</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The human solute carrier (SLC) transporters are important targets for drug development.  Structure-based drug discovery for SLC transporters requires the description of their structure, dynamics, and mechanism of interaction with small mol. ligands and ions.  The recent detn. of at. structures of human SLC transporters and their homologs, combined with improved computational power and prediction methods, has led to an increased applicability of structure-based drug design methods for human SLC members.  In this review, we provide an overview of the SLC transporters' structures and transport mechanisms.  We then describe computational techniques, such as homol. modeling and virtual screening that are emerging as key tools to discover chem. probes for human SLC members.  We illustrate the utility of these methods by presenting case studies in which rational integration of computation and expt. was used to characterize SLC members that transport key nutrients and metabolites, including the amino acid transporters LAT-1 and ASCT2, the SLC13 family of citric acid cycle intermediates transporters, and the glucose transporter GLUT1.  We conclude with a brief discussion about future directions in structure-based drug discovery for the human SLC superfamily, one of the most structurally and functionally diverse protein families in human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5sBwcRO3JnbVg90H21EOLACvtfcHk0lgAR1Vt1xHV9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGhtL4%253D&md5=3b31e4a50f1d25db9e6756163360e086</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2FC6MD00005C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00005C%26sid%3Dliteratum%253Aachs%26aulast%3DColas%26aufirst%3DC.%26aulast%3DUng%26aufirst%3DP.%2BM.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DSLC%2520transporters%253A%2520structure%252C%2520function%252C%2520and%2520drug%2520discovery%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26issue%3D6%26spage%3D1069%26epage%3D1081%26doi%3D10.1039%2FC6MD00005C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drew, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudker, O.</span></span> <span> </span><span class="NLM_article-title">Shared molecular mechanisms of membrane transporters</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">572</span>, <span class="refDoi">Â DOI: 10.1146/annurev-biochem-060815-014520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1146%2Fannurev-biochem-060815-014520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27023848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XltFGrs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2016&pages=543-572&author=D.+Drewauthor=O.+Boudker&title=Shared+molecular+mechanisms+of+membrane+transporters&doi=10.1146%2Fannurev-biochem-060815-014520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Shared Molecular Mechanisms of Membrane Transporters</span></div><div class="casAuthors">Drew, David; Boudker, Olga</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-572</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The detn. of the crystal structures of small-mol. transporters has shed light on the conformational changes that take place during structural isomerization from outward- to inward-facing states.  Rather than using a simple rocking movement of two bundles around a central substrate-binding site, it has become clear that even the most simplistic transporters utilize rearrangements of nonrigid bodies.  In the most dramatic cases, one bundle is fixed while the other, structurally divergent, bundle carries the substrate some 18 Ã across the membrane, which in this review is termed an elevator alternating-access mechanism.  Here, we compare and contrast rocker-switch, rocking-bundle, and elevator alternating-access mechanisms to highlight shared features and novel refinements to the basic alternating-access model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojfB2giGzclrVg90H21EOLACvtfcHk0lgAR1Vt1xHV9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltFGrs7s%253D&md5=5c586b058975893286ea63406126ef29</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060815-014520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060815-014520%26sid%3Dliteratum%253Aachs%26aulast%3DDrew%26aufirst%3DD.%26aulast%3DBoudker%26aufirst%3DO.%26atitle%3DShared%2520molecular%2520mechanisms%2520of%2520membrane%2520transporters%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2016%26volume%3D85%26spage%3D543%26epage%3D572%26doi%3D10.1146%2Fannurev-biochem-060815-014520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, N.</span></span> <span> </span><span class="NLM_article-title">Structural advances for the major facilitator superfamily (MFS) transporters</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2013.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tibs.2013.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23403214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1yrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=151-159&issue=3&author=N.+Yan&title=Structural+advances+for+the+major+facilitator+superfamily+%28MFS%29+transporters&doi=10.1016%2Fj.tibs.2013.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural advances for the major facilitator superfamily (MFS) transporters</span></div><div class="casAuthors">Yan, Nieng</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The major facilitator superfamily (MFS) is one of the largest groups of secondary active transporters conserved from bacteria to humans.  MFS proteins selectively transport a wide spectrum of substrates across biomembranes and play a pivotal role in multiple physiol. processes.  Despite intense investigation, only seven MFS proteins from six subfamilies have been structurally elucidated.  These structures were captured in distinct states during a transport cycle involving alternating access to binding sites from either side of the membrane.  This review discusses recent progress in MFS structure anal. and focuses on the mol. basis for substrate binding, co-transport coupling, and alternating access.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOoE0sVI2ux7Vg90H21EOLACvtfcHk0lgAR1Vt1xHV9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1yrtL8%253D&md5=afedff31eec0011b04efd4a86127b1f2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2013.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2013.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DN.%26atitle%3DStructural%2520advances%2520for%2520the%2520major%2520facilitator%2520superfamily%2520%2528MFS%2529%2520transporters%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2013%26volume%3D38%26issue%3D3%26spage%3D151%26epage%3D159%26doi%3D10.1016%2Fj.tibs.2013.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, N.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human glucose transporter GLUT1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>510</i></span> (<span class="NLM_issue">7503</span>),  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1038/nature13306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature13306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24847886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFGitL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=510&publication_year=2014&pages=121-125&issue=7503&author=D.+Dengauthor=C.+Xuauthor=P.+Sunauthor=J.+Wuauthor=C.+Yanauthor=M.+Huauthor=N.+Yan&title=Crystal+structure+of+the+human+glucose+transporter+GLUT1&doi=10.1038%2Fnature13306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human glucose transporter GLUT1</span></div><div class="casAuthors">Deng, Dong; Xu, Chao; Sun, Pengcheng; Wu, Jianping; Yan, Chuangye; Hu, Mingxu; Yan, Nieng</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">510</span>
        (<span class="NLM_cas:issue">7503</span>),
    <span class="NLM_cas:pages">121-125</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The glucose transporter GLUT1 catalyzes facilitative diffusion of glucose into erythrocytes and is responsible for glucose supply to the brain and other organs.  Dysfunctional mutations may lead to GLUT1 deficiency syndrome, whereas overexpression of GLUT1 is a prognostic indicator for cancer.  Despite decades of investigation, the structure of GLUT1 remains unknown.  Here we report the crystal structure of human GLUT1 at 3.2 Ã resoln.  The full-length protein, which has a canonical major facilitator superfamily fold, is captured in an inward-open conformation.  This structure allows accurate mapping and potential mechanistic interpretation of disease-assocd. mutations in GLUT1.  Structure-based anal. of these mutations provides an insight into the alternating access mechanism of GLUT1 and other members of the sugar porter subfamily.  Structural comparison of the uniporter GLUT1 with its bacterial homolog XylE, a proton-coupled xylose symporter, allows examn. of the transport mechanisms of both passive facilitators and active transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSeBmEBIMIurVg90H21EOLACvtfcHk0lgAR1Vt1xHV9g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFGitL8%253D&md5=b9426a934cddf7347fdc6c9073aa8636</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature13306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13306%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DN.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520glucose%2520transporter%2520GLUT1%26jtitle%3DNature%26date%3D2014%26volume%3D510%26issue%3D7503%26spage%3D121%26epage%3D125%26doi%3D10.1038%2Fnature13306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, N.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of ligand recognition and transport by glucose transporters</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span> (<span class="NLM_issue">7573</span>),  <span class="NLM_fpage">391</span>â <span class="NLM_lpage">396</span>, <span class="refDoi">Â DOI: 10.1038/nature14655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature14655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26176916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyltLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=391-396&issue=7573&author=D.+Dengauthor=P.+Sunauthor=C.+Yanauthor=M.+Keauthor=X.+Jiangauthor=L.+Xiongauthor=W.+Renauthor=K.+Hirataauthor=M.+Yamamotoauthor=S.+Fanauthor=N.+Yan&title=Molecular+basis+of+ligand+recognition+and+transport+by+glucose+transporters&doi=10.1038%2Fnature14655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of ligand recognition and transport by glucose transporters</span></div><div class="casAuthors">Deng, Dong; Sun, Pengcheng; Yan, Chuangye; Ke, Meng; Jiang, Xin; Xiong, Lei; Ren, Wenlin; Hirata, Kunio; Yamamoto, Masaki; Fan, Shilong; Yan, Nieng</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7573</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The major facilitator superfamily glucose transporters, exemplified by human GLUT1-4, have been central to the study of solute transport.  Using lipidic cubic phase crystn. and microfocus X-ray diffraction, we detd. the structure of human GLUT3 in complex with D-glucose at 1.5 Ã resoln. in an outward-occluded conformation.  The high-resoln. structure allows discrimination of both Î±- and Î²-anomers of D-glucose.  Two addnl. structures of GLUT3 bound to the exofacial inhibitor maltose were obtained at 2.6 Ã in the outward-open and 2.4 Ã in the outward-occluded states.  In all three structures, the ligands are predominantly coordinated by polar residues from the carboxy terminal domain.  Conformational transition from outward-open to outward-occluded entails a prominent local rearrangement of the extracellular part of transmembrane segment TM7.  Comparison of the outward-facing GLUT3 structures with the inward-open GLUT1 provides insights into the alternating access cycle for GLUTs, whereby the C-terminal domain provides the primary substrate-binding site and the amino-terminal domain undergoes rigid-body rotation with respect to the C-terminal domain.  Our studies provide an important framework for the mechanistic and kinetic understanding of GLUTs and shed light on structure-guided ligand design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3p8Y2gV917LVg90H21EOLACvtfcHk0lguwlKHoT9oFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyltLzO&md5=77ab999156155b38156394961682804d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature14655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14655%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DKe%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DN.%26atitle%3DMolecular%2520basis%2520of%2520ligand%2520recognition%2520and%2520transport%2520by%2520glucose%2520transporters%26jtitle%3DNature%26date%3D2015%26volume%3D526%26issue%3D7573%26spage%3D391%26epage%3D396%26doi%3D10.1038%2Fnature14655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporters: structure, intrinsic dynamics and allosteric regulation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">545</span>â <span class="NLM_lpage">556</span>, <span class="refDoi">Â DOI: 10.1038/s41594-019-0253-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-019-0253-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31270469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamurrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=545-556&issue=7&author=M.+H.+Chengauthor=I.+Bahar&title=Monoamine+transporters%3A+structure%2C+intrinsic+dynamics+and+allosteric+regulation&doi=10.1038%2Fs41594-019-0253-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporters: structure, intrinsic dynamics and allosteric regulation</span></div><div class="casAuthors">Cheng, Mary Hongying; Bahar, Ivet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Monoamine transporters (MATs) regulate neurotransmission via the reuptake of dopamine, serotonin and norepinephrine from extra-neuronal regions and thus maintain neurotransmitter homeostasis.  As targets of a wide range of compds., including antidepressants, substances of abuse and drugs for neuropsychiatric and neurodegenerative disorders, their mechanism of action and their modulation by small mols. have long been of broad interest.  Recent advances in the structural characterization of dopamine and serotonin transporters have opened the way for structure-based modeling and simulations, which, together with exptl. data, now provide mechanistic understanding of their transport function and interactions.  Here we review recent progress in the elucidation of the structural dynamics of MATs and their conformational landscape and transitions, as well as allosteric regulation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoruK1kJTRahrVg90H21EOLACvtfcHk0lguwlKHoT9oFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamurrN&md5=dd8add19bafb1252816b2b9f2ca3c207</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41594-019-0253-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-019-0253-7%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BH.%26aulast%3DBahar%26aufirst%3DI.%26atitle%3DMonoamine%2520transporters%253A%2520structure%252C%2520intrinsic%2520dynamics%2520and%2520allosteric%2520regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D7%26spage%3D545%26epage%3D556%26doi%3D10.1038%2Fs41594-019-0253-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazmier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claxton, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHaourab, H. S.</span></span> <span> </span><span class="NLM_article-title">Alternating access mechanisms of LeuT-fold transporters: trailblazing towards the promised energy landscapes</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">100</span>â <span class="NLM_lpage">108</span>, <span class="refDoi">Â DOI: 10.1016/j.sbi.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.sbi.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28040635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGis7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=100-108&author=K.+Kazmierauthor=D.+P.+Claxtonauthor=H.+S.+McHaourab&title=Alternating+access+mechanisms+of+LeuT-fold+transporters%3A+trailblazing+towards+the+promised+energy+landscapes&doi=10.1016%2Fj.sbi.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Alternating access mechanisms of LeuT-fold transporters: trailblazing towards the promised energy landscapes</span></div><div class="casAuthors">Kazmier, Kelli; Claxton, Derek P.; Mchaourab, Hassane S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100-108</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Secondary active transporters couple the uphill translocation of substrates to electrochem. ion gradients.  Transporter conformational motion, generically referred to as alternating access, enables a central ligand binding site to change its orientation relative to the membrane.  Here we review themes of alternating access and the transduction of ion gradient energy to power this process in the LeuT-fold class of transporters where crystallog., computational and spectroscopic approaches have converged to yield detailed models of transport cycles.  Specifically, we compare findings for the Na+-coupled amino acid transporter LeuT and the Na+-coupled hydantoin transporter Mhp1.  Although these studies have illuminated multiple aspects of transporter structures and dynamics, a no. of questions remain unresolved that so far hinder understanding transport mechanisms in an energy landscape perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppHcxtGMp5PLVg90H21EOLACvtfcHk0lguwlKHoT9oFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGis7%252FM&md5=d91709d4c68e4fcd6233b64d19e77ae7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DKazmier%26aufirst%3DK.%26aulast%3DClaxton%26aufirst%3DD.%2BP.%26aulast%3DMcHaourab%26aufirst%3DH.%2BS.%26atitle%3DAlternating%2520access%2520mechanisms%2520of%2520LeuT-fold%2520transporters%253A%2520trailblazing%2520towards%2520the%2520promised%2520energy%2520landscapes%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2017%26volume%3D45%26spage%3D100%26epage%3D108%26doi%3D10.1016%2Fj.sbi.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postis, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, A.</span></span> <span> </span><span class="NLM_article-title">Transport mechanism of a glutamate transporter homologue GltPh</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">898</span>â <span class="NLM_lpage">904</span>, <span class="refDoi">Â DOI: 10.1042/BST20160055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1042%2FBST20160055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27284058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1WmtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=898-904&issue=3&author=Y.+Jiauthor=V.+L.+Postisauthor=Y.+Wangauthor=M.+Bartlamauthor=A.+Goldman&title=Transport+mechanism+of+a+glutamate+transporter+homologue+GltPh&doi=10.1042%2FBST20160055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Transport mechanism of a glutamate transporter homologue GltPh</span></div><div class="casAuthors">Ji, Yurui; Postis, Vincent L. G.; Wang, Yingying; Bartlam, Mark; Goldman, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">898-904</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Glutamate transporters are responsible for uptake of the neurotransmitter glutamate in mammalian central nervous systems.  Their archaeal homolog GltPh, an aspartate transporter isolated from Pyrococcus horikoshii, has been the focus of extensive studies through crystallog., MD simulations and single-mol. FRET (smFRET).  Here, we summarize the recent research progress on GltPh, in the hope of gaining some insights into the transport mechanism of this aspartate transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPAGbGP2Xf_LVg90H21EOLACvtfcHk0lguwlKHoT9oFA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1WmtLY%253D&md5=c96357a2a275e2e85341bd909a42a37f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1042%2FBST20160055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20160055%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DY.%26aulast%3DPostis%26aufirst%3DV.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DGoldman%26aufirst%3DA.%26atitle%3DTransport%2520mechanism%2520of%2520a%2520glutamate%2520transporter%2520homologue%2520GltPh%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2016%26volume%3D44%26issue%3D3%26spage%3D898%26epage%3D904%26doi%3D10.1042%2FBST20160055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canul-Tec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamot-Rooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, N.</span></span> <span> </span><span class="NLM_article-title">Structure and allosteric inhibition of excitatory amino acid transporter 1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>544</i></span> (<span class="NLM_issue">7651</span>),  <span class="NLM_fpage">446</span>â <span class="NLM_lpage">451</span>, <span class="refDoi">Â DOI: 10.1038/nature22064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature22064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28424515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlalt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2017&pages=446-451&issue=7651&author=J.+C.+Canul-Tecauthor=R.+Assalauthor=E.+Cirriauthor=P.+Legrandauthor=S.+Brierauthor=J.+Chamot-Rookeauthor=N.+Reyes&title=Structure+and+allosteric+inhibition+of+excitatory+amino+acid+transporter+1&doi=10.1038%2Fnature22064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and allosteric inhibition of excitatory amino acid transporter 1</span></div><div class="casAuthors">Canul-Tec, Juan C.; Assal, Reda; Cirri, Erica; Legrand, Pierre; Brier, Sebastien; Chamot-Rooke, Julia; Reyes, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">7651</span>),
    <span class="NLM_cas:pages">446-451</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human members of the solute carrier 1 (SLC1) family of transporters take up excitatory neurotransmitters in the brain and amino acids in peripheral organs.  Dysregulation of the function of SLC1 transporters is assocd. with neurodegenerative disorders and cancer.  Here we present crystal structures of a thermostabilized human SLC1 transporter, the excitatory amino acid transporter 1 (EAAT1), with and without allosteric and competitive inhibitors bound.  The structures reveal architectural features of the human transporters, such as intra- and extracellular domains that have potential roles in transport function, regulation by lipids and post-translational modifications.  The coordination of the allosteric inhibitor in the structures and the change in the transporter dynamics measured by hydrogen-deuterium exchange mass spectrometry reveal a mechanism of inhibition, in which the transporter is locked in the outward-facing states of the transport cycle.  Our results provide insights into the mol. mechanisms underlying the function and pharmacol. of human SLC1 transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2niGusxCYIbVg90H21EOLACvtfcHk0lgMaJaCgXI5LA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlalt7k%253D&md5=1107e965f53e44801b6f51152f29ba13</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature22064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22064%26sid%3Dliteratum%253Aachs%26aulast%3DCanul-Tec%26aufirst%3DJ.%2BC.%26aulast%3DAssal%26aufirst%3DR.%26aulast%3DCirri%26aufirst%3DE.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DBrier%26aufirst%3DS.%26aulast%3DChamot-Rooke%26aufirst%3DJ.%26aulast%3DReyes%26aufirst%3DN.%26atitle%3DStructure%2520and%2520allosteric%2520inhibition%2520of%2520excitatory%2520amino%2520acid%2520transporter%25201%26jtitle%3DNature%26date%3D2017%26volume%3D544%26issue%3D7651%26spage%3D446%26epage%3D451%26doi%3D10.1038%2Fnature22064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navale, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranjape, A. N.</span></span> <span> </span><span class="NLM_article-title">Glucose transporters: physiological and pathological roles</span>. <i>Biophys. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1007/s12551-015-0186-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs12551-015-0186-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28510148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2isb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=5-9&issue=1&author=A.+M.+Navaleauthor=A.+N.+Paranjape&title=Glucose+transporters%3A+physiological+and+pathological+roles&doi=10.1007%2Fs12551-015-0186-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose transporters: physiological and pathological roles</span></div><div class="casAuthors">Navale, Archana M.; Paranjape, Archana N.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-9</span>CODEN:
                <span class="NLM_cas:coden">BRIECG</span>;
        ISSN:<span class="NLM_cas:issn">1867-2450</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Glucose is a primary energy source for most cells and an important substrate for many biochem. reactions.  As glucose is a need of each and every cell of the body, so are the glucose transporters.  Consequently, all cells express these important proteins on their surface.  In recent years developments in genetics have shed new light on the types and physiol. of various glucose transporters, of which there are two main types-sodium-glucose linked transporters (SGLTs) and facilitated diffusion glucose transporters (GLUT)-which can be divided into many more subclasses.  Transporters differ in terms of their substrate specificity, distribution and regulatory mechanisms.  Glucose transporters have also received much attention as therapeutic targets for various diseases.  In this review, we attempt to present a simplified view of this complex topic which may be of interest to researchers involved in biochem. and pharmacol. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHTI_CfH8WbVg90H21EOLACvtfcHk0lgMaJaCgXI5LA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2isb0%253D&md5=e328a4728ff6bca082764e1d06372066</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs12551-015-0186-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12551-015-0186-2%26sid%3Dliteratum%253Aachs%26aulast%3DNavale%26aufirst%3DA.%2BM.%26aulast%3DParanjape%26aufirst%3DA.%2BN.%26atitle%3DGlucose%2520transporters%253A%2520physiological%2520and%2520pathological%2520roles%26jtitle%3DBiophys.%2520Rev.%26date%3D2016%26volume%3D8%26issue%3D1%26spage%3D5%26epage%3D9%26doi%3D10.1007%2Fs12551-015-0186-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, P. C.</span></span> <span> </span><span class="NLM_article-title">Reconstitution and purification of the D-glucose transporter from human erythrocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>252</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7384</span>â <span class="NLM_lpage">7390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=903365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaE2sXls1eit7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1977&pages=7384-7390&issue=20&author=M.+Kasaharaauthor=P.+C.+Hinkle&title=Reconstitution+and+purification+of+the+D-glucose+transporter+from+human+erythrocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Reconstitution and purification of the D-glucose transporter from human erythrocytes</span></div><div class="casAuthors">Kasahara, Michihiro; Hinkle, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">252</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7384-90</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The D-glucose transporter from human erythrocytes was solubilized from washed membranes using Triton X 100.  After removal of the Triton X 100, the protein was incorporated into phospholipid vesicles by the sonication method of M. Kasahara and P. C. Hinkle (1976), but including a freeze-thaw step after adding the protein to the phospholipids.  The component catalyzing transport was purified from the Triton ext. by DEAE-cellulose chromatog.  The active fraction contained 1 major protein (96%) with apparent mol. wt. from Na dodecyl sulfate-polyacrylamide gel electrophoresis of 55,000.  The protein had a high lipid content and is probably a glycoprotein.  Antibody absorption expts. indicated that the protein is exposed to the inner face of the erythrocyte membrane.  D-glucose transport into liposomes reconstituted with the purified protein fraction was inhibited by Hg2+ or cytochalasin B, but not by phloretin or stilbestrol.  The specific activity of D-glucose transport was 85 nmol/min/mg of protein at 0.2 mM D-glucose, which is 10-fold higher than that of reconstituted liposomes with crude Triton ext.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjEDaKsQOX2bVg90H21EOLACvtfcHk0lgMaJaCgXI5LA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXls1eit7k%253D&md5=a7c100824a2c7c7ef92418d27dbe7ee0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKasahara%26aufirst%3DM.%26aulast%3DHinkle%26aufirst%3DP.%2BC.%26atitle%3DReconstitution%2520and%2520purification%2520of%2520the%2520D-glucose%2520transporter%2520from%2520human%2520erythrocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1977%26volume%3D252%26issue%3D20%26spage%3D7384%26epage%3D7390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueckler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blench, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienhard, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodish, H. F.</span></span> <span> </span><span class="NLM_article-title">Sequence and structure of a human glucose transporter</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>229</i></span> (<span class="NLM_issue">4717</span>),  <span class="NLM_fpage">941</span>â <span class="NLM_lpage">945</span>, <span class="refDoi">Â DOI: 10.1126/science.3839598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.3839598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=3839598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaL2MXlvFSkt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1985&pages=941-945&issue=4717&author=M.+Muecklerauthor=C.+Carusoauthor=S.+A.+Baldwinauthor=M.+Panicoauthor=I.+Blenchauthor=H.+R.+Morrisauthor=W.+J.+Allardauthor=G.+E.+Lienhardauthor=H.+F.+Lodish&title=Sequence+and+structure+of+a+human+glucose+transporter&doi=10.1126%2Fscience.3839598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence and structure of a human glucose transporter</span></div><div class="casAuthors">Mueckler, Mike; Caruso, Carla; Baldwin, Stephen A.; Panico, Maria; Blench, Ian; Morris, Howard R.; Allard, W. Jeffrey; Lienhard, Gustav E.; Lodish, Harvey F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">4717</span>),
    <span class="NLM_cas:pages">941-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The amino acid sequence of the glucose  [50-99-7] transport protein from human HepG2 hepatoma cells was deduced from anal. of a cDNA clone.  Structural anal. of the purified human erythrocyte glucose transport by fast atom bombardment mapping and gas-phase Edman degrdn. confirmed the identity of the clone and demonstrated that the HepG2 and erythrocyte transporters are highly homologous and may be identical.  The protein lacks a cleavable N-terminal signal sequence.  Anal. of the primary structure suggests the presence of 12 membrane-spanning domains.  Several of these may form amphipathic Î±-helices and contain abundant OH and amide side chains that could participate in glucose binding or line a transmembrane pore through which the sugar moves.  The N-terminus, C-terminus, and a highly hydrophilic domain in the center of the protein are all predicted to lie on the cytoplasmic face.  Species of mRNA homologous to HepG2 glucose transporter mRNA were detected in K562 leukemia cells, HT29 colon adenocarcinoma cells, and human kidney tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkan9yoEzSPrVg90H21EOLACvtfcHk0lhxpremeeXVvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvFSkt70%253D&md5=6ee2bbe2380641b3cc4bce47a611cdc0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.3839598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3839598%26sid%3Dliteratum%253Aachs%26aulast%3DMueckler%26aufirst%3DM.%26aulast%3DCaruso%26aufirst%3DC.%26aulast%3DBaldwin%26aufirst%3DS.%2BA.%26aulast%3DPanico%26aufirst%3DM.%26aulast%3DBlench%26aufirst%3DI.%26aulast%3DMorris%26aufirst%3DH.%2BR.%26aulast%3DAllard%26aufirst%3DW.%2BJ.%26aulast%3DLienhard%26aufirst%3DG.%2BE.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DSequence%2520and%2520structure%2520of%2520a%2520human%2520glucose%2520transporter%26jtitle%3DScience%26date%3D1985%26volume%3D229%26issue%3D4717%26spage%3D941%26epage%3D945%26doi%3D10.1126%2Fscience.3839598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGraw, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span> <span> </span><span class="NLM_article-title">30 sweet years of GLUT4</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">11369</span>â <span class="NLM_lpage">11381</span>, <span class="refDoi">Â DOI: 10.1074/jbc.REV119.008351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.REV119.008351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31175156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVOgur%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=11369-11381&issue=30&author=A.+Klipauthor=T.+E.+McGrawauthor=D.+E.+James&title=30+sweet+years+of+GLUT4&doi=10.1074%2Fjbc.REV119.008351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty sweet years of GLUT4</span></div><div class="casAuthors">Klip, Amira; McGraw, Timothy E.; James, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">11369-11382</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  A pivotal metabolic function of insulin is the stimulation of glucose uptake into muscle and adipose tissues.  The discovery of the insulin-responsive glucose transporter type 4 (GLUT4) protein in 1988 inspired its mol. cloning in the following year.  It also spurred numerous cellular mechanistic studies laying the foundations for how insulin regulates glucose uptake by muscle and fat cells.  Here, we reflect on the importance of the GLUT4 discovery and chronicle addnl. key findings made in the past 30 years.  That exocytosis of a multispanning membrane protein regulates cellular glucose transport illuminated a novel adaptation of the secretory pathway, which is to transiently modulate the protein compn. of the cellular plasma membrane.  GLUT4 controls glucose transport into fat and muscle tissues in response to insulin and also into muscle during exercise.  Thus, investigation of regulated GLUT4 trafficking provides a major means by which to map the essential signaling components that transmit the effects of insulin and exercise.  Manipulation of the expression of GLUT4 or GLUT4-regulating mols. in mice has revealed the impact of glucose uptake on whole-body metab.  Remaining gaps in our understanding of GLUT4 function and regulation are highlighted here, along with opportunities for future discoveries and for the development of therapeutic approaches to manage metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEuNcY_josbVg90H21EOLACvtfcHk0lhxpremeeXVvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVOgur%252FJ&md5=4d47e51735afa6837332b8aff4246aa7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.REV119.008351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.REV119.008351%26sid%3Dliteratum%253Aachs%26aulast%3DKlip%26aufirst%3DA.%26aulast%3DMcGraw%26aufirst%3DT.%2BE.%26aulast%3DJames%26aufirst%3DD.%2BE.%26atitle%3D30%2520sweet%2520years%2520of%2520GLUT4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26issue%3D30%26spage%3D11369%26epage%3D11381%26doi%3D10.1074%2Fjbc.REV119.008351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueckler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorens, B.</span></span> <span> </span><span class="NLM_article-title">The SLC2 (GLUT) family of membrane transporters</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">138</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2juro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=121-138&issue=2%E2%80%933&author=M.+Muecklerauthor=B.+Thorens&title=The+SLC2+%28GLUT%29+family+of+membrane+transporters&doi=10.1016%2Fj.mam.2012.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC2 (GLUT) family of membrane transporters</span></div><div class="casAuthors">Mueckler, Mike; Thorens, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">121-138</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  GLUT proteins are encoded by the SLC2 genes and are members of the major facilitator superfamily of membrane transporters.  Fourteen GLUT proteins are expressed in the human and they are categorized into three classes based on sequence similarity.  All GLUTs appear to transport hexoses or polyols when expressed ectopically, but the primary physiol. substrates for several of the GLUTs remain uncertain.  GLUTs 1-5 are the most thoroughly studied and all have well established roles as glucose and/or fructose transporters in various tissues and cell types.  The GLUT proteins are comprised of â¼500 amino acid residues, possess a single N-linked oligosaccharide, and have 12 membrane-spanning domains.  In this review we briefly describe the major characteristics of the 14 GLUT family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl2JJBNd-e3LVg90H21EOLACvtfcHk0lhxpremeeXVvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2juro%253D&md5=67435eebb5f373cd6b5624b1e02ebcb7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMueckler%26aufirst%3DM.%26aulast%3DThorens%26aufirst%3DB.%26atitle%3DThe%2520SLC2%2520%2528GLUT%2529%2520family%2520of%2520membrane%2520transporters%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D121%26epage%3D138%26doi%3D10.1016%2Fj.mam.2012.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirayama, B. A.</span></span> <span> </span><span class="NLM_article-title">Biology of human sodium glucose transporters</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">733</span>â <span class="NLM_lpage">794</span>, <span class="refDoi">Â DOI: 10.1152/physrev.00055.2009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fphysrev.00055.2009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21527736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2011&pages=733-794&issue=2&author=E.+M.+Wrightauthor=D.+D.+Looauthor=B.+A.+Hirayama&title=Biology+of+human+sodium+glucose+transporters&doi=10.1152%2Fphysrev.00055.2009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Biology of human sodium glucose transporters</span></div><div class="casAuthors">Wright, Ernest M.; Loo, Donald D. F.; Hirayama, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">733-794</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  There are two classes of glucose transporters involved in glucose homeostasis in the body, the facilitated transporters or uniporters (GLUTs) and the active transporters or symporters (SGLTs).  The energy for active glucose transport is provided by the sodium gradient across the cell membrane, the Na+ glucose cotransport hypothesis first proposed in 1960 by Crane.  Since the cloning of SGLT1 in 1987, there have been advances in the genetics, mol. biol., biochem., biophysics, and structure of SGLTs.  There are 12 members of the human SGLT (SLC5) gene family, including cotransporters for sugars, anions, vitamins, and short-chain fatty acids.  Here we give a personal review of these advances.  The SGLTs belong to a structural class of membrane proteins from unrelated gene families of antiporters and Na+ and H+ symporters.  This class shares a common at. architecture and a common transport mechanism.  SGLTs also function as water and urea channels, glucose sensors, and coupled-water and urea transporters.  We also discuss the physiol. and pathophysiol. of SGLTs, e.g., glucose galactose malabsorption and familial renal glycosuria, and briefly report on targeting of SGLTs for new therapies for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquMSW1jSySGbVg90H21EOLACvtfcHk0lhxpremeeXVvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7g%253D&md5=e3863e27fb78867488347b4289bc13e0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00055.2009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00055.2009%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DE.%2BM.%26aulast%3DLoo%26aufirst%3DD.%2BD.%26aulast%3DHirayama%26aufirst%3DB.%2BA.%26atitle%3DBiology%2520of%2520human%2520sodium%2520glucose%2520transporters%26jtitle%3DPhysiol.%2520Rev.%26date%3D2011%26volume%3D91%26issue%3D2%26spage%3D733%26epage%3D794%26doi%3D10.1152%2Fphysrev.00055.2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, B. C.</span></span> <span> </span><span class="NLM_article-title">The SLC37 family of sugar-phosphate/phosphate exchangers</span>. <i>Curr. Top. Membr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">357</span>â <span class="NLM_lpage">382</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-800223-0.00010-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FB978-0-12-800223-0.00010-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24745989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlymsLfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=357-382&author=J.+Y.+Chouauthor=B.+C.+Mansfield&title=The+SLC37+family+of+sugar-phosphate%2Fphosphate+exchangers&doi=10.1016%2FB978-0-12-800223-0.00010-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC37 family of sugar-phosphate/phosphate exchangers</span></div><div class="casAuthors">Chou, Janice Y.; Mansfield, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Membranes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">Exchangers</span>),
    <span class="NLM_cas:pages">357-382</span>CODEN:
                <span class="NLM_cas:coden">CTMEET</span>;
        ISSN:<span class="NLM_cas:issn">1063-5823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The SLC37 family members are endoplasmic reticulum (ER)-assocd. sugar-phosphate/phosphate (Pi) exchangers.  Three of the four members, SLC37A1, SLC37A2, and SLC37A4, function as Pi-linked glucose-6-phosphate (G6P) antiporters catalyzing G6P:P, and Pi:Pi exchanges.  The activity of SLC37A3 is unknown.  SLC37A4, better known as the G6P transporter (G6PT), has been extensively characterized, functionally and structurally, and is the best characterized family member.  G6PT contains 10 transmembrane helixes with both N and C termini facing the cytoplasm.  The primary in vivo function of the G6PT protein is to translocate G6P from the cytoplasm into the ER lumen where it couples with either the liver/kidney/intestine-restricted glucose-6-phosphatase-Î± (G6Pase-Î± or G6PC) or the ubiquitously expressed G6Pase-Î² (or G6PC3) to hydrolyze G6P to glucose and Pi.  The G6PT/G6Pase-Î± complex maintains interprandial glucose homeostasis, and the G6PT/G6Pase-Î² complex maintains neutrophil energy homeostasis and functionality.  G6PT is highly selective for G6P and is competitively inhibited by cholorogenic acid and its derivs.  Neither SLC37A1 nor SLC37A2 can couple functionally with G6Pase-Î± or G6Pase-Î², and the antiporter activities of SLC37A1 or SLC37A2 are not inhibited by cholorogenic acid.  Deficiencies in G6PT cause glycogen storage disease type Ib (GSD-Ib), a metabolic and immune disorder.  To date, 91 sep. SLC37A4 mutations, including 39 missense mutations, have been identified in GSD-Ib patients.  Characterization of missense mutations has yielded valuable information on functionally important residues in the G6PT protein.  The biol. roles of the other SLC37 proteins remain to be detd. and deficiencies have not yet been correlated to diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprz6xKKGufkbVg90H21EOLACvtfcHk0ljBadP32OUK0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlymsLfM&md5=b488bb135a090e8d1ae0e8a5c5b1187e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800223-0.00010-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800223-0.00010-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DJ.%2BY.%26aulast%3DMansfield%26aufirst%3DB.%2BC.%26atitle%3DThe%2520SLC37%2520family%2520of%2520sugar-phosphate%252Fphosphate%2520exchangers%26jtitle%3DCurr.%2520Top.%2520Membr.%26date%3D2014%26volume%3D73%26spage%3D357%26epage%3D382%26doi%3D10.1016%2FB978-0-12-800223-0.00010-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyimesi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span> <span> </span><span class="NLM_article-title">Amino acid transporters revisited: new views in health and disease</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">789</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2018.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tibs.2018.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30177408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=752-789&issue=10&author=P.+Kandasamyauthor=G.+Gyimesiauthor=Y.+Kanaiauthor=M.+A.+Hediger&title=Amino+acid+transporters+revisited%3A+new+views+in+health+and+disease&doi=10.1016%2Fj.tibs.2018.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid transporters revisited: New views in health and disease</span></div><div class="casAuthors">Kandasamy, Palanivel; Gyimesi, Gergely; Kanai, Yoshikatsu; Hediger, Matthias A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">752-789</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Amino acid transporters (AATs) are membrane-bound transport proteins that mediate transfer of amino acids into and out of cells or cellular organelles.  AATs have diverse functional roles ranging from neurotransmission to acid-base balance, intracellular energy metab., and anabolic and catabolic reactions.  In cancer cells and diabetes, dysregulation of AATs leads to metabolic reprogramming, which changes intracellular amino acid levels, contributing to the pathogenesis of cancer, obesity and diabetes.  Indeed, the neutral amino acid transporters (NATs) SLC7A5/LAT1 and SLC1A5/ASCT2 are likely involved in several human malignancies.  However, a clin. therapy that directly targets AATs has not yet been developed.  The purpose of this review is to highlight the structural and functional diversity of AATs, their diverse physiol. roles in different tissues and organs, their wide-ranging implications in human diseases and the emerging strategies and tools that will be necessary to target AATs therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5BHLRYRsmE7Vg90H21EOLACvtfcHk0ljBadP32OUK0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb7J&md5=ca03f1ef10cf9929ae6be316ecff547f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2018.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2018.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DKandasamy%26aufirst%3DP.%26aulast%3DGyimesi%26aufirst%3DG.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26atitle%3DAmino%2520acid%2520transporters%2520revisited%253A%2520new%2520views%2520in%2520health%2520and%2520disease%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2018%26volume%3D43%26issue%3D10%26spage%3D752%26epage%3D789%26doi%3D10.1016%2Fj.tibs.2018.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shigeri, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamoto, K.</span></span> <span> </span><span class="NLM_article-title">Molecular pharmacology of glutamate transporters, EAATs and VGLUTs</span>. <i>Brain Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">250</span>â <span class="NLM_lpage">265</span>, <span class="refDoi">Â DOI: 10.1016/j.brainresrev.2004.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.brainresrev.2004.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15210307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVCgsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=250-265&issue=3&author=Y.+Shigeriauthor=R.+P.+Sealauthor=K.+Shimamoto&title=Molecular+pharmacology+of+glutamate+transporters%2C+EAATs+and+VGLUTs&doi=10.1016%2Fj.brainresrev.2004.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of glutamate transporters, EAATs and VGLUTs</span></div><div class="casAuthors">Shigeri, Yasushi; Seal, Rebecca P.; Shimamoto, Keiko</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-265</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  L-Glutamate serves as a major excitatory neurotransmitter in the mammalian central nervous system (CNS) and is stored in synaptic vesicles by an uptake system that is dependent on the proton electrochem. gradient (VGLUTs).  Following its exocytotic release, glutamate activates fast-acting, excitatory ionotropic receptors and slower-acting metabotropic receptors to mediate neurotransmission.  Na+-dependent glutamate transporters (EAATs) located on the plasma membrane of neurons and glial cells rapidly terminate the action of glutamate and maintain its extracellular concn. below excitotoxic levels.  Thus far, 5 Na+-dependent glutamate transporters (EAATs 1-5) and 3 vesicular glutamate transporters (VGLUTs 1-3) have been identified.  Examn. of EAATs and VGLUTs in brain prepns. and by heterologous expression of the various cloned subtypes shows these 2 transporter families differ in many of their functional properties including substrate specificity and ion requirements.  Alterations in the function and/or expression of these carriers have been implicated in a range of psychiatric and neurol. disorders.  EAATs have been implicated in cerebral stroke, epilepsy, Alzheimer's disease, HIV-assocd. dementia, Huntington's disease, amyotrophic lateral sclerosis (ALS), and malignant glioma, while VGLUTs have been implicated in schizophrenia.  To examine the physiol. role of glutamate transporters in more detail, several classes of transportable and non-transportable inhibitors have been developed, many of which are derivs. of the natural amino acids, aspartate and glutamate.  This review summarizes the development of these indispensable pharmacol. tools, which have been crit. to our understanding of normal and abnormal synaptic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN0PzoN_wZ07Vg90H21EOLACvtfcHk0ljBadP32OUK0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVCgsr8%253D&md5=d1898c51836320739c1cc8acc4c99e7b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2004.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2004.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DShigeri%26aufirst%3DY.%26aulast%3DSeal%26aufirst%3DR.%2BP.%26aulast%3DShimamoto%26aufirst%3DK.%26atitle%3DMolecular%2520pharmacology%2520of%2520glutamate%2520transporters%252C%2520EAATs%2520and%2520VGLUTs%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2004%26volume%3D45%26issue%3D3%26spage%3D250%26epage%3D265%26doi%3D10.1016%2Fj.brainresrev.2004.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fotiadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacin, M.</span></span> <span> </span><span class="NLM_article-title">The SLC3 and SLC7 families of amino acid transporters</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">139</span>â <span class="NLM_lpage">158</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2js7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=139-158&issue=2%E2%80%933&author=D.+Fotiadisauthor=Y.+Kanaiauthor=M.+Palacin&title=The+SLC3+and+SLC7+families+of+amino+acid+transporters&doi=10.1016%2Fj.mam.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC3 and SLC7 families of amino acid transporters</span></div><div class="casAuthors">Fotiadis, Dimitrios; Kanai, Yoshikatsu; Palacin, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">139-158</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Amino acids are necessary for all living cells and organisms.  Specialized transporters mediate the transfer of amino acids across plasma membranes.  Malfunction of these proteins can affect whole-body homoeostasis giving raise to diverse human diseases.  Here, we review the main features of the SLC3 and SLC7 families of amino acid transporters.  The SLC7 family is divided into two subfamilies, the cationic amino acid transporters (CATs), and the L-type amino acid transporters (LATs).  The latter are the light or catalytic subunits of the heteromeric amino acid transporters (HATs), which are assocd. by a disulfide bridge with the heavy subunits 4F2hc or rBAT.  These two subunits are glycoproteins and form the SLC3 family.  Most CAT subfamily members were functionally characterized and shown to function as facilitated diffusers mediating the entry and efflux of cationic amino acids.  In certain cells, CATs play an important role in the delivery of L-arginine for the synthesis of nitric oxide.  HATs are mostly exchangers with a broad spectrum of substrates and are crucial in renal and intestinal re-absorption and cell redox balance.  Furthermore, the role of the HAT 4F2hc/LAT1 in tumor growth and the application of LAT1 inhibitors and PET tracers for redn. of tumor progression and imaging of tumors are discussed.  Finally, we describe the link between specific mutations in HATs and the primary inherited aminoacidurias, cystinuria and lysinuric protein intolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzCY992BVM0LVg90H21EOLACvtfcHk0ljBadP32OUK0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2js7g%253D&md5=9a39bcc649b0b4bcf71cc83ad2d6c836</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DFotiadis%26aufirst%3DD.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DPalacin%26aufirst%3DM.%26atitle%3DThe%2520SLC3%2520and%2520SLC7%2520families%2520of%2520amino%2520acid%2520transporters%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D139%26epage%3D158%26doi%3D10.1016%2Fj.mam.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scalise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluccio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Console, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pochini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indiveri, C.</span></span> <span> </span><span class="NLM_article-title">The human SLC7A5 (LAT1): The intriguing histidine/large neutral amino acid transporter and its relevance to human health</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">243</span>, <span class="refDoi">Â DOI: 10.3389/fchem.2018.00243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffchem.2018.00243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29988369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFait7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=243&author=M.+Scaliseauthor=M.+Galluccioauthor=L.+Consoleauthor=L.+Pochiniauthor=C.+Indiveri&title=The+human+SLC7A5+%28LAT1%29%3A+The+intriguing+histidine%2Flarge+neutral+amino+acid+transporter+and+its+relevance+to+human+health&doi=10.3389%2Ffchem.2018.00243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health</span></div><div class="casAuthors">Scalise, Mariafrancesca; Galluccio, Michele; Console, Lara; Pochini, Lorena; Indiveri, Cesare</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243/1-243/12</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">SLC7A5, known as LAT1, belongs to the APC superfamily and forms a heterodimeric amino acid transporter interacting with the glycoprotein CD98 (SLC3A2) through a conserved disulfide.  The complex is responsible for uptake of essential amino acids in crucial body districts such as placenta and blood brain barrier.  LAT1/CD98 heterodimer has been studied over the years to unravel the transport mechanism and the role of each subunit.  Studies conducted in intact cells demonstrated that LAT1/CD98 mediates a Na+ and pH independent antiport of amino acids.  Some novel insights into the function of LAT1 derived from studies conducted in proteoliposomes reconstituted with the recombinant human LAT1.  Using this exptl. tool, it has been demonstrated that the preferred substrate is histidine and that CD98 is not required for transport being, plausibly, involved in routing LAT1 to the plasma membrane.  Since a 3D structure of LAT1 is not available, homol. models have been built on the basis of the AdiC transporter from E.coli.  Crucial residues for substrate recognition and gating have been identified using a combined approach of bioinformatics and site-directed mutagenesis coupled to functional assays.  Over the years, the interest around LAT1 increased because this transporter is involved in important human diseases such as neurol. disorders and cancer.  Therefore, LAT1 became an important pharmacol. target together with other nutrient membrane transporters.  Moving from knowledge on structure/function relationships, two cysteine residues, lying on the substrate binding site, have been exploited for designing thiol reacting covalent inhibitors.  Some lead compds. have been characterized whose efficacy has been tested in a cancer cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreoyv-71qXBbVg90H21EOLACvtfcHk0livqxqtIq4gDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFait7%252FF&md5=fe939bf29b7965b1b2cbe1805e492be0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00243%26sid%3Dliteratum%253Aachs%26aulast%3DScalise%26aufirst%3DM.%26aulast%3DGalluccio%26aufirst%3DM.%26aulast%3DConsole%26aufirst%3DL.%26aulast%3DPochini%26aufirst%3DL.%26aulast%3DIndiveri%26aufirst%3DC.%26atitle%3DThe%2520human%2520SLC7A5%2520%2528LAT1%2529%253A%2520The%2520intriguing%2520histidine%252Flarge%2520neutral%2520amino%2520acid%2520transporter%2520and%2520its%2520relevance%2520to%2520human%2520health%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D243%26doi%3D10.3389%2Ffchem.2018.00243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. A.</span></span> <span> </span><span class="NLM_article-title">System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01480.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fj.1476-5381.2011.01480.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21564084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=20-34&issue=1&author=R.+J.+Bridgesauthor=N.+R.+Nataleauthor=S.+A.+Patel&title=System+xc-+cystine%2Fglutamate+antiporter%3A+an+update+on+molecular+pharmacology+and+roles+within+the+CNS&doi=10.1111%2Fj.1476-5381.2011.01480.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS</span></div><div class="casAuthors">Bridges, Richard J.; Natale, Nicholas R.; Patel, Sarjubhai A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-34</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">System xc- is an amino acid antiporter that typically mediates the exchange of extracellular L-cystine and intracellular L-glutamate across the cellular plasma membrane.  Studied in a variety of cell types, the import of L-cystine through this transporter is crit. to glutathione prodn. and oxidative protection.  The exchange-mediated export of L-glutamate takes on added significance within the CNS, as it represents a non-vesicular route of release through which this excitatory neurotransmitter can participate in either neuronal signalling or excitotoxic pathol.  When both the import of L-cystine and the export of L-glutamate are taken into consideration, system xc- has now been linked to a wide range of CNS functions, including oxidative protection, the operation of the blood-brain barrier, neurotransmitter release, synaptic organization, viral pathol., drug addiction, chemosensitivity and chemoresistance, and brain tumor growth.  The ability to selectively manipulate system xc-, delineate its function, probe its structure and evaluate it as a therapeutic target is closely linked to understanding its pharmacol. and the subsequent development of selective inhibitors and substrates.  Towards that goal, this review will examine the current status of our understanding of system xc- pharmacol. and the structure-activity relationships that have guided the development of an initial pharmacophore model, including the presence of lipophilic domains adjacent to the substrate binding site.  A special emphasis is placed on the roles of system xc- within the CNS, as it is these actions that are among the most exciting as potential long-range therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkHeqBt_KsJLVg90H21EOLACvtfcHk0livqxqtIq4gDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLjM&md5=ed3ade4d1aee288820b85fb2fdf7c573</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01480.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01480.x%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DR.%2BJ.%26aulast%3DNatale%26aufirst%3DN.%2BR.%26aulast%3DPatel%26aufirst%3DS.%2BA.%26atitle%3DSystem%2520xc-%2520cystine%252Fglutamate%2520antiporter%253A%2520an%2520update%2520on%2520molecular%2520pharmacology%2520and%2520roles%2520within%2520the%2520CNS%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26issue%3D1%26spage%3D20%26epage%3D34%26doi%3D10.1111%2Fj.1476-5381.2011.01480.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesema, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moerings, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verrey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennemann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visser, T. J.</span></span> <span> </span><span class="NLM_article-title">Thyroid hormone transport by the heterodimeric human system L amino acid transporter</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4339</span>â <span class="NLM_lpage">4438</span>, <span class="refDoi">Â DOI: 10.1210/endo.142.10.8418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1210%2Fendo.142.10.8418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11564694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1ertL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2001&pages=4339-4438&issue=10&author=E.+C.+Friesemaauthor=R.+Docterauthor=E.+P.+Moeringsauthor=F.+Verreyauthor=E.+P.+Krenningauthor=G.+Hennemannauthor=T.+J.+Visser&title=Thyroid+hormone+transport+by+the+heterodimeric+human+system+L+amino+acid+transporter&doi=10.1210%2Fendo.142.10.8418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Thyroid hormone transport by the heterodimeric human system L-amino acid transporter</span></div><div class="casAuthors">Friesema, Edith C. H.; Docter, Roel; Moerings, Ellis P. C. M.; Verrey, Francois; Krenning, Eric P.; Hennemann, Georg; Visser, Theo J.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4339-4348</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Transport of thyroid hormone across the cell membrane is required for thyroid hormone action and metab.  The authors have investigated the possible transport of iodothyronines by the human system L-amino acid transporter, a protein consisting of the human 4F2 heavy chain and the human LAT1 light chain.  Xenopus oocytes were injected with the cRNAs coding for human 4F2 heavy chain and/or human LAT1 light chain, and after 2 d were incubated at 25Â° with 0.01-10 Î¼M [125I]T4, [125I]T3, [125I]rT3, or [125I]3,3'-diiodothyronine or with 10-100 Î¼M [3H]arginine, [3H]leucine, [3H]phenylalanine, [3H]tyrosine, or [3H]tryptophan.  Injection of human 4F2 heavy chain cRNA alone stimulated the uptake of leucine and arginine due to dimerization of human 4F2 heavy chain with an endogenous Xenopus light chain, but did not affect the uptake of other ligands.  Injection of human LAT1 light chain cRNA alone did not stimulate the uptake of any ligand.  Coinjection of cRNAs for human 4F2 heavy chain and human LAT1 light chain stimulated the uptake of phenylalanine > tyrosine > leucine > tryptophan (100 Î¼M) and of 3,3'-diiodothyronine > rT3 â¼ T3 > T4 (10 nM), which in all cases was Na+ independent.  Satn. anal. provided apparent Michaelis const. (Km) values of 7.9 Î¼M for T4, 0.8 Î¼M for T3, 12.5 Î¼M for rT3, 7.9 Î¼M for 3,3'-diiodothyronine, 46 Î¼M for leucine, and 19 Î¼M for tryptophan.  Uptake of leucine, tyrosine, and tryptophan (10 Î¼M) was inhibited by the different iodothyronines (10 Î¼M), in particular T3.  Vice versa, uptake of 0.1 Î¼M T3 was almost completely blocked by coincubation with 100 Î¼M leucine, tryptophan, tyrosine, or phenylalanine.  The authors' results demonstrate stereospecific Na+-independent transport of iodothyronines by the human heterodimeric system L-amino acid transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhpkVGbyImrVg90H21EOLACvtfcHk0livqxqtIq4gDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1ertL4%253D&md5=c1073ef8ec3599165c7a34da7fefc690</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1210%2Fendo.142.10.8418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.142.10.8418%26sid%3Dliteratum%253Aachs%26aulast%3DFriesema%26aufirst%3DE.%2BC.%26aulast%3DDocter%26aufirst%3DR.%26aulast%3DMoerings%26aufirst%3DE.%2BP.%26aulast%3DVerrey%26aufirst%3DF.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26aulast%3DHennemann%26aufirst%3DG.%26aulast%3DVisser%26aufirst%3DT.%2BJ.%26atitle%3DThyroid%2520hormone%2520transport%2520by%2520the%2520heterodimeric%2520human%2520system%2520L%2520amino%2520acid%2520transporter%26jtitle%3DEndocrinology%26date%3D2001%26volume%3D142%26issue%3D10%26spage%3D4339%26epage%3D4438%26doi%3D10.1210%2Fendo.142.10.8418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Amino acid transporters in cancer and their relevance to â³glutamine addictionâ³: novel targets for the design of a new class of anticancer drugs</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1782</span>â <span class="NLM_lpage">1788</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-14-3745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1158%2F0008-5472.CAN-14-3745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25855379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFemu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1782-1788&issue=9&author=Y.+D.+Bhutiaauthor=E.+Babuauthor=S.+Ramachandranauthor=V.+Ganapathy&title=Amino+acid+transporters+in+cancer+and+their+relevance+to+%E2%80%B3glutamine+addiction%E2%80%B3%3A+novel+targets+for+the+design+of+a+new+class+of+anticancer+drugs&doi=10.1158%2F0008-5472.CAN-14-3745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Amino Acid Transporters in Cancer and Their Relevance to "Glutamine Addiction": Novel Targets for the Design of a New Class of Anticancer Drugs</span></div><div class="casAuthors">Bhutia, Yangzom D.; Babu, Ellappan; Ramachandran, Sabarish; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1782-1788</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor cells have an increased demand for amino acids because of their rapid proliferation rate.  In addn. to their need in protein synthesis, several amino acids have other roles in supporting cancer growth.  There are approx. two-dozen amino acid transporters in humans, and tumor cells must upregulate one or more of these transporters to satisfy their demand for amino acids.  If the transporters that specifically serve this purpose in tumor cells are identified, they can be targeted for the development of a brand new class of anticancer drugs; the logical basis of such a strategy would be to starve the tumor cells of an important class of nutrients.  To date, four amino acid transporters have been found to be expressed at high levels in cancer: SLC1A5, SLC7A5, SLC7A11, and SLC6A14.  Their induction occurs in a cancer type-specific manner with a direct or indirect involvement of the oncogene c-Myc.  Further, these transporters are functionally coupled, thus maximizing their ability to promote cancer growth and chemoresistance.  Progress has been made in preclin. studies, exploiting these transporters as drug targets in cancer therapy.  These transporters also show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents.  Cancer Res; 75(9); 1782-8. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHCUEzyXW3qLVg90H21EOLACvtfcHk0lh9vqGgJ_lbrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFemu7Y%253D&md5=f15ce2573ab5ae5fb4ed7a048da69f38</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3745%26sid%3Dliteratum%253Aachs%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DAmino%2520acid%2520transporters%2520in%2520cancer%2520and%2520their%2520relevance%2520to%2520%25E2%2580%25B3glutamine%2520addiction%25E2%2580%25B3%253A%2520novel%2520targets%2520for%2520the%2520design%2520of%2520a%2520new%2520class%2520of%2520anticancer%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D9%26spage%3D1782%26epage%3D1788%26doi%3D10.1158%2F0008-5472.CAN-14-3745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span> <span> </span><span class="NLM_article-title">Amino acid transporters as disease modifiers and drug targets</span>. <i>Slas Discov</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">303</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1177/2472555218755629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1177%2F2472555218755629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29557284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1yisbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=303-320&issue=4&author=S.+Broer&title=Amino+acid+transporters+as+disease+modifiers+and+drug+targets&doi=10.1177%2F2472555218755629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Amino Acid Transporters as Disease Modifiers and Drug Targets</span></div><div class="casAuthors">Broer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">SLAS Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-320</span>CODEN:
                <span class="NLM_cas:coden">SDLIBT</span>;
        ISSN:<span class="NLM_cas:issn">2472-5560</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Amino acids perform a variety of functions in cells and organisms, particularly in the synthesis of proteins, as energy metabolites, neurotransmitters, and precursors for many other mols.  Amino acid transport plays a key role in all these functions.  Inhibition of amino acid transport is pursued as a therapeutic strategy in several areas, such as diabetes and related metabolic disorders, neurol. disorders, cancer, and stem cell biol.  The role of amino acid transporters in these disorders and processes is well established, but the implementation of amino acid transporters as drug targets is still in its infancy.  This is at least in part due to the underdeveloped pharmacol. of this group of membrane proteins.  Recent advances in structural biol., membrane protein expression, and inhibitor screening methodol. will see an increased no. of improved and selective inhibitors of amino acid transporters that can serve as tool compds. for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX0fAODZizB7Vg90H21EOLACvtfcHk0lh9vqGgJ_lbrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1yisbc%253D&md5=e6ccf34920a48643a07ad307a9f6b6f0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1177%2F2472555218755629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555218755629%26sid%3Dliteratum%253Aachs%26aulast%3DBroer%26aufirst%3DS.%26atitle%3DAmino%2520acid%2520transporters%2520as%2520disease%2520modifiers%2520and%2520drug%2520targets%26jtitle%3DSlas%2520Discov%26date%3D2018%26volume%3D23%26issue%3D4%26spage%3D303%26epage%3D320%26doi%3D10.1177%2F2472555218755629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromgaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span> <span> </span><span class="NLM_article-title">SLC6 neurotransmitter transporters: structure, function, and regulation</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">585</span>â <span class="NLM_lpage">640</span>, <span class="refDoi">Â DOI: 10.1124/pr.108.000869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fpr.108.000869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21752877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=585-640&issue=3&author=A.+S.+Kristensenauthor=J.+Andersenauthor=T.+N.+Jorgensenauthor=L.+Sorensenauthor=J.+Eriksenauthor=C.+J.+Lolandauthor=K.+Stromgaardauthor=U.+Gether&title=SLC6+neurotransmitter+transporters%3A+structure%2C+function%2C+and+regulation&doi=10.1124%2Fpr.108.000869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6 neurotransmitter transporters: structure, function, and regulation</span></div><div class="casAuthors">Kristensen, Anders S.; Andersen, Jacob; Joergensen, Trine N.; Soerensen, Lena; Eriksen, Jacob; Loland, Claus J.; Stroemgaard, Kristian; Gether, Ulrik</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">585-640</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The neurotransmitter transporters (NTTs) belonging to the solute carrier 6 (SLC6) gene family (also referred to as the neurotransmitter-sodium-symporter family or Na+/Cl--dependent transporters) comprise a group of nine sodium- and chloride-dependent plasma membrane transporters for the monoamine neurotransmitters serotonin (5-hydroxytryptamine), dopamine, and norepinephrine, and the amino acid neurotransmitters GABA and glycine.  The SLC6 NTTs are widely expressed in the mammalian brain and play an essential role in regulating neurotransmitter signaling and homeostasis by mediating uptake of released neurotransmitters from the extracellular space into neurons and glial cells.  The transporters are targets for a wide range of therapeutic drugs used in treatment of psychiatric diseases, including major depression, anxiety disorders, attention deficit hyperactivity disorder and epilepsy.  Furthermore, psychostimulants such as cocaine and amphetamines have the SLC6 NTTs as primary targets.  Beginning with the detn. of a high-resoln. structure of a prokaryotic homolog of the mammalian SLC6 transporters in 2005, the understanding of the mol. structure, function, and pharmacol. of these proteins has advanced rapidly.  Furthermore, intensive efforts have been directed toward understanding the mol. and cellular mechanisms involved in regulation of the activity of this important class of transporters, leading to new methodol. developments and important insights.  This review provides an update of these advances and their implications for the current understanding of the SLC6 NTTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa7rqrgWDrurVg90H21EOLACvtfcHk0lh9vqGgJ_lbrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtb3O&md5=354a72260448d8ec68cb8b5e0e3c45d4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fpr.108.000869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.108.000869%26sid%3Dliteratum%253Aachs%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26aulast%3DAndersen%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DT.%2BN.%26aulast%3DSorensen%26aufirst%3DL.%26aulast%3DEriksen%26aufirst%3DJ.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DStromgaard%26aufirst%3DK.%26aulast%3DGether%26aufirst%3DU.%26atitle%3DSLC6%2520neurotransmitter%2520transporters%253A%2520structure%252C%2520function%252C%2520and%2520regulation%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26issue%3D3%26spage%3D585%26epage%3D640%26doi%3D10.1124%2Fpr.108.000869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pramod, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. K.</span></span> <span> </span><span class="NLM_article-title">SLC6 transporters: structure, function, regulation, disease association and therapeutics</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">219</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=197-219&issue=2%E2%80%933&author=A.+B.+Pramodauthor=J.+Fosterauthor=L.+Carvelliauthor=L.+K.+Henry&title=SLC6+transporters%3A+structure%2C+function%2C+regulation%2C+disease+association+and+therapeutics&doi=10.1016%2Fj.mam.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6 transporters: Structure, function, regulation, disease association and therapeutics</span></div><div class="casAuthors">Pramod, Akula Bala; Foster, James; Carvelli, Lucia; Henry, L. Keith</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">197-219</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The SLC6 family of secondary active transporters are integral membrane solute carrier proteins characterized by the Na+-dependent translocation of small amino acid or amino acid-like substrates.  SLC6 transporters, which include the serotonin, dopamine, norepinephrine, GABA, taurine, creatine, as well as amino acid transporters, are assocd. with a no. of human diseases and disorders making this family a crit. target for therapeutic development.  In addn., several members of this family are directly involved in the action of drugs of abuse such as cocaine, amphetamines, and ecstasy.  Recent advances providing structural insight into this family have vastly accelerated our ability to study these proteins and their involvement in complex biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAzktUjNxilrVg90H21EOLACvtfcHk0lh9vqGgJ_lbrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jurg%253D&md5=4a6f7cbd7781c11178de3d6b8e2516be</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DPramod%26aufirst%3DA.%2BB.%26aulast%3DFoster%26aufirst%3DJ.%26aulast%3DCarvelli%26aufirst%3DL.%26aulast%3DHenry%26aufirst%3DL.%2BK.%26atitle%3DSLC6%2520transporters%253A%2520structure%252C%2520function%252C%2520regulation%252C%2520disease%2520association%2520and%2520therapeutics%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D197%26epage%3D219%26doi%3D10.1016%2Fj.mam.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M. W.</span></span> <span> </span><span class="NLM_article-title">Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6</span>. <i>Pfluegers Arch.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">519</span>â <span class="NLM_lpage">531</span>, <span class="refDoi">Â DOI: 10.1007/s00424-003-1064-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00424-003-1064-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12719981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVygs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2004&pages=519-531&issue=5&author=N.+H.+Chenauthor=M.+E.+Reithauthor=M.+W.+Quick&title=Synaptic+uptake+and+beyond%3A+the+sodium-+and+chloride-dependent+neurotransmitter+transporter+family+SLC6&doi=10.1007%2Fs00424-003-1064-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6</span></div><div class="casAuthors">Chen, Nian-Hang; Reith, Maarten E. A.; Quick, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Pfluegers Archiv</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-531</span>CODEN:
                <span class="NLM_cas:coden">PFLABK</span>;
        ISSN:<span class="NLM_cas:issn">0031-6768</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  The SLC6 family is a diverse set of transporters that mediate solute translocation across cell plasma membranes by coupling solute transport to the cotransport of sodium and chloride down their electrochem. gradients.  These transporters probably have 12 transmembrane domains, with cytoplasmic N- and C-terminal tails, and at least some may function as homo-oligomers.  Family members include the transporters for the inhibitory neurotransmitters GABA and glycine, the aminergic transmitters norepinephrine, serotonin, and dopamine, the osmolytes betaine and taurine, the amino acid proline, and the metabolic compd. creatine.  In addn., this family includes a system B0+ cationic and neutral amino acid transporter, and two transporters for which the solutes are unknown.  In general, SLC6 transporters act to regulate the level of extracellular solute concns.  In the central and the peripheral nervous system, these transporters can regulate signaling among neurons, are the sites of action of various drugs of abuse, and naturally occurring mutations in several of these proteins are assocd. with a variety of neurol. disorders.  For example, transgenic animals lacking specific aminergic transporters show profoundly disturbed behavioral phenotypes and probably represent excellent systems for investigating psychiatric disease.  SLC6 transporters are also found in many non-neural tissues, including kidney, intestine, and testis, consistent with their diverse physiol. roles.  Transporters in this family represent attractive therapeutic targets because they are subject to multiple forms of regulation by many different signaling cascades, and because a no. of pharmacol. agents have been identified that act specifically on these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN0HkC6ZQG77Vg90H21EOLACvtfcHk0lg5vXWWdV2NTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVygs7o%253D&md5=a1f3ae53461103ce9f2d7435c014022a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs00424-003-1064-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00424-003-1064-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%2BH.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DQuick%26aufirst%3DM.%2BW.%26atitle%3DSynaptic%2520uptake%2520and%2520beyond%253A%2520the%2520sodium-%2520and%2520chloride-dependent%2520neurotransmitter%2520transporter%2520family%2520SLC6%26jtitle%3DPfluegers%2520Arch.%26date%3D2004%26volume%3D447%26issue%3D5%26spage%3D519%26epage%3D531%26doi%3D10.1007%2Fs00424-003-1064-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scimemi, A.</span></span> <span> </span><span class="NLM_article-title">Structure, function, and plasticity of GABA transporters</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">161</span>, <span class="refDoi">Â DOI: 10.3389/fncel.2014.00161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffncel.2014.00161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24987330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGnurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=161&author=A.+Scimemi&title=Structure%2C+function%2C+and+plasticity+of+GABA+transporters&doi=10.3389%2Ffncel.2014.00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, function, and plasticity of GABA transporters</span></div><div class="casAuthors">Scimemi, Annalisa</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161/1-161/14</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  GABA transporters belong to a large family of neurotransmitter:sodium symporters.  They are widely expressed throughout the brain, with different levels of expression in different brain regions.  GABA transporters are present in neurons and in astrocytes and their activity is crucial to regulate the extracellular concn. of GABA under basal conditions and during ongoing synaptic events.  Numerous efforts have been devoted to det. the structural and functional properties of GABA transporters.  There is also evidence that the expression of GABA transporters on the cell membrane and their lateral mobility can be modulated by different intracellular signaling cascades.  The strength of individual synaptic contacts and the activity of entire neuronal networks may be finely tuned by altering the d., distribution and diffusion rate of GABA transporters within the cell membrane.  These findings are intriguing because they suggest the existence of complex regulatory systems that control the plasticity of GABAergic transmission in the brain.  Here we review the current knowledge on the structural and functional properties of GABA transporters and highlight the mol. mechanisms that alter the expression and mobility of GABA transporters at central synapses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcN1Rw0fET2LVg90H21EOLACvtfcHk0lg5vXWWdV2NTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGnurvP&md5=e142869ea8efd357282a6fd212febedf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2014.00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2014.00161%26sid%3Dliteratum%253Aachs%26aulast%3DScimemi%26aufirst%3DA.%26atitle%3DStructure%252C%2520function%252C%2520and%2520plasticity%2520of%2520GABA%2520transporters%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D161%26doi%3D10.3389%2Ffncel.2014.00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Indiveri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobazzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giangregorio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infantino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Convertini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Console, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span> <span> </span><span class="NLM_article-title">The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4â6</span>),  <span class="NLM_fpage">223</span>â <span class="NLM_lpage">233</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22020112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2rsL%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=223-233&issue=4%E2%80%936&author=C.+Indiveriauthor=V.+Iacobazziauthor=A.+Tonazziauthor=N.+Giangregorioauthor=V.+Infantinoauthor=P.+Convertiniauthor=L.+Consoleauthor=F.+Palmieri&title=The+mitochondrial+carnitine%2Facylcarnitine+carrier%3A+function%2C+structure+and+physiopathology&doi=10.1016%2Fj.mam.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology</span></div><div class="casAuthors">Indiveri, Cesare; Iacobazzi, Vito; Tonazzi, Annamaria; Giangregorio, Nicola; Infantino, Vittoria; Convertini, Paolo; Console, Lara; Palmieri, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">223-233</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The carnitine/acylcarnitine carrier (CAC) is a transport protein of the inner mitochondrial membrane that belongs to the mitochondrial carrier protein family.  In its cytosolic conformation the carrier consists of a bundle of six transmembrane Î±-helixes, which delimit a water filled cavity opened towards the cytosol and closed towards the matrix by a network of interacting charged residues.  Most of the functional data on this transporter come from studies performed with the protein purified from rat liver mitochondria or recombinant proteins from different sources incorporated into phospholipid vesicles (liposomes).  The carnitine/acylcarnitine carrier transports carnitine and acylcarnitines with acyl chains of various lengths from 2 to 18 carbon atoms.  The mammalian transporter exhibits higher affinity for acylcarnitines with longer carbon chains.  The functional data indicate that CAC plays the important function of catalyzing transport of acylcarnitines into the mitochondria in exchange for intramitochondrial free carnitine.  This results in net transport of fatty acyl units into the mitochondrial matrix where they are oxidized by the Î²-oxidn. enzymes.  The essential role of the transporter in cell metab. is demonstrated by the fact that alterations of the human gene SLC25A20 coding for CAC are assocd. with a severe disease known as carnitine carrier deficiency.  This autosomal recessive disorder is characterized by life-threatening episodes of coma induced by fasting, cardiomyopathy, liver dysfunction, muscle weakness, respiratory distress and seizures.  Until now 35 different mutations of CAC gene have been identified in carnitine carrier deficient patients.  Some missense mutations concern residues of the signature motif present in all mitochondrial carriers.  Diagnosis of carnitine carrier deficiency requires biochem. and genetic tests; treatment is essentially limited to important dietetic measures.  Recently, a pharmacol. approach based on the use of statins and/or fibrates for the treatment of CAC-deficient patients with mild phenotype has been proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoy5f8AJp477Vg90H21EOLACvtfcHk0lg5vXWWdV2NTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2rsL%252FO&md5=431e35a560cf1ddf81647de62b92f4bf</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DIndiveri%26aufirst%3DC.%26aulast%3DIacobazzi%26aufirst%3DV.%26aulast%3DTonazzi%26aufirst%3DA.%26aulast%3DGiangregorio%26aufirst%3DN.%26aulast%3DInfantino%26aufirst%3DV.%26aulast%3DConvertini%26aufirst%3DP.%26aulast%3DConsole%26aufirst%3DL.%26aulast%3DPalmieri%26aufirst%3DF.%26atitle%3DThe%2520mitochondrial%2520carnitine%252Facylcarnitine%2520carrier%253A%2520function%252C%2520structure%2520and%2520physiopathology%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2011%26volume%3D32%26issue%3D4%25E2%2580%25936%26spage%3D223%26epage%3D233%26doi%3D10.1016%2Fj.mam.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepien, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torroni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D. C.</span></span> <span> </span><span class="NLM_article-title">Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">14592</span>â <span class="NLM_lpage">14597</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1378836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK38Xlt1ymuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=14592-14597&issue=21&author=G.+Stepienauthor=A.+Torroniauthor=A.+B.+Chungauthor=J.+A.+Hodgeauthor=D.+C.+Wallace&title=Differential+expression+of+adenine+nucleotide+translocator+isoforms+in+mammalian+tissues+and+during+muscle+cell+differentiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation</span></div><div class="casAuthors">Stepien, Georges; Torroni, Antonio; Chung, Andrew B.; Hodge, Judy A.; Wallace, Douglas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">14592-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The adenine nucleotide translocator (ANT) catalyzes the exchange of ADP and ATP across the mitochondrial internal membrane.  Its 3 isoforms, ANT1, ANT2, and ANT3 are coded by differentially regulated nuclear genes.  The patterns of expression of these genes in human, bovine, and mouse tissue are similar.  ANT1 is highly expressed in heart and skeletal muscle and is induced during myoblast differentiation.  It is coordinately regulated with the nuclear gene for the mitochondrial ATP synthase Î² subunit, with which it shares the pos. muscle cis element, OXBOX.  ANT2 is either absent or weakly expressed in all tissues.  ANT3 is ubiquitously expressed in all tissues, and its transcript level is proportional to the level of oxidative metab.  The tissue-specific expression of the ANT gene family thus provides insight into the mol. basis of the differential reliance of mammalian tissues on oxidative phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhX6W_NrJ6KLVg90H21EOLACvtfcHk0lhkBPNWylLp2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xlt1ymuro%253D&md5=ab29cfead648041d2772bb26e673e5d5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStepien%26aufirst%3DG.%26aulast%3DTorroni%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DA.%2BB.%26aulast%3DHodge%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DD.%2BC.%26atitle%3DDifferential%2520expression%2520of%2520adenine%2520nucleotide%2520translocator%2520isoforms%2520in%2520mammalian%2520tissues%2520and%2520during%2520muscle%2520cell%2520differentiation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26issue%3D21%26spage%3D14592%26epage%3D14597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedorenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lishko, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirichok, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>151</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">400</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2012.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2012.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23063128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qtL7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2012&pages=400-413&issue=2&author=A.+Fedorenkoauthor=P.+V.+Lishkoauthor=Y.+Kirichok&title=Mechanism+of+fatty-acid-dependent+UCP1+uncoupling+in+brown+fat+mitochondria&doi=10.1016%2Fj.cell.2012.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Fatty-Acid-Dependent UCP1 Uncoupling in Brown Fat Mitochondria</span></div><div class="casAuthors">Fedorenko, Andriy; Lishko, Polina V.; Kirichok, Yuriy</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">400-413</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mitochondrial uncoupling protein 1 (UCP1) is responsible for nonshivering thermogenesis in brown adipose tissue (BAT).  Upon activation by long-chain fatty acids (LCFAs), UCP1 increases the conductance of the inner mitochondrial membrane (IMM) to make BAT mitochondria generate heat rather than ATP.  Despite being a member of the family of mitochondrial anion carriers (SLC25), UCP1 is believed to transport H+ by an unusual mechanism that has long remained unresolved.  Here, we achieved direct patch-clamp measurements of UCP1 currents from the IMM of BAT mitochondria.  We show that UCP1 is an LCFA anion/H+ symporter.  However, the LCFA anions cannot dissoc. from UCP1 due to hydrophobic interactions established by their hydrophobic tails, and UCP1 effectively operates as an H+ carrier activated by LCFA.  A similar LCFA-dependent mechanism of transmembrane H+ transport may be employed by other SLC25 members and be responsible for mitochondrial uncoupling and regulation of metabolic efficiency in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrid7PUVLnEC7Vg90H21EOLACvtfcHk0lhkBPNWylLp2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qtL7P&md5=0f2dbf775c28a5981e45da22104eca87</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DFedorenko%26aufirst%3DA.%26aulast%3DLishko%26aufirst%3DP.%2BV.%26aulast%3DKirichok%26aufirst%3DY.%26atitle%3DMechanism%2520of%2520fatty-acid-dependent%2520UCP1%2520uncoupling%2520in%2520brown%2520fat%2520mitochondria%26jtitle%3DCell%26date%3D2012%26volume%3D151%26issue%3D2%26spage%3D400%26epage%3D413%26doi%3D10.1016%2Fj.cell.2012.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonne, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler-Keylin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luijten, I. H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajimura, S.</span></span> <span> </span><span class="NLM_article-title">ThermoMouse: an in vivo model to identify modulators of UCP1 expression in brown adipose tissue</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1584</span>â <span class="NLM_lpage">1593</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2014.10.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.celrep.2014.10.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25466254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2gs7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1584-1593&issue=5&author=A.+Galmozziauthor=S.+B.+Sonneauthor=S.+Altshuler-Keylinauthor=Y.+Hasegawaauthor=K.+Shinodaauthor=I.+H.+N.+Luijtenauthor=J.+W.+Changauthor=L.+Z.+Sharpauthor=B.+F.+Cravattauthor=E.+Saezauthor=S.+Kajimura&title=ThermoMouse%3A+an+in+vivo+model+to+identify+modulators+of+UCP1+expression+in+brown+adipose+tissue&doi=10.1016%2Fj.celrep.2014.10.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ThermoMouse: An In Vivo Model to Identify Modulators of UCP1 Expression in Brown Adipose Tissue</span></div><div class="casAuthors">Galmozzi, Andrea; Sonne, Si B.; Altshuler-Keylin, Svetlana; Hasegawa, Yutaka; Shinoda, Kosaku; Luijten, Ineke H. N.; Chang, Jae Won; Sharp, Louis Z.; Cravatt, Benjamin F.; Saez, Enrique; Kajimura, Shingo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1584-1593</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Obesity develops when energy intake chronically exceeds energy expenditure.  Because brown adipose tissue (BAT) dissipates energy in the form of heat, increasing energy expenditure by augmenting BAT-mediated thermogenesis may represent an approach to counter obesity and its complications.  The ability of BAT to dissipate energy is dependent on expression of mitochondrial uncoupling protein 1 (UCP1).  To facilitate the identification of pharmacol. modulators of BAT UCP1 levels, which may have potential as antiobesity medications, we developed a transgenic model in which luciferase activity faithfully mimics endogenous UCP1 expression and its response to physiol. stimuli.  Phenotypic screening of a library using cells derived from this model yielded a small mol. that increases UCP1 expression in brown fat cells and mice.  Upon adrenergic stimulation, compd.-treated mice showed increased energy expenditure.  These tools offer an opportunity to identify pharmacol. modulators of UCP1 expression and uncover regulatory pathways that impact BAT-mediated thermogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFEGenyPvq5rVg90H21EOLACvtfcHk0lhkBPNWylLp2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2gs7%252FE&md5=4fb09e6c83ab5a2da2e30d27f6e8e7ee</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.10.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.10.066%26sid%3Dliteratum%253Aachs%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DSonne%26aufirst%3DS.%2BB.%26aulast%3DAltshuler-Keylin%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DShinoda%26aufirst%3DK.%26aulast%3DLuijten%26aufirst%3DI.%2BH.%2BN.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DSharp%26aufirst%3DL.%2BZ.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DKajimura%26aufirst%3DS.%26atitle%3DThermoMouse%253A%2520an%2520in%2520vivo%2520model%2520to%2520identify%2520modulators%2520of%2520UCP1%2520expression%2520in%2520brown%2520adipose%2520tissue%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D9%26issue%3D5%26spage%3D1584%26epage%3D1593%26doi%3D10.1016%2Fj.celrep.2014.10.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madejczyk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballatori, N.</span></span> <span> </span><span class="NLM_article-title">The iron transporter ferroportin can also function as a manganese exporter</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1818</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">651</span>â <span class="NLM_lpage">657</span>, <span class="refDoi">Â DOI: 10.1016/j.bbamem.2011.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bbamem.2011.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFartbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1818&publication_year=2012&pages=651-657&issue=3&author=M.+S.+Madejczykauthor=N.+Ballatori&title=The+iron+transporter+ferroportin+can+also+function+as+a+manganese+exporter&doi=10.1016%2Fj.bbamem.2011.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The iron transporter ferroportin can also function as a manganese exporter</span></div><div class="casAuthors">Madejczyk, Michael S.; Ballatori, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1818</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">651-657</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study examd. the hypothesis that the iron exporter ferroportin (FPN1/SLC40A1) can also mediate cellular export of the essential trace element manganese, using Xenopus laevis oocytes expressing human FPN1.  When compared to oocytes expressing only the divalent metal transporter-1 (DMT1/NRAMP2), 54Mn accumulation was lower in oocytes also expressing FPN1.  FPN1-expressing oocytes exported more 54Mn than control oocytes (26.6 Â± 0.6% vs. 7.1 Â± 0.5%, resp., over 4 h at pH 7.4 when preloaded with approx. 16 Î¼M 54Mn); however, there was no difference in 54Mn uptake between control and FPN1-expressing oocytes.  FPN1-mediated Mn export was concn. dependent and could be partially cis-inhibited by 100 Î¼M Fe, Co, and Ni, but not by Rb.  In addn., Mn export ability was significantly reduced when the extracellular pH was reduced from 7.4 to 5.5, and when Na+ was substituted with K+ in the incubation media.  These results indicate that Mn is a substrate for FPN1, and that this export process is inhibited by a low extracellular pH and by incubation in a high K+ medium, indicating the involvement of transmembrane ion gradients in FPN1-mediated transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1RobrQmbJ7Vg90H21EOLACvtfcHk0lhkBPNWylLp2g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFartbk%253D&md5=b6eca99ba543e2de81fc68e6df23c7c0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2011.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2011.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DMadejczyk%26aufirst%3DM.%2BS.%26aulast%3DBallatori%26aufirst%3DN.%26atitle%3DThe%2520iron%2520transporter%2520ferroportin%2520can%2520also%2520function%2520as%2520a%2520manganese%2520exporter%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2012%26volume%3D1818%26issue%3D3%26spage%3D651%26epage%3D657%26doi%3D10.1016%2Fj.bbamem.2011.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalbetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span> <span> </span><span class="NLM_article-title">Mammalian iron transporters: families SLC11 and SLC40</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">270</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2013.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2013.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=270-287&issue=2%E2%80%933&author=N.+Montalbettiauthor=A.+Simoninauthor=G.+Kovacsauthor=M.+A.+Hediger&title=Mammalian+iron+transporters%3A+families+SLC11+and+SLC40&doi=10.1016%2Fj.mam.2013.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian iron transporters: Families SLC11 and SLC40</span></div><div class="casAuthors">Montalbetti, Nicolas; Simonin, Alexandre; Kovacs, Gergely; Hediger, Matthias A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">270-287</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This review is focused on the mammalian SLC11 and SLC40 families and their roles in iron homeostasis.  The SLC11 family is composed of two members, SLC11A1 and SLC11A2.  SLC11A1 is expressed in the lysosomal compartment of macrophages and in the tertiary granules of neutrophils, playing a key role in innate resistance against infection by intracellular microbes.  SLC11A2 is a key player in iron metab. and is ubiquitously expressed, most notably in the proximal duodenum, immature erythroid cells, brain, placenta and kidney.  Intestinal iron absorption is mediated by SLC11A2 at the apical membrane of enterocytes, followed by basolateral exit via SLC40A1.  To meet the daily requirement for iron, approx. 80% of the iron comes from the breakdown of Hb following macrophage phagocytosis of senescent erythrocytes (iron recycling).  Both SLC11A1 and SLC11A2 play an important role in macrophage iron recycling.  SLC11A2 also transports iron into the cytosol across the membrane of endocytotic vesicles of the transferrin receptor-cycle.  SLC40A1 is the sole member of the SLC40 family and is involved in the only cellular iron efflux mechanism described.  SLC40A1 is highly expressed in several tissues and cells that play a crit. role in body iron homeostasis.  The signaling pathways that regulate SLC11A2 and SLC40A1 expression at transcriptional, post-transcriptional and post-translational levels are discussed.  The roles of SLC11A2 and/or SLC40A1 in iron-assocd. disorders such as hemochromatosis, neurodegenerative diseases, and breast cancer are also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9krct7mErb7Vg90H21EOLACvtfcHk0lgFiLdopq5rCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jtL4%253D&md5=b17d4baaf3fadb6915ea4b6f5108647e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontalbetti%26aufirst%3DN.%26aulast%3DSimonin%26aufirst%3DA.%26aulast%3DKovacs%26aufirst%3DG.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26atitle%3DMammalian%2520iron%2520transporters%253A%2520families%2520SLC11%2520and%2520SLC40%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D270%26epage%3D287%26doi%3D10.1016%2Fj.mam.2013.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eide, D. J.</span></span> <span> </span><span class="NLM_article-title">Zinc transporters and the cellular trafficking of zinc</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1763</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">711</span>â <span class="NLM_lpage">722</span>, <span class="refDoi">Â DOI: 10.1016/j.bbamcr.2006.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bbamcr.2006.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=16675045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFGqu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1763&publication_year=2006&pages=711-722&issue=7&author=D.+J.+Eide&title=Zinc+transporters+and+the+cellular+trafficking+of+zinc&doi=10.1016%2Fj.bbamcr.2006.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc transporters and the cellular trafficking of zinc</span></div><div class="casAuthors">Eide, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1763</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">711-722</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Zinc is an essential nutrient for all organisms because this metal serves as a catalytic or structural cofactor for many different proteins.  Zinc-dependent proteins are found in the cytoplasm and within many organelles of the eukaryotic cell including the nucleus, the endoplasmic reticulum, Golgi, secretory vesicles, and mitochondria.  Thus, cells require zinc transport mechanisms to allow cells to efficiently accumulate the metal ion and distribute it within the cell.  Our current knowledge of these transport systems in eukaryotes is the focus of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWy56fsCOa5bVg90H21EOLACvtfcHk0lgFiLdopq5rCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFGqu7g%253D&md5=a0aff8021307e525093d9ba2fccf6350</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2006.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2006.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DD.%2BJ.%26atitle%3DZinc%2520transporters%2520and%2520the%2520cellular%2520trafficking%2520of%2520zinc%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2006%26volume%3D1763%26issue%3D7%26spage%3D711%26epage%3D722%26doi%3D10.1016%2Fj.bbamcr.2006.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petris, M. J.</span></span> <span> </span><span class="NLM_article-title">The SLC31 (Ctr) copper transporter family</span>. <i>Pfluegers Arch.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">755</span>, <span class="refDoi">Â DOI: 10.1007/s00424-003-1092-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00424-003-1092-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12827356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVygsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2004&pages=752-755&issue=5&author=M.+J.+Petris&title=The+SLC31+%28Ctr%29+copper+transporter+family&doi=10.1007%2Fs00424-003-1092-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC31 (Ctr) copper transporter family</span></div><div class="casAuthors">Petris, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Pfluegers Archiv</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">752-755</span>CODEN:
                <span class="NLM_cas:coden">PFLABK</span>;
        ISSN:<span class="NLM_cas:issn">0031-6768</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Copper is essential for many copper-dependent processes, including mitochondrial oxidative phosphorylation, free-radical detoxification, pigmentation, neurotransmitter synthesis, and iron metab.  The identification of proteins for high affinity copper uptake and export has greatly expanded our understanding of cellular copper homeostasis.  Copper export in human cells is mediated by the ATP7A and ATP7B P-type ATPases, which are, resp., affected in the genetic disorders of copper metab., Menkes disease and Wilson disease.  A different class of transporter known as the SLC31 or Ctr family of proteins mediates cellular copper uptake.  These high-affinity copper transporters exist in all eukaryotes and their discovery has provided new insights into how cells acquire and regulate this essential nutrient.  The following is a brief overview of the SLC31 copper transporter family with a focus on the human hCtr1 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoob5ur56LA1bVg90H21EOLACvtfcHk0lgFiLdopq5rCw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVygsbs%253D&md5=ca8058867568cd43ef00ebf23499b7b3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00424-003-1092-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00424-003-1092-1%26sid%3Dliteratum%253Aachs%26aulast%3DPetris%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520SLC31%2520%2528Ctr%2529%2520copper%2520transporter%2520family%26jtitle%3DPfluegers%2520Arch.%26date%3D2004%26volume%3D447%26issue%3D5%26spage%3D752%26epage%3D755%26doi%3D10.1007%2Fs00424-003-1092-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schweigel-Rontgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolisek, M.</span></span> <span> </span><span class="NLM_article-title">SLC41 transporters-molecular identification and functional role</span>. <i>Curr. Top. Membr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">410</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-800223-0.00011-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FB978-0-12-800223-0.00011-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24745990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2cnltFajsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=383-410&author=M.+Schweigel-Rontgenauthor=M.+Kolisek&title=SLC41+transporters-molecular+identification+and+functional+role&doi=10.1016%2FB978-0-12-800223-0.00011-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">SLC41 transporters--molecular identification and functional role</span></div><div class="casAuthors">Schweigel-Rontgen Monika; Kolisek Martin</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in membranes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">383-410</span>
        ISSN:<span class="NLM_cas:issn">1063-5823</span>.
    </div><div class="casAbstract">The solute carrier family 41 (SLC41) encompasses three members A1, A2, and A3.  Based on their distant homology to the bacterial Mg2+ channel MgtE, all have been linked to Mg2+ transport.  There is only very limited knowledge on the molecular biology and exact functions of SLC41A2 and SLC41A3.  SLC41A1 is ubiquitously expressed and data on its functional and molecular properties, regulation, complex-forming ability, and spectrum of binding partners are available.  SLC41A1 was recently identified as being the Na+/Mg2+ exchanger (NME)-a predominant Mg2+ efflux system.  Mg2+-dependent and hormonal regulation of NME activity is now known to depend on the intracellular N terminus of SLC41A1 that is involved in Mg2+ sensing and contains phosphorylation sites for protein kinase (PK) A and PKC.  Data showing a link between SLC41A1 and human disorders such as Parkinson's disease, nephronophthisis (induced by the null mutation c.698G>T in renal SLC41A1), and preeclampsia make the protein a candidate therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjyOa2EH75A0EksK8CslK8fW6udTcc2eYnwryjveR3ZLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnltFajsA%253D%253D&md5=6564cf6c16fa36094fe7710a745b8a32</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800223-0.00011-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800223-0.00011-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchweigel-Rontgen%26aufirst%3DM.%26aulast%3DKolisek%26aufirst%3DM.%26atitle%3DSLC41%2520transporters-molecular%2520identification%2520and%2520functional%2520role%26jtitle%3DCurr.%2520Top.%2520Membr.%26date%3D2014%26volume%3D73%26spage%3D383%26epage%3D410%26doi%3D10.1016%2FB978-0-12-800223-0.00011-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrion, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. A.</span></span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2017/18: transporters</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">S360</span>â <span class="NLM_lpage">S446</span>, <span class="refDoi">Â DOI: 10.1111/bph.13883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fbph.13883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29055035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=S360-S446&author=S.+P.+Alexanderauthor=E.+Kellyauthor=N.+V.+Marrionauthor=J.+A.+Petersauthor=E.+Faccendaauthor=S.+D.+Hardingauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=C.+Southanauthor=J.+A.+Davies&title=The+concise+guide+to+pharmacology+2017%2F18%3A+transporters&doi=10.1111%2Fbph.13883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters</span></div><div class="casAuthors">Alexander, Stephen P. H.; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena; Harding, Simon D.; Pawson, Adam J.; Sharman, Joanna L.; Southan, Christopher; Davies, Jamie A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">S360-S446</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Concise Guide to PHARMACOl. 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacol. (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacol.org), which provides more detailed views of target and ligand properties.  Although the Concise Guide represents approx. 400 pages, the material presented is substantially reduced compared to information and links presented on the website.  It provides a permanent, citable, point-in-time record that will survive database updates.  The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13883/full.  Transporters are one of the eight major pharmacol. targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors and enzymes.  These are presented with nomenclature guidance and summary information on the best available pharmacol. tools, alongside key refs. and suggestions for further reading.  The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels.  It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clin. Pharmacol. (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVLQ5zlSHuY7Vg90H21EOLACvtfcHk0ljoR6KlgYJUNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FL&md5=cd03a74d7c3f1c0c959211704ebe1cd2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fbph.13883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13883%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DMarrion%26aufirst%3DN.%2BV.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DS.%2BD.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202017%252F18%253A%2520transporters%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D174%26spage%3DS360%26epage%3DS446%26doi%3D10.1111%2Fbph.13883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maret, W.</span></span> <span> </span><span class="NLM_article-title">Zinc in cellular regulation: the nature and significance of â³zinc signalsâ³</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2285</span>, <span class="refDoi">Â DOI: 10.3390/ijms18112285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3390%2Fijms18112285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgu7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2285&issue=11&author=W.+Maret&title=Zinc+in+cellular+regulation%3A+the+nature+and+significance+of+%E2%80%B3zinc+signals%E2%80%B3&doi=10.3390%2Fijms18112285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc in cellular regulation: the nature and significance of "zinc signals"</span></div><div class="casAuthors">Maret, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2285/1-2285/12</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the last decade, we witnessed discoveries that established Zn2+ as a second major signalling metal ion in the transmission of information within cells and in communication between cells.  Together with Ca2+ and Mg2+, Zn2+ covers biol. regulation with redox-inert metal ions over many orders of magnitude in concns.  The regulatory functions of zinc ions, together with their functions as a cofactor in about three thousand zinc metalloproteins, impact virtually all aspects of cell biol.  This article attempts to define the regulatory functions of zinc ions, and focuses on the nature of zinc signals and zinc signalling in pathways where zinc ions are either extracellular stimuli or intracellular messengers.  These pathways interact with Ca2+, redox, and phosphorylation signalling.  The regulatory functions of zinc require a complex system of precise homeostatic control for transients, subcellular distribution and traffic, organellar homeostasis, and vesicular storage and exocytosis of zinc ions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1-5UXm4cj0bVg90H21EOLACvtfcHk0ljoR6KlgYJUNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgu7vK&md5=44287582ded0f3f7319b4326ad03f119</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3390%2Fijms18112285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18112285%26sid%3Dliteratum%253Aachs%26aulast%3DMaret%26aufirst%3DW.%26atitle%3DZinc%2520in%2520cellular%2520regulation%253A%2520the%2520nature%2520and%2520significance%2520of%2520%25E2%2580%25B3zinc%2520signals%25E2%2580%25B3%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D2285%26doi%3D10.3390%2Fijms18112285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzlau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, R. M.</span></span> <span> </span><span class="NLM_article-title">Zinc transporter 8 (ZnT8) and beta cell function</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">424</span>, <span class="refDoi">Â DOI: 10.1016/j.tem.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tem.2014.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24751356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFCms7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=415-424&issue=8&author=H.+W.+Davidsonauthor=J.+M.+Wenzlauauthor=R.+M.+O%E2%80%99Brien&title=Zinc+transporter+8+%28ZnT8%29+and+beta+cell+function&doi=10.1016%2Fj.tem.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc transporter 8 (ZnT8) and Î² cell function</span></div><div class="casAuthors">Davidson, Howard W.; Wenzlau, Janet M.; O'Brien, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">415-424</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human pancreatic Î² cells have exceptionally high zinc content.  In Î² cells the highest zinc concn. is in insulin secretory granules, from which it is cosecreted with the hormone.  Uptake of zinc into secretory granules is mainly mediated by zinc transporter 8 (ZnT8), the product of the SLC30A8 [solute carrier family 30 (zinc transporter), member 8] gene.  The minor alleles of several single-nucleotide polymorphisms (SNPs) in SLC30A8 are assocd. with decreased risk of type 2 diabetes (T2D), but the precise mechanisms underlying the protective effects remain uncertain.  In this article we review current knowledge of the role of ZnT8 in maintaining zinc homeostasis in Î² cells, its role in glucose metab. based on knockout mouse studies, and current theories regarding the link between ZnT8 function and T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcprSfV2FvIbVg90H21EOLACvtfcHk0ljoR6KlgYJUNg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFCms7Y%253D&md5=24c8474701fe010bb771fd53f40c6501</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DH.%2BW.%26aulast%3DWenzlau%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DR.%2BM.%26atitle%3DZinc%2520transporter%25208%2520%2528ZnT8%2529%2520and%2520beta%2520cell%2520function%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2014%26volume%3D25%26issue%3D8%26spage%3D415%26epage%3D424%26doi%3D10.1016%2Fj.tem.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettifer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chichester, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willighagen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evelo, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mons, B.</span></span> <span> </span><span class="NLM_article-title">Open PHACTS: semantic interoperability for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">21â22</span>),  <span class="NLM_fpage">1188</span>â <span class="NLM_lpage">1198</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2012.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.drudis.2012.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22683805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC38jgsVWqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1188-1198&issue=21%E2%80%9322&author=A.+J.+Williamsauthor=L.+Harlandauthor=P.+Grothauthor=S.+Pettiferauthor=C.+Chichesterauthor=E.+L.+Willighagenauthor=C.+T.+Eveloauthor=N.+Blombergauthor=G.+Eckerauthor=C.+Gobleauthor=B.+Mons&title=Open+PHACTS%3A+semantic+interoperability+for+drug+discovery&doi=10.1016%2Fj.drudis.2012.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Open PHACTS: semantic interoperability for drug discovery</span></div><div class="casAuthors">Williams Antony J; Harland Lee; Groth Paul; Pettifer Stephen; Chichester Christine; Willighagen Egon L; Evelo Chris T; Blomberg Niklas; Ecker Gerhard; Goble Carole; Mons Barend</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21-22</span>),
    <span class="NLM_cas:pages">1188-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Open PHACTS is a public-private partnership between academia, publishers, small and medium sized enterprises and pharmaceutical companies.  The goal of the project is to deliver and sustain an 'open pharmacological space' using and enhancing state-of-the-art semantic web standards and technologies.  It is focused on practical and robust applications to solve specific questions in drug discovery research.  OPS is intended to facilitate improvements in drug discovery in academia and industry and to support open innovation and in-house non-public drug discovery research.  This paper lays out the challenges and how the Open PHACTS project is hoping to address these challenges technically and socially.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgQwQiZHAzrVw2ofyr07jXfW6udTcc2eYMZgwbFBip_rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jgsVWqtQ%253D%253D&md5=ae3584b34948d7f6e92aee3ef36cc6a8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DHarland%26aufirst%3DL.%26aulast%3DGroth%26aufirst%3DP.%26aulast%3DPettifer%26aufirst%3DS.%26aulast%3DChichester%26aufirst%3DC.%26aulast%3DWillighagen%26aufirst%3DE.%2BL.%26aulast%3DEvelo%26aufirst%3DC.%2BT.%26aulast%3DBlomberg%26aufirst%3DN.%26aulast%3DEcker%26aufirst%3DG.%26aulast%3DGoble%26aufirst%3DC.%26aulast%3DMons%26aufirst%3DB.%26atitle%3DOpen%2520PHACTS%253A%2520semantic%2520interoperability%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D21%25E2%2580%259322%26spage%3D1188%26epage%3D1198%26doi%3D10.1016%2Fj.drudis.2012.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Solute carriers as drug targets: current use, clinical trials and prospective</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">702</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=702-710&issue=2%E2%80%933&author=M.+Rask-Andersenauthor=S.+Masuramauthor=R.+Fredrikssonauthor=H.+B.+Schioth&title=Solute+carriers+as+drug+targets%3A+current+use%2C+clinical+trials+and+prospective&doi=10.1016%2Fj.mam.2012.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Solute carriers as drug targets: Current use, clinical trials and prospective</span></div><div class="casAuthors">Rask-Andersen, Mathias; Masuram, Surendar; Fredriksson, Robert; Schioeth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">702-710</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Solute carriers (SLCs) comprise a large family of membrane transporters responsible for the transmembrane transport of a wide variety of substrates such as inorg. ions, amino acids, neurotransmitters and sugars.  Despite being the largest family of membrane transport proteins, SLCs have been relatively under-utilized as therapeutic drug targets by approved drugs.  In this paper, we aim to catalog therapeutic SLCs utilized by approved drugs or currently in clin. trials.  By mining information on clin. trials from the Centerwatch.com "drugs in clin. trials database" we were able to identify potentially novel SLC drug targets currently under development.  We also searched the literature for SLCs that have been discussed as future therapeutic drug targets.  We find SLCs to be utilized as therapeutic targets in treatment of a wide variety of diseases and disorders, such as major depression, ADHD, osteoporosis and hypertension.  Drugs targeting SLCs for treatment of diabetes, constipation and hypercholesterolemia are currently in clin. trials.  SLC drug targets have also been explored in clin. trials for cardioprotection after an ischemic event.  SLCs are of particular interest as targets in antineoplastic treatment and for the targeted transport of cytotoxic drugs into tumors, e.g. via the glucose transporters GLUT1-5 and SGLT1-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDkN3N6VPYB7Vg90H21EOLACvtfcHk0lgLaY_il1DUgw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jsrc%253D&md5=a3c4d6f2da377bcea88b644524edd530</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DMasuram%26aufirst%3DS.%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DSolute%2520carriers%2520as%2520drug%2520targets%253A%2520current%2520use%252C%2520clinical%2520trials%2520and%2520prospective%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D702%26epage%3D710%26doi%3D10.1016%2Fj.mam.2012.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestler, E. J.</span></span> <span> </span><span class="NLM_article-title">The molecular neurobiology of depression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span> (<span class="NLM_issue">7215</span>),  <span class="NLM_fpage">894</span>â <span class="NLM_lpage">902</span>, <span class="refDoi">Â DOI: 10.1038/nature07455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature07455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=18923511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=894-902&issue=7215&author=V.+Krishnanauthor=E.+J.+Nestler&title=The+molecular+neurobiology+of+depression&doi=10.1038%2Fnature07455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular neurobiology of depression</span></div><div class="casAuthors">Krishnan, Vaishnav; Nestler, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">894-902</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Unraveling the pathophysiol. of depression is a unique challenge.  Not only are depressive syndromes heterogeneous and their etiologies diverse, but symptoms such as guilt and suicidality are impossible to reproduce in animal models.  Nevertheless, other symptoms have been accurately modeled, and these, together with clin. data, are providing insight into the neurobiol. of depression.  Recent studies combining behavioral, mol. and electrophysiol. techniques reveal that certain aspects of depression result from maladaptive stress-induced neuroplastic changes in specific neural circuits.  They also show that understanding the mechanisms of resilience to stress offers a crucial new dimension for the development of fundamentally novel antidepressant treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHLnyp4sMWLVg90H21EOLACvtfcHk0ljORuQtYWRRBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrE&md5=bed2e4ae1259f3670459ddaf2dbd3057</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnature07455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07455%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520molecular%2520neurobiology%2520of%2520depression%26jtitle%3DNature%26date%3D2008%26volume%3D455%26issue%3D7215%26spage%3D894%26epage%3D902%26doi%3D10.1038%2Fnature07455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarakad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Shahed, J.</span></span> <span> </span><span class="NLM_article-title">VMAT2 inhibitors in neuropsychiatric disorders</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1131</span>â <span class="NLM_lpage">1144</span>, <span class="refDoi">Â DOI: 10.1007/s40263-018-0580-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs40263-018-0580-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30306450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2qsrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1131-1144&issue=12&author=A.+Tarakadauthor=J.+Jimenez-Shahed&title=VMAT2+inhibitors+in+neuropsychiatric+disorders&doi=10.1007%2Fs40263-018-0580-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">VMAT2 Inhibitors in Neuropsychiatric Disorders</span></div><div class="casAuthors">Tarakad, Arjun; Jimenez-Shahed, Joohi</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1131-1144</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders.  Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have recently gained more attention following their development for specific indications in the United States.  At present, there are three com. available VMAT2 inhibitors: tetrabenazine, deutetrabenazine, and valbenazine.  Pharmacokinetics, metab., and dosing vary significantly between the three drugs, and likely underlie the more favorable side effect profile of the newer agents (deutetrabenazine and valbenazine).  Tetrabenazine and deutetrabenazine have demonstrated safety and efficacy in the treatment of chorea assocd. with Huntington's disease, including in randomized controlled trials, although direct comparison studies are limited.  Both deutetrabenazine and valbenazine have demonstrated safety and efficacy in the treatment of tardive dyskinesia, with multiple double-blind, placebo-controlled trials, whereas tetrabenazine has been studied less rigorously.  There have been no blinded, prospective trials with tetrabenazine in Tourette's syndrome (TS); however, double-blind, placebo-controlled trials in TS are ongoing for both deutetrabenazine and valbenazine.  Given the favored side effect profile of newer VMAT2 inhibitors, clinicians should be aware of the distinctions between agents and become familiar with differences in their use, esp. as there is potential for their utilization to increase across the range of hyperkinetic movement disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl38BcsTPsKbVg90H21EOLACvtfcHk0ljORuQtYWRRBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2qsrzO&md5=392d8e968bc87370060157b180035f8b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0580-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0580-y%26sid%3Dliteratum%253Aachs%26aulast%3DTarakad%26aufirst%3DA.%26aulast%3DJimenez-Shahed%26aufirst%3DJ.%26atitle%3DVMAT2%2520inhibitors%2520in%2520neuropsychiatric%2520disorders%26jtitle%3DCNS%2520Drugs%26date%3D2018%26volume%3D32%26issue%3D12%26spage%3D1131%26epage%3D1144%26doi%3D10.1007%2Fs40263-018-0580-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. L. G.</span></span> <span> </span><span class="NLM_article-title">Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3489</span>â <span class="NLM_lpage">3506</span>, <span class="refDoi">Â DOI: 10.1007/s00018-015-1937-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00018-015-1937-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26033496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFejtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=3489-3506&issue=18&author=K.+Takahashiauthor=J.+B.+Fosterauthor=C.+L.+G.+Lin&title=Glutamate+transporter+EAAT2%3A+regulation%2C+function%2C+and+potential+as+a+therapeutic+target+for+neurological+and+psychiatric+disease&doi=10.1007%2Fs00018-015-1937-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate transporter EAAT2- regulation, function, and potential as a therapeutic target for neurological and psychiatric disease</span></div><div class="casAuthors">Takahashi, Kou; Foster, Joshua B.; Lin, Chien-Liang Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3489-3506</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Glutamate is the predominant excitatory neurotransmitter in the central nervous system.  Excitatory amino acid transporter 2 (EAAT2) is primarily responsible for clearance of extracellular glutamate to prevent neuronal excitotoxicity and hyperexcitability.  EAAT2 plays a crit. role in regulation of synaptic activity and plasticity.  In addn., EAAT2 has been implicated in the pathogenesis of many central nervous system disorders.  In this review, we summarize current understanding of EAAT2, including structure, pharmacol., physiol., and functions, as well as disease relevancy, such as in stroke, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, major depressive disorder, and addiction.  A large no. of studies have demonstrated that up-regulation of EAAT2 protein provides significant beneficial effects in many disease models suggesting EAAT2 activation is a promising therapeutic approach.  Several EAAT2 activators have been identified.  Further understanding of EAAT2 regulatory mechanisms could improve development of drug-like compds. that spatiotemporally regulate EAAT2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSDfRKc3x_9LVg90H21EOLACvtfcHk0ljORuQtYWRRBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFejtbg%253D&md5=b4635bb27ff03306fd4fb3a1a87ebceb</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-1937-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-1937-8%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DFoster%26aufirst%3DJ.%2BB.%26aulast%3DLin%26aufirst%3DC.%2BL.%2BG.%26atitle%3DGlutamate%2520transporter%2520EAAT2%253A%2520regulation%252C%2520function%252C%2520and%2520potential%2520as%2520a%2520therapeutic%2520target%2520for%2520neurological%2520and%2520psychiatric%2520disease%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26issue%3D18%26spage%3D3489%26epage%3D3506%26doi%3D10.1007%2Fs00018-015-1937-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kegelman, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barral, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span> <span> </span><span class="NLM_article-title">Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>226</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2484</span>â <span class="NLM_lpage">2493</span>, <span class="refDoi">Â DOI: 10.1002/jcp.22609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fjcp.22609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21792905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt1Clt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2011&pages=2484-2493&issue=10&author=K.+Kimauthor=S.+G.+Leeauthor=T.+P.+Kegelmanauthor=Z.+Z.+Suauthor=S.+K.+Dasauthor=R.+Dashauthor=S.+Dasguptaauthor=P.+M.+Barralauthor=M.+Hedvatauthor=P.+Diazauthor=J.+C.+Reedauthor=J.+L.+Stebbinsauthor=M.+Pellecchiaauthor=D.+Sarkarauthor=P.+B.+Fisher&title=Role+of+excitatory+amino+acid+transporter-2+%28EAAT2%29+and+glutamate+in+neurodegeneration%3A+opportunities+for+developing+novel+therapeutics&doi=10.1002%2Fjcp.22609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Excitatory Amino Acid Transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics</span></div><div class="casAuthors">Kim, Keetae; Lee, Seok-Geun; Kegelman, Timothy P.; Su, Zhao-Zhong; Das, Swadesh K.; Dash, Rupesh; Dasgupta, Santanu; Barral, Paola M.; Hedvat, Michael; Diaz, Paul; Reed, John C.; Stebbins, John L.; Pellecchia, Maurizio; Sarkar, Devanand; Fisher, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2484-2493</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Glutamate is an essential excitatory neurotransmitter regulating brain functions.  Excitatory amino acid transporter (EAAT)-2 is one of the major glutamate transporters expressed predominantly in astroglial cells and is responsible for 90% of total glutamate uptake.  Glutamate transporters tightly regulate glutamate concn. in the synaptic cleft.  Dysfunction of EAAT2 and accumulation of excessive extracellular glutamate has been implicated in the development of several neurodegenerative diseases including Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis.  Anal. of the 2.5 kb human EAAT2 promoter showed that NF-ÎºB is an important regulator of EAAT2 expression in astrocytes.  Screening of approx. 1,040 FDA-approved compds. and nutritionals led to the discovery that many Î²-lactam antibiotics are transcriptional activators of EAAT2 resulting in increased EAAT2 protein levels.  Treatment of animals with ceftriaxone (CEF), a Î²-lactam antibiotic, led to an increase of EAAT2 expression and glutamate transport activity in the brain.  CEF has neuroprotective effects in both in vitro and in vivo models based on its ability to inhibit neuronal cell death by preventing glutamate excitotoxicity.  CEF increases EAAT2 transcription in primary human fetal astrocytes through the NF-ÎºB signaling pathway.  The NF-ÎºB binding site at -272 position was crit. in CEF-mediated EAAT2 protein induction.  These studies emphasize the importance of transcriptional regulation in controlling glutamate levels in the brain.  They also emphasize the potential utility of the EAAT2 promoter for developing both low and high throughput screening assays to identify novel small mol. regulators of glutamate transport with potential to ameliorate pathol. changes occurring during and causing neurodegeneration.  J. Cell. Physiol. 226: 2484-2493, 2011. Â© 2010 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdoPAeaC_5rVg90H21EOLACvtfcHk0ljmJaHtYI97_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt1Clt7g%253D&md5=4e837820dbfe500409a6178a229a8464</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fjcp.22609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.22609%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DKegelman%26aufirst%3DT.%2BP.%26aulast%3DSu%26aufirst%3DZ.%2BZ.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DDash%26aufirst%3DR.%26aulast%3DDasgupta%26aufirst%3DS.%26aulast%3DBarral%26aufirst%3DP.%2BM.%26aulast%3DHedvat%26aufirst%3DM.%26aulast%3DDiaz%26aufirst%3DP.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPellecchia%26aufirst%3DM.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26atitle%3DRole%2520of%2520excitatory%2520amino%2520acid%2520transporter-2%2520%2528EAAT2%2529%2520and%2520glutamate%2520in%2520neurodegeneration%253A%2520opportunities%2520for%2520developing%2520novel%2520therapeutics%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2011%26volume%3D226%26issue%3D10%26spage%3D2484%26epage%3D2493%26doi%3D10.1002%2Fjcp.22609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Javitt, D. C.</span></span> <span> </span><span class="NLM_article-title">Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions</span>. <i>Int. Rev. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">108</span>, <span class="refDoi">Â DOI: 10.1016/S0074-7742(06)78003-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0074-7742%2806%2978003-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17349858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2007&pages=69-108&author=D.+C.+Javitt&title=Glutamate+and+schizophrenia%3A+phencyclidine%2C+N-methyl-D-aspartate+receptors%2C+and+dopamine-glutamate+interactions&doi=10.1016%2FS0074-7742%2806%2978003-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions</span></div><div class="casAuthors">Javitt, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">Integrating the Neurobiology of Schizophrenia</span>),
    <span class="NLM_cas:pages">69-108,, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide.  As of yet, neurochem. mechanisms underlying schizophrenia remain unknown.  To date, the most widely considered neurochem. hypothesis of schizophrenia is the dopamine hypothesis, which postulates that symptoms of schizophrenia may result from excess dopaminergic neurotransmission particularly in striatal brain regions, along with dopaminergic deficits in prefrontal brain regions.  Alternative neurochem. models of schizophrenia, however, have been proposed involving glutamatergic mechanisms in general and N-methyl-D-aspartate (NMDA) receptors in particular.  A potential role for glutamatergic mechanisms in schizophrenia was first proposed â¼15 years ago based on the observation that the psychotomimetic agents phencyclidine (PCP) and ketamine induce psychotic symptoms and neurocognitive disturbances similar to those of schizophrenia by blocking neurotransmission at NMDA-type glutamate receptors.  Since that time, significant addnl. evidence has accumulated supporting a role for NMDA hypofunction in the pathophysiol. of schizophrenia.  Clin. challenge studies with PCP and ketamine have confirmed the close resemblance between NMDA antagonist-induced symptoms and neurocognitive deficits and those obsd. in schizophrenia, and suggest that NMDA dysfunction may lead to secondary dopaminergic dysregulation in striatal and prefrontal brain regions.  As compared to dopaminergic agents, NMDA antagonists induce neg. and cognitive symptoms of schizophrenia, as well as pos. symptoms.  Treatment studies with NMDA modulators, such as glycine, D-serine, and glycine transport inhibitors (GTIs), have yielded encouraging findings, although results remain controversial.  Finally, genetic linkage and in vivo neurochem. studies in schizophrenia highlight potential etiol. mechanisms giving rise to glutamatergic/NMDA dysfunction in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ZhuFfD0tJ7Vg90H21EOLACvtfcHk0ljmJaHtYI97_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Gmt74%253D&md5=dd081e288a66cdc6e3a98d0cfb49fa50</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0074-7742%2806%2978003-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0074-7742%252806%252978003-5%26sid%3Dliteratum%253Aachs%26aulast%3DJavitt%26aufirst%3DD.%2BC.%26atitle%3DGlutamate%2520and%2520schizophrenia%253A%2520phencyclidine%252C%2520N-methyl-D-aspartate%2520receptors%252C%2520and%2520dopamine-glutamate%2520interactions%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2007%26volume%3D78%26spage%3D69%26epage%3D108%26doi%3D10.1016%2FS0074-7742%2806%2978003-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R. A.</span>; <span class="NLM_string-name">Dawson, L. A.</span></span>, <span> </span><span class="NLM_article-title">GlyT-1 Inhibitors: From Hits to Clinical Candidates</span>. In  <i>Small Molecule Therapeutics for Schizophrenia</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Celanire, S.</span>, <span class="NLM_string-name">Poli, S.</span></span>, Eds.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham</span>, <span class="NLM_year">2015</span>; pp  <span class="NLM_fpage">51</span>â <span class="NLM_lpage">99</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=51-99&author=R.+A.+Porter&author=L.+A.+Dawsonauthor=S.+Celanire&author=S.+Poli&title=Small+Molecule+Therapeutics+for+Schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DR.%2BA.%26atitle%3DGlyT-1%2520Inhibitors%253A%2520From%2520Hits%2520to%2520Clinical%2520Candidates%26btitle%3DSmall%2520Molecule%2520Therapeutics%2520for%2520Schizophrenia%26aulast%3DCelanire%26aufirst%3DS.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2015%26spage%3D51%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tillman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span> <span> </span><span class="NLM_article-title">Crossing the chloride channel: the current and potential therapeutic value of the neuronal K+-Cl- cotransporter KCC2</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">8941046</span>, <span class="refDoi">Â DOI: 10.1155/2019/8941046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1155%2F2019%2F8941046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31240228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3MzgvVChsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=8941046&author=L.+Tillmanauthor=J.+W.+Zhang&title=Crossing+the+chloride+channel%3A+the+current+and+potential+therapeutic+value+of+the+neuronal+K%2B-Cl-+cotransporter+KCC2&doi=10.1155%2F2019%2F8941046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Crossing the Chloride Channel: The Current and Potential Therapeutic Value of the Neuronal K(+)-Cl(-) Cotransporter KCC2</span></div><div class="casAuthors">Tillman Luke; Zhang Jinwei</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8941046</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chloride (Cl(-)) homeostasis is an essential process involved in neuronal signalling and cell survival.  Inadequate regulation of intracellular Cl(-) interferes with synaptic signalling and is implicated in several neurological diseases.  The main inhibitory neurotransmitter of the central nervous system is Î³-aminobutyric acid (GABA).  GABA hyperpolarises the membrane potential by activating Cl(-) permeable GABAA receptor channels (GABAAR).  This process is reliant on Cl(-) extruder K(+)-Cl(-) cotransporter 2 (KCC2), which generates the neuron's inward, hyperpolarising Cl(-) gradient.  KCC2 is encoded by the fifth member of the solute carrier 12 family (SLC12A5) and has remained a poorly understood component in the development and severity of many neurological diseases for many years.  Recent advancements in next-generation sequencing and specific gene targeting, however, have indicated that loss of KCC2 activity is involved in a number of diseases including epilepsy and schizophrenia.  It has also been implicated in neuropathic pain following spinal cord injury.  Any variant of SLC12A5 that negatively regulates the transporter's expression may, therefore, be implicated in neurological disease.  A recent whole exome study has discovered several causative mutations in patients with epilepsy.  Here, we discuss the implications of KCC2 in neurological disease and consider the evolving evidence for KCC2's potential as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTygwrSuFoU5WtyewyzkyLfW6udTcc2eajAISTMntuubntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzgvVChsA%253D%253D&md5=bceb220afddc338ce01be9bf93e01415</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1155%2F2019%2F8941046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2019%252F8941046%26sid%3Dliteratum%253Aachs%26aulast%3DTillman%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26atitle%3DCrossing%2520the%2520chloride%2520channel%253A%2520the%2520current%2520and%2520potential%2520therapeutic%2520value%2520of%2520the%2520neuronal%2520K%252B-Cl-%2520cotransporter%2520KCC2%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2019%26volume%3D2019%26spage%3D8941046%26doi%3D10.1155%2F2019%2F8941046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockenhauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleta, R.</span></span> <span> </span><span class="NLM_article-title">Aminoacidurias: clinical and molecular aspects</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">918</span>â <span class="NLM_lpage">925</span>, <span class="refDoi">Â DOI: 10.1038/sj.ki.5002790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fsj.ki.5002790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=18200002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVWmt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=918-925&issue=8&author=S.+M.+Camargoauthor=D.+Bockenhauerauthor=R.+Kleta&title=Aminoacidurias%3A+clinical+and+molecular+aspects&doi=10.1038%2Fsj.ki.5002790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoacidurias: Clinical and molecular aspects</span></div><div class="casAuthors">Camargo, S. M. R.; Bockenhauer, D.; Kleta, R.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inherited aminoacidurias are caused by defective amino-acid transport through renal (reabsorption) and in many cases also small intestinal epithelia (absorption).  Recently, many of the genes causing this abnormal transport have been molecularly identified.  In this review, we summarize the latest findings in the clin. and mol. aspects concerning the principal aminoacidurias, cystinuria, lysinuric protein intolerance, Hartnup disorder, iminoglycinuria, and dicarboxylic aminoaciduria.  Signs, symptoms, diagnosis, treatment, causative or candidate genes, functional characterization of the encoded transporters, and animal models are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmAYl1-I6pObVg90H21EOLACvtfcHk0lgLic4HB0bzDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVWmt7g%253D&md5=0ddb2b94f84836fc9bb5fdc1efe16423</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5002790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5002790%26sid%3Dliteratum%253Aachs%26aulast%3DCamargo%26aufirst%3DS.%2BM.%26aulast%3DBockenhauer%26aufirst%3DD.%26aulast%3DKleta%26aufirst%3DR.%26atitle%3DAminoacidurias%253A%2520clinical%2520and%2520molecular%2520aspects%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D73%26issue%3D8%26spage%3D918%26epage%3D925%26doi%3D10.1038%2Fsj.ki.5002790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feliubadalo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbones, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chillaron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorzano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, V.</span></span> <span> </span><span class="NLM_article-title">SLC7A9-deficient mice develop cystinuria non-i and cystine urolithiasis</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2097</span>â <span class="NLM_lpage">2108</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddg228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Fhmg%2Fddg228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12915471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsV2ntbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=2097-2108&issue=17&author=L.+Feliubadaloauthor=M.+L.+Arbonesauthor=S.+Manasauthor=J.+Chillaronauthor=J.+Visaauthor=M.+Rodesauthor=F.+Rousaudauthor=A.+Zorzanoauthor=M.+Palacinauthor=V.+Nunes&title=SLC7A9-deficient+mice+develop+cystinuria+non-i+and+cystine+urolithiasis&doi=10.1093%2Fhmg%2Fddg228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis</span></div><div class="casAuthors">Feliubadalo, Lidia; Arbones, Maria Lourdes; Manas, Sandra; Chillaron, Josep; Visa, Joana; Rodes, Margot; Rousaud, Ferran; Zorzano, Antonio; Palacin, Manuel; Nunes, Virginia</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2097-2108</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cystinuria is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids that results in urolithiasis of cystine.  Cystinuria is caused by defects in the amino acid transport system b0,+ (i.e. the rBAT/b0,+ AT heteromeric complex).  Mutations in SLC3A1, encoding rBAT, cause cystinuria type A, characterized by a silent phenotype in heterozygotes (phenotype I).  Mutations in SLC7A9, encoding b0,+ AT, cause cystinuria type B, in which heterozygotes in most cases hyperexcrete cystine and dibasic amino acids (phenotype non-I).  To facilitate in vivo investigation of b0,+ AT in cystinuria, Slc7a9 knockout mice have been generated.  Expression of b0,+ AT protein is completely abolished in the kidney of Slc7a9-/- mice ("Stones").  In contrast, Stones expressed significant amts. of rBAT protein, which is covalently linked to unidentified light subunit(s).  Stones mice present a dramatic hyperexcretion of cystine and dibasic amino acids, while Slc7a9+/- mice show moderate but significant hyperexcretion of these amino acids (phenotype non-I).  Forty-two per cent of Stones mice develop cystine calculi in the urinary system.  Calculi develop during the first month of life and grow throughout the life span of the animals.  Histopathol. in kidney reveals typical changes for urolithiasis (tubular and pelvic dilatation, tubular necrosis, tubular hyaline droplets and chronic interstitial nephritis).  The fact that some Stones mice, generated in a mixed genetic background, develop cystine calculi from an early age, while others do not develop them in their first year of life, suggests the involvement of modifier genes in the lithiasis phenotype.  Thus, Stones provide a valid model of cystinuria which can be used in the study of genetic, pharmacol. and environmental factors involved in cystine urolithiasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP9HcLSyQrWbVg90H21EOLACvtfcHk0lgLic4HB0bzDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsV2ntbo%253D&md5=d8d289e95f5ab1093c5d535179ca132f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddg228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddg228%26sid%3Dliteratum%253Aachs%26aulast%3DFeliubadalo%26aufirst%3DL.%26aulast%3DArbones%26aufirst%3DM.%2BL.%26aulast%3DManas%26aufirst%3DS.%26aulast%3DChillaron%26aufirst%3DJ.%26aulast%3DVisa%26aufirst%3DJ.%26aulast%3DRodes%26aufirst%3DM.%26aulast%3DRousaud%26aufirst%3DF.%26aulast%3DZorzano%26aufirst%3DA.%26aulast%3DPalacin%26aufirst%3DM.%26aulast%3DNunes%26aufirst%3DV.%26atitle%3DSLC7A9-deficient%2520mice%2520develop%2520cystinuria%2520non-i%2520and%2520cystine%2520urolithiasis%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2003%26volume%3D12%26issue%3D17%26spage%3D2097%26epage%3D2108%26doi%3D10.1093%2Fhmg%2Fddg228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouffard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiermonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalikin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makalowska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petty, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesecker, L. G.</span></span> <span> </span><span class="NLM_article-title">Mutant deoxynucleotide carrier is associated with congenital microcephaly</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">179</span>, <span class="refDoi">Â DOI: 10.1038/ng948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fng948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12185364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ajs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=175-179&issue=1&author=M.+J.+Rosenbergauthor=R.+Agarwalaauthor=G.+Bouffardauthor=J.+Davisauthor=G.+Fiermonteauthor=M.+S.+Hilliardauthor=T.+Kochauthor=L.+M.+Kalikinauthor=I.+Makalowskaauthor=D.+H.+Mortonauthor=E.+M.+Pettyauthor=J.+L.+Weberauthor=F.+Palmieriauthor=R.+I.+Kelleyauthor=A.+A.+Schafferauthor=L.+G.+Biesecker&title=Mutant+deoxynucleotide+carrier+is+associated+with+congenital+microcephaly&doi=10.1038%2Fng948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant deoxynucleotide carrier is associated with congenital microcephaly</span></div><div class="casAuthors">Rosenberg, Marjorie J.; Agarwala, Richa; Bouffard, Gerard; Davis, Joie; Fiermonte, Giuseppe; Hilliard, Mark S.; Koch, Thorsten; Kalikin, Linda M.; Makalowska, Izabela; Morton, D. Holmes; Petty, Elizabeth M.; Weber, James L.; Palmieri, Ferdinando; Kelley, Richard I.; Schaeffer, Alejandro A.; Biesecker, Leslie G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-179</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The disorder Amish microcephaly (MCPHA) is characterized by severe congenital microcephaly, elevated levels of Î±-ketoglutarate in the urine and premature death.  The disorder is inherited in an autosomal recessive pattern and has been obsd. only in Old Order Amish families whose ancestors lived in Lancaster County, Pennsylvania.  Here the authors show, by using a genealogy database and automated pedigree software, that 23 nuclear families affected with MCPHA are connected to a single ancestral couple.  Through a whole-genome scan, fine mapping and haplotype anal., the authors localized the gene affected in MCPHA to a region of 3 cM, or 2 Mb, on chromosome 17q25.  The authors constructed a map of contiguous genomic clones spanning this region.  One of the genes in this region, SLC25A19, which encodes a nuclear mitochondrial deoxynucleotide carrier (DNC), contains a substitution that segregates with the disease in affected individuals and alters an amino acid that is highly conserved in similar proteins.  Functional anal. shows that the mutant DNC protein lacks the normal transport activity, implying that failed deoxynucleotide transport across the inner mitochondrial membrane causes MCPHA.  These data indicate that mitochondrial deoxynucleotide transport may be essential for prenatal brain growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnW7rF-OfndrVg90H21EOLACvtfcHk0lgLic4HB0bzDA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ajs70%253D&md5=065e61fe41acb1fee84e3df2ef3d2656</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fng948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng948%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BJ.%26aulast%3DAgarwala%26aufirst%3DR.%26aulast%3DBouffard%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DFiermonte%26aufirst%3DG.%26aulast%3DHilliard%26aufirst%3DM.%2BS.%26aulast%3DKoch%26aufirst%3DT.%26aulast%3DKalikin%26aufirst%3DL.%2BM.%26aulast%3DMakalowska%26aufirst%3DI.%26aulast%3DMorton%26aufirst%3DD.%2BH.%26aulast%3DPetty%26aufirst%3DE.%2BM.%26aulast%3DWeber%26aufirst%3DJ.%2BL.%26aulast%3DPalmieri%26aufirst%3DF.%26aulast%3DKelley%26aufirst%3DR.%2BI.%26aulast%3DSchaffer%26aufirst%3DA.%2BA.%26aulast%3DBiesecker%26aufirst%3DL.%2BG.%26atitle%3DMutant%2520deoxynucleotide%2520carrier%2520is%2520associated%2520with%2520congenital%2520microcephaly%26jtitle%3DNat.%2520Genet.%26date%3D2002%26volume%3D32%26issue%3D1%26spage%3D175%26epage%3D179%26doi%3D10.1038%2Fng948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindhurst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiermonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Leonardis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castegna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesecker, L. G.</span></span> <span> </span><span class="NLM_article-title">Knockout of SLC25A19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">15927</span>â <span class="NLM_lpage">15932</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0607661103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.0607661103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17035501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymurfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=15927-15932&issue=43&author=M.+J.+Lindhurstauthor=G.+Fiermonteauthor=S.+Songauthor=E.+Struysauthor=F.+De+Leonardisauthor=P.+L.+Schwartzbergauthor=A.+Chenauthor=A.+Castegnaauthor=N.+Verhoevenauthor=C.+K.+Mathewsauthor=F.+Palmieriauthor=L.+G.+Biesecker&title=Knockout+of+SLC25A19+causes+mitochondrial+thiamine+pyrophosphate+depletion%2C+embryonic+lethality%2C+CNS+malformations%2C+and+anemia&doi=10.1073%2Fpnas.0607661103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Knockout of SLc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia</span></div><div class="casAuthors">Lindhurst, Marjorie J.; Fiermonte, Giuseppe; Song, Shiwei; Struys, Eduard; De Leonardis, Francesco; Schwartzberg, Pamela L.; Chen, Amy; Castegna, Alessandra; Verhoeven, Nanda; Mathews, Christopher K.; Palmieri, Ferdinando; Biesecker, Leslie G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15927-15932</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">SLC25A19 mutations cause Amish lethal microcephaly (MCPHA), which markedly retards brain development and leads to Î±-ketoglutaric aciduria.  Previous data suggested that SLC25A19, also called DNC, is a mitochondrial deoxyribonucleotide transporter.  We generated a knockout mouse model of SLc25a19.  These animals had 100% prenatal lethality by embryonic day 12.  Affected embryos at embryonic day 10.5 have a neural-tube closure defect with ruffling of the neural fold ridges, a yolk sac erythropoietic failure, and elevated a-ketoglutarate in the amniotic fluid.  We found that these animals have normal mitochondrial ribo- and deoxyribonucleoside triphosphate levels, suggesting that transport of these mols. is not the primary role of SLC25A19.  We identified thiamine pyrophosphate (ThPP) transport as a candidate function of SLC25A19 through homol. searching and confirmed it by transport assays of the recombinant reconstituted protein.  The mitochondria of 51c25a1-/1 and MCPHA cells have undetectable and markedly reduced ThPP content, resp.  The redn. of ThPP levels causes dysfunction of the Î±-ketoglutarate dehydrogenase complex, which explains the high levels of this org. acid in MCPHA and suggests that mitochondrial ThPP transport is important for CNS development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeGKeUDEIW97Vg90H21EOLACvtfcHk0lg_VsdJIjnK6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymurfO&md5=455daa1bdcb8abc75cec8fb2b325d62e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607661103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607661103%26sid%3Dliteratum%253Aachs%26aulast%3DLindhurst%26aufirst%3DM.%2BJ.%26aulast%3DFiermonte%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DStruys%26aufirst%3DE.%26aulast%3DDe%2BLeonardis%26aufirst%3DF.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DCastegna%26aufirst%3DA.%26aulast%3DVerhoeven%26aufirst%3DN.%26aulast%3DMathews%26aufirst%3DC.%2BK.%26aulast%3DPalmieri%26aufirst%3DF.%26aulast%3DBiesecker%26aufirst%3DL.%2BG.%26atitle%3DKnockout%2520of%2520SLC25A19%2520causes%2520mitochondrial%2520thiamine%2520pyrophosphate%2520depletion%252C%2520embryonic%2520lethality%252C%2520CNS%2520malformations%252C%2520and%2520anemia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D43%26spage%3D15927%26epage%3D15932%26doi%3D10.1073%2Fpnas.0607661103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornholm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallberg-Henriksson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zierath, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, G. D.</span></span> <span> </span><span class="NLM_article-title">Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">647</span>â <span class="NLM_lpage">654</span>, <span class="refDoi">Â DOI: 10.2337/diabetes.49.4.647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2337%2Fdiabetes.49.4.647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10871204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFylsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2000&pages=647-654&issue=4&author=J.+W.+Ryderauthor=J.+Yangauthor=D.+Galuskaauthor=J.+Rinconauthor=M.+Bjornholmauthor=A.+Krookauthor=S.+Lundauthor=O.+Pedersenauthor=H.+Wallberg-Henrikssonauthor=J.+R.+Zierathauthor=G.+D.+Holman&title=Use+of+a+novel+impermeable+biotinylated+photolabeling+reagent+to+assess+insulin-+and+hypoxia-stimulated+cell+surface+GLUT4+content+in+skeletal+muscle+from+type+2+diabetic+patients&doi=10.2337%2Fdiabetes.49.4.647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients</span></div><div class="casAuthors">Ryder, Jeffrey W.; Yang, Jing; Galuska, Dana; Rincon, Jorge; Bjornholm, Marie; Krook, Anna; Lund, Sten; Pedersen, Oluf; Wallberg-Henriksson, Harriet; Zierath, Juleen R.; Holman, Geoffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">647-654</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Cell surface GLUT4 levels in skeletal muscle from nine type 2 diabetic subjects and nine healthy control subjects have been assessed by a new technique that involves the use of a biotinylated photo-affinity label.  A profound impairment in GLUT4 translocation to the skeletal muscle cell surface in response to insulin was obsd. in type 2 diabetic patients.  Levels of insulin-stimulated cell surface GLUT4 above basal in type 2 diabetic patients were only â¼10% of those obsd. in healthy subjects.  The magnitude of the defect in GLUT4 translocation in type 2 diabetic patients was greater than that obsd. for glucose transport activity, which was â¼50% of that in healthy subjects.  Reduced GLUT4 translocation is therefore a major contributor to the impaired glucose transport activity in skeletal muscle from type 2 diabetic subjects.  When a marked impairment in GLUT4 translocation occurs, the contribution of other transporters to transport activity becomes apparent.  In response to hypoxia, marked redns. in skeletal muscle cell surface GLUT4 levels were also obsd. in type 2 diabetic patients.  Therefore, a defect in a common late stage in signal transduction and/or a direct impairment in the GLUT4 translocation process accounts for reduced glucose transport in type 2 diabetic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5K0u2Njim9rVg90H21EOLACvtfcHk0lg_VsdJIjnK6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFylsbw%253D&md5=4926551052cef030ed85e3910af565fa</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.49.4.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.49.4.647%26sid%3Dliteratum%253Aachs%26aulast%3DRyder%26aufirst%3DJ.%2BW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGaluska%26aufirst%3DD.%26aulast%3DRincon%26aufirst%3DJ.%26aulast%3DBjornholm%26aufirst%3DM.%26aulast%3DKrook%26aufirst%3DA.%26aulast%3DLund%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DO.%26aulast%3DWallberg-Henriksson%26aufirst%3DH.%26aulast%3DZierath%26aufirst%3DJ.%2BR.%26aulast%3DHolman%26aufirst%3DG.%2BD.%26atitle%3DUse%2520of%2520a%2520novel%2520impermeable%2520biotinylated%2520photolabeling%2520reagent%2520to%2520assess%2520insulin-%2520and%2520hypoxia-stimulated%2520cell%2520surface%2520GLUT4%2520content%2520in%2520skeletal%2520muscle%2520from%2520type%25202%2520diabetic%2520patients%26jtitle%3DDiabetes%26date%3D2000%26volume%3D49%26issue%3D4%26spage%3D647%26epage%3D654%26doi%3D10.2337%2Fdiabetes.49.4.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroyanagi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuzono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1785</span>â <span class="NLM_lpage">1790</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2019.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2019.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31101471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVGjtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1785-1790&issue=14&author=T.+Tsujiauthor=M.+Yamaguchiauthor=J.+Kuroyanagiauthor=S.+Furuzonoauthor=M.+Konishiauthor=K.+Terayamaauthor=J.+Tanakaauthor=M.+Saitoauthor=Y.+Kobayashi&title=Discovery+of+novel+pyridazine+derivatives+as+glucose+transporter+type+4+%28GLUT4%29+translocation+activators&doi=10.1016%2Fj.bmcl.2019.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators</span></div><div class="casAuthors">Tsuji, Takashi; Yamaguchi, Mitsuhiro; Kuroyanagi, Junichi; Furuzono, Shinji; Konishi, Masahiro; Terayama, Koji; Tanaka, Jun; Saito, Motoko; Kobayashi, Yoshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1785-1790</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fused pyridazines such as I were prepd. as glucose transporter type 4 (GLUT4) translocation activators for potential use in the treatment of type 2 diabetes; their structure-activity relationships were detd.  I lowered blood glucose levels in severely diabetic mice (10-wk aged db/db mice) after oral dosing even at 10 mg/kg; the pharmacokinetics (Cmax, AUC) of I in mice was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFtpEOLNFBFbVg90H21EOLACvtfcHk0lg_VsdJIjnK6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVGjtb4%253D&md5=43c6debc12b869f9157e1f46e4aea01c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DTsuji%26aufirst%3DT.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DKuroyanagi%26aufirst%3DJ.%26aulast%3DFuruzono%26aufirst%3DS.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DTerayama%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520pyridazine%2520derivatives%2520as%2520glucose%2520transporter%2520type%25204%2520%2528GLUT4%2529%2520translocation%2520activators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D14%26spage%3D1785%26epage%3D1790%26doi%3D10.1016%2Fj.bmcl.2019.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, J. P. H.</span></span> <span> </span><span class="NLM_article-title">A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.1111/dom.13650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fdom.13650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31081592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsFWiurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=9-18&author=E.+Brownauthor=S.+P.+Rajeevauthor=D.+J.+Cuthbertsonauthor=J.+P.+H.+Wilding&title=A+review+of+the+mechanism+of+action%2C+metabolic+profile+and+haemodynamic+effects+of+sodium-glucose+co-transporter-2+inhibitors&doi=10.1111%2Fdom.13650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors</span></div><div class="casAuthors">Brown, Emily; Rajeev, Surya P.; Cuthbertson, Daniel J.; Wilding, John P. H.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">S2</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Inhibition of glucose transport in the kidney, to produce glucosuria and thus directly lower blood glucose seems a remarkably simple way to treat diabetes (type 1 or type 2).  The development of sodium-glucose co-transporter-2 (SGLT2) inhibitors and their subsequent clin. development has on one hand shown this to be true, but at another level has helped reveal a complex web of interacting effects starting in the kidney and modulating multiple metabolic pathways in a variety of other organs.  These underlie the now clear benefits of this class of drugs in the management of type 2 diabetes from glucose lowering, wt. loss and blood pressure redn. through to the redns. in cardiovascular and renal complications obsd. in long-term outcomes trials.  They also explain some of the adverse effects that have emerged, including the risk of diabetic ketoacidosis.  This review describes the effects of SGLT2 inhibition in relation to this complex physiol., and shows how this can favorably alter the pathophysiol. of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuhyP9kd2nBbVg90H21EOLACvtfcHk0ljrg0nHcosHRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsFWiurs%253D&md5=da83e388ab48406551ea865a65164b19</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fdom.13650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.13650%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DRajeev%26aufirst%3DS.%2BP.%26aulast%3DCuthbertson%26aufirst%3DD.%2BJ.%26aulast%3DWilding%26aufirst%3DJ.%2BP.%2BH.%26atitle%3DA%2520review%2520of%2520the%2520mechanism%2520of%2520action%252C%2520metabolic%2520profile%2520and%2520haemodynamic%2520effects%2520of%2520sodium-glucose%2520co-transporter-2%2520inhibitors%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2019%26volume%3D21%26spage%3D9%26epage%3D18%26doi%3D10.1111%2Fdom.13650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rusu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercader, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gymrek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartigan, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Grotthuss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanillas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spooner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deik, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. C.Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centeno-Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerrweck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, S. B.R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. C.Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shriner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielinski, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanek, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalls, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen-Torvik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenknecht, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snively, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudgal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langefeld, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mychaleckyj, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffel, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodarzi, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y-D I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerwinkle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeyemo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doumatey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonderman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igo, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabagambe, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siscovick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielak, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Province, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottinger, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blot, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacheco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loos, R. J.F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borecki, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyser, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Psaty, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, W.H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sale, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotimi, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercader, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta-Chagoya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ortiz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Macias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtt, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar-Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tusie-Luna, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Hernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centeno-Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barajas-Olmos, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerrweck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras-Cubas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza-Caamal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revilla-Monsalve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islas-Andrade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soberon, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Villalpando, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Villalpando, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Marchand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano-Campos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordonez-Sanchez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura-Kato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Guillen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Bautista, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Hernandez, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvirde, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeda-Valdes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, M. L.</span></span> <span> </span><span class="NLM_article-title">Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">212</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2017.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28666119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsb7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=199-212&author=V.+Rusuauthor=E.+Hochauthor=J.+M.+Mercaderauthor=D.+E.+Tenenauthor=M.+Gymrekauthor=C.+R.+Hartiganauthor=M.+DeRanauthor=M.+von+Grotthussauthor=P.+Fontanillasauthor=A.+Spoonerauthor=G.+Guzmanauthor=A.+A.+Deikauthor=K.+A.+Pierceauthor=C.+Dennisauthor=C.+B.+Clishauthor=S.+A.+Carrauthor=B.+K.+Wagnerauthor=M.+Schenoneauthor=M.+C.Y.+Ngauthor=B.+H.+Chenauthor=F.+Centeno-Cruzauthor=C.+Zerrweckauthor=L.+Orozcoauthor=D.+M.+Altshulerauthor=S.+L.+Schreiberauthor=J.+C.+Florezauthor=S.+B.R.+Jacobsauthor=E.+S.+Landerauthor=M.+C.Y.+Ngauthor=D.+Shrinerauthor=B.+H.+Chenauthor=J.+Liauthor=W.-M.+Chenauthor=X.+Guoauthor=J.+Liuauthor=S.+J.+Bielinskiauthor=L.+R.+Yanekauthor=M.+A.+Nallsauthor=M.+E.+Comeauauthor=L.+J.+Rasmussen-Torvikauthor=R.+A.+Jensenauthor=D.+S.+Evansauthor=Y.+V.+Sunauthor=P.+Anauthor=S.+R.+Patelauthor=Y.+Luauthor=J.+Longauthor=L.+L.+Armstrongauthor=L.+Wagenknechtauthor=L.+Yangauthor=B.+M.+Snivelyauthor=N.+D.+Palmerauthor=P.+Mudgalauthor=C.+D.+Langefeldauthor=K.+L.+Keeneauthor=B.+I.+Freedmanauthor=J.+C.+Mychaleckyjauthor=U.+Nayakauthor=L.+J.+Raffelauthor=M.+O.+Goodarziauthor=Y-D+I.+Chenauthor=H.+A.+Taylorauthor=A.+Correaauthor=M.+Simsauthor=D.+Couperauthor=J.+S.+Pankowauthor=E.+Boerwinkleauthor=A.+Adeyemoauthor=A.+Doumateyauthor=G.+Chenauthor=R.+A.+Mathiasauthor=D.+Vaidyaauthor=A.+B.+Singletonauthor=A.+B.+Zondermanauthor=R.+P.+Igoauthor=J.+R.+Sedorauthor=E.+K.+Kabagambeauthor=D.+S.+Siscovickauthor=B.+McKnightauthor=K.+Riceauthor=Y.+Liuauthor=W.-C.+Hsuehauthor=W.+Zhaoauthor=L.+F.+Bielakauthor=A.+Krajaauthor=M.+A.+Provinceauthor=E.+P.+Bottingerauthor=O.+Gottesmanauthor=Q.+Caiauthor=W.+Zhengauthor=W.+J.+Blotauthor=W.+L.+Loweauthor=J.+A.+Pachecoauthor=D.+C.+Crawfordauthor=E.+Grundbergauthor=S.+S.+Richauthor=M.+G.+Hayesauthor=X.-O.+Shuauthor=R.+J.F.+Loosauthor=I.+B.+Boreckiauthor=P.+A.+Peyserauthor=S.+R.+Cummingsauthor=B.+M.+Psatyauthor=M.+Fornageauthor=S.+K.+Iyengarauthor=M.+K.+Evansauthor=D.+M.+Beckerauthor=W.H.+L.+Kaoauthor=J.+G.+Wilsonauthor=J.+I.+Rotterauthor=M.+M.+Saleauthor=S.+Liuauthor=C.+N.+Rotimiauthor=D.+W.+Bowdenauthor=J.+M.+Mercaderauthor=A.+Huerta-Chagoyaauthor=H.+Garcia-Ortizauthor=H.+Moreno-Maciasauthor=A.+Manningauthor=L.+Caulkinsauthor=N.+P.+Burttauthor=J.+Flannickauthor=N.+Pattersonauthor=C.+A.+Aguilar-Salinasauthor=T.+Tusie-Lunaauthor=D.+Altshulerauthor=J.+C.+Florezauthor=A.+Martinez-Hernandezauthor=F.+Centeno-Cruzauthor=F.+M.+Barajas-Olmosauthor=C.+Zerrweckauthor=C.+Contreras-Cubasauthor=E.+Mendoza-Caamalauthor=C.+Revilla-Monsalveauthor=S.+Islas-Andradeauthor=E.+Cordovaauthor=X.+Soberonauthor=L.+Orozcoauthor=C.+Gonzalez-Villalpandoauthor=M.+E.+Gonzalez-Villalpandoauthor=C.+A.+Haimanauthor=L.+Wilkensauthor=L.+Le+Marchandauthor=K.+Monroeauthor=L.+Kolonelauthor=O.+Arellano-Camposauthor=M.+L.+Ordonez-Sanchezauthor=M.+Rodriguez-Torresauthor=Y.+Segura-Katoauthor=R.+Rodriguez-Guillenauthor=I.+Cruz-Bautistaauthor=L.+L.+Munoz-Hernandezauthor=T.+Saenzauthor=D.+Gomezauthor=U.+Alvirdeauthor=P.+Almeda-Valdesauthor=M.+L.+Cortes&title=Type+2+diabetes+variants+disrupt+function+of+SLC16A11+through+two+distinct+mechanisms&doi=10.1016%2Fj.cell.2017.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms</span></div><div class="casAuthors">Rusu, Victor; Hoch, Eitan; Mercader, Josep M.; Tenen, Danielle E.; Gymrek, Melissa; Hartigan, Christina R.; DeRan, Michael; von Grotthuss, Marcin; Fontanillas, Pierre; Spooner, Alexandra; Guzman, Gaelen; Deik, Amy A.; Pierce, Kerry A.; Dennis, Courtney; Clish, Clary B.; Carr, Steven A.; Wagner, Bridget K.; Schenone, Monica; Ng, Maggie C. Y.; Chen, Brian H.; Centeno-Cruz, Federico; Zerrweck, Carlos; Orozco, Lorena; Altshuler, David M.; Schreiber, Stuart L.; Florez, Jose C.; Jacobs, Suzanne B. R.; Lander, Eric S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">199-212.e20</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Type 2 diabetes (T2D) affects Latinos at twice the rate seen in populations of European descent.  We recently identified a risk haplotype spanning SLC16A11 that explains â¼20% of the increased T2D prevalence in Mexico.  Here, through genetic fine-mapping, we define a set of tightly linked variants likely to contain the causal allele(s).  We show that variants on the T2D-assocd. haplotype have two distinct effects: (1) decreasing SLC16A11 expression in liver and (2) disrupting a key interaction with basigin, thereby reducing cell-surface localization.  Both independent mechanisms reduce SLC16A11 function and suggest SLC16A11 is the causal gene at this locus.  To gain insight into how SLC16A11 disruption impacts T2D risk, we demonstrate that SLC16A11 is a proton-coupled monocarboxylate transporter and that genetic perturbation of SLC16A11 induces changes in fatty acid and lipid metab. that are assocd. with increased T2D risk.  Our findings suggest that increasing SLC16A11 function could be therapeutically beneficial for T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW0nTWwH_PrLVg90H21EOLACvtfcHk0lhJLoyYprB69w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsb7N&md5=9e78f244ed37f88a8ebc9c5b2ad7a204</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DRusu%26aufirst%3DV.%26aulast%3DHoch%26aufirst%3DE.%26aulast%3DMercader%26aufirst%3DJ.%2BM.%26aulast%3DTenen%26aufirst%3DD.%2BE.%26aulast%3DGymrek%26aufirst%3DM.%26aulast%3DHartigan%26aufirst%3DC.%2BR.%26aulast%3DDeRan%26aufirst%3DM.%26aulast%3Dvon%2BGrotthuss%26aufirst%3DM.%26aulast%3DFontanillas%26aufirst%3DP.%26aulast%3DSpooner%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DG.%26aulast%3DDeik%26aufirst%3DA.%2BA.%26aulast%3DPierce%26aufirst%3DK.%2BA.%26aulast%3DDennis%26aufirst%3DC.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DM.%2BC.Y.%26aulast%3DChen%26aufirst%3DB.%2BH.%26aulast%3DCenteno-Cruz%26aufirst%3DF.%26aulast%3DZerrweck%26aufirst%3DC.%26aulast%3DOrozco%26aufirst%3DL.%26aulast%3DAltshuler%26aufirst%3DD.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DFlorez%26aufirst%3DJ.%2BC.%26aulast%3DJacobs%26aufirst%3DS.%2BB.R.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DNg%26aufirst%3DM.%2BC.Y.%26aulast%3DShriner%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DB.%2BH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.-M.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBielinski%26aufirst%3DS.%2BJ.%26aulast%3DYanek%26aufirst%3DL.%2BR.%26aulast%3DNalls%26aufirst%3DM.%2BA.%26aulast%3DComeau%26aufirst%3DM.%2BE.%26aulast%3DRasmussen-Torvik%26aufirst%3DL.%2BJ.%26aulast%3DJensen%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BS.%26aulast%3DSun%26aufirst%3DY.%2BV.%26aulast%3DAn%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DArmstrong%26aufirst%3DL.%2BL.%26aulast%3DWagenknecht%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DSnively%26aufirst%3DB.%2BM.%26aulast%3DPalmer%26aufirst%3DN.%2BD.%26aulast%3DMudgal%26aufirst%3DP.%26aulast%3DLangefeld%26aufirst%3DC.%2BD.%26aulast%3DKeene%26aufirst%3DK.%2BL.%26aulast%3DFreedman%26aufirst%3DB.%2BI.%26aulast%3DMychaleckyj%26aufirst%3DJ.%2BC.%26aulast%3DNayak%26aufirst%3DU.%26aulast%3DRaffel%26aufirst%3DL.%2BJ.%26aulast%3DGoodarzi%26aufirst%3DM.%2BO.%26aulast%3DChen%26aufirst%3DY-D%2BI.%26aulast%3DTaylor%26aufirst%3DH.%2BA.%26aulast%3DCorrea%26aufirst%3DA.%26aulast%3DSims%26aufirst%3DM.%26aulast%3DCouper%26aufirst%3DD.%26aulast%3DPankow%26aufirst%3DJ.%2BS.%26aulast%3DBoerwinkle%26aufirst%3DE.%26aulast%3DAdeyemo%26aufirst%3DA.%26aulast%3DDoumatey%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMathias%26aufirst%3DR.%2BA.%26aulast%3DVaidya%26aufirst%3DD.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26aulast%3DZonderman%26aufirst%3DA.%2BB.%26aulast%3DIgo%26aufirst%3DR.%2BP.%26aulast%3DSedor%26aufirst%3DJ.%2BR.%26aulast%3DKabagambe%26aufirst%3DE.%2BK.%26aulast%3DSiscovick%26aufirst%3DD.%2BS.%26aulast%3DMcKnight%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHsueh%26aufirst%3DW.-C.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DBielak%26aufirst%3DL.%2BF.%26aulast%3DKraja%26aufirst%3DA.%26aulast%3DProvince%26aufirst%3DM.%2BA.%26aulast%3DBottinger%26aufirst%3DE.%2BP.%26aulast%3DGottesman%26aufirst%3DO.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DBlot%26aufirst%3DW.%2BJ.%26aulast%3DLowe%26aufirst%3DW.%2BL.%26aulast%3DPacheco%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DD.%2BC.%26aulast%3DGrundberg%26aufirst%3DE.%26aulast%3DRich%26aufirst%3DS.%2BS.%26aulast%3DHayes%26aufirst%3DM.%2BG.%26aulast%3DShu%26aufirst%3DX.-O.%26aulast%3DLoos%26aufirst%3DR.%2BJ.F.%26aulast%3DBorecki%26aufirst%3DI.%2BB.%26aulast%3DPeyser%26aufirst%3DP.%2BA.%26aulast%3DCummings%26aufirst%3DS.%2BR.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DFornage%26aufirst%3DM.%26aulast%3DIyengar%26aufirst%3DS.%2BK.%26aulast%3DEvans%26aufirst%3DM.%2BK.%26aulast%3DBecker%26aufirst%3DD.%2BM.%26aulast%3DKao%26aufirst%3DW.H.%2BL.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DSale%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRotimi%26aufirst%3DC.%2BN.%26aulast%3DBowden%26aufirst%3DD.%2BW.%26aulast%3DMercader%26aufirst%3DJ.%2BM.%26aulast%3DHuerta-Chagoya%26aufirst%3DA.%26aulast%3DGarcia-Ortiz%26aufirst%3DH.%26aulast%3DMoreno-Macias%26aufirst%3DH.%26aulast%3DManning%26aufirst%3DA.%26aulast%3DCaulkins%26aufirst%3DL.%26aulast%3DBurtt%26aufirst%3DN.%2BP.%26aulast%3DFlannick%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DN.%26aulast%3DAguilar-Salinas%26aufirst%3DC.%2BA.%26aulast%3DTusie-Luna%26aufirst%3DT.%26aulast%3DAltshuler%26aufirst%3DD.%26aulast%3DFlorez%26aufirst%3DJ.%2BC.%26aulast%3DMartinez-Hernandez%26aufirst%3DA.%26aulast%3DCenteno-Cruz%26aufirst%3DF.%26aulast%3DBarajas-Olmos%26aufirst%3DF.%2BM.%26aulast%3DZerrweck%26aufirst%3DC.%26aulast%3DContreras-Cubas%26aufirst%3DC.%26aulast%3DMendoza-Caamal%26aufirst%3DE.%26aulast%3DRevilla-Monsalve%26aufirst%3DC.%26aulast%3DIslas-Andrade%26aufirst%3DS.%26aulast%3DCordova%26aufirst%3DE.%26aulast%3DSoberon%26aufirst%3DX.%26aulast%3DOrozco%26aufirst%3DL.%26aulast%3DGonzalez-Villalpando%26aufirst%3DC.%26aulast%3DGonzalez-Villalpando%26aufirst%3DM.%2BE.%26aulast%3DHaiman%26aufirst%3DC.%2BA.%26aulast%3DWilkens%26aufirst%3DL.%26aulast%3DLe%2BMarchand%26aufirst%3DL.%26aulast%3DMonroe%26aufirst%3DK.%26aulast%3DKolonel%26aufirst%3DL.%26aulast%3DArellano-Campos%26aufirst%3DO.%26aulast%3DOrdonez-Sanchez%26aufirst%3DM.%2BL.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DSegura-Kato%26aufirst%3DY.%26aulast%3DRodriguez-Guillen%26aufirst%3DR.%26aulast%3DCruz-Bautista%26aufirst%3DI.%26aulast%3DMunoz-Hernandez%26aufirst%3DL.%2BL.%26aulast%3DSaenz%26aufirst%3DT.%26aulast%3DGomez%26aufirst%3DD.%26aulast%3DAlvirde%26aufirst%3DU.%26aulast%3DAlmeda-Valdes%26aufirst%3DP.%26aulast%3DCortes%26aufirst%3DM.%2BL.%26atitle%3DType%25202%2520diabetes%2520variants%2520disrupt%2520function%2520of%2520SLC16A11%2520through%2520two%2520distinct%2520mechanisms%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D199%26epage%3D212%26doi%3D10.1016%2Fj.cell.2017.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltsova, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapilevich, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusakova, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulin, N. O.</span></span> <span> </span><span class="NLM_article-title">NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension</span>. <i>Genes Dis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1016/j.gendis.2015.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.gendis.2015.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26114157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFKrur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=186-196&issue=2&author=S.+N.+Orlovauthor=S.+V.+Koltsovaauthor=L.+V.+Kapilevichauthor=S.+V.+Gusakovaauthor=N.+O.+Dulin&title=NKCC1+and+NKCC2%3A+The+pathogenetic+role+of+cation-chloride+cotransporters+in+hypertension&doi=10.1016%2Fj.gendis.2015.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension</span></div><div class="casAuthors">Orlov, Sergei N.; Koltsova, Svetlana V.; Kapilevich, Leonid V.; Gusakova, Svetlana V.; Dulin, Nickolai O.</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-196</span>CODEN:
                <span class="NLM_cas:coden">GDEIAV</span>;
        ISSN:<span class="NLM_cas:issn">2352-3042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This review summarizes the data on the functional significance of ubiquitous (NKCC1) and renal-specific (NKCC2) isoforms of electroneutral sodium, potassium and chloride cotransporters.  These carriers contribute to the pathogenesis of hypertension via regulation of intracellular chloride concn. in vascular smooth muscle and neuronal cells and via sensing chloride concn. in the renal tubular fluid, resp.  Both NKCC1 and NKCC2 are inhibited by furosemide and other high-ceiling diuretics widely used for attenuation of extracellular fluid vol.  However, the chronic usage of these compds. for the treatment of hypertension and other vol.-expanded disorders may have diverse side-effects due to suppression of myogenic response in microcirculatory beds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorW1zx-rv8bLVg90H21EOLACvtfcHk0lhJLoyYprB69w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFKrur8%253D&md5=f5bd38fd2477cbaec53730f37b2ec1c4</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.gendis.2015.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gendis.2015.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DOrlov%26aufirst%3DS.%2BN.%26aulast%3DKoltsova%26aufirst%3DS.%2BV.%26aulast%3DKapilevich%26aufirst%3DL.%2BV.%26aulast%3DGusakova%26aufirst%3DS.%2BV.%26aulast%3DDulin%26aufirst%3DN.%2BO.%26atitle%3DNKCC1%2520and%2520NKCC2%253A%2520The%2520pathogenetic%2520role%2520of%2520cation-chloride%2520cotransporters%2520in%2520hypertension%26jtitle%3DGenes%2520Dis%26date%3D2015%26volume%3D2%26issue%3D2%26spage%3D186%26epage%3D196%26doi%3D10.1016%2Fj.gendis.2015.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miner, J. N.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">665</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-00706-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41598-017-00706-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28386072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1cvlsVymsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=665&author=P.+K.+Tanauthor=S.+Liuauthor=E.+Gunicauthor=J.+N.+Miner&title=Discovery+and+characterization+of+verinurad%2C+a+potent+and+specific+inhibitor+of+URAT1+for+the+treatment+of+hyperuricemia+and+gout&doi=10.1038%2Fs41598-017-00706-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout</span></div><div class="casAuthors">Tan Philip K; Liu Sha; Miner Jeffrey N; Gunic Esmir</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">665</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1.  Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy.  Verinurad specifically inhibits URAT1 with a potency of 25 nM.  High affinity inhibition of uric acid transport requires URAT1 residues Cys-32, Ser-35, Phe-365 and Ile-481.  Unlike other available uricosuric agents, the requirement for Cys-32 is unique to verinurad.  Two of these residues, Ser-35 and Phe-365, are also important for urate transport kinetics.  A URAT1 binding assay using radiolabeled verinurad revealed that distinct URAT1 inhibitors benzbromarone, sulfinpyrazone and probenecid all inhibit verinurad binding via a competitive mechanism.  However, mutations made within the predicted transporter substrate channel differentially altered the potency for individual URAT1 inhibitors.  Overall, our results suggest that URAT1 inhibitors bind to a common site in the core of the transporter and sterically hinder the transit of uric acid through the substrate channel, albeit with vastly different potencies and with differential interactions with specific URAT1 amino acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR5U-7IZ-EeOb6AVA-44PTfW6udTcc2eaN3Mis-9YR7bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvlsVymsA%253D%253D&md5=94bb439f7fa518dbff9b2e312d50074b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-00706-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-00706-7%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DP.%2BK.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGunic%26aufirst%3DE.%26aulast%3DMiner%26aufirst%3DJ.%2BN.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520verinurad%252C%2520a%2520potent%2520and%2520specific%2520inhibitor%2520of%2520URAT1%2520for%2520the%2520treatment%2520of%2520hyperuricemia%2520and%2520gout%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D665%26doi%3D10.1038%2Fs41598-017-00706-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Dury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, H.-U.</span></span> <span> </span><span class="NLM_article-title">Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">931</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.00931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffphar.2018.00931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30186169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVartrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=931&author=S.+Al-Duryauthor=H.-U.+Marschall&title=Ileal+bile+acid+transporter+inhibition+for+the+treatment+of+chronic+constipation%2C+cholestatic+pruritus%2C+and+NASH&doi=10.3389%2Ffphar.2018.00931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH</span></div><div class="casAuthors">Al-Dury, Samer; Marschall, Hanns-Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">931/1-931/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Bile acids are synthesized from cholesterol in the liver, excreted with bile into the duodenum, almost completely taken up again in the distal ileum and finally returned to the liver with portal blood in a process termed enterohepatic circulation.  Bile acid synthesis, excretion, and reuptake are tightly regulated.  The apical sodium-dependent bile acid transporter [ASBT; also known as ileal bile acid transporter (IBAT) and SLC10A2] is pivotal for the almost complete reabsorption of conjugated bile acids in the ileum.  Dysfunctional IBAT may be the cause of bile acid diarrhea.  Pharmacol. IBAT inhibition results in an increased bile acid load in the colon and subsequently a lower bile acid pool, which is assocd. with improved liver histol. in animal models of cholestatic liver disease and non-alc. steatohepatitis (NASH).  In humans, IBAT inhibitors have been tested in clin. trials with widely different indications: in patients with idiopathic chronic constipation, an increased no. of bowel movements was obsd.  In adult and pediatric cholestatic liver diseases with pruritus, various IBAT inhibitors showed potential to improve itching.  Adverse events of IBAT inhibitors, based on their mode of action, are abdominal pain and diarrhea which might patients to withdraw from study medications.  So far, no data are available of a study of IBAT inhibitors in patients with NASH.  In this review we summarize the preclin. and most recent clin. studies with various IBAT inhibitors and discuss the difficulties that should be addressed in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8e8NYHl9dubVg90H21EOLACvtfcHk0lhgZUeTjIntQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVartrk%253D&md5=066fd4a7da22b886f98d35823f3a54a0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00931%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Dury%26aufirst%3DS.%26aulast%3DMarschall%26aufirst%3DH.-U.%26atitle%3DIleal%2520bile%2520acid%2520transporter%2520inhibition%2520for%2520the%2520treatment%2520of%2520chronic%2520constipation%252C%2520cholestatic%2520pruritus%252C%2520and%2520NASH%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D931%26doi%3D10.3389%2Ffphar.2018.00931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willmes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heifetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helfand, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkenfeld, A. L.</span></span> <span> </span><span class="NLM_article-title">The longevity gene INDY (Iâm Not Dead Yet) in metabolic control: potential as pharmacological target</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">11</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.pharmthera.2017.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28987323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVygu73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2018&pages=1-11&author=D.+M.+Willmesauthor=A.+Kurzbachauthor=C.+Henkeauthor=T.+Schumannauthor=G.+Zahnauthor=A.+Heifetzauthor=J.+Jordanauthor=S.+L.+Helfandauthor=A.+L.+Birkenfeld&title=The+longevity+gene+INDY+%28I%E2%80%99m+Not+Dead+Yet%29+in+metabolic+control%3A+potential+as+pharmacological+target&doi=10.1016%2Fj.pharmthera.2017.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The longevity gene INDY (I'm Not Dead Yet) in metabolic control: Potential as pharmacological target</span></div><div class="casAuthors">Willmes, Diana M.; Kurzbach, Anica; Henke, Christine; Schumann, Tina; Zahn, Grit; Heifetz, Alexander; Jordan, Jens; Helfand, Stephen L.; Birkenfeld, Andreas L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The regulation of metabolic processes by the Indy (I'm Not Dead Yet) (SLC13A5/NaCT) gene was revealed through studies in Drosophila melanogaster and Caenorhabditis elegans.  Reducing the expression of Indy in these species extended their life span by a mechanism resembling caloric restriction, without reducing food intake.  In D. melanogaster, mutating the Indy gene reduced body fat content, insulin-like proteins and reactive oxygen species prodn.  Subsequent studies indicated that Indy encodes a citrate transporter located on the cell plasma membrane.  The transporter is highly expressed in the mammalian liver.  We generated a mammalian knock out model deleting the mammalian homolog mIndy (SLC13A5).  The knock out animals were protected from HFD induced obesity, fatty liver and insulin resistance.  Moreover, we have shown that inducible and liver selective knock down of mIndy protects against the development of fatty liver and insulin resistance and that obese humans with type 2 diabetes and non-alc. fatty liver disease have increased levels of mIndy.  Therefore, the transporter mINDY (NaCT) has been proposed to be an 'ideal target for the treatment of metabolic disease'.  A small mol. inhibitor of the mINDY transporter has been generated, normalizing glucose levels and reducing fatty liver in a model of diet induced obese mice.  Taken together, studies from lower organisms, mammals and humans suggest that mINDY (NaCT) is an attractive target for the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGSuu3ENLlo7Vg90H21EOLACvtfcHk0lhgZUeTjIntQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVygu73E&md5=ac9c4b9b44b0985b9ac700902d49e170</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DWillmes%26aufirst%3DD.%2BM.%26aulast%3DKurzbach%26aufirst%3DA.%26aulast%3DHenke%26aufirst%3DC.%26aulast%3DSchumann%26aufirst%3DT.%26aulast%3DZahn%26aufirst%3DG.%26aulast%3DHeifetz%26aufirst%3DA.%26aulast%3DJordan%26aufirst%3DJ.%26aulast%3DHelfand%26aufirst%3DS.%2BL.%26aulast%3DBirkenfeld%26aufirst%3DA.%2BL.%26atitle%3DThe%2520longevity%2520gene%2520INDY%2520%2528I%25E2%2580%2599m%2520Not%2520Dead%2520Yet%2529%2520in%2520metabolic%2520control%253A%2520potential%2520as%2520pharmacological%2520target%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D185%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.pharmthera.2017.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maratou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atanur, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotroneo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabosseau, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponsa-Cobas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frid, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldashev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aitman, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>524</i></span> (<span class="NLM_issue">7565</span>),  <span class="NLM_fpage">356</span>â <span class="NLM_lpage">360</span>, <span class="refDoi">Â DOI: 10.1038/nature14620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature14620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26258299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=524&publication_year=2015&pages=356-360&issue=7565&author=L.+Zhaoauthor=E.+Oliverauthor=K.+Maratouauthor=S.+S.+Atanurauthor=O.+D.+Duboisauthor=E.+Cotroneoauthor=C.+N.+Chenauthor=L.+Wangauthor=C.+Arceauthor=P.+L.+Chabosseauauthor=J.+Ponsa-Cobasauthor=M.+G.+Fridauthor=B.+Moyonauthor=Z.+Websterauthor=A.+Aldashevauthor=J.+Ferrerauthor=G.+A.+Rutterauthor=K.+R.+Stenmarkauthor=T.+J.+Aitmanauthor=M.+R.+Wilkins&title=The+zinc+transporter+ZIP12+regulates+the+pulmonary+vascular+response+to+chronic+hypoxia&doi=10.1038%2Fnature14620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia</span></div><div class="casAuthors">Zhao, Lan; Oliver, Eduardo; Maratou, Klio; Atanur, Santosh S.; Dubois, Olivier D.; Cotroneo, Emanuele; Chen, Chien-Nien; Wang, Lei; Arce, Cristina; Chabosseau, Pauline L.; Ponsa-Cobas, Joan; Frid, Maria G.; Moyon, Benjamin; Webster, Zoe; Aldashev, Almaz; Ferrer, Jorge; Rutter, Guy A.; Stenmark, Kurt R.; Aitman, Timothy J.; Wilkins, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">524</span>
        (<span class="NLM_cas:issue">7565</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The typical response of the adult mammalian pulmonary circulation to a low oxygen environment is vasoconstriction and structural remodelling of pulmonary arterioles, leading to chronic elevation of pulmonary artery pressure (pulmonary hypertension) and right ventricular hypertrophy.  Some mammals, however, exhibit genetic resistance to hypoxia-induced pulmonary hypertension.  We used a congenic breeding program and comparative genomics to exploit this variation in the rat and identified the gene Slc39a12 as a major regulator of hypoxia-induced pulmonary vascular remodelling.  Slc39a12 encodes the zinc transporter ZIP12.  Here we report that ZIP12 expression is increased in many cell types, including endothelial, smooth muscle and interstitial cells, in the remodelled pulmonary arterioles of rats, cows and humans susceptible to hypoxia-induced pulmonary hypertension.  We show that ZIP12 expression in pulmonary vascular smooth muscle cells is hypoxia dependent and that targeted inhibition of ZIP12 inhibits the rise in intracellular labile zinc in hypoxia-exposed pulmonary vascular smooth muscle cells and their proliferation in culture.  We demonstrate that genetic disruption of ZIP12 expression attenuates the development of pulmonary hypertension in rats housed in a hypoxic atm.  This new and unexpected insight into the fundamental role of a zinc transporter in mammalian pulmonary vascular homeostasis suggests a new drug target for the pharmacol. management of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohKfta06gnfLVg90H21EOLACvtfcHk0ljK3-Q3jFHC4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FO&md5=d1f204ffbb9e3f697da9a86b01d96bfa</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnature14620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14620%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DOliver%26aufirst%3DE.%26aulast%3DMaratou%26aufirst%3DK.%26aulast%3DAtanur%26aufirst%3DS.%2BS.%26aulast%3DDubois%26aufirst%3DO.%2BD.%26aulast%3DCotroneo%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DArce%26aufirst%3DC.%26aulast%3DChabosseau%26aufirst%3DP.%2BL.%26aulast%3DPonsa-Cobas%26aufirst%3DJ.%26aulast%3DFrid%26aufirst%3DM.%2BG.%26aulast%3DMoyon%26aufirst%3DB.%26aulast%3DWebster%26aufirst%3DZ.%26aulast%3DAldashev%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DJ.%26aulast%3DRutter%26aufirst%3DG.%2BA.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DAitman%26aufirst%3DT.%2BJ.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DThe%2520zinc%2520transporter%2520ZIP12%2520regulates%2520the%2520pulmonary%2520vascular%2520response%2520to%2520chronic%2520hypoxia%26jtitle%3DNature%26date%3D2015%26volume%3D524%26issue%3D7565%26spage%3D356%26epage%3D360%26doi%3D10.1038%2Fnature14620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adekola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M.</span></span> <span> </span><span class="NLM_article-title">Glucose transporters in cancer metabolism</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">654</span>, <span class="refDoi">Â DOI: 10.1097/CCO.0b013e328356da72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1097%2FCCO.0b013e328356da72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22913968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCltr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=650-654&issue=6&author=K.+Adekolaauthor=S.+T.+Rosenauthor=M.+Shanmugam&title=Glucose+transporters+in+cancer+metabolism&doi=10.1097%2FCCO.0b013e328356da72"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose transporters in cancer metabolism</span></div><div class="casAuthors">Adekola, Kehinde; Rosen, Steven T.; Shanmugam, Mala</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-654</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Transformed cells exhibit a high rate of glucose consumption beyond that necessary for ATP synthesis.  Glucose aids in the generation of biomass and regulates cellular signaling crit. for oncogenic progression.  A key rate-limiting step in glucose utilization is the transport of glucose across the plasma membrane.  This review will highlight key glucose transporters (GLUTs) and current therapies targeting this class of proteins.  Recent findings: GLUTs, enabling the facilitative entry of glucose into a cell, are increasingly found to be deregulated in cancer.  Although cancer-specific expression patterns for GLUTs are being identified, comprehensive analyses substantiating a role for individual GLUTs are still required.  Studies defining GLUTs as being rate-limiting in specific tumor contexts, the identification of GLUT1 inhibitors via synthetic lethality screens, novel engagement of the insulin-responsive GLUT4 in myeloma and identification of GLUT9 being a urate transporter, are key advances underscoring the need for continued investigation of this large and enigmatic class of proteins.  Summary: Tumor cells exhibit elevated levels of glucose uptake, a phenomenon that has been capitalized upon for the prognostic and diagnostic imaging of a wide range of cancers using radio-labeled glucose analogs.  We have, however, not yet been able to target glucose entry in a tumor cell-specific manner for therapy.  GLUTs have been identified as rate-limiting in specific tumor contexts.  The identification and targeting of tumor-specific GLUTs provide a promising approach to block glucose-regulated metab. and signaling more comprehensively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGmT18-me7D7Vg90H21EOLACvtfcHk0ljK3-Q3jFHC4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCltr%252FL&md5=5ad6bc3f29caf6f7bb508123dcb256f1</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328356da72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328356da72%26sid%3Dliteratum%253Aachs%26aulast%3DAdekola%26aufirst%3DK.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DShanmugam%26aufirst%3DM.%26atitle%3DGlucose%2520transporters%2520in%2520cancer%2520metabolism%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2012%26volume%3D24%26issue%3D6%26spage%3D650%26epage%3D654%26doi%3D10.1097%2FCCO.0b013e328356da72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">Glutamine addiction: a new therapeutic target in cancer</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">433</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tibs.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20570523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=427-433&issue=8&author=D.+R.+Wiseauthor=C.+B.+Thompson&title=Glutamine+addiction%3A+a+new+therapeutic+target+in+cancer&doi=10.1016%2Fj.tibs.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine addiction: A new therapeutic target in cancer</span></div><div class="casAuthors">Wise, David R.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">427-433</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Most cancers depend on a high rate of aerobic glycolysis for their continued growth and survival.  Paradoxically, some cancer cell lines also display addiction to glutamine despite the fact that glutamine is a nonessential amino acid that can be synthesized from glucose.  The high rate of glutamine uptake exhibited by glutamine-dependent cells does not appear to result solely from its role as a nitrogen donor in nucleotide and amino acid biosynthesis.  Instead, glutamine plays a required role in the uptake of essential amino acids and in maintaining activation of TOR (target of rapamycin) kinase.  Moreover, in many cancer cells, glutamine is the primary mitochondrial substrate and is required for maintenance of mitochondrial membrane potential and integrity and for support of the NADPH prodn. needed for redox control and macromol. synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Gv_LsNdulLVg90H21EOLACvtfcHk0ljK3-Q3jFHC4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D&md5=915fa51996bc1c9b3ec3970b2dae7163</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DGlutamine%2520addiction%253A%2520a%2520new%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2010%26volume%3D35%26issue%3D8%26spage%3D427%26epage%3D433%26doi%3D10.1016%2Fj.tibs.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stine, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span> <span> </span><span class="NLM_article-title">From Krebs to clinic: glutamine metabolism to cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">619</span>â <span class="NLM_lpage">634</span>, <span class="refDoi">Â DOI: 10.1038/nrc.2016.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrc.2016.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27492215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=619-634&issue=10&author=B.+J.+Altmanauthor=Z.+E.+Stineauthor=C.+V.+Dang&title=From+Krebs+to+clinic%3A+glutamine+metabolism+to+cancer+therapy&doi=10.1038%2Fnrc.2016.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">From Krebs to clinic: glutamine metabolism to cancer therapy</span></div><div class="casAuthors">Altman, Brian J.; Stine, Zachary E.; Dang, Chi V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">619-634</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The resurgence of research into cancer metab. has recently broadened interests beyond glucose and the Warburg effect to other nutrients, including glutamine.  Because oncogenic alterations of metab. render cancer cells addicted to nutrients, pathways involved in glycolysis or glutaminolysis could be exploited for therapeutic purposes.  In this Review, we provide an updated overview of glutamine metab. and its involvement in tumorigenesis in vitro and in vivo, and explore the recent potential applications of basic science discoveries in the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2GDHcwHXcnLVg90H21EOLACvtfcHk0ljK3-Q3jFHC4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurbI&md5=00b34261d90a91151a3e833605c4aaec</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.71%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DB.%2BJ.%26aulast%3DStine%26aufirst%3DZ.%2BE.%26aulast%3DDang%26aufirst%3DC.%2BV.%26atitle%3DFrom%2520Krebs%2520to%2520clinic%253A%2520glutamine%2520metabolism%2520to%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26issue%3D10%26spage%3D619%26epage%3D634%26doi%3D10.1038%2Fnrc.2016.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Geldermalsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beith, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selinger, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâToole, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasko, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J.</span></span> <span> </span><span class="NLM_article-title">ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3201</span>â <span class="NLM_lpage">3208</span>, <span class="refDoi">Â DOI: 10.1038/onc.2015.381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fonc.2015.381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26455325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1eks73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=3201-3208&issue=24&author=M.+van%0AGeldermalsenauthor=Q.+Wangauthor=R.+Nagarajahauthor=A.+D.+Marshallauthor=A.+Thoengauthor=D.+Gaoauthor=W.+Ritchieauthor=Y.+Fengauthor=C.+G.+Baileyauthor=N.+Dengauthor=K.+Harveyauthor=J.+M.+Beithauthor=C.+I.+Selingerauthor=S.+A.+O%E2%80%99Tooleauthor=J.+E.+J.+Raskoauthor=J.+Holst&title=ASCT2%2FSLC1A5+controls+glutamine+uptake+and+tumour+growth+in+triple-negative+basal-like+breast+cancer&doi=10.1038%2Fonc.2015.381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">ASCT2/SLC1A5 controls glutamine uptake and tumor growth in triple-negative basal-like breast cancer</span></div><div class="casAuthors">van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Deng, N.; Harvey, K.; Beith, J. M.; Selinger, C. I.; O'Toole, S. A.; Rasko, J. E. J.; Holst, J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3201-3208</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumor cells.  Uptake of glutamine and subsequent glutaminolysis is crit. for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells.  This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes.  Pharmacol. inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signaling, cell growth and cell cycle progression.  Notably, these effects were subtype-dependent, with ASCT2 transport crit. only for triple-neg. (TN) basal-like breast cancer cell growth compared with minimal effects in luminal breast cancer cells.  Both stable and inducible shRNA-mediated ASCT2 knockdown confirmed that inhibiting ASCT2 function was sufficient to prevent cellular proliferation and induce rapid cell death in TN basal-like breast cancer cells, but not in luminal cells.  Using a bioluminescent orthotopic xenograft mouse model, ASCT2 expression was then shown to be necessary for both successful engraftment and growth of HCC1806 TN breast cancer cells in vivo.  Lower tumoral expression of ASCT2 conferred a significant survival advantage in xenografted mice.  These responses remained intact in primary breast cancers, where gene expression anal. showed high expression of ASCT2 and glutamine metab.-related genes, including GLUL and GLS, in a cohort of 90 TN breast cancer patients, as well as correlations with the transcriptional regulators, MYC and ATF4.  This study provides preclin. evidence for the feasibility of novel therapies exploiting ASCT2 transporter activity in breast cancer, particularly in the high-risk basal-like subgroup of TN breast cancer where there is not only high expression of ASCT2, but also a marked reliance on its activity for sustained cellular proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-no_vuezZeLVg90H21EOLACvtfcHk0lh8ktksEOMRAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1eks73J&md5=9f79dc0c47998d477eb1debe4ad3303a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.381%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGeldermalsen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DNagarajah%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DA.%2BD.%26aulast%3DThoeng%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DRitchie%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBailey%26aufirst%3DC.%2BG.%26aulast%3DDeng%26aufirst%3DN.%26aulast%3DHarvey%26aufirst%3DK.%26aulast%3DBeith%26aufirst%3DJ.%2BM.%26aulast%3DSelinger%26aufirst%3DC.%2BI.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DRasko%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DHolst%26aufirst%3DJ.%26atitle%3DASCT2%252FSLC1A5%2520controls%2520glutamine%2520uptake%2520and%2520tumour%2520growth%2520in%2520triple-negative%2520basal-like%2520breast%2520cancer%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D24%26spage%3D3201%26epage%3D3208%26doi%3D10.1038%2Fonc.2015.381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicklin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triantafellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyfeler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKeigan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L. O.</span></span> <span> </span><span class="NLM_article-title">Bidirectional transport of amino acids regulates mTOR and autophagy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">521</span>â <span class="NLM_lpage">534</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2008.11.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2008.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19203585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=521-534&issue=3&author=P.+Nicklinauthor=P.+Bergmanauthor=B.+L.+Zhangauthor=E.+Triantafellowauthor=H.+Wangauthor=B.+Nyfelerauthor=H.+D.+Yangauthor=M.+Hildauthor=C.+Kungauthor=C.+Wilsonauthor=V.+E.+Myerauthor=J.+P.+MacKeiganauthor=J.+A.+Porterauthor=Y.+K.+Wangauthor=L.+C.+Cantleyauthor=P.+M.+Finanauthor=L.+O.+Murphy&title=Bidirectional+transport+of+amino+acids+regulates+mTOR+and+autophagy&doi=10.1016%2Fj.cell.2008.11.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Bidirectional transport of amino acids regulates mTOR and autophagy</span></div><div class="casAuthors">Nicklin, Paul; Bergman, Philip; Zhang, Bailin; Triantafellow, Ellen; Wang, Henry; Nyfeler, Beat; Yang, Haidi; Hild, Marc; Kung, Charles; Wilson, Christopher; Myer, Vic E.; MacKeigan, Jeffrey P.; Porter, Jeffrey A.; Karen Wang, Y.; Cantley, Lewis C.; Finan, Peter M.; Murphy, Leon O.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-534</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Amino acids are required for activation of the mammalian target of rapamycin (mTOR) kinase which regulates protein translation, cell growth, and autophagy.  Cell surface transporters that allow amino acids to enter the cell and signal to mTOR are unknown.  We show that cellular uptake of L-glutamine and its subsequent rapid efflux in the presence of essential amino acids (EAA) is the rate-limiting step that activates mTOR.  L-Glutamine uptake is regulated by SLC1A5 and loss of SLC1A5 function inhibits cell growth and activates autophagy.  The mol. basis for L-glutamine sensitivity is due to SLC7A5/SLC3A2, a bidirectional transporter that regulates the simultaneous efflux of L-glutamine out of cells and transport of L-leucine/EAA into cells.  Certain tumor cell lines with high basal cellular levels of L-glutamine bypass the need for L-glutamine uptake and are primed for mTOR activation.  Thus, L-glutamine flux regulates mTOR, translation and autophagy to coordinate cell growth and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou-WsQFP-BcbVg90H21EOLACvtfcHk0lh8ktksEOMRAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnsrc%253D&md5=bc244efe138359f3090f6fcebe2134cd</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DNicklin%26aufirst%3DP.%26aulast%3DBergman%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DB.%2BL.%26aulast%3DTriantafellow%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNyfeler%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BD.%26aulast%3DHild%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DMacKeigan%26aufirst%3DJ.%2BP.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DMurphy%26aufirst%3DL.%2BO.%26atitle%3DBidirectional%2520transport%2520of%2520amino%2520acids%2520regulates%2520mTOR%2520and%2520autophagy%26jtitle%3DCell%26date%3D2009%26volume%3D136%26issue%3D3%26spage%3D521%26epage%3D534%26doi%3D10.1016%2Fj.cell.2008.11.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, B.</span></span> <span> </span><span class="NLM_article-title">The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">14240</span>â <span class="NLM_lpage">14249</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M117.798405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M117.798405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28630042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2iurzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=14240-14249&issue=34&author=P.+Koppulaauthor=Y.+Zhangauthor=J.+Shiauthor=W.+Liauthor=B.+Gan&title=The+glutamate%2Fcystine+antiporter+SLC7A11%2FxCT+enhances+cancer+cell+dependency+on+glucose+by+exporting+glutamate&doi=10.1074%2Fjbc.M117.798405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate</span></div><div class="casAuthors">Koppula, Pranavi; Zhang, Yilei; Shi, Jiejun; Li, Wei; Gan, Boyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">14240-14249</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cancer cells with specific genetic alterations may be highly dependent on certain nutrients for survival, which can inform therapeutic strategies to target these cancer-specific metabolic vulnerabilities.  The glutamate/cystine antiporter solute carrier family 7 member 11 (SLC7A11, also called xCT) is overexpressed in several cancers.  Contrasting the established pro-survival roles of SLC7A11 under other stress conditions, here we report the unexpected finding that SLC7A11 overexpression enhances cancer cell dependence on glucose and renders cancer cells more sensitive to glucose starvation-induced cell death and, conversely, that SLC7A11 deficiency by either knockdown or pharmacol. inhibition promotes cancer cell survival upon glucose starvation.  We further show that glucose starvation induces SLC7A11 expression through ATF4 and NRF2 transcription factors and, correspondingly, that ATF4 or NRF2 deficiency also renders cancer cells more resistant to glucose starvation.  Finally, we show that SLC7A11 overexpression decreases whereas SLC7A11 deficiency increases intracellular glutamate levels because of SLC7A11-mediated glutamate export and that supplementation of Î±-ketoglutarate, a key downstream metabolite of glutamate, fully restores survival in SLC7A11-overexpressing cells under glucose starvation.  Together, our results support the notion that both glucose and glutamate have important roles in maintaining cancer cell survival and uncover a previously unappreciated role of SLC7A11 to promote cancer cell dependence on glucose.  Our study therefore informs therapeutic strategies to target the metabolic vulnerability in tumors with high SLC7A11 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJkn9sw8AinbVg90H21EOLACvtfcHk0lh8ktksEOMRAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2iurzF&md5=df0b727df322afb7ea0b95cc6d159b40</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.798405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.798405%26sid%3Dliteratum%253Aachs%26aulast%3DKoppula%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DGan%26aufirst%3DB.%26atitle%3DThe%2520glutamate%252Fcystine%2520antiporter%2520SLC7A11%252FxCT%2520enhances%2520cancer%2520cell%2520dependency%2520on%2520glucose%2520by%2520exporting%2520glutamate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26issue%3D34%26spage%3D14240%26epage%3D14249%26doi%3D10.1074%2Fjbc.M117.798405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coothankandaswamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elangovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy-Thandavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnanaprakasam, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenlein, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangaraju, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">SLC6A14 (ATB(0,+)) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">31830</span>â <span class="NLM_lpage">31838</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.229518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M111.229518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21771784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=31830-31838&issue=36&author=S.+Karunakaranauthor=S.+Ramachandranauthor=V.+Coothankandaswamyauthor=S.+Elangovanauthor=E.+Babuauthor=S.+Periyasamy-Thandavanauthor=A.+Guravauthor=J.+P.+Gnanaprakasamauthor=N.+Singhauthor=P.+V.+Schoenleinauthor=P.+D.+Prasadauthor=M.+Thangarajuauthor=V.+Ganapathy&title=SLC6A14+%28ATB%280%2C%2B%29%29+protein%2C+a+highly+concentrative+and+broad+specific+amino+acid+transporter%2C+is+a+novel+and+effective+drug+target+for+treatment+of+estrogen+receptor-positive+breast+cancer&doi=10.1074%2Fjbc.M111.229518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</span></div><div class="casAuthors">Karunakaran, Senthil; Ramachandran, Sabarish; Coothankandaswamy, Veena; Elangovan, Selvakumar; Babu, Ellappan; Periyasamy-Thandavan, Sudharsan; Gurav, Ashish; Gnanaprakasam, Jaya P.; Singh, Nagendra; Schoenlein, Patricia V.; Prasad, Puttur D.; Thangaraju, Muthusamy; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">31830-31838</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SLC6A14, also known as ATB0,+, is an amino acid transporter with unique characteristics.  It transports 18 of the 20 proteinogenic amino acids.  However, this transporter is expressed only at low levels in normal tissues.  Here, we show that the transporter is up-regulated specifically in estrogen receptor (ER)-pos. breast cancer, demonstrable with primary human breast cancer tissues and human breast cancer cell lines.  SLC6A14 is an estrogen/ER target.  The transport features of SLC6A14 include concentrative transport of leucine (an activator of mTOR), glutamine (an essential amino acid for nucleotide biosynthesis and substrate for glutaminolysis), and arginine (an essential amino acid for tumor cells), suggesting that ER-pos. breast cancer cells up-regulate SLC6A14 to meet their increased demand for these amino acids.  Consequently, treatment of ER-pos. breast cancer cells in vitro with Î±-methyl-DL-tryptophan (Î±-MT), a selective blocker of SLC6A14, induces amino acid deprivation, inhibits mTOR, and activates autophagy.  Prolongation of the treatment with Î±-MT causes apoptosis.  Addn. of an autophagy inhibitor (3-methyladenine) during Î±-MT treatment also induces apoptosis.  These effects of Î±-MT are specific to ER-pos. breast cancer cells, which express the transporter.  The ability of Î±-MT to cause amino acid deprivation is significantly attenuated in MCF-7 cells, an ER-pos. breast cancer cell line, when SLC6A14 is silenced with shRNA.  In mouse xenograft studies, Î±-MT by itself is able to reduce the growth of the ER-pos. ZR-75-1 breast cancer cells.  These studies identify SLC6A14 as a novel and effective drug target for the treatment of ER-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfDE1psCVVsrVg90H21EOLACvtfcHk0ljkNfZhAFBYAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO&md5=046c74001108f451cd741e46d2ab5ec8</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.229518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.229518%26sid%3Dliteratum%253Aachs%26aulast%3DKarunakaran%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DCoothankandaswamy%26aufirst%3DV.%26aulast%3DElangovan%26aufirst%3DS.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DPeriyasamy-Thandavan%26aufirst%3DS.%26aulast%3DGurav%26aufirst%3DA.%26aulast%3DGnanaprakasam%26aufirst%3DJ.%2BP.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DSchoenlein%26aufirst%3DP.%2BV.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DThangaraju%26aufirst%3DM.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DSLC6A14%2520%2528ATB%25280%252C%252B%2529%2529%2520protein%252C%2520a%2520highly%2520concentrative%2520and%2520broad%2520specific%2520amino%2520acid%2520transporter%252C%2520is%2520a%2520novel%2520and%2520effective%2520drug%2520target%2520for%2520treatment%2520of%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D36%26spage%3D31830%26epage%3D31838%26doi%3D10.1074%2Fjbc.M111.229518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span> <span> </span><span class="NLM_article-title">Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">13194</span>â <span class="NLM_lpage">13205</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.700534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M115.700534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27129276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=13194-13205&issue=25&author=A.+Broerauthor=F.+Rahimiauthor=S.+Broer&title=Deletion+of+amino+acid+transporter+ASCT2+%28SLC1A5%29+reveals+an+essential+role+for+transporters+SNAT1+%28SLC38A1%29+and+SNAT2+%28SLC38A2%29+to+sustain+glutaminolysis+in+cancer+cells&doi=10.1074%2Fjbc.M115.700534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells</span></div><div class="casAuthors">Broer, Angelika; Rahimi, Farid; Broer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">13194-13205</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Many cancer cells depend on glutamine as they use the glutaminolysis pathway to generate building blocks and energy for anabolic purposes.  As a result, glutamine transporters are essential for cancer growth and are potential targets for cancer chemotherapy with ASCT2 (SLC1A5) being investigated most intensively.  Here we show that HeLa epithelial cervical cancer cells and 143B osteosarcoma cells express a set of glutamine transporters including SNAT1 (SLC38A1), SNAT2 (SLC38A2), SNAT4 (SLC38A4), LAT1 (SLC7A5), and ASCT2 (SLC1A5).  Net glutamine uptake did not depend on ASCT2 but required expression of SNAT1 and SNAT2.  Deletion of ASCT2 did not reduce cell growth but caused an amino acid starvation response and up-regulation of SNAT1 to replace ASCT2 functionally.  Silencing of GCN2 in the ASCT2(-/-) background reduced cell growth, showing that a combined targeted approach would inhibit growth of glutamine-dependent cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT3LAc1IdgBLVg90H21EOLACvtfcHk0ljkNfZhAFBYAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksLvE&md5=efe20f840b3c528ec6ce07791ab4849b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.700534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.700534%26sid%3Dliteratum%253Aachs%26aulast%3DBroer%26aufirst%3DA.%26aulast%3DRahimi%26aufirst%3DF.%26aulast%3DBroer%26aufirst%3DS.%26atitle%3DDeletion%2520of%2520amino%2520acid%2520transporter%2520ASCT2%2520%2528SLC1A5%2529%2520reveals%2520an%2520essential%2520role%2520for%2520transporters%2520SNAT1%2520%2528SLC38A1%2529%2520and%2520SNAT2%2520%2528SLC38A2%2529%2520to%2520sustain%2520glutaminolysis%2520in%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26issue%3D25%26spage%3D13194%26epage%3D13205%26doi%3D10.1074%2Fjbc.M115.700534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watrous, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAurelio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. C.</span></span> <span> </span><span class="NLM_article-title">The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15074</span>, <span class="refDoi">Â DOI: 10.1038/ncomms15074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fncomms15074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28429737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1cvpvVChtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15074&author=C.+S.+Shinauthor=P.+Mishraauthor=J.+D.+Watrousauthor=V.+Carelliauthor=M.+D%E2%80%99Aurelioauthor=M.+Jainauthor=D.+C.+Chan&title=The+glutamate%2Fcystine+xCT+antiporter+antagonizes+glutamine+metabolism+and+reduces+nutrient+flexibility&doi=10.1038%2Fncomms15074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility</span></div><div class="casAuthors">Shin Chun-Shik; Mishra Prashant; Chan David C; Mishra Prashant; Watrous Jeramie D; Jain Mohit; Carelli Valerio; Carelli Valerio; D'Aurelio Marilena</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15074</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As noted by Warburg, many cancer cells depend on the consumption of glucose.  We performed a genetic screen to identify factors responsible for glucose addiction and recovered the two subunits of the xCT antiporter (system xc(-)), which plays an antioxidant role by exporting glutamate for cystine.  Disruption of the xCT antiporter greatly improves cell viability after glucose withdrawal, because conservation of glutamate enables cells to maintain mitochondrial respiration.  In some breast cancer cells, xCT antiporter expression is upregulated through the antioxidant transcription factor Nrf2 and contributes to their requirement for glucose as a carbon source.  In cells carrying patient-derived mitochondrial DNA mutations, the xCT antiporter is upregulated and its inhibition improves mitochondrial function and cell viability.  Therefore, although upregulation of the xCT antiporter promotes antioxidant defence, it antagonizes glutamine metabolism and restricts nutrient flexibility.  In cells with mitochondrial dysfunction, the potential utility of xCT antiporter inhibition should be further tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRClV9KJBGDkcLvDNbOD4DfW6udTcc2eaPi7BJn_UQ8rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvpvVChtg%253D%253D&md5=4745c5aa46dac5683db415920a023c3f</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fncomms15074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15074%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DC.%2BS.%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DWatrous%26aufirst%3DJ.%2BD.%26aulast%3DCarelli%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Aurelio%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DD.%2BC.%26atitle%3DThe%2520glutamate%252Fcystine%2520xCT%2520antiporter%2520antagonizes%2520glutamine%2520metabolism%2520and%2520reduces%2520nutrient%2520flexibility%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15074%26doi%3D10.1038%2Fncomms15074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardie, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geldermalsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreuder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metierre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasko, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J.</span></span> <span> </span><span class="NLM_article-title">Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development</span>. <i>J. Pathol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>236</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">278</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1002/path.4518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fpath.4518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25693838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpslOksb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2015&pages=278-289&issue=3&author=Q.+Wangauthor=R.+A.+Hardieauthor=A.+J.+Hoyauthor=M.+van+Geldermalsenauthor=D.+Gaoauthor=L.+Fazliauthor=M.+C.+Sadowskiauthor=S.+Balabanauthor=M.+Schreuderauthor=R.+Nagarajahauthor=J.+J.+Wongauthor=C.+Metierreauthor=N.+Pinelloauthor=N.+J.+Otteauthor=M.+L.+Lehmanauthor=M.+Gleaveauthor=C.+C.+Nelsonauthor=C.+G.+Baileyauthor=W.+Ritchieauthor=J.+E.+Raskoauthor=J.+Holst&title=Targeting+ASCT2-mediated+glutamine+uptake+blocks+prostate+cancer+growth+and+tumour+development&doi=10.1002%2Fpath.4518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development</span></div><div class="casAuthors">Wang, Qian; Hardie, Rae-Anne; Hoy, Andrew J.; van Geldermalsen, Michelle; Gao, Dadi; Fazli, Ladan; Sadowski, Martin C.; Balaban, Seher; Schreuder, Mark; Nagarajah, Rajini; Wong, Justin J.-L.; Metierre, Cynthia; Pinello, Natalia; Otte, Nicholas J.; Lehman, Melanie L.; Gleave, Martin; Nelson, Colleen C.; Bailey, Charles G.; Ritchie, William; Rasko, John E. J.; Holst, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">278-289</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Glutamine is conditionally essential in cancer cells, being utilized as a carbon and nitrogen source for macromol. prodn., as well as for anaplerotic reactions fuelling the tricarboxylic acid (TCA) cycle.  In this study, we demonstrated that the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer patient samples.  Using LNCaP and PC-3 prostate cancer cell lines, we showed that chem. or shRNA-mediated inhibition of ASCT2 function in vitro decreases glutamine uptake, cell cycle progression through E2F transcription factors, mTORC1 pathway activation and cell growth.  Chem. inhibition also reduces basal oxygen consumption and fatty acid synthesis, showing that downstream metabolic function is reliant on ASCT2-mediated glutamine uptake.  Furthermore, shRNA knockdown of ASCT2 in PC-3 cell xenografts significantly inhibits tumor growth and metastasis in vivo, assocd. with the down-regulation of E2F cell cycle pathway proteins.  In conclusion, ASCT2-mediated glutamine uptake is essential for multiple pathways regulating the cell cycle and cell growth, and is therefore a putative therapeutic target in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowVIpseGk9_rVg90H21EOLACvtfcHk0lh_G-jIzWcwow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpslOksb8%253D&md5=71c4189e331afdca39ff610f8fa5b5ae</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fpath.4518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4518%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHardie%26aufirst%3DR.%2BA.%26aulast%3DHoy%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGeldermalsen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DFazli%26aufirst%3DL.%26aulast%3DSadowski%26aufirst%3DM.%2BC.%26aulast%3DBalaban%26aufirst%3DS.%26aulast%3DSchreuder%26aufirst%3DM.%26aulast%3DNagarajah%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DJ.%2BJ.%26aulast%3DMetierre%26aufirst%3DC.%26aulast%3DPinello%26aufirst%3DN.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DLehman%26aufirst%3DM.%2BL.%26aulast%3DGleave%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DC.%2BC.%26aulast%3DBailey%26aufirst%3DC.%2BG.%26aulast%3DRitchie%26aufirst%3DW.%26aulast%3DRasko%26aufirst%3DJ.%2BE.%26aulast%3DHolst%26aufirst%3DJ.%26atitle%3DTargeting%2520ASCT2-mediated%2520glutamine%2520uptake%2520blocks%2520prostate%2520cancer%2520growth%2520and%2520tumour%2520development%26jtitle%3DJ.%2520Pathol%26date%3D2015%26volume%3D236%26issue%3D3%26spage%3D278%26epage%3D289%26doi%3D10.1002%2Fpath.4518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleveland, J. L.</span></span> <span> </span><span class="NLM_article-title">Targeting lactate metabolism for cancer therapeutics</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3685</span>â <span class="NLM_lpage">3692</span>, <span class="refDoi">Â DOI: 10.1172/JCI69741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1172%2FJCI69741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23999443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3685-3692&issue=9&author=J.+R.+Dohertyauthor=J.+L.+Cleveland&title=Targeting+lactate+metabolism+for+cancer+therapeutics&doi=10.1172%2FJCI69741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting lactate metabolism for cancer therapeutics</span></div><div class="casAuthors">Doherty, Joanne R.; Cleveland, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3685-3692</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Lactate, once considered a waste product of glycolysis, has emerged as a crit. regulator of cancer development, maintenance, and metastasis.  Indeed, tumor lactate levels correlate with increased metastasis, tumor recurrence, and poor outcome.  Lactate mediates cancer cell intrinsic effects on metab. and has addnl. non-tumor cell autonomous effects that drive tumorigenesis.  Tumor cells can metabolize lactate as an energy source and shuttle lactate to neighboring cancer cells, adjacent stroma, and vascular endothelial cells, which induces metabolic reprogramming.  Lactate also plays roles in promoting tumor inflammation and in functioning as a signaling mol. that stimulates tumor angiogenesis.  Here we review the mechanisms of lactate prodn. and transport and highlight emerging evidence indicating that targeting lactate metab. is a promising approach for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFmg5ARs0RTbVg90H21EOLACvtfcHk0lh_G-jIzWcwow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bE&md5=aace1060fc624a520881b8e341ef33fe</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1172%2FJCI69741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69741%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DJ.%2BR.%26aulast%3DCleveland%26aufirst%3DJ.%2BL.%26atitle%3DTargeting%2520lactate%2520metabolism%2520for%2520cancer%2520therapeutics%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26issue%3D9%26spage%3D3685%26epage%3D3692%26doi%3D10.1172%2FJCI69741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espindola Camacho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maresh, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagryanova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krotee, P. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behbahan, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinghoff, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinett, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdistani, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodglick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span> <span> </span><span class="NLM_article-title">MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1590</span>â <span class="NLM_lpage">1601</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.01.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.celrep.2016.01.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26876179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFOht7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=1590-1601&issue=7&author=C.+S.+Hongauthor=N.+A.+Grahamauthor=W.+Guauthor=C.+Espindola+Camachoauthor=V.+Mahauthor=E.+L.+Mareshauthor=M.+Alaviauthor=L.+Bagryanovaauthor=P.+A.+L.+Kroteeauthor=B.+K.+Gardnerauthor=I.+S.+Behbahanauthor=S.+Horvathauthor=D.+Chiaauthor=I.+K.+Mellinghoffauthor=S.+A.+Hurvitzauthor=S.+M.+Dubinettauthor=S.+E.+Critchlowauthor=S.+K.+Kurdistaniauthor=L.+Goodglickauthor=D.+Braasauthor=T.+G.+Graeberauthor=H.+R.+Christofk&title=MCT1+modulates+cancer+cell+pyruvate+export+and+growth+of+tumors+that+co-express+MCT1+and+MCT4&doi=10.1016%2Fj.celrep.2016.01.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4</span></div><div class="casAuthors">Hong, Candice Sun; Graham, Nicholas A.; Gu, Wen; Espindola Camacho, Carolina; Mah, Vei; Maresh, Erin L.; Alavi, Mohammed; Bagryanova, Lora; Krotee, Pascal A. L.; Gardner, Brian K.; Behbahan, Iman Saramipoor; Horvath, Steve; Chia, David; Mellinghoff, Ingo K.; Hurvitz, Sara A.; Dubinett, Steven M.; Critchlow, Susan E.; Kurdistani, Siavash K.; Goodglick, Lee; Braas, Daniel; Graeber, Thomas G.; Christofk, Heather R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1590-1601</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Monocarboxylate transporter 1 (MCT1) inhibition is thought to block tumor growth through disruption of lactate transport and glycolysis.  Here, we show MCT1 inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 and MCT4 via disruption of pyruvate rather than lactate export.  MCT1 expression is elevated in glycolytic breast tumors, and high MCT1 expression predicts poor prognosis in breast and lung cancer patients.  Acute MCT1 inhibition reduces pyruvate export but does not consistently alter lactate transport or glycolytic flux in breast cancer cells that co-express MCT1 and MCT4.  Despite the lack of glycolysis impairment, MCT1 loss-of-function decreases breast cancer cell proliferation and blocks growth of mammary fat pad xenograft tumors.  Our data suggest MCT1 expression is elevated in glycolytic cancers to promote pyruvate export that when inhibited, enhances oxidative metab. and reduces proliferation.  This study presents an alternative mol. consequence of MCT1 inhibitors, further supporting their use as anti-cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriOSyxhbJmb7Vg90H21EOLACvtfcHk0lh_G-jIzWcwow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFOht7o%253D&md5=2d8a976ab178e2aaa41f387a6773c18c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.01.057%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DC.%2BS.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DEspindola%2BCamacho%26aufirst%3DC.%26aulast%3DMah%26aufirst%3DV.%26aulast%3DMaresh%26aufirst%3DE.%2BL.%26aulast%3DAlavi%26aufirst%3DM.%26aulast%3DBagryanova%26aufirst%3DL.%26aulast%3DKrotee%26aufirst%3DP.%2BA.%2BL.%26aulast%3DGardner%26aufirst%3DB.%2BK.%26aulast%3DBehbahan%26aufirst%3DI.%2BS.%26aulast%3DHorvath%26aufirst%3DS.%26aulast%3DChia%26aufirst%3DD.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DDubinett%26aufirst%3DS.%2BM.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DKurdistani%26aufirst%3DS.%2BK.%26aulast%3DGoodglick%26aufirst%3DL.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26atitle%3DMCT1%2520modulates%2520cancer%2520cell%2520pyruvate%2520export%2520and%2520growth%2520of%2520tumors%2520that%2520co-express%2520MCT1%2520and%2520MCT4%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D14%26issue%3D7%26spage%3D1590%26epage%3D1601%26doi%3D10.1016%2Fj.celrep.2016.01.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghergurovich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morscher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esparza, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanxiang
Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span> <span> </span><span class="NLM_article-title">Glucose feeds the TCA cycle via circulating lactate</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>551</i></span>,  <span class="NLM_fpage">115</span>â <span class="NLM_lpage">118</span>, <span class="refDoi">Â DOI: 10.1038/nature24057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature24057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29045397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1M7itVeitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=551&publication_year=2017&pages=115-118&author=S.+Huiauthor=J.+M.+Ghergurovichauthor=R.+J.+Morscherauthor=C.+Jangauthor=X.+Tengauthor=W.+Luauthor=L.+A.+Esparzaauthor=T.+Reyaauthor=L.+Zhanauthor=J.+Yanxiang%0AGuoauthor=E.+Whiteauthor=J.+D.+Rabinowitz&title=Glucose+feeds+the+TCA+cycle+via+circulating+lactate&doi=10.1038%2Fnature24057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose feeds the TCA cycle via circulating lactate</span></div><div class="casAuthors">Hui Sheng; Ghergurovich Jonathan M; Morscher Raphael J; Jang Cholsoon; Teng Xin; Lu Wenyun; Rabinowitz Joshua D; Hui Sheng; Morscher Raphael J; Jang Cholsoon; Teng Xin; Lu Wenyun; Rabinowitz Joshua D; Ghergurovich Jonathan M; Esparza Lourdes A; Reya Tannishtha; Le Zhan; Yanxiang Guo Jessie; White Eileen; Rabinowitz Joshua D; Le Zhan; White Eileen; Yanxiang Guo Jessie; Yanxiang Guo Jessie</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">551</span>
        (<span class="NLM_cas:issue">7678</span>),
    <span class="NLM_cas:pages">115-118</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mammalian tissues are fuelled by circulating nutrients, including glucose, amino acids, and various intermediary metabolites.  Under aerobic conditions, glucose is generally assumed to be burned fully by tissues via the tricarboxylic acid cycle (TCA cycle) to carbon dioxide.  Alternatively, glucose can be catabolized anaerobically via glycolysis to lactate, which is itself also a potential nutrient for tissues and tumours.  The quantitative relevance of circulating lactate or other metabolic intermediates as fuels remains unclear.  Here we systematically examine the fluxes of circulating metabolites in mice, and find that lactate can be a primary source of carbon for the TCA cycle and thus of energy.  Intravenous infusions of (13)C-labelled nutrients reveal that, on a molar basis, the circulatory turnover flux of lactate is the highest of all metabolites and exceeds that of glucose by 1.1-fold in fed mice and 2.5-fold in fasting mice; lactate is made primarily from glucose but also from other sources.  In both fed and fasted mice, (13)C-lactate extensively labels TCA cycle intermediates in all tissues.  Quantitative analysis reveals that during the fasted state, the contribution of glucose to tissue TCA metabolism is primarily indirect (via circulating lactate) in all tissues except the brain.  In genetically engineered lung and pancreatic cancer tumours in fasted mice, the contribution of circulating lactate to TCA cycle intermediates exceeds that of glucose, with glutamine making a larger contribution than lactate in pancreatic cancer.  Thus, glycolysis and the TCA cycle are uncoupled at the level of lactate, which is a primary circulating TCA substrate in most tissues and tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRg5xRraXiXr7BItaL1WaVAfW6udTcc2eYecGYBQxlE3Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7itVeitA%253D%253D&md5=52d11bb82116a571b4bf551ecd2c4690</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnature24057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature24057%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DS.%26aulast%3DGhergurovich%26aufirst%3DJ.%2BM.%26aulast%3DMorscher%26aufirst%3DR.%2BJ.%26aulast%3DJang%26aufirst%3DC.%26aulast%3DTeng%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DEsparza%26aufirst%3DL.%2BA.%26aulast%3DReya%26aufirst%3DT.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DYanxiang%2BGuo%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DE.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26atitle%3DGlucose%2520feeds%2520the%2520TCA%2520cycle%2520via%2520circulating%2520lactate%26jtitle%3DNature%26date%3D2017%26volume%3D551%26spage%3D115%26epage%3D118%26doi%3D10.1038%2Fnature24057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faubert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, Q. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burguete, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrealba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenkinski, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malloy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachsmann, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernstine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span> <span> </span><span class="NLM_article-title">Lactate metabolism in human lung tumors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">358</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2017.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28985563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=358-371&issue=2&author=B.+Faubertauthor=K.+Y.+Liauthor=L.+Caiauthor=C.+T.+Hensleyauthor=J.+Kimauthor=L.+G.+Zachariasauthor=C.+Yangauthor=Q.+N.+Doauthor=S.+Doucetteauthor=D.+Burgueteauthor=H.+Liauthor=G.+Huetauthor=Q.+Yuanauthor=T.+Wigalauthor=Y.+Buttauthor=M.+Niauthor=J.+Torrealbaauthor=D.+Oliverauthor=R.+E.+Lenkinskiauthor=C.+R.+Malloyauthor=J.+W.+Wachsmannauthor=J.+D.+Youngauthor=K.+Kernstineauthor=R.+J.+DeBerardinis&title=Lactate+metabolism+in+human+lung+tumors&doi=10.1016%2Fj.cell.2017.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lactate Metabolism in Human Lung Tumors</span></div><div class="casAuthors">Faubert, Brandon; Li, Kevin Y.; Cai, Ling; Hensley, Christopher T.; Kim, Jiyeon; Zacharias, Lauren G.; Yang, Chendong; Do, Quyen N.; Doucette, Sarah; Burguete, Daniel; Li, Hong; Huet, Giselle; Yuan, Qing; Wigal, Trevor; Butt, Yasmeen; Ni, Min; Torrealba, Jose; Oliver, Dwight; Lenkinski, Robert E.; Malloy, Craig R.; Wachsmann, Jason W.; Young, Jamey D.; Kernstine, Kemp; De Berardinis, Ralph J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">358-371.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cancer cells consume glucose and secrete lactate in culture.  It is unknown whether lactate contributes to energy metab. in living tumors.  We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in the tricarboxylic acid (TCA) cycle.  Here, we show that lactate is also a TCA cycle carbon source for NSCLC.  In human NSCLC, evidence of lactate utilization was most apparent in tumors with high 18fluorodeoxyglucose uptake and aggressive oncol. behavior.  Infusing human NSCLC patients with 13C-lactate revealed extensive labeling of TCA cycle metabolites.  In mice, deleting monocarboxylate transporter-1 (MCT1) from tumor cells eliminated lactate-dependent metabolite labeling, confirming tumor-cell-autonomous lactate uptake.  Strikingly, directly comparing lactate and glucose metab. in vivo indicated that lactate's contribution to the TCA cycle predominates.  The data indicate that tumors, including bona fide human NSCLC, can use lactate as a fuel in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFvHZlHeZHzrVg90H21EOLACvtfcHk0ljjhYZJztx02w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfJ&md5=efdddf0b938cd359030d28964f642873</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DFaubert%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DK.%2BY.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DHensley%26aufirst%3DC.%2BT.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DZacharias%26aufirst%3DL.%2BG.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DQ.%2BN.%26aulast%3DDoucette%26aufirst%3DS.%26aulast%3DBurguete%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuet%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DQ.%26aulast%3DWigal%26aufirst%3DT.%26aulast%3DButt%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DTorrealba%26aufirst%3DJ.%26aulast%3DOliver%26aufirst%3DD.%26aulast%3DLenkinski%26aufirst%3DR.%2BE.%26aulast%3DMalloy%26aufirst%3DC.%2BR.%26aulast%3DWachsmann%26aufirst%3DJ.%2BW.%26aulast%3DYoung%26aufirst%3DJ.%2BD.%26aulast%3DKernstine%26aufirst%3DK.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26atitle%3DLactate%2520metabolism%2520in%2520human%2520lung%2520tumors%26jtitle%3DCell%26date%3D2017%26volume%3D171%26issue%3D2%26spage%3D358%26epage%3D371%26doi%3D10.1016%2Fj.cell.2017.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elia, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broekaert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doglioni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gorsel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escalona-Noguero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verfaillie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmeliet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendt, S. M.</span></span> <span> </span><span class="NLM_article-title">Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>568</i></span> (<span class="NLM_issue">7750</span>),  <span class="NLM_fpage">117</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-0977-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-0977-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30814728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVyqtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=568&publication_year=2019&pages=117-121&issue=7750&author=I.+Eliaauthor=M.+Rossiauthor=S.+Stegenauthor=D.+Broekaertauthor=G.+Doglioniauthor=M.+van+Gorselauthor=R.+Boonauthor=C.+Escalona-Nogueroauthor=S.+Torrekensauthor=C.+Verfaillieauthor=E.+Verbekenauthor=G.+Carmelietauthor=S.+M.+Fendt&title=Breast+cancer+cells+rely+on+environmental+pyruvate+to+shape+the+metastatic+niche&doi=10.1038%2Fs41586-019-0977-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</span></div><div class="casAuthors">Elia, Ilaria; Rossi, Matteo; Stegen, Steve; Broekaert, Dorien; Doglioni, Ginevra; van Gorsel, Marit; Boon, Ruben; Escalona-Noguero, Carmen; Torrekens, Sophie; Verfaillie, Catherine; Verbeken, Erik; Carmeliet, Geert; Fendt, Sarah-Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">568</span>
        (<span class="NLM_cas:issue">7750</span>),
    <span class="NLM_cas:pages">117-121</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The extracellular matrix is a major component of the local environment - i.e., the niche - that dets. cell behavior.  During metastatic growth, cancer cells shape the extracellular matrix of the metastatic niche by hydroxylating collagen to promote their own metastatic growth.  However, only particular nutrients might support the ability of cancer cells to hydroxylate collagen, because nutrients dictate which enzymic reactions are active in cancer cells.  Here we show that breast cancer cells rely on the nutrient pyruvate to drive collagen-based remodelling of the extracellular matrix in the lung metastatic niche.  Specifically, we discovered that pyruvate uptake induces the prodn. of Î±-ketoglutarate.  This metabolite in turn activates collagen hydroxylation by increasing the activity of the enzyme collagen prolyl-4-hydroxylase (P4HA).  Inhibition of pyruvate metab. was sufficient to impair collagen hydroxylation and consequently the growth of breast-cancer-derived lung metastases in different mouse models.  In summary, we provide a mechanistic understanding of the link between collagen remodelling and the nutrient environment in the metastatic niche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT_tkXiytetbVg90H21EOLACvtfcHk0lhSlyDYrksDdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVyqtbY%253D&md5=522f26dd89ea6261a38d79a88b9934ca</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-0977-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-0977-x%26sid%3Dliteratum%253Aachs%26aulast%3DElia%26aufirst%3DI.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DStegen%26aufirst%3DS.%26aulast%3DBroekaert%26aufirst%3DD.%26aulast%3DDoglioni%26aufirst%3DG.%26aulast%3Dvan%2BGorsel%26aufirst%3DM.%26aulast%3DBoon%26aufirst%3DR.%26aulast%3DEscalona-Noguero%26aufirst%3DC.%26aulast%3DTorrekens%26aufirst%3DS.%26aulast%3DVerfaillie%26aufirst%3DC.%26aulast%3DVerbeken%26aufirst%3DE.%26aulast%3DCarmeliet%26aufirst%3DG.%26aulast%3DFendt%26aufirst%3DS.%2BM.%26atitle%3DBreast%2520cancer%2520cells%2520rely%2520on%2520environmental%2520pyruvate%2520to%2520shape%2520the%2520metastatic%2520niche%26jtitle%3DNature%26date%3D2019%26volume%3D568%26issue%3D7750%26spage%3D117%26epage%3D121%26doi%3D10.1038%2Fs41586-019-0977-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bafaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempski, R. E.</span></span> <span> </span><span class="NLM_article-title">The emerging role of zinc transporters in cellular homeostasis and cancer</span>. <i>Signal. Transduct. Target Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">17029</span>, <span class="refDoi">Â DOI: 10.1038/sigtrans.2017.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fsigtrans.2017.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29218234" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=17029&author=E.+Bafaroauthor=Y.+Liuauthor=Y.+Xuauthor=R.+E.+Dempski&title=The+emerging+role+of+zinc+transporters+in+cellular+homeostasis+and+cancer&doi=10.1038%2Fsigtrans.2017.29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2017.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2017.29%26sid%3Dliteratum%253Aachs%26aulast%3DBafaro%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDempski%26aufirst%3DR.%2BE.%26atitle%3DThe%2520emerging%2520role%2520of%2520zinc%2520transporters%2520in%2520cellular%2520homeostasis%2520and%2520cancer%26jtitle%3DSignal.%2520Transduct.%2520Target%2520Ther.%26date%3D2017%26volume%3D2%26spage%3D17029%26doi%3D10.1038%2Fsigtrans.2017.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoene, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, K. Y.</span></span> <span> </span><span class="NLM_article-title">Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells</span>. <i>Am. J. Physiol Cell Physiol</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>297</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">C1188</span>â <span class="NLM_lpage">1199</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00042.2009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpcell.00042.2009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19657064" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2009&pages=C1188-1199&issue=5&author=C.+T.+Hanauthor=N.+W.+Schoeneauthor=K.+Y.+Lei&title=Influence+of+zinc+deficiency+on+Akt-Mdm2-p53+and+Akt-p21+signaling+axes+in+normal+and+malignant+human+prostate+cells&doi=10.1152%2Fajpcell.00042.2009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00042.2009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00042.2009%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%2BT.%26aulast%3DSchoene%26aufirst%3DN.%2BW.%26aulast%3DLei%26aufirst%3DK.%2BY.%26atitle%3DInfluence%2520of%2520zinc%2520deficiency%2520on%2520Akt-Mdm2-p53%2520and%2520Akt-p21%2520signaling%2520axes%2520in%2520normal%2520and%2520malignant%2520human%2520prostate%2520cells%26jtitle%3DAm.%2520J.%2520Physiol%2520Cell%2520Physiol%26date%3D2009%26volume%3D297%26issue%3D5%26spage%3DC1188%26epage%3D1199%26doi%3D10.1152%2Fajpcell.00042.2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>â <span class="NLM_lpage">867</span>, <span class="refDoi">Â DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&issue=6&author=P.+T.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lhSlyDYrksDdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26issue%3D6%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brady, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turski, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Counter, C. M.</span></span> <span> </span><span class="NLM_article-title">Copper is required for oncogenic BRAF signaling and tumorigenesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span> (<span class="NLM_issue">7501</span>),  <span class="NLM_fpage">492</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1038/nature13180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature13180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24717435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotlymsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=492-496&issue=7501&author=D.+C.+Bradyauthor=M.+S.+Croweauthor=M.+L.+Turskiauthor=G.+A.+Hobbsauthor=X.+Yaoauthor=A.+Chaikuadauthor=S.+Knappauthor=K.+Xiaoauthor=S.+L.+Campbellauthor=D.+J.+Thieleauthor=C.+M.+Counter&title=Copper+is+required+for+oncogenic+BRAF+signaling+and+tumorigenesis&doi=10.1038%2Fnature13180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Copper is required for oncogenic BRAF signalling and tumorigenesis</span></div><div class="casAuthors">Brady, Donita C.; Crowe, Matthew S.; Turski, Michelle L.; Hobbs, G. Aaron; Yao, Xiaojie; Chaikuad, Apirat; Knapp, Stefan; Xiao, Kunhong; Campbell, Sharon L.; Thiele, Dennis J.; Counter, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7501</span>),
    <span class="NLM_cas:pages">492-496</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The BRAF kinase is mutated, typically Val 600âGlu (V600E), to induce an active oncogenic state in a large fraction of melanomas, thyroid cancers, hairy cell leukemias and, to a smaller extent, a wide spectrum of other cancers.  BRAFV600E phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer.  Targeting MEK1/2 is proving to be an important therapeutic strategy, given that a MEK1/2 inhibitor provides a survival advantage in metastatic melanoma, an effect that is increased when administered together with a BRAFV600E inhibitor.  We previously found that copper (Cu) influx enhances MEK1 phosphorylation of ERK1/2 through a Cu-MEK1 interaction.  Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAFV600E-driven signaling and tumorigenesis in mice and human cell settings.  Conversely, a MEK1-MEK5 chimera that phosphorylated ERK1/2 independently of Cu or an active ERK2 restored the tumor growth of murine cells lacking Ctr1.  Cu chelators used in the treatment of Wilson disease decreased tumor growth of human or murine cells transformed by BRAFV600E or engineered to be resistant to BRAF inhibition.  Taken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers contg. the BRAFV600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFwn_1AXDxbVg90H21EOLACvtfcHk0lhSlyDYrksDdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotlymsbo%253D&md5=e9514d73a334e9636f500763a78fa5bb</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnature13180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13180%26sid%3Dliteratum%253Aachs%26aulast%3DBrady%26aufirst%3DD.%2BC.%26aulast%3DCrowe%26aufirst%3DM.%2BS.%26aulast%3DTurski%26aufirst%3DM.%2BL.%26aulast%3DHobbs%26aufirst%3DG.%2BA.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DS.%2BL.%26aulast%3DThiele%26aufirst%3DD.%2BJ.%26aulast%3DCounter%26aufirst%3DC.%2BM.%26atitle%3DCopper%2520is%2520required%2520for%2520oncogenic%2520BRAF%2520signaling%2520and%2520tumorigenesis%26jtitle%3DNature%26date%3D2014%26volume%3D509%26issue%3D7501%26spage%3D492%26epage%3D496%26doi%3D10.1038%2Fnature13180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theofilopoulos, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccala, R.</span></span> <span> </span><span class="NLM_article-title">The multiple pathways to autoimmunity</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">724</span>, <span class="refDoi">Â DOI: 10.1038/ni.3731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fni.3731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28632714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWls7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=716-724&issue=7&author=A.+N.+Theofilopoulosauthor=D.+H.+Konoauthor=R.+Baccala&title=The+multiple+pathways+to+autoimmunity&doi=10.1038%2Fni.3731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The multiple pathways to autoimmunity</span></div><div class="casAuthors">Theofilopoulos, Argyrios N.; Kono, Dwight H.; Baccala, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">716-724</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Efforts to understand autoimmunity have been pursued relentlessly for several decades.  It has become apparent that the immune system evolved multiple mechanisms for controlling self-reactivity, and defects in one or more of these mechanisms can lead to a breakdown of tolerance.  Among the multitude of lesions assocd. with disease, the most common seem to affect peripheral tolerance rather than central tolerance.  The initial trigger for both systemic autoimmune disorders and organ-specific autoimmune disorders probably involves the recognition of self or foreign mols., esp. nucleic acids, by innate sensors.  Such recognition, in turn, triggers inflammatory responses and the engagement of previously quiescent autoreactive T cells and B cells.  Here we summarize the most prominent autoimmune pathways and identify key issues that require resoln. for full understanding of pathogenic autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr53DAy516zrLVg90H21EOLACvtfcHk0lh6ctSsrhrfhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWls7zF&md5=e352c17c1fd221b5892ac4c93d9d0130</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fni.3731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3731%26sid%3Dliteratum%253Aachs%26aulast%3DTheofilopoulos%26aufirst%3DA.%2BN.%26aulast%3DKono%26aufirst%3DD.%2BH.%26aulast%3DBaccala%26aufirst%3DR.%26atitle%3DThe%2520multiple%2520pathways%2520to%2520autoimmunity%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26issue%3D7%26spage%3D716%26epage%3D724%26doi%3D10.1038%2Fni.3731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baccala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Quintial, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasius, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theofilopoulos, A. N.</span></span> <span> </span><span class="NLM_article-title">Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2940</span>â <span class="NLM_lpage">2945</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1222798110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.1222798110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23382217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVyqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2940-2945&issue=8&author=R.+Baccalaauthor=R.+Gonzalez-Quintialauthor=A.+L.+Blasiusauthor=I.+Rimannauthor=K.+Ozatoauthor=D.+H.+Konoauthor=B.+Beutlerauthor=A.+N.+Theofilopoulos&title=Essential+requirement+for+IRF8+and+SLC15A4+implicates+plasmacytoid+dendritic+cells+in+the+pathogenesis+of+lupus&doi=10.1073%2Fpnas.1222798110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus</span></div><div class="casAuthors">Baccala, Oberto; Gonzalez-Quintial, Rosana; Blasius, Amanda L.; Rimann, Ivo; Ozato, Keiko; Kono, Dwight H.; Beutler, Bruce; Theofilopoulos, Argyrios N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2940-2945, S2940/1-S2940/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In vitro evidence suggests that plasmacytoid dendritic cells (pDCs) are intimately involved in the pathogenesis of lupus.  However, it remains to be detd. whether these cells are required in vivo for disease development and whether their contribution is restricted to hyperprodn. of type I IFNs.  To address these issues, we created lupus-predisposed mice lacking the IFN regulatory factor 8 (IRF8) or carrying a mutation that impairs the peptide/histidine transporter solute carrier family 15, member 4 (SLC15A4).  IRFS-deficient NZB mice, lacking pDCs, showed almost complete absence of anti-nuclear, anti-chromatin, and anti-erythrocyte autoantibodies, along with reduced kidney disease.  These effects were obsd. despite normal B-cell responses to Toll-like receptor (TLR) 7 and TLR9 stimuli and intact humoral responses to conventional T-dependent and -independent antigens.  Moreover, Slc1Sa4 mutant 0578176-Falpr in which pDCs are present but unable to produce type I IFNs in response to endosomal TLR ligands, also showed an absence of autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival.  Taken together, our results demonstrate that pDCs and the prodn. of type I IFNs by these cells are crit. contributors to the pathogenesis of lupus-like autoimmunity in these models.  Thus, IRF8 and SLC15A4 may provide important targets for therapeutic intervention in human lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OkV7hXLrh7Vg90H21EOLACvtfcHk0lh6ctSsrhrfhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVyqtLg%253D&md5=b3db2d5641c0dd28dea536bb6c835abc</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1222798110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1222798110%26sid%3Dliteratum%253Aachs%26aulast%3DBaccala%26aufirst%3DR.%26aulast%3DGonzalez-Quintial%26aufirst%3DR.%26aulast%3DBlasius%26aufirst%3DA.%2BL.%26aulast%3DRimann%26aufirst%3DI.%26aulast%3DOzato%26aufirst%3DK.%26aulast%3DKono%26aufirst%3DD.%2BH.%26aulast%3DBeutler%26aufirst%3DB.%26aulast%3DTheofilopoulos%26aufirst%3DA.%2BN.%26atitle%3DEssential%2520requirement%2520for%2520IRF8%2520and%2520SLC15A4%2520implicates%2520plasmacytoid%2520dendritic%2520cells%2520in%2520the%2520pathogenesis%2520of%2520lupus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D8%26spage%3D2940%26epage%3D2945%26doi%3D10.1073%2Fpnas.1222798110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakalarski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Maziere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlatter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span> <span> </span><span class="NLM_article-title">Endosomes are specialized platforms for bacterial sensing and NOD2 signalling</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span> (<span class="NLM_issue">7499</span>),  <span class="NLM_fpage">240</span>â <span class="NLM_lpage">244</span>, <span class="refDoi">Â DOI: 10.1038/nature13133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature13133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24695226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Wqsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=240-244&issue=7499&author=N.+Nakamuraauthor=J.+R.+Lillauthor=Q.+Phungauthor=Z.+Jiangauthor=C.+Bakalarskiauthor=A.+de+Maziereauthor=J.+Klumpermanauthor=M.+Schlatterauthor=L.+Delamarreauthor=I.+Mellman&title=Endosomes+are+specialized+platforms+for+bacterial+sensing+and+NOD2+signalling&doi=10.1038%2Fnature13133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Endosomes are specialized platforms for bacterial sensing and NOD2 signalling</span></div><div class="casAuthors">Nakamura, Norihiro; Lill, Jennie R.; Phung, Qui; Jiang, Zhaoshi; Bakalarski, Corey; de Maziere, Ann; Klumperman, Judith; Schlatter, Megan; Delamarre, Lelia; Mellman, Ira</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7499</span>),
    <span class="NLM_cas:pages">240-244</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detection of microbial pathogens involves the recognition of conserved microbial components by host cell sensors such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs).  TLRs are membrane receptors that survey the extracellular environment for microbial infections, whereas NLRs are cytosolic complexes that detect microbial products that reach the cytosol.  Upon detection, both sensor classes trigger innate inflammatory responses and allow the engagement of adaptive immunity.  Endo-lysosomes are the entry sites for a variety of pathogens, and therefore the sites at which the immune system first senses their presence.  Pathogens internalized by endocytosis are well known to activate TLRs 3 and 7-9 that are localized to endocytic compartments and detect ligands present in the endosomal lumen.  Internalized pathogens also activate sensors in the cytosol such as NOD1 and NOD2 (ref. 2), indicating that endosomes also provide for the translocation of bacterial components across the endosomal membrane.  Despite the fact that NOD2 is well understood to have a key role in regulating innate immune responses and that mutations at the NOD2 locus are a common risk factor in inflammatory bowel disease and possibly other chronic inflammatory states, little is known about how its ligands escape from endosomes.  Here we show that two endo-lysosomal peptide transporters, SLC15A3 and SLC15A4, are preferentially expressed by dendritic cells, esp. after TLR stimulation.  The transporters mediate the egress of bacterially derived components, such as the NOD2 cognate ligand muramyl dipeptide (MDP), and are selectively required for NOD2 responses to endosomally derived MDP.  Enhanced expression of the transporters also generates endosomal membrane tubules characteristic of dendritic cells, which further enhanced the NOD2-dependent response to MDP.  Finally, sensing required the recruitment of NOD2 and its effector kinase RIPK2 to the endosomal membrane, possibly by forming a complex with SLC15A3 or SLC15A4.  Thus, dendritic cell endosomes are specialized platforms for both the lumenal and cytosolic sensing of pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoppdcGuBL0_bVg90H21EOLACvtfcHk0lh6ctSsrhrfhA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Wqsrw%253D&md5=dd38ce753d9529651acea52f83a753b1</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnature13133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13133%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DN.%26aulast%3DLill%26aufirst%3DJ.%2BR.%26aulast%3DPhung%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DBakalarski%26aufirst%3DC.%26aulast%3Dde%2BMaziere%26aufirst%3DA.%26aulast%3DKlumperman%26aufirst%3DJ.%26aulast%3DSchlatter%26aufirst%3DM.%26aulast%3DDelamarre%26aufirst%3DL.%26aulast%3DMellman%26aufirst%3DI.%26atitle%3DEndosomes%2520are%2520specialized%2520platforms%2520for%2520bacterial%2520sensing%2520and%2520NOD2%2520signalling%26jtitle%3DNature%26date%3D2014%26volume%3D509%26issue%3D7499%26spage%3D240%26epage%3D244%26doi%3D10.1038%2Fnature13133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span> <span> </span><span class="NLM_article-title">Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">770</span>, <span class="refDoi">Â DOI: 10.1038/s41419-018-0809-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41419-018-0809-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29991810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FmslSktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=770&author=F.+Songauthor=Y.+Yiauthor=C.+Liauthor=Y.+Huauthor=J.+Wangauthor=D.+E.+Smithauthor=H.+Jiang&title=Regulation+and+biological+role+of+the+peptide%2Fhistidine+transporter+SLC15A3+in+Toll-like+receptor-mediated+inflammatory+responses+in+macrophage&doi=10.1038%2Fs41419-018-0809-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage</span></div><div class="casAuthors">Song Feifeng; Yi Yaodong; Li Cui; Jiang Huidi; Hu Yongjun; Smith David E; Wang Jinhai</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">770</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The peptide/histidine transporter SLC15A3 is responsible for transporting histidine, certain dipeptide and peptidomimetics from inside the lysosome to cytosol.  Previous studies have indicated that SLC15A3 transcripts are mainly expressed in the lymphatic system, however, its regulation and biological role in innate immune responses and inflammatory diseases are as yet unknown.  In this study, mouse peritoneal macrophages (PMs), mouse bone marrow-derived macrophages (BMDMs), the human acute monocytic leukemia cell line THP-1 and the human lung epithelial carcinoma cell line A549 were used to investigate the regulation and biological role of SLC15A3 in TLR-mediated inflammatory responses.  Our results showed that SLC15A3 was upregulated by TLR2, TLR4, TLR7 and TLR9 ligands in macrophages at both the mRNA and protein levels via activation of NF-ÎºB (nuclear factor-kappa-B), MAPK (mitogen-activated protein kinase) and IRF3 (interferon regulatory factor 3).  Furthermore, knockdown or overexpression of SLC15A3 influenced the TLR4-triggered expression of proinflammatory cytokines.  A reporter gene assay showed that the SLC15A3 promotor contained potential NF-ÎºB binding sites, which were reasonable for regulating SLC15A3 by TLR-activation through NF-ÎºB signaling.  Additionally, SLC15A3 expression was increased and positively related to inflammation in mice with bacterial peritonitis.  The collective findings suggest that SLC15A3 is regulated by various TLRs, and that it plays an important role in regulating TLR4-mediated inflammatory responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJU6z_OohDxfx2phytoz6_fW6udTcc2ebQpLOYJeLNzbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FmslSktw%253D%253D&md5=d0b6becff64c3926b196b4e5d2ff1ce0</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0809-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0809-1%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BE.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DRegulation%2520and%2520biological%2520role%2520of%2520the%2520peptide%252Fhistidine%2520transporter%2520SLC15A3%2520in%2520Toll-like%2520receptor-mediated%2520inflammatory%2520responses%2520in%2520macrophage%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D770%26doi%3D10.1038%2Fs41419-018-0809-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peltekova, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintle, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amos, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Oene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St George-Hyslop, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siminovitch, K. A.</span></span> <span> </span><span class="NLM_article-title">Functional variants of OCTN cation transporter genes are associated with Crohn disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">471</span>â <span class="NLM_lpage">475</span>, <span class="refDoi">Â DOI: 10.1038/ng1339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fng1339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15107849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSntrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=471-475&author=V.+D.+Peltekovaauthor=R.+F.+Wintleauthor=L.+A.+Rubinauthor=C.+I.+Amosauthor=Q.+Q.+Huangauthor=X.+J.+Guauthor=B.+Newmanauthor=M.+Van+Oeneauthor=D.+Cesconauthor=G.+Greenbergauthor=A.+M.+Griffithsauthor=P.+H.+St+George-Hyslopauthor=K.+A.+Siminovitch&title=Functional+variants+of+OCTN+cation+transporter+genes+are+associated+with+Crohn+disease&doi=10.1038%2Fng1339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Functional variants of OCTN cation transporter genes are associated with Crohn disease</span></div><div class="casAuthors">Peltekova, Vanya D.; Wintle, Richard F.; Rubin, Laurence A.; Amos, Christopher I.; Huang, Qiqing; Gu, Xiangjun; Newman, Bill; Van Oene, Mark; Cescon, David; Greenberg, Gordon; Griffiths, Anne M.; St. George-Hyslop, Peter H.; Siminovitch, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-475</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Crohn disease is a chronic, inflammatory disease of the gastrointestinal tract.  A locus of â¼250 kb at 5q31 (IBD5) was previously assocd. with susceptibility to Crohn disease, as indicated by increased prevalence of a risk haplotype of 11 single-nucleotide polymorphisms among individuals with Crohn disease, but the pathogenic lesion in the region has not yet been identified.  We report here that two variants in the org. cation transporter cluster at 5q31 (a missense substitution in SLC22A4 and a GâC transversion in the SLC22A5 promoter) form a haplotype assocd. with susceptibility to Crohn disease.  These variants alter transcription and transporter functions of the org. cation transporters and interact with variants in another gene assocd. with Crohn disease, CARD15, to increase risk of Crohn disease.  These results suggest that SLC22A4, SLC22A5 and CARD15 act in a common pathogenic pathway to cause Crohn disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowLMxh8RtbV7Vg90H21EOLACvtfcHk0lhURNrVyMErtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSntrg%253D&md5=4c6bd30ff5675377797905d36c9e50a9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fng1339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1339%26sid%3Dliteratum%253Aachs%26aulast%3DPeltekova%26aufirst%3DV.%2BD.%26aulast%3DWintle%26aufirst%3DR.%2BF.%26aulast%3DRubin%26aufirst%3DL.%2BA.%26aulast%3DAmos%26aufirst%3DC.%2BI.%26aulast%3DHuang%26aufirst%3DQ.%2BQ.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DNewman%26aufirst%3DB.%26aulast%3DVan%2BOene%26aufirst%3DM.%26aulast%3DCescon%26aufirst%3DD.%26aulast%3DGreenberg%26aufirst%3DG.%26aulast%3DGriffiths%26aufirst%3DA.%2BM.%26aulast%3DSt%2BGeorge-Hyslop%26aufirst%3DP.%2BH.%26aulast%3DSiminovitch%26aufirst%3DK.%2BA.%26atitle%3DFunctional%2520variants%2520of%2520OCTN%2520cation%2520transporter%2520genes%2520are%2520associated%2520with%2520Crohn%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D471%26epage%3D475%26doi%3D10.1038%2Fng1339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekhawat, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boriack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(â/â)) mice</span>. <i>Mol. Genet. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1016/j.ymgme.2007.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.ymgme.2007.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17884651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1WltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=315-324&issue=4&author=P.+S.+Shekhawatauthor=S.+R.+Srinivasauthor=D.+Maternauthor=M.+J.+Bennettauthor=R.+Boriackauthor=V.+Georgeauthor=H.+Xuauthor=P.+D.+Prasadauthor=P.+Roonauthor=V.+Ganapathy&title=Spontaneous+development+of+intestinal+and+colonic+atrophy+and+inflammation+in+the+carnitine-deficient+jvs+%28OCTN2%28%E2%88%92%2F%E2%88%92%29%29+mice&doi=10.1016%2Fj.ymgme.2007.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2-/-) mice</span></div><div class="casAuthors">Shekhawat, Prem S.; Srinivas, Sonne R.; Matern, Dietrich; Bennett, Michael J.; Boriack, Richard; George, Varghese; Xu, Hongyan; Prasad, Puttur D.; Roon, Penny; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">MGMEFF</span>;
        ISSN:<span class="NLM_cas:issn">1096-7192</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Carnitine is essential for transport of long-chain fatty acids into mitochondria for their subsequent Î²-oxidn., but its role in the gastrointestinal tract was not well described.  Recently several genetic epidemiol. studies have shown strong assocn. between mutations in carnitine transporter genes OCTN1 and OCTN2 and a propensity to develop Crohn's disease.  This study aims to investigate role of carnitine and Î²-oxidn. in the GI tract.  The authors have studied the gastrointestinal tract effects of carnitine deficiency in a mouse model with loss-of-function mutation in the OCTN2 carnitine transporter.  Juvenile visceral steatosis (OCTN2-/-) mouse spontaneously develops intestinal villous atrophy, breakdown and inflammation with intense lymphocytic and macrophage infiltration, leading to ulcer formation and gut perforation.  There is increased apoptosis of jvs (OCTN2-/-) gut epithelial cells.  The authors obsd. an up-regulation of heat shock factor-1 (HSF-1) and several heat shock proteins (HSPs) which are known to regulate OCTN2 gene expression.  Intestinal and colonic epithelial cells in wild type mice showed high expression and activity of the enzymes of Î²-oxidn. pathway.  These studies provide evidence of an obligatory role for carnitine in the maintenance of normal intestinal and colonic structure and morphol.  Fatty acid oxidn., a metabolic pathway regulated by carnitine-dependent entry of long-chain fatty acids into mitochondrial matrix, is likely essential for normal gut function.  The authors' studies suggest that carnitine supplementation, as a means of boosting fatty acid oxidn., may be therapeutically beneficial in patients with inflammation of the intestinal tract.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy69j9_oGADbVg90H21EOLACvtfcHk0lhURNrVyMErtQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1WltA%253D%253D&md5=9cb7593fdfadfbad17278cd9ecfac3ca</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2007.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2007.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DShekhawat%26aufirst%3DP.%2BS.%26aulast%3DSrinivas%26aufirst%3DS.%2BR.%26aulast%3DMatern%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DBoriack%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DV.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DRoon%26aufirst%3DP.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DSpontaneous%2520development%2520of%2520intestinal%2520and%2520colonic%2520atrophy%2520and%2520inflammation%2520in%2520the%2520carnitine-deficient%2520jvs%2520%2528OCTN2%2528%25E2%2588%2592%252F%25E2%2588%2592%2529%2529%2520mice%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2007%26volume%3D92%26issue%3D4%26spage%3D315%26epage%3D324%26doi%3D10.1016%2Fj.ymgme.2007.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakir, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainin, N.</span></span> <span> </span><span class="NLM_article-title">Role of L-alanine in the response of human lymphocytes to PHA and Con A</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1726</span>â <span class="NLM_lpage">1731</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=573302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaE1MXmtV2it7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=1979&pages=1726-1731&issue=4&author=V.+Rotterauthor=Y.+Yakirauthor=N.+Trainin&title=Role+of+L-alanine+in+the+response+of+human+lymphocytes+to+PHA+and+Con+A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Role of L-alanine in the response of human lymphocytes to PHA and Con A</span></div><div class="casAuthors">Rotter, Varda; Yakir, Yeshayahu; Trainin, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1726-31</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">L-Alanine was responsible for the plasma-restoring activity of a crude thymus ext. in the response of umbilical cord lymphocytes to phytohemagglutinin and concanavalin A.  The impaired allogeneic response of umbilical cord lymphocytes in dialyzed plasma was also restored by L-alanine.  Thus, L-alanine is essential for lymphocyte allogeneic or mitogenic stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJzSPAQElCjrVg90H21EOLACvtfcHk0ljS-z_zFp6GjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXmtV2it7c%253D&md5=b68c0f3fda3fee9d0885f1c2e50ee536</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRotter%26aufirst%3DV.%26aulast%3DYakir%26aufirst%3DY.%26aulast%3DTrainin%26aufirst%3DN.%26atitle%3DRole%2520of%2520L-alanine%2520in%2520the%2520response%2520of%2520human%2520lymphocytes%2520to%2520PHA%2520and%2520Con%2520A%26jtitle%3DJ.%2520Immunol.%26date%3D1979%26volume%3D123%26issue%3D4%26spage%3D1726%26epage%3D1731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ron-Harel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghergurovich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notarangelo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubosaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, M. C.</span></span> <span> </span><span class="NLM_article-title">T cell activation depends on extracellular alanine</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3011</span>â <span class="NLM_lpage">3021</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2019.08.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.celrep.2019.08.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31533027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWktLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=3011-3021&issue=12&author=N.+Ron-Harelauthor=J.+M.+Ghergurovichauthor=G.+Notarangeloauthor=M.+W.+LaFleurauthor=Y.+Tsubosakaauthor=A.+H.+Sharpeauthor=J.+D.+Rabinowitzauthor=M.+C.+Haigis&title=T+cell+activation+depends+on+extracellular+alanine&doi=10.1016%2Fj.celrep.2019.08.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">T Cell Activation Depends on Extracellular Alanine</span></div><div class="casAuthors">Ron-Harel, Noga; Ghergurovich, Jonathan M.; Notarangelo, Giulia; LaFleur, Martin W.; Tsubosaka, Yoshiki; Sharpe, Arlene H.; Rabinowitz, Joshua D.; Haigis, Marcia C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3011-3021.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">T cell stimulation is metabolically demanding.  To exit quiescence, T cells rely on environmental nutrients, including glucose and the amino acids glutamine, leucine, serine, and arginine.  The expression of transporters for these nutrients is tightly regulated and required for T cell activation.  In contrast to these amino acids, which are essential or require multi-step biosynthesis, alanine can be made from pyruvate by a single transamination.  Here, we show that extracellular alanine is nevertheless required for efficient exit from quiescence during naive T cell activation and memory T cell restimulation.  Alanine deprivation leads to metabolic and functional impairments.  Mechanistically, this vulnerability reflects the low expression of alanine aminotransferase, the enzyme required for interconverting pyruvate and alanine, whereas activated T cells instead induce alanine transporters.  Stable isotope tracing reveals that alanine is not catabolized but instead supports protein synthesis.  Thus, T cells depend on exogenous alanine for protein synthesis and normal activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3RKbs2lUIbVg90H21EOLACvtfcHk0ljS-z_zFp6GjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWktLrP&md5=975467884a99eb75b4b05b40563496fb</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.08.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.08.034%26sid%3Dliteratum%253Aachs%26aulast%3DRon-Harel%26aufirst%3DN.%26aulast%3DGhergurovich%26aufirst%3DJ.%2BM.%26aulast%3DNotarangelo%26aufirst%3DG.%26aulast%3DLaFleur%26aufirst%3DM.%2BW.%26aulast%3DTsubosaka%26aufirst%3DY.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26aulast%3DHaigis%26aufirst%3DM.%2BC.%26atitle%3DT%2520cell%2520activation%2520depends%2520on%2520extracellular%2520alanine%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D28%26issue%3D12%26spage%3D3011%26epage%3D3021%26doi%3D10.1016%2Fj.celrep.2019.08.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wals, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapiteanu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weekes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antrobus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neil, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, P. J.</span></span> <span> </span><span class="NLM_article-title">Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">409</span>â <span class="NLM_lpage">423</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2015.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.chom.2015.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26439863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SqsLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=409-423&issue=4&author=N.+J.+Mathesonauthor=J.+Sumnerauthor=K.+Walsauthor=R.+Rapiteanuauthor=M.+P.+Weekesauthor=R.+Viganauthor=J.+Weineltauthor=M.+Schindlerauthor=R.+Antrobusauthor=A.+S.+Costaauthor=C.+Frezzaauthor=C.+B.+Clishauthor=S.+J.+Neilauthor=P.+J.+Lehner&title=Cell+surface+proteomic+map+of+HIV+infection+reveals+antagonism+of+amino+acid+metabolism+by+Vpu+and+Nef&doi=10.1016%2Fj.chom.2015.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef</span></div><div class="casAuthors">Matheson, Nicholas J.; Sumner, Jonathan; Wals, Kim; Rapiteanu, Radu; Weekes, Michael P.; Vigan, Raphael; Weinelt, Julia; Schindler, Michael; Antrobus, Robin; Costa, Ana S. H.; Frezza, Christian; Clish, Clary B.; Neil, Stuart J. D.; Lehner, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-423</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Crit. cell surface immunoreceptors downregulated during HIV infection have previously been identified using non-systematic, candidate approaches.  To gain a comprehensive, unbiased overview of how HIV infection remodels the T cell surface, we took a distinct, systems-level, quant. proteomic approach. >100 plasma membrane proteins, many without characterized immune functions, were downregulated during HIV infection.  Host factors targeted by the viral accessory proteins Vpu or Nef included the amino acid transporter SNAT1 and the serine carriers SERINC3/5.  We focused on SNAT1, a Î²-TrCP-dependent Vpu substrate.  SNAT1 antagonism was acquired by Vpu variants from the lineage of SIVcpz/HIV-1 viruses responsible for pandemic AIDS.  We found marked SNAT1 induction in activated primary human CD4+ T cells, and used Consumption and Release (CoRe) metabolomics to identify alanine as an endogenous SNAT1 substrate required for T cell mitogenesis.  Downregulation of SNAT1 therefore defines a unique paradigm of HIV interference with immunometabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCRR3G4C4N9bVg90H21EOLACvtfcHk0ljS-z_zFp6GjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SqsLzJ&md5=ce53b41dc5992aa615ee19d377e31ca6</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2015.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2015.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DN.%2BJ.%26aulast%3DSumner%26aufirst%3DJ.%26aulast%3DWals%26aufirst%3DK.%26aulast%3DRapiteanu%26aufirst%3DR.%26aulast%3DWeekes%26aufirst%3DM.%2BP.%26aulast%3DVigan%26aufirst%3DR.%26aulast%3DWeinelt%26aufirst%3DJ.%26aulast%3DSchindler%26aufirst%3DM.%26aulast%3DAntrobus%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DA.%2BS.%26aulast%3DFrezza%26aufirst%3DC.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DNeil%26aufirst%3DS.%2BJ.%26aulast%3DLehner%26aufirst%3DP.%2BJ.%26atitle%3DCell%2520surface%2520proteomic%2520map%2520of%2520HIV%2520infection%2520reveals%2520antagonism%2520of%2520amino%2520acid%2520metabolism%2520by%2520Vpu%2520and%2520Nef%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2015%26volume%3D18%26issue%3D4%26spage%3D409%26epage%3D423%26doi%3D10.1016%2Fj.chom.2015.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaratne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K. E.</span></span> <span> </span><span class="NLM_article-title">The role of ion transporters in the pathophysiology of infectious diarrhea</span>. <i>Cell Mol. Gastroenterol Hepatol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.1016/j.jcmgh.2018.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.jcmgh.2018.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29928670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1MbpvFaqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=33-45&issue=1&author=S.+Dasauthor=R.+Jayaratneauthor=K.+E.+Barrett&title=The+role+of+ion+transporters+in+the+pathophysiology+of+infectious+diarrhea&doi=10.1016%2Fj.jcmgh.2018.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Ion Transporters in the Pathophysiology of Infectious Diarrhea</span></div><div class="casAuthors">Das Soumita; Jayaratne Rashini; Barrett Kim E</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular gastroenterology and hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>
        ISSN:<span class="NLM_cas:issn">2352-345X</span>.
    </div><div class="casAbstract">Every year, enteric infections and associated diarrhea kill millions of people.  The situation is compounded by increases in the number of enteric pathogens that are acquiring resistance to antibiotics, as well as (hitherto) a relative paucity of information on host molecular targets that may contribute to diarrhea.  Many forms of diarrheal disease depend on the dysregulation of intestinal ion transporters, and an associated imbalance between secretory and absorptive functions of the intestinal epithelium.  A number of major transporters have been implicated in the pathogenesis of diarrheal diseases and thus an understanding of their expression, localization, and regulation after infection with various bacteria, viruses, and protozoa likely will prove critical in designing new therapies.  This article surveys our understanding of transporters that are modulated by specific pathogens and the mechanism(s) involved, thereby illuminating targets that might be exploited for new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTU2_b4Qx962a91pGlMMoT5fW6udTcc2eYXphBs3B8nn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbpvFaqsQ%253D%253D&md5=98e87eab395154f187e9a221a41d4b5e</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmgh.2018.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmgh.2018.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DS.%26aulast%3DJayaratne%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DK.%2BE.%26atitle%3DThe%2520role%2520of%2520ion%2520transporters%2520in%2520the%2520pathophysiology%2520of%2520infectious%2520diarrhea%26jtitle%3DCell%2520Mol.%2520Gastroenterol%2520Hepatol%26date%3D2018%26volume%3D6%26issue%3D1%26spage%3D33%26epage%3D45%26doi%3D10.1016%2Fj.jcmgh.2018.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujral, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priyamvada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrefai, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudeja, P. K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of DRA recycling in intestinal epithelial cells: effect of enteropathogenic E. coli</span>. <i>Am. J. Physiol Cell Physiol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>309</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">C835</span>â <span class="NLM_lpage">846</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00107.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpcell.00107.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26447204" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=C835-846&issue=12&author=T.+Gujralauthor=A.+Kumarauthor=S.+Priyamvadaauthor=S.+Saksenaauthor=R.+K.+Gillauthor=K.+Hodgesauthor=W.+A.+Alrefaiauthor=G.+A.+Hechtauthor=P.+K.+Dudeja&title=Mechanisms+of+DRA+recycling+in+intestinal+epithelial+cells%3A+effect+of+enteropathogenic+E.+coli&doi=10.1152%2Fajpcell.00107.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00107.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00107.2015%26sid%3Dliteratum%253Aachs%26aulast%3DGujral%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DPriyamvada%26aufirst%3DS.%26aulast%3DSaksena%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DHodges%26aufirst%3DK.%26aulast%3DAlrefai%26aufirst%3DW.%2BA.%26aulast%3DHecht%26aufirst%3DG.%2BA.%26aulast%3DDudeja%26aufirst%3DP.%2BK.%26atitle%3DMechanisms%2520of%2520DRA%2520recycling%2520in%2520intestinal%2520epithelial%2520cells%253A%2520effect%2520of%2520enteropathogenic%2520E.%2520coli%26jtitle%3DAm.%2520J.%2520Physiol%2520Cell%2520Physiol%26date%3D2015%26volume%3D309%26issue%3D12%26spage%3DC835%26epage%3D846%26doi%3D10.1152%2Fajpcell.00107.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laiko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtazina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malyukova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boedeker, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutsal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâMalley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovbasnjuk, O.</span></span> <span> </span><span class="NLM_article-title">Shiga toxin 1 interaction with enterocytes causes apical protein mistargeting through the depletion of intracellular galectin-3</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">657</span>â <span class="NLM_lpage">666</span>, <span class="refDoi">Â DOI: 10.1016/j.yexcr.2009.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.yexcr.2009.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19744479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCmt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2010&pages=657-666&author=M.+Laikoauthor=R.+Murtazinaauthor=I.+Malyukovaauthor=C.+R.+Zhuauthor=E.+C.+Boedekerauthor=O.+Gutsalauthor=R.+O%E2%80%99Malleyauthor=R.+N.+Coleauthor=P.+I.+Tarrauthor=K.+F.+Murrayauthor=A.+Kaneauthor=M.+Donowitzauthor=O.+Kovbasnjuk&title=Shiga+toxin+1+interaction+with+enterocytes+causes+apical+protein+mistargeting+through+the+depletion+of+intracellular+galectin-3&doi=10.1016%2Fj.yexcr.2009.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Shiga toxin 1 interaction with enterocytes causes apical protein mistargeting through the depletion of intracellular galectin-3</span></div><div class="casAuthors">Laiko, Marina; Murtazina, Rakhilya; Malyukova, Irina; Zhu, Chengru; Boedeker, Edgar C.; Gutsal, Oksana; O'Malley, Robert; Cole, Robert N.; Tarr, Phillip I.; Murray, Karen F.; Kane, Anne; Donowitz, Mark; Kovbasnjuk, Olga</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-666</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Shiga toxins (Stx) 1 and 2 are responsible for intestinal and systemic sequelae of infection by enterohemorrhagic Escherichia coli (EHEC).  However, the mechanisms through which enterocytes are damaged remain unclear.  While secondary damage from ischemia and inflammation are postulated mechanisms for all intestinal effects, little evidence excludes roles for more primary toxin effects on intestinal epithelial cells.  We now document direct pathol. effects of Stx on intestinal epithelial cells.  We study a well-characterized rabbit model of EHEC infection, intestinal tissue and stool samples from EHEC-infected patients, and T84 intestinal epithelial cells treated with Stx1.  Toxin uptake by intestinal epithelial cells in vitro and in vivo causes galectin-3 depletion from enterocytes by increasing the apical galectin-3 secretion.  This Shiga toxin-mediated galectin-3 depletion impairs trafficking of several brush border structural proteins and transporters, including villin, dipeptidyl peptidase IV, and the sodium-proton exchanger 2, a major colonic sodium absorptive protein.  The mistargeting of proteins responsible for the absorptive function might be a key event in Stx1-induced diarrhea.  These observations provide new evidence that human enterocytes are directly damaged by Stx1.  Conceivably, depletion of galectin-3 from enterocytes and subsequent apical protein mistargeting might even provide a means whereby other pathogens might alter intestinal epithelial absorption and produce diarrhea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbliVqfBUzbVg90H21EOLACvtfcHk0lgJ1I9Jrf91Eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCmt7o%253D&md5=c861bbc8dd78ff4771ec2bc757073489</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2009.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2009.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DLaiko%26aufirst%3DM.%26aulast%3DMurtazina%26aufirst%3DR.%26aulast%3DMalyukova%26aufirst%3DI.%26aulast%3DZhu%26aufirst%3DC.%2BR.%26aulast%3DBoedeker%26aufirst%3DE.%2BC.%26aulast%3DGutsal%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DR.%26aulast%3DCole%26aufirst%3DR.%2BN.%26aulast%3DTarr%26aufirst%3DP.%2BI.%26aulast%3DMurray%26aufirst%3DK.%2BF.%26aulast%3DKane%26aufirst%3DA.%26aulast%3DDonowitz%26aufirst%3DM.%26aulast%3DKovbasnjuk%26aufirst%3DO.%26atitle%3DShiga%2520toxin%25201%2520interaction%2520with%2520enterocytes%2520causes%2520apical%2520protein%2520mistargeting%2520through%2520the%2520depletion%2520of%2520intracellular%2520galectin-3%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2010%26volume%3D316%26spage%3D657%26epage%3D666%26doi%3D10.1016%2Fj.yexcr.2009.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeruva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamprecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogema, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. C.</span></span> <span> </span><span class="NLM_article-title">Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">649</span>â <span class="NLM_lpage">658</span>, <span class="refDoi">Â DOI: 10.1053/j.gastro.2009.09.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1053%2Fj.gastro.2009.09.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19800338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVCns7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2010&pages=649-658&issue=2&author=S.+Linauthor=S.+Yeruvaauthor=P.+Heauthor=A.+K.+Singhauthor=H.+Zhangauthor=M.+Chenauthor=G.+Lamprechtauthor=H.+R.+de+Jongeauthor=M.+Tseauthor=M.+Donowitzauthor=B.+M.+Hogemaauthor=J.+Chunauthor=U.+Seidlerauthor=C.+C.+Yun&title=Lysophosphatidic+acid+stimulates+the+intestinal+brush+border+Na%28%2B%29%2FH%28%2B%29+exchanger+3+and+fluid+absorption+via+LPA%285%29+and+NHERF2&doi=10.1053%2Fj.gastro.2009.09.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Lysophosphatidic acid stimulates the intestinal brush border Na+/H+ exchanger 3 and fluid absorption via LPA5 and NHERF2</span></div><div class="casAuthors">Lin, Songbai; Yeruva, Sunil; He, Peijian; Singh, Anurag Kumar; Zhang, Huanchun; Chen, Mingmin; Lamprecht, Georg; de Jonge, Hugo R.; Tse, Ming; Donowitz, Mark; Hogema, Boris M.; Chun, Jerold; Seidler, Ursula; Yun, C. Chris</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">649-658</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background & Aims: Diarrhea results from reduced net fluid and salt absorption caused by an imbalance in intestinal absorption and secretion.  The bulk of sodium and water absorption in the intestine is mediated by Na+/H+ exchanger 3 (NHE3), located in the luminal membrane of enterocytes.  We investigated the effect of lysophosphatidic acid (LPA) on Na+/H+ exchanger activity and Na+-dependent fluid absorption in the intestine.  Methods: We analyzed the effects of LPA on fluid absorption in intestines of wild-type mice and mice deficient in Na+/H+ exchanger regulatory factor 2 (NHERF2; Nherf2-/-), or LPA2 (Lpa2-/-).  Roles of LPA5 and NHERF2 were detd. by anal. of heterologous expression.  Results: Under basal conditions, LPA increased fluid absorption in an NHE3-dependent manner and restored the net fluid loss in a mouse model of acute diarrhea.  Expression of the LPA receptor LPA5 was necessary for LPA-induced stimulation of NHE3 activity in colonic epithelial cells.  Stimulation of NHE3 by the LPA-LPA5 signaling required coexpression of NHERF2, which interacted with LPA5.  LPA-mediated intestinal fluid absorption was impaired in Nherf2-/- mice, demonstrating the requirement for NHERF2 in LPA5 activity.  However, fluid absorption was unaltered in Lpa2-/- mice.  LPA stimulated NHE3 and fluid absorption in part by increasing NHE3 protein abundance at the brush border membrane of intestinal epithelial cells.  Conclusions: LPA is a potent stimulant of NHE3 and fluid absorption in the intestine, signaling through LPA5.  Regulation by LPA5 depends on its interaction with NHERF2.  LPA might be useful in the treatment of certain diarrheal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojl5tXr1pzqbVg90H21EOLACvtfcHk0lgJ1I9Jrf91Eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVCns7w%253D&md5=99cef518c40f1ddd437b35540fbd0033</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2009.09.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2009.09.055%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%26aulast%3DYeruva%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLamprecht%26aufirst%3DG.%26aulast%3Dde%2BJonge%26aufirst%3DH.%2BR.%26aulast%3DTse%26aufirst%3DM.%26aulast%3DDonowitz%26aufirst%3DM.%26aulast%3DHogema%26aufirst%3DB.%2BM.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DSeidler%26aufirst%3DU.%26aulast%3DYun%26aufirst%3DC.%2BC.%26atitle%3DLysophosphatidic%2520acid%2520stimulates%2520the%2520intestinal%2520brush%2520border%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%25203%2520and%2520fluid%2520absorption%2520via%2520LPA%25285%2529%2520and%2520NHERF2%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26issue%3D2%26spage%3D649%26epage%3D658%26doi%3D10.1053%2Fj.gastro.2009.09.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anbazhagan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priyamvada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujral, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrefai, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudeja, P. K.</span></span> <span> </span><span class="NLM_article-title">Lactobacillus acidophilus counteracts inhibition of NHE3 and DRA expression and alleviates diarrheal phenotype in mice infected with Citrobacter rodentium</span>. <i>Am. J. Physiol Gastrointest Liver Physiol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>311</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">G817</span>â <span class="NLM_lpage">G826</span>, <span class="refDoi">Â DOI: 10.1152/ajpgi.00173.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpgi.00173.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27634011" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2016&pages=G817-G826&issue=5&author=A.+Kumarauthor=A.+N.+Anbazhaganauthor=H.+Coffingauthor=I.+Chatterjeeauthor=S.+Priyamvadaauthor=T.+Gujralauthor=S.+Saksenaauthor=R.+K.+Gillauthor=W.+A.+Alrefaiauthor=A.+Borthakurauthor=P.+K.+Dudeja&title=Lactobacillus+acidophilus+counteracts+inhibition+of+NHE3+and+DRA+expression+and+alleviates+diarrheal+phenotype+in+mice+infected+with+Citrobacter+rodentium&doi=10.1152%2Fajpgi.00173.2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00173.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00173.2016%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DAnbazhagan%26aufirst%3DA.%2BN.%26aulast%3DCoffing%26aufirst%3DH.%26aulast%3DChatterjee%26aufirst%3DI.%26aulast%3DPriyamvada%26aufirst%3DS.%26aulast%3DGujral%26aufirst%3DT.%26aulast%3DSaksena%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DAlrefai%26aufirst%3DW.%2BA.%26aulast%3DBorthakur%26aufirst%3DA.%26aulast%3DDudeja%26aufirst%3DP.%2BK.%26atitle%3DLactobacillus%2520acidophilus%2520counteracts%2520inhibition%2520of%2520NHE3%2520and%2520DRA%2520expression%2520and%2520alleviates%2520diarrheal%2520phenotype%2520in%2520mice%2520infected%2520with%2520Citrobacter%2520rodentium%26jtitle%3DAm.%2520J.%2520Physiol%2520Gastrointest%2520Liver%2520Physiol%26date%3D2016%26volume%3D311%26issue%3D5%26spage%3DG817%26epage%3DG826%26doi%3D10.1152%2Fajpgi.00173.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">19</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&issue=1&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0lj_E41Y22ofgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D1%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillhouse, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. H.</span></span> <span> </span><span class="NLM_article-title">A brief history of the development of antidepressant drugs: from monoamines to glutamate</span>. <i>Exp. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">21</span>, <span class="refDoi">Â DOI: 10.1037/a0038550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1037%2Fa0038550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25643025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlyhsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1-21&issue=1&author=T.+M.+Hillhouseauthor=J.+H.+Porter&title=A+brief+history+of+the+development+of+antidepressant+drugs%3A+from+monoamines+to+glutamate&doi=10.1037%2Fa0038550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">A brief history of the development of antidepressant drugs: from monoamines to glutamate</span></div><div class="casAuthors">Hillhouse, Todd M.; Porter, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">ECLPES</span>;
        ISSN:<span class="NLM_cas:issn">1936-2293</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States.  It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacol. treatment for MDD was discovered.  Several monoamine-based pharmacol. drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved.  As a result of a "proof-of-concept" study in 2000 with the noncompetitive NMDA antagonist ketamine, a no. of studies have examd. the glutamatergic systems as viable targets for the treatment of MDD.  This review will provide a brief history on the development of clin. available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiol. of MDD.  Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD.  The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a no. of clin. studies, has shown the most promise as a novel glutamatergic-based treatment for MDD.  However, compds. that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clin. trials.  Thus, the clin. findings to date are encouraging and support the continued search for and the development of novel compds. that target glutamatergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVRSP4bo13rVg90H21EOLACvtfcHk0lj_E41Y22ofgg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlyhsbg%253D&md5=d2c0f346f720c66bbdb9d29429b42f5c</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1037%2Fa0038550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252Fa0038550%26sid%3Dliteratum%253Aachs%26aulast%3DHillhouse%26aufirst%3DT.%2BM.%26aulast%3DPorter%26aufirst%3DJ.%2BH.%26atitle%3DA%2520brief%2520history%2520of%2520the%2520development%2520of%2520antidepressant%2520drugs%253A%2520from%2520monoamines%2520to%2520glutamate%26jtitle%3DExp.%2520Clin.%2520Psychopharmacol.%26date%3D2015%26volume%3D23%26issue%3D1%26spage%3D1%26epage%3D21%26doi%3D10.1037%2Fa0038550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of antidepressants and related compounds at human monoamine transporters</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>340</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">258</span>, <span class="refDoi">Â DOI: 10.1016/S0014-2999(97)01393-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0014-2999%2897%2901393-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9537821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2sXotVyjsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1997&pages=249-258&issue=2%E2%80%933&author=M.+Tatsumiauthor=K.+Groshanauthor=R.+D.+Blakelyauthor=E.+Richelson&title=Pharmacological+profile+of+antidepressants+and+related+compounds+at+human+monoamine+transporters&doi=10.1016%2FS0014-2999%2897%2901393-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of antidepressants and related compounds at human monoamine transporters</span></div><div class="casAuthors">Tatsumi, Masahiko; Groshan, Karen; Blakely, Randy D.; Richelson, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">249-258</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Using radioligand binding assays, we detd. the equil. dissocn. consts. (KD's) for 37 antidepressants, three of their metabolites (desmethylcitalopram, desmethylsertraline, and norfluoxetine), some mood stabilizers, and assorted other compds. (some antiepileptics, Ca2+ channel antagonists, benzodiazepines, psychostimulants, antihistamines, and monoamines) for the human serotonin, norepinephrine, and dopamine transporters.  Among the compds. that we tested, mazindol was the most potent at the human norepinephrine and dopamine transporters with KD's of 0.45Â±0.03 nM and 8.1Â±0.4 nM, resp.  Sertraline (KD=25Â±2 nM) and nomifensine (56Â±3 nM) were the two most potent antidepressants at the human dopamine transporter.  We showed significant correlations for antidepressant affinities at binding to serotonin (R=0.93), norepinephrine (R=0.97), and dopamine (R=0.87) transporters in comparison to their resp. values for inhibiting uptake of monoamines into rat brain synaptosomes.  These data are useful in predicting some possible adverse effects and drug-drug interactions of antidepressants and related compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpHZLfaFAMerVg90H21EOLACvtfcHk0ljeiQXNSvea0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVyjsbo%253D&md5=0aa5f4372309c8f244f960897362aa2a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901393-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901393-9%26sid%3Dliteratum%253Aachs%26aulast%3DTatsumi%26aufirst%3DM.%26aulast%3DGroshan%26aufirst%3DK.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26aulast%3DRichelson%26aufirst%3DE.%26atitle%3DPharmacological%2520profile%2520of%2520antidepressants%2520and%2520related%2520compounds%2520at%2520human%2520monoamine%2520transporters%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D340%26issue%3D2%25E2%2580%25933%26spage%3D249%26epage%3D258%26doi%3D10.1016%2FS0014-2999%2897%2901393-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyanoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lytton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, S. C.</span></span> <span> </span><span class="NLM_article-title">Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2749</span>â <span class="NLM_lpage">2753</span>, <span class="refDoi">Â DOI: 10.1073/pnas.90.7.2749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.90.7.2749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8464884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK3sXksVels7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=2749-2753&issue=7&author=G.+Gambaauthor=S.+N.+Saltzbergauthor=M.+Lombardiauthor=A.+Miyanoshitaauthor=J.+Lyttonauthor=M.+A.+Hedigerauthor=B.+M.+Brennerauthor=S.+C.+Hebert&title=Primary+structure+and+functional+expression+of+a+cDNA+encoding+the+thiazide-sensitive%2C+electroneutral+sodium-chloride+cotransporter&doi=10.1073%2Fpnas.90.7.2749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter</span></div><div class="casAuthors">Gamba, Gerardo; Saltzberg, Samuel N.; Lombardi, Michael; Miyanoshita, Akihiko; Lytton, Jonathan; Hediger, Matthias A.; Brenner, Barry M.; Hebert, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2749-53</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Electroneutral Na+:Cl- cotransport systems are involved in a no. of important physiol. processes including salt absorption and secretion by epithelia and cell vol. regulation.  One group of Na+:Cl- cotransporters is specifically inhibited by the benzothiadiazine (thiazide) class of diuretic agents and can be distinguished from Na+:K+:2Cl- cotransporters based on a lack of K+ requirement and insensitivity to sulfamoylbenzoic acid diuretics like bumetanide.  The isolation of a cDNA encoding a thiazide-sensitive, electroneutral sodium-chloride cotransporter from the winter flounder urinary bladder using an expression cloning strategy is reported here.  The pharmacol. and kinetic characteristics of the cloned cotransporter are consistent with the properties of native thiazide-sensitive sodium-chloride cotransporters in teleost urinary bladder and mammalian renal distal tubule epithelia.  The nucleotide sequence predicts a protein of 1023 amino acids (112 kDa) with 12 putative membrane-spanning regions, which is not related to other previously cloned sodium or chloride transporters.  Northern hybridization shows two different gene products: a 3.7-kb mRNA localized only to the urinary bladder and a 3.0-kb mRNA present in several nonbladder/kidney tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGiIVaH4HPW7Vg90H21EOLACvtfcHk0ljeiQXNSvea0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXksVels7Y%253D&md5=15e400762c2f3d153883f32aa6245f9a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.7.2749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.7.2749%26sid%3Dliteratum%253Aachs%26aulast%3DGamba%26aufirst%3DG.%26aulast%3DSaltzberg%26aufirst%3DS.%2BN.%26aulast%3DLombardi%26aufirst%3DM.%26aulast%3DMiyanoshita%26aufirst%3DA.%26aulast%3DLytton%26aufirst%3DJ.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DBrenner%26aufirst%3DB.%2BM.%26aulast%3DHebert%26aufirst%3DS.%2BC.%26atitle%3DPrimary%2520structure%2520and%2520functional%2520expression%2520of%2520a%2520cDNA%2520encoding%2520the%2520thiazide-sensitive%252C%2520electroneutral%2520sodium-chloride%2520cotransporter%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26issue%3D7%26spage%3D2749%26epage%3D2753%26doi%3D10.1073%2Fpnas.90.7.2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lytle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbush, B.,  3rd</span></span> <span> </span><span class="NLM_article-title">Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2201</span>â <span class="NLM_lpage">2205</span>, <span class="refDoi">Â DOI: 10.1073/pnas.91.6.2201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.91.6.2201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8134373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFOqt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=2201-2205&issue=6&author=J.+C.+Xuauthor=C.+Lytleauthor=T.+T.+Zhuauthor=J.+A.+Payneauthor=E.+Benzauthor=B.+Forbush&title=Molecular+cloning+and+functional+expression+of+the+bumetanide-sensitive+Na-K-Cl+cotransporter&doi=10.1073%2Fpnas.91.6.2201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter</span></div><div class="casAuthors">Xu, Jian Chao; Lytle, Christian; Zhu, Tracey T.; Payne, John A.; Benz, Edward, Jr.; Forbush, Bliss, III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2201-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">By mediating the coupled movement of Na, K, and Cl ions across the plasma membrane of most animal cells, the bumetanide-sensitive Na-K-Cl cotransporter (NKCC) plays a vital role in the regulation of ionic balance and cell vol.  The transporter is a central element in the process of vectorial salt transport in secretory and absorptive epithelia.  A cDNA encoding a Na-K-Cl cotransport protein was isolated from a shark rectal gland library by screening with monoclonal antibodies to the native shark cotransporter.  The 1191-residue protein predicted from the cDNA sequence has 12 putative transmembrane domains flanked by large cytoplasmic N and C termini.  Regulatory phosphoacceptor residues in isolated peptides are identified as Thr-189 and Thr-1114 in the predicted sequence.  Northern blot anal. identified a 7.4-kb mRNA in rectal gland and most other shark tissues; a 5.2-kb mRNA was restricted to shark kidney.  Homol. with an uncharacterized gene from Caenorhabditis elegans and with the thiazide-sensitive Na-Cl cotransporter of flounder urinary bladder was found over most of the coding region; shorter stretches of homol. were found with a C. elegans cDNA and with an uncharacterized gene of cyanobacterium.  Human HEK-293 cells have been stably transfected with the shark cDNA and shown to express Na-K-Cl cotransport activity with the bumetanide sensitivity of the shark protein.  The expressed transporter is functionally quiescent in the host cells and can be activated by depleting the cells of chloride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUXRH86GV2V7Vg90H21EOLACvtfcHk0ljeiQXNSvea0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFOqt78%253D&md5=9d10163f151cb950440a9c4f57dc5996</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.6.2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.6.2201%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%2BC.%26aulast%3DLytle%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DT.%2BT.%26aulast%3DPayne%26aufirst%3DJ.%2BA.%26aulast%3DBenz%26aufirst%3DE.%26aulast%3DForbush%26aufirst%3DB.%26atitle%3DMolecular%2520cloning%2520and%2520functional%2520expression%2520of%2520the%2520bumetanide-sensitive%2520Na-K-Cl%2520cotransporter%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D6%26spage%3D2201%26epage%3D2205%26doi%3D10.1073%2Fpnas.91.6.2201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miner, P. B.</span></span> <span> </span><span class="NLM_article-title">Elobixibat, the first-in-class ileal bile acid transporter inhibitor, for the treatment of chronic idiopathic constipation</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1381</span>â <span class="NLM_lpage">1388</span>, <span class="refDoi">Â DOI: 10.1080/14656566.2018.1508450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1080%2F14656566.2018.1508450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30129377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1381-1388&issue=12&author=P.+B.+Miner&title=Elobixibat%2C+the+first-in-class+ileal+bile+acid+transporter+inhibitor%2C+for+the+treatment+of+chronic+idiopathic+constipation&doi=10.1080%2F14656566.2018.1508450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation</span></div><div class="casAuthors">Miner, Philip B. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1381-1388</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Elobixibat is the first in class ileal bile acid transporter (IBAT) inhibitor.  IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon.  Increasing colonic bile acids causes mucosal fluid secretion and enhances colonic motor activity.  Changes in colonic physiol. may be useful in treating constipation.  In this review, the author reviews the prevalence and medical cost of Chronic Idiopathic Constipation (CIC) and the heterogeneity of the CIC patient population as a complicating factor in drug development and clin. care.  And also reviews the history of Bile Acid cathartics and the complex pharmacophysiol. of bile therapy with fluid and electrolyte shifts, colonic motor function changes and mucosal immunol. activation.  Finally, the author reviews elobixabat development and the clin. trials that demonstrate improvement in constipation.  The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon assocd. with expected physiol. changes.  Elobixibat as a treatment of CIC appears promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6CcsditpIz7Vg90H21EOLACvtfcHk0ljeiQXNSvea0g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF&md5=5ba00fab2446a3a735368df82bb5429a</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1508450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1508450%26sid%3Dliteratum%253Aachs%26aulast%3DMiner%26aufirst%3DP.%2BB.%26atitle%3DElobixibat%252C%2520the%2520first-in-class%2520ileal%2520bile%2520acid%2520transporter%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520idiopathic%2520constipation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3D1381%26epage%3D1388%26doi%3D10.1080%2F14656566.2018.1508450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgkinson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span> <span> </span><span class="NLM_article-title">Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">926</span>â <span class="NLM_lpage">937</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-2270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1158%2F1078-0432.CCR-13-2270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24277449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=926-937&issue=4&author=R.+Polanskiauthor=C.+L.+Hodgkinsonauthor=A.+Fusiauthor=D.+Nonakaauthor=L.+Priestauthor=P.+Kellyauthor=F.+Trapaniauthor=P.+W.+Bishopauthor=A.+Whiteauthor=S.+E.+Critchlowauthor=P.+D.+Smithauthor=F.+Blackhallauthor=C.+Diveauthor=C.+J.+Morrow&title=Activity+of+the+monocarboxylate+transporter+1+inhibitor+AZD3965+in+small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-13-2270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer</span></div><div class="casAuthors">Polanski, Radoslaw; Hodgkinson, Cassandra L.; Fusi, Alberto; Nonaka, Daisuke; Priest, Lynsey; Kelly, Paul; Trapani, Francesca; Bishop, Paul W.; White, Anne; Critchlow, Susan E.; Smith, Paul D.; Blackhall, Fiona; Dive, Caroline; Morrow, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">926-937</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom.  AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis.  We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clin. testing in this disease and putative predictive biomarkers for trial use.  Exptl. Design: AZD3965 sensitivity was detd. for seven SCLC cell lines, in normoxia and hypoxia, and for a tumor xenograft model.  Proof of mechanism was sought via changes in intracellular/tumor lactate.  Expression of MCT1 and related transporter MCT4 was assessed by Western blot anal.  Drug resistance was investigated via MCT4 siRNAi and overexpression.  The expression and clin. significance of MCT1 and MCT4 were explored in a tissue microarray (TMA) from 78 patients with SCLC.  Results: AZD3965 sensitivity varied in vitro and was highest in hypoxia.  Resistance in hypoxia was assocd. with increased MCT4 expression.  In vivo, AZD3965 reduced tumor growth and increased intratumor lactate.  In the TMA, high MCT1 expression was assocd. with worse prognosis (P = 0.014).  MCT1 and hypoxia marker CA IX expression in the absence of MCT4 was obsd. in 21% of SCLC tumors.  Conclusions: This study provides a rationale to test AZD3965 in patients with SCLC.  Our results suggest that patients with tumors expressing MCT1 and lacking in MCT4 are most likely to respond.  Clin Cancer Res; 20(4); 926-37. 2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSspebNlIjdbVg90H21EOLACvtfcHk0lirmSJ6XVCK3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejtLo%253D&md5=9609fad6b0c2e5b4ebc9d2465743f6bb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2270%26sid%3Dliteratum%253Aachs%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DHodgkinson%26aufirst%3DC.%2BL.%26aulast%3DFusi%26aufirst%3DA.%26aulast%3DNonaka%26aufirst%3DD.%26aulast%3DPriest%26aufirst%3DL.%26aulast%3DKelly%26aufirst%3DP.%26aulast%3DTrapani%26aufirst%3DF.%26aulast%3DBishop%26aufirst%3DP.%2BW.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DDive%26aufirst%3DC.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26atitle%3DActivity%2520of%2520the%2520monocarboxylate%2520transporter%25201%2520inhibitor%2520AZD3965%2520in%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D4%26spage%3D926%26epage%3D937%26doi%3D10.1158%2F1078-0432.CCR-13-2270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Cruz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. E.</span></span> <span> </span><span class="NLM_article-title">Cellular uptake of MCT1 inhibitors AR-C155858 and AZD3965 and their effects on MCT-mediated transport of L-lactate in murine 4T1 breast tumor cancer cells</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi">Â DOI: 10.1208/s12248-018-0279-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1208%2Fs12248-018-0279-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30617815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3cnovVymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=13&author=X.+Guanauthor=V.+Rodriguez-Cruzauthor=M.+E.+Morris&title=Cellular+uptake+of+MCT1+inhibitors+AR-C155858+and+AZD3965+and+their+effects+on+MCT-mediated+transport+of+L-lactate+in+murine+4T1+breast+tumor+cancer+cells&doi=10.1208%2Fs12248-018-0279-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells</span></div><div class="casAuthors">Guan Xiaowen; Rodriguez-Cruz Vivian; Morris Marilyn E</div><div class="citationInfo"><span class="NLM_cas:title">The AAPS journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AR-C155858 and AZD3965, pyrrole pyrimidine derivatives, represent potent monocarboxylate transporter 1 (MCT1) inhibitors, with potential immunomodulatory and chemotherapeutic properties.  Currently, there is limited information on the inhibitory properties of this new class of MCT1 inhibitors.  The purpose of this study was to characterize the concentration- and time-dependent inhibition of L-lactate transport and the membrane permeability properties of AR-C155858 and AZD3965 in the murine 4T1 breast tumor cells that express MCT1.  Our results demonstrated time-dependent inhibition of L-lactate uptake by AR-C155858 and AZD3965 with maximal inhibition occurring after a 5-min pre-incubation period and prolonged inhibition.  Following removal of AR-C155858 or AZD3965 from the incubation buffer, inhibition of L-lactate uptake was only fully reversed after 3 and 12 h, respectively, indicating that these inhibitors are slowly reversible.  The uptake of AR-C155858 was concentration-dependent in 4T1 cells, whereas the uptake of AZD3965 exhibited no concentration dependence over the range of concentrations examined.  The uptake kinetics of AR-C155858 was best fitted to a Michaelis-Menten equation with a diffusional clearance component, P (Km = 0.399 Â± 0.067 Î¼M, Vmax = 4.79 Â± 0.58 pmol/mg/min, and P = 0.330 Â± 0.088 Î¼L/mg/min).  AR-C155858 uptake, but not AZD3965 uptake, was significantly inhibited by alpha-cyano-4-hydroxycinnamic acid, a known nonspecific inhibitor of MCTs 1, 2, and 4.  AR-C155858 demonstrated a trend toward higher uptake at lower pH, a characteristic of proton-dependent MCT1.  These findings provide evidence that AR-C155858 and AZD3965 exert slowly reversible inhibition of MCT1-mediated L-lactate uptake in 4T1 cells, with AR-C155858 representing a potential substrate of MCT1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGRzsabYqKBGxpATR2EQURfW6udTcc2ebJ5PWhgvoqSbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnovVymuw%253D%253D&md5=a71fe4cd8bd0e400f5314eee18f3fa94</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1208%2Fs12248-018-0279-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-018-0279-5%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DRodriguez-Cruz%26aufirst%3DV.%26aulast%3DMorris%26aufirst%3DM.%2BE.%26atitle%3DCellular%2520uptake%2520of%2520MCT1%2520inhibitors%2520AR-C155858%2520and%2520AZD3965%2520and%2520their%2520effects%2520on%2520MCT-mediated%2520transport%2520of%2520L-lactate%2520in%2520murine%25204T1%2520breast%2520tumor%2520cancer%2520cells%26jtitle%3DAAPS%2520J.%26date%3D2019%26volume%3D21%26spage%3D13%26doi%3D10.1208%2Fs12248-018-0279-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McColm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbury, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyas, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, S. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benschop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witcher, D. R.</span></span> <span> </span><span class="NLM_article-title">Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">935</span>â <span class="NLM_lpage">948</span>, <span class="refDoi">Â DOI: 10.1111/bcp.13877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fbcp.13877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30677788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1amsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2019&pages=935-948&issue=5&author=M.+Sheetzauthor=P.+Barringtonauthor=S.+Calliesauthor=P.+H.+Bergauthor=J.+McColmauthor=T.+Marburyauthor=B.+Deckerauthor=G.+L.+Dyasauthor=S.+M.+E.+Truhlarauthor=R.+Benschopauthor=D.+Leungauthor=J.+Bergauthor=D.+R.+Witcher&title=Targeting+the+hepcidin-ferroportin+pathway+in+anaemia+of+chronic+kidney+disease&doi=10.1111%2Fbcp.13877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease</span></div><div class="casAuthors">Sheetz, Matthew; Barrington, Philip; Callies, Sophie; Berg, Paul H.; McColm, Juliet; Marbury, Thomas; Decker, Brian; Dyas, Gregory L.; Truhlar, Stephanie M. E.; Benschop, Robert; Leung, Donmienne; Berg, Jolene; Witcher, Derrick R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-948</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease (CKD) have been assocd. with cardiovascular adverse events.  Hepcidin prodn., controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin.  High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anemia in CKD patients.  To investigate alternative therapies to erythropoiesis-stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin resp., were tested in CKD patients.  Methods : Preclin. in vitro/vivo data and clin. data in healthy subjects and CKD patients were used to illustrate the translation of pharmacol. properties of LY3113593 and LY2928057, highlighting the novelty of targeting these nodes within the hepcidin-ferroportin pathway.  Results : LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux, leading to increased serum iron and transferrin satn. levels and increased hepcidin in monkeys and humans.  In CKD patients, LY2928057 led to slower Hb decline and redn. in ferritin (compared to placebo).  Serum iron increase was (mean [90% confidence interval]) 1.98 [1.46-2.68] and 1.36 [1.22-1.51] fold-relative to baseline following LY2928057 600 mg and LY311593 150 mg resp. in CKD patients.  LY3113593 specifically blocked BMP6 binding to its receptor and produced increases in iron and transferrin satn. and decreases in hepcidin preclinically and clin.  In CKD patients, LY3113593 produced an increase in Hb and redn. in ferritin (compared to placebo).  Conclusion : LY3113593 and LY2928057 pharmacol. effects (serum iron and ferritin) were translated from preclin.-to-clin. development.  Such interventions may lead to new CKD anemia treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTgEW1JOMNDrVg90H21EOLACvtfcHk0lirmSJ6XVCK3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1amsbw%253D&md5=3467865b463c2619e22d92705a078ba3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13877%26sid%3Dliteratum%253Aachs%26aulast%3DSheetz%26aufirst%3DM.%26aulast%3DBarrington%26aufirst%3DP.%26aulast%3DCallies%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DP.%2BH.%26aulast%3DMcColm%26aufirst%3DJ.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DB.%26aulast%3DDyas%26aufirst%3DG.%2BL.%26aulast%3DTruhlar%26aufirst%3DS.%2BM.%2BE.%26aulast%3DBenschop%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DWitcher%26aufirst%3DD.%2BR.%26atitle%3DTargeting%2520the%2520hepcidin-ferroportin%2520pathway%2520in%2520anaemia%2520of%2520chronic%2520kidney%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D85%26issue%3D5%26spage%3D935%26epage%3D948%26doi%3D10.1111%2Fbcp.13877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danila, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathkopf, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slovin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. J.</span></span> <span> </span><span class="NLM_article-title">A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1052</span>â <span class="NLM_lpage">1060</span>, <span class="refDoi">Â DOI: 10.1007/s10637-019-00731-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs10637-019-00731-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30725389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1052-1060&author=D.+McHughauthor=M.+Eisenbergerauthor=E.+I.+Heathauthor=J.+Bruceauthor=D.+C.+Danilaauthor=D.+E.+Rathkopfauthor=J.+Feldmanauthor=S.+F.+Slovinauthor=B.+Anandauthor=R.+Chuauthor=J.+Lackeyauthor=L.+Reynoauthor=E.+S.+Antonarakisauthor=M.+J.+Morris&title=A+phase+I+study+of+the+antibody+drug+conjugate+ASG-5ME%2C+an+SLC44A4-targeting+antibody+carrying+auristatin+E%2C+in+metastatic+castration-resistant+prostate+cancer&doi=10.1007%2Fs10637-019-00731-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">McHugh, Deaglan; Eisenberger, Mario; Heath, Elisabeth I.; Bruce, Justine; Danila, Daniel C.; Rathkopf, Dana E.; Feldman, Jarett; Slovin, Susan F.; Anand, Banmeet; Chu, Rong; Lackey, Jacqueline; Reyno, Leonard; Antonarakis, Emmanuel S.; Morris, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1052-1060</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The primary objective of this phase I study was to det. max. tolerated dose (MTD) and recommended phase II dose.  Secondary objectives were safety, antitumor activity, pharmacokinetic properties, immunogenicity, and the detection of SLC44A4 on circulating tumor cells.  Patients (pts) were treated among 7 dose levels every 21 days.  A dose expansion phase enrolled 20 addnl. pts. at the MTD.  Twenty-six and 20 pts. were treated in dose escalation and dose expansion cohorts resp.  The MTD was 2.7 mg/kg.  Dose-limiting toxicities occurred in 4 pts.: grade 3 fatigue (n = 1); grade 3 abdominal pain, diarrhea and fatigue (n = 1); grade 4 neutropenia and hyponatremia and grade 3 maculopapular rash, constipation and hypoxia (n = 1); grade 3 troponin elevation without cardiac sequelae (n = 1).  Fatigue and diarrhea were the most prevalent adverse events (AEs) across all cycles.  Two grade 5 AEs occurred in the dose expansion cohort, each after 1 dose: 1 pt. developed grade 3 hyperglycemia, renal insufficiency and leukopenia; 1 pt. developed grade 3 hyperglycemia complicated by bacteremia.  Free MMAE levels did not accumulate with repeat dosing.  Of evaluable pts., 52% had either stable disease or a partial response.  Some toxicities were potentially related to on-target effects on normal tissue expressing the SLC44A4 protein.  However, other toxicities were consistent with studies of previous MMAE-contg. ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphkoY7dWx0rLVg90H21EOLACvtfcHk0lgG1lxZpUrVrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrt7bI&md5=bf9ec283a033f9a1969353cf563b57b6</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00731-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00731-5%26sid%3Dliteratum%253Aachs%26aulast%3DMcHugh%26aufirst%3DD.%26aulast%3DEisenberger%26aufirst%3DM.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBruce%26aufirst%3DJ.%26aulast%3DDanila%26aufirst%3DD.%2BC.%26aulast%3DRathkopf%26aufirst%3DD.%2BE.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DSlovin%26aufirst%3DS.%2BF.%26aulast%3DAnand%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DR.%26aulast%3DLackey%26aufirst%3DJ.%26aulast%3DReyno%26aufirst%3DL.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520antibody%2520drug%2520conjugate%2520ASG-5ME%252C%2520an%2520SLC44A4-targeting%2520antibody%2520carrying%2520auristatin%2520E%252C%2520in%2520metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D1052%26epage%3D1060%26doi%3D10.1007%2Fs10637-019-00731-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nigam, S. K.</span></span> <span> </span><span class="NLM_article-title">What do drug transporters really do?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">44</span>, <span class="refDoi">Â DOI: 10.1038/nrd4461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd4461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25475361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=29-44&issue=1&author=S.+K.+Nigam&title=What+do+drug+transporters+really+do%3F&doi=10.1038%2Fnrd4461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">What do drug transporters really do?</span></div><div class="casAuthors">Nigam, Sanjay K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-44</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Potential drug-drug interactions mediated by the ATP-binding cassette (ABC) transporter and solute carrier (SLC) transporter families are of clin. and regulatory concern.  However, the endogenous functions of these drug transporters are not well understood.  Discussed here is evidence for the roles of ABC and SLC transporters in the handling of diverse substrates, including metabolites, antioxidants, signaling mols., hormones, nutrients, and neurotransmitters.  It is suggested that these transporters may be part of a larger system of remote communication ('remote sensing and signaling') between cells, organs, body fluid compartments, and perhaps even sep. organisms.  This broader view may help to clarify disease mechanisms, drug-metabolite interactions, and drug effects relevant to diabetes, chronic kidney disease, metabolic syndrome, hypertension, gout, liver disease, neuropsychiatric disorders, inflammatory syndromes, and organ injury, as well as prenatal and postnatal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeezdvl3p-z7Vg90H21EOLACvtfcHk0lgG1lxZpUrVrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClu7rN&md5=41debd2dfed0f0c0282be88583c1b0a6</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnrd4461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4461%26sid%3Dliteratum%253Aachs%26aulast%3DNigam%26aufirst%3DS.%2BK.%26atitle%3DWhat%2520do%2520drug%2520transporters%2520really%2520do%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D1%26spage%3D29%26epage%3D44%26doi%3D10.1038%2Fnrd4461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahrmayr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, J.</span></span> <span> </span><span class="NLM_article-title">Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">380</span>â <span class="NLM_lpage">401</span>, <span class="refDoi">Â DOI: 10.3109/03602530903491683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3109%2F03602530903491683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20100011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=380-401&issue=3&author=C.+Fahrmayrauthor=M.+F.+Frommauthor=J.+Konig&title=Hepatic+OATP+and+OCT+uptake+transporters%3A+their+role+for+drug-drug+interactions+and+pharmacogenetic+aspects&doi=10.3109%2F03602530903491683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects</span></div><div class="casAuthors">Fahrmayr, Christina; Fromm, Martin F.; Koenig, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">380-401</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Uptake transporters in the basolateral membrane of hepatocytes are important for the hepatobiliary elimination of drugs.  Further, since drug-metabolizing enzymes are located intracellularly, uptake into hepatocytes is a prerequisite for their subsequent metab.  Therefore, alteration of uptake transporter function (e.g., by concomitantly administered drugs or due to functional consequences of genetic variations, leading to reduced transport function) may result in a change in drug pharmacokinetics.  In this review, we focus on the hepatocellularly expressed members of the OATP and OCT family, their impact on transport-mediated drug-drug interactions, and on the functional consequences of variations in genes encoding these transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkKPXsJ_nkLVg90H21EOLACvtfcHk0lgG1lxZpUrVrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7s%253D&md5=3ef70a9fdaf699f3261b26d0f02b1406</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3109%2F03602530903491683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602530903491683%26sid%3Dliteratum%253Aachs%26aulast%3DFahrmayr%26aufirst%3DC.%26aulast%3DFromm%26aufirst%3DM.%2BF.%26aulast%3DKonig%26aufirst%3DJ.%26atitle%3DHepatic%2520OATP%2520and%2520OCT%2520uptake%2520transporters%253A%2520their%2520role%2520for%2520drug-drug%2520interactions%2520and%2520pharmacogenetic%2520aspects%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26issue%3D3%26spage%3D380%26epage%3D401%26doi%3D10.3109%2F03602530903491683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rizwan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burckhardt, G.</span></span> <span> </span><span class="NLM_article-title">Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">450</span>â <span class="NLM_lpage">470</span>, <span class="refDoi">Â DOI: 10.1007/s11095-006-9181-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs11095-006-9181-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17245646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWisr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2007&pages=450-470&issue=3&author=A.+N.+Rizwanauthor=G.+Burckhardt&title=Organic+anion+transporters+of+the+SLC22+family%3A+biopharmaceutical%2C+physiological%2C+and+pathological+roles&doi=10.1007%2Fs11095-006-9181-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles</span></div><div class="casAuthors">Rizwan, Ahsan N.; Burckhardt, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">450-470</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The human org. anion transporters OAT1, OAT2, OAT3, OAT4 and URAT1 belong to a family of poly-specific transporters mainly located in kidneys.  Selected OATs occur also in liver, placenta, and brain.  OATs interact with endogenous metabolic end products such as urate and acidic neurotransmitter metabolites, as well as with a multitude of widely used drugs, including antibiotics, antihypertensives, antivirals, anti-inflammatory drugs, diuretics and uricosurics.  Thereby, OATs play an important role in renal drug elimination and have an impact on pharmacokinetics.  In this review the authors focus on the interaction of human OATs with drugs.  The authors report the affinities of human OATs for drug classes and compare the putative importance of individual OATs for renal drug excretion.  The role of OATs as sites of drug-drug interaction and mediators cell toxicity, their gender-dependent regulation in health and diseased states, and the possible impact of single nucleotide polymorphisms are also dealt with.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIQcFgXPgVbbVg90H21EOLACvtfcHk0lg8enSK_882NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWisr4%253D&md5=40ecfcb70a2c404fd2710a2da1810e3f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs11095-006-9181-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-006-9181-4%26sid%3Dliteratum%253Aachs%26aulast%3DRizwan%26aufirst%3DA.%2BN.%26aulast%3DBurckhardt%26aufirst%3DG.%26atitle%3DOrganic%2520anion%2520transporters%2520of%2520the%2520SLC22%2520family%253A%2520biopharmaceutical%252C%2520physiological%252C%2520and%2520pathological%2520roles%26jtitle%3DPharm.%2520Res.%26date%3D2007%26volume%3D24%26issue%3D3%26spage%3D450%26epage%3D470%26doi%3D10.1007%2Fs11095-006-9181-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roubert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haboubi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohring, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrenberger, F.</span></span> <span> </span><span class="NLM_article-title">Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi">Â DOI: 10.1002/ajh.25670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fajh.25670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31674058" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=F.+Richardauthor=J.+J.+van+Lierauthor=B.+Roubertauthor=T.+Haboubiauthor=U.+M.+Gohringauthor=F.+Durrenberger&title=Oral+ferroportin+inhibitor+VIT-2763%3A+first-in-human%2C+phase+1+study+in+healthy+volunteers&doi=10.1002%2Fajh.25670"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fajh.25670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.25670%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DF.%26aulast%3Dvan%2BLier%26aufirst%3DJ.%2BJ.%26aulast%3DRoubert%26aufirst%3DB.%26aulast%3DHaboubi%26aufirst%3DT.%26aulast%3DGohring%26aufirst%3DU.%2BM.%26aulast%3DDurrenberger%26aufirst%3DF.%26atitle%3DOral%2520ferroportin%2520inhibitor%2520VIT-2763%253A%2520first-in-human%252C%2520phase%25201%2520study%2520in%2520healthy%2520volunteers%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2019%26doi%3D10.1002%2Fajh.25670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visentin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span> <span> </span><span class="NLM_article-title">Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">145</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1124/jpet.115.227546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fjpet.115.227546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26330539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=145-151&issue=2&author=M.+Visentinauthor=B.+Stiegerauthor=M.+Merzauthor=G.+A.+Kullak-Ublick&title=Octreotide+inhibits+the+bilirubin+carriers+organic+anion+transporting+polypeptides+1B1+and+1B3+and+the+multidrug+resistance-associated+protein+2&doi=10.1124%2Fjpet.115.227546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2</span></div><div class="casAuthors">Visentin, Michele; Stieger, Bruno; Merz, Michael; Kullak-Ublick, Gerd A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The somatostatin analog octreotide can lead to hyperbilirubinemia without evidence of liver injury.  Here we investigate whether octreotide inhibits the main sinusoidal/canalicular bilirubin carriers and whether it is a transport substrate.  Octreotide showed the most potent inhibitory effect toward OATP1B1-mediated transport and weaker inhibition for OATP1B3- and MRP2-mediated transport.  Octreotide had no effect on OATP2B1-mediated transport.  Octreotide inhibited [3H]estradiol-17-Î²-glucuronide (E17Î²G) influx mediated by OATP1B1, 1B3, and multidrug resistance-assocd. protein 2 (MRP2) in a concn.-dependent manner, and the IC50 values were computed to be 23 Î¼M (95% confidence interval [CI] 18-29), 68 Î¼M (95% CI 50-91), and 116.6 Î¼M (95% CI 74.5-182.4), resp.  The interaction between octreotide and OATP1B1 was further studied.  Inhibition of [3H]E17Î²G OATP1B1-mediated transport was purely competitive with no changes in max. transport capacity (Vmax) and a twofold Km increase when the influx kinetics of [3H]E17Î²G were measured in the presence of octreotide (8.8 Â± 3.1 vs. 4.4 Â± 1.2 Î¼M, P = 0.03).  The inhibition const. (Ki) of octreotide for the transport of [3H]E17Î²G was calcd. at 33.5 Â± 5.5 Î¼M.  Uptake of radiolabeled octreotide by OATP1B1-CHO cells was higher than in wild-type CHO cells and nonlabeled octreotide at the extracellular compartment was able to trans-stimulate the OATP1B1-mediated efflux of intracellular [3H]E17Î²G, suggesting that octreotide is a substrate of OATP1B1.  In summary, this study shows interaction of octreotide on the human hepatocellular bilirubin transporters OATP1B1, OATP1B3, and MRP2, notably OATP1B1.  These findings are in line with the clin. observation that a fraction of patients under treatment with octreotide exhibit hyperbilirubinemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEjLsy1D61J7Vg90H21EOLACvtfcHk0lg8enSK_882NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsrg%253D&md5=dbe35dfc2b95cc861ce8d76be91cf4d3</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227546%26sid%3Dliteratum%253Aachs%26aulast%3DVisentin%26aufirst%3DM.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26atitle%3DOctreotide%2520inhibits%2520the%2520bilirubin%2520carriers%2520organic%2520anion%2520transporting%2520polypeptides%25201B1%2520and%25201B3%2520and%2520the%2520multidrug%2520resistance-associated%2520protein%25202%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26issue%3D2%26spage%3D145%26epage%3D151%26doi%3D10.1124%2Fjpet.115.227546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonezawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, K.</span></span> <span> </span><span class="NLM_article-title">Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1762</span>â <span class="NLM_lpage">1767</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2010.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bcp.2010.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20813096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSmsbfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=1762-1767&issue=11&author=T.+Nakamuraauthor=A.+Yonezawaauthor=S.+Hashimotoauthor=T.+Katsuraauthor=K.+Inui&title=Disruption+of+multidrug+and+toxin+extrusion+MATE1+potentiates+cisplatin-induced+nephrotoxicity&doi=10.1016%2Fj.bcp.2010.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Nakamura, Takanori; Yonezawa, Atsushi; Hashimoto, Shinya; Katsura, Toshiya; Inui, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1762-1767</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug and toxin extrusion 1 (MATE1/SLC47A1) is expressed in the brush-border membrane of renal proximal tubules and mediates the efflux of cationic drugs.  In the present study, the role of MATE1 in the nephrotoxicity of cisplatin was investigated in vivo and in vitro.  Cisplatin (15 mg/kg) was administered i.p. to wild-type (Mate1(+/+)) and Mate1 knockout (Mate1(-/-)) mice.  Lifespan was significantly shorter in Mate1(-/-) mice than Mate1(+/+) mice.  Three days after the administration of cisplatin, plasma creatinine and blood urea nitrogen (BUN) levels were increased in both Mate1(+/+) and Mate1(-/-) mice compared with vehicle-treated controls, and creatinine clearance was decreased.  Moreover, a significant rise in creatinine and BUN levels was obsd. in cisplatin-treated Mate1(-/-) mice in comparison to Mate1(+/+) mice.  A pharmacokinetic anal. revealed the plasma concn. and renal accumulation of cisplatin to be higher in Mate1(-/-) mice than Mate1(+/+) mice 1 h after a single i.v. administration of cisplatin (0.5 mg/kg).  Furthermore, the combination of a selective MATE inhibitor, pyrimethamine, with cisplatin also elevated creatinine and BUN levels compared to cisplatin alone.  In expts. in vitro, the cellular uptake of cisplatin was stimulated by the expression of mouse MATE1 as well as org. cation transporters OCT1 and OCT2.  In conclusion, MATE1 mediates the efflux of cisplatin and is involved in cisplatin-induced nephrotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHzSPRW77TrVg90H21EOLACvtfcHk0lg8enSK_882NQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSmsbfP&md5=6dfaa19521622cf8425fe87bfbbc8094</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DYonezawa%26aufirst%3DA.%26aulast%3DHashimoto%26aufirst%3DS.%26aulast%3DKatsura%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DK.%26atitle%3DDisruption%2520of%2520multidrug%2520and%2520toxin%2520extrusion%2520MATE1%2520potentiates%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26issue%3D11%26spage%3D1762%26epage%3D1767%26doi%3D10.1016%2Fj.bcp.2010.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cundy, K. C.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">143</span>, <span class="refDoi">Â DOI: 10.2165/00003088-199936020-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2165%2F00003088-199936020-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10092959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1MXitFCntLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1999&pages=127-143&issue=2&author=K.+C.+Cundy&title=Clinical+pharmacokinetics+of+the+antiviral+nucleotide+analogues+cidofovir+and+adefovir&doi=10.2165%2F00003088-199936020-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir</span></div><div class="casAuthors">Cundy, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-143</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs. Cidofovir and adefovir are members of a new class of antiviral compds.  They are acyclic phosphonate analogs of deoxynucleoside monophosphates.  Both compds. undergo intracellular activation to form diphosphates that are potent inhibitors of viral DNA polymerases.  Cidofovir has broad-spectrum antiviral activity against herpesviruses, papillomaviruses and poxviruses, whereas adefovir has potent activity against retroviruses and certain DNA viruses, including herpesviruses and hepadnaviruses.  I.v. cidofovir is approved for treatment of cytomegalovirus retinitis in patients with AIDS.  Cidofovir and adefovir are dianionic at physiol. pH and have low oral bioavailability in animals and humans.  After i.v. administration to HIV-infected patients, the pharmacokinetics of both drugs are independent of dose and are consistent with preclin. data.  Systemic exposure is proportional to the i.v. dose, and both drugs are cleared by the kidneys and excreted extensively as unchanged drug in the urine.  Intracellular activation of a small fraction (<10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies.  The rate of elimination of cidofovir and adefovir from serum may not reflect the true duration of action of these drugs, since the antiviral effect is dependent on concns. of the active phosphorylated metabolites that are present within cells.  For both drugs, >90% of an i.v. dose is recovered unchanged in the urine over 24 h.  Metab. does not contribute significantly to the total clearance of either drug.  Concomitant oral probenecid decreases both the renal clearance of cidofovir and the incidence of nephrotoxicity, presumably by blocking its active tubular secretion.  This is the basis of the clin. use of concomitant probenecid as a nephroprotectant during cidofovir therapy.  S.c. administration produces exposure equiv. to that following i.v. administration.  Drug- interaction studies with cidofovir are ongoing, but there is no evidence of an interaction between zidovudine and either cidofovir or adefovir.  Clearance of cidofovir in patients with renal impairment showed a linear relationship to creatinine clearance.  The low oral bioavailability of adefovir has led to the development of an oral prodrug, adefovir dipivoxil, currently in development for the treatment of HIV and hepatitis B infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6qJXBxXebNLVg90H21EOLACvtfcHk0lgW7ncjLtx6cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFCntLs%253D&md5=04b0ffcafdb4a1d9faf74ee58ffe0feb</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.2165%2F00003088-199936020-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199936020-00004%26sid%3Dliteratum%253Aachs%26aulast%3DCundy%26aufirst%3DK.%2BC.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520the%2520antiviral%2520nucleotide%2520analogues%2520cidofovir%2520and%2520adefovir%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1999%26volume%3D36%26issue%3D2%26spage%3D127%26epage%3D143%26doi%3D10.2165%2F00003088-199936020-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibach, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span> <span> </span><span class="NLM_article-title">Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>250</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">246</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1006/bbrc.1998.9298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1006%2Fbbrc.1998.9298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9753615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1cXmt1ygsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=1998&pages=246-251&issue=2&author=P.+V.+Balimaneauthor=I.+Tamaiauthor=A.+Guoauthor=T.+Nakanishiauthor=H.+Kitadaauthor=F.+H.+Leibachauthor=A.+Tsujiauthor=P.+J.+Sinko&title=Direct+evidence+for+peptide+transporter+%28PepT1%29-mediated+uptake+of+a+nonpeptide+prodrug%2C+valacyclovir&doi=10.1006%2Fbbrc.1998.9298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir</span></div><div class="casAuthors">Balimane, Praveen V.; Tamai, Ikumi; Guo, Ailan; Nakanishi, Takeo; Kitada, Hideyuki; Leibach, Frederick H.; Tsuji, Akira; Sinko, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-251</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Xenopus laevis oocytes were used as a gene expression system to characterize the carrier-mediated transport of valacyclovir (vacv), the L-valine ester prodrug of the acyclic nucleoside acyclovir (acv).  A significant increase in the uptake of [3H]vacv by Xenopus laevis oocytes injected with human intestinal peptide transporter (hPepT1) cRNA compared to the uptake by water injected oocytes indicated that vacv was translocated by hPepT1.  Vacv uptake was concn. dependent, saturable (Km = 5.94Â±1.91mM and Jmax = 1.68Â±0.25 nmoles/h/oocyte), pH dependent, and inhibited by various known substrates of hPepT1 but not by acv, valine or pentaglycine.  Vacv also inhibited the uptake of 14C-glycylsarcosine, a known substrate of hPepT1, in a concn.-dependent manner (Ki = 4.08Â±1.02mM).  These results demonstrate that human intestinal peptide transporter hPepT1 has broad specificity since it recognizes vacv as a substrate even though it lacks a typical peptide bond.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI2khMq3L7ZbVg90H21EOLACvtfcHk0lgW7ncjLtx6cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmt1ygsbc%253D&md5=eed4e80e2285a3ab9e519ffb99aab29c</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1998.9298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1998.9298%26sid%3Dliteratum%253Aachs%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DTamai%26aufirst%3DI.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DNakanishi%26aufirst%3DT.%26aulast%3DKitada%26aufirst%3DH.%26aulast%3DLeibach%26aufirst%3DF.%2BH.%26aulast%3DTsuji%26aufirst%3DA.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DDirect%2520evidence%2520for%2520peptide%2520transporter%2520%2528PepT1%2529-mediated%2520uptake%2520of%2520a%2520nonpeptide%2520prodrug%252C%2520valacyclovir%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1998%26volume%3D250%26issue%3D2%26spage%3D246%26epage%3D251%26doi%3D10.1006%2Fbbrc.1998.9298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aouida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramotar, D.</span></span> <span> </span><span class="NLM_article-title">A new twist in cellular resistance to the anticancer drug bleomycin-A5</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">595</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.2174/138920010792927307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2174%2F138920010792927307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20812903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=595-602&issue=7&author=M.+Aouidaauthor=D.+Ramotar&title=A+new+twist+in+cellular+resistance+to+the+anticancer+drug+bleomycin-A5&doi=10.2174%2F138920010792927307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A new twist in cellular resistance to the anticancer drug bleomycin-A5</span></div><div class="casAuthors">Aouida, Mustapha; Ramotar, Dindial</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">595-602</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Bleomycin is a potent chemotherapeutic agent that can mediate cell killing by attacking the DNA.  It is used in combination with other antineoplastic agents to effectively treat lymphomas, testicular carcinomas and squamous cell carcinomas of the cervix, head and neck.  However, resistance to bleomycin remains a persistent limitation in exploiting the full therapeutic benefit of the drug for other types of cancers.  Herein, we review recent findings frm both yeast and human cells showing that uptake of bleomycin-A5 is a key mechanism that limits toxicity of the drug.  We also discuss how the mammalian transporter hCT2 (SLC22A16) could be used to predict the outcome of tumor responses towards bleomycin therapy, and highlight the importance of further exploring this permease with respect to its regulation and pharmacol. substrates for treating a wide range of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrButD5pmCYarVg90H21EOLACvtfcHk0lgW7ncjLtx6cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrF&md5=4f4e992fb25bb454ad3caaec80d7258b</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.2174%2F138920010792927307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920010792927307%26sid%3Dliteratum%253Aachs%26aulast%3DAouida%26aufirst%3DM.%26aulast%3DRamotar%26aufirst%3DD.%26atitle%3DA%2520new%2520twist%2520in%2520cellular%2520resistance%2520to%2520the%2520anticancer%2520drug%2520bleomycin-A5%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2010%26volume%3D11%26issue%3D7%26spage%3D595%26epage%3D602%26doi%3D10.2174%2F138920010792927307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trefzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klampfl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kralovics, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Capetillo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummelkamp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">768</span>â <span class="NLM_lpage">773</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnchembio.1590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25064833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ait7bO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=768-773&issue=9&author=G.+E.+Winterauthor=B.+Radicauthor=C.+Mayor-Ruizauthor=V.+A.+Blomenauthor=C.+Trefzerauthor=R.+K.+Kandasamyauthor=K.+V.+M.+Huberauthor=M.+Gridlingauthor=D.+Chenauthor=T.+Klampflauthor=R.+Kralovicsauthor=S.+Kubicekauthor=O.+Fernandez-Capetilloauthor=T.+R.+Brummelkampauthor=G.+Superti-Furga&title=The+solute+carrier+SLC35F2+enables+YM155-mediated+DNA+damage+toxicity&doi=10.1038%2Fnchembio.1590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity</span></div><div class="casAuthors">Winter, Georg E.; Radic, Branka; Mayor-Ruiz, Cristina; Blomen, Vincent A.; Trefzer, Claudia; Kandasamy, Richard K.; Huber, Kilian V. M.; Gridling, Manuela; Chen, Doris; Klampfl, Thorsten; Kralovics, Robert; Kubicek, Stefan; Fernandez-Capetillo, Oscar; Brummelkamp, Thijn R.; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">768-773</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genotoxic chemotherapy is the most common cancer treatment strategy.  However, its untargeted generic DNA-damaging nature and assocd. systemic cytotoxicity greatly limit its therapeutic applications.  Here, the authors used a haploid genetic screen in human cells to discover an abs. dependency of the clin. evaluated anticancer compd. YM155 on solute carrier family member 35 F2 (SLC35F2), an uncharacterized member of the solute carrier protein family that is highly expressed in a variety of human cancers.  YM155 generated DNA damage through intercalation, which was contingent on the expression of SLC35F2 and its drug-importing activity.  SLC35F2 expression and YM155 sensitivity correlated across a panel of cancer cell lines, and targeted genome editing verified SLC35F2 as the main determinant of YM155-mediated DNA damage toxicity in vitro and in vivo.  These findings suggest a new route to targeted DNA damage by exploiting tumor and patient-specific import of YM155.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGoPhFyyw9DrVg90H21EOLACvtfcHk0lgW7ncjLtx6cQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ait7bO&md5=e3d936a3d37c869cda174c8ef47ad150</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1590%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DRadic%26aufirst%3DB.%26aulast%3DMayor-Ruiz%26aufirst%3DC.%26aulast%3DBlomen%26aufirst%3DV.%2BA.%26aulast%3DTrefzer%26aufirst%3DC.%26aulast%3DKandasamy%26aufirst%3DR.%2BK.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DGridling%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DKlampfl%26aufirst%3DT.%26aulast%3DKralovics%26aufirst%3DR.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26aulast%3DBrummelkamp%26aufirst%3DT.%2BR.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520solute%2520carrier%2520SLC35F2%2520enables%2520YM155-mediated%2520DNA%2520damage%2520toxicity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D9%26spage%3D768%26epage%3D773%26doi%3D10.1038%2Fnchembio.1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensbol, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">912</span>â <span class="NLM_lpage">915</span>, <span class="refDoi">Â DOI: 10.1021/jm8013458</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8013458" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSqs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=912-915&issue=4&author=A.+A.+Jensenauthor=M.+N.+Erichsenauthor=C.+W.+Nielsenauthor=T.+B.+Stensbolauthor=J.+Kehlerauthor=L.+Bunch&title=Discovery+of+the+first+selective+inhibitor+of+excitatory+amino+acid+transporter+subtype+1&doi=10.1021%2Fjm8013458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First Selective Inhibitor of Excitatory Amino Acid Transporter Subtype 1</span></div><div class="casAuthors">Jensen, Anders A.; Erichsen, Mette N.; Nielsen, Christina W.; Stensboel, Tine B.; Kehler, Jan; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">912-915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of the first class of subtype-selective inhibitors of the human excitatory amino acid transporter subtype 1 (EAAT1) and its rat orthologue GLAST is reported.  An opening structure-activity relationship of 25 analogs is presented that addresses the influence of substitutions at the 4- and 7-positions of the parental skeleton 2-amino-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile.  The most potent analog 10 displays high nanomolar inhibitory activity at EAAT1 and a >400-fold selectivity over EAAT2 and EAAT3, making it a highly valuable pharmacol. tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVu7PAOshxerVg90H21EOLACvtfcHk0ljwy37ixg1p-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSqs78%253D&md5=7036a6fe617a9908a36fda6a87400e2c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm8013458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8013458%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DErichsen%26aufirst%3DM.%2BN.%26aulast%3DNielsen%26aufirst%3DC.%2BW.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26aulast%3DKehler%26aufirst%3DJ.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520the%2520first%2520selective%2520inhibitor%2520of%2520excitatory%2520amino%2520acid%2520transporter%2520subtype%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D4%26spage%3D912%26epage%3D915%26doi%3D10.1021%2Fjm8013458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strobel, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mseeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopinathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor restricted to the intestinal lumen, for the treatment of diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">710</span>â <span class="NLM_lpage">721</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01541</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01541" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=710-721&issue=2&author=N.+C.+Goodwinauthor=Z.+M.+Dingauthor=B.+A.+Harrisonauthor=E.+D.+Strobelauthor=A.+L.+Harrisauthor=M.+Smithauthor=A.+Y.+Thompsonauthor=W.+Xiongauthor=F.+Mseehauthor=D.+J.+Bruceauthor=D.+Diazauthor=S.+Gopinathanauthor=L.+Liauthor=E.+O%E2%80%99Neillauthor=M.+Thielauthor=A.+G.+Wilsonauthor=K.+G.+Carsonauthor=D.+R.+Powellauthor=D.+B.+Rawlins&title=Discovery+of+LX2761%2C+a+sodium-dependent+glucose+cotransporter+1+%28SGLT1%29+inhibitor+restricted+to+the+intestinal+lumen%2C+for+the+treatment+of+diabetes&doi=10.1021%2Facs.jmedchem.6b01541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes</span></div><div class="casAuthors">Goodwin, Nicole C.; Ding, Zhi-Ming; Harrison, Bryce A.; Strobel, Eric D.; Harris, Angela L.; Smith, Melinda; Thompson, Andrea Y.; Xiong, Wendy; Mseeh, Faika; Bruce, Debra J.; Diaz, Damaris; Gopinathan, Suma; Li, Ling; O'Neill, Emily; Thiel, Mary; Wilson, Alan G. E.; Carson, Kenneth G.; Powell, David R.; Rawlins, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">710-721</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing no. of people afflicted with diabetes throughout the world is a major health issue.  Inhibitors of the sodium-dependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patients.  Herein the authors report the discovery of LX2761, a locally-acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_jImP-MX5y7Vg90H21EOLACvtfcHk0ljwy37ixg1p-w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yqtA%253D%253D&md5=d07c28561e0bb9be4320391a94020d5c</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01541%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DN.%2BC.%26aulast%3DDing%26aufirst%3DZ.%2BM.%26aulast%3DHarrison%26aufirst%3DB.%2BA.%26aulast%3DStrobel%26aufirst%3DE.%2BD.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DThompson%26aufirst%3DA.%2BY.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DMseeh%26aufirst%3DF.%26aulast%3DBruce%26aufirst%3DD.%2BJ.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DGopinathan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DThiel%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DA.%2BG.%26aulast%3DCarson%26aufirst%3DK.%2BG.%26aulast%3DPowell%26aufirst%3DD.%2BR.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520LX2761%252C%2520a%2520sodium-dependent%2520glucose%2520cotransporter%25201%2520%2528SGLT1%2529%2520inhibitor%2520restricted%2520to%2520the%2520intestinal%2520lumen%252C%2520for%2520the%2520treatment%2520of%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D2%26spage%3D710%26epage%3D721%26doi%3D10.1021%2Facs.jmedchem.6b01541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues as atypical dopamine transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10676</span>â <span class="NLM_lpage">10691</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10676-10691&issue=23&author=J.+Caoauthor=R.+D.+Slackauthor=O.+M.+Bakareauthor=C.+Burzynskiauthor=R.+Raisauthor=B.+S.+Slusherauthor=T.+Kopajticauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=H.+Yanoauthor=Y.+Heauthor=G.+H.+Biauthor=Z.+X.+Xiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Novel+and+high+affinity+2-%5B%28diphenylmethyl%29sulfinyl%5Dacetamide+%28modafinil%29+analogues+as+atypical+dopamine+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.6b01373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Cao, Jianjing; Slack, Rachel D.; Bakare, Oluyomi M.; Burzynski, Caitlin; Rais, Rana; Slusher, Barbara S.; Kopajtic, Theresa; Bonifazi, Alessandro; Ellenberger, Michael P.; Yano, Hideaki; He, Yi; Bi, Guo-Hua; Xi, Zheng-Xiong; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10676-10691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT).  The atypical DAT inhibitors have received attention due to their promising pharmacol. profiles in animal models of cocaine and methamphetamine abuse.  Herein the authors report a series of modafinil analogs that have an atypical DAT inhibitor profile.  The authors extended SAR by chem. manipulating the oxidn. states of the sulfoxide and the amide functional groups, halogenating the Ph rings, and/or functionalizing the terminal nitrogen with substituted piperazines, resulting in several novel leads such as 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (compd. 11b), which demonstrated high DAT affinity (Ki = 2.5 nM) and selectivity without producing concomitant locomotor stimulation in mice, as compared to cocaine.  These results are consistent with an atypical DAT inhibitor profile and suggest that 11b may be a potential lead for development as a psychostimulant abuse medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL0BwESHNuRbVg90H21EOLACvtfcHk0lhQtmxnWPoi5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP&md5=e912f256c764249ad606d83ac9c570fb</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01373%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520high%2520affinity%25202-%255B%2528diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528modafinil%2529%2520analogues%2520as%2520atypical%2520dopamine%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D23%26spage%3D10676%26epage%3D10691%26doi%3D10.1021%2Facs.jmedchem.6b01373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tremont, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Both, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeller, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziej, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischke, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollefson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, D. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5837</span>â <span class="NLM_lpage">5852</span>, <span class="refDoi">Â DOI: 10.1021/jm040215+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040215%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVChtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5837-5852&issue=18&author=S.+J.+Tremontauthor=L.+F.+Leeauthor=H.+C.+Huangauthor=B.+T.+Kellerauthor=S.+C.+Banerjeeauthor=S.+R.+Bothauthor=A.+J.+Carpenterauthor=C.+C.+Wangauthor=D.+J.+Garlandauthor=W.+Huangauthor=C.+Jonesauthor=K.+J.+Koellerauthor=S.+A.+Kolodziejauthor=J.+Liauthor=R.+E.+Manningauthor=M.+W.+Mahoneyauthor=R.+E.+Millerauthor=D.+A.+Mischkeauthor=N.+P.+Rathauthor=T.+Fletcherauthor=E.+J.+Reinhardauthor=M.+B.+Tollefsonauthor=W.+F.+Vernierauthor=G.+M.+Wagnerauthor=S.+R.+Rappauthor=J.+Beaudryauthor=K.+Glennauthor=K.+Reginaauthor=J.+R.+Schuhauthor=M.+E.+Smithauthor=J.+S.+Trivediauthor=D.+B.+Reitz&title=Discovery+of+potent%2C+nonsystemic+apical+sodium-codependent+bile+acid+transporter+inhibitors+%28Part+1%29&doi=10.1021%2Fjm040215%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Nonsystemic Apical Sodium-Codependent Bile Acid Transporter Inhibitors (Part 1)</span></div><div class="casAuthors">Tremont, Samuel J.; Lee, Len F.; Huang, Horng-Chih; Keller, Bradley T.; Banerjee, Shyamal C.; Both, Scott R.; Carpenter, Andrew J.; Wang, Ching-Cheng; Garland, Danny J.; Huang, Wei; Jones, Claude; Koeller, Kevin J.; Kolodziej, Steve A.; Li, James; Manning, Robert E.; Mahoney, Matthew W.; Miller, Raymond E.; Mischke, Deborah A.; Rath, Nigam P.; Fletcher, Theresa; Reinhard, Emily J.; Tollefson, Michael B.; Vernier, William F.; Wagner, Grace M.; Rapp, Steve R.; Beaudry, Judy; Glenn, Kevin; Regina, Karen; Schuh, Joe R.; Smith, Mark E.; Trivedi, Jay S.; Reitz, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5837-5852</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Elevated plasma levels of low-d. lipoprotein (LDL) cholesterol are a major risk factor for atherosclerosis leading to coronary artery disease (CAD), which remains the main cause of mortality in Western society.  By preventing the reabsorption of bile acids, a minimally absorbed apical sodium-codependent bile acid transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side effects of an absorbed drug.  A series of novel benzothiepins (3R,3R'-2,3,4,5-tetrahydro-5-aryl-1-benzothiepin-4-ol 1,1-dioxides) I (R1 = H, 7-Me, 7-H2N, 7-MeS, 7-Br, 7-Ph, 8-OH, 9-F, etc.; R2 = Ph, 4-FC6H4, 4-MeOC6H4, etc.; R3 = R4 = Me, Et, n-Pr, n-Bu, n-pentyl; R3 = Et, R4 = Bu) was synthesized and tested for their ability to inhibit the apical sodium dependent bile acid transport (ASBT)-mediated uptake of [14C]taurocholate in H14 cells.  A 3R,4R,5R/3S,4S,5S racemate was found to have greater potency than the other three possible racemates.  Addn. of electron-donating groups such as a dimethylamino substituent at the 7 position greatly enhanced potency, and incorporation of a long-chain quaternary ammonium substituent on the 5-Ph ring was useful in minimizing systemic exposure of this locally active ASBT inhibitor while also increasing water soly. and maintaining potency.  The reported results describe the synthesis and SAR development of this benzothiepin class of ASBT inhibitors resulting in an 6000-fold improvement in ASBT inhibition with desired minimal systemic exposure of this locally acting drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0bgwePkZi7Vg90H21EOLACvtfcHk0lhQtmxnWPoi5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVChtrk%253D&md5=e730b5e2d4c63e6717c85bca8192c800</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm040215%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040215%252B%26sid%3Dliteratum%253Aachs%26aulast%3DTremont%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DKeller%26aufirst%3DB.%2BT.%26aulast%3DBanerjee%26aufirst%3DS.%2BC.%26aulast%3DBoth%26aufirst%3DS.%2BR.%26aulast%3DCarpenter%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DGarland%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKoeller%26aufirst%3DK.%2BJ.%26aulast%3DKolodziej%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DR.%2BE.%26aulast%3DMahoney%26aufirst%3DM.%2BW.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRath%26aufirst%3DN.%2BP.%26aulast%3DFletcher%26aufirst%3DT.%26aulast%3DReinhard%26aufirst%3DE.%2BJ.%26aulast%3DTollefson%26aufirst%3DM.%2BB.%26aulast%3DVernier%26aufirst%3DW.%2BF.%26aulast%3DWagner%26aufirst%3DG.%2BM.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DBeaudry%26aufirst%3DJ.%26aulast%3DGlenn%26aufirst%3DK.%26aulast%3DRegina%26aufirst%3DK.%26aulast%3DSchuh%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%26aulast%3DTrivedi%26aufirst%3DJ.%2BS.%26aulast%3DReitz%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520potent%252C%2520nonsystemic%2520apical%2520sodium-codependent%2520bile%2520acid%2520transporter%2520inhibitors%2520%2528Part%25201%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D18%26spage%3D5837%26epage%3D5852%26doi%3D10.1021%2Fjm040215%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P. C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoi, M. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G. P. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human equilibrative nucleoside transporters by 4((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-y1)-1,3,5-triazin-2-amine</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>791</i></span>,  <span class="NLM_fpage">544</span>â <span class="NLM_lpage">551</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2016.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.ejphar.2016.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27388143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyrurrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=791&publication_year=2016&pages=544-551&author=P.+C.+T.+Tangauthor=C.+Yangauthor=R.+W.+S.+Liauthor=S.+M.+Y.+Leeauthor=M.+P.+M.+Hoiauthor=S.+W.+Chanauthor=Y.+W.+Kwanauthor=C.+M.+Tseauthor=G.+P.+H.+Leung&title=Inhibition+of+human+equilibrative+nucleoside+transporters+by+4%28%284-%282-fluorophenyl%29piperazin-1-yl%29methyl%29-6-imino-N-%28naphthalen-2-y1%29-1%2C3%2C5-triazin-2-amine&doi=10.1016%2Fj.ejphar.2016.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human equilibrative nucleoside transporters by 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine</span></div><div class="casAuthors">Tang, Philip C. T.; Yang, Cui; Li, Rachel Wai-Sum; Lee, Simon Ming-Yuen; Hoi, Maggie Pui-man; Chan, Shun-Wan; Kwan, Yiu-Wa; Tse, Chung-Ming; Leung, George Pak-Heng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">791</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">544-551</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Equilibrative nucleoside transporters (ENTs) play a crucial role in the transport of nucleoside and nucleoside analogs, which are important for nucleotide synthesis and chemotherapy.  In addn., ENTs regulate extracellular adenosine levels in the vicinity of its receptors and hence influence adenosine-related functions.  The clin. applications of ENT inhibitors in the treatment of cardiovascular diseases and cancer therapy have been explored in numerous studies.  However, all ENT inhibitors to date are selective for ENT1 but not ENT2.  In the present study, we investigated the novel compd. 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) as an inhibitor of ENT1 and ENT2.  Nucleoside transporter-deficient PK15NTD cells stably expressing ENT1 and ENT2 showed that FPMINT inhibited [3H]uridine and [3H]adenosine transport through both ENT1 and ENT2 in a concn.-dependent manner.  The IC50 value of FPMINT for ENT2 was 5-10-fold less than for ENT1, and FPMINT could not be displaced with excess washing.  Kinetic studies revealed that FPMINT reduced Vmax of [3H]uridine transport in ENT1 and ENT2 without affecting KM.  Therefore, we conclude that FPMINT inhibits ENTs in an irreversible and non-competitive manner.  Although already selective for ENT2 over ENT1, further modification of the chem. structure of FPMINT may lead to even better ENT2-selective inhibitors of potential clin., physiol. and pharmacol. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-nWSJEs3jwbVg90H21EOLACvtfcHk0lieIYuymx4E8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyrurrK&md5=e53131e025f9a337b8041befc5808d1e</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2016.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2016.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DP.%2BC.%2BT.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DR.%2BW.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BM.%2BY.%26aulast%3DHoi%26aufirst%3DM.%2BP.%2BM.%26aulast%3DChan%26aufirst%3DS.%2BW.%26aulast%3DKwan%26aufirst%3DY.%2BW.%26aulast%3DTse%26aufirst%3DC.%2BM.%26aulast%3DLeung%26aufirst%3DG.%2BP.%2BH.%26atitle%3DInhibition%2520of%2520human%2520equilibrative%2520nucleoside%2520transporters%2520by%25204%2528%25284-%25282-fluorophenyl%2529piperazin-1-yl%2529methyl%2529-6-imino-N-%2528naphthalen-2-y1%2529-1%252C3%252C5-triazin-2-amine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D791%26spage%3D544%26epage%3D551%26doi%3D10.1016%2Fj.ejphar.2016.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haist, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplita, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmazyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirrane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madwed, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleymanzadeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7114</span>â <span class="NLM_lpage">7140</span>, <span class="refDoi">Â DOI: 10.1021/jm300601d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300601d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7114-7140&issue=16&author=J.+D.+Huberauthor=J.+Bentzienauthor=S.+J.+Boyerauthor=J.+Burkeauthor=S.+De+Lombaertauthor=C.+Eickmeierauthor=X.+Guoauthor=J.+V.+Haistauthor=E.+R.+Hickeyauthor=P.+Kaplitaauthor=M.+Karmazynauthor=R.+Kemperauthor=C.+A.+Kennedyauthor=T.+Kirraneauthor=J.+B.+Madwedauthor=E.+Mainolfiauthor=N.+Nagarajaauthor=F.+Soleymanzadehauthor=A.+Swinamerauthor=A.+B.+Eldrup&title=Identification+of+a+potent+sodium+hydrogen+exchanger+isoform+1+%28NHE1%29+inhibitor+with+a+suitable+profile+for+chronic+dosing+and+demonstrated+cardioprotective+effects+in+a+preclinical+model+of+myocardial+infarction+in+the+rat&doi=10.1021%2Fjm300601d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat</span></div><div class="casAuthors">Huber, John D.; Bentzien, Jorg; Boyer, Stephen J.; Burke, Jennifer; De Lombaert, Stephane; Eickmeier, Christian; Guo, Xin; Haist, James V.; Hickey, Eugene R.; Kaplita, Paul; Karmazyn, Morris; Kemper, Raymond; Kennedy, Charles A.; Kirrane, Thomas; Madwed, Jeffrey B.; Mainolfi, Elizabeth; Nagaraja, Nelamangara; Soleymanzadeh, Fariba; Swinamer, Alan; Eldrup, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7114-7140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation.  During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular processes, leading to myocardial stunning, arrhythmias, and ultimately cell damage and death.  The role of NHE1 in cardiac injury has prompted interest in the development of NHE1 inhibitors for the treatment of heart failure.  This report outlines our efforts to identify a compd. suitable for once daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor sabiporide.  Substitution of a piperidine for the piperazine of sabiporide followed by replacement of the pyrrole moiety and subsequent optimization to improve potency and eliminate off-target activities resulted in the identification of N-[4-(1-acetyl-piperidin-4-yl)-3-trifluoromethylbenzoyl]guanidine (I).  Pharmacol. evaluation of I revealed a remarkable ability to prevent ischemic damage in an ex vivo model of ischemia reperfusion injury in isolated rat hearts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL--7k8Ug8F7Vg90H21EOLACvtfcHk0lieIYuymx4E8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7zJ&md5=bb7ec3a582e03d620e226fb150800cb2</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm300601d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300601d%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DJ.%2BD.%26aulast%3DBentzien%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BJ.%26aulast%3DBurke%26aufirst%3DJ.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DEickmeier%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DHaist%26aufirst%3DJ.%2BV.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DKaplita%26aufirst%3DP.%26aulast%3DKarmazyn%26aufirst%3DM.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26aulast%3DKirrane%26aufirst%3DT.%26aulast%3DMadwed%26aufirst%3DJ.%2BB.%26aulast%3DMainolfi%26aufirst%3DE.%26aulast%3DNagaraja%26aufirst%3DN.%26aulast%3DSoleymanzadeh%26aufirst%3DF.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26atitle%3DIdentification%2520of%2520a%2520potent%2520sodium%2520hydrogen%2520exchanger%2520isoform%25201%2520%2528NHE1%2529%2520inhibitor%2520with%2520a%2520suitable%2520profile%2520for%2520chronic%2520dosing%2520and%2520demonstrated%2520cardioprotective%2520effects%2520in%2520a%2520preclinical%2520model%2520of%2520myocardial%2520infarction%2520in%2520the%2520rat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D16%26spage%3D7114%26epage%3D7140%26doi%3D10.1021%2Fjm300601d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruggiero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmstrand, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ennis, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">767</span>â <span class="NLM_lpage">781</span>, <span class="refDoi">Â DOI: 10.1021/cn3000718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn3000718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=767-781&issue=10&author=A.+M.+Ruggieroauthor=J.+Wrightauthor=S.+M.+Fergusonauthor=M.+Lewisauthor=K.+S.+Emersonauthor=H.+Iwamotoauthor=M.+T.+Ivyauthor=E.+C.+Holmstrandauthor=E.+A.+Ennisauthor=C.+D.+Weaverauthor=R.+D.+Blakely&title=Nonoisotopic+assay+for+the+presynaptic+choline+transporter+reveals+capacity+for+allosteric+modulation+of+choline+uptake&doi=10.1021%2Fcn3000718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Nonoisotopic Assay for the Presynaptic Choline Transporter Reveals Capacity for Allosteric Modulation of Choline Uptake</span></div><div class="casAuthors">Ruggiero, Alicia M.; Wright, Jane; Ferguson, Shawn M.; Lewis, Michelle; Emerson, Katie S.; Iwamoto, Hideki; Ivy, Michael T.; Holmstrand, Ericka C.; Ennis, Elizabeth. A.; Weaver, C. David; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">767-781</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Current therapies to enhance CNS cholinergic function rely primarily on extracellular acetylcholinesterase (AChE) inhibition, a pharmacotherapeutic strategy that produces dose-limiting side effects.  The Na+-dependent, high-affinity choline transporter (CHT) is an unexplored target for cholinergic medication development.  Although functional at the plasma membrane, CHT at steady-state is localized to synaptic vesicles such that vesicular fusion can support a biosynthetic response to neuronal excitation.  To identify allosteric potentiators of CHT activity, the authors mapped endocytic sequences in the C-terminus of human CHT, identifying transporter mutants that exhibit significantly increased transport function.  A stable HEK-293 cell line was generated from one of these mutants (CHT LV-AA) and used to establish a high-throughput screen (HTS) compatible assay based on the electrogenic nature of the transporter.  The authors established that the addn. of choline to these cells, at concns. appropriate for high-affinity choline transport at presynaptic terminals, generates a hemicholinium-3 (HC-3)-sensitive, membrane depolarization that can be used for the screening of CHT inhibitors and activators.  Using this assay, the authors discovered that staurosporine increased CHT LV-AA choline uptake activity, an effect mediated by a decrease in choline Km with no change in Vmax.  As staurosporine did not change surface levels of CHT, nor inhibit HC-3 binding, the authors propose that its action is directly or indirectly allosteric in nature.  Surprisingly, staurosporine reduced choline-induced membrane depolarization, suggesting that increased substrate coupling to ion gradients, arising at the expense of nonstoichiometric ion flow, accompanies a shift of CHT to a higher-affinity state.  The authors' findings provide a new approach for the identification of CHT modulators that is compatible with high-throughput screening approaches and presents a novel model by which small mols. can enhance substrate flux through enhanced gradient coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELuyUK7m6sbVg90H21EOLACvtfcHk0lieIYuymx4E8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKltb8%253D&md5=4f8022c6b7b76e2aed0a9b71e597f462</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fcn3000718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn3000718%26sid%3Dliteratum%253Aachs%26aulast%3DRuggiero%26aufirst%3DA.%2BM.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DS.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DEmerson%26aufirst%3DK.%2BS.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DIvy%26aufirst%3DM.%2BT.%26aulast%3DHolmstrand%26aufirst%3DE.%2BC.%26aulast%3DEnnis%26aufirst%3DE.%2BA.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3DNonoisotopic%2520assay%2520for%2520the%2520presynaptic%2520choline%2520transporter%2520reveals%2520capacity%2520for%2520allosteric%2520modulation%2520of%2520choline%2520uptake%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26issue%3D10%26spage%3D767%26epage%3D781%26doi%3D10.1021%2Fcn3000718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sindelar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanner, K. T.</span></span> <span> </span><span class="NLM_article-title">Library screening by means of mass spectrometry (MS) binding assays-exemplarily demonstrated for a pseudostatic library addressing gamma-aminobutyric acid (GABA) transporter 1 (GAT1)</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1678</span>â <span class="NLM_lpage">1690</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201200201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201200201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22689508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Khu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1678-1690&issue=9&author=M.+Sindelarauthor=K.+T.+Wanner&title=Library+screening+by+means+of+mass+spectrometry+%28MS%29+binding+assays-exemplarily+demonstrated+for+a+pseudostatic+library+addressing+gamma-aminobutyric+acid+%28GABA%29+transporter+1+%28GAT1%29&doi=10.1002%2Fcmdc.201200201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Library Screening by Means of Mass Spectrometry (MS) Binding Assays-Exemplarily Demonstrated for a Pseudostatic Library Addressing Î³-Aminobutyric Acid (GABA) Transporter 1 (GAT1)</span></div><div class="casAuthors">Sindelar, Miriam; Wanner, Klaus T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1678-1690, S1678/1-S1678/7</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In the present study, the application of mass spectrometry (MS) binding assays as a tool for library screening is reported.  For library generation, dynamic combinatorial chem. (DCC) was used.  These libraries can be screened by MS binding assays when appropriate measures are taken to render the libraries pseudostatic.  That way, the efficiency of MS binding assays to det. ligand binding in compd. screening with the ease of library generation by DCC is combined.  The feasibility of this approach is shown for Î³-aminobutyric acid (GABA) transporter 1 (GAT1) as a target, representing the most important subtype of the GABA transporters.  For the screening, hydrazone libraries were employed that were generated in the presence of the target by reacting various sets of aldehydes with a hydrazine deriv. that is delineated from piperidine-3-carboxylic acid (nipecotic acid), a common fragment of known GAT1 inhibitors.  To ensure that the library generated is pseudostatic, a large excess of the nipecotic acid deriv. is employed.  As the library is generated in a buffer system suitable for binding and the target is already present, the mixts. can be directly analyzed by MS binding assays-the process of library generation and screening thus becoming simple to perform.  The binding affinities of the hits identified by deconvolution were confirmed in conventional competitive MS binding assays performed with single compds. obtained by sep. synthesis.  In this way, two nipecotic acid derivs. exhibiting a biaryl moiety, 1-{2-[2'-(1,1'-biphenyl-2-ylmethylidene)hydrazine]ethyl}piperidine-3-carboxylic acid and 1-(2-{2'-[1-(2-thiophenylphenyl)methylidene]hydrazine}ethyl)piperidine-3-carboxylic acid, were potent GAT1 ligands exhibiting pKi values of 6.186Â±0.028 and 6.229Â±0.039, resp.  This method enables screening of libraries, whether generated by conventional chem. or DCC, and is applicable to all kinds of targets including membrane-bound targets such as G protein coupled receptors (GPCRs), ion channels and transporters.  As such, this strategy displays high potential in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSKnSrfzoNbVg90H21EOLACvtfcHk0lhm5M52dVhC1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Khu7c%253D&md5=98216d9b84dca9be3dd0b34fe4602461</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200201%26sid%3Dliteratum%253Aachs%26aulast%3DSindelar%26aufirst%3DM.%26aulast%3DWanner%26aufirst%3DK.%2BT.%26atitle%3DLibrary%2520screening%2520by%2520means%2520of%2520mass%2520spectrometry%2520%2528MS%2529%2520binding%2520assays-exemplarily%2520demonstrated%2520for%2520a%2520pseudostatic%2520library%2520addressing%2520gamma-aminobutyric%2520acid%2520%2528GABA%2529%2520transporter%25201%2520%2528GAT1%2529%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D9%26spage%3D1678%26epage%3D1690%26doi%3D10.1002%2Fcmdc.201200201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narvaiza, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Ligand and target discovery by fragment-based screening in human cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">527</span>â <span class="NLM_lpage">541</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2016.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28111073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=527-541&issue=3&author=C.+G.+Parkerauthor=A.+Galmozziauthor=Y.+J.+Wangauthor=B.+E.+Correiaauthor=K.+Sasakiauthor=C.+M.+Joslynauthor=A.+S.+Kimauthor=C.+L.+Cavallaroauthor=R.+M.+Lawrenceauthor=S.+R.+Johnsonauthor=I.+Narvaizaauthor=E.+Saezauthor=B.+F.+Cravatt&title=Ligand+and+target+discovery+by+fragment-based+screening+in+human+cells&doi=10.1016%2Fj.cell.2016.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand and Target Discovery by Fragment-Based Screening in Human Cells</span></div><div class="casAuthors">Parker, Christopher G.; Galmozzi, Andrea; Wang, Yujia; Correia, Bruno E.; Sasaki, Kenji; Joslyn, Christopher M.; Kim, Arthur S.; Cavallaro, Cullen L.; Lawrence, R. Michael; Johnson, Stephen R.; Narvaiza, Inigo; Saez, Enrique; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-541.e29</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in the synthesis and screening of small-mol. libraries have accelerated the discovery of chem. probes for studying biol. processes.  Still, only a small fraction of the human proteome has chem. ligands.  Here, we describe a platform that marries fragment-based ligand discovery with quant. chem. proteomics to map thousands of reversible small mol.-protein interactions directly in human cells, many of which can be site-specifically detd.  We show that fragment hits can be advanced to furnish selective ligands that affect the activity of proteins heretofore lacking chem. probes.  We further combine fragment-based chem. proteomics with phenotypic screening to identify small mols. that promote adipocyte differentiation by engaging the poorly characterized membrane protein PGRMC2.  Fragment-based screening in human cells thus provides an extensive proteome-wide map of protein ligandability and facilitates the coordinated discovery of bioactive small mols. and their mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPk-YJwFlDwbVg90H21EOLACvtfcHk0lhm5M52dVhC1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D&md5=835264291015037ab9b7e446992caba3</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DCorreia%26aufirst%3DB.%2BE.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DJoslyn%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DCavallaro%26aufirst%3DC.%2BL.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DNarvaiza%26aufirst%3DI.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DLigand%2520and%2520target%2520discovery%2520by%2520fragment-based%2520screening%2520in%2520human%2520cells%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D3%26spage%3D527%26epage%3D541%26doi%3D10.1016%2Fj.cell.2016.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttruff, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrall, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josyln, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norremark, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunstl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Chemical proteomics identifies SLC25A20 as a functional target of the ingenol class of actinic keratosis drugs</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1276</span>â <span class="NLM_lpage">1285</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.7b00420</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00420" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWnsrfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1276-1285&issue=12&author=C.+G.+Parkerauthor=C.+A.+Kuttruffauthor=A.+Galmozziauthor=L.+Jorgensenauthor=C.+H.+Yehauthor=D.+J.+Hermansonauthor=Y.+J.+Wangauthor=M.+Artolaauthor=S.+J.+McKerrallauthor=C.+M.+Josylnauthor=B.+Norremarkauthor=G.+Dunstlauthor=J.+Feldingauthor=E.+Saezauthor=P.+S.+Baranauthor=B.+F.+Cravatt&title=Chemical+proteomics+identifies+SLC25A20+as+a+functional+target+of+the+ingenol+class+of+actinic+keratosis+drugs&doi=10.1021%2Facscentsci.7b00420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs</span></div><div class="casAuthors">Parker, Christopher G.; Kuttruff, Christian A.; Galmozzi, Andrea; Joergensen, Lars; Yeh, Chien-Hung; Hermanson, Daniel J.; Wang, Yujia; Artola, Marta; McKerrall, Steven J.; Josyln, Christopher M.; Noerremark, Bjarne; Dunstl, Georg; Felding, Jakob; Saez, Enrique; Baran, Phil S.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1276-1285</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The diterpenoid ester ingenol mebutate (IngMeb) is the active ingredient in the topical drug Picato, a first-in-class treatment for the precancerous skin condition actinic keratosis.  IngMeb is proposed to exert its therapeutic effects through a dual mode of action involving (i) induction of cell death that is assocd. with mitochondrial dysfunction followed by (ii) stimulation of a local inflammatory response, at least partially driven by protein kinase C (PKC) activation.  Although this therapeutic model has been well characterized, the complete set of mol. targets responsible for mediating IngMeb activity remains ill-defined.  Here, the authors have synthesized a photoreactive, clickable analog of IngMeb and used this probe in quant. proteomic expts. to map several protein targets of IngMeb in human cancer cell lines and primary human keratinocytes.  Prominent among these targets was the mitochondrial carnitine-acylcarnitine translocase SLC25A20, which the authors proceed to show is inhibited in cells by IngMeb and the more stable analog ingenol disoxate (IngDsx), but not by the canonical PKC agonist 12-O-tetradecanoylphorbal-13-acetate (TPA).  SLC25A20 blockade by IngMeb and IngDsx leads to a buildup of cellular acylcarnitines and blockade of fatty acid oxidn. (FAO), pointing to a possible mechanism for IngMeb-mediated perturbations in mitochondrial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvBH7tPLoN-bVg90H21EOLACvtfcHk0lhm5M52dVhC1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWnsrfM&md5=af15c86bf1f8ac2de2bfded316e58ad3</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00420%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DKuttruff%26aufirst%3DC.%2BA.%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DJorgensen%26aufirst%3DL.%26aulast%3DYeh%26aufirst%3DC.%2BH.%26aulast%3DHermanson%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DArtola%26aufirst%3DM.%26aulast%3DMcKerrall%26aufirst%3DS.%2BJ.%26aulast%3DJosyln%26aufirst%3DC.%2BM.%26aulast%3DNorremark%26aufirst%3DB.%26aulast%3DDunstl%26aufirst%3DG.%26aulast%3DFelding%26aufirst%3DJ.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DChemical%2520proteomics%2520identifies%2520SLC25A20%2520as%2520a%2520functional%2520target%2520of%2520the%2520ingenol%2520class%2520of%2520actinic%2520keratosis%2520drugs%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26issue%3D12%26spage%3D1276%26epage%3D1285%26doi%3D10.1021%2Facscentsci.7b00420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovega, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Tracking cancer drugs in living cells by thermal profiling of the proteome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">6205</span>),  <span class="NLM_fpage">1255784</span>, <span class="refDoi">Â DOI: 10.1126/science.1255784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1255784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25278616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1255784&issue=6205&author=M.+M.+Savitskiauthor=F.+B.+M.+Reinhardauthor=H.+Frankenauthor=T.+Wernerauthor=M.+F.+Savitskiauthor=D.+Eberhardauthor=D.+M.+Molinaauthor=R.+Jafariauthor=R.+B.+Dovegaauthor=S.+Klaegerauthor=B.+Kusterauthor=P.+Nordlundauthor=M.+Bantscheffauthor=G.+Drewes&title=Tracking+cancer+drugs+in+living+cells+by+thermal+profiling+of+the+proteome&doi=10.1126%2Fscience.1255784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Tracking cancer drugs in living cells by thermal profiling of the proteome</span></div><div class="casAuthors">Savitski Mikhail M; Reinhard Friedrich B M; Franken Holger; Werner Thilo; Savitski Maria Falth; Eberhard Dirk; Bantscheff Marcus; Drewes Gerard; Martinez Molina Daniel; Jafari Rozbeh; Dovega Rebecca Bakszt; Klaeger Susan; Kuster Bernhard; Nordlund Par</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">6205</span>),
    <span class="NLM_cas:pages">1255784</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The thermal stability of proteins can be used to assess ligand binding in living cells.  We have generalized this concept by determining the thermal profiles of more than 7000 proteins in human cells by means of mass spectrometry.  Monitoring the effects of small-molecule ligands on the profiles delineated more than 50 targets for the kinase inhibitor staurosporine.  We identified the heme biosynthesis enzyme ferrochelatase as a target of kinase inhibitors and suggest that its inhibition causes the phototoxicity observed with vemurafenib and alectinib.  Thermal shifts were also observed for downstream effectors of drug treatment.  In live cells, dasatinib induced shifts in BCR-ABL pathway proteins, including CRK/CRKL.  Thermal proteome profiling provides an unbiased measure of drug-target engagement and facilitates identification of markers for drug efficacy and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0ur3d8ba-Bu2mnZh2OgS0fW6udTcc2eZB0wzs-CQ3Gbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D&md5=493a89ad107e656e0f0786ff5c8e5f63</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1126%2Fscience.1255784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1255784%26sid%3Dliteratum%253Aachs%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DSavitski%26aufirst%3DM.%2BF.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DDovega%26aufirst%3DR.%2BB.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DTracking%2520cancer%2520drugs%2520in%2520living%2520cells%2520by%2520thermal%2520profiling%2520of%2520the%2520proteome%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6205%26spage%3D1255784%26doi%3D10.1126%2Fscience.1255784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olek, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colinge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1055</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1038/nmeth.3590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnmeth.3590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26389571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFersL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1055-1057&issue=11&author=K.+V.+M.+Huberauthor=K.+M.+Olekauthor=A.+C.+Mullerauthor=C.+S.+H.+Tanauthor=K.+L.+Bennettauthor=J.+Colingeauthor=G.+Superti-Furga&title=Proteome-wide+drug+and+metabolite+interaction+mapping+by+thermal-stability+profiling&doi=10.1038%2Fnmeth.3590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling</span></div><div class="casAuthors">Huber, Kilian V. M.; Olek, Karin M.; Mueller, Andre C.; Tan, Chris Soon Heng; Bennett, Keiryn L.; Colinge, Jacques; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1055-1057</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal stabilization of proteins after ligand binding provides an efficient means to assess the binding of small mols. to proteins.  We show here that in combination with quant. mass spectrometry, the approach allows for the systematic survey of protein engagement by cellular metabolites and drugs.  We profiled the targets of the drugs methotrexate and (S)-crizotinib and the metabolite 2'3'-cGAMP in intact cells and identified the 2'3'-cGAMP cognate transmembrane receptor STING, involved in immune signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrow66ugdg1oLVg90H21EOLACvtfcHk0ljzK-620rGsLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFersL%252FI&md5=619a2c08c4f151f4e3ab8bd8fc45c2b6</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3590%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DOlek%26aufirst%3DK.%2BM.%26aulast%3DMuller%26aufirst%3DA.%2BC.%26aulast%3DTan%26aufirst%3DC.%2BS.%2BH.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DProteome-wide%2520drug%2520and%2520metabolite%2520interaction%2520mapping%2520by%2520thermal-stability%2520profiling%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26issue%3D11%26spage%3D1055%26epage%3D1057%26doi%3D10.1038%2Fnmeth.3590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Detection of chemical engagement of solute carrier proteins by a cellular thermal shift assay</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1480</span>â <span class="NLM_lpage">1486</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.8b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCksrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1480-1486&issue=6&author=M.+Hashimotoauthor=E.+Girardiauthor=R.+Eichnerauthor=G.+Superti-Furga&title=Detection+of+chemical+engagement+of+solute+carrier+proteins+by+a+cellular+thermal+shift+assay&doi=10.1021%2Facschembio.8b00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of Chemical Engagement of Solute Carrier Proteins by a Cellular Thermal Shift Assay</span></div><div class="casAuthors">Hashimoto, Mari; Girardi, Enrico; Eichner, Ruth; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1480-1486</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Solute carriers (SLCs) are transmembrane proteins that transport various nutrients, metabolites, and drugs across cellular membranes.  Despite the relevance of SLCs to cell homeostasis, metab., and disease states, for the majority of SLCs the authors lack exptl. evidence regarding the nature of the cognate ligands, whether endobiotic or xenobiotic.  Moreover, even for the roughly 20 SLCs for which inhibitors have been characterized, engagement assays in cells are limited to the accessibility of radiolabeled or fluorescent probes.  The cellular thermal shift assay (CETSA) has been introduced as a powerful method to assess target engagement by monitoring ligand-induced changes in the thermal stability of cellular proteins.  The authors addressed the question of whether CETSA could be modified to become routinely applicable to membrane transporters such as SLCs.  The authors used SLC16A1 (MCT1) and SLC1A2 (EAAT2) as targets to establish robust conditions by which chem. engagement of SLCs can be detected.  Using immunoblotting, the authors demonstrate that treatment with the SLC16A1 inhibitors AZD3965 and AR-C155858 stabilized endogenous SLC16A1 in HEK293 cell lysates as well as intact cells.  In addn., the high-affinity ligand of SLC16A1, L-lactate, and the low-affinity ligand, formate, resulted in strong and weak stabilization of SLC16A1, resp.  Moreover, the authors obsd. stabilization of SLC1A2 upon treatment with the selective inhibitor WAY-213613.  The authors propose that the exptl. approach presented here should be generally and easily applicable for monitoring the engagement of chem. ligands by SLCs in cellular settings and thus assisting in their deorphanization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEpqIcKteWbVg90H21EOLACvtfcHk0ljzK-620rGsLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCksrjP&md5=06a1a4f91a1ffa3de49b59ce6f95fb1c</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00270%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DM.%26aulast%3DGirardi%26aufirst%3DE.%26aulast%3DEichner%26aufirst%3DR.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DDetection%2520of%2520chemical%2520engagement%2520of%2520solute%2520carrier%2520proteins%2520by%2520a%2520cellular%2520thermal%2520shift%2520assay%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D1480%26epage%3D1486%26doi%3D10.1021%2Facschembio.8b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Earl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Ezetimibe</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1038/nrd1015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd1015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12572539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot12ltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=97-98&issue=2&author=J.+Earlauthor=P.+Kirkpatrick&title=Ezetimibe&doi=10.1038%2Fnrd1015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Fresh from the pipeline: Ezetimibe</span></div><div class="casAuthors">Earl, John; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-98</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ezetimibe (Zetia), the first in a new class of agents that inhibit cholesterol absorption in the intestine, was approved by the FDA in Oct. 2002 for the redn. of cholesterol levels in patients with hypercholesterolemia.  What impact is it likely to have on the multi-billion-dollar market for cholesterol-lowering drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon7pUdtXVW1bVg90H21EOLACvtfcHk0lgEsL05rM13GQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot12ltQ%253D%253D&md5=39ef80f0d152e413fcfb579adcdced41</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnrd1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1015%26sid%3Dliteratum%253Aachs%26aulast%3DEarl%26aufirst%3DJ.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DEzetimibe%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26issue%3D2%26spage%3D97%26epage%3D98%26doi%3D10.1038%2Fnrd1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golovko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgolo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, M. P.</span></span> <span> </span><span class="NLM_article-title">Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>303</i></span> (<span class="NLM_issue">5661</span>),  <span class="NLM_fpage">1201</span>â <span class="NLM_lpage">1204</span>, <span class="refDoi">Â DOI: 10.1126/science.1093131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1093131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=14976318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVWgtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2004&pages=1201-1204&issue=5661&author=S.+W.+Altmannauthor=H.+R.+Davisauthor=L.+J.+Zhuauthor=X.+R.+Yaoauthor=L.+M.+Hoosauthor=G.+Tetzloffauthor=S.+P.+N.+Iyerauthor=M.+Maguireauthor=A.+Golovkoauthor=M.+Zengauthor=L.+Q.+Wangauthor=N.+Murgoloauthor=M.+P.+Graziano&title=Niemann-Pick+C1+like+1+protein+is+critical+for+intestinal+cholesterol+absorption&doi=10.1126%2Fscience.1093131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption</span></div><div class="casAuthors">Altmann, Scott W.; Davis, Harry R., Jr.; Zhu, Li-ji; Yao, Xiaorui; Hoos, Lizbeth M.; Tetzloff, Glen; Iyer, Sai Prasad N.; Maguire, Maureen; Golovko, Andrei; Zeng, Ming; Wang, Luquan; Murgolo, Nicholas; Graziano, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">5661</span>),
    <span class="NLM_cas:pages">1201-1204</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dietary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol levels, a risk factor for coronary heart disease.  The mol. mechanism of sterol uptake from the lumen of the small intestine is poorly defined.  We show that Niemann-Pick C1 Like 1 (NPC1L1) protein plays a crit. role in the absorption of intestinal cholesterol.  NPC1L1 expression is enriched in the small intestine and is in the brush border membrane of enterocytes.  Although otherwise phenotypically normal, NPC1L1-deficient mice exhibit a substantial redn. in absorbed cholesterol, which is unaffected by dietary supplementation of bile acids.  Ezetimibe, a drug that inhibits cholesterol absorption, had no effect in NPC1L1 knockout mice, suggesting that NPC1L1 resides in an ezetimibe-sensitive pathway responsible for intestinal cholesterol absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk89QuURahR7Vg90H21EOLACvtfcHk0lgEsL05rM13GQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVWgtbc%253D&md5=d845c6a42d62bd3e9bcb783612c043f0</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1126%2Fscience.1093131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1093131%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DS.%2BW.%26aulast%3DDavis%26aufirst%3DH.%2BR.%26aulast%3DZhu%26aufirst%3DL.%2BJ.%26aulast%3DYao%26aufirst%3DX.%2BR.%26aulast%3DHoos%26aufirst%3DL.%2BM.%26aulast%3DTetzloff%26aufirst%3DG.%26aulast%3DIyer%26aufirst%3DS.%2BP.%2BN.%26aulast%3DMaguire%26aufirst%3DM.%26aulast%3DGolovko%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%2BQ.%26aulast%3DMurgolo%26aufirst%3DN.%26aulast%3DGraziano%26aufirst%3DM.%2BP.%26atitle%3DNiemann-Pick%2520C1%2520like%25201%2520protein%2520is%2520critical%2520for%2520intestinal%2520cholesterol%2520absorption%26jtitle%3DScience%26date%3D2004%26volume%3D303%26issue%3D5661%26spage%3D1201%26epage%3D1204%26doi%3D10.1126%2Fscience.1093131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B. L.</span></span> <span> </span><span class="NLM_article-title">The clathrin adaptor proteins ARH, Dab2, and Numb play distinct roles in Niemann-Pick C1-Like 1 versus low density lipoprotein receptor-mediated cholesterol uptake</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">33689</span>â <span class="NLM_lpage">33700</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.593764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M114.593764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25331956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=33689-33700&issue=48&author=J.+Weiauthor=Z.+Y.+Fuauthor=P.+S.+Liauthor=H.+H.+Miaoauthor=B.+L.+Liauthor=Y.+T.+Maauthor=B.+L.+Song&title=The+clathrin+adaptor+proteins+ARH%2C+Dab2%2C+and+Numb+play+distinct+roles+in+Niemann-Pick+C1-Like+1+versus+low+density+lipoprotein+receptor-mediated+cholesterol+uptake&doi=10.1074%2Fjbc.M114.593764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">The Clathrin Adaptor Proteins ARH, Dab2, and Numb Play Distinct Roles in Niemann-Pick C1-Like 1 Versus Low Density Lipoprotein Receptor-mediated Cholesterol Uptake</span></div><div class="casAuthors">Wei, Jian; Fu, Zhen-Yan; Li, Pei-Shan; Miao, Hong-Hua; Li, Bo-Liang; Ma, Yi-Tong; Song, Bao-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">33689-33700</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The uptake of circulating low d. lipoproteins (LDL) is mediated by LDL receptor (LDLR) through clathrin-dependent endocytosis.  At the early stage of this process, adaptor proteins ARH and Dab2 specifically bind the endocytic signal motif in LDLR and recruit clathrin/AP2 to initiate internalization.  On the other hand, intestinal cholesterol is absorbed by Niemann-Pick C1-Like 1 (NPC1L1) through clathrin-dependent endocytosis.  Another adaptor protein, Numb recognizes the endocytic motif in NPC1L1 C terminus and couples NPC1L1 to endocytic machinery.  The ARH, Dab2, and Numb proteins contain a homogeneous phosphotyrosine binding (PTB) domain that directly binds endocytic motifs.  Because ARH, Dab2, and Numb are all PTB domain family members, the emerging mystery is whether these adaptors act complementally in LDLR and NPC1L1 endocytosis.  Here, we found that ARH and Dab2 did not bind NPC1L1 and were not required for NPC1L1 internalization.  Similarly, Numb lacked the ability to interact with the LDLR C terminus and was dispensable for LDL uptake.  Only the Numb isoforms with shorter PTB domain could facilitate NPC1L1 endocytosis.  Besides the reported function in intestinal cholesterol absorption, Numb also mediated cholesterol reabsorption from bile in liver.  We further identified a Numb variant with G595D substitution in humans of low blood LDL-cholesterol.  The G595D substitution impaired NPC1L1 internalization and cholesterol reabsorption, due to attenuating affinity of Numb to clathrin/AP2.  These results demonstrate that Numb specifically regulates NPC1L1-mediated cholesterol absorption both in human intestine and liver, distinct from ARH and Dab2, which selectively participate in LDLR-mediated LDL uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMiWfmDyFEG7Vg90H21EOLACvtfcHk0lgEsL05rM13GQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsbnN&md5=bd0b283b3a495568add306eebfcb813a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.593764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.593764%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DP.%2BS.%26aulast%3DMiao%26aufirst%3DH.%2BH.%26aulast%3DLi%26aufirst%3DB.%2BL.%26aulast%3DMa%26aufirst%3DY.%2BT.%26aulast%3DSong%26aufirst%3DB.%2BL.%26atitle%3DThe%2520clathrin%2520adaptor%2520proteins%2520ARH%252C%2520Dab2%252C%2520and%2520Numb%2520play%2520distinct%2520roles%2520in%2520Niemann-Pick%2520C1-Like%25201%2520versus%2520low%2520density%2520lipoprotein%2520receptor-mediated%2520cholesterol%2520uptake%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D48%26spage%3D33689%26epage%3D33700%26doi%3D10.1074%2Fjbc.M114.593764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Irizarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span> <span> </span><span class="NLM_article-title">Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>306</i></span> (<span class="NLM_issue">5694</span>),  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1126/science.1102160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1102160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15472075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFWnsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2004&pages=269-271&issue=5694&author=A.+P.+Wengauthor=A.+A.+Ferrandoauthor=W.+Leeauthor=J.+P.+Morrisauthor=L.+B.+Silvermanauthor=C.+Sanchez-Irizarryauthor=S.+C.+Blacklowauthor=A.+T.+Lookauthor=J.+C.+Aster&title=Activating+mutations+of+NOTCH1+in+human+T+cell+acute+lymphoblastic+leukemia&doi=10.1126%2Fscience.1102160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia</span></div><div class="casAuthors">Weng, Andrew P.; Ferrando, Adolfo A.; Lee, Woojoong; Morris, John P., IV; Silverman, Lewis B.; Sanchez-Irizarry, Cheryll; Blacklow, Stephen C.; Look, A. Thomas; Aster, Jon C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">5694</span>),
    <span class="NLM_cas:pages">269-271</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Very rare cases of human T cell acute lymphoblastic leukemia (T-ALL) harbor chromosomal translocations that involve NOTCH1, a gene encoding a transmembrane receptor that regulates normal T cell development.  Here, we report that more than 50% of human T-ALLs, including tumors from all major mol. oncogenic subtypes, have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1.  These findings greatly expand the role of activated NOTCH1 in the mol. pathogenesis of human T-ALL and provide a strong rationale for targeted therapies that interfere with NOTCH signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsYJ5knLWfRbVg90H21EOLACvtfcHk0limLDLkP6FEzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFWnsbo%253D&md5=e538239c4757048377f5173543e67639</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1126%2Fscience.1102160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1102160%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DA.%2BP.%26aulast%3DFerrando%26aufirst%3DA.%2BA.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DJ.%2BP.%26aulast%3DSilverman%26aufirst%3DL.%2BB.%26aulast%3DSanchez-Irizarry%26aufirst%3DC.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26atitle%3DActivating%2520mutations%2520of%2520NOTCH1%2520in%2520human%2520T%2520cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DScience%26date%3D2004%26volume%3D306%26issue%3D5694%26spage%3D269%26epage%3D271%26doi%3D10.1126%2Fscience.1102160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llamas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi-Elias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuierer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beibel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigoillot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece-Hoyes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weihofen, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyskiewicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepfner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canham, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boynton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antczak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a ZIP7 inhibitor from a NOTCH pathway screen</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">188</span>, <span class="refDoi">Â DOI: 10.1038/s41589-018-0200-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41589-018-0200-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30643281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFSgu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=179-188&issue=2&author=E.+Nolinauthor=S.+Gansauthor=L.+Llamasauthor=S.+Bandyopadhyayauthor=S.+M.+Brittainauthor=P.+Bernasconi-Eliasauthor=K.+P.+Carterauthor=J.+J.+Loureiroauthor=J.+R.+Thomasauthor=M.+Schirleauthor=Y.+Yangauthor=N.+Guoauthor=G.+Romaauthor=S.+Schuiererauthor=M.+Beibelauthor=A.+Lindemanauthor=F.+Sigoillotauthor=A.+Chenauthor=K.+X.+Xieauthor=S.+Hoauthor=J.+Reece-Hoyesauthor=W.+A.+Weihofenauthor=K.+Tyskiewiczauthor=D.+Hoepfnerauthor=R.+I.+McDonaldauthor=N.+Guthrieauthor=A.+Dograauthor=H.+B.+Guoauthor=J.+Shaoauthor=J.+Dingauthor=S.+M.+Canhamauthor=G.+Boyntonauthor=E.+L.+Georgeauthor=Z.+B.+Kangauthor=C.+Antczakauthor=J.+A.+Porterauthor=O.+Wallaceauthor=J.+A.+Tallaricoauthor=A.+E.+Palmerauthor=J.+L.+Jenkinsauthor=R.+K.+Jainauthor=S.+M.+Bushellauthor=C.+Fryer&title=Discovery+of+a+ZIP7+inhibitor+from+a+NOTCH+pathway+screen&doi=10.1038%2Fs41589-018-0200-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a ZIP7 inhibitor from a Notch pathway screen</span></div><div class="casAuthors">Nolin, Erin; Gans, Sara; Llamas, Luis; Bandyopadhyay, Somnath; Brittain, Scott M.; Bernasconi-Elias, Paula; Carter, Kyle P.; Loureiro, Joseph J.; Thomas, Jason R.; Schirle, Markus; Yang, Yi; Guo, Ning; Roma, Guglielmo; Schuierer, Sven; Beibel, Martin; Lindeman, Alicia; Sigoillot, Frederic; Chen, Amy; Xie, Kevin X.; Ho, Samuel; Reece-Hoyes, John; Weihofen, Wilhelm A.; Tyskiewicz, Kayla; Hoepfner, Dominic; McDonald, Richard I.; Guthrie, Nicolette; Dogra, Abhishek; Guo, Haibing; Shao, Jian; Ding, Jian; Canham, Stephen M.; Boynton, Geoff; George, Elizabeth L.; Kang, Zhao B.; Antczak, Christophe; Porter, Jeffery A.; Wallace, Owen; Tallarico, John A.; Palmer, Amy E.; Jenkins, Jeremy L.; Jain, Rishi K.; Bushell, Simon M.; Fryer, Christy J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The identification of activating mutations in NOTCH1 in 50% of T cell acute lymphoblastic leukemia has generated interest in elucidating how these mutations contribute to oncogenic transformation and in targeting the pathway.  A phenotypic screen identified compds. that interfere with trafficking of Notch and induce apoptosis via an endoplasmic reticulum (ER) stress mechanism.  Target identification approaches revealed a role for SLC39A7 (ZIP7), a zinc transport family member, in governing Notch trafficking and signaling.  Generation and sequencing of a compd.-resistant cell line identified a V430E mutation in ZIP7 that confers transferable resistance to the compd. NVS-ZP7-4.  NVS-ZP7-4 altered zinc in the ER, and an analog of the compd. photoaffinity labeled ZIP7 in cells, suggesting a direct interaction between the compd. and ZIP7.  NVS-ZP7-4 is the first reported chem. tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra24KMO8msebVg90H21EOLACvtfcHk0limLDLkP6FEzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFSgu78%253D&md5=fa168063f96b38f489b69f8418358149</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0200-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0200-7%26sid%3Dliteratum%253Aachs%26aulast%3DNolin%26aufirst%3DE.%26aulast%3DGans%26aufirst%3DS.%26aulast%3DLlamas%26aufirst%3DL.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DBrittain%26aufirst%3DS.%2BM.%26aulast%3DBernasconi-Elias%26aufirst%3DP.%26aulast%3DCarter%26aufirst%3DK.%2BP.%26aulast%3DLoureiro%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DN.%26aulast%3DRoma%26aufirst%3DG.%26aulast%3DSchuierer%26aufirst%3DS.%26aulast%3DBeibel%26aufirst%3DM.%26aulast%3DLindeman%26aufirst%3DA.%26aulast%3DSigoillot%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DXie%26aufirst%3DK.%2BX.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DReece-Hoyes%26aufirst%3DJ.%26aulast%3DWeihofen%26aufirst%3DW.%2BA.%26aulast%3DTyskiewicz%26aufirst%3DK.%26aulast%3DHoepfner%26aufirst%3DD.%26aulast%3DMcDonald%26aufirst%3DR.%2BI.%26aulast%3DGuthrie%26aufirst%3DN.%26aulast%3DDogra%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%2BB.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DCanham%26aufirst%3DS.%2BM.%26aulast%3DBoynton%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DE.%2BL.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DAntczak%26aufirst%3DC.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DTallarico%26aufirst%3DJ.%2BA.%26aulast%3DPalmer%26aufirst%3DA.%2BE.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DBushell%26aufirst%3DS.%2BM.%26aulast%3DFryer%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520ZIP7%2520inhibitor%2520from%2520a%2520NOTCH%2520pathway%2520screen%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26issue%3D2%26spage%3D179%26epage%3D188%26doi%3D10.1038%2Fs41589-018-0200-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garibsingh, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges in rational drug design for SLCs</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">790</span>â <span class="NLM_lpage">800</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2019.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tips.2019.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31519459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12rt7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=790-800&issue=10&author=R.+A.+Garibsinghauthor=A.+Schlessinger&title=Advances+and+challenges+in+rational+drug+design+for+SLCs&doi=10.1016%2Fj.tips.2019.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and Challenges in Rational Drug Design for SLCs</span></div><div class="casAuthors">Garibsingh, Rachel-Ann A.; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-800</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  There are over 420 human solute carrier (SLC) transporters from 65 families that are expressed ubiquitously in the body.  The SLCs mediate the movement of ions, drugs, and metabolites across membranes and their dysfunction has been assocd. with a variety of diseases, such as diabetes, cancer, and central nervous system (CNS) disorders.  Thus, SLCs are emerging as important targets for therapeutic intervention.  Recent technol. advances in exptl. and computational biol. allow better characterization of SLC pharmacol.  Here we describe recent approaches to modulate SLC transporter function, with an emphasis on the use of computational approaches and computer-aided drug design (CADD) to study nutrient transporters.  Finally, we discuss future perspectives in the rational design of SLC drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYk4nUrMsR7Vg90H21EOLACvtfcHk0lhlICzbhEsO4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12rt7vK&md5=419fe074bf6001b78a0d111505ee2446</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DGaribsingh%26aufirst%3DR.%2BA.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DAdvances%2520and%2520challenges%2520in%2520rational%2520drug%2520design%2520for%2520SLCs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26issue%3D10%26spage%3D790%26epage%3D800%26doi%3D10.1016%2Fj.tips.2019.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahlke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">116</span>â <span class="NLM_lpage">123</span>, <span class="refDoi">Â DOI: 10.1016/j.coph.2014.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.coph.2014.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25466154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCktbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=116-123&author=A.+A.+Jensenauthor=C.+Fahlkeauthor=W.+E.+Bjorn-Yoshimotoauthor=L.+Bunch&title=Excitatory+amino+acid+transporters%3A+recent+insights+into+molecular+mechanisms%2C+novel+modes+of+modulation+and+new+therapeutic+possibilities&doi=10.1016%2Fj.coph.2014.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities</span></div><div class="casAuthors">Jensen, Anders A.; Fahlke, Christoph; Bjoern-Yoshimoto, Walden E.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-123</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The five excitatory amino acid transporters (EAAT1-5) mediating the synaptic uptake of the major excitatory neurotransmitter glutamate are differently expressed throughout the CNS and at the synaptic level.  Although EAATs are crucial for normal excitatory neurotransmission, explorations into the physiol. functions mediated by the different transporter subtypes and their resp. therapeutic potential have so far been sparse, in no small part due to the limited selection of pharmacol. tools available.  In the present update, we outline important new insights into the mol. compns. of EAATs and their intricate transport process, the novel approaches to pharmacol. modulation of the transporters that have emerged, and interesting new perspectives in EAAT as drug targets proposed in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHCPIMplW6KLVg90H21EOLACvtfcHk0lhlICzbhEsO4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCktbvF&md5=4619d6aebdc64cfd77a44bae4379eb53</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2014.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2014.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DFahlke%26aufirst%3DC.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DExcitatory%2520amino%2520acid%2520transporters%253A%2520recent%2520insights%2520into%2520molecular%2520mechanisms%252C%2520novel%2520modes%2520of%2520modulation%2520and%2520new%2520therapeutic%2520possibilities%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D20%26spage%3D116%26epage%3D123%26doi%3D10.1016%2Fj.coph.2014.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yumoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeri, Y.</span></span> <span> </span><span class="NLM_article-title">Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1008</span>â <span class="NLM_lpage">1015</span>, <span class="refDoi">Â DOI: 10.1124/mol.65.4.1008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fmol.65.4.1008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15044631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFaltbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2004&pages=1008-1015&issue=4&author=K.+Shimamotoauthor=R.+Sakaiauthor=K.+Takaokaauthor=N.+Yumotoauthor=T.+Nakajimaauthor=S.+G.+Amaraauthor=Y.+Shigeri&title=Characterization+of+novel+L-threo-beta-benzyloxyaspartate+derivatives%2C+potent+blockers+of+the+glutamate+transporters&doi=10.1124%2Fmol.65.4.1008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of novel L-threo-Î²-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters</span></div><div class="casAuthors">Shimamoto, Keiko; Sakai, Ryuichi; Takaoka, Kiyo; Yumoto, Noboru; Nakajima, Terumi; Amara, Susan G.; Shigeri, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1008-1015</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Nontransportable blockers of the glutamate transporters are important tools for investigating mechanisms of synaptic transmission.  DL-threo-Î²-Benzyloxyaspartate (DL-TBOA) is a potent blocker of all subtypes of the excitatory amino acid transporters (EAATs).  We characterized novel L-TBOA analogs possessing a substituent on their resp. benzene rings.  The analogs significantly inhibited labeled glutamate uptake, the most potent of which was (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA).  In an uptake assay using cells transiently expressing EAATs, the IC50 values of TFB-TBOA for EAAT1, EAAT2, and EAAT3 were 22, 17, and 300 nM, resp.  TFB-TBOA was significantly more potent at inhibiting EAAT1 and EAAT2 compared with L-TBOA (IC50 values for EAAT1-3 were 33, 6.2, and 15 Î¼M, resp.).  Electrophysiol. analyses revealed that TBOA analogs block the transport-assocd. currents in all five EAAT subtypes and also block leak currents in EAAT5.  The rank order of the analogs for potencies at inhibiting substrate-induced currents was identical to that obsd. in the uptake assay.  However, the kinetics of TFB-TBOA differed from the kinetics of L-TBOA, probably because of the strong binding affinity.  Notably, TFB-TBOA did not affect other representative neurotransmitter transporters or receptors, including ionotropic and metabotropic glutamate receptors, indicating that it is highly selective for EAATs.  Moreover, intracerebroventricular administration of the TBOA analogs induced severe convulsive behaviors in mice, probably because of the accumulation of glutamate.  Taken together, these findings indicate that novel TBOA analogs, esp. TFB-TBOA, should serve as useful tools for elucidating the physiol. roles of the glutamate transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2c5VUbloVLLVg90H21EOLACvtfcHk0lhlICzbhEsO4A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFaltbo%253D&md5=48cc0d672b697001a4161172920406e8</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1124%2Fmol.65.4.1008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.65.4.1008%26sid%3Dliteratum%253Aachs%26aulast%3DShimamoto%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DR.%26aulast%3DTakaoka%26aufirst%3DK.%26aulast%3DYumoto%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DAmara%26aufirst%3DS.%2BG.%26aulast%3DShigeri%26aufirst%3DY.%26atitle%3DCharacterization%2520of%2520novel%2520L-threo-beta-benzyloxyaspartate%2520derivatives%252C%2520potent%2520blockers%2520of%2520the%2520glutamate%2520transporters%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D65%26issue%3D4%26spage%3D1008%26epage%3D1015%26doi%3D10.1124%2Fmol.65.4.1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poelarends, G. J.</span></span> <span> </span><span class="NLM_article-title">Chemoenzymatic synthesis and pharmacological characterization of functionalized aspartate analogues as novel excitatory amino acid transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7741</span>â <span class="NLM_lpage">7753</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00700</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00700" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlantb3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7741-7753&issue=17&author=H.+G.+Fuauthor=J.+L.+Zhangauthor=P.+G.+Tepperauthor=L.+Bunchauthor=A.+A.+Jensenauthor=G.+J.+Poelarends&title=Chemoenzymatic+synthesis+and+pharmacological+characterization+of+functionalized+aspartate+analogues+as+novel+excitatory+amino+acid+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.8b00700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoenzymatic Synthesis and Pharmacological Characterization of Functionalized Aspartate Analogues As Novel Excitatory Amino Acid Transporter Inhibitors</span></div><div class="casAuthors">Fu, Haigen; Zhang, Jielin; Tepper, Pieter G.; Bunch, Lennart; Jensen, Anders A.; Poelarends, Gerrit J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7741-7753</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aspartate (Asp) derivs. are privileged compds. for investigating the roles governed by excitatory amino acid transporters (EAATs) in glutamatergic neurotransmission.  Here, we report the synthesis of various Asp derivs. with (cyclo)alkyloxy and (hetero)aryloxy substituents at C-3.  Their pharmacol. properties were characterized at the EAAT1-4 subtypes.  The L-threo-3-substituted Asp derivs. (I) (R1 = cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-thiophenyl, 3-thiophenyl, 2-furanyl, 3-furanyl, propargyl) were non-substrate inhibitors, exhibiting pan activity at EAAT1-4 with IC50 values ranging from 0.49 to 15 Î¼M.  Comparisons between (DL-threo)- and (DL-erythro)-Asp analogs I (R1 = cyclopropyl, 3-thiophenyl, propargyl) confirmed that the threo configuration is crucial for the EAAT1-4 inhibitory activities.  Analogs I (R1 = cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) of L-TFB-TBOA I (R1 = cyclopropyl) were shown to be potent EAAT1-4 inhibitors, with IC50 values ranging from 5-530 nM.  Hybridization of the nonselective EAAT inhibitor L-TBOA with EAAT2-selective inhibitor WAY-213613 or EAAT3-preferring inhibitor NBI-59159 yielded compds. (II)(R2 = III and IV) resp., which were non-selective EAAT inhibitors displaying considerably lower IC50 values at EAAT1-4 (11-140 nM) than those displayed by the resp. parent mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgfCBuGDnErVg90H21EOLACvtfcHk0lgeHKJlCtJUrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlantb3E&md5=7cc9859a2743c381856009492c23de2c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00700%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DH.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%2BL.%26aulast%3DTepper%26aufirst%3DP.%2BG.%26aulast%3DBunch%26aufirst%3DL.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DPoelarends%26aufirst%3DG.%2BJ.%26atitle%3DChemoenzymatic%2520synthesis%2520and%2520pharmacological%2520characterization%2520of%2520functionalized%2520aspartate%2520analogues%2520as%2520novel%2520excitatory%2520amino%2520acid%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7741%26epage%3D7753%26doi%3D10.1021%2Facs.jmedchem.8b00700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haym, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahamsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">New insight into the structure-activity relationships of the selective excitatory amino acid transporter subtype1 (EAAT1) inhibitors UCPH-101 and UCPH-102</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">382</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201500525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26757239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=382-402&issue=4&author=S.+W.+Hansenauthor=M.+N.+Erichsenauthor=T.+H.+V.+Huynhauthor=J.+A.+Ruizauthor=I.+Haymauthor=W.+E.+Bjorn-Yoshimotoauthor=B.+Abrahamsenauthor=J.+Hansenauthor=M.+Storgaardauthor=A.+L.+Eriksenauthor=A.+A.+Jensenauthor=L.+Bunch&title=New+insight+into+the+structure-activity+relationships+of+the+selective+excitatory+amino+acid+transporter+subtype1+%28EAAT1%29+inhibitors+UCPH-101+and+UCPH-102&doi=10.1002%2Fcmdc.201500525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">New Insight into the Structure-Activity Relationships of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors UCPH-101 and UCPH-102</span></div><div class="casAuthors">Hansen, Stinne W.; Erichsen, Mette N.; Huynh, Tri H. V.; Ruiz, Josep A.; Haym, Isabell; Bjorn-Yoshimoto, Walden E.; Abrahamsen, Bjarke; Hansen, Jeanette; Storgaard, Morten; Eriksen, Anette L.; Jensen, Anders A.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">382-402</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In the present study, the authors made further investigations on the structure-activity requirements of the selective excitatory amino acid transporter 1 (EAAT1) inhibitor, (UCPH-101), by exploring 15 different substituents (R1) at the 7-position in combination with eight different substituents (R2) at the 4-position.  Among the 63 new analogs synthesized, the authors identified a no. of compds. that unexpectedly displayed inhibitory activities at EAAT1 in light of understanding the structure-activity relationship (SAR) of this inhibitor class extd. from previous studies.  Moreover, the nature of the R1 and R2 substituents were obsd. to contribute to the functional properties of the various analogs in additive and nonadditive ways.  Finally, sepn. of the four stereoisomers of analog I was carried out, and in agreement with a study of a related scaffold, the R configuration at C4 was found to be mandatory for inhibitory activity, while both the C7 diastereomers were found to be active as EAAT1 inhibitors.  A study of the stereochem. stability of the four pure stereoisomers I-A-D showed that epimerization takes places at C7 via a ring-opening, C-C bond rotation, ring-closing mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfOLZ4EMNW9bVg90H21EOLACvtfcHk0lgeHKJlCtJUrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOmsw%253D%253D&md5=b3bef8333896eda1a6790c07bb40f8c3</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500525%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DS.%2BW.%26aulast%3DErichsen%26aufirst%3DM.%2BN.%26aulast%3DHuynh%26aufirst%3DT.%2BH.%2BV.%26aulast%3DRuiz%26aufirst%3DJ.%2BA.%26aulast%3DHaym%26aufirst%3DI.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DAbrahamsen%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DJ.%26aulast%3DStorgaard%26aufirst%3DM.%26aulast%3DEriksen%26aufirst%3DA.%2BL.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DNew%2520insight%2520into%2520the%2520structure-activity%2520relationships%2520of%2520the%2520selective%2520excitatory%2520amino%2520acid%2520transporter%2520subtype1%2520%2528EAAT1%2529%2520inhibitors%2520UCPH-101%2520and%2520UCPH-102%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D382%26epage%3D402%26doi%3D10.1002%2Fcmdc.201500525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haym, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gynther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahamsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastlund, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Bioavailability studies and in vitro profiling of the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-102</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">403</span>â <span class="NLM_lpage">419</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201500527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26797816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=403-419&issue=4&author=I.+Haymauthor=T.+H.+Huynhauthor=S.+W.+Hansenauthor=M.+H.+Pedersenauthor=J.+A.+Ruizauthor=M.+N.+Erichsenauthor=M.+Gyntherauthor=W.+E.+Bjorn-Yoshimotoauthor=B.+Abrahamsenauthor=J.+F.+Bastlundauthor=C.+Bundgaardauthor=A.+L.+Eriksenauthor=A.+A.+Jensenauthor=L.+Bunch&title=Bioavailability+studies+and+in+vitro+profiling+of+the+selective+excitatory+amino+acid+transporter+subtype+1+%28EAAT1%29+inhibitor+UCPH-102&doi=10.1002%2Fcmdc.201500527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102</span></div><div class="casAuthors">Haym, Isabell; Huynh, Tri H. V.; Hansen, Stinne W.; Pedersen, Martin H. F.; Ruiz, Josep A.; Erichsen, Mette N.; Gynther, Mikko; Bjorn-Yoshimoto, Walden E.; Abrahamsen, Bjarke; Bastlund, Jesper F.; Bundgaard, Christoffer; Eriksen, Anette L.; Jensen, Anders A.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-419</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-101 has become a std. pharmacol. tool compd. for in vitro and ex vivo studies in the EAAT research field, its inability to penetrate the blood-brain barrier makes it unsuitable for in vivo studies.  In the present study, per os (p.o.) administration (40 mg kg-1) of the closely related analog UCPH-102 in rats yielded resp. plasma and brain concns. of 10.5 and 6.67 Î¼m after 1 h.  Three analog series were designed and synthesized to improve the bioavailability profile of UCPH-102, but none displayed substantially improved properties in this respect.  In vitro profiling of UCPH-102 (10 Î¼m) at 51 central nervous system targets in radioligand binding assays strongly suggests that the compd. is completely selective for EAAT1.  Finally, in a rodent locomotor model, p.o. administration of UCPH-102 (20 mg kg-1) did not induce acute effects or any visible changes in behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3bgLF5KR1jLVg90H21EOLACvtfcHk0lgeHKJlCtJUrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWitbY%253D&md5=1486540624603e2c18d5127eea3a6124</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500527%26sid%3Dliteratum%253Aachs%26aulast%3DHaym%26aufirst%3DI.%26aulast%3DHuynh%26aufirst%3DT.%2BH.%26aulast%3DHansen%26aufirst%3DS.%2BW.%26aulast%3DPedersen%26aufirst%3DM.%2BH.%26aulast%3DRuiz%26aufirst%3DJ.%2BA.%26aulast%3DErichsen%26aufirst%3DM.%2BN.%26aulast%3DGynther%26aufirst%3DM.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DAbrahamsen%26aufirst%3DB.%26aulast%3DBastlund%26aufirst%3DJ.%2BF.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DEriksen%26aufirst%3DA.%2BL.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DBioavailability%2520studies%2520and%2520in%2520vitro%2520profiling%2520of%2520the%2520selective%2520excitatory%2520amino%2520acid%2520transporter%2520subtype%25201%2520%2528EAAT1%2529%2520inhibitor%2520UCPH-102%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D403%26epage%3D419%26doi%3D10.1002%2Fcmdc.201500527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ognyanov, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tham, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klitenick, M. A.</span></span> <span> </span><span class="NLM_article-title">ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1414</span>â <span class="NLM_lpage">1420</span>, <span class="refDoi">Â DOI: 10.1124/mol.60.6.1414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fmol.60.6.1414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11723250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVOitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=1414-1420&issue=6&author=B.+N.+Atkinsonauthor=S.+C.+Bellauthor=M.+De+Vivoauthor=L.+R.+Kowalskiauthor=S.+M.+Lechnerauthor=V.+I.+Ognyanovauthor=C.+S.+Thamauthor=C.+Tsaiauthor=J.+Jiaauthor=D.+Ashtonauthor=M.+A.+Klitenick&title=ALX+5407%3A+a+potent%2C+selective+inhibitor+of+the+hGlyT1+glycine+transporter&doi=10.1124%2Fmol.60.6.1414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter</span></div><div class="casAuthors">Atkinson, B. N.; Bell, S. C.; De Vivo, M.; Kowalski, L. R.; Lechner, S. M.; Ognyanov, V. I.; Tham, C.-S.; Tsai, C.; Jia, J.; Ashton, D.; Klitenick, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1414-1420</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">High-affinity glycine transport in neurons and glial cells is a primary means of inactivating synaptic glycine.  We have synthesized a potent selective inhibitor of glycine transporter 1 (GlyT1), and characterized its activity using a quail fibroblast cell line (QT6).  The glycine transporters GlyT1A, GlyT1B, GlyT1C, and GlyT2 were stably expressed in QT6 cells.  The transporters expressed in these cells exhibited appropriate characteristics as described previously for these genes: Na+/Cl- dependence, appropriate Km values for glycine uptake, and appropriate pharmacol., as defined in part by the ability of N-Me glycine (sarcosine) to competitively inhibit glycine transport.  Furthermore, the characteristics of the transporters in the cell lines recapitulate the characteristics of glycine transporters obsd. in tissue prepns.  We developed a sarcosine deriv., (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (ALX 5407), and examd. its activity against the cloned glycine transporters.  ALX 5407 completely inhibited glycine transport in the GlyT1 cells, with an IC50 value of 3 nM, but had little or no activity at the human GlyT2 transporter, at other binding sites for glycine, or at other neurotransmitter transporters.  The inhibition of glycine transport was essentially irreversible.  ALX 5407 represents a novel tool in the investigation of N-methyl-D-aspartate-receptor function.  This class of drug may lead to novel therapies in the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa7gbKMbogbbVg90H21EOLACvtfcHk0liGgzLGD6B4Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVOitb8%253D&md5=f7b88d389e78e8bdae009cd3d81de6c9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fmol.60.6.1414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.60.6.1414%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DB.%2BN.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DL.%2BR.%26aulast%3DLechner%26aufirst%3DS.%2BM.%26aulast%3DOgnyanov%26aufirst%3DV.%2BI.%26aulast%3DTham%26aufirst%3DC.%2BS.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DAshton%26aufirst%3DD.%26aulast%3DKlitenick%26aufirst%3DM.%2BA.%26atitle%3DALX%25205407%253A%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520the%2520hGlyT1%2520glycine%2520transporter%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26issue%3D6%26spage%3D1414%26epage%3D1420%26doi%3D10.1124%2Fmol.60.6.1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlyle, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of org 24598-a selective glycine uptake inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2007</span>â <span class="NLM_lpage">2009</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00355-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0960-894X%2801%2900355-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11454468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVWqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2007-2009&issue=15&author=A.+Brownauthor=I.+Carlyleauthor=J.+Clarkauthor=W.+Hamiltonauthor=S.+Gibsonauthor=G.+McGarryauthor=S.+McEachenauthor=D.+Raeauthor=S.+Thornauthor=G.+Walker&title=Discovery+and+SAR+of+org+24598-a+selective+glycine+uptake+inhibitor&doi=10.1016%2FS0960-894X%2801%2900355-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of Org 24598-A Selective Glycine Uptake Inhibitor</span></div><div class="casAuthors">Brown, A.; Carlyle, I.; Clark, J.; Hamilton, W.; Gibson, S.; McGarry, G.; McEachen, S.; Rae, D.; Thorn, S.; Walker, G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2007-2009</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The authors describe the discovery of a series of selective GlyT-1b inhibitors, by application of solid-phase chem. and library design.  Specifically the discovery of Org 24598, one of the first potent and selective inhibitors of the glycine transporter is discussed.  In vitro structure-activity relationships (SARs) data for interaction of a ligand with this system is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoapnLrELt37bVg90H21EOLACvtfcHk0liGgzLGD6B4Qw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVWqtrY%253D&md5=4e06a1947df00eda93404605167f1ccb</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900355-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900355-9%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DCarlyle%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DHamilton%26aufirst%3DW.%26aulast%3DGibson%26aufirst%3DS.%26aulast%3DMcGarry%26aufirst%3DG.%26aulast%3DMcEachen%26aufirst%3DS.%26aulast%3DRae%26aufirst%3DD.%26aulast%3DThorn%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520org%252024598-a%2520selective%2520glycine%2520uptake%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D15%26spage%3D2007%26epage%3D2009%26doi%3D10.1016%2FS0960-894X%2801%2900355-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marston, H. M.</span></span> <span> </span><span class="NLM_article-title">Effect of the selective glycine re-uptake (GlyT-1) inhibitor Org 25935 on glycine levels in CSF and dialysates</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">S497</span>â <span class="NLM_lpage">S498</span>, <span class="refDoi">Â DOI: 10.1016/S0924-977X(07)70764-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0924-977X%2807%2970764-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=S497-S498&author=N.+Andrewsauthor=J.+Geauthor=G.+Walkerauthor=J.+Schipperauthor=H.+M.+Marston&title=Effect+of+the+selective+glycine+re-uptake+%28GlyT-1%29+inhibitor+Org+25935+on+glycine+levels+in+CSF+and+dialysates&doi=10.1016%2FS0924-977X%2807%2970764-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2FS0924-977X%2807%2970764-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-977X%252807%252970764-2%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DN.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DG.%26aulast%3DSchipper%26aufirst%3DJ.%26aulast%3DMarston%26aufirst%3DH.%2BM.%26atitle%3DEffect%2520of%2520the%2520selective%2520glycine%2520re-uptake%2520%2528GlyT-1%2529%2520inhibitor%2520Org%252025935%2520on%2520glycine%2520levels%2520in%2520CSF%2520and%2520dialysates%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D17%26spage%3DS497%26epage%3DS498%26doi%3D10.1016%2FS0924-977X%2807%2970764-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunayevich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia</span>. <i>Schizophr Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">90</span>â <span class="NLM_lpage">97</span>, <span class="refDoi">Â DOI: 10.1016/j.schres.2016.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.schres.2016.10.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27789188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2sngsVOhug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2017&pages=90-97&author=E.+Dunayevichauthor=R.+W.+Buchananauthor=C.+Y.+Chenauthor=J.+Yangauthor=J.+Nilsenauthor=J.+M.+Dietrichauthor=H.+Sunauthor=S.+Marder&title=Efficacy+and+safety+of+the+glycine+transporter+type-1+inhibitor+AMG+747+for+the+treatment+of+negative+symptoms+associated+with+schizophrenia&doi=10.1016%2Fj.schres.2016.10.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia</span></div><div class="casAuthors">Dunayevich Eduardo; Buchanan Robert W; Chen Chao-Yin; Yang Jun; Nilsen Jon; Dietrich Julie M; Sun Hong; Marder Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine the safety and efficacy of AMG 747, an oral inhibitor of glycine transporter type-1 (GlyT1), as an add-on to antipsychotic therapy in clinically stable people with schizophrenia with enduring negative symptoms.  METHOD:  Analysis of pooled data from two phase 2 studies.  Adults diagnosed with schizophrenia stabilized on antipsychotic medication randomized (2:2:2:3) to orally receive daily AMG 747 (5mg, 15mg, or 40mg) or placebo.  Primary endpoint was Negative Symptom Assessment (NSA)-16 total score change from baseline to week 12.  RESULTS:  Studies were terminated early after a report of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) in one participant (40-mg AMG 747).  At termination, 232 participants had enrolled and 153 completed 12weeks of treatment.  At week 12, change from baseline NSA-16 total score showed no differences between groups.  Mean decrease in Positive and Negative Syndrome Scale (PANSS) Negative Symptom Factor Score (NSFS) and NSA-16 global score were greater with 15-mg AMG 747 than placebo (p<0.05).  Changes in PANSS-Positive Symptom Factor Scale were not significantly different for any group.  Changes in patient-reported outcomes (Sheehan Disability Scale and Quality of Life Enjoyment and Satisfaction Questionnaire) showed trends consistent with greater efficacy of 15-mg AMG 747 compared with placebo (pâ¤0.1).  Adverse event rates were similar among all groups, with no clear differences observed.  CONCLUSIONS:  Significant treatment effects of 15-mg AMG 747, but not higher or lower doses, were observed on secondary endpoints but not on the primary outcome.  These results replicate previous reports of an inverted-U dose response curve and suggest further evaluation of GlyT1 inhibitors in schizophrenia negative symptoms is warranted.  TRIAL REGISTRATION:  Clinicaltrials.govNCT01568216 (https://clinicaltrials.gov/ct2/show/NCT01568216) and NCT01568229 (https://clinicaltrials.gov/ct2/show/NCT01568229?term=NCT01568229&rank=1); EudraCT number 2011-004844-23 and 2011-004845-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpl0hAmcYkA0cLvDNbOD4DfW6udTcc2eYwXq49r7ZNdbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngsVOhug%253D%253D&md5=57bc1aa2a1f7c1efbc396235dbe527a6</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2016.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2016.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DDunayevich%26aufirst%3DE.%26aulast%3DBuchanan%26aufirst%3DR.%2BW.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNilsen%26aufirst%3DJ.%26aulast%3DDietrich%26aufirst%3DJ.%2BM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DMarder%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520glycine%2520transporter%2520type-1%2520inhibitor%2520AMG%2520747%2520for%2520the%2520treatment%2520of%2520negative%2520symptoms%2520associated%2520with%2520schizophrenia%26jtitle%3DSchizophr%2520Res.%26date%3D2017%26volume%3D182%26spage%3D90%26epage%3D97%26doi%3D10.1016%2Fj.schres.2016.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koerner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umbricht, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberati, D.</span></span> <span> </span><span class="NLM_article-title">Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">477</span>â <span class="NLM_lpage">484</span>, <span class="refDoi">Â DOI: 10.2533/chimia.2018.477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2533%2Fchimia.2018.477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30158010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVShsb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=477-484&issue=7&author=E.+Pinardauthor=E.+Borroniauthor=A.+Koernerauthor=D.+Umbrichtauthor=D.+Alberati&title=Glycine+transporter+type+I+%28GlyT1%29+inhibitor%2C+bitopertin%3A+a+journey+from+lab+to+patient&doi=10.2533%2Fchimia.2018.477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient</span></div><div class="casAuthors">Pinard, Emmanuel; Borroni, Edilio; Koerner, Annette; Umbricht, Daniel; Alberati, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">477-484</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness.  More recently, preclin. results have suggested that this approach could also have therapeutic potential for CNS disorders beyond schizophrenia as well as for non-CNS indications.  Over the past 17 years, Roche has been a key player in the GlyT1 field with the discovery and development of bitopertin, the most advanced GlyT1 inhibitor to date and the only one which completed Phase III clin. studies for schizophrenia.  In this article, we relate the eventful journey of the discovery and development of bitopertin, from project initiation in 2001 to its evaluation today in patients suffering from beta-thalassemia, a monogenic hereditary haematol. disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7gCBfO1rCa7Vg90H21EOLACvtfcHk0lgUF0AoBSxD6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVShsb%252FE&md5=12bdce99341fb48ee481354999e1a5fd</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2018.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2018.477%26sid%3Dliteratum%253Aachs%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DBorroni%26aufirst%3DE.%26aulast%3DKoerner%26aufirst%3DA.%26aulast%3DUmbricht%26aufirst%3DD.%26aulast%3DAlberati%26aufirst%3DD.%26atitle%3DGlycine%2520transporter%2520type%2520I%2520%2528GlyT1%2529%2520inhibitor%252C%2520bitopertin%253A%2520a%2520journey%2520from%2520lab%2520to%2520patient%26jtitle%3DChimia%26date%3D2018%26volume%3D72%26issue%3D7%26spage%3D477%26epage%3D484%26doi%3D10.2533%2Fchimia.2018.477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peakman, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebel, L.</span></span> <span> </span><span class="NLM_article-title">A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1675</span>â <span class="NLM_lpage">1678</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2006.12.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17257843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1yrsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1675-1678&issue=6&author=J.+Loweauthor=S.+Drozdaauthor=W.+Qianauthor=M.+C.+Peakmanauthor=J.+Liuauthor=J.+Gibbsauthor=J.+Harmsauthor=C.+Schmidtauthor=K.+Fisherauthor=C.+Strickauthor=A.+Schmidtauthor=M.+Vanaseauthor=L.+Lebel&title=A+novel%2C+non-substrate-based+series+of+glycine+type+1+transporter+inhibitors+derived+from+high-throughput+screening&doi=10.1016%2Fj.bmcl.2006.12.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening</span></div><div class="casAuthors">Lowe, J.; Drozda, S.; Qian, W.; Peakman, M.-C.; Liu, J.; Gibbs, J.; Harms, J.; Schmidt, C.; Fisher, K.; Strick, C.; Schmidt, A.; Vanase, M.; Lebel, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1675-1678</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aryloxadiazoles (and a pyridine) with piperidine- or piperazine-substituted indane or tetralin moieties such as I are prepd. as selective inhibitors of the glycine type 1 transporter for use as potential antischizophrenic agents; their inhibition of glycine type 1 and glycine type 2 transporters, 5-HT1B receptors, and cytochrome P450 2D6 (CYP2D6) and their binding to the potassium channel HERG are detd. as well as their half-lives in human microsomes.  I inhibits the glycine type 1 transporter with a Ki value of 15.9 nM while inhibiting the corresponding type 2 transporter with a Ki value of 319 nM; I inhibits 96% of CYP2D6 activity at a concn. of 1.5 Î¼M and has a human microsomal half-life of 22 min. while displacing dofetillide from HERG with a Ki value of 271 nM.  The four stereoisomers of I differ little in their inhibition of the glycine type 1 transporter and in their binding to HERG.  Selective inhibition of the glycine type 1 transporter by some of the compds. is found; attempts to decrease the inhibition of CYP2D6, the binding to HERG, and the degrdn. by human microsomes by the compds. did not succeed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeJwwmheK9oLVg90H21EOLACvtfcHk0lgUF0AoBSxD6A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1yrsLc%253D&md5=5d09da74ffc4d0f869fd97e65aa29fe6</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.109%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DJ.%26aulast%3DDrozda%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DPeakman%26aufirst%3DM.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGibbs%26aufirst%3DJ.%26aulast%3DHarms%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DFisher%26aufirst%3DK.%26aulast%3DStrick%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DVanase%26aufirst%3DM.%26aulast%3DLebel%26aufirst%3DL.%26atitle%3DA%2520novel%252C%2520non-substrate-based%2520series%2520of%2520glycine%2520type%25201%2520transporter%2520inhibitors%2520derived%2520from%2520high-throughput%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D6%26spage%3D1675%26epage%3D1678%26doi%3D10.1016%2Fj.bmcl.2006.12.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâSouza, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driesen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannesen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbuto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâSouza, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâSouza, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabulsi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driesen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannesen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelernter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, B.</span></span> <span> </span><span class="NLM_article-title">Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">413</span>â <span class="NLM_lpage">421</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2017.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.biopsych.2017.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29499855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkt1Gns7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=413-421&issue=6&author=D.+C.+D%E2%80%99Souzaauthor=R.+E.+Carsonauthor=N.+Driesenauthor=J.+Johannesenauthor=M.+Ranganathanauthor=J.+H.+Krystalauthor=K.-H.+Ahnauthor=K.+Bielenauthor=M.+Carbutoauthor=E.+Deasoauthor=D.+C.+D%E2%80%99Souzaauthor=M.+Ranganathanauthor=M.+Naganawaauthor=M.+Ranganathanauthor=D.+C.+D%E2%80%99Souzaauthor=N.+Nabulsiauthor=M.-Q.+Zhengauthor=S.-f.+Linauthor=Y.+Huangauthor=R.+E.+Carsonauthor=N.+Driesenauthor=K.-H.+Ahnauthor=P.+T.+Morganauthor=R.+Suckowauthor=G.+Heauthor=G.+McCarthyauthor=J.+H.+Krystalauthor=J.+Johannesenauthor=J.+Kenneyauthor=J.+Gelernterauthor=R.+Gueorguievaauthor=B.+Pittman&title=Dose-related+target+occupancy+and+effects+on+circuitry%2C+behavior%2C+and+neuroplasticity+of+the+glycine+transporter-1+inhibitor+PF-03463275+in+healthy+and+schizophrenia+subjects&doi=10.1016%2Fj.biopsych.2017.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects</span></div><div class="casAuthors">D'Souza, Deepak Cyril; Carson, Richard E.; Driesen, Naomi; Johannesen, Jason; Ranganathan, Mohini; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">413-421</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Glycine transporter-1 (GlyT1) inhibitors may ameliorate cognitive impairments assocd. with schizophrenia.  The dose-related occupancy and target engagement of the GlyT1 inhibitor PF-03463275 were studied to inform optimal dose selection for a clin. trial for cognitive impairments assocd. with schizophrenia.  In substudy 1, the effects of PF-03463275 (10, 20, and 40 mg twice a day) on occupancy of GlyT1 were tested using positron emission tomog. and 18F-MK-6577, and visual long-term potentiation (LTP) in schizophrenia patients (SZs) and healthy control subjects.  Furthermore, the capacity of PF-03463275 to attenuate ketamine-induced disruption of working memory-related activation of a "working memory" circuit was tested only in healthy control subjects using functional magnetic resonance imaging.  Subsequently, the effects of PF-03463275 (60 mg twice a day) on occupancy of GlyT1 and long-term potentiation were examd. only in SZs (substudy 2).  PF-03463275 at 10, 20, 40, and 60 mg twice a day produced â¼44%, 61%, 76%, and 83% GlyT1 occupancy, resp., in SZs with higher ligand binding to GlyT1 in subcortical vs. cortical regions.  PF-03463275 did not attenuate any ketamine-induced effects but did improve working memory accuracy in healthy control subjects.  PF-03463275 increased long-term potentiation only in SZs with peak effects at 40 mg twice a day (â¼75% GlyT1 occupancy) and with a profile suggestive of an inverted U dose response.  PF-03463275 was well-tolerated.  The dose-related GlyT1 occupancy of PF-03463275 is linear.  While PF-03463275 did not show evidence of facilitating N-methyl-D-aspartate receptor function in the ketamine assay, it enhanced neuroplasticity in SZs.  These findings provide support for a clin. trial to test the ability of PF-03463275 to enhance cognitive remediation toward addressing cognitive impairments assocd. with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEEhrKOulSj7Vg90H21EOLACvtfcHk0lh_z4AJCYhg1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkt1Gns7g%253D&md5=e44174bf6bb9cc6e17f7e992beb84622</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DDriesen%26aufirst%3DN.%26aulast%3DJohannesen%26aufirst%3DJ.%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26aulast%3DAhn%26aufirst%3DK.-H.%26aulast%3DBielen%26aufirst%3DK.%26aulast%3DCarbuto%26aufirst%3DM.%26aulast%3DDeaso%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DNaganawa%26aufirst%3DM.%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26aulast%3DNabulsi%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DM.-Q.%26aulast%3DLin%26aufirst%3DS.-f.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DDriesen%26aufirst%3DN.%26aulast%3DAhn%26aufirst%3DK.-H.%26aulast%3DMorgan%26aufirst%3DP.%2BT.%26aulast%3DSuckow%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DMcCarthy%26aufirst%3DG.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26aulast%3DJohannesen%26aufirst%3DJ.%26aulast%3DKenney%26aufirst%3DJ.%26aulast%3DGelernter%26aufirst%3DJ.%26aulast%3DGueorguieva%26aufirst%3DR.%26aulast%3DPittman%26aufirst%3DB.%26atitle%3DDose-related%2520target%2520occupancy%2520and%2520effects%2520on%2520circuitry%252C%2520behavior%252C%2520and%2520neuroplasticity%2520of%2520the%2520glycine%2520transporter-1%2520inhibitor%2520PF-03463275%2520in%2520healthy%2520and%2520schizophrenia%2520subjects%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26issue%3D6%26spage%3D413%26epage%3D421%26doi%3D10.1016%2Fj.biopsych.2017.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morioka, N.</span></span> <span> </span><span class="NLM_article-title">Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">79</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2009.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.pharmthera.2009.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19393690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1ahsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2009&pages=54-79&issue=1&author=T.+Dohiauthor=K.+Moritaauthor=T.+Kitayamaauthor=N.+Motoyamaauthor=N.+Morioka&title=Glycine+transporter+inhibitors+as+a+novel+drug+discovery+strategy+for+neuropathic+pain&doi=10.1016%2Fj.pharmthera.2009.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain</span></div><div class="casAuthors">Dohi, Toshihiro; Morita, Katsuya; Kitayama, Tomoya; Motoyama, Naoyo; Morioka, Norimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-79</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Injury to peripheral or spinal nerves following either trauma or disease has several consequences including the development of neuropathic pain.  This syndrome is often refractory against conventional analgesics; and thus, novel medicaments are desired for its treatment.  Recent studies have emphasized that dysfunction of inhibitory neuronal regulation of pain signal transduction may be relevant to the development of neuropathic pain.  Glycinergic neurons are localized in specific brain regions and the spinal cord, where they play an important role in the prevention of pathol. pain symptoms.  Thus, an enhancement of glycinergic control in the spinal cord is a promising strategy for pain relief from neuropathic pain.  Glycine transporter (GlyT) 1 and GlyT2, which are located in glial cells and neurons, resp. play important roles by clearing synaptically released glycine or supplying glycine to glycinergic neurons to regulate glycinergic neurotransmission.  Thus, an inhibition of GlyTs could be used to modify pain signal transmission in the spinal cord.  Recently developed specific inhibitors of GlyTs have made this possibility a reality.  Both GlyT1 and GlyT2 inhibitors produced potential anti-nociceptive effect in various neuropathic pain models, chronic and acute inflammatory models in animals.  Their anti-allodynia effects are mediated by the inhibition of GlyTs following activation of spinal glycine receptor Î±3.  These results established GlyTs as target mols. for medicaments for neuropathic pain.  Moreover, the phase-dependent anti-allodynia effects of GlyT inhibitors have provided important information on effective therapeutic strategies and also understanding the underlying mol. mechanisms of the development of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAkxcSLELFbbVg90H21EOLACvtfcHk0lh_z4AJCYhg1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1ahsbw%253D&md5=962c43949acb185c71037acd12855c2b</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DDohi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DK.%26aulast%3DKitayama%26aufirst%3DT.%26aulast%3DMotoyama%26aufirst%3DN.%26aulast%3DMorioka%26aufirst%3DN.%26atitle%3DGlycine%2520transporter%2520inhibitors%2520as%2520a%2520novel%2520drug%2520discovery%2520strategy%2520for%2520neuropathic%2520pain%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D123%26issue%3D1%26spage%3D54%26epage%3D79%26doi%3D10.1016%2Fj.pharmthera.2009.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caulfield, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collie, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, H.</span></span> <span> </span><span class="NLM_article-title">The first potent and selective inhibitors of the glycine transporter type 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2679</span>â <span class="NLM_lpage">2682</span>, <span class="refDoi">Â DOI: 10.1021/jm0011272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0011272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlClsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2679-2682&issue=17&author=W.+L.+Caulfieldauthor=I.+T.+Collieauthor=R.+S.+Dickinsauthor=O.+Epemoluauthor=R.+McGuireauthor=D.+R.+Hillauthor=G.+McVeyauthor=J.+R.+Morphyauthor=Z.+Rankovicauthor=H.+Sundaram&title=The+first+potent+and+selective+inhibitors+of+the+glycine+transporter+type+2&doi=10.1021%2Fjm0011272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The first potent and selective inhibitors of the glycine transporter type 2</span></div><div class="casAuthors">Caulfield, Wilson L.; Collie, Iain T.; Dickins, Rachel S.; Epemolu, Ola; McGuire, Ross; Hill, David R.; McVey, Gillian; Morphy, J. Richard; Rankovic, Zoran; Sundaram, Hardy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2679-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycine is one of the major inhibitory neurotransmitters in the spinal cord and brain stem of vertebrates.  The inhibitory actions of glycine are mediated by the strychnine-sensitive glycine receptor, a ligand-gated chloride channel distributed throughout the spinal cord and brain stem.  Glycine is also known to potentiate the action of glutamate acting as an essential co-agonist on postsynaptic N-methyl-d-aspartate (NMDA) receptors.  Synaptic levels of glycine are believed to be controlled by high-affinity glycine transporters.  These transporters are members of a large family of sodium/chloride-dependent transporters, which are composed of single oligomeric proteins contg. 12 hydrophobic membrane-spanning domains.  There is evidence that glycine-mediated inhibition produces muscle relaxation and blockade of this inhibition produces convulsions.  Therefore, we postulated that modulators of endogenous levels of glycine might provide skeletal muscle relaxation.  A significant amt. of data has accumulated over recent years, indicating that glycine also has an important role in the modulation of nociceptive pathways.  Thus, it was anticipated that an increase in synaptic levels of endogenous glycine by a selective inhibition of the GlyT-2 transporter in the spinal cord may offer a unique approach for developing a novel muscle relaxant, anesthetic, and/or analgesic reagent, suitable for use during surgical anesthesia.  Due to the discrete localization of both ssGlyR and the GlyT-2 transporter within the spinal cord and brain stem, a glycine modulator might not be expected to lead to serious CNS side effects that are characteristic for currently used Î¼-opioid analgesics.  Since testing of this hypothesis has been hampered by the lack of a suitable GlyT-2 inhibitor, we sought a potent and selective inhibitor of the transporter that would enable us to conduct proof-of-principle studies.  In summary, high-throughput screening of Organon's compd. collection provided an attractive drug-like GlyT-2 inhibitor suitable for high-throughput synthesis.  A detailed study of the SAR and rapid hit optimization were achieved through synthesis of a soln.-phase 2D library.  This led to identification of 4-benzyloxy-3,5-dimethoxy-N-[(1-dimethylaminocyclopentyl)methyl]benzamide, the first potent and selective GlyT-2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpVNVN55SHKrVg90H21EOLACvtfcHk0lh_z4AJCYhg1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlClsrg%253D&md5=25df8d1d93a08022c361df0e0031414c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm0011272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0011272%26sid%3Dliteratum%253Aachs%26aulast%3DCaulfield%26aufirst%3DW.%2BL.%26aulast%3DCollie%26aufirst%3DI.%2BT.%26aulast%3DDickins%26aufirst%3DR.%2BS.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DMcGuire%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DD.%2BR.%26aulast%3DMcVey%26aufirst%3DG.%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DSundaram%26aufirst%3DH.%26atitle%3DThe%2520first%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520glycine%2520transporter%2520type%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26issue%3D17%26spage%3D2679%26epage%3D2682%26doi%3D10.1021%2Fjm0011272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mingorance-Le Meur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisdal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Perren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famelart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Asperen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jnoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courade, J. P.</span></span> <span> </span><span class="NLM_article-title">Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1063</span>, <span class="refDoi">Â DOI: 10.1111/bph.12343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fbph.12343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23962079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1SlurfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=1053-1063&issue=5&author=A.+Mingorance-Le+Meurauthor=P.+Ghisdalauthor=B.+Mullierauthor=P.+De+Ronauthor=P.+Downeyauthor=C.+Van+Der+Perrenauthor=V.+Declercqauthor=S.+Cornelisauthor=M.+Famelartauthor=J.+Van+Asperenauthor=E.+Jnoffauthor=J.+P.+Courade&title=Reversible+inhibition+of+the+glycine+transporter+GlyT2+circumvents+acute+toxicity+while+preserving+efficacy+in+the+treatment+of+pain&doi=10.1111%2Fbph.12343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain</span></div><div class="casAuthors">Mingorance-Le Meur, A.; Ghisdal, P.; Mullier, B.; De Ron, P.; Downey, P.; Van Der Perren, C.; Declercq, V.; Cornelis, S.; Famelart, M.; Van Asperen, J.; Jnoff, E.; Courade, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1053-1063</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Available medications for chronic pain provide only partial relief and often cause unacceptable side effects.  There is therefore a need for novel mol. targets to develop new therapeutics with improved efficacy and tolerability.  Despite encouraging efficacy data in rodents with inhibitors of the neuronal glycine transporter-2 (GlyT2), there are also some reports of toxicity and their development was discontinued.  Exptl. Approach : In order to clarify the possibility of targeting GlyT2 for the treatment of pain, we have used an integrated approach comprising in vitro pharmacol., selectivity, bioavailability, in vivo efficacy and safety assessment to analyze the properties and efficacy of ALX-1393 and Org-25543, the two published GlyT2 inhibitors from which in vivo data are available.  Key Results : We report that these compds. have a different set of undesirable properties that limit their usefulness as pharmacol. tools.  Importantly, we discover that inhibitors of GlyT2 can exert an apparent reversible or irreversible inhibition of the transporter and describe a new class of reversible GlyT2 inhibitors that preserves efficacy while avoiding acute toxicity.  Conclusions and Implications : Our pharmacol. comparison of two closely related GlyT2 inhibitors with different modes of inhibition provides important insights into their safety and efficacy profiles, uncovering that in the presence of a GlyT2 mechanism-based toxicity, reversible inhibitors might allow a tolerable balance between efficacy and toxicity.  These findings shed light into the drawbacks assocd. with the early GlyT2 inhibitors and describe a new mechanism that might serve as the starting point for new drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqu9AgzGlvlLVg90H21EOLACvtfcHk0lgZzqtTi_YbkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1SlurfL&md5=73c0b4d4dd102b75e02b2272f6b00283</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1111%2Fbph.12343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12343%26sid%3Dliteratum%253Aachs%26aulast%3DMingorance-Le%2BMeur%26aufirst%3DA.%26aulast%3DGhisdal%26aufirst%3DP.%26aulast%3DMullier%26aufirst%3DB.%26aulast%3DDe%2BRon%26aufirst%3DP.%26aulast%3DDowney%26aufirst%3DP.%26aulast%3DVan%2BDer%2BPerren%26aufirst%3DC.%26aulast%3DDeclercq%26aufirst%3DV.%26aulast%3DCornelis%26aufirst%3DS.%26aulast%3DFamelart%26aufirst%3DM.%26aulast%3DVan%2BAsperen%26aufirst%3DJ.%26aulast%3DJnoff%26aufirst%3DE.%26aulast%3DCourade%26aufirst%3DJ.%2BP.%26atitle%3DReversible%2520inhibition%2520of%2520the%2520glycine%2520transporter%2520GlyT2%2520circumvents%2520acute%2520toxicity%2520while%2520preserving%2520efficacy%2520in%2520the%2520treatment%2520of%2520pain%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26issue%3D5%26spage%3D1053%26epage%3D1063%26doi%3D10.1111%2Fbph.12343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haranishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, T.</span></span> <span> </span><span class="NLM_article-title">The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">615</span>â <span class="NLM_lpage">621</span>, <span class="refDoi">Â DOI: 10.1213/ANE.0b013e3181c7ebbb</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1213%2FANE.0b013e3181c7ebbb" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20081141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fjt1Cltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=615-621&issue=2&author=Y.+Haranishiauthor=K.+Haraauthor=T.+Teradaauthor=S.+Nakamuraauthor=T.+Sata&title=The+antinociceptive+effect+of+intrathecal+administration+of+glycine+transporter-2+inhibitor+ALX1393+in+a+rat+acute+pain+model&doi=10.1213%2FANE.0b013e3181c7ebbb"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model</span></div><div class="casAuthors">Haranishi Yasunori; Hara Koji; Terada Tadanori; Nakamura Seiya; Sata Takeyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia and analgesia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">615-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glycinergic neurons in the spinal dorsal horn have been implicated in the inhibition of spinal pain processing in peripheral inflammation and chronic pain states.  Neuronal isoform glycine transporter-2 (GlyT2) reuptakes presynaptically released glycine and regulates the glycinergic neurotransmission.  In this study, we examined whether a selective GlyT2 inhibitor, ALX1393, elicits an antinociceptive effect in a rat acute pain model.  METHODS:  Male Sprague-Dawley rats were implanted with a catheter intrathecally.  The effects of intrathecal administration of ALX1393 (4, 20, or 40 microg) on thermal, mechanical, and chemical nociception were evaluated by tail flick, hot plate, paw pressure, and formalin tests.  Furthermore, to explore whether ALX1393 affects motor function, a rotarod test was performed.  RESULTS:  ALX1393 exhibited antinociceptive effects on the thermal and mechanical stimulations in a dose-dependent manner.  The maximal effect of ALX1393 was observed at 15 min after administration, and a significant effect lasted for about 60 min.  These antinociceptive effects were reversed completely by strychnine injected immediately after the administration of ALX1393.  In the formalin test, ALX1393 inhibited pain behaviors in a dose-dependent manner, both in the early and late phases, although the influence was greater in the late phase.  In contrast to antinociceptive action, ALX1393 did not affect motor function up to 40 microg.  CONCLUSIONS:  This study demonstrates the antinociceptive action of ALX1393 on acute pain.  These findings suggest that the inhibitory neurotransmitter transporters are promising targets for the treatment of acute pain and that the selective inhibitor of GlyT2 could be a novel therapeutic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScnwYgIQdufuvW160gIxP_fW6udTcc2ebvNAspVK4fs7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fjt1Cltw%253D%253D&md5=a34ae7550e9ba9b1e5a763c694888fd3</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1213%2FANE.0b013e3181c7ebbb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252FANE.0b013e3181c7ebbb%26sid%3Dliteratum%253Aachs%26aulast%3DHaranishi%26aufirst%3DY.%26aulast%3DHara%26aufirst%3DK.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DSata%26aufirst%3DT.%26atitle%3DThe%2520antinociceptive%2520effect%2520of%2520intrathecal%2520administration%2520of%2520glycine%2520transporter-2%2520inhibitor%2520ALX1393%2520in%2520a%2520rat%2520acute%2520pain%2520model%26jtitle%3DAnesth.%2520Analg.%26date%3D2010%26volume%3D110%26issue%3D2%26spage%3D615%26epage%3D621%26doi%3D10.1213%2FANE.0b013e3181c7ebbb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osanai-Sasakawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumitomo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomura-Suruki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, R.</span></span> <span> </span><span class="NLM_article-title">An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1499</span>â <span class="NLM_lpage">1513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30210919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKmu7nL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1499-1513&issue=8&author=A.+Osanai-Sasakawaauthor=K.+Hosomiauthor=Y.+Sumitomoauthor=T.+Takizawaauthor=S.+Tomura-Surukiauthor=M.+Imaizumiauthor=N.+Kasaiauthor=T.+W.+Pohauthor=K.+Yamanoauthor=W.+P.+Yongauthor=K.+Konoauthor=S.+Nakamuraauthor=T.+Ishiiauthor=R.+Nakai&title=An+anti-ASCT2+monoclonal+antibody+suppresses+gastric+cancer+growth+by+inducing+oxidative+stress+and+antibody+dependent+cellular+toxicity+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models</span></div><div class="casAuthors">Osanai-Sasakawa, Aya; Hosomi, Kenta; Sumitomo, Yoshiki; Takizawa, Takuya; Tomura-Suruki, Shiho; Imaizumi, Minami; Kasai, Noriyuki; Poh, Tze Wei; Yamano, Kazuya; Yong, Wei Peng; Kono, Koji; Nakamura, Satoshi; Ishii, Toshihiko; Nakai, Ryuichiro</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1499-1513</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Glutamine is a major nutrient for cancer cells during rapid proliferation.  Alanine-serine-cysteine (ASC) transporter 2 (ASCT2; SLC1A5) mediates glutamine uptake in a variety of cancer cells.  We previously reported that KM8094, a novel anti-ASCT2 humanized monoclonal antibody, possesses anti-tumor efficacy in gastric cancer patient-derived xenografts.  The aim of this study was to investigate the mol. mechanism underlying the effect of KM8094 and to further substantiate the preclin. feasibility of using KM8094 as a potential therapeutic agent against gastric cancer.  First, ASCT2 was found to be highly expressed in cancer tissues derived from gastric cancer patients by an immunohistochem. anal.  Next, we performed in vitro studies using multiple gastric cancer cell lines and obsd. that several gastric cancer cells expressing ASCT2 showed glutamine-dependent cell growth, which was repressed by KM8094.  We found that KM8094 inhibited the glutamine uptake, leading to the redn. of glutathione (GSH) level and the elevation of oxidative stress.  KM8094 suppressed the cell cycle progression and increased the apoptosis.  Furthermore, KM8094 exerted antibody dependent cellular cytotoxicity (ADCC) against human gastric cancer cells in vitro.  Finally, in vivo studies revealed that KM8094 suppressed tumor growth in several gastric cancer xenografts.  This effect was enhanced by docetaxel, one of the agents commonly used in gastric cancer therapy.  Thus, our findings suggest that KM8094 is a potential new therapeutic agent for gastric cancer expressing ASCT2, which blocks the cellular glutamine metab. and possesses ADCC activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSIRGLTft4bVg90H21EOLACvtfcHk0lgZzqtTi_YbkA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKmu7nL&md5=f3aa44164ca980f4c978be31eca69b2e</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsanai-Sasakawa%26aufirst%3DA.%26aulast%3DHosomi%26aufirst%3DK.%26aulast%3DSumitomo%26aufirst%3DY.%26aulast%3DTakizawa%26aufirst%3DT.%26aulast%3DTomura-Suruki%26aufirst%3DS.%26aulast%3DImaizumi%26aufirst%3DM.%26aulast%3DKasai%26aufirst%3DN.%26aulast%3DPoh%26aufirst%3DT.%2BW.%26aulast%3DYamano%26aufirst%3DK.%26aulast%3DYong%26aufirst%3DW.%2BP.%26aulast%3DKono%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DNakai%26aufirst%3DR.%26atitle%3DAn%2520anti-ASCT2%2520monoclonal%2520antibody%2520suppresses%2520gastric%2520cancer%2520growth%2520by%2520inducing%2520oxidative%2520stress%2520and%2520antibody%2520dependent%2520cellular%2520toxicity%2520in%2520preclinical%2520models%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2018%26volume%3D8%26issue%3D8%26spage%3D1499%26epage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esslinger, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cybulski, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhoderick, J. F.</span></span> <span> </span><span class="NLM_article-title">N-gamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1111</span>â <span class="NLM_lpage">1118</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2004.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmc.2004.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15670919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFWgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=1111-1118&issue=4&author=C.+S.+Esslingerauthor=K.+A.+Cybulskiauthor=J.+F.+Rhoderick&title=N-gamma-aryl+glutamine+analogues+as+probes+of+the+ASCT2+neutral+amino+acid+transporter+binding+site&doi=10.1016%2Fj.bmc.2004.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">NÎ³-Aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site</span></div><div class="casAuthors">Esslinger, C. Sean; Cybulski, Kimberly A.; Rhoderick, Joseph F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1111-1118</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Analogs of L-glutamine were designed and synthesized to test a hydrogen-bond hypothesis between ligand and neutral amino acid transporter ASCT2.  The key design feature contains a substituted Ph ring on the amide nitrogen that contains electron withdrawing and electron donating groups that alter the pKa of the amide NH.  Through this study a preliminary binding site map has been developed, and a potent com. available competitive inhibitor of the ASCT2 transporter has been identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp35ku5ItCIXrVg90H21EOLACvtfcHk0lgIiIXvJYLCVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFWgtw%253D%253D&md5=ba6ab757e14e18c4b5abbcbfffe98eb7</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DEsslinger%26aufirst%3DC.%2BS.%26aulast%3DCybulski%26aufirst%3DK.%2BA.%26aulast%3DRhoderick%26aufirst%3DJ.%2BF.%26atitle%3DN-gamma-aryl%2520glutamine%2520analogues%2520as%2520probes%2520of%2520the%2520ASCT2%2520neutral%2520amino%2520acid%2520transporter%2520binding%2520site%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26issue%3D4%26spage%3D1111%26epage%3D1118%26doi%3D10.1016%2Fj.bmc.2004.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span> <span> </span><span class="NLM_article-title">2-Substituted N gamma-glutamylanilides as novel probes of ASCT2 with improved potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">113</span>â <span class="NLM_lpage">116</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.10.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2014.10.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25435145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGitLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=113-116&issue=1&author=M.+L.+Schulteauthor=E.+S.+Dawsonauthor=S.+A.+Salehauthor=M.+L.+Cuthbertsonauthor=H.+C.+Manning&title=2-Substituted+N+gamma-glutamylanilides+as+novel+probes+of+ASCT2+with+improved+potency&doi=10.1016%2Fj.bmcl.2014.10.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">2-Substituted NÎ³-glutamylanilides as novel probes of ASCT2 with improved potency</span></div><div class="casAuthors">Schulte, Michael L.; Dawson, Eric S.; Saleh, Sam A.; Cuthbertson, Madison L.; Manning, H. Charles</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-116</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the discovery and structure-activity relationships (SAR) of 2-substituted glutamylanilides as novel probes of the steric environment comprising the amino acid binding domain of alanine-serine-cysteine transporter subtype 2 (ASCT2).  Focused library development led to three novel, highly potent ASCT2 inhibitors, with N-(2-(morpholinomethyl)phenyl)-L-glutamine exhibiting the greatest potency in a live-cell glutamine uptake assay.  This level of potency represents a three-fold improvement over the most potent, previously reported inhibitor in this series, GPNA.  Furthermore, this and other compds. in the series exhibit tractable chem. properties for further development as potential therapeutic leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDrPfsuvI6VbVg90H21EOLACvtfcHk0lgIiIXvJYLCVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGitLzP&md5=8be732f1654803cd62a665bc18cdce36</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.098%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DM.%2BL.%26aulast%3DDawson%26aufirst%3DE.%2BS.%26aulast%3DSaleh%26aufirst%3DS.%2BA.%26aulast%3DCuthbertson%26aufirst%3DM.%2BL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26atitle%3D2-Substituted%2520N%2520gamma-glutamylanilides%2520as%2520novel%2520probes%2520of%2520ASCT2%2520with%2520improved%2520potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D1%26spage%3D113%26epage%3D116%26doi%3D10.1016%2Fj.bmcl.2014.10.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khodadadi, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span> <span> </span><span class="NLM_article-title">2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: a novel scaffold for inhibition of ASCT2-mediated glutamine transport</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1044</span>â <span class="NLM_lpage">1047</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2015.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26750251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVGr" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1044-1047&issue=3&author=M.+L.+Schulteauthor=A.+B.+Khodadadiauthor=M.+L.+Cuthbertsonauthor=J.+A.+Smithauthor=H.+C.+Manning&title=2-Amino-4-bis%28aryloxybenzyl%29aminobutanoic+acids%3A+a+novel+scaffold+for+inhibition+of+ASCT2-mediated+glutamine+transport&doi=10.1016%2Fj.bmcl.2015.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport</span></div><div class="casAuthors">Schulte, Michael L.; Khodadadi, Alexandra B.; Cuthbertson, Madison L.; Smith, Jarrod A.; Manning, H. Charles</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1044-1047</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the discovery of 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids as novel inhibitors of ASCT2(SLC1A5)-mediated glutamine accumulation in mammalian cells.  Focused library development led to two novel ASCT2 inhibitors that exhibit significantly improved potency compared with prior art in C6 (rat) and HEK293 (human) cells.  The potency of leads reported here represents a 40-fold improvement over our most potent, previously reported inhibitor and represents, to our knowledge, the most potent pharmacol. inhibitors of ASCT2-mediated glutamine accumulation in live cells.  These and other compds. in this novel series exhibit tractable chem. properties for further development as potential therapeutic leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq536mhHh5MXbVg90H21EOLACvtfcHk0lgIiIXvJYLCVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVGr&md5=d6a393c6948b0fec0d7b490d244a7d14</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DM.%2BL.%26aulast%3DKhodadadi%26aufirst%3DA.%2BB.%26aulast%3DCuthbertson%26aufirst%3DM.%2BL.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DManning%26aufirst%3DH.%2BC.%26atitle%3D2-Amino-4-bis%2528aryloxybenzyl%2529aminobutanoic%2520acids%253A%2520a%2520novel%2520scaffold%2520for%2520inhibition%2520of%2520ASCT2-mediated%2520glutamine%2520transport%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D3%26spage%3D1044%26epage%3D1047%26doi%3D10.1016%2Fj.bmcl.2015.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairweather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span> <span> </span><span class="NLM_article-title">Disruption of amino acid homeostasis by novel ASCT2 inhibitors involves multiple targets</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">785</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.00785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffphar.2018.00785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30072900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1ertbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=785&author=A.+Broerauthor=S.+Fairweatherauthor=S.+Broer&title=Disruption+of+amino+acid+homeostasis+by+novel+ASCT2+inhibitors+involves+multiple+targets&doi=10.3389%2Ffphar.2018.00785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of amino acid homeostasis by novel ASCT2 inhibitors involves multiple targets</span></div><div class="casAuthors">Broer, Angelika; Fairweather, Stephen; Broer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">785/1-785/11</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The glutamine transporter ASCT2 (SLC1A5) is actively investigated as an oncol. target, but the field lacks efficient ASCT2 inhibitors.  A new group of ASCT2 inhibitors, 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids (AABA), were developed recently and shown to suppress tumor growth in preclin. in vivo models.  To test its specificity, we deleted ASCT2 in two human cancer cell lines.  Surprisingly, growth of parental and ASCT2-knockout cells was equally sensitive to AABA compds.  AABA compds. inhibited glutamine transport in cells lacking ASCT2, but not in parental cells.  Deletion of ASCT2 and amino acid (AA) depletion induced expression of SNAT2 (SLC38A2), the activity of which was inhibited by AABA compds.  They also potently inhibited isoleucine uptake via LAT1 (SLC7A5), a transporter that is upregulated in cancer cells together with ASCT2.  Inhibition of SNAT2 and LAT1 was confirmed by recombinant expression in Xenopus laevis oocytes.  The reported redn. of tumor growth in preclin. models may be explained by a significant disruption of AA homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8y0sCAGi7A7Vg90H21EOLACvtfcHk0lgIiIXvJYLCVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1ertbw%253D&md5=5b3b18bfe87c063be793152df7e51a38</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00785%26sid%3Dliteratum%253Aachs%26aulast%3DBroer%26aufirst%3DA.%26aulast%3DFairweather%26aufirst%3DS.%26aulast%3DBroer%26aufirst%3DS.%26atitle%3DDisruption%2520of%2520amino%2520acid%2520homeostasis%2520by%2520novel%2520ASCT2%2520inhibitors%2520involves%2520multiple%2520targets%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D785%26doi%3D10.3389%2Ffphar.2018.00785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gameiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shere, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">Ligand discovery for the alanine-serine-cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">e1004477</span>, <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1004477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1371%2Fjournal.pcbi.1004477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26444490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVelsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004477&issue=10&author=C.+Colasauthor=C.+Grewerauthor=N.+J.+Otteauthor=A.+Gameiroauthor=T.+Albersauthor=K.+Singhauthor=H.+Shereauthor=M.+Bonomiauthor=J.+Holstauthor=A.+Schlessinger&title=Ligand+discovery+for+the+alanine-serine-cysteine+transporter+%28ASCT2%2C+SLC1A5%29+from+homology+modeling+and+virtual+screening&doi=10.1371%2Fjournal.pcbi.1004477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand discovery for the alanine-serine- cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening</span></div><div class="casAuthors">Colas, Claire; Grewer, Christof; Otte, Nicholas James; Gameiro, Armanda; Albers, Thomas; Singh, Kurnvir; Shere, Helen; Bonomi, Massimiliano; Holst, Jeff; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1004477/1-e1004477/22</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The Alanine-Serine-Cysteine transporter ASCT2 (SLC1A5) is a membrane protein that transports neutral amino acids into cells in exchange for outward movement of intracellular amino acids.  ASCT2 is highly expressed in peripheral tissues such as the lung and intestines where it contributes to the homeostasis of intracellular concns. of neutral amino acids.  ASCT2 also plays an important role in the development of a variety of cancers such as melanoma by transporting amino acid nutrients such as glutamine into the proliferating tumors.  Therefore, ASCT2 is a key drug target with potentially great pharmacol. importance.  Here, we identify seven ASCT2 ligands by computational modeling and exptl. testing.  In particular, we construct homol. models based on crystallog. structures of the aspartate transporter GltPh in two different conformations.  Optimization of the models' binding sites for protein-ligand complementarity reveals new putative pockets that can be targeted via structure-based drug design.  Virtual screening of drugs, metabolites, fragments- like, and lead-like mols. from the ZINC database, followed by exptl. testing of 14 top hits with functional measurements using electrophysiol. methods reveals seven ligands, including five activators and two inhibitors.  For example, aminooxetane-3- carboxylate is a more efficient activator than any other known ASCT2 natural or unnatural substrate.  Furthermore, two of the hits inhibited ASCT2 mediated glutamine uptake and proliferation of a melanoma cancer cell line.  Our results improve our understanding of how substrate specificity is detd. in amino acid transporters, as well as provide novel scaffolds for developing chem. tools targeting ASCT2, an emerging therapeutic target for cancer and neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotIg3GUAwXMLVg90H21EOLACvtfcHk0ljZ44v0OTwV3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVelsbk%253D&md5=85170aa0e74b109de3e1f283b1a6d816</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004477%26sid%3Dliteratum%253Aachs%26aulast%3DColas%26aufirst%3DC.%26aulast%3DGrewer%26aufirst%3DC.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DGameiro%26aufirst%3DA.%26aulast%3DAlbers%26aufirst%3DT.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DShere%26aufirst%3DH.%26aulast%3DBonomi%26aufirst%3DM.%26aulast%3DHolst%26aufirst%3DJ.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DLigand%2520discovery%2520for%2520the%2520alanine-serine-cysteine%2520transporter%2520%2528ASCT2%252C%2520SLC1A5%2529%2520from%2520homology%2520modeling%2520and%2520virtual%2520screening%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D10%26spage%3De1004477%26doi%3D10.1371%2Fjournal.pcbi.1004477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gameiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewer, C.</span></span> <span> </span><span class="NLM_article-title">Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">398</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.12.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2016.12.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28057420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=398-402&issue=3&author=K.+Singhauthor=R.+Tanuiauthor=A.+Gameiroauthor=G.+Eisenbergauthor=C.+Colasauthor=A.+Schlessingerauthor=C.+Grewer&title=Structure+activity+relationships+of+benzylproline-derived+inhibitors+of+the+glutamine+transporter+ASCT2&doi=10.1016%2Fj.bmcl.2016.12.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2</span></div><div class="casAuthors">Singh, Kurnvir; Tanui, Rose; Gameiro, Armanda; Eisenberg, Gilad; Colas, Claire; Schlessinger, Avner; Grewer, Christof</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">398-402</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The glutamine transporter ASCT2 has been identified as a promising target to inhibit rapid growth of cancer cells.  However, ASCT2 pharmacol. is not well established.  The authors performed a systematic structure activity anal. of a series of substituted benzylproline derivs.  Substitutions on the Ph ring resulted in compds. with characteristics of ASCT2 inhibitors.  Apparent binding affinity increased with increasing hydrophobicity of the side chain.  In contrast, interaction of the ASCT2 binding site with specific positions on the Ph ring was not obsd.  The most potent compd. inhibits the ASCT2 anion conductance with a Ki of 3 Î¼M, which is in the same range as that of more bulky and higher mol. wt. inhibitors recently reported by others.  The exptl. results are consistent with computational anal. based on docking of the inhibitors against an ASCT2 homol. model.  The benzylproline scaffold provides a valuable tool for further improving binding potency of future ASCT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo78M_phvAZbVg90H21EOLACvtfcHk0ljZ44v0OTwV3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGkuw%253D%253D&md5=96407ed37caa7d14526d272edb3e8d41</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.063%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DTanui%26aufirst%3DR.%26aulast%3DGameiro%26aufirst%3DA.%26aulast%3DEisenberg%26aufirst%3DG.%26aulast%3DColas%26aufirst%3DC.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DGrewer%26aufirst%3DC.%26atitle%3DStructure%2520activity%2520relationships%2520of%2520benzylproline-derived%2520inhibitors%2520of%2520the%2520glutamine%2520transporter%2520ASCT2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D398%26epage%3D402%26doi%3D10.1016%2Fj.bmcl.2016.12.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Leucine signals to mTORC1 via its metabolite acetyl-coenzyme A</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">192</span>â <span class="NLM_lpage">201</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cmet.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30197302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=192-201&issue=1&author=S.+M.+Sonauthor=S.+J.+Parkauthor=H.+Leeauthor=F.+Siddiqiauthor=J.+E.+Leeauthor=F.+M.+Menziesauthor=D.+C.+Rubinsztein&title=Leucine+signals+to+mTORC1+via+its+metabolite+acetyl-coenzyme+A&doi=10.1016%2Fj.cmet.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A</span></div><div class="casAuthors">Son, Sung Min; Park, So Jung; Lee, Huikyong; Siddiqi, Farah; Lee, Jong Eun; Menzies, Fiona M.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">192-201.e7</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is a master regulator of cell growth and metab.  Leucine (Leu) activates mTORC1 and many have tried to identify the mechanisms whereby cells sense Leu in this context.  Here we describe that the Leu metabolite acetyl-CoA (AcCoA) pos. regulates mTORC1 activity by EP300-mediated acetylation of the mTORC1 regulator, Raptor, at K1097.  Leu metab. and consequent mTORC1 activity are regulated by intermediary enzymes.  As AcCoA is a Leu metabolite, this process directly correlates with Leu abundance, and does not require Leu sensing via intermediary proteins, as has been described previously.  Importantly, we describe that this pathway regulates mTORC1 in a cell-type-specific manner.  Finally, we obsd. decreased acetylated Raptor, and inhibited mTORC1 and EP300 activity in fasted mice tissues.  These results provide a direct mechanism for mTORC1 regulation by Leu metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8c-YTdEjqnbVg90H21EOLACvtfcHk0ljZ44v0OTwV3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7nN&md5=fad5d32f5d03e129634c89da99bc9444</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DS.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSiddiqi%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DMenzies%26aufirst%3DF.%2BM.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DLeucine%2520signals%2520to%2520mTORC1%2520via%2520its%2520metabolite%2520acetyl-coenzyme%2520A%26jtitle%3DCell%2520Metab.%26date%3D2019%26volume%3D29%26issue%3D1%26spage%3D192%26epage%3D201%26doi%3D10.1016%2Fj.cmet.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engleman, E. A.</span></span> <span> </span><span class="NLM_article-title">Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>â <span class="NLM_lpage">441</span>, <span class="refDoi">Â DOI: 10.1016/0024-3205(95)00209-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2F0024-3205%2895%2900209-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=7623609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2MXmsFOiurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1995&pages=411-441&issue=5&author=D.+T.+Wongauthor=F.+P.+Bymasterauthor=E.+A.+Engleman&title=Prozac+%28fluoxetine%2C+Lilly+110140%29%2C+the+first+selective+serotonin+uptake+inhibitor+and+an+antidepressant+drug%3A+twenty+years+since+its+first+publication&doi=10.1016%2F0024-3205%2895%2900209-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication</span></div><div class="casAuthors">Wong, David T.; Bymaster, Frank P.; Engleman, Eric A.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-41</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 325 refs. of discovery of the selective 5-HT uptake inhibitor, fluoxetine, and of the scientific research performed on fluoxetine in the 20 yr since the first publication.  The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed.  The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochem. and behavioral models are summarized.  In addn., the clin. effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscSsLvemfnbVg90H21EOLACvtfcHk0lilhxaXawx8SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsFOiurs%253D&md5=a189792f11d27491df125afde67630d2</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2895%2900209-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252895%252900209-O%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BT.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DEngleman%26aufirst%3DE.%2BA.%26atitle%3DProzac%2520%2528fluoxetine%252C%2520Lilly%2520110140%2529%252C%2520the%2520first%2520selective%2520serotonin%2520uptake%2520inhibitor%2520and%2520an%2520antidepressant%2520drug%253A%2520twenty%2520years%2520since%2520its%2520first%2520publication%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D57%26issue%3D5%26spage%3D411%26epage%3D441%26doi%3D10.1016%2F0024-3205%2895%2900209-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plott, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeroff, C. B.</span></span> <span> </span><span class="NLM_article-title">Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1305</span>â <span class="NLM_lpage">1322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9400006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1cXis1GmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=1305-1322&issue=3&author=M.+J.+Owensauthor=W.+N.+Morganauthor=S.+J.+Plottauthor=C.+B.+Nemeroff&title=Neurotransmitter+receptor+and+transporter+binding+profile+of+antidepressants+and+their+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites</span></div><div class="casAuthors">Owens, Michael J.; Morgan, W. Neal; Plott, Susan J.; Nemeroff, Charles B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1305-1322</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Several new antidepressants that inhibit the serotonin (SERT) and norepinephrine transporters (NET) have been introduced into clin. practice the past several years.  This report focuses on the further pharmacol. characterization of nefazodone and its metabolites within the serotonergic and noradrenergic systems, in comparison with other antidepressants.  By use of radioligand binding assays, we measured the affinity (Ki) of 13 antidepressants and 6 metabolites for the rat and human SERT and NET.  The Ki values for eight of the antidepressants and three metabolites were also detd. for the rat 5-HT1A, 5-HT2A and muscarinic cholinergic receptors, the guinea pig histamine1 receptor and the human alpha-1 and alpha-2 receptors.  These data are useful for predicting side effect profiles and the potential for pharmacodynamic drug-drug interactions of antidepressants.  Of particular interest were the findings that paroxetine, generally thought of as a selective SERT antagonist, possesses moderately high affinity for the NET and that venlafaxine, which has been described as a "dual uptake inhibitor", possesses weak affinity for the NET.  We obsd. significant correlations in SERT (r = 0.965) or NET (r = 0.983) affinity between rat and human transporters.  Significant correlations were also obsd. between muscarinic cholinergic and NET affinity.  There are several significant correlations between affinities for the 5-HT1A, 5-HT2A, histamine1, alpha-1 and alpha-2 receptors.  These novel findings, not widely described previously, suggest that many of the, individual drugs studied in these expts. possess some structural characteristic that dets. affinity for several G protein-coupled, but not muscarinic, receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGradn8u7KxbQrVg90H21EOLACvtfcHk0lilhxaXawx8SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1GmtQ%253D%253D&md5=fa8d12aed5de3875493c77cd9a869933</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DM.%2BJ.%26aulast%3DMorgan%26aufirst%3DW.%2BN.%26aulast%3DPlott%26aufirst%3DS.%2BJ.%26aulast%3DNemeroff%26aufirst%3DC.%2BB.%26atitle%3DNeurotransmitter%2520receptor%2520and%2520transporter%2520binding%2520profile%2520of%2520antidepressants%2520and%2520their%2520metabolites%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26issue%3D3%26spage%3D1305%26epage%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindmarch, I.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors</span>. <i>Acta Psychiatr. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">s403</span>),  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1111/j.1600-0447.2000.tb10944.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fj.1600-0447.2000.tb10944.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2000&pages=17-25&issue=s403&author=S.+Perettiauthor=R.+Judgeauthor=I.+Hindmarch&title=Safety+and+tolerability+considerations%3A+tricyclic+antidepressants+vs.+selective+serotonin+reuptake+inhibitors&doi=10.1111%2Fj.1600-0447.2000.tb10944.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.2000.tb10944.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.2000.tb10944.x%26sid%3Dliteratum%253Aachs%26aulast%3DPeretti%26aufirst%3DS.%26aulast%3DJudge%26aufirst%3DR.%26aulast%3DHindmarch%26aufirst%3DI.%26atitle%3DSafety%2520and%2520tolerability%2520considerations%253A%2520tricyclic%2520antidepressants%2520vs.%2520selective%2520serotonin%2520reuptake%2520inhibitors%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D2000%26volume%3D101%26issue%3Ds403%26spage%3D17%26epage%3D25%26doi%3D10.1111%2Fj.1600-0447.2000.tb10944.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennacef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotbolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">311</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1124/jpet.112.202895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fjpet.112.202895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23685546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=311-317&issue=2&author=R.+A.+Comleyauthor=C.+A.+Salinasauthor=M.+Slifsteinauthor=M.+Petroneauthor=C.+Marzanoauthor=I.+Bennacefauthor=P.+Shotboltauthor=J.+Van+der+Aartauthor=M.+Neveauthor=L.+Iavaroneauthor=R.+Gomeniauthor=M.+Laruelleauthor=F.+A.+Grayauthor=R.+N.+Gunnauthor=E.+A.+Rabiner&title=Monoamine+transporter+occupancy+of+a+novel+triple+reuptake+inhibitor+in+baboons+and+humans+using+positron+emission+tomography&doi=10.1124%2Fjpet.112.202895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span></div><div class="casAuthors">Comley, Robert A.; Salinas, Cristian A.; Slifstein, Mark; Petrone, Marcella; Marzano, Carmine; Bennacef, Idriss; Shotbolt, Paul; Van der Aart, Jasper; Neve, Marta; Iavarone, Laura; Gomeni, Roberto; Laruelle, Marc; Gray, Frank A.; Gunn, Roger N.; Rabiner, Eugenii A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The selection of a therapeutically meaningful dose of a novel pharmaceutical is a crucial step in drug development.  Positron emission tomog. (PET) allows the in vivo estn. of the relationship between the plasma concn. of a drug and its target occupancy, optimizing dose selection and reducing the time and cost of early development.  Triple reuptake inhibitors (TRIs), also referred to as serotonin-norepinephrine-dopamine reuptake inhibitors, enhance monoaminergic neurotransmission by blocking the action of the monoamine transporters, raising extracellular concns. of those neurotransmitters.  GSK1360707 [(1R,6S)-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane] is a novel TRI that until recently was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.  We present the results of an in vivo assessment of the relationship between plasma exposure and transporter blockade (occupancy).  Studies were performed in baboons (Papio anubis) to det. the relationship between plasma concn. and occupancy of brain serotonin reuptake transporter (SERT), dopamine reuptake transporter (DAT), and norepinephrine uptake transporter (NET) using the radioligands [11C]DASB [(N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine], [11C]PE2I [N-(3-iodoprop-2E-enyl)-2Î²-carbomethoxy-3Î²-(4-methylphenyl)nortropane], and [11C]2-[(2-methoxyphenoxy)phenylmethyl]morpholine (also known as [11C]MRB) and in humans using [11C]DASB and [11C]PE2I.  In P. anubis, plasma concns. resulting in half-maximal occupancy at SERT, DAT, and NET were 15.16, 15.56, and 0.97 ng/mL, resp.  In humans, the corresponding values for SERT and DAT were 6.80 and 18.00 ng/mL.  GSK1360707 dose-dependently blocked the signal of SERT-, DAT-, and NET-selective PET ligands, confirming its penetration across the blood-brain barrier and blockade of all three monoamine transporters in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOk3b2TA00rVg90H21EOLACvtfcHk0lilhxaXawx8SA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE&md5=b92262955a074c2d981015dc436127bb</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202895%26sid%3Dliteratum%253Aachs%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DSalinas%26aufirst%3DC.%2BA.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DPetrone%26aufirst%3DM.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DBennacef%26aufirst%3DI.%26aulast%3DShotbolt%26aufirst%3DP.%26aulast%3DVan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DNeve%26aufirst%3DM.%26aulast%3DIavarone%26aufirst%3DL.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DLaruelle%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DMonoamine%2520transporter%2520occupancy%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%2520in%2520baboons%2520and%2520humans%2520using%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26issue%3D2%26spage%3D311%26epage%3D317%26doi%3D10.1124%2Fjpet.112.202895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreshfield-Ahmad, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threlkeld, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemrick-Luecke, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span> <span> </span><span class="NLM_article-title">Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">871</span>â <span class="NLM_lpage">880</span>, <span class="refDoi">Â DOI: 10.1016/S0893-133X(01)00298-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0893-133X%2801%2900298-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11750180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1antLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=871-880&issue=6&author=F.+P.+Bymasterauthor=L.+J.+Dreshfield-Ahmadauthor=P.+G.+Threlkeldauthor=J.+L.+Shawauthor=L.+Thompsonauthor=D.+L.+Nelsonauthor=S.+K.+Hemrick-Lueckeauthor=D.+T.+Wong&title=Comparative+affinity+of+duloxetine+and+venlafaxine+for+serotonin+and+norepinephrine+transporters+in+vitro+and+in+vivo%2C+human+serotonin+receptor+subtypes%2C+and+other+neuronal+receptors&doi=10.1016%2FS0893-133X%2801%2900298-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors</span></div><div class="casAuthors">Bymaster, Frank P.; Dreshfield-Ahmad, Laura J.; Threlkeld, Penny G.; Shaw, Janice L.; Thompson, Linda; Nelson, David L.; Hemrick-Luecke, Susan K.; Wong, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">871-880</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The blockade of serotonin (5-HT) and norepinephrine (NE) transporters in vitro and in vivo by the dual 5-HT/NE reuptake inhibitors duloxetine and venlafaxine was compared.  Duloxetine inhibited binding to the human NE and 5-HT transporters with Ki values of 7.5 and 0.8 nM, resp., and with a Ki ratio of 9.  Venlafaxine inhibited binding to the human NE and 5-HT transporters with Ki values of 2480 and 82 nM, resp., and with a Ki ratio of 30.  Duloxetine inhibited ex vivo binding to rat 5-HT transporters and NE transporters with ED50 values of 0.03 and 0.7 mg/kg, resp., whereas venlafaxine had ED50 values of 2 and 54 mg/kg, resp.  The depletion of rat brain 5-HT by p-chloramphetamine and depletion of rat hypothalamic NE by 6-hydroxydopamine was blocked by duloxetine with ED50 values of 2.3 and 12 mg/kg, resp.  Venlafaxine had ED50 values of 5.9 and 94 mg/kg for blocking p-chloramphetamine- and 6-hydroxydopamine-induced monoamine depletion, resp.  Thus, duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiyEG228XhLVg90H21EOLACvtfcHk0lidIlXLxCcZNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1antLo%253D&md5=5e394cdee917e0189acf774233617e60</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2801%2900298-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252801%252900298-6%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DDreshfield-Ahmad%26aufirst%3DL.%2BJ.%26aulast%3DThrelkeld%26aufirst%3DP.%2BG.%26aulast%3DShaw%26aufirst%3DJ.%2BL.%26aulast%3DThompson%26aufirst%3DL.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DHemrick-Luecke%26aufirst%3DS.%2BK.%26aulast%3DWong%26aufirst%3DD.%2BT.%26atitle%3DComparative%2520affinity%2520of%2520duloxetine%2520and%2520venlafaxine%2520for%2520serotonin%2520and%2520norepinephrine%2520transporters%2520in%2520vitro%2520and%2520in%2520vivo%252C%2520human%2520serotonin%2520receptor%2520subtypes%252C%2520and%2520other%2520neuronal%2520receptors%26jtitle%3DNeuropsychopharmacology%26date%3D2001%26volume%3D25%26issue%3D6%26spage%3D871%26epage%3D880%26doi%3D10.1016%2FS0893-133X%2801%2900298-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papakostas, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R. C.</span></span> <span> </span><span class="NLM_article-title">Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1217</span>â <span class="NLM_lpage">1227</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2007.03.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.biopsych.2007.03.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17588546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ymu7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=1217-1227&issue=11&author=G.+I.+Papakostasauthor=M.+E.+Thaseauthor=M.+Favaauthor=J.+C.+Nelsonauthor=R.+C.+Shelton&title=Are+antidepressant+drugs+that+combine+serotonergic+and+noradrenergic+mechanisms+of+action+more+effective+than+the+selective+serotonin+reuptake+inhibitors+in+treating+major+depressive+disorder%3F+A+meta-analysis+of+studies+of+newer+agents&doi=10.1016%2Fj.biopsych.2007.03.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents</span></div><div class="casAuthors">Papakostas, George I.; Thase, Michael E.; Fava, Maurizio; Nelson, J. Craig; Shelton, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1217-1227</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Recent studies suggest that the treatment of major depressive disorder (MDD) with newer antidepressant drugs that simultaneously enhance norepinephrine and serotonin neurotransmission might result in higher response and remission rates than the selective serotonin reuptake inhibitors (SSRIs).  The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs.  Methods: Medline/Pubmed, EMBase, clin. trial registries, program syllabi from major psychiatric meetings held since 1995, and documents from relevant pharmaceutical companies were searched for double-blind, randomized trials comparing a newer serotonergic-noradrenergic antidepressant drug (venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, or moclobemide) with an SSRI for MDD.  Results: Ninety-three trials (n = 17,036) were combined using a random-effects model.  Treatment with serotonergic + noradrenergic antidepressant drugs was more likely to result in clin. response than the SSRIs (risk ratio [RR] = 1.059; response rates 63.6% vs. 59.3%; p = .003).  There was no evidence for heterogeneity among studies combined (p = 1.0).  Excluding each individual agent did not significantly alter the pooled RR.  With the exception of duloxetine (.985), RRs for response for each individual serotonergic + noradrenergic antidepressant drug were within the 95% confidence interval of the pooled RR (1.019-1.101).  Conclusions: Serotonergic-noradrenergic antidepressant drugs seem to have a modest efficacy advantage compared with SSRIs in MDD.  With the No. Needed to Treat (NNT) statistic as one indicator of clin. significance, nearly 24 patients would need to be treated with dual-action antidepressant drugs instead of SSRIs in order to obtain one addnl. responder.  This difference falls well below the mark of NNT = 10 suggested by the United Kingdom's National Institute of Clin. Excellence but nonetheless might be of public health relevance given the large no. of depressed patients treated with SSRI /serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant drugs.  Further research is needed to examine whether larger differences between classes of antidepressant drugs might exist in specific MDD sub-populations or for specific MDD symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFTcv5V6MlT7Vg90H21EOLACvtfcHk0lidIlXLxCcZNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ymu7jI&md5=4c4bd9fe021e6fab91cb3a18b779c4e5</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.03.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.03.027%26sid%3Dliteratum%253Aachs%26aulast%3DPapakostas%26aufirst%3DG.%2BI.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DFava%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DJ.%2BC.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26atitle%3DAre%2520antidepressant%2520drugs%2520that%2520combine%2520serotonergic%2520and%2520noradrenergic%2520mechanisms%2520of%2520action%2520more%2520effective%2520than%2520the%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520treating%2520major%2520depressive%2520disorder%253F%2520A%2520meta-analysis%2520of%2520studies%2520of%2520newer%2520agents%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D62%26issue%3D11%26spage%3D1217%26epage%3D1227%26doi%3D10.1016%2Fj.biopsych.2007.03.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morabito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscatello, M. R.</span></span> <span> </span><span class="NLM_article-title">The role of levomilnacipran in the management of major depressive disorder: a comprehensive review</span>. <i>Current Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">199</span>, <span class="refDoi">Â DOI: 10.2174/1570159X14666151117122458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2174%2F1570159X14666151117122458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26572745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVGntbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=191-199&issue=2&author=A.+Brunoauthor=P.+Morabitoauthor=E.+Spinaauthor=M.+R.+Muscatello&title=The+role+of+levomilnacipran+in+the+management+of+major+depressive+disorder%3A+a+comprehensive+review&doi=10.2174%2F1570159X14666151117122458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review</span></div><div class="casAuthors">Bruno, Antonio; Morabito, Paolo; Spina, Edoardo; Muscatello, Maria Rosaria</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-199</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Levomilnacipran, the more active enantiomer of the serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in the US for the treatment of major depressive disorder (MDD).  The drug was developed as an extended release (ER) capsule formulation to allow for once-daily administration, thereby improving patient adherence.  This agent differs from other available SNRIs in having a greater potency for inhibition of norepinephrine relative to serotonin reuptake.  The efficacy of levomilnacipran ER has been evaluated in seven randomized, double-blind clin. trials (one Phase II and four Phase III trials, and two long-term efficacy studies).  These studies documented that levomilnacipran is generally more effective than placebo for the treatment of MDD in the short-term, whereas no firm evidence exists on long-term efficacy for relapse prevention.  Preliminary evidence suggests that levomilnacipran ER may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life).  Short-and longer-term studies found that the rate of withdrawal from levomilnacipran therapy due to adverse events was rather low.  Moreover the drug appeared to be generally well tolerated.  The most common adverse effects included nausea, hyperhidrosis, constipation, tachycardia, palpitations, erectile dysfunction and ejaculation disorder.  As hypertension or orthostatic hypotension may occur in a few patients, the cardiovascular safety of levomilnacipran needs to be more extensively investigated esp. on long-term treatment.  Addnl. active comparator trials evaluating efficacy, tolerability and cost-effectiveness are required to better define the role of levomilnacipran ER in the treatment of MDD in relation to currently available antidepressants including other SNRIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSH4IjUxNj7Vg90H21EOLACvtfcHk0lidIlXLxCcZNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVGntbY%253D&md5=c29309495b78cedbc3cad6eb1e0d8da7</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.2174%2F1570159X14666151117122458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X14666151117122458%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DMorabito%26aufirst%3DP.%26aulast%3DSpina%26aufirst%3DE.%26aulast%3DMuscatello%26aufirst%3DM.%2BR.%26atitle%3DThe%2520role%2520of%2520levomilnacipran%2520in%2520the%2520management%2520of%2520major%2520depressive%2520disorder%253A%2520a%2520comprehensive%2520review%26jtitle%3DCurrent%2520Neuropharmacology%26date%3D2016%26volume%3D14%26issue%3D2%26spage%3D191%26epage%3D199%26doi%3D10.2174%2F1570159X14666151117122458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradko, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haight, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modell, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockett, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learned-Coughlin, S.</span></span> <span> </span><span class="NLM_article-title">A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor</span>. <i>Prim. Care Companion J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">166</span>, <span class="refDoi">Â DOI: 10.4088/PCC.v06n0403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.4088%2FPCC.v06n0403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15361919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2sbnvFaqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=159-166&issue=4&author=S.+M.+Stahlauthor=J.+F.+Pradkoauthor=B.+R.+Haightauthor=J.+G.+Modellauthor=C.+B.+Rockettauthor=S.+Learned-Coughlin&title=A+review+of+the+neuropharmacology+of+bupropion%2C+a+dual+norepinephrine+and+dopamine+reuptake+inhibitor&doi=10.4088%2FPCC.v06n0403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor</span></div><div class="casAuthors">Stahl Stephen M.; Pradko James F.; Haight Barbara R.; Modell Jack G.; Rockett Carol B.; Learned-Coughlin Susan</div><div class="citationInfo"><span class="NLM_cas:title">Primary care companion to the Journal of clinical psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">159-166</span>
        ISSN:<span class="NLM_cas:issn">1523-5998</span>.
    </div><div class="casAbstract">BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade.  When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain.  Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity.  This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles.  DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases.  CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors.  Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile.  Bupropion has demonstrated efficacy comparable to that of other antidepressants.  However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-_ZTfnJrdW_6AExegM5LLfW6udTcc2eZ2uEf-a5G1Yrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbnvFaqsw%253D%253D&md5=58cacfbd299dd471fb1d5a09f17c0fd6</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.4088%2FPCC.v06n0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.v06n0403%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DS.%2BM.%26aulast%3DPradko%26aufirst%3DJ.%2BF.%26aulast%3DHaight%26aufirst%3DB.%2BR.%26aulast%3DModell%26aufirst%3DJ.%2BG.%26aulast%3DRockett%26aufirst%3DC.%2BB.%26aulast%3DLearned-Coughlin%26aufirst%3DS.%26atitle%3DA%2520review%2520of%2520the%2520neuropharmacology%2520of%2520bupropion%252C%2520a%2520dual%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitor%26jtitle%3DPrim.%2520Care%2520Companion%2520J.%2520Clin.%2520Psychiatry%26date%3D2004%26volume%3D6%26issue%3D4%26spage%3D159%26epage%3D166%26doi%3D10.4088%2FPCC.v06n0403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glase, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, N. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5550</span>â <span class="NLM_lpage">5553</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=18805691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5550-5553&issue=20&author=W.+J.+Xuauthor=D.+L.+Grayauthor=S.+A.+Glaseauthor=N.+S.+Barta&title=Design+and+synthesis+of+reboxetine+analogs+morpholine+derivatives+as+selective+norepinephrine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2008.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors</span></div><div class="casAuthors">Xu, Wenjian; Gray, David L.; Glase, Shelly A.; Barta, Nancy S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5550-5553</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">As part of a discovery effort aimed at identifying novel norepinephrine reuptake inhibitors (NRIs), a no. of substituted morpholines were designed and synthesized.  The target compds. contain vicinal stereogenic centers, and the program was greatly facilitated by the adoption of efficient synthetic routes which allowed for the late stage incorporation of structural and physicochem. diversity into the targets.  Structure-activity relationships were developed by optimizing individual ring components of the structure for NRI potency and for selectivity against other monoamine reuptake transporters.  Several novel morpholine derivs. with a potent and selective NRI profile are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplQjUTJkL2frVg90H21EOLACvtfcHk0li0-7pg-4PR1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs73L&md5=97804088401d35c78cdd0acad155888d</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%2BJ.%26aulast%3DGray%26aufirst%3DD.%2BL.%26aulast%3DGlase%26aufirst%3DS.%2BA.%26aulast%3DBarta%26aufirst%3DN.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520reboxetine%2520analogs%2520morpholine%2520derivatives%2520as%2520selective%2520norepinephrine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D20%26spage%3D5550%26epage%3D5553%26doi%3D10.1016%2Fj.bmcl.2008.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partilla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.drugalcdep.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.drugalcdep.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25548026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=1-19&author=M.+E.+A.+Reithauthor=B.+E.+Bloughauthor=W.+M.+C.+Hongauthor=K.+T.+Jonesauthor=K.+C.+Schmittauthor=M.+H.+Baumannauthor=J.+S.+Partillaauthor=R.+B.+Rothmanauthor=J.+L.+Katz&title=Behavioral%2C+biological%2C+and+chemical+perspectives+on+atypical+agents+targeting+the+dopamine+transporter&doi=10.1016%2Fj.drugalcdep.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span></div><div class="casAuthors">Reith, Maarten E. A.; Blough, Bruce E.; Hong, Weimin C.; Jones, Kymry T.; Schmitt, Kyle C.; Baumann, Michael H.; Partilla, John S.; Rothman, Richard B.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of stimulant-use disorders remains a formidable challenge, and the dopamine transporter (DAT) remains a potential target for antagonist or agonist-like substitution therapies, so this review focuses on DAT ligands, such as benztropine, GBR 12909, modafinil, and DAT substrates derived from phenethylamine or cathinone that have atypical DAT-inhibitor effects, either in vitro or in vivo.  The compds. are described from a mol. mechanistic, behavioral, and medicinal-chem. perspective.Possible mechanisms for atypicality at the mol. level can be deduced from the conformational cycle for substrate translocation.  For each conformation, a crystal structure of a bacterial homolog is available, with a possible role of cholesterol, which is also present in the crystal of Drosophila DAT.  Although there is a direct relationship between behavioral potencies of most DAT inhibitors and their DAT affinities, a no. of compds. bind to the DAT and inhibit dopamine uptake but do not share cocaine-like effects.  Such atypical behavior, depending on the compd., may be related to slow DAT assocn., combined sigma-receptor actions, or bias for cytosol-facing DAT.  Some structures are sterically small enough to serve as DAT substrates but large enough to also inhibit transport.  Such compds. may display partial DA releasing effects, and may be combined with release or uptake inhibition at other monoamine transporters.  Mechanisms of atypical DAT inhibitors may serve as targets for the development of treatments for stimulant abuse.  These mechanisms are novel and their further exploration may produce compds. with unique therapeutic potential as treatments for stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsfVrk5h43rVg90H21EOLACvtfcHk0li0-7pg-4PR1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D&md5=d6f46c4fd505810f64eafc748702d299</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DHong%26aufirst%3DW.%2BM.%2BC.%26aulast%3DJones%26aufirst%3DK.%2BT.%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DPartilla%26aufirst%3DJ.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DBehavioral%252C%2520biological%252C%2520and%2520chemical%2520perspectives%2520on%2520atypical%2520agents%2520targeting%2520the%2520dopamine%2520transporter%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2015%26volume%3D147%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.drugalcdep.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetin, M.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors (TRIs): do they promise us a rose garden?</span>. <i>Psychiat Clin Psych</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">122</span>, <span class="refDoi">Â DOI: 10.1080/24750573.2018.1443386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1080%2F24750573.2018.1443386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt12isbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=119-122&issue=2&author=S.+Koseauthor=M.+Cetin&title=Triple+reuptake+inhibitors+%28TRIs%29%3A+do+they+promise+us+a+rose+garden%3F&doi=10.1080%2F24750573.2018.1443386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors (TRIs): do they promise us a rose garden?</span></div><div class="casAuthors">Kose, Samet; Cetin, Mesut</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-122</span>CODEN:
                <span class="NLM_cas:coden">PCPSC6</span>;
        ISSN:<span class="NLM_cas:issn">2475-0581</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPo_iFHjGTpbVg90H21EOLACvtfcHk0lhL_Npkn9EvjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt12isbk%253D&md5=f68227c50a6eacb71f0937055ae4fba5</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1080%2F24750573.2018.1443386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F24750573.2018.1443386%26sid%3Dliteratum%253Aachs%26aulast%3DKose%26aufirst%3DS.%26aulast%3DCetin%26aufirst%3DM.%26atitle%3DTriple%2520reuptake%2520inhibitors%2520%2528TRIs%2529%253A%2520do%2520they%2520promise%2520us%2520a%2520rose%2520garden%253F%26jtitle%3DPsychiat%2520Clin%2520Psych%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D119%26epage%3D122%26doi%3D10.1080%2F24750573.2018.1443386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">X-ray structures and mechanism of the human serotonin transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span> (<span class="NLM_issue">7599</span>),  <span class="NLM_fpage">334</span>â <span class="NLM_lpage">339</span>, <span class="refDoi">Â DOI: 10.1038/nature17629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature17629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27049939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=334-339&issue=7599&author=J.+A.+Colemanauthor=E.+M.+Greenauthor=E.+Gouaux&title=X-ray+structures+and+mechanism+of+the+human+serotonin+transporter&doi=10.1038%2Fnature17629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structures and mechanism of the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Green, Evan M.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7599</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) terminates serotonergic signaling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons.  SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signaling.  Here the authors report x-ray crystallog. structures of human SERT at 3.15 Ã resoln. bound to the antidepressants (S)-citalopram or paroxetine.  Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helixes 1, 3, 6, 8 and 10, directly blocking serotonin binding.  The authors further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helixes 1, 6, 10 and 11.  Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand.  These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAxl5tROCorVg90H21EOLACvtfcHk0lhL_Npkn9EvjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D&md5=e4fa11a1e5abdd7b39f44375506aa249</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1038%2Fnature17629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17629%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DE.%2BM.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DX-ray%2520structures%2520and%2520mechanism%2520of%2520the%2520human%2520serotonin%2520transporter%26jtitle%3DNature%26date%3D2016%26volume%3D532%26issue%3D7599%26spage%3D334%26epage%3D339%26doi%3D10.1038%2Fnature17629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for recognition of diverse antidepressants by the human serotonin transporter</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">170</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1038/s41594-018-0026-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-018-0026-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29379174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlCqu7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=170-175&issue=2&author=J.+A.+Colemanauthor=E.+Gouaux&title=Structural+basis+for+recognition+of+diverse+antidepressants+by+the+human+serotonin+transporter&doi=10.1038%2Fs41594-018-0026-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for recognition of diverse antidepressants by the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-175</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Selective serotonin reuptake inhibitors are clin. prescribed antidepressants that act by increasing the local concns. of neurotransmitters at synapses and in extracellular spaces via blockade of the serotonin transporter.  Here we report X-ray structures of engineered thermostable variants of the human serotonin transporter bound to the antidepressants sertraline, fluvoxamine, and paroxetine.  The drugs prevent serotonin binding by occupying the central substrate-binding site and stabilizing the transporter in an outward-open conformation.  These structures explain how residues within the central site orchestrate binding of chem. diverse inhibitors and mediate transporter drug selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwSIgd0WTZL7Vg90H21EOLACvtfcHk0lhL_Npkn9EvjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlCqu7jN&md5=1ea0418315d7c7a134ddef48e36c6d07</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0026-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0026-8%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DStructural%2520basis%2520for%2520recognition%2520of%2520diverse%2520antidepressants%2520by%2520the%2520human%2520serotonin%2520transporter%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D170%26epage%3D175%26doi%3D10.1038%2Fs41594-018-0026-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiden, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. J.</span></span> <span> </span><span class="NLM_article-title">Expression cloning of a reserpine-sensitive vesicular monoamine transporter</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10993</span>â <span class="NLM_lpage">10997</span>, <span class="refDoi">Â DOI: 10.1073/pnas.89.22.10993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.89.22.10993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1438304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK3sXkvV2ht7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=10993-10997&issue=22&author=J.+D.+Ericksonauthor=L.+E.+Eidenauthor=B.+J.+Hoffman&title=Expression+cloning+of+a+reserpine-sensitive+vesicular+monoamine+transporter&doi=10.1073%2Fpnas.89.22.10993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Expression cloning of a reserpine-sensitive vesicular monoamine transporter</span></div><div class="casAuthors">Erickson, Jeffrey D.; Eiden, Lee E.; Hoffman, Beth J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10993-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A cDNA for a rat vesicular monoamine transporter, designated MAT, was isolated by expression cloning in a mammalian cell line (CV-1).  The cDNA sequence predicts a protein of 515 amino acids with 12 putative membrane-spanning domains.  The characteristics of [3H]serotonin accumulation by CV-1 cells expressing the cDNA clone suggested sequestration by an intracellular compartment.  In cells permeabilized with digitonin, uptake was ATP dependent with an apparent Km of 1.3 Î¼M.  Uptake was abolished by the proton-translocating ionophore carbonylcyanide p-trifluoromethoxyphenylhydrazone and with tri-(n-butyl)tin, an inhibitor of the vacuolar H+-ATPase.  The rank order of potency to inhibit uptake was reserpine > tetrabenazine > serotonin > dopamine > norepinephrine > epinephrine.  Direct comparison of [3H]monoamine uptake indicated that serotonin was the preferred substrate.  Photolabeling of membranes prepd. form CV-1 cells expressing MAT with 7-azido-8-[125I]iodoketanserin revealed a predominant tetrabenazine-sensitive photolabeled glycoprotein with an apparent mol. mass of â75 kDa.  The mRNA that encodes MAT was present specifically in monoamine-contg. cells of the locus coeruleus, substantia nigra, and raphe nucleus of rat brain, each of which expresses a unique plasma membrane reuptake transporter.  The MAT cDNA clone defines a vesicular monoamine transporter representing a distinct class of neurotransmitter transport mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5IYDWkYJGhrVg90H21EOLACvtfcHk0lg-_rvdrmToBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvV2ht7o%253D&md5=ff81153925159172ceb476d60bf1eeac</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.22.10993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.22.10993%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DJ.%2BD.%26aulast%3DEiden%26aufirst%3DL.%2BE.%26aulast%3DHoffman%26aufirst%3DB.%2BJ.%26atitle%3DExpression%2520cloning%2520of%2520a%2520reserpine-sensitive%2520vesicular%2520monoamine%2520transporter%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26issue%3D22%26spage%3D10993%26epage%3D10997%26doi%3D10.1073%2Fpnas.89.22.10993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. H.</span></span> <span> </span><span class="NLM_article-title">The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">7231</span>â <span class="NLM_lpage">7237</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8125935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2cXitV2htrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=7231-7237&issue=10&author=D.+Peterauthor=J.+Jimenezauthor=Y.+Liuauthor=J.+Kimauthor=R.+H.+Edwards&title=The+chromaffin+granule+and+synaptic+vesicle+amine+transporters+differ+in+substrate+recognition+and+sensitivity+to+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors</span></div><div class="casAuthors">Peter, Doris; Jimenez, Juan; Liu, Yongjian; Kim, Jung; Edwards, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">7231-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Classical studies using bovine chromaffin granules have defined the physiol. and pharmacol. properties of the vesicular amine transporter that packages monoamine transmitters into intracellular vesicles for subsequent regulated release.  The recent isolation of two distinct but closely related cDNA clones encoding vesicular amine transport suggests that the activity expressed in the brain (synaptic vesicle amine transporter or SVAT) may differ significantly from the previously described adrenal gland activity (chromaffin granule amine transporter or CGAT).  A direct comparison of the two transporters now shows that SVAT has a higher affinity than CGAT for monoamine substrates, in particular for histamine.  In addn., SVAT shows approx. 10-fold greater sensitivity to tetrabenazine than CGAT.  [3H]Dihydrotetrabenazine shows no detectable binding to CGAT but does bind to SVAT, accounting for the differential sensitivity.  Furthermore, methamphetamine preferentially inhibits transport by SVAT relative to CGAT, apparently by competing at the site of amine recognition rather than by disrupting the vesicular pH gradient.  These previously unsuspected differences in the storage of monoamine transmitter in the central nervous system and the adrenal gland may help to account for several classic pharmacol. observations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKKuFUbOWyY7Vg90H21EOLACvtfcHk0lg-_rvdrmToBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitV2htrY%253D&md5=a8b0b97f74061b1c2e00922aff725e11</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DD.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DR.%2BH.%26atitle%3DThe%2520chromaffin%2520granule%2520and%2520synaptic%2520vesicle%2520amine%2520transporters%2520differ%2520in%2520substrate%2520recognition%2520and%2520sensitivity%2520to%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26issue%3D10%26spage%3D7231%26epage%3D7237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWitt, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Deuterated drug molecules: focus on FDA-approved deutetrabenazine</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">472</span>â <span class="NLM_lpage">473</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.7b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=472-473&issue=5&author=S.+H.+DeWittauthor=B.+E.+Maryanoff&title=Deuterated+drug+molecules%3A+focus+on+FDA-approved+deutetrabenazine&doi=10.1021%2Facs.biochem.7b00765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine</span></div><div class="casAuthors">DeWitt, Sheila H.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-473</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The approval of Austedo (deutetrabenazine) as a new chem. entity (NCE) via the 505(b)(2) regulatory pathway established an important milestone for the development and marketing of deuterated drugs.  Its notable introduction into clin. medicine could well be the harbinger of a new era for the utility of deuterium-substituted drug mols.  This point of view is further supported by the sizable collection of other deuterated mols. that are currently in clin. trials, some of which will hopefully emerge successful for the benefit of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcRjVCOoN5bVg90H21EOLACvtfcHk0lg-_rvdrmToBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL&md5=a1aecdd9f8b539b9e3988d8b135d881a</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00765%26sid%3Dliteratum%253Aachs%26aulast%3DDeWitt%26aufirst%3DS.%2BH.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDeuterated%2520drug%2520molecules%253A%2520focus%2520on%2520FDA-approved%2520deutetrabenazine%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26issue%3D5%26spage%3D472%26epage%3D473%26doi%3D10.1021%2Facs.biochem.7b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harriott, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozigian, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, D. E.</span></span> <span> </span><span class="NLM_article-title">VMAT2 inhibitors and the path to ingrezza (valbenazine)</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">111</span>, <span class="refDoi">Â DOI: 10.1016/bs.pmch.2017.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fbs.pmch.2017.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29680151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltFOgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=87-111&issue=1&author=N.+D.+Harriottauthor=J.+P.+Williamsauthor=E.+B.+Smithauthor=H.+P.+Bozigianauthor=D.+E.+Grigoriadis&title=VMAT2+inhibitors+and+the+path+to+ingrezza+%28valbenazine%29&doi=10.1016%2Fbs.pmch.2017.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)</span></div><div class="casAuthors">Harriott Nicole D; Williams John P; Smith Evan B; Bozigian Haig P; Grigoriadis Dimitri E</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-111</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">The dopaminergic system plays a key role in the central nervous system, regulating executive function, arousal, reward, and motor control.  Dysregulation of this critical monoaminergic system has been associated with diseases of the central nervous system including schizophrenia, Parkinson's disease, and disorders such as attention deficit hyperactivity disorders and addiction.  Drugs that modify the dopaminergic system by modulating the activity of dopamine have been successful in demonstrating clinical efficacy by providing treatments for these diseases.  Specifically, antipsychotics, both typical and atypical, while acting on a number of monoaminergic systems in the brain, primarily target the dopamine system via inhibition of postsynaptic dopamine receptors.  The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent release of dopamine and other monoamines from neuronal vesicles into the synapse.  Despite acting on opposing sides of the synapse, both antipsychotics and VMAT2 inhibitors act to decrease the activity of central dopaminergic systems.  Tardive dyskinesia is a disorder characterized by involuntary repetitive movements and thought to be a result of a hyperdopaminergic state precipitated by the use of antipsychotics.  Valbenazine (NBI-98854), a novel compound that selectively inhibits VMAT2 through an active metabolite, has been developed for the treatment of tardive dyskinesia and is the first drug approved for the treatment of this disorder.  This chapter describes the process leading to the discovery of valbenazine, its pharmacological characteristics, along with preclinical and clinical evidence of its efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ9pfcWWVZ5sSzjBFCN0BJfW6udTcc2eYfXDe-_CfpYrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltFOgtw%253D%253D&md5=dec4e8c08f90ec962a10204bb8f32da7</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2017.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2017.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DHarriott%26aufirst%3DN.%2BD.%26aulast%3DWilliams%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DBozigian%26aufirst%3DH.%2BP.%26aulast%3DGrigoriadis%26aufirst%3DD.%2BE.%26atitle%3DVMAT2%2520inhibitors%2520and%2520the%2520path%2520to%2520ingrezza%2520%2528valbenazine%2529%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D57%26issue%3D1%26spage%3D87%26epage%3D111%26doi%3D10.1016%2Fbs.pmch.2017.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwoskin, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1016/S0006-2952(01)00899-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0006-2952%2801%2900899-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11841781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtF2js7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2002&pages=89-98&issue=2&author=L.+P.+Dwoskinauthor=P.+A.+Crooks&title=A+novel+mechanism+of+action+and+potential+use+for+lobeline+as+a+treatment+for+psychostimulant+abuse&doi=10.1016%2FS0006-2952%2801%2900899-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse</span></div><div class="casAuthors">Dwoskin, Linda P.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Lobeline, an alkaloidal constituent of Lobelia inflata LINN., has a long history of therapeutic usage ranging from emetic and respiratory stimulant to tobacco smoking cessation agent.  Although classified as both an agonist and an antagonist at nicotinic receptors, lobeline has no structural resemblance to nicotine, and structure-function relationships do not suggest a common pharmacophore.  Lobeline inhibits nicotine-evoked dopamine release and [3H]nicotine binding, thus acting as a potent antagonist at both Î±3Î²2* and Î±4Î²2* neuronal nicotinic receptor subtypes.  However, lobeline does not release dopamine from its presynaptic terminal, but appears to induce the metab. of dopamine intraneuronally.  Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2).  Thus, lobeline appears to perturb the fundamental mechanisms of dopamine storage and release.  Based on its neurochem. mechanism, the ability of lobeline to functionally antagonize the neurochem. and behavioral effects of the psychostimulants amphetamine and methamphetamine was examd.  Lobeline was found to inhibit the amphetamine-induced release of dopamine in vitro, and amphetamine-induced hyperactivity, drug discrimination, and self-administration.  However, lobeline does not support self-administration in rats, suggesting a lack of addiction liability.  Thus, lobeline may reduce the abuse liability of these psychostimulants.  The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS8SVN_Ah01bVg90H21EOLACvtfcHk0lj2nDNkj85xYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtF2js7s%253D&md5=fb59db7757c56baa802bf94df924f673</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2801%2900899-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252801%252900899-1%26sid%3Dliteratum%253Aachs%26aulast%3DDwoskin%26aufirst%3DL.%2BP.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520mechanism%2520of%2520action%2520and%2520potential%2520use%2520for%2520lobeline%2520as%2520a%2520treatment%2520for%2520psychostimulant%2520abuse%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2002%26volume%3D63%26issue%3D2%26spage%3D89%26epage%3D98%26doi%3D10.1016%2FS0006-2952%2801%2900899-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, N. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of monoamine-oxidase by amphetamine and related compounds</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2073</span>â <span class="NLM_lpage">2077</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(76)90432-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2F0006-2952%2876%2990432-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=985546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaE2sXisFymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1976&pages=2073-2077&issue=18&author=T.+J.+Mantleauthor=K.+F.+Tiptonauthor=N.+J.+Garrett&title=Inhibition+of+monoamine-oxidase+by+amphetamine+and+related+compounds&doi=10.1016%2F0006-2952%2876%2990432-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of monoamine oxidase by amphetamine and related compounds</span></div><div class="casAuthors">Mantle, Timothy J.; Tipton, Keith F.; Garrett, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2073-7</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Dl-Î±-methylbenzylamine-HCl [13437-79-1] (0.1, 1, or 10mM), dl-Î±-methyltryptamine-HCl [879-36-7], and d- [51-63-8] and l-amphetamine sulfate [51-62-7] (0-1.0mM) competitively inhibited the oxidn. of benzylamine-HCl [3287-99-8], tyramine-HCl [60-19-5], and serotonin creatinine sulfate [971-74-4] by partially purified, sol. or membrane-bound rat liver monoamine oxidase (I) [9001-66-5].  Serotonin oxidn. was more potently inhibited than benzylamine oxidn, Î±-methyltryptamine being the most and Î±-methylbenzylamine the least selective.  The kinetics of inhibition of tyramine oxidn. suggested it was acted on by 2 enzyme species with different inhibitor sensitivities.  The substrate selectivity of the inhibitors towards the sol. enzyme was abolished by treatment with the chaotropic agent, Na perchlorate.  The significance of I inhibition in the pharmacol. action of amphetamine is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF9wuUKrYGaLVg90H21EOLACvtfcHk0lj2nDNkj85xYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXisFymuw%253D%253D&md5=b5cc73d9b6373f5bcb643cd3b71405fa</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2876%2990432-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252876%252990432-9%26sid%3Dliteratum%253Aachs%26aulast%3DMantle%26aufirst%3DT.%2BJ.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26aulast%3DGarrett%26aufirst%3DN.%2BJ.%26atitle%3DInhibition%2520of%2520monoamine-oxidase%2520by%2520amphetamine%2520and%2520related%2520compounds%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1976%26volume%3D25%26issue%3D18%26spage%3D2073%26epage%3D2077%26doi%3D10.1016%2F0006-2952%2876%2990432-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chasis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolliffe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. W.</span></span> <span> </span><span class="NLM_article-title">The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1933</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1083</span>â <span class="NLM_lpage">1090</span>, <span class="refDoi">Â DOI: 10.1172/JCI100559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1172%2FJCI100559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=16694183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaA2cXhsVGltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1933&pages=1083-1090&issue=6&author=H.+Chasisauthor=N.+Jolliffeauthor=H.+W.+Smith&title=The+action+of+phlorizin+on+the+excretion+of+glucose%2C+xylose%2C+sucrose%2C+creatinine+and+urea+by+man&doi=10.1172%2FJCI100559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man</span></div><div class="casAuthors">Chasis, Herbert; Jolliffe, Norman; Smith, Homer W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1933</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1083-90</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">The min. requirement of phlorizin by man for complete phlorizinization, i. e., raising of the glucose clearance to xylose clearance, is 10-20 mg. per kg.  A dose of 65 mg. did not raise the glucose clearance above that for xylose, and one of 59.4 mg. did not cause deviation between the xylose and sucrose clearances.  With the largest dose given there was no significant depressive action on the ratio creatinine:xylose clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOgugOsK5o7Vg90H21EOLACvtfcHk0lj2nDNkj85xYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2cXhsVGltg%253D%253D&md5=0d80d580fc08681f0ecbe3663e2bfa52</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1172%2FJCI100559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI100559%26sid%3Dliteratum%253Aachs%26aulast%3DChasis%26aufirst%3DH.%26aulast%3DJolliffe%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DH.%2BW.%26atitle%3DThe%2520action%2520of%2520phlorizin%2520on%2520the%2520excretion%2520of%2520glucose%252C%2520xylose%252C%2520sucrose%252C%2520creatinine%2520and%2520urea%2520by%2520man%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1933%26volume%3D12%26issue%3D6%26spage%3D1083%26epage%3D1090%26doi%3D10.1172%2FJCI100559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oku, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuronuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endou, H.</span></span> <span> </span><span class="NLM_article-title">T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1794</span>â <span class="NLM_lpage">1800</span>, <span class="refDoi">Â DOI: 10.2337/diabetes.48.9.1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2337%2Fdiabetes.48.9.1794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10480610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVaitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1999&pages=1794-1800&issue=9&author=A.+Okuauthor=K.+Uetaauthor=K.+Arakawaauthor=T.+Ishiharaauthor=M.+Nawanoauthor=Y.+Kuronumaauthor=M.+Matsumotoauthor=A.+Saitoauthor=K.+Tsujiharaauthor=M.+Anaiauthor=T.+Asanoauthor=Y.+Kanaiauthor=H.+Endou&title=T-1095%2C+an+inhibitor+of+renal+Na%2B-glucose+cotransporters%2C+may+provide+a+novel+approach+to+treating+diabetes&doi=10.2337%2Fdiabetes.48.9.1794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes</span></div><div class="casAuthors">Oku, Akira; Ueta, Kiichiro; Arakawa, Kenji; Ishihara, Tomomi; Nawano, Masao; Kuronuma, Yasuo; Matsumoto, Mamoru; Saito, Akira; Tsujihara, Kenji; Anai, Motonobu; Asano, Tomoichiro; Kanai, Yoshikatsu; Endou, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1794-1800</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">T-1095A and T-1095 are synthetic agents derived from phlorizin, a specific inhibitor of Na+-glucose cotransporters (SGLTs).  Unlike phlorizin, T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney.  Orally administered T-1095 increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels.  Indeed, the postprandial hyperglycemia after a meal load was shown to be suppressed by this compd. in streptozotocin (STZ)-induced diabetic rats.  With longterm T-1095 treatment, both blood glucose and HbA1c levels were reduced in STZ-induced diabetic rats and yellow KK mice.  In addn., there was amelioration of abnormal carbohydrate metab., i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice.  Thus, T-1095 may be a useful antidiabetic drug, providing a novel therapeutic approach for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKtVa6y9Aet7Vg90H21EOLACvtfcHk0lhqW_lSIaZ_EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVaitLk%253D&md5=16ec9fefe5fbb3f3bc7e8fedd4815916</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.48.9.1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.48.9.1794%26sid%3Dliteratum%253Aachs%26aulast%3DOku%26aufirst%3DA.%26aulast%3DUeta%26aufirst%3DK.%26aulast%3DArakawa%26aufirst%3DK.%26aulast%3DIshihara%26aufirst%3DT.%26aulast%3DNawano%26aufirst%3DM.%26aulast%3DKuronuma%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DA.%26aulast%3DTsujihara%26aufirst%3DK.%26aulast%3DAnai%26aufirst%3DM.%26aulast%3DAsano%26aufirst%3DT.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DEndou%26aufirst%3DH.%26atitle%3DT-1095%252C%2520an%2520inhibitor%2520of%2520renal%2520Na%252B-glucose%2520cotransporters%252C%2520may%2520provide%2520a%2520novel%2520approach%2520to%2520treating%2520diabetes%26jtitle%3DDiabetes%26date%3D1999%26volume%3D48%26issue%3D9%26spage%3D1794%26epage%3D1800%26doi%3D10.2337%2Fdiabetes.48.9.1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. I.</span></span> <span> </span><span class="NLM_article-title">Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1136</span>, <span class="refDoi">Â DOI: 10.3390/molecules21091136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3390%2Fmolecules21091136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKis7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1136&issue=9&author=C.+I.+Choi&title=Sodium-glucose+cotransporter+2+%28SGLT2%29+inhibitors+from+natural+products%3A+discovery+of+next-generation+antihyperglycemic+agents&doi=10.3390%2Fmolecules21091136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents</span></div><div class="casAuthors">Choi, Chang-Ik</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1136/1-1136/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Diabetes mellitus is a chronic condition assocd. with the metabolic impairment of insulin actions, leading to the development of life-threatening complications.  Although many kinds of oral antihyperglycemic agents with different therapeutic mechanisms have been marketed, their undesirable adverse effects, such as hypoglycemia, wt. gain, and hepato-renal toxicity, have increased demand for the discovery of novel, safer antidiabetic drugs.  Since the important roles of the sodium-glucose cotransporter 2 (SGLT2) for glucose homeostasis in the kidney were recently elucidated, pharmacol. inhibition of SGLT2 has been considered a promising therapeutic target for the treatment of type 2 diabetes.  Since the discovery of the first natural SGLT2 inhibitor, phlorizin, several synthetic glucoside analogs have been developed and introduced into the market.  Furthermore, many efforts to find new active constituents with SGLT2 inhibition from natural products are still ongoing.  This review introduces the history of research on the development of early-generation SGLT2 inhibitors, and recent progress on the discovery of novel candidates for SGLT2 inhibitor from several natural products that are widely used in traditional herbal medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCiOqML4-LirVg90H21EOLACvtfcHk0lhqW_lSIaZ_EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKis7rO&md5=68a60f0c2c669cf328bf9a123491f6c6</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21091136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21091136%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DC.%2BI.%26atitle%3DSodium-glucose%2520cotransporter%25202%2520%2528SGLT2%2529%2520inhibitors%2520from%2520natural%2520products%253A%2520discovery%2520of%2520next-generation%2520antihyperglycemic%2520agents%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D9%26spage%3D1136%26doi%3D10.3390%2Fmolecules21091136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Sotagliflozin: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1023</span>â <span class="NLM_lpage">1029</span>, <span class="refDoi">Â DOI: 10.1007/s40265-019-01146-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs40265-019-01146-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31172412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWlt7fI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1023-1029&issue=9&author=A.+Markhamauthor=S.+J.+Keam&title=Sotagliflozin%3A+first+global+approval&doi=10.1007%2Fs40265-019-01146-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Sotagliflozin: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1023-1029</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Sotagliflozin (Zynquista) is a dual inhibitor of sodium-glucose co-transporters (SGLT) 1 and 2 being developed by Lexicon Pharmaceuticals and Sanofi as a treatment for type 1 (T1DM) and type 2 diabetes mellitus (T2DM).  The drug has a dual action, blunting and delaying absorption of glucose from the gastrointestinal tract and the reabsorption of glucose in the proximal tubule of the kidney, resp.  In the phase III inTandem clin. trial program in patients with T1DM, sotagliflozin as an adjunct to optimized insulin therapy produced a clin. meaningful redn. in HbA1c levels, but was assocd. with a higher incidence of diabetic ketoacidosis than placebo.  Sotagliflozin was recently approved for use as an adjunct to insulin in T1DM in the EU.  However, the FDA Endocrinol. and Metabolic Drugs Advisory Committee was divided, citing concerns regarding diabetic ketoacidosis, leading the FDA to issue an Complete Response Letter for this indication in the USA.  This article summarizes the milestones in the development of sotagliflozin leading to this first approval in the EU as an adjunct to insulin in patients with T1DM with a body mass index â¥ 27 kg/m2 who have failed to achieve adequate glycemic control despite optimal insulin therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqA4Ji2ApgWrVg90H21EOLACvtfcHk0lhqW_lSIaZ_EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWlt7fI&md5=b3980fb997c5f7f33e25a2816b9f0c3a</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01146-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01146-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DSotagliflozin%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D9%26spage%3D1023%26epage%3D1029%26doi%3D10.1007%2Fs40265-019-01146-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomperts, B. N.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2440</span>â <span class="NLM_lpage">2444</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-1209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1158%2F1078-0432.CCR-14-1209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25838393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2440-2444&issue=11&author=A.+T.+Ooiauthor=B.+N.+Gomperts&title=Molecular+pathways%3A+targeting+cellular+energy+metabolism+in+cancer+via+inhibition+of+SLC2A1+and+LDHA&doi=10.1158%2F1078-0432.CCR-14-1209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA</span></div><div class="casAuthors">Ooi, Aik T.; Gomperts, Brigitte N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2440-2444</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reprogramming of cellular energy metab. is widely accepted to be one of the main hallmarks of cancer.  The aberrant expression pattern of key regulators in the glycolysis pathway in cancer cells corroborates with the hypothesis that most cancer cells utilize aerobic glycolysis as their main ATP prodn. method instead of mitochondrial oxidative phosphorylation.  Overexpression of SLC2A1 and LDHA, both important regulators of the glycolysis pathway, was detected in the premalignant lesions and tumors of lung cancer patients, suggesting the involvement of these proteins in early carcinogenesis and tumor progression in cancer.  Preclin. studies demonstrated that inhibiting SLC2A1 or LDHA led to diminished tumor growth in vitro and in vivo.  SLC2A1 and LDHA inhibitors, when administered in combination with other chemotherapeutic agents, showed synergistic antitumor effects by resensitizing chemoresistant cancer cells to the chemotherapies.  These results indicate that disrupting SLC2A1, LDHA, or other regulators in cancer cell energetics is a very promising approach for new targeted therapies.  Clin Cancer Res; 21(11); 2440-4. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnAZlM7OEMh7Vg90H21EOLACvtfcHk0lhqW_lSIaZ_EQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktLc%253D&md5=59d9fc4a918571c1be9d2036a1597805</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1209%26sid%3Dliteratum%253Aachs%26aulast%3DOoi%26aufirst%3DA.%2BT.%26aulast%3DGomperts%26aufirst%3DB.%2BN.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520cellular%2520energy%2520metabolism%2520in%2520cancer%2520via%2520inhibition%2520of%2520SLC2A1%2520and%2520LDHA%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D11%26spage%3D2440%26epage%3D2444%26doi%3D10.1158%2F1078-0432.CCR-14-1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siebeneicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehwinkel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, B.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2261</span>â <span class="NLM_lpage">2271</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201600276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201600276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27552707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyktr3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2261-2271&issue=20&author=H.+Siebeneicherauthor=A.+Cleveauthor=H.+Rehwinkelauthor=R.+Neuhausauthor=I.+Heislerauthor=T.+Mullerauthor=M.+Bauserauthor=B.+Buchmann&title=Identification+and+optimization+of+the+first+highly+selective+GLUT1+inhibitor+BAY-876&doi=10.1002%2Fcmdc.201600276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876</span></div><div class="casAuthors">Siebeneicher, Holger; Cleve, Arwed; Rehwinkel, Hartmut; Neuhaus, Roland; Heisler, Iring; Mueller, Thomas; Bauser, Marcus; Buchmann, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2261-2271</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite the long-known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1-selective small-mol. inhibitor.  Because other transporters of the GLUT1 family are involved in crucial processes, these transporters should not be addressed by such an inhibitor.  A high-throughput screen against a library of â¼3 million compds. was performed to find a small mol. with this challenging potency and selectivity profile.  The N-(1H-pyrazol-4-yl)quinoline-4-carboxamides were identified as an excellent starting point for further compd. optimization.  After extensive structure-activity relationship explorations, single-digit nanomolar inhibitors with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4 were obtained.  The most promising compd., BAY-876 [N4-[1-(4-cyanobenzyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide], showed good metabolic stability in vitro and high oral bioavailability in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFnF7Pnmxup7Vg90H21EOLACvtfcHk0lgmbGxNIZ3KyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyktr3L&md5=bcad707900882f937d137dc3925862a7</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600276%26sid%3Dliteratum%253Aachs%26aulast%3DSiebeneicher%26aufirst%3DH.%26aulast%3DCleve%26aufirst%3DA.%26aulast%3DRehwinkel%26aufirst%3DH.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DT.%26aulast%3DBauser%26aufirst%3DM.%26aulast%3DBuchmann%26aufirst%3DB.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520the%2520first%2520highly%2520selective%2520GLUT1%2520inhibitor%2520BAY-876%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D20%26spage%3D2261%26epage%3D2271%26doi%3D10.1002%2Fcmdc.201600276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idowu, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temkin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X. J.</span></span> <span> </span><span class="NLM_article-title">Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>, <span class="refDoi">Â DOI: 10.3390/cancers11010033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3390%2Fcancers11010033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=33&issue=1&author=Y.+B.+Maauthor=W.+Wangauthor=M.+O.+Idowuauthor=U.+Ohauthor=X.+Y.+Wangauthor=S.+M.+Temkinauthor=X.+J.+Fang&title=Ovarian+cancer+relies+on+glucose+transporter+1+to+fuel+glycolysis+and+growth%3A+anti-tumor+activity+of+BAY-876&doi=10.3390%2Fcancers11010033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876</span></div><div class="casAuthors">Ma, Yibao; Wang, Wei; Idowu, Michael O.; Oh, Unsong; Wang, Xiang-Yang; Temkin, Sarah M.; Fang, Xianjun</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies.  However, therapeutic targeting of glycolysis to treat cancer remains unsuccessful due to complex mechanisms of tumor glycolysis and the lack of selective, potent and safe glycolytic inhibitors.  Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer.  Notably, BAY-876 has not been evaluated in any cell or preclin. animal models since its discovery.  We herein took advantage of BAY-876 and mol. approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis.  The anti-tumor activity of BAY-876 was evaluated with ovarian cancer cell line- and patient-derived xenograft (PDX) models.  Our results show that inhibition of GLUT1 is sufficient to block basal and stress-regulated glycolysis, and anchorage-dependent and independent growth of ovarian cancer cells.  BAY-876 dramatically inhibits tumorigenicity of both cell line-derived xenografts and PDXs.  These studies provide direct evidence that GLUT1 is causally linked to the glycolytic phenotype in ovarian cancer.  BAY-876 is a potent blocker of GLUT1 activity, glycolytic metab. and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfLuPYZrtc5LVg90H21EOLACvtfcHk0lgmbGxNIZ3KyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL%252FK&md5=d1a3f34ef50838e475009a2de554bb7e</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.3390%2Fcancers11010033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11010033%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DIdowu%26aufirst%3DM.%2BO.%26aulast%3DOh%26aufirst%3DU.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DTemkin%26aufirst%3DS.%2BM.%26aulast%3DFang%26aufirst%3DX.%2BJ.%26atitle%3DOvarian%2520cancer%2520relies%2520on%2520glucose%2520transporter%25201%2520to%2520fuel%2520glycolysis%2520and%2520growth%253A%2520anti-tumor%2520activity%2520of%2520BAY-876%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D1%26spage%3D33%26doi%3D10.3390%2Fcancers11010033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siebeneicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehwinkel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, L.</span></span> <span> </span><span class="NLM_article-title">Identification of novel GLUT inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1732</span>â <span class="NLM_lpage">1737</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2016.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26949183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1akt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1732-1737&issue=7&author=H.+Siebeneicherauthor=M.+Bauserauthor=B.+Buchmannauthor=I.+Heislerauthor=T.+Mullerauthor=R.+Neuhausauthor=H.+Rehwinkelauthor=J.+Telserauthor=L.+Zorn&title=Identification+of+novel+GLUT+inhibitors&doi=10.1016%2Fj.bmcl.2016.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel GLUT inhibitors</span></div><div class="casAuthors">Siebeneicher, Holger; Bauser, Marcus; Buchmann, Bernd; Heisler, Iring; Mueller, Thomas; Neuhaus, Roland; Rehwinkel, Hartmut; Telser, Joachim; Zorn, Ludwig</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1732-1737</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The compd. class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS (high-throughput screening) as very potent inhibitors of facilitated glucose transporter 1 (GLUT1).  Extensive structure-activity relationship studies (SAR) of each ring system of the mol. framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine).  The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvoI6G3pWwZrVg90H21EOLACvtfcHk0lgmbGxNIZ3KyA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1akt70%253D&md5=79f2a3d68a3e38656b0b3ed4c99bd636</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DSiebeneicher%26aufirst%3DH.%26aulast%3DBauser%26aufirst%3DM.%26aulast%3DBuchmann%26aufirst%3DB.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DT.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DRehwinkel%26aufirst%3DH.%26aulast%3DTelser%26aufirst%3DJ.%26aulast%3DZorn%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520novel%2520GLUT%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D7%26spage%3D1732%26epage%3D1737%26doi%3D10.1016%2Fj.bmcl.2016.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finer-Moore, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caboni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillig, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebeneicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4711</span>â <span class="NLM_lpage">4716</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1603735113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.1603735113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27078104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvV2nsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=4711-4716&issue=17&author=K.+Kapoorauthor=J.+S.+Finer-Mooreauthor=B.+P.+Pedersenauthor=L.+Caboniauthor=A.+Waightauthor=R.+C.+Hilligauthor=P.+Bringmannauthor=I.+Heislerauthor=T.+Mullerauthor=H.+Siebeneicherauthor=R.+M.+Stroud&title=Mechanism+of+inhibition+of+human+glucose+transporter+GLUT1+is+conserved+between+cytochalasin+B+and+phenylalanine+amides&doi=10.1073%2Fpnas.1603735113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides</span></div><div class="casAuthors">Kapoor, Khyati; Finer-Moore, Janet S.; Pedersen, Bjoern P.; Caboni, Laura; Waight, Andrew; Hillig, Roman C.; Bringmann, Peter; Heisler, Iring; Muller, Thomas; Siebeneicher, Holger; Stroud, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4711-4716</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cancerous cells have an acutely increased demand for energy, leading to increased levels of human glucose transporter 1 (hGLUT1).  This up-regulation suggests hGLUT1 as a target for therapeutic inhibitors addressing a multitude of cancer types.  Here, the authors present three inhibitor-bound, inward-open structures of WT-hGLUT1 crystd. with three different inhibitors: cytochalasin B, a nine-membered bicyclic ring fused to a 14-membered macrocycle, which has been described extensively in the literature of hGLUTs, and two previously undescribed Phe amide-derived inhibitors.  Despite very different chem. backbones, all three compds. bind in the central cavity of the inward-open state of hGLUT1, and all binding sites overlap the glucose-binding site.  The inhibitory action of the compds. was detd. for hGLUT family members, hGLUT1-4, using cell-based assays, and compared with homol. models for these hGLUT members.  This comparison uncovered a probable basis for the obsd. differences in inhibition between family members.  The authors pinpoint regions of the hGLUT proteins that can be targeted to achieve isoform selectivity, and show that these same regions are used for inhibitors with very distinct structural backbones.  The inhibitor cocomplex structures of hGLUT1 provide an important structural insight for the design of more selective inhibitors for hGLUTs and hGLUT1 in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopyfWMOg2jvLVg90H21EOLACvtfcHk0liTWslbcdt1lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvV2nsLw%253D&md5=473eb5209694681cf2df4be5603aaabc</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1603735113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1603735113%26sid%3Dliteratum%253Aachs%26aulast%3DKapoor%26aufirst%3DK.%26aulast%3DFiner-Moore%26aufirst%3DJ.%2BS.%26aulast%3DPedersen%26aufirst%3DB.%2BP.%26aulast%3DCaboni%26aufirst%3DL.%26aulast%3DWaight%26aufirst%3DA.%26aulast%3DHillig%26aufirst%3DR.%2BC.%26aulast%3DBringmann%26aufirst%3DP.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DT.%26aulast%3DSiebeneicher%26aufirst%3DH.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26atitle%3DMechanism%2520of%2520inhibition%2520of%2520human%2520glucose%2520transporter%2520GLUT1%2520is%2520conserved%2520between%2520cytochalasin%2520B%2520and%2520phenylalanine%2520amides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D17%26spage%3D4711%26epage%3D4716%26doi%3D10.1073%2Fpnas.1603735113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrecca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atanasiu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrier, A.</span></span> <span> </span><span class="NLM_article-title">Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">H709</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1152/ajpheart.1999.276.2.H709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpheart.1999.276.2.H709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9950874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlCktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1999&pages=H709-717&issue=2&author=K.+Petreccaauthor=R.+Atanasiuauthor=S.+Grinsteinauthor=J.+Orlowskiauthor=A.+Shrier&title=Subcellular+localization+of+the+Na%2B%2FH%2B+exchanger+NHE1+in+rat+myocardium&doi=10.1152%2Fajpheart.1999.276.2.H709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium</span></div><div class="casAuthors">Petrecca, Kevin; Atanasiu, Roxana; Grinstein, Sergio; Orlowski, John; Shrier, Alvin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">H709-H717</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">The Na+/H+ exchanger NHE1 isoform is an integral component of cardiac intracellular pH homeostasis that is critically important for myocardial contractility.  To gain further insight into its physiol. significance, the authors detd. its cellular distribution in adult rat heart by using immunohistochem. and confocal microscopy.  NHE1 was localized predominantly at the intercalated disk regions in close proximity to the gap junction protein, connexin 43 (Cx43), of atrial and ventricular muscle cells.  Significant labeling of NHE1 was also obsd. along the transverse tubular systems, but not the lateral sarcolemmal membranes, of both cell types.  In contrast, the (Na+,K+)-ATPase Î±1 subunit was readily labeled by a specific mouse monoclonal antibody (McK1) along the entire ventricular sarcolemma and intercalated disks and, to a lesser extent, in the transverse tubules.  These results indicate that NHE1 has a distinct distribution in heart and may fulfill specialized roles by selectively regulating the pH microenvironment of pH-sensitive proteins at the intercalated disks (e.g., Cx43) and near the cytosolic surface of sarcoplasmic reticulum cisternae (e.g., ryanodine receptor), thereby influencing impulse conduction and excitation-contraction coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgzM6kR1g6a7Vg90H21EOLACvtfcHk0liTWslbcdt1lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlCktLg%253D&md5=b31d256d3f2503f05ab37a792566573d</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.1999.276.2.H709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.1999.276.2.H709%26sid%3Dliteratum%253Aachs%26aulast%3DPetrecca%26aufirst%3DK.%26aulast%3DAtanasiu%26aufirst%3DR.%26aulast%3DGrinstein%26aufirst%3DS.%26aulast%3DOrlowski%26aufirst%3DJ.%26aulast%3DShrier%26aufirst%3DA.%26atitle%3DSubcellular%2520localization%2520of%2520the%2520Na%252B%252FH%252B%2520exchanger%2520NHE1%2520in%2520rat%2520myocardium%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1999%26volume%3D276%26issue%3D2%26spage%3DH709%26epage%3D717%26doi%3D10.1152%2Fajpheart.1999.276.2.H709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karmazyn, M.</span></span> <span> </span><span class="NLM_article-title">Amiloride enhances postischemic ventricular recovery: possible role of Na+-H+ exchange</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>255</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">H608</span>â <span class="NLM_lpage">H615</span>, <span class="refDoi">Â DOI: 10.1152/ajpheart.1988.255.3.H608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpheart.1988.255.3.H608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=2843057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaL1cXls1eiu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1988&pages=H608-H615&issue=3&author=M.+Karmazyn&title=Amiloride+enhances+postischemic+ventricular+recovery%3A+possible+role+of+Na%2B-H%2B+exchange&doi=10.1152%2Fajpheart.1988.255.3.H608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Amiloride enhances postischemic ventricular recovery:  possible role of sodium-proton exchange</span></div><div class="casAuthors">Karmazyn, Morris</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">H608-H615</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    </div><div class="casAbstract">The effect of amiloride (40 Î¼g/mL) was studied in the isolated rat heart subjected to low-flow ischemia followed by reperfusion.  Reperfusion after 30 min of ischemia produced recoveries of force, rate of force development (+dF/dt), and rate of relaxation (-dF/dt) of 42, 82, and 71%, resp., in control hearts.  Amiloride did not enhance the max. degree of recovery, although, when present during ischemia, it markedly shortened the time required for peak recovery.  Reperfusion after 60 min of ischemia resulted in 18, 43, and 34% recovery of force, +dF/dt, and -dF/dt, resp.  Amiloride enhanced recovery to a max. of 39, 88, and 78% for force, +dF/dt, and -dF/dt, resp.  The improved contractile recovery was accompanied by substantial redns. in the release of creatine kinase and 6-ketoprostaglandin F1Î±.  Coronary perfusion pressure and resting tension were generally unaffected by amiloride, although there was a moderate tendency to attenuate these parameters after reperfusion.  The salutary effects of amiloride were dependent on the drug's presence during ischemia, with max. protection when it was administered during both ischemia and reperfusion and no benefit when added only at the time of reperfusion.  Because of amiloride's well-documented property in inhibiting Na+-H+ exchange, it is possible that this process plays an important role in modulating the cardiac response to reperfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNYJHJhRIbnbVg90H21EOLACvtfcHk0liTWslbcdt1lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXls1eiu7c%253D&md5=b87f4354c954c7339dd1c1fa945dbb53</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.1988.255.3.H608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.1988.255.3.H608%26sid%3Dliteratum%253Aachs%26aulast%3DKarmazyn%26aufirst%3DM.%26atitle%3DAmiloride%2520enhances%2520postischemic%2520ventricular%2520recovery%253A%2520possible%2520role%2520of%2520Na%252B-H%252B%2520exchange%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1988%26volume%3D255%26issue%3D3%26spage%3DH608%26epage%3DH615%26doi%3D10.1152%2Fajpheart.1988.255.3.H608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harguindey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arranz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polo Orozco, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reshkin, S. J.</span></span> <span> </span><span class="NLM_article-title">Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs - an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">282</span>, <span class="refDoi">Â DOI: 10.1186/1479-5876-11-282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1186%2F1479-5876-11-282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24195657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislOrtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=282&author=S.+Harguindeyauthor=J.+L.+Arranzauthor=J.+D.+Polo+Orozcoauthor=C.+Rauchauthor=S.+Faisauthor=R.+A.+Cardoneauthor=S.+J.+Reshkin&title=Cariporide+and+other+new+and+powerful+NHE1+inhibitors+as+potentially+selective+anticancer+drugs+-+an+integral+molecular%2Fbiochemical%2Fmetabolic%2Fclinical+approach+after+one+hundred+years+of+cancer+research&doi=10.1186%2F1479-5876-11-282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs - an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research</span></div><div class="casAuthors">Harguindey, Salvador; Arranz, Jose Luis; Orozco, Julian David Polo; Rauch, Cyril; Fais, Stefano; Cardone, Rosa Angela; Reshkin, Stephan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">282/1-282/17, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years an increasing no. of publications have emphasized the growing importance of hydrogen ion dynamics in modern cancer research, from etiopathogenesis and treatment.  A proton [H+]-related mechanism underlying the initiation and progression of the neoplastic process has been recently described by different research groups as a new paradigm in which all cancer cells and tissues, regardless of their origin and genetic background, have a pivotal energetic and homeostatic disturbance of their metab. that is completely different from all normal tissues: an aberrant regulation of hydrogen ion dynamics leading to a reversal of the pH gradient in cancer cells and tissues (âpHi/âpHe, or "proton reversal").  Tumor cells survive their hostile microenvironment due to membrane-bound proton pumps and transporters, and their main defensive strategy is to never allow internal acidification because that could lead to their death through apoptosis.  In this context, one of the primary and best studied regulators of both pHi and pHe in tumors is the Na+/H+ exchanger isoform 1 (NHE1).  An elevated NHE1 activity can be correlated with both an increase in cell pH and a decrease in the extracellular pH of tumors, and such proton reversal is assocd. with the origin, local growth, activation and further progression of the metastatic process.  Consequently, NHE1 pharmaceutical inhibition by new and potent NHE1 inhibitors represents a potential and highly selective target in anticancer therapy.  Cariporide, being one of the better studied specific and powerful NHE1 inhibitors, has proven to be well tolerated by humans in the cardiol. context, however some side-effects, mainly related to drug accumulation and cerebrovascular complications were reported.  Thus, cariporide could become a new, slightly toxic and effective anticancer agent in different human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr5c_Sda6F1LVg90H21EOLACvtfcHk0livOD5IfL24WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislOrtro%253D&md5=f0faba61fdae83c1481ba3fe1dc8b382</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-11-282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-11-282%26sid%3Dliteratum%253Aachs%26aulast%3DHarguindey%26aufirst%3DS.%26aulast%3DArranz%26aufirst%3DJ.%2BL.%26aulast%3DPolo%2BOrozco%26aufirst%3DJ.%2BD.%26aulast%3DRauch%26aufirst%3DC.%26aulast%3DFais%26aufirst%3DS.%26aulast%3DCardone%26aufirst%3DR.%2BA.%26aulast%3DReshkin%26aufirst%3DS.%2BJ.%26atitle%3DCariporide%2520and%2520other%2520new%2520and%2520powerful%2520NHE1%2520inhibitors%2520as%2520potentially%2520selective%2520anticancer%2520drugs%2520-%2520an%2520integral%2520molecular%252Fbiochemical%252Fmetabolic%252Fclinical%2520approach%2520after%2520one%2520hundred%2520years%2520of%2520cancer%2520research%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2013%26volume%3D11%26spage%3D282%26doi%3D10.1186%2F1479-5876-11-282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karmazyn, M.</span></span> <span> </span><span class="NLM_article-title">NHE-1: still a viable therapeutic target</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">82</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.yjmcc.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23429008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVOjsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=77-82&author=M.+Karmazyn&title=NHE-1%3A+still+a+viable+therapeutic+target&doi=10.1016%2Fj.yjmcc.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">NHE-1: Still a viable therapeutic target</span></div><div class="casAuthors">Karmazyn, Morris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The concept of NaH exchange (NHE) involvement in cardiac pathol. has been espoused for decades and supported by a plethora of exptl. studies demonstrating salutary effects of NHE inhibition in protecting the myocardium against ischemic and reperfusion injury as well as attenuating myocardial remodelling and heart failure.  NHE is actually a family of sodium and proton transporting proteins of which 10 isoforms have been identified.  Myocardial NHE is represented primarily by the ubiquitous NHE-1 subtype which is expressed in most tissues.  The robust pos. results seen with NHE-1 inhibitors in exptl. studies have led to relatively rapid development of these pharmacol. agents for clin. assessment esp. as potential cardioprotective therapies.  Yet clin. studies have revealed, at best, inconsistent results as evidenced by poor efficacy and serious side effects, the latter revealed with the use of the NHE-1 inhibitor cariporide in high-risk patients undergoing coronary artery bypass grafting and evidenced by an increased incidence of cerebrovascular events of thromboembolic origin.  The lack of success in clin. trials coupled with potential for toxicity has had a neg. impact on development of cardiac therapeutic agents which have been developed based on the concept of NHE-1 inhibition.  Whether this response is justified is open for discussion although a close scrutiny of clin. trial outcomes suggests that it may not be and that NHE-1 inhibition, if applied appropriately continues to represent an effective, if not the most effective approach for myocardial salvage following ischemic insult.  Moreover, in addn. to its cardioprotective effects, emerging evidence further suggests that NHE-1 inhibition is an effective strategy to minimize myocardial remodelling as well as a potentially effective strategy to improve efficacy of resuscitation following cardiac arrest.  Thus, NHE-1 inhibition continues to represent a potentially highly effective therapeutic approach for the treatment of heart disease.  This article is part of a Special Issue entitled "Na+ Regulation in Cardiac Myocytes".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriJ-lt41Mnu7Vg90H21EOLACvtfcHk0livOD5IfL24WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVOjsbc%253D&md5=0b7503b3b998c76153d8c7807103624b</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKarmazyn%26aufirst%3DM.%26atitle%3DNHE-1%253A%2520still%2520a%2520viable%2520therapeutic%2520target%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2013%26volume%3D61%26spage%3D77%26epage%3D82%26doi%3D10.1016%2Fj.yjmcc.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliegel, L.</span></span> <span> </span><span class="NLM_article-title">KR-33028, a potent inhibitor of the Na(+)/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">31</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bcp.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27521504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=31-39&author=S.+R.+Amithauthor=J.+M.+Wilkinsonauthor=L.+Fliegel&title=KR-33028%2C+a+potent+inhibitor+of+the+Na%28%2B%29%2FH%28%2B%29+exchanger+NHE1%2C+suppresses+metastatic+potential+of+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.bcp.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">KR-33028, a potent inhibitor of the Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span></div><div class="casAuthors">Amith, Schammim Ray; Wilkinson, Jodi Marie; Fliegel, Larry</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hyper-activation of the Na+/H+ exchanger NHE1 occurs at the onset of oncogenic transformation and plays a crit. role in breast cancer carcinogenesis.  Dysregulation of NHE1 activity results in intracellular alkalinization and the acidification of the extracellular tumor microenvironment that promotes metastasis.  Hence, the use of chem. inhibitors of NHE1 as chemotherapeutic agents is an alluring prospect.  We previously demonstrated that two structurally different NHE1 inhibitors, EMD87580 [(2-methyl-4,5-di-(methylsulfonyl)-benzoyl)-guanidine], and HMA [5-(N,N-hexamethylene)-amiloride], were effective as co-adjuvants to potentiate paclitaxel-mediated cytotoxic chemotherapy in triple-neg. breast cancer (TNBC) cells.  Both these drugs, however, had reduced or minimal anti-cancer effects when used alone.  Here, we tested KR-33028 (4-cyano (benzo[b]thiophene-2-carbonyl)guanidine), a potent and selective inhibitor of NHE1, to det. its efficacy in inhibition of metastatic potential of TNBC cells.  In highly invasive MDA-MB-231, moderately invasive MDA-MB-468, and lowly invasive Hs578T TNBC cells, KR-33028 considerably reduced rates of cell migration and anchorage-independent colony growth.  Invasion of MDA-MB-231 and MDA-MB-468 cells through extracellular matrix was also dramatically decreased in response to KR-33028.  We further tested the effect of KR-33028 on MDA-MB-231 cells lacking NHE1 expression (231koNHE1); no differences were obsd. between untreated control and KR-33028-treated 231koNHE1 cells.  Taken together, our results highlight the in vitro efficacy of KR-33028-mediated NHE1 inhibition on limiting cellular functions that are predictive of metastasis in vivo.  We suggest that targeting NHE1 in the development of novel chemotherapeutics could be highly effective in combating triple-neg. breast cancer and that KR-33028 is potentially useful in prevention of metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5F9yBhpgG87Vg90H21EOLACvtfcHk0livOD5IfL24WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F&md5=12416b156b9e1e32cfdc604327c4112c</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAmith%26aufirst%3DS.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%2BM.%26aulast%3DFliegel%26aufirst%3DL.%26atitle%3DKR-33028%252C%2520a%2520potent%2520inhibitor%2520of%2520the%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%2520NHE1%252C%2520suppresses%2520metastatic%2520potential%2520of%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D118%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hropot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juretschke, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwark, J. R.</span></span> <span> </span><span class="NLM_article-title">S3226, a novel NHE3 inhibitor, attenuates ischemia-induced acute renal failure in rats</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2283</span>â <span class="NLM_lpage">2289</span>, <span class="refDoi">Â DOI: 10.1046/j.1523-1755.2001.00058.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1046%2Fj.1523-1755.2001.00058.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11737601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1KjsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=2283-2289&issue=6&author=M.+Hropotauthor=H.+P.+Juretschkeauthor=K.+H.+Langerauthor=J.+R.+Schwark&title=S3226%2C+a+novel+NHE3+inhibitor%2C+attenuates+ischemia-induced+acute+renal+failure+in+rats&doi=10.1046%2Fj.1523-1755.2001.00058.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">S3226, a novel NHE3 inhibitor, attenuates ischemia-induced acute renal failure in rats</span></div><div class="casAuthors">Hropot, Max; Juretschke, Hans-Paul; Langer, Karl Heinz; Schwark, Jan-Robert</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2283-2289</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Acute renal failure (ARF) remains a major problem in clin. nephrol. characterized by sudden loss of the kidney function due to ischemia, trauma, and/or nephrotoxic drugs.  The current therapy of ARF is symptomatic with mortality rates exceeding 50%.  The aim of this study was to investigate the effects of an i.v. infusion of S3226 (3-[2-(3-guanidino-2-methyl-3-oxopropenyl)-5-methylphenyl]-N-isopropylidene-2-methylacrylamide dihydrochloride), a selective Na+/H+ exchange subtype 3 (NHE3) blocker, in ischemia-induced ARF in rats.  In a second series of expts. cytosolic pH (pHi) changes in the kidney during ARF were continuously measured by NMR spectroscopy (MRS).  ARF was induced by bilateral occlusion of renal arteries for 40 min in three groups of anesthetized Wistar rats.  Control rats (N = 12) were infused with saline (6.25 mL/kg over 30 min) before occlusion and the compd. groups (each N = 12) were infused with S3226 at a dose of 20 mg/kg over 30 min either before initiation of ischemia or immediately after release of clamps.  Plasma creatinine (PCr), creatinine clearance (CCr), urine vol., sodium, and potassium excretion were detd. up to seven days after release of clamps.  In the second series of expts. in anesthetized rats the left kidney was exposed by flank incision and fixed in a non-magnetic device.  An inflatable cuff was positioned around the pedicle to induce ischemia without removing animals from the magnet.  A double-tuned 1H-31P home-built surface coil was placed above the exposed kidney for the detection of pHi.  At day 1 after ischemia CCr in the control group was significantly lower as compared to S3226-treated animals (control 0.30Â±0.05 vs. before 0.90Â±0.26 and reperfusion 0.83Â±0.15 mL/min/kg, resp.).  PCr increased from 18Â±0.1 Î¼mol/L before occlusion to 245Â±7 Î¼mol/L in the control.  The increase in PCr was significantly lower in the S3226 treated groups on days 1, 2, and 3 post-infusion.  Fractional sodium excretion decreased significantly from 8.17% in the control to 1.42% and 1.88% in the treated groups.  Renal pHi was significantly decreased by 0.15 units vs. control during reperfusion.  Histol. examn. of the kidneys on day 7 revealed pronounced redn. of tubular necrosis, dilatation, protein casts and cellular infiltration.  These results demonstrate that an i.v. administration of S3226 acutely improves GFR and kidney function and structure in both treated groups.  In addn., in a sep. set of studies S3226 significantly decreased post-occlusion renal pHi values.  Thus, the inhibition of NHE3 with S3226 may be beneficial in treatment of ischemic ARF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2cDF05pnp8bVg90H21EOLACvtfcHk0livOD5IfL24WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1KjsL0%253D&md5=7781a921802834fc30b89057881971d5</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.2001.00058.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.2001.00058.x%26sid%3Dliteratum%253Aachs%26aulast%3DHropot%26aufirst%3DM.%26aulast%3DJuretschke%26aufirst%3DH.%2BP.%26aulast%3DLanger%26aufirst%3DK.%2BH.%26aulast%3DSchwark%26aufirst%3DJ.%2BR.%26atitle%3DS3226%252C%2520a%2520novel%2520NHE3%2520inhibitor%252C%2520attenuates%2520ischemia-induced%2520acute%2520renal%2520failure%2520in%2520rats%26jtitle%3DKidney%2520Int.%26date%3D2001%26volume%3D60%26issue%3D6%26spage%3D2283%26epage%3D2289%26doi%3D10.1046%2Fj.1523-1755.2001.00058.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo-McCoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minassian, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafri, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaraswamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson-Rylander, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromstedt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryden-Bergsten, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor Arroyo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernando, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">456</span>),  <span class="NLM_fpage">eaam6474</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aam6474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscitranslmed.aam6474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30158152" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=eaam6474&issue=456&author=A.+J.+Kingauthor=M.+Siegelauthor=Y.+Heauthor=B.+Nieauthor=J.+Wangauthor=S.+Koo-McCoyauthor=N.+A.+Minassianauthor=Q.+Jafriauthor=D.+Panauthor=J.+Kohlerauthor=P.+Kumaraswamyauthor=K.+Kozukaauthor=J.+G.+Lewisauthor=D.+Dragoliauthor=D.+P.+Rosenbaumauthor=D.+O%E2%80%99Neillauthor=A.+Plainauthor=P.+J.+Greasleyauthor=A.+C.+Jonsson-Rylanderauthor=D.+Karlssonauthor=M.+Behrendtauthor=M.+Stromstedtauthor=T.+Ryden-Bergstenauthor=T.+Knopfelauthor=E.+M.+Pastor+Arroyoauthor=N.+Hernandoauthor=J.+Marksauthor=M.+Donowitzauthor=C.+A.+Wagnerauthor=R.+T.+Alexanderauthor=J.+S.+Caldwell&title=Inhibition+of+sodium%2Fhydrogen+exchanger+3+in+the+gastrointestinal+tract+by+tenapanor+reduces+paracellular+phosphate+permeability&doi=10.1126%2Fscitranslmed.aam6474"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam6474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam6474%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DSiegel%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DNie%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKoo-McCoy%26aufirst%3DS.%26aulast%3DMinassian%26aufirst%3DN.%2BA.%26aulast%3DJafri%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DD.%26aulast%3DKohler%26aufirst%3DJ.%26aulast%3DKumaraswamy%26aufirst%3DP.%26aulast%3DKozuka%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DJ.%2BG.%26aulast%3DDragoli%26aufirst%3DD.%26aulast%3DRosenbaum%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DD.%26aulast%3DPlain%26aufirst%3DA.%26aulast%3DGreasley%26aufirst%3DP.%2BJ.%26aulast%3DJonsson-Rylander%26aufirst%3DA.%2BC.%26aulast%3DKarlsson%26aufirst%3DD.%26aulast%3DBehrendt%26aufirst%3DM.%26aulast%3DStromstedt%26aufirst%3DM.%26aulast%3DRyden-Bergsten%26aufirst%3DT.%26aulast%3DKnopfel%26aufirst%3DT.%26aulast%3DPastor%2BArroyo%26aufirst%3DE.%2BM.%26aulast%3DHernando%26aufirst%3DN.%26aulast%3DMarks%26aufirst%3DJ.%26aulast%3DDonowitz%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DC.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%2BT.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520sodium%252Fhydrogen%2520exchanger%25203%2520in%2520the%2520gastrointestinal%2520tract%2520by%2520tenapanor%2520reduces%2520paracellular%2520phosphate%2520permeability%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26issue%3D456%26spage%3Deaam6474%26doi%3D10.1126%2Fscitranslmed.aam6474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremont, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Both, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeller, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziej, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischke, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollefson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, D. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (part 2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5853</span>â <span class="NLM_lpage">5868</span>, <span class="refDoi">Â DOI: 10.1021/jm0402162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0402162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVChtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5853-5868&issue=18&author=H.+C.+Huangauthor=S.+J.+Tremontauthor=L.+F.+Leeauthor=B.+T.+Kellerauthor=A.+J.+Carpenterauthor=C.+C.+Wangauthor=S.+C.+Banerjeeauthor=S.+R.+Bothauthor=T.+Fletcherauthor=D.+J.+Garlandauthor=W.+Huangauthor=C.+Jonesauthor=K.+J.+Koellerauthor=S.+A.+Kolodziejauthor=J.+Liauthor=R.+E.+Manningauthor=M.+W.+Mahoneyauthor=R.+E.+Millerauthor=D.+A.+Mischkeauthor=N.+P.+Rathauthor=E.+J.+Reinhardauthor=M.+B.+Tollefsonauthor=W.+F.+Vernierauthor=G.+M.+Wagnerauthor=S.+R.+Rappauthor=J.+Beaudryauthor=K.+Glennauthor=K.+Reginaauthor=J.+R.+Schuhauthor=M.+E.+Smithauthor=J.+S.+Trivediauthor=D.+B.+Reitz&title=Discovery+of+potent%2C+nonsystemic+apical+sodium-codependent+bile+acid+transporter+inhibitors+%28part+2%29&doi=10.1021%2Fjm0402162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Nonsystemic Apical Sodium-Codependent Bile Acid Transporter Inhibitors (Part 2)</span></div><div class="casAuthors">Huang, Horng-Chih; Tremont, Samuel J.; Lee, Len F.; Keller, Bradley T.; Carpenter, Andrew J.; Wang, Ching-Cheng; Banerjee, Shyamal C.; Both, Scott R.; Fletcher, Theresa; Garland, Danny J.; Huang, Wei; Jones, Claude; Koeller, Kevin J.; Kolodziej, Steve A.; Li, James; Manning, Robert E.; Mahoney, Matthew W.; Miller, Raymond E.; Mischke, Deborah A.; Rath, Nigam P.; Reinhard, Emily J.; Tollefson, Michael B.; Vernier, William F.; Wagner, Grace M.; Rapp, Steve R.; Beaudry, Judy; Glenn, Kevin; Regina, Karen; Schuh, Joe R.; Smith, Mark E.; Trivedi, Jay S.; Reitz, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5853-5868</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the primary site for active bile acid reabsorption is via apical sodium-codependent bile acid transporter (ASBT), which is localized on the luminal surface of the distal ileum, a nonsystemic inhibitor would be desirable to minimize or eliminate potential systemic side effects of an absorbed drug.  To ensure bioequivalency and product stability, it was also essential that a nonhygroscopic inhibitor in its most stable cryst. form was identified.  A series of benzothiepins I [R = Ph, 4-HOC6H4, 4-(Me2NCH2CH2)C6H4, 1-naphthyl, 2-thienyl, 3-pyridyl, etc.] was prepd. to refine the structure-activity relationship of the substituted Ph ring at the 5-position of benzothiepin ring and to identify potent, cryst., nonhygroscopic, and efficacious ASBT inhibitors with low systemic exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzy0VNrbGYxLVg90H21EOLACvtfcHk0liIZVMRKRPiQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVChtrY%253D&md5=beeef9fb2676b3e2e7787b6dfbc75f7a</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1021%2Fjm0402162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0402162%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DTremont%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BF.%26aulast%3DKeller%26aufirst%3DB.%2BT.%26aulast%3DCarpenter%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DBanerjee%26aufirst%3DS.%2BC.%26aulast%3DBoth%26aufirst%3DS.%2BR.%26aulast%3DFletcher%26aufirst%3DT.%26aulast%3DGarland%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKoeller%26aufirst%3DK.%2BJ.%26aulast%3DKolodziej%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DR.%2BE.%26aulast%3DMahoney%26aufirst%3DM.%2BW.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRath%26aufirst%3DN.%2BP.%26aulast%3DReinhard%26aufirst%3DE.%2BJ.%26aulast%3DTollefson%26aufirst%3DM.%2BB.%26aulast%3DVernier%26aufirst%3DW.%2BF.%26aulast%3DWagner%26aufirst%3DG.%2BM.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DBeaudry%26aufirst%3DJ.%26aulast%3DGlenn%26aufirst%3DK.%26aulast%3DRegina%26aufirst%3DK.%26aulast%3DSchuh%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%26aulast%3DTrivedi%26aufirst%3DJ.%2BS.%26aulast%3DReitz%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520potent%252C%2520nonsystemic%2520apical%2520sodium-codependent%2520bile%2520acid%2520transporter%2520inhibitors%2520%2528part%25202%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D18%26spage%3D5853%26epage%3D5868%26doi%3D10.1021%2Fjm0402162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mells, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setchell, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amanso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpen, S. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">357</span>),  <span class="NLM_fpage">357ra122</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aaf4823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscitranslmed.aaf4823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27655848" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=357ra122&issue=357&author=A.+Raoauthor=A.+Kostersauthor=J.+E.+Mellsauthor=W.+Zhangauthor=K.+D.+Setchellauthor=A.+M.+Amansoauthor=G.+M.+Wynnauthor=T.+Xuauthor=B.+T.+Kellerauthor=H.+Yinauthor=S.+Bantonauthor=D.+P.+Jonesauthor=H.+Wuauthor=P.+A.+Dawsonauthor=S.+J.+Karpen&title=Inhibition+of+ileal+bile+acid+uptake+protects+against+nonalcoholic+fatty+liver+disease+in+high-fat+diet-fed+mice&doi=10.1126%2Fscitranslmed.aaf4823"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaf4823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaf4823%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DA.%26aulast%3DKosters%26aufirst%3DA.%26aulast%3DMells%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSetchell%26aufirst%3DK.%2BD.%26aulast%3DAmanso%26aufirst%3DA.%2BM.%26aulast%3DWynn%26aufirst%3DG.%2BM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DKeller%26aufirst%3DB.%2BT.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DBanton%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DD.%2BP.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDawson%26aufirst%3DP.%2BA.%26aulast%3DKarpen%26aufirst%3DS.%2BJ.%26atitle%3DInhibition%2520of%2520ileal%2520bile%2520acid%2520uptake%2520protects%2520against%2520nonalcoholic%2520fatty%2520liver%2520disease%2520in%2520high-fat%2520diet-fed%2520mice%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D357%26spage%3D357ra122%26doi%3D10.1126%2Fscitranslmed.aaf4823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, S. R.</span></span> <span> </span><span class="NLM_article-title">Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">14</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1016/j.amjcard.2005.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.amjcard.2005.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFGmurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2005&pages=14-23&author=S.+R.+Goldsmith&title=Current+treatments+and+novel+pharmacologic+treatments+for+hyponatremia+in+congestive+heart+failure&doi=10.1016%2Fj.amjcard.2005.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure</span></div><div class="casAuthors">Goldsmith, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">9A</span>),
    <span class="NLM_cas:pages">14B-23B</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Hyponatremia in congestive heart failure (CHF) is assocd. with increased morbidity and mortality, underlining the importance of adequate assessment and treatment of this electrolyte imbalance in patients with CHF.  Current treatment options for hyponatremia in CHF include hypertonic saline soln., loop diuretics, fluid restriction, and other pharmacol. agents, such as demeclocycline, lithium carbonate, and urea.  Hypertonic saline soln. must be administered with extreme caution because excessively slow or rapid sodium correction can lead to severe neurol. adverse effects.  Loop diuretics are useful for reducing the water retention caused by CHF.  However, the potent diuresis induced by agents such as furosemide results in loss of sodium and other essential electrolytes, which may exacerbate hyponatremia.  Fluid restriction is only moderately effective and often difficult to implement in the hospital setting.  Agents such as demeclocycline and lithium have potentially serious renal and cardiovascular side effects.  The arginine vasopressin (AVP) receptor antagonists are a promising new class of aquaretic agents that increase free-water excretion while maintaining levels of sodium and other essential electrolytes.  Tolvaptan (OPC-41061), lixivaptan (VPA-985), and conivaptan (YM-087) are currently under development for the treatment of hyponatremia.  Although tolvaptan and lixivaptan are selective for the vasopressin-2 (V2) receptor responsible for the antidiuretic actions of AVP, conivaptan demonstrates activity at both the V2 receptor and the V1a receptor responsible for the vasoconstricting properties of AVP.  This dual receptor activity may be particularly useful in patients with CHF.  These patients may benefit from the increased cardiac output, reduced total peripheral resistance, and reduced mean arterial blood pressure that results from V1a receptor blockade as well as the reduced congestion, reduced cardiac preload, and increased sodium concns. induced by V2 receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrkyMd35k0gLVg90H21EOLACvtfcHk0lg3KdPIauNdQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFGmurs%253D&md5=ed2bbacb19e2ae395fc45b477f77b1a6</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2005.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2005.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGoldsmith%26aufirst%3DS.%2BR.%26atitle%3DCurrent%2520treatments%2520and%2520novel%2520pharmacologic%2520treatments%2520for%2520hyponatremia%2520in%2520congestive%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2005%26volume%3D95%26spage%3D14%26epage%3D23%26doi%3D10.1016%2Fj.amjcard.2005.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phuan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5942</span>â <span class="NLM_lpage">5950</span>, <span class="refDoi">Â DOI: 10.1021/jm300491y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300491y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Snur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5942-5950&issue=12&author=M.+O.+Andersonauthor=J.+Zhangauthor=Y.+Liuauthor=C.+Yaoauthor=P.+W.+Phuanauthor=A.+S.+Verkman&title=Nanomolar+potency+and+metabolically+stable+inhibitors+of+kidney+urea+transporter+UT-B&doi=10.1021%2Fjm300491y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomolar Potency and Metabolically Stable Inhibitors of Kidney Urea Transporter UT-B</span></div><div class="casAuthors">Anderson, Marc O.; Zhang, Jicheng; Liu, Yan; Yao, Chenjuan; Phuan, Puay-Wah; Verkman, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5942-5950</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea transporters, which include UT-B in kidney microvessels, are potential targets for development of drugs with a novel diuretic ('urearetic') mechanism.  We recently identified, by high-throughput screening, a triazolothienopyrimidine UT-B inhibitor, 1, that selectively and reversibly inhibited urea transport with IC50 = 25.1 nM and reduced urinary concn. in mice (Yao et al. J. Am. Soc. Nephrol., in press).  Here, we analyzed com. available analogs of (I) to establish a structure-activity series and synthesized a targeted library of 11 analogs to identify potent, metabolically stable UT-B inhibitors.  The best compd., {3-[4-(1,1-difluoroethyl)benzenesulfonyl]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}thiophen-2-ylmethylamine, (II), had IC50 of 23 and 15 nM for inhibition of urea transport by mouse and human UT-B, resp., and â¼40-fold improved in vitro metabolic stability compared to I.  In mice, II accumulated in kidney and urine and reduced max. urinary concn.  Triazolothienopyrimidine may be useful for therapy of diuretic-refractory edema in heart and liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPSG5UZkS2D7Vg90H21EOLACvtfcHk0lg3KdPIauNdQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Snur4%253D&md5=a1140ee5f316022648a8140fbd6607df</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fjm300491y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300491y%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BO.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DPhuan%26aufirst%3DP.%2BW.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DNanomolar%2520potency%2520and%2520metabolically%2520stable%2520inhibitors%2520of%2520kidney%2520urea%2520transporter%2520UT-B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D12%26spage%3D5942%26epage%3D5950%26doi%3D10.1021%2Fjm300491y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cil, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez-Cecilia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">Nanomolar-potency 1,2,4-triazoloquinoxaline inhibitors of the kidney urea transporter UT-A1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3209</span>â <span class="NLM_lpage">3217</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00343</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00343" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFCntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3209-3217&issue=7&author=S.+Leeauthor=O.+Cilauthor=E.+Diez-Ceciliaauthor=M.+O.+Andersonauthor=A.+S.+Verkman&title=Nanomolar-potency+1%2C2%2C4-triazoloquinoxaline+inhibitors+of+the+kidney+urea+transporter+UT-A1&doi=10.1021%2Facs.jmedchem.8b00343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomolar-Potency 1,2,4-Triazoloquinoxaline Inhibitors of the Kidney Urea Transporter UT-A1</span></div><div class="casAuthors">Lee, Sujin; Cil, Onur; Diez-Cecilia, Elena; Anderson, Marc O.; Verkman, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3209-3217</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea transporter A (UT-A) isoforms encoded by the Slc14a2 gene are expressed in kidney tubule epithelial cells, where they facilitate urinary concn.  UT-A1 inhibition is predicted to produce a unique salt-sparing diuretic action in edema and hyponatremia.  Here we report the discovery of 1,2,4-triazoloquinoxalines and the anal. of 37 synthesized analogs.  The most potent compd., 8ay, contg. 1,2,4-triazolo[4,3-a]quinoxaline-substituted benzenesulfonamide linked by an aryl ether, rapidly and reversibly inhibited UT-A1 urea transport by a noncompetitive mechanism with IC50 â 150 nM; the IC50 was â¼2 Î¼M for the related urea transporter UT-B encoded by the Slc14a1 gene.  Mol. modeling suggested a putative binding site on the UT-A1 cytoplasmic domain.  In vitro metab. showing quinoxaline ring oxidn. prompted the synthesis of metabolically stable 7,8-difluoroquinoxaline analog 8bl, which when administered to rats produced marked diuresis and reduced urinary osmolality. 8bl has substantially improved UT-A1 inhibition potency and metabolic stability compared with prior compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox0SlHYp1XHrVg90H21EOLACvtfcHk0lg3KdPIauNdQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFCntrs%253D&md5=665fb027518f2ce8e7db3d20a0873523</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00343%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DCil%26aufirst%3DO.%26aulast%3DDiez-Cecilia%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DM.%2BO.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DNanomolar-potency%25201%252C2%252C4-triazoloquinoxaline%2520inhibitors%2520of%2520the%2520kidney%2520urea%2520transporter%2520UT-A1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D3209%26epage%3D3217%26doi%3D10.1021%2Facs.jmedchem.8b00343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anzai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutabha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amonpatumrat-Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, H.</span></span> <span> </span><span class="NLM_article-title">Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies</span>. <i>Clin. Exp. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1007/s10157-011-0532-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs10157-011-0532-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22038265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFGmsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=89-95&issue=1&author=N.+Anzaiauthor=P.+Jutabhaauthor=S.+Amonpatumrat-Takahashiauthor=H.+Sakurai&title=Recent+advances+in+renal+urate+transport%3A+characterization+of+candidate+transporters+indicated+by+genome-wide+association+studies&doi=10.1007%2Fs10157-011-0532-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide associated studies</span></div><div class="casAuthors">Anzai, Naohiko; Jutabha, Promsuk; Amonpatumrat-Takahashi, Sirirat; Sakurai, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-95</span>CODEN:
                <span class="NLM_cas:coden">CENPFV</span>;
        ISSN:<span class="NLM_cas:issn">1342-1751</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Nephrology</span>)
        </div><div class="casAbstract">A review.  Humans have higher serum uric acid levels than other mammalian species owing to the genetic silencing of the hepatic enzyme uricase that metabolizes uric acid into allantoin.  Urate (the ionized form of uric acid) is generated from purine metab. and it may provide antioxidant defense in the human body.  Despite its potential advantage, sustained hyperuricemia has pathogenetic causes in gout and renal diseases, and putative roles in hypertension and cardiovascular diseases.  Since the kidney plays a dominant role in maintaining plasma urate levels through the excretion process, it is important to understand the mol. mechanism of renal urate handling.  Although the mol. identification of a kidney-specific urate/anion exchanger URAT1 in 2002 paved the way for successive identification of several urate transport-related proteins, the entire picture of effective renal urate handling in humans has not yet been clarified.  Recently, several genome-wide assocn. studies identified a substantial assocn. between uric acid concn. and single nucleotide polymorphisms in at least ten genetic loci including eight transporter-coding genes.  In 2008, we functionally characterized the facilitatory glucose transporter family member SLC2A9 (GLUT9), one of the candidate genes for urate handling, as a voltage-driven urate transporter URATv1 at the basolateral side of renal proximal tubules that comprises the main route of the urate reabsorption pathway, in tandem with URAT1 at the apical side.  In this review, recent findings concerning these candidate mols. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpywqSn8IxMg7Vg90H21EOLACvtfcHk0ljqKVuPqBqG0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFGmsLw%253D&md5=36da5733dd8a6b861ffb70a53acf37b7</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1007%2Fs10157-011-0532-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10157-011-0532-z%26sid%3Dliteratum%253Aachs%26aulast%3DAnzai%26aufirst%3DN.%26aulast%3DJutabha%26aufirst%3DP.%26aulast%3DAmonpatumrat-Takahashi%26aufirst%3DS.%26aulast%3DSakurai%26aufirst%3DH.%26atitle%3DRecent%2520advances%2520in%2520renal%2520urate%2520transport%253A%2520characterization%2520of%2520candidate%2520transporters%2520indicated%2520by%2520genome-wide%2520association%2520studies%26jtitle%3DClin.%2520Exp.%2520Nephrol.%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D89%26epage%3D95%26doi%3D10.1007%2Fs10157-011-0532-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chairoungdua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutabha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoyamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endou, H.</span></span> <span> </span><span class="NLM_article-title">Molecular identification of a renal urate-anion exchanger that regulates blood urate levels</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">447</span>â <span class="NLM_lpage">452</span>, <span class="refDoi">Â DOI: 10.1038/nature742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12024214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=447-452&author=A.+Enomotoauthor=H.+Kimuraauthor=A.+Chairoungduaauthor=Y.+Shigetaauthor=P.+Jutabhaauthor=S.+H.+Chaauthor=M.+Hosoyamadaauthor=M.+Takedaauthor=T.+Sekineauthor=T.+Igarashiauthor=H.+Matsuoauthor=Y.+Kikuchiauthor=T.+Odaauthor=K.+Ichidaauthor=T.+Hosoyaauthor=K.+Shimokataauthor=T.+Niwaauthor=Y.+Kanaiauthor=H.+Endou&title=Molecular+identification+of+a+renal+urate-anion+exchanger+that+regulates+blood+urate+levels&doi=10.1038%2Fnature742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular identification of a renal urate-anion exchanger that regulates blood urate levels</span></div><div class="casAuthors">Enomoto, Atsushi; Kimura, Hiroaki; Chairoungdua, Arthit; Shigeta, Yasuhiro; Jutabha, Promsuk; Cha, Seok Ho; Hosoyamada, Makoto; Takeda, Michio; Sekine, Takashi; Igarashi, Takashi; Matsuo, Hirotaka; Kikuchi, Yuichi; Oda, Takashi; Ichida, Kimiyoshi; Hosoya, Tatsuo; Shimokata, Kaoru; Niwa, Toshimitsu; Kanai, Yoshikatsu; Endou, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">447-452</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Urate, a naturally occurring product of purine metab., is a scavenger of biol. oxidants implicated in numerous disease processes, as demonstrated by its capacity of neuroprotection.  It is present at higher levels in human blood (200-500 Î¼M) than in other mammals, because humans have an effective renal urate resorption system, despite their evolutionary loss of hepatic uricase by mutational silencing.  The mol. basis for urate handling in the human kidney remains unclear because of difficulties in understanding diverse urate transport systems and species differences.  Here we identify the long-hypothesized urate transporter in the human kidney (URAT1, encoded by SLC22A12), a urate-anion exchanger regulating blood urate levels and targeted by uricosuric and antiuricosuric agents (which affect excretion of uric acid).  Moreover, we provide evidence that patients with idiopathic renal hypouricemia (lack of blood uric acid) have defects in SLC22A12.  Identification of URAT1 should provide insights into the nature of urate homeostasis, as well as lead to the development of better agents against hyperuricemia, a disadvantage concomitant with human evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyAZNPywCQaLVg90H21EOLACvtfcHk0ljqKVuPqBqG0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersrs%253D&md5=3d4b19696eef041d9da8269a94a49ac6</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1038%2Fnature742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature742%26sid%3Dliteratum%253Aachs%26aulast%3DEnomoto%26aufirst%3DA.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DChairoungdua%26aufirst%3DA.%26aulast%3DShigeta%26aufirst%3DY.%26aulast%3DJutabha%26aufirst%3DP.%26aulast%3DCha%26aufirst%3DS.%2BH.%26aulast%3DHosoyamada%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DSekine%26aufirst%3DT.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DMatsuo%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DY.%26aulast%3DOda%26aufirst%3DT.%26aulast%3DIchida%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DShimokata%26aufirst%3DK.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DEndou%26aufirst%3DH.%26atitle%3DMolecular%2520identification%2520of%2520a%2520renal%2520urate-anion%2520exchanger%2520that%2520regulates%2520blood%2520urate%2520levels%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D447%26epage%3D452%26doi%3D10.1038%2Fnature742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref239"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref239'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milner, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyndman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iverson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanavati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerty, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terkeltaub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quart, B.</span></span> <span> </span><span class="NLM_article-title">Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1186%2Fs13075-016-1107-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27716403" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=214&issue=1&author=J.+N.+Milnerauthor=P.+K.+Tanauthor=D.+Hyndmanauthor=S.+Liuauthor=C.+Iversonauthor=P.+Nanavatiauthor=D.+T.+Hagertyauthor=K.+Manhardauthor=Z.+Shenauthor=J.+L.+Girardetauthor=L.+T.+Yehauthor=R.+Terkeltaubauthor=B.+Quart&title=Lesinurad%2C+a+novel%2C+oral+compound+for+gout%2C+acts+to+decrease+serum+uric+acid+through+inhibition+of+urate+transporters+in+the+kidney"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1186%2Fs13075-016-1107-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-016-1107-x%26sid%3Dliteratum%253Aachs%26aulast%3DMilner%26aufirst%3DJ.%2BN.%26aulast%3DTan%26aufirst%3DP.%2BK.%26aulast%3DHyndman%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DIverson%26aufirst%3DC.%26aulast%3DNanavati%26aufirst%3DP.%26aulast%3DHagerty%26aufirst%3DD.%2BT.%26aulast%3DManhard%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DGirardet%26aufirst%3DJ.%2BL.%26aulast%3DYeh%26aufirst%3DL.%2BT.%26aulast%3DTerkeltaub%26aufirst%3DR.%26aulast%3DQuart%26aufirst%3DB.%26atitle%3DLesinurad%252C%2520a%2520novel%252C%2520oral%2520compound%2520for%2520gout%252C%2520acts%2520to%2520decrease%2520serum%2520uric%2520acid%2520through%2520inhibition%2520of%2520urate%2520transporters%2520in%2520the%2520kidney%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2016%26volume%3D18%26issue%3D1%26spage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiramoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span> <span> </span><span class="NLM_article-title">Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1602</span>â <span class="NLM_lpage">1610</span>, <span class="refDoi">Â DOI: 10.1093/rheumatology/key100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Frheumatology%2Fkey100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29868853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWksbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1602-1610&issue=9&author=M.+Shiramotoauthor=S.+Liuauthor=Z.+C.+Shenauthor=X.+H.+Yanauthor=A.+Yamamotoauthor=M.+Gillenauthor=Y.+Itoauthor=J.+Hall&title=Verinurad+combined+with+febuxostat+in+Japanese+adults+with+gout+or+asymptomatic+hyperuricaemia%3A+a+phase+2a%2C+open-label+study&doi=10.1093%2Frheumatology%2Fkey100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study</span></div><div class="casAuthors">Shiramoto, Masanari; Liu, Sha; Shen, Zancong; Yan, Xiaohong; Yamamoto, Amy; Gillen, Michael; Ito, Yasushi; Hall, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1602-1610</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives.  Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clin. development for treating gout and asymptomatic hyperuricemia.  The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-dose pharmacodynamics, pharmacokinetics and safety of oral verinurad combined with febuxostat vs febuxostat alone and verinurad alone.  Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricemia (n = 35) and serum urate (sUA) â¥8 mg/dL were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2.5-10 mg), verinurad alone (2.5-15 mg), febuxostat alone (10, 20, 40 mg) or benzbromarone alone (50 mg).  There were four treatment periods per cohort and each treatment period was 7 days.  Study drugs were administered once-daily after breakfast.  Plasma, serum and urine samples were measured at pre-set intervals on days-1, 7, 14, 21 and 28.  Verinurad combined with febuxostat decreased sUA in dose-dependent manner, providing greater sUA lowering than febuxostat alone at the same dose (P < 0.001).  Urinary uric acid excretion rate was increased by verinurad, reduced by febuxostat and comparable to baseline for verinurad combined with febuxostat.  Verinurad from 2.5 mg to 15 mg was well tolerated, with no withdrawals due to adverse events.  Lab. assessments showed no clin. meaningful changes during combination treatment.  Conclusion.  Verinurad combined with febuxostat decreased sUA dose-dependently while maintaining uric acid excretion similar to baseline.  All dose combinations of verinurad and febuxostat were generally well tolerated.  These data support continued investigation of oral verinurad in patients with gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4fFMzekvydLVg90H21EOLACvtfcHk0lhem8zyafqQqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWksbvL&md5=21b2c58df0621579f2f85ae05bcce019</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkey100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkey100%26sid%3Dliteratum%253Aachs%26aulast%3DShiramoto%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DZ.%2BC.%26aulast%3DYan%26aufirst%3DX.%2BH.%26aulast%3DYamamoto%26aufirst%3DA.%26aulast%3DGillen%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DVerinurad%2520combined%2520with%2520febuxostat%2520in%2520Japanese%2520adults%2520with%2520gout%2520or%2520asymptomatic%2520hyperuricaemia%253A%2520a%2520phase%25202a%252C%2520open-label%2520study%26jtitle%3DRheumatology%26date%3D2018%26volume%3D57%26issue%3D9%26spage%3D1602%26epage%3D1610%26doi%3D10.1093%2Frheumatology%2Fkey100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filone, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ory, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>477</i></span> (<span class="NLM_issue">7364</span>),  <span class="NLM_fpage">344</span>â <span class="NLM_lpage">348</span>, <span class="refDoi">Â DOI: 10.1038/nature10380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature10380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21866101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=344-348&issue=7364&author=M.+Coteauthor=J.+Misasiauthor=T.+Renauthor=A.+Bruchezauthor=K.+Leeauthor=C.+M.+Filoneauthor=L.+Hensleyauthor=Q.+Liauthor=D.+Oryauthor=K.+Chandranauthor=J.+Cunningham&title=Small+molecule+inhibitors+reveal+Niemann-Pick+C1+is+essential+for+Ebola+virus+infection&doi=10.1038%2Fnature10380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span></div><div class="casAuthors">Cote, Marceline; Misasi, John; Ren, Tao; Bruchez, Anna; Lee, Kyung-Ae; Filone, Claire Marie; Hensley, Lisa; Li, Qi; Ory, Daniel; Chandran, Kartik; Cunningham, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">7364</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa.  The clin. symptoms are manifestations of the massive prodn. of pro-inflammatory cytokines in response to infection and in many outbreaks, mortality exceeds 75%.  The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV.  Here, the authors report the identification of a novel benzylpiperazine adamantane diamide-derived compd. that inhibits EboV infection.  Using mutant cell lines and informative derivs. of the lead compd., they show that the target of the inhibitor is the endosomal membrane protein Niemann-Pick C1 (NPC1).  They find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compds. interfere with GP binding to NPC1.  Combined with the results of previous studies on GP structure and function, these findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit.  Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH09MFk31Ol7Vg90H21EOLACvtfcHk0lhem8zyafqQqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI&md5=99e7763b2b95af9d046992a9d36fd3a2</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1038%2Fnature10380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10380%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DM.%26aulast%3DMisasi%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DBruchez%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DFilone%26aufirst%3DC.%2BM.%26aulast%3DHensley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DOry%26aufirst%3DD.%26aulast%3DChandran%26aufirst%3DK.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520reveal%2520Niemann-Pick%2520C1%2520is%2520essential%2520for%2520Ebola%2520virus%2520infection%26jtitle%3DNature%26date%3D2011%26volume%3D477%26issue%3D7364%26spage%3D344%26epage%3D348%26doi%3D10.1038%2Fnature10380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. C.</span></span> <span> </span><span class="NLM_article-title">Structure of human Niemann-Pick C1 (NPC1) protein and NPC1-NPC2 complex</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">629.2</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=629.2&author=X.+C.+Li&title=Structure+of+human+Niemann-Pick+C1+%28NPC1%29+protein+and+NPC1-NPC2+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BC.%26atitle%3DStructure%2520of%2520human%2520Niemann-Pick%2520C1%2520%2528NPC1%2529%2520protein%2520and%2520NPC1-NPC2%2520complex%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D629.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloveva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dedic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of potent Ebola virus entry inhibitors with suitable properties for in vivo studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6293</span>â <span class="NLM_lpage">6307</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00704</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00704" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsrbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6293-6307&issue=14&author=H.+Liuauthor=Y.+Tianauthor=K.+Leeauthor=P.+Krishnanauthor=M.+K.+Wangauthor=S.+Whelanauthor=E.+Meversauthor=V.+Solovevaauthor=B.+Dedicauthor=X.+Liuauthor=J.+M.+Cunningham&title=Identification+of+potent+Ebola+virus+entry+inhibitors+with+suitable+properties+for+in+vivo+studies&doi=10.1021%2Facs.jmedchem.8b00704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Ebola Virus Entry Inhibitors with Suitable Properties for in Vivo Studies</span></div><div class="casAuthors">Liu, Hu; Tian, Ye; Lee, Kyungae; Krishnan, Pranav; Wang, May Kwang-Mei; Whelan, Sean; Mevers, Emily; Soloveva, Veronica; Dedic, Benjamin; Liu, Xinyong; Cunningham, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6293-6307</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous studies identified an adamantane dipeptide piperazine 3.47 that inhibits Ebola virus (EBOV) infection by targeting the essential receptor Niemann-Pick C1 (NPC1).  The physicochem. properties of 3.47 limit its potential for testing in vivo.  Optimization by improving potency, reducing hydrophobicity, and replacing labile moieties identified 3.47 derivs. with improved in vitro ADME properties that are also highly active against EBOV infection, including when tested in the presence of 50% normal human serum (NHS).  In addn., 3A4 was identified as the major cytochrome P 450 isoform that metabolizes these compds., and accordingly, mouse microsome stability was significantly improved when tested in the presence of the CYP3A4 inhibitor ritonavir that is approved for clin. use as a booster of anti-HIV drugs.  Oral administration of the EBOV inhibitors with ritonavir resulted in a pharmacokinetic profile that supports a b.i.d. dosing regimen for efficacy studies in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJSxVgYCh0kLVg90H21EOLACvtfcHk0liq_DytlJyxvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsrbM&md5=c25d32ae9dbbd336b1e7d60dbf4949ff</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00704%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKrishnan%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DM.%2BK.%26aulast%3DWhelan%26aufirst%3DS.%26aulast%3DMevers%26aufirst%3DE.%26aulast%3DSoloveva%26aufirst%3DV.%26aulast%3DDedic%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCunningham%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520potent%2520Ebola%2520virus%2520entry%2520inhibitors%2520with%2520suitable%2520properties%2520for%2520in%2520vivo%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D6293%26epage%3D6307%26doi%3D10.1021%2Facs.jmedchem.8b00704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Mosleh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Brabander, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. S.</span></span> <span> </span><span class="NLM_article-title">Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e12177</span>, <span class="refDoi">Â DOI: 10.7554/eLife.12177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.7554%2FeLife.12177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26646182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVCms7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e12177&author=F.+R.+Luauthor=Q.+R.+Liangauthor=L.+Abi-Moslehauthor=A.+Dasauthor=J.+K.+De+Brabanderauthor=J.+L.+Goldsteinauthor=M.+S.+Brown&title=Identification+of+NPC1+as+the+target+of+U18666A%2C+an+inhibitor+of+lysosomal+cholesterol+export+and+Ebola+infection&doi=10.7554%2FeLife.12177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection</span></div><div class="casAuthors">Lu, Feiran; Liang, Qiren; Abi-Mosleh, Lina; Das, Akash; De Brabander, Jef K.; Goldstein, Joseph L.; Brown, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e12177/1-e12177/16</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Niemann-Pick C1 (NPC1) is a lysosomal membrane protein that exports cholesterol derived from receptor-mediated uptake of LDL, and it also mediates cellular entry of Ebola virus.  Cholesterol export is inhibited by nanomolar concns. of U18666A, a cationic sterol.  To identify the target of U18666A, we synthesized U-X, a U18666A deriv. with a benzophenone that permits UV-induced crosslinking.  When added to CHO cells, U-X crosslinked to NPC1.  Crosslinking was blocked by U18666A derivs. that block cholesterol export, but not derivs. lacking blocking activity.  Crosslinking was prevented by point mutation in the sterol-sensing domain (SSD) of NPC1, but not by point mutation in the N-terminal domain (NTD).  These data suggest that the SSD contains a U18666A-inhibitable site required for cholesterol export distinct from the cholesterol-binding site in the NTD.  Inasmuch as inhibition of Ebola requires 100-fold higher concns. of U18666A, the high affinity U16888A-binding site is likely not required for virus entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJQTKeiWz3U7Vg90H21EOLACvtfcHk0liq_DytlJyxvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVCms7c%253D&md5=d008fe46541036d0f78a73b0aa6e433a</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.7554%2FeLife.12177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.12177%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DF.%2BR.%26aulast%3DLiang%26aufirst%3DQ.%2BR.%26aulast%3DAbi-Mosleh%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DDe%2BBrabander%26aufirst%3DJ.%2BK.%26aulast%3DGoldstein%26aufirst%3DJ.%2BL.%26aulast%3DBrown%26aufirst%3DM.%2BS.%26atitle%3DIdentification%2520of%2520NPC1%2520as%2520the%2520target%2520of%2520U18666A%252C%2520an%2520inhibitor%2520of%2520lysosomal%2520cholesterol%2520export%2520and%2520Ebola%2520infection%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De12177%26doi%3D10.7554%2FeLife.12177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. H.</span></span> <span> </span><span class="NLM_article-title">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e00049</span>, <span class="refDoi">Â DOI: 10.7554/eLife.00049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.7554%2FeLife.00049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23150796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=e00049&author=H.+Yanauthor=G.+C.+Zhongauthor=G.+W.+Xuauthor=W.+H.+Heauthor=Z.+Y.+Jingauthor=Z.+C.+Gaoauthor=Y.+Huangauthor=Y.+H.+Qiauthor=B.+Pengauthor=H.+M.+Wangauthor=L.+R.+Fuauthor=M.+Songauthor=P.+Chenauthor=W.+Q.+Gaoauthor=B.+J.+Renauthor=Y.+Y.+Sunauthor=T.+Caiauthor=X.+F.+Fengauthor=J.+H.+Suiauthor=W.+H.+Li&title=Sodium+taurocholate+cotransporting+polypeptide+is+a+functional+receptor+for+human+hepatitis+B+and+D+virus&doi=10.7554%2FeLife.00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span></div><div class="casAuthors">Yan, Huan; Zhong, Guocai; Xu, Guangwei; He, Wenhui; Jing, Zhiyi; Gao, Zhenchao; Huang, Yi; Qi, Yonghe; Peng, Bo; Wang, Haimin; Fu, Liran; Song, Mei; Chen, Pan; Gao, Wenqing; Ren, Bijie; Sun, Yinyan; Cai, Tao; Feng, Xiaofeng; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00049, 28 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem.  Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease.  Cellular entry of both viruses is mediated by HBV envelope proteins.  The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding.  However, the identity of the receptor(s) is unknown.  Here, by using near zero distance photo-crosslinking and tandem affinity purifn., the authors revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver.  Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections.  Moreover, replacing amino acids 157-165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections.  The authors' results demonstrate that NTCP is a functional receptor for HBV and HDV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0tqZhmqs37Vg90H21EOLACvtfcHk0li5aUH86OFbhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK&md5=7380905d92bd82b9cf3407b7c113bdfb</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.7554%2FeLife.00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00049%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DHe%26aufirst%3DW.%2BH.%26aulast%3DJing%26aufirst%3DZ.%2BY.%26aulast%3DGao%26aufirst%3DZ.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BM.%26aulast%3DFu%26aufirst%3DL.%2BR.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DW.%2BQ.%26aulast%3DRen%26aufirst%3DB.%2BJ.%26aulast%3DSun%26aufirst%3DY.%2BY.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DX.%2BF.%26aulast%3DSui%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DW.%2BH.%26atitle%3DSodium%2520taurocholate%2520cotransporting%2520polypeptide%2520is%2520a%2520functional%2520receptor%2520for%2520human%2520hepatitis%2520B%2520and%2520D%2520virus%26jtitle%3DeLife%26date%3D2012%26volume%3D1%26spage%3De00049%26doi%3D10.7554%2FeLife.00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Passioura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saso, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">De novo macrocyclic peptide inhibitors of hepatitis B virus cellular entry</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">906</span>â <span class="NLM_lpage">915</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2018.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.chembiol.2018.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29779957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVemsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=906-915&issue=7&author=T.+Passiouraauthor=K.+Watashiauthor=K.+Fukanoauthor=S.+Shimuraauthor=W.+Sasoauthor=R.+Morishitaauthor=Y.+Ogasawaraauthor=Y.+Tanakaauthor=M.+Mizokamiauthor=C.+Sureauauthor=H.+Sugaauthor=T.+Wakita&title=De+novo+macrocyclic+peptide+inhibitors+of+hepatitis+B+virus+cellular+entry&doi=10.1016%2Fj.chembiol.2018.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry</span></div><div class="casAuthors">Passioura, Toby; Watashi, Koichi; Fukano, Kento; Shimura, Satomi; Saso, Wakana; Morishita, Ryo; Ogasawara, Yuki; Tanaka, Yasuhito; Mizokami, Masashi; Sureau, Camille; Suga, Hiroaki; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">906-915.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) constitutes a significant public health burden, and currently available treatment options are not generally curative, necessitating the development of new therapeutics.  Here we have applied random non-std. peptide integrated discovery (RaPID) screening to identify small macrocyclic peptide inhibitors of HBV entry that target the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP).  In addn. to their anti-HBV activity, these mols. also inhibit cellular entry by the related hepatitis D virus (HDV), and are active against diverse strains of HBV (including clin. relevant nucleos(t)ide analog-resistant and vaccine escaping strains).  Importantly, these macrocyclic peptides, in contrast to other NTCP-binding HBV entry inhibitors, exhibited no inhibition of NTCP-mediated bile acid uptake, making them appealing candidates for therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxE9mDycbKobVg90H21EOLACvtfcHk0li5aUH86OFbhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVemsL4%253D&md5=abb5f4c3bae8a692b7153546e520f218</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPassioura%26aufirst%3DT.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DFukano%26aufirst%3DK.%26aulast%3DShimura%26aufirst%3DS.%26aulast%3DSaso%26aufirst%3DW.%26aulast%3DMorishita%26aufirst%3DR.%26aulast%3DOgasawara%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DSuga%26aufirst%3DH.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DDe%2520novo%2520macrocyclic%2520peptide%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520cellular%2520entry%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D7%26spage%3D906%26epage%3D915%26doi%3D10.1016%2Fj.chembiol.2018.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamisuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">A novel tricyclic polyketide, vanitaracin a, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">11945</span>â <span class="NLM_lpage">11953</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01855-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1128%2FJVI.01855-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26378168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFyiur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=11945-11953&issue=23&author=M.+Kanekoauthor=K.+Watashiauthor=S.+Kamisukiauthor=H.+Matsunagaauthor=M.+Iwamotoauthor=F.+Kawaiauthor=H.+Ohashiauthor=S.+Tsukudaauthor=S.+Shimuraauthor=R.+Suzukiauthor=H.+Aizakiauthor=M.+Sugiyamaauthor=S.+Y.+Parkauthor=T.+Itoauthor=N.+Ohtaniauthor=F.+Sugawaraauthor=Y.+Tanakaauthor=M.+Mizokamiauthor=C.+Sureauauthor=T.+Wakita&title=A+novel+tricyclic+polyketide%2C+vanitaracin+a%2C+specifically+inhibits+the+entry+of+hepatitis+B+and+D+viruses+by+targeting+sodium+taurocholate+cotransporting+polypeptide&doi=10.1128%2FJVI.01855-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide</span></div><div class="casAuthors">Kaneko, Manabu; Watashi, Koichi; Kamisuki, Shinji; Matsunaga, Hiroki; Iwamoto, Masashi; Kawai, Fumihiro; Ohashi, Hirofumi; Tsukuda, Senko; Shimura, Satomi; Suzuki, Ryosuke; Aizaki, Hideki; Sugiyama, Masaya; Park, Sam-Yong; Ito, Takayoshi; Ohtani, Naoko; Sugawara, Fumio; Tanaka, Yasuhito; Mizokami, Masashi; Sureau, Camille; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11945-11953</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Anti-hepatitis B virus (HBV) drugs are currently limited to nucleos(t)ide analogs (NAs) and interferons.  A challenge of drug development is the identification of small mols. that suppress HBV infection from new chem. sources.  Here, from a fungus-derived secondary metabolite library, we identify a structurally novel tricyclic polyketide, named vanitaracin A, which specifically inhibits HBV infection.  Vanitaracin A inhibited the viral entry process with a submicromolar 50% inhibitory concn. (IC50) (IC50 = 0.61 Â± 0.23 Î¼M), without evident cytotoxicity (50% cytotoxic concn. of >256 Î¼M; selectivity index value of >419) in primary human hepatocytes.  Vanitaracin A did not affect the HBV replication process.  This compd. was found to directly interact with the HBV entry receptor sodium taurocholate cotransporting polypeptide (NTCP) and impaired its bile acid transport activity.  Consistent with this NTCP targeting, antiviral activity of vanitaracin A was obsd. with hepatitis D virus (HDV) but not hepatitis C virus.  Importantly, vanitaracin A inhibited infection by all HBV genotypes tested (genotypes A to D) and clin. relevant NA-resistant HBV isolate.  Thus, we identified a fungal metabolite, vanitaracin A, which was a potent, well-tolerated, and broadly active inhibitor of HBV and HDV entry.  This compd., or its related analogs, could be part of an antiviral strategy for preventing reinfection with HBV, including clin. relevant nucleos(t)ide analog-resistant virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiy8gZypawebVg90H21EOLACvtfcHk0ljTiSYgGmbxGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFyiur0%253D&md5=a474e23328a4f350415610cb08697512</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1128%2FJVI.01855-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01855-15%26sid%3Dliteratum%253Aachs%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DKamisuki%26aufirst%3DS.%26aulast%3DMatsunaga%26aufirst%3DH.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DKawai%26aufirst%3DF.%26aulast%3DOhashi%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DS.%26aulast%3DShimura%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DAizaki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DOhtani%26aufirst%3DN.%26aulast%3DSugawara%26aufirst%3DF.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DA%2520novel%2520tricyclic%2520polyketide%252C%2520vanitaracin%2520a%252C%2520specifically%2520inhibits%2520the%2520entry%2520of%2520hepatitis%2520B%2520and%2520D%2520viruses%2520by%2520targeting%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26issue%3D23%26spage%3D11945%26epage%3D11953%26doi%3D10.1128%2FJVI.01855-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Chemical genetics: where genetics and pharmacology meet</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">425</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2007.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2007.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17289560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Wlt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=425-430&issue=3&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Chemical+genetics%3A+where+genetics+and+pharmacology+meet&doi=10.1016%2Fj.cell.2007.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics: where genetics and pharmacology meet</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-430</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Genetics and pharmacol. can elicit surprisingly different phenotypes despite targeting the same protein.  This Essay explores these unexpected differences and their implications for biol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq056BEgxFUHrVg90H21EOLACvtfcHk0ljTiSYgGmbxGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Wlt74%253D&md5=8b5d8733dc3b3f699907709cd0ba6f62</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DChemical%2520genetics%253A%2520where%2520genetics%2520and%2520pharmacology%2520meet%26jtitle%3DCell%26date%3D2007%26volume%3D128%26issue%3D3%26spage%3D425%26epage%3D430%26doi%3D10.1016%2Fj.cell.2007.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&issue=2&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljTiSYgGmbxGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belshaw, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4604</span>â <span class="NLM_lpage">4607</span>, <span class="refDoi">Â DOI: 10.1073/pnas.93.10.4604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.93.10.4604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8643450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK28XjtVKmu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=4604-4607&issue=10&author=P.+J.+Belshawauthor=S.+N.+Hoauthor=G.+R.+Crabtreeauthor=S.+L.+Schreiber&title=Controlling+protein+association+and+subcellular+localization+with+a+synthetic+ligand+that+induces+heterodimerization+of+proteins&doi=10.1073%2Fpnas.93.10.4604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins</span></div><div class="casAuthors">Belshaw, Peter J.; Ho, Steffan N.; Crabtree, Gerald R.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4604-4607</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Extracellular growth and differentiation factors induce changes in gene expression in the nucleus by initiating a series of protein assocns. that alter the subcellular localization of intracellular signaling proteins.  Initial events involve receptor homo- or heterodimerization and subsequent recruitment of cytosolic signaling proteins to the inner leaflet of the plasma membrane.  Intermediate events involve the translocation of proteins into the nucleus.  Late events involve the recruitment of transcriptional activators to the vicinity of specific genes in the nucleus, resulting in increased gene transcription.  The ability to induce signals at each of these three phases of signaling pathways is illustrated by the use of a heterodimeric chem. inducer of dimerization that causes a proximal relation between two different target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSpwL7vAnV27Vg90H21EOLACvtfcHk0lidkGBBtgCokg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtVKmu70%253D&md5=1af6cf4a977b80807c763f0cc07f76dc</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.10.4604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.10.4604%26sid%3Dliteratum%253Aachs%26aulast%3DBelshaw%26aufirst%3DP.%2BJ.%26aulast%3DHo%26aufirst%3DS.%2BN.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DControlling%2520protein%2520association%2520and%2520subcellular%2520localization%2520with%2520a%2520synthetic%2520ligand%2520that%2520induces%2520heterodimerization%2520of%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26issue%3D10%26spage%3D4604%26epage%3D4607%26doi%3D10.1073%2Fpnas.93.10.4604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taurino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussolati, O.</span></span> <span> </span><span class="NLM_article-title">GPNA inhibits the sodium-independent transport system L for neutral amino acids</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1365</span>â <span class="NLM_lpage">1372</span>, <span class="refDoi">Â DOI: 10.1007/s00726-017-2436-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00726-017-2436-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28516268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGru78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=1365-1372&issue=8&author=M.+Chiuauthor=C.+Sabinoauthor=G.+Taurinoauthor=M.+G.+Bianchiauthor=R.+Andreoliauthor=N.+Giulianiauthor=O.+Bussolati&title=GPNA+inhibits+the+sodium-independent+transport+system+L+for+neutral+amino+acids&doi=10.1007%2Fs00726-017-2436-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">GPNA inhibits the sodium-independent transport system L for neutral amino acids</span></div><div class="casAuthors">Chiu, Martina; Sabino, Cosimo; Taurino, Giuseppe; Bianchi, Massimiliano G.; Andreoli, Roberta; Giuliani, Nicola; Bussolati, Ovidio</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1365-1372</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">L-Î³-Glutamyl-p-nitroanilide (GPNA) is widely used to inhibit the glutamine transporter ASCT2, although it is known that it also inhibits other sodium-dependent amino acid transporters.  In a panel of human cancer cell lines, which express the system L transporters LAT1 and LAT2, GPNA inhibits the sodium-independent influx of leucine and glutamine.  The kinetics of the effect suggests that GPNA is a low affinity, competitive inhibitor of system L transporters.  In Hs683 human oligodendroglioma cells, the incubation in the presence of GPNA, but not ASCT2 silencing, lowers the cell content of leucine.  Under the same conditions the activity of mTORC1 is inhibited.  Decreased cell content of branched chain amino acids and mTORC1 inhibition are obsd. in most of the other cell lines upon incubation with GPNA.  It is concluded that GPNA hinders the uptake of essential amino acids through system L transporters and lowers their cell content.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq52nlDMnvrbVg90H21EOLACvtfcHk0lidkGBBtgCokg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGru78%253D&md5=3598df6817c38f0e0baf8ff85fd6c360</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1007%2Fs00726-017-2436-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-017-2436-z%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DM.%26aulast%3DSabino%26aufirst%3DC.%26aulast%3DTaurino%26aufirst%3DG.%26aulast%3DBianchi%26aufirst%3DM.%2BG.%26aulast%3DAndreoli%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DN.%26aulast%3DBussolati%26aufirst%3DO.%26atitle%3DGPNA%2520inhibits%2520the%2520sodium-independent%2520transport%2520system%2520L%2520for%2520neutral%2520amino%2520acids%26jtitle%3DAmino%2520Acids%26date%3D2017%26volume%3D49%26issue%3D8%26spage%3D1365%26epage%3D1372%26doi%3D10.1007%2Fs00726-017-2436-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">231</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McAlister, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusinow, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrychowski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuhr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttlin, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span> <span> </span><span class="NLM_article-title">MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">7150</span>â <span class="NLM_lpage">7158</span>, <span class="refDoi">Â DOI: 10.1021/ac502040v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac502040v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Kmur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=7150-7158&issue=14&author=G.+C.+McAlisterauthor=D.+P.+Nusinowauthor=M.+P.+Jedrychowskiauthor=M.+Wuhrauthor=E.+L.+Huttlinauthor=B.+K.+Ericksonauthor=R.+Radauthor=W.+Haasauthor=S.+P.+Gygi&title=MultiNotch+MS3+enables+accurate%2C+sensitive%2C+and+multiplexed+detection+of+differential+expression+across+cancer+cell+line+proteomes&doi=10.1021%2Fac502040v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes</span></div><div class="casAuthors">McAlister, Graeme C.; Nusinow, David P.; Jedrychowski, Mark P.; Wuhr, Martin; Huttlin, Edward L.; Erickson, Brian K.; Rad, Ramin; Haas, Wilhelm; Gygi, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7150-7158</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multiplexed quantitation via isobaric chem. tags (e.g., tandem mass tags (TMT) and isobaric tags for relative and abs. quantitation (iTRAQ)) has the potential to revolutionize quant. proteomics.  However, until recently the utility of these tags was questionable due to reporter ion ratio distortion resulting from fragmentation of coisolated interfering species.  These interfering signals can be negated through addnl. gas-phase manipulations (e.g., MS/MS/MS (MS3) and proton-transfer reactions (PTR)).  These methods, however, have a significant sensitivity penalty.  Using isolation waveforms with multiple frequency notches (i.e., synchronous precursor selection, SPS), the authors coisolated and cofragmented multiple MS2 fragment ions, thereby increasing the no. of reporter ions in the MS3 spectrum 10-fold over the std. MS3 method (i.e., MultiNotch MS3).  By increasing the reporter ion signals, this method improves the dynamic range of reporter ion quantitation, reduces reporter ion signal variance, and ultimately produces more high-quality quant. measurements.  To demonstrate utility, the authors analyzed biol. triplicates of eight colon cancer cell lines using the MultiNotch MS3 method.  Across all the replicates the authors quantified 8378 proteins in union and 6168 proteins in common.  Taking into account that each of these quantified proteins contains eight distinct cell-line measurements, this data set encompasses 174,704 quant. ratios each measured in triplicate across the biol. replicates.  Herein, the MultiNotch MS3 method uniquely combines multiplexing capacity with quant. sensitivity and accuracy, drastically increasing the informational value obtainable from proteomic expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonIBGSGUtKzbVg90H21EOLACvtfcHk0lidkGBBtgCokg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Kmur8%253D&md5=bda847612d4a16030b7921bc8ae6f5c6</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fac502040v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac502040v%26sid%3Dliteratum%253Aachs%26aulast%3DMcAlister%26aufirst%3DG.%2BC.%26aulast%3DNusinow%26aufirst%3DD.%2BP.%26aulast%3DJedrychowski%26aufirst%3DM.%2BP.%26aulast%3DWuhr%26aufirst%3DM.%26aulast%3DHuttlin%26aufirst%3DE.%2BL.%26aulast%3DErickson%26aufirst%3DB.%2BK.%26aulast%3DRad%26aufirst%3DR.%26aulast%3DHaas%26aufirst%3DW.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26atitle%3DMultiNotch%2520MS3%2520enables%2520accurate%252C%2520sensitive%252C%2520and%2520multiplexed%2520detection%2520of%2520differential%2520expression%2520across%2520cancer%2520cell%2520line%2520proteomes%26jtitle%3DAnal.%2520Chem.%26date%3D2014%26volume%3D86%26issue%3D14%26spage%3D7150%26epage%3D7158%26doi%3D10.1021%2Fac502040v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref231"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref231'); return false;" data-citation="" class="refNumLink">232</a></strong><div class="NLM_citation" id="cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kienle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, C.</span></span> <span> </span><span class="NLM_article-title">Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1895</span>â <span class="NLM_lpage">1904</span>, <span class="refDoi">Â DOI: 10.1021/ac0262560</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac0262560" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSmtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2003&pages=1895-1904&issue=8&author=A.+Thompsonauthor=J.+Schaferauthor=K.+Kuhnauthor=S.+Kienleauthor=J.+Schwarzauthor=G.+Schmidtauthor=T.+Neumannauthor=C.+Hamon&title=Tandem+mass+tags%3A+a+novel+quantification+strategy+for+comparative+analysis+of+complex+protein+mixtures+by+MS%2FMS&doi=10.1021%2Fac0262560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS</span></div><div class="casAuthors">Thompson, Andrew; Schaefer, Juergen; Kuhn, Karsten; Kienle, Stefan; Schwarz, Josef; Schmidt, Guenter; Neumann, Thomas; Hamon, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1895-1904</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel MS/MS-based anal. strategy using isotopomer labels, referred to as "tandem mass tags" (TMTs), for the accurate quantification of peptides and proteins is described.  The new tags are designed to ensure that identical peptides labeled with different TMTs exactly comigrate in all sepns.  The tags require novel methods of quantification anal. using tandem mass spectrometry.  The new tags and anal. methods allow peptides from different samples to be identified by their relative abundance with greater ease and accuracy than other methods.  The new TMTs permit simultaneous detn. of both the identity and relative abundances of peptide pairs using a collision induced dissocn. (CID)-based anal. method.  Relative abundance measurements made in the MS/MS mode using the new tags are accurate and sensitive.  Compared to MS-mode measurements, a very high signal-to-noise ratio is achieved with MS/MS based detection.  The new tags should be applicable to a wide variety of peptide isolation methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZtFmu3650nbVg90H21EOLACvtfcHk0lidkGBBtgCokg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSmtbw%253D&md5=6d73dfc7a2af2f2e2bf4c429ae3881bc</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1021%2Fac0262560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac0262560%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DSchafer%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DK.%26aulast%3DKienle%26aufirst%3DS.%26aulast%3DSchwarz%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DNeumann%26aufirst%3DT.%26aulast%3DHamon%26aufirst%3DC.%26atitle%3DTandem%2520mass%2520tags%253A%2520a%2520novel%2520quantification%2520strategy%2520for%2520comparative%2520analysis%2520of%2520complex%2520protein%2520mixtures%2520by%2520MS%252FMS%26jtitle%3DAnal.%2520Chem.%26date%3D2003%26volume%3D75%26issue%3D8%26spage%3D1895%26epage%3D1904%26doi%3D10.1021%2Fac0262560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref232"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref232'); return false;" data-citation="" class="refNumLink">233</a></strong><div class="NLM_citation" id="cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Multiplexed thiol reactivity profiling for target discovery of electrophilic natural products</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1416</span>â <span class="NLM_lpage">1427</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.chembiol.2017.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28988947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aitrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1416-1427&issue=11&author=C.+Tianauthor=R.+Sunauthor=K.+Liuauthor=L.+Fuauthor=X.+Liuauthor=W.+Zhouauthor=Y.+Yangauthor=J.+Yang&title=Multiplexed+thiol+reactivity+profiling+for+target+discovery+of+electrophilic+natural+products&doi=10.1016%2Fj.chembiol.2017.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Multiplexed Thiol Reactivity Profiling for Target Discovery of Electrophilic Natural Products</span></div><div class="casAuthors">Tian, Caiping; Sun, Rui; Liu, Keke; Fu, Ling; Liu, Xiaoyu; Zhou, Wanqi; Yang, Yong; Yang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1416-1427.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Electrophilic groups, such as Michael acceptors, expoxides, are common motifs in natural products (NPs).  Electrophilic NPs can act through covalent modification of cysteinyl thiols on functional proteins, and exhibit potent cytotoxicity and anti-inflammatory/cancer activities.  Here we describe a new chemoproteomic strategy, termed multiplexed thiol reactivity profiling (MTRP), and its use in target discovery of electrophilic NPs.  We demonstrate the utility of MTRP by identifying cellular targets of gambogic acid, an electrophilic NP that is currently under evaluation in clin. trials as anticancer agent.  Moreover, MTRP enables simultaneous comparison of seven structurally diversified Î±,Î²-unsatd. Î³-lactones, which provides insights into the relative proteomic reactivity and target preference of diverse structural scaffolds coupled to a common electrophilic motif and reveals various potential druggable targets with liganded cysteines.  We anticipate that this new method for thiol reactivity profiling in a multiplexed manner will find broad application in redox biol. and drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SRVKEa8-2bVg90H21EOLACvtfcHk0li9hof5kjrbUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aitrrL&md5=c5f482f57b0b6e63a61f73eb4789e1ce</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMultiplexed%2520thiol%2520reactivity%2520profiling%2520for%2520target%2520discovery%2520of%2520electrophilic%2520natural%2520products%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D1416%26epage%3D1427%26doi%3D10.1016%2Fj.chembiol.2017.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref233"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref233'); return false;" data-citation="" class="refNumLink">234</a></strong><div class="NLM_citation" id="cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remsberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalocsay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1113</span>â <span class="NLM_lpage">1123</span>, <span class="refDoi">Â DOI: 10.1038/s41557-019-0351-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41557-019-0351-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31659311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1113-1123&author=Y.+Wangauthor=M.+M.+Dixauthor=G.+Biancoauthor=J.+R.+Remsbergauthor=H.-Y.+Leeauthor=M.+Kalocsayauthor=S.+P.+Gygiauthor=S.+Forliauthor=G.+Viteauthor=R.+M.+Lawrenceauthor=C.+G.+Parkerauthor=B.+F.+Cravatt&title=Expedited+mapping+of+the+ligandable+proteome+using+fully+functionalized+enantiomeric+probe+pairs&doi=10.1038%2Fs41557-019-0351-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs</span></div><div class="casAuthors">Wang, Yujia; Dix, Melissa M.; Bianco, Giulia; Remsberg, Jarrett R.; Lee, Hsin-Yu; Kalocsay, Marian; Gygi, Steven P.; Forli, Stefano; Vite, Gregory; Lawrence, R. Michael; Parker, Christopher G.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1113-1123</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A fundamental challenge in chem. biol. and medicine is to understand and expand the fraction of the human proteome that can be targeted by small mols.  We recently described a strategy that integrates fragment-based ligand discovery with chem. proteomics to furnish global portraits of reversible small-mol./protein interactions in human cells.  Excavating clear structure-activity relationships from these 'ligandability' maps, however, was confounded by the distinct physicochem. properties and corresponding overall protein-binding potential of individual fragments.  Here, we describe a compelling soln. to this problem by introducing a next-generation set of fully functionalized fragments differing only in abs. stereochem.  Using these enantiomeric probe pairs, or 'enantioprobes', we identify numerous stereoselective protein-fragment interactions in cells and show that these interactions occur at functional sites on proteins from diverse classes.  Our findings thus indicate that incorporating chirality into fully functionalized fragment libraries provides a robust and streamlined method to discover ligandable proteins in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfe1dis0v5rVg90H21EOLACvtfcHk0li9hof5kjrbUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrt7rN&md5=f84988523b6c03c9fa616ccd684f9d6d</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1038%2Fs41557-019-0351-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41557-019-0351-5%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DBianco%26aufirst%3DG.%26aulast%3DRemsberg%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DKalocsay%26aufirst%3DM.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DForli%26aufirst%3DS.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DExpedited%2520mapping%2520of%2520the%2520ligandable%2520proteome%2520using%2520fully%2520functionalized%2520enantiomeric%2520probe%2520pairs%26jtitle%3DNat.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D1113%26epage%3D1123%26doi%3D10.1038%2Fs41557-019-0351-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref234"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref234'); return false;" data-citation="" class="refNumLink">235</a></strong><div class="NLM_citation" id="cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordova, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">SLC19A1 is an importer of the immunotransmitter cGAMP</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">372</span>â <span class="NLM_lpage">381</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.molcel.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31126740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=372-381&author=C.+Ritchieauthor=A.+F.+Cordovaauthor=G.+T.+Hessauthor=M.+C.+Bassikauthor=L.+Li&title=SLC19A1+is+an+importer+of+the+immunotransmitter+cGAMP&doi=10.1016%2Fj.molcel.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">SLC19A1 Is an Importer of the Immunotransmitter cGAMP</span></div><div class="casAuthors">Ritchie, Christopher; Cordova, Anthony F.; Hess, Gaelen T.; Bassik, Michael C.; Li, Lingyin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">372-381.e5</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">2'3'-cyclic-GMP-AMP (cGAMP) is a second messenger that activates the antiviral stimulator of interferon genes (STING) pathway.  We recently identified a novel role for cGAMP as a sol., extracellular immunotransmitter that is produced and secreted by cancer cells.  Secreted cGAMP is then sensed by host cells, eliciting an antitumoral immune response.  Due to the antitumoral effects of cGAMP, other CDN-based STING agonists are currently under investigation in clin. trials for metastatic solid tumors.  However, it is unknown how cGAMP and other CDNs cross the cell membrane to activate intracellular STING.  Using a genome-wide CRISPR screen, we identified SLC19A1 as the first known importer of cGAMP and other CDNs, including the investigational new drug 2'3'-bisphosphosphothioate-cyclic-di-AMP (2'3'-CDAS).  These discoveries will provide insight into cGAMP's role as an immunotransmitter and aid in the development of more targeted CDN-based cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyOzQ3QS5zDbVg90H21EOLACvtfcHk0li9hof5kjrbUQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurnJ&md5=c018cb15cd2b8b138ecd61d147d32138</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DC.%26aulast%3DCordova%26aufirst%3DA.%2BF.%26aulast%3DHess%26aufirst%3DG.%2BT.%26aulast%3DBassik%26aufirst%3DM.%2BC.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DSLC19A1%2520is%2520an%2520importer%2520of%2520the%2520immunotransmitter%2520cGAMP%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D75%26spage%3D372%26epage%3D381%26doi%3D10.1016%2Fj.molcel.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref235"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref235'); return false;" data-citation="" class="refNumLink">236</a></strong><div class="NLM_citation" id="cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luteijn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaver, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garelis, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWhirter, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katibah, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raulet, D. H.</span></span> <span> </span><span class="NLM_article-title">SLC19A1 transports immunoreactive cyclic dinucleotides</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>573</i></span> (<span class="NLM_issue">7774</span>),  <span class="NLM_fpage">434</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-1553-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-1553-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31511694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKhsrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=573&publication_year=2019&pages=434-438&issue=7774&author=R.+D.+Luteijnauthor=S.+A.+Zaverauthor=B.+G.+Gowenauthor=S.+K.+Wymanauthor=N.+E.+Garelisauthor=L.+Oniaauthor=S.+M.+McWhirterauthor=G.+E.+Katibahauthor=J.+E.+Cornauthor=J.+J.+Woodwardauthor=D.+H.+Raulet&title=SLC19A1+transports+immunoreactive+cyclic+dinucleotides&doi=10.1038%2Fs41586-019-1553-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">SLC19A1 transports immunoreactive cyclic dinucleotides</span></div><div class="casAuthors">Luteijn, Rutger D.; Zaver, Shivam A.; Gowen, Benjamin G.; Wyman, Stacia K.; Garelis, Nick E.; Onia, Liberty; McWhirter, Sarah M.; Katibah, George E.; Corn, Jacob E.; Woodward, Joshua J.; Raulet, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">573</span>
        (<span class="NLM_cas:issue">7774</span>),
    <span class="NLM_cas:pages">434-438</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The accumulation of DNA in the cytosol serves as a key immunostimulatory signal assocd. with infections, cancer and genomic damage.  Cytosolic DNA triggers immune responses by activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway.  The binding of DNA to cGAS activates its enzymic activity, leading to the synthesis of a second messenger, cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP).  This cyclic dinucleotide (CDN) activates STING, which in turn activates the transcription factors interferon regulatory factor 3 (IRF3) and nuclear factor Îº-light-chain-enhancer of activated B cells (NF-ÎºB), promoting the transcription of genes encoding type I interferons and other cytokines and mediators that stimulate a broader immune response.  Exogenous 2'3'-cGAMP produced by malignant cells and other CDNs, including those produced by bacteria and synthetic CDNs used in cancer immunotherapy, must traverse the cell membrane to activate STING in target cells.  How these charged CDNs pass through the lipid bilayer is unknown.  Here we used a genome-wide CRISPR-interference screen to identify the reduced folate carrier SLC19A1, a folate-org. phosphate antiporter, as the major transporter of CDNs.  Depleting SLC19A1 in human cells inhibits CDN uptake and functional responses, and overexpressing SLC19A1 increases both uptake and functional responses.  In human cell lines and primary cells ex vivo, CDN uptake is inhibited by folates as well as two medications approved for treatment of inflammatory diseases, sulfasalazine and the antifolate methotrexate.  The identification of SLC19A1 as the major transporter of CDNs into cells has implications for the immunotherapeutic treatment of cancer, host responsiveness to CDN-producing pathogenic microorganisms and-potentially-for some inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBWRAJX5Hmb7Vg90H21EOLACvtfcHk0lgdnn38Aa06DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKhsrzP&md5=df739b1bb167208e3640651ee4d03a58</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1553-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1553-0%26sid%3Dliteratum%253Aachs%26aulast%3DLuteijn%26aufirst%3DR.%2BD.%26aulast%3DZaver%26aufirst%3DS.%2BA.%26aulast%3DGowen%26aufirst%3DB.%2BG.%26aulast%3DWyman%26aufirst%3DS.%2BK.%26aulast%3DGarelis%26aufirst%3DN.%2BE.%26aulast%3DOnia%26aufirst%3DL.%26aulast%3DMcWhirter%26aufirst%3DS.%2BM.%26aulast%3DKatibah%26aufirst%3DG.%2BE.%26aulast%3DCorn%26aufirst%3DJ.%2BE.%26aulast%3DWoodward%26aufirst%3DJ.%2BJ.%26aulast%3DRaulet%26aufirst%3DD.%2BH.%26atitle%3DSLC19A1%2520transports%2520immunoreactive%2520cyclic%2520dinucleotides%26jtitle%3DNature%26date%3D2019%26volume%3D573%26issue%3D7774%26spage%3D434%26epage%3D438%26doi%3D10.1038%2Fs41586-019-1553-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref236"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref236'); return false;" data-citation="" class="refNumLink">237</a></strong><div class="NLM_citation" id="cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moskovskich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartnig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiume, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">10471</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-46952-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41598-019-46952-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31320712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3MzovVeqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=10471&author=A.+Moskovskichauthor=U.+Goldmannauthor=F.+Kartnigauthor=S.+Lindingerauthor=J.+Koneckaauthor=G.+Fiumeauthor=E.+Girardiauthor=G.+Superti-Furga&title=The+transporters+SLC35A1+and+SLC30A1+play+opposite+roles+in+cell+survival+upon+VSV+virus+infection&doi=10.1038%2Fs41598-019-46952-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection</span></div><div class="casAuthors">Moskovskich Anna; Goldmann Ulrich; Kartnig Felix; Lindinger Sabrina; Konecka Justyna; Fiume Giuseppe; Girardi Enrico; Superti-Furga Giulio; Superti-Furga Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10471</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Host factor requirements for different classes of viruses have not been fully unraveled.  Replication of the viral genome and synthesis of viral proteins within the human host cell are associated with an increased demand for nutrients and specific metabolites.  With more than 400 acknowledged members to date in humans, solute carriers (SLCs) represent the largest family of transmembrane proteins dedicated to the transport of ions and small molecules such as amino acids, sugars and nucleotides.  Consistent with their impact on cellular metabolism, several SLCs have been implicated as host factors affecting the viral life cycle and the cellular response to infection.  In this study, we aimed at characterizing the role of host SLCs in cell survival upon viral infection by performing unbiased genetic screens using a focused CRISPR knockout library.  Genetic screens with the cytolytic vesicular stomatitis virus (VSV) showed that the loss of two SLCs genes, encoding the sialic acid transporter SLC35A1/CST and the zinc transporter SLC30A1/ZnT1, affected cell survival upon infection.  Further characterization of these genes suggests a role for both of these transporters in the apoptotic response induced by VSV, offering new insights into the cellular response to oncolytic virus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfuXnPZcPYSsK3uFsUIZtkfW6udTcc2eb4cAlmo69R57ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzovVeqtw%253D%253D&md5=41f6db78279a18fe6339dd5c5ee06571</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-46952-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-46952-9%26sid%3Dliteratum%253Aachs%26aulast%3DMoskovskich%26aufirst%3DA.%26aulast%3DGoldmann%26aufirst%3DU.%26aulast%3DKartnig%26aufirst%3DF.%26aulast%3DLindinger%26aufirst%3DS.%26aulast%3DKonecka%26aufirst%3DJ.%26aulast%3DFiume%26aufirst%3DG.%26aulast%3DGirardi%26aufirst%3DE.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520transporters%2520SLC35A1%2520and%2520SLC30A1%2520play%2520opposite%2520roles%2520in%2520cell%2520survival%2520upon%2520VSV%2520virus%2520infection%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D10471%26doi%3D10.1038%2Fs41598-019-46952-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref237"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref237'); return false;" data-citation="" class="refNumLink">238</a></strong><div class="NLM_citation" id="cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanisevic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siuzdak, G.</span></span> <span> </span><span class="NLM_article-title">Metabolomics: beyond biomarkers and towards mechanisms</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">451</span>â <span class="NLM_lpage">459</span>, <span class="refDoi">Â DOI: 10.1038/nrm.2016.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrm.2016.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26979502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlCnsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=451-459&issue=7&author=C.+H.+Johnsonauthor=J.+Ivanisevicauthor=G.+Siuzdak&title=Metabolomics%3A+beyond+biomarkers+and+towards+mechanisms&doi=10.1038%2Fnrm.2016.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics: beyond biomarkers and towards mechanisms</span></div><div class="casAuthors">Johnson, Caroline H.; Ivanisevic, Julijana; Siuzdak, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">451-459</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabolomics, which is the profiling of metabolites in biofluids, cells and tissues, is routinely applied as a tool for biomarker discovery.  Owing to innovative developments in informatics and anal. technologies, and the integration of orthogonal biol. approaches, it is now possible to expand metabolomic analyses to understand the systems-level effects of metabolites.  Moreover, because of the inherent sensitivity of metabolomics, subtle alterations in biol. pathways can be detected to provide insight into the mechanisms that underlie various physiol. conditions and aberrant processes, including diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrESvDJCSJiw7Vg90H21EOLACvtfcHk0lgdnn38Aa06DQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlCnsrY%253D&md5=a162bf9977253b31ca956f27a99ef2b1</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.25%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BH.%26aulast%3DIvanisevic%26aufirst%3DJ.%26aulast%3DSiuzdak%26aufirst%3DG.%26atitle%3DMetabolomics%253A%2520beyond%2520biomarkers%2520and%2520towards%2520mechanisms%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26issue%3D7%26spage%3D451%26epage%3D459%26doi%3D10.1038%2Fnrm.2016.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref240"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref240'); return false;" data-citation="" class="refNumLink">239</a></strong><div class="NLM_citation" id="cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudarsanam, S.</span></span> <span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5600</span>),  <span class="NLM_fpage">1912</span>â <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&issue=5600&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0liOUo5zWWbfGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5600%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref241"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref241'); return false;" data-citation="" class="refNumLink">240</a></strong><div class="NLM_citation" id="cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Silva, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">EspaÃ±ol, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, V.</span></span> <span> </span><span class="NLM_article-title">The degradome database: expanding roles of mammalian proteases in life and disease</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">351</span>â <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Fnar%2Fgkv1201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=351-355&issue=1&author=J.+G.+P%C3%A9rez-Silvaauthor=Y.+Espa%C3%B1olauthor=G.+Velascoauthor=V.+Quesada&title=The+degradome+database%3A+expanding+roles+of+mammalian+proteases+in+life+and+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">The Degradome database: expanding roles of mammalian proteases in life and disease</span></div><div class="casAuthors">Perez-Silva, Jose G.; Espanol, Yaiza; Velasco, Gloria; Quesada, Victor</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D351-D355</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Since the definition of the degradome as the complete repertoire of proteases in a given organism, the combined effort of numerous labs. has greatly expanded our knowledge of its roles in biol. and pathol.  Once the genomic sequences of several important model organisms were made available, we presented the Degradome database contg. the curated sets of known protease genes in human, chimpanzee, mouse and rat.  Here, we describe the updated Degradome database, featuring 81 new protease genes and 7 new protease families.  Notably, in this short time span, the no. of known hereditary diseases caused by mutations in protease genes has increased from 77 to 119.  This increase reflects the growing interest on the roles of the degradome in multiple diseases, including cancer and aging.  Finally, we have leveraged the widespread adoption of new webtools to provide interactive graphic views that show information about proteases in the global context of the degradome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZefQmIYrGg7Vg90H21EOLACvtfcHk0liOUo5zWWbfGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrvP&md5=e1fce13cc5838391d45b7d563eadcacd</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv1201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv1201%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Silva%26aufirst%3DJ.%2BG.%26aulast%3DEspa%25C3%25B1ol%26aufirst%3DY.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DQuesada%26aufirst%3DV.%26atitle%3DThe%2520degradome%2520database%253A%2520expanding%2520roles%2520of%2520mammalian%2520proteases%2520in%2520life%2520and%2520disease%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26issue%3D1%26spage%3D351%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref238"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref238'); return false;" data-citation="" class="refNumLink">241</a></strong><div class="NLM_citation" id="cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, T. E.</span></span> <span> </span><span class="NLM_article-title">UCSF Chimera--a visualization system for exploratory research and analysis</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1605</span>â <span class="NLM_lpage">1612</span>, <span class="refDoi">Â DOI: 10.1002/jcc.20084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fjcc.20084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1605-1612&issue=13&author=E.+F.+Pettersenauthor=T.+D.+Goddardauthor=C.+C.+Huangauthor=G.+S.+Couchauthor=D.+M.+Greenblattauthor=E.+C.+Mengauthor=T.+E.+Ferrin&title=UCSF+Chimera%2D%2Da+visualization+system+for+exploratory+research+and+analysis&doi=10.1002%2Fjcc.20084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">UCSF Chimera-A visualization system for exploratory research and analysis</span></div><div class="casAuthors">Pettersen, Eric F.; Goddard, Thomas D.; Huang, Conrad C.; Couch, Gregory S.; Greenblatt, Daniel M.; Meng, Elaine C.; Ferrin, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1612</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed.  Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality.  This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features.  Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale mol. assemblies such as viral coats, and Collab., which allows researchers to share a Chimera session interactively despite being at sep. locales.  Other extensions include Multalign Viewer, for showing multiple sequence alignments and assocd. structures; ViewDock, for screening docked ligand orientations; Movie, for replaying mol. dynamics trajectories; and Vol. Viewer, for display and anal. of volumetric data.  A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions.  Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmD4M5S0cPbVg90H21EOLACvtfcHk0liOUo5zWWbfGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D&md5=944b175f440c1ff323705987cf937ee7</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20084%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DE.%2BF.%26aulast%3DGoddard%26aufirst%3DT.%2BD.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DCouch%26aufirst%3DG.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BM.%26aulast%3DMeng%26aufirst%3DE.%2BC.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26atitle%3DUCSF%2520Chimera--a%2520visualization%2520system%2520for%2520exploratory%2520research%2520and%2520analysis%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26issue%3D13%26spage%3D1605%26epage%3D1612%26doi%3D10.1002%2Fjcc.20084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref239':['cit239'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230'],'ref231':['cit231'],'ref232':['cit232'],'ref233':['cit233'],'ref234':['cit234'],'ref235':['cit235'],'ref236':['cit236'],'ref237':['cit237'],'ref240':['cit240'],'ref241':['cit241'],'ref238':['cit238']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">David Drew, Rachel A. North, Kumar Nagarathinam, <span class="NLM_string-name hlFld-ContribAuthor">Mikio Tanabe</span>. </span><span class="cited-content_cbyCitation_article-title">Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS). </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (9)
                                     , 5289-5335. <a href="https://doi.org/10.1021/acs.chemrev.0c00983" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00983</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00983&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00983%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DStructures%252Band%252BGeneral%252BTransport%252BMechanisms%252Bby%252Bthe%252BMajor%252BFacilitator%252BSuperfamily%252B%252528MFS%252529%26aulast%3DDrew%26aufirst%3DDavid%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09092020%26date%3D22042021%26volume%3D121%26issue%3D9%26spage%3D5289%26epage%3D5335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hubert J.  Sijben</span>, <span class="hlFld-ContribAuthor ">Julie J. E.  van den Berg</span>, <span class="hlFld-ContribAuthor ">Jeremy D.  Broekhuis</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>. </span><span class="cited-content_cbyCitation_article-title">A study of the dopamine transporter using the TRACT assay, a novel in vitro tool for solute carrier drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-79218-w" title="DOI URL">https://doi.org/10.1038/s41598-020-79218-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-79218-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-79218-w%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252Bstudy%252Bof%252Bthe%252Bdopamine%252Btransporter%252Busing%252Bthe%252BTRACT%252Bassay%25252C%252Ba%252Bnovel%252Bin%252Bvitro%252Btool%252Bfor%252Bsolute%252Bcarrier%252Bdrug%252Bdiscovery%26aulast%3DSijben%26aufirst%3DHubert%2BJ.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hubert J.  Sijben</span>, <span class="hlFld-ContribAuthor ">Wieke M.  van Oostveen</span>, <span class="hlFld-ContribAuthor ">Peter B. R.  Hartog</span>, <span class="hlFld-ContribAuthor ">Laura  Stucchi</span>, <span class="hlFld-ContribAuthor ">Andrea  Rossignoli</span>, <span class="hlFld-ContribAuthor ">Giovanna  Maresca</span>, <span class="hlFld-ContribAuthor ">Lia  Scarabottolo</span>, <span class="hlFld-ContribAuthor ">Adriaan P.  IJzerman</span>, <span class="hlFld-ContribAuthor ">Laura H.  Heitman</span>. </span><span class="cited-content_cbyCitation_article-title">Label-free high-throughput screening assay for the identification of norepinephrine transporter (NET/SLC6A2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-91700-7" title="DOI URL">https://doi.org/10.1038/s41598-021-91700-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-91700-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-91700-7%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DLabel-free%252Bhigh-throughput%252Bscreening%252Bassay%252Bfor%252Bthe%252Bidentification%252Bof%252Bnorepinephrine%252Btransporter%252B%252528NET%25252FSLC6A2%252529%252Binhibitors%26aulast%3DSijben%26aufirst%3DHubert%2BJ.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shadi  Zaheri</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Hassanipour</span>. </span><span class="cited-content_cbyCitation_article-title">A mathematical modeling toolbox for ion channels and transporters across cell membranes. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Heat and Mass Transfer</span><span> <strong>2021,</strong> <em>177 </em>, 121423. <a href="https://doi.org/10.1016/j.ijheatmasstransfer.2021.121423" title="DOI URL">https://doi.org/10.1016/j.ijheatmasstransfer.2021.121423</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijheatmasstransfer.2021.121423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijheatmasstransfer.2021.121423%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Heat%2520and%2520Mass%2520Transfer%26atitle%3DA%252Bmathematical%252Bmodeling%252Btoolbox%252Bfor%252Bion%252Bchannels%252Band%252Btransporters%252Bacross%252Bcell%252Bmembranes%26aulast%3DZaheri%26aufirst%3DShadi%26date%3D2021%26volume%3D177%26spage%3D121423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoon-Jee  Chae</span>, <span class="hlFld-ContribAuthor ">Ji-Eun  Chang</span>, <span class="hlFld-ContribAuthor ">Mi-Kyung  Lee</span>, <span class="hlFld-ContribAuthor ">Juhee  Lim</span>, <span class="hlFld-ContribAuthor ">Kwang-Hee  Shin</span>, <span class="hlFld-ContribAuthor ">Kyeong-Ryoon  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of drug transporters by microRNA and implications in disease treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Investigation</span><span> <strong>2021,</strong> <em>285 </em><a href="https://doi.org/10.1007/s40005-021-00538-8" title="DOI URL">https://doi.org/10.1007/s40005-021-00538-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40005-021-00538-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40005-021-00538-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Investigation%26atitle%3DRegulation%252Bof%252Bdrug%252Btransporters%252Bby%252BmicroRNA%252Band%252Bimplications%252Bin%252Bdisease%252Btreatment%26aulast%3DChae%26aufirst%3DYoon-Jee%26date%3D2021%26date%3D2021%26volume%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Casiraghi</span>, <span class="hlFld-ContribAuthor ">Ariel  Bensimon</span>, <span class="hlFld-ContribAuthor ">Giulio  Superti-Furga</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in ligands and chemical probes targeting solute carrier transporters. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2021,</strong> <em>62 </em>, 53-63. <a href="https://doi.org/10.1016/j.cbpa.2021.01.012" title="DOI URL">https://doi.org/10.1016/j.cbpa.2021.01.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2021.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2021.01.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DRecent%252Bdevelopments%252Bin%252Bligands%252Band%252Bchemical%252Bprobes%252Btargeting%252Bsolute%252Bcarrier%252Btransporters%26aulast%3DCasiraghi%26aufirst%3DAndrea%26date%3D2021%26volume%3D62%26spage%3D53%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mattia D.  Pizzagalli</span>, <span class="hlFld-ContribAuthor ">Ariel  Bensimon</span>, <span class="hlFld-ContribAuthor ">Giulio  SupertiâFurga</span>. </span><span class="cited-content_cbyCitation_article-title">A guide to plasma membrane solute carrier proteins. </span><span class="cited-content_cbyCitation_journal-name">The FEBS Journal</span><span> <strong>2021,</strong> <em>288 </em>
                                    (9)
                                     , 2784-2835. <a href="https://doi.org/10.1111/febs.15531" title="DOI URL">https://doi.org/10.1111/febs.15531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/febs.15531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Ffebs.15531%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520FEBS%2520Journal%26atitle%3DA%252Bguide%252Bto%252Bplasma%252Bmembrane%252Bsolute%252Bcarrier%252Bproteins%26aulast%3DPizzagalli%26aufirst%3DMattia%2BD.%26date%3D2021%26date%3D2020%26volume%3D288%26issue%3D9%26spage%3D2784%26epage%3D2835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isabella  Gigante</span>, <span class="hlFld-ContribAuthor ">Valeria  Tutino</span>, <span class="hlFld-ContribAuthor ">Francesco  Russo</span>, <span class="hlFld-ContribAuthor ">Valentina  De Nunzio</span>, <span class="hlFld-ContribAuthor ">Sergio  Coletta</span>, <span class="hlFld-ContribAuthor ">Raffaele  Armentano</span>, <span class="hlFld-ContribAuthor ">Alberto  Crovace</span>, <span class="hlFld-ContribAuthor ">Maria Gabriella  Caruso</span>, <span class="hlFld-ContribAuthor ">Antonella  Orlando</span>, <span class="hlFld-ContribAuthor ">Maria  Notarnicola</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (6)
                                     , 2880. <a href="https://doi.org/10.3390/ijms22062880" title="DOI URL">https://doi.org/10.3390/ijms22062880</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22062880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22062880%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DCannabinoid%252BReceptors%252BOverexpression%252Bin%252Ba%252BRat%252BModel%252Bof%252BIrritable%252BBowel%252BSyndrome%252B%252528IBS%252529%252Bafter%252BTreatment%252Bwith%252Ba%252BKetogenic%252BDiet%26aulast%3DGigante%26aufirst%3DIsabella%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D6%26spage%3D2880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amy B. P.  Ribet</span>, <span class="hlFld-ContribAuthor ">Pei Ying  Ng</span>, <span class="hlFld-ContribAuthor ">Nathan J.  Pavlos</span>. </span><span class="cited-content_cbyCitation_article-title">Membrane Transport Proteins in Osteoclasts: The Ins and Outs. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.644986" title="DOI URL">https://doi.org/10.3389/fcell.2021.644986</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.644986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.644986%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DMembrane%252BTransport%252BProteins%252Bin%252BOsteoclasts%25253A%252BThe%252BIns%252Band%252BOuts%26aulast%3DRibet%26aufirst%3DAmy%2BB.%2BP.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claire  Colas</span>, <span class="hlFld-ContribAuthor ">Elodie  Laine</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Solute Carrier Transporters through Functional Mapping. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2021,</strong> <em>42 </em>
                                    (1)
                                     , 3-6. <a href="https://doi.org/10.1016/j.tips.2020.11.005" title="DOI URL">https://doi.org/10.1016/j.tips.2020.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2020.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2020.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DTargeting%252BSolute%252BCarrier%252BTransporters%252Bthrough%252BFunctional%252BMapping%26aulast%3DColas%26aufirst%3DClaire%26date%3D2021%26volume%3D42%26issue%3D1%26spage%3D3%26epage%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lyn H.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Target ValidationâProsecuting the Target. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00014-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00014-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00014-1%26sid%3Dliteratum%253Aachs%26atitle%3DTarget%252BValidation%2525E2%252580%252594Prosecuting%252Bthe%252BTarget%26aulast%3DJones%26aufirst%3DLyn%2BH.%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dario  Doller</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Modulation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00057-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00057-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00057-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00057-8%26sid%3Dliteratum%253Aachs%26atitle%3DAllosteric%252BModulation%26aulast%3DDoller%26aufirst%3DDario%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaheng  Xie</span>, <span class="hlFld-ContribAuthor ">Zhechen  Zhu</span>, <span class="hlFld-ContribAuthor ">Yuan  Cao</span>, <span class="hlFld-ContribAuthor ">Shujie  Ruan</span>, <span class="hlFld-ContribAuthor ">Ming  Wang</span>, <span class="hlFld-ContribAuthor ">Jingping  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Solute carrier transporter superfamily member SLC16A1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma. </span><span class="cited-content_cbyCitation_journal-name">Channels</span><span> <strong>2021,</strong> <em>15 </em>
                                    (1)
                                     , 483-495. <a href="https://doi.org/10.1080/19336950.2021.1953322" title="DOI URL">https://doi.org/10.1080/19336950.2021.1953322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/19336950.2021.1953322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F19336950.2021.1953322%26sid%3Dliteratum%253Aachs%26jtitle%3DChannels%26atitle%3DSolute%252Bcarrier%252Btransporter%252Bsuperfamily%252Bmember%252BSLC16A1%252Bis%252Ba%252Bpotential%252Bprognostic%252Bbiomarker%252Band%252Bassociated%252Bwith%252Bimmune%252Binfiltration%252Bin%252Bskin%252Bcutaneous%252Bmelanoma%26aulast%3DXie%26aufirst%3DJiaheng%26date%3D2021%26date%3D2021%26volume%3D15%26issue%3D1%26spage%3D483%26epage%3D495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junpeng  Qi</span>, <span class="hlFld-ContribAuthor ">Christoph  Rader</span>. </span><span class="cited-content_cbyCitation_article-title">Redirecting cytotoxic T cells with chemically programmed antibodies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (24)
                                     , 115834. <a href="https://doi.org/10.1016/j.bmc.2020.115834" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115834</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115834%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DRedirecting%252Bcytotoxic%252BT%252Bcells%252Bwith%252Bchemically%252Bprogrammed%252Bantibodies%26aulast%3DQi%26aufirst%3DJunpeng%26date%3D2020%26volume%3D28%26issue%3D24%26spage%3D115834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Toshihiko  Tashima</span>. </span><span class="cited-content_cbyCitation_article-title">Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (21)
                                     , 5188. <a href="https://doi.org/10.3390/molecules25215188" title="DOI URL">https://doi.org/10.3390/molecules25215188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25215188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25215188%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DShortcut%252BApproaches%252Bto%252BSubstance%252BDelivery%252Binto%252Bthe%252BBrain%252BBased%252Bon%252BIntranasal%252BAdministration%252BUsing%252BNanodelivery%252BStrategies%252Bfor%252BInsulin%26aulast%3DTashima%26aufirst%3DToshihiko%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D21%26spage%3D5188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0032.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Size of the SLC family relative to other protein families. Graph displays number of genes for each protein family, including: SLC (solute carrier family), GPCRs-NO (nonolfactory G-protein coupled receptors), NRs (nuclear receptors), ion channels, and ABC (ATP binding cassette) transporters. See <a class="ref internalNav" href="#sec8" aria-label="Methods section">Methods section</a> for further details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General types (A) and conformational mechanisms (B) of SLC mediated transport. (A) In facilitated transport, substrates move down their concentration gradient across biological membranes. In antiport-based transport, multiple substrates are exchanged in opposite directions, whereas in symport-based transport, substrates are transferred in the same direction. SLCs with orphan transport mechanisms are yet to be annotated. (B) SLCs move substances through membranes via multiple conformational mechanisms. In the rocker switch mechanism, the transporter opens outward to capture its substrate, shields it from the membrane environment, followed by its release. The gated-pore mechanism involves the opening of the transporter to the extracellular environment via conformational changes, which then binds the substrate in a fixed stoichiometric fashion. A scaffold domain remains static during this process. The binding site is enclosed on the extracellular side, which then opens on the intracellular side. In the elevator mechanism, the substrate binds to a transport domain, resulting in a piston-like movement to transport the substrate to the other side of the membrane.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. âRocker-switchâ conformational mechanism. Conformation changes from outward open SLC2A3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWC">4ZWC</a>, cocrystallized with maltose) to inward open SLC2A1 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PYP">4PYP</a>, cocrystallized with Î²-nonylglucoside). The N-domain (TM 1â6) is shown in blue, C-domain (TM 7â12) in light brown, ICH domain in magenta, and ligands as red and gray spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. âGated-poreâ conformational mechanism. Conformational changes of SERT revealed by cryo-EM. Outward-open human SERT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZY">6DZY</a>, cocrystallized with Ibogaine, gray) to inward-open human SERT (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZZ">6DZZ</a>; TM 1a and TM 1b shown in magenta, TM 6a and TM 6b shown in green, TM2, 5, 7, 8, and EL4 (extracellular loop) are shown in brown, and TM 3, 4, 9, 10, 11, and 12 are shown in blue).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. âElevatorâ conformational mechanism. The conformational switch from outward open SLC1A3 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LLU">5LLU</a>, cocrystallized with aspartic acid) to inward open SLC1A5 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCT">6GCT</a>, cocrystallized with glutamine) is shown. The scaffold domain is depicted in blue, transport domain in brown, helical loop HP1 in green, and the helical loop HP2 in magenta.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Examples of SLC function in human physiology. (A) In proximal convoluted tubules of kidney nephrons, SLC5A2 (SGLT2) is the main glucose transporter from the apical membrane, glucose is reabsorbed into blood via SLC2A2 (GLUT2). (B) Astrocytes express both SLC1A2 (EAAT2) and SLC1A3 (EAAT1). SLC1A2 is the main glutamate (Glu) transporter to remove Glu from the synaptic cleft to avoid excitotoxicity. Glutamine synthase (GS) converts Glu to glutamine (Gln), which is secreted and transported into neurons by SLC38A2 (SNAT2). In neurons, glutaminase (GLS) converts Gln to Glu, which is transported into storage vesicles by SLC17A6 (vGLUT2). (C) In response to cold temperatures, sympathetic postganglionic neurons release norepinephrine that induces triglyceride breakdown into free fatty acids, which in turn activates SLC25A7 (UCP1) in brown adipose tissue (BAT). SLC25A7 dissipates the proton motive force to generate heat. (D) In islet of Langerhans Î² cells, SLC30A8 is a critical transporter to ensure the crystallization of insulin by mediating the transport of zinc ions to form hexameric insulin in a ratio of two Zn<sup>2+</sup> for every six molecules of insulin.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. SLC25A19 transports ThPP. SLC25A19 transports thiamine pyrophosphate (ThPP), which is a cofactor for pyruvate dehydrogenase (PDH) and Î±-ketoglutarate dehydrogenase (KGDH). Impaired SLC25A19 function attenuates mitochondrial ThPP, as observed in the disorder Amish lethal microcephaly (MCPHA), leading to mitochondrial dysfunction.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Various roles of glutamine-mediated transport in cancer. SLC1A5 is one of the major glutamine (Gln) transporters in cells. Upon entering the cell, glutaminase (GLS) converts Gln to glutamate (Glu), which participates in nucleic acid, glutathione, and amino acid synthesis. SLC7A11 exchanges Glu for cystine, which is reduced to cysteine by Trx1/TR1 and Grx/GSH/GR. SLC7A5 exchanges Gln for leucine and other amino acids, which can lead to mTOR activation. SLC38A1 and A2 modulate the transport of neutral amino acids, while SLC6A14 is involved in transporting neutral and cationic amino acids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. SLC16A7 modulates the remodeling of metastatic niches. SLC16A7 transports pyruvate which is metabolized to Î±-ketoglutarate. Î±-Ketoglutarate was shown to metabolically activate prolyl 4-hydroxylase subunit alpha 1 (P4HA). P4HA-mediated modification of procollagen results in triple procollagen molecule formation, which is deposited onto the extracellular space as mature collagen fibrils.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. SLC15A3 and SLC15A4 roles in inflammatory immune response. Immune cells, such as macrophages, engulf invading pathogens that have penetrated through the endothelial barrier. Microbes are digested and endolysosomal SLCs are thought to mediate the transport of oligopeptides derived from pathogens to the cytosol, such as muramyl dipeptide, a component of bacterial cell walls. This event leads to the activation of nucleotide-binding oligomerization domain (NODs), which induces inflammatory NFÎºB-mediated transcription of pro-inflammatory genes. In addition, activation of Toll-like receptors (TLR) 7/9 and subsequent type I IFN production has been shown to be dependent on SLC15A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Fraction of protein families with individual members associated with 0, 1â100, or more than 100 compounds. See <a class="ref internalNav" href="#sec8" aria-label="Methods">Methods</a>  section for details regarding this analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Additional drugs and compounds targeting SLCs. Imipramine (<b>16</b>) targets SLC6A2/4. Furosemide (<b>17</b>) targets SLC12A1/2. Elobixibat (<b>18</b>) targets SLC10A2. AZD3965 (<b>19</b>) targets SLC16A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Examples of screening strategies that have been used for the discovery of SLC modulators. (A) Cellular substrate uptake assays with radioactivity or fluorescence detection. (B) Downstream functional assays represented by methods based on detection of pH and membrane potential. (C) Ligand binding assays with detection methods including radioactivity, fluorescence, mass spectrometry, or thermal shift (e.g., CETSA). (D) Phenotypic screening assays with different target identification methods.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Representative compounds identified as SLC inhibitors using various target deconvolution strategies. Compound <b>20</b>, ingenol mebutate (<b>21</b>), and omeprazole (<b>22</b>) target SLC25A20. NVS-ZP7-4 (<b>23</b>) targets SLC39A7.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. EAATs inhibitors. L-TFB-TBOA (<b>24</b>) targets SLC1A1/2/3, WAY-213613 (<b>25</b>) targets SLC1A2, UCPH-101 (<b>26</b>), and UCPH-102 (<b>27</b>) target SLC1A3.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Human SLC1A3 bound with competitive inhibitor TFB-TBOA (magenta) at substrate pocket, and noncompetitive inhibitor UCPH-101 (yellow) at described allosteric pocket (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MJU">5MJU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Glycine transporter inhibitors. Sarcosine (<b>28</b>), ALX-5407 (<b>29</b>), ORG24598 (<b>30</b>), ORG-25935 (<b>31</b>), AMG-747 (<b>32</b>), Bitopertin (<b>33</b>), and PF-03463275 (<b>34</b>) target SLC6A9. ORG-25543 (<b>35</b>), and ALX-1393 (<b>36</b>) target SLC6A5. VVZ-149 (<b>37</b>) targets both SLC6A5 and 5HT2A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Glutamine transporter inhibitors. GPNA (<b>38</b>) and compound <b>39</b> target SLC1A5. JPH203 (<b>41</b>) targets SLC7A5. V9302 (<b>40</b>) has been discovered to target multiple glutamine transporters, including SLC1A5, SLC7A5, and SLC38A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Representative MRIs. Paroxetine (<b>42</b>), sertraline (<b>43</b>), citalopram (<b>44</b>), and escitalopram (<b>45</b>) are SSRIs targeting SLC6A4. Venlafaxine (<b>46</b>), duloxetine (<b>47</b>), and levomilnacipran (<b>48</b>) are SNRIs targeting SLC6A2 and SLC6A4. Bupropion (<b>49</b>) is an NDRI targeting SLC6A2 and SLC6A3. Atomoxetine (<b>50</b>) is an NRI targeting SLC6A2. Vanoxerine (<b>51</b>) and modafinil (<b>52</b>) are DRIs targeting SLC6A3. Ansofaxine (<b>53</b>), centanafadine (<b>54</b>), and dasotraline (<b>55</b>) are TRIs targeting SLC6A2, SLC6A3, and SLC6A4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Crystal structure of human SLC6A4 bound by two molecules of (<i>S</i>)-citalopram at the central (bottom inset) and allosteric (top inset) pockets (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73">5I73</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. VMAT2 inhibitors. Tetrabenazine (<b>56</b>) and deutetrabenazine (<b>57</b>) target SLC18A2 at the site different from reserpine. Lobeline (<b>58</b>) shares the binding pocket with reserpine at SLC18A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. SGLT1/2 inhibitors. T1095 (<b>59</b>), sergliflozin (<b>60</b>), and remogliflozin (<b>61</b>) are <i>O</i>-glycosides targeting SLC5A2. Dapagliflozin (<b>62</b>), empagliflozin (<b>63</b>), and ipragliflozin (<b>64</b>) are <i>C</i>-glycosides targeting SLC5A2. Sotagliflozin (<b>65</b>) is a <i>C</i>-glycoside targeting SLC5A1/2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Facilitative glucose transporter inhibitors. BAY-876 (<b>66</b>) and GLUT-i1 (<b>67</b>) both target SLC2A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Comparison of SLC2A1 binding poses between substrate analogue Î²-nonylglucoside (tan, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PYP">4PYP</a>) and inhibitor GLUTi1 (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EQG">5EQG</a>)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. NHE1 inhibitors. Amiloride (<b>68</b>), sabiporide (<b>69</b>), zoniporide (<b>70</b>), cariporide (<b>71</b>), and eniporide (<b>72</b>) target SLC9A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. IBAT inhibitors. 2164U90 (<b>73</b>), SC-435 (<b>74</b>), GSK2330672 (<b>75</b>), and A4250 (<b>76</b>) target SLC10A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Urea transporter inhibitors. UTB<sub>inh</sub>-14 (<b>77</b>) and its analogue <b>78</b> target SLC14A1. Compound <b>79</b> targets SLC14A2.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. URAT1 inhibitors. Benzbromarone (<b>80</b>) targets SLC22A12 but also potently inhibits CYP2C9. Verinurad (<b>81</b>) and UR-1102 (<b>82</b>) target SLC22A12 selectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/medium/jm9b01237_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. SLC inhibitors and probes for viral infection. Compound <b>83</b>, and its photo-cross-linking analogue <b>84</b>, targets SLC65A1. U18666A (<b>85</b>), and its photo-cross-linking analogue <b>86</b> target SLC65A1 at a different domain. Cyclic peptide (<b>87</b>) and vanitaracin A (<b>88</b>) target SLC10A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b01237/20200416/images/large/jm9b01237_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01237&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 241 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shima, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apeltsin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span> <span> </span><span class="NLM_article-title">Comparison of human solute carriers</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">412</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1002/pro.320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fpro.320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20052679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=412-428&issue=3&author=A.+Schlessingerauthor=P.+Matssonauthor=J.+E.+Shimaauthor=U.+Pieperauthor=S.+W.+Yeeauthor=L.+Kellyauthor=L.+Apeltsinauthor=R.+M.+Stroudauthor=T.+E.+Ferrinauthor=K.+M.+Giacominiauthor=A.+Sali&title=Comparison+of+human+solute+carriers&doi=10.1002%2Fpro.320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of human solute carriers</span></div><div class="casAuthors">Schlessinger, Avner; Matsson, Paer; Shima, James E.; Pieper, Ursula; Yee, Sook Wah; Kelly, Libusha; Apeltsin, Leonard; Stroud, Robert M.; Ferrin, Thomas E.; Giacomini, Kathleen M.; Sali, Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">412-428</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Solute carriers are eukaryotic membrane proteins that control the uptake and efflux of solutes, including essential cellular compds., environmental toxins, and therapeutic drugs.  Solute carriers can share similar structural features despite weak sequence similarities.  Identification of sequence relationships among solute carriers is needed to enhance our ability to model individual carriers and to elucidate the mol. mechanisms of their substrate specificity and transport.  Here, we describe a comprehensive comparison of solute carriers.  We link the proteins using sensitive profile-profile alignments and two classification approaches, including similarity networks.  The clusters are analyzed in view of substrate type, transport mode, organism conservation, and tissue specificity.  Solute carrier families with similar substrates generally cluster together, despite exhibiting relatively weak sequence similarities.  In contrast, some families cluster together with no apparent reason, revealing unexplored relationships.  We demonstrate computationally and exptl. the functional overlap between representative members of these families.  Finally, we identify four putative solute carriers in the human genome.  The solute carriers include a biomedically important group of membrane proteins that is diverse in sequence and structure.  The proposed classification of solute carriers, combined with expt., reveals new relationships among the individual families and identifies new solute carriers.  The classification scheme will inform future attempts directed at modeling the structures of the solute carriers, a prerequisite for describing the substrate specificities of the individual families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDKLcThSY89rVg90H21EOLACvtfcHk0lhXm3AHjexa6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhurc%253D&md5=3a19c72447ca4f6bfada62c80e5c8fad</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fpro.320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.320%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DMatsson%26aufirst%3DP.%26aulast%3DShima%26aufirst%3DJ.%2BE.%26aulast%3DPieper%26aufirst%3DU.%26aulast%3DYee%26aufirst%3DS.%2BW.%26aulast%3DKelly%26aufirst%3DL.%26aulast%3DApeltsin%26aufirst%3DL.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DSali%26aufirst%3DA.%26atitle%3DComparison%2520of%2520human%2520solute%2520carriers%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26issue%3D3%26spage%3D412%26epage%3D428%26doi%3D10.1002%2Fpro.320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cesar-Razquin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frappier-Brinton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isserlin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyimesi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reithmeier, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">A call for systematic research on solute carriers</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>162</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">478</span>â <span class="NLM_lpage">487</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2015.07.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2015.07.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26232220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jsr%252FP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2015&pages=478-487&issue=3&author=A.+Cesar-Razquinauthor=B.+Snijderauthor=T.+Frappier-Brintonauthor=R.+Isserlinauthor=G.+Gyimesiauthor=X.+Baiauthor=R.+A.+Reithmeierauthor=D.+Hepworthauthor=M.+A.+Hedigerauthor=A.+M.+Edwardsauthor=G.+Superti-Furga&title=A+call+for+systematic+research+on+solute+carriers&doi=10.1016%2Fj.cell.2015.07.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">A Call for Systematic Research on Solute Carriers</span></div><div class="casAuthors">Cesar-Razquin, Adrian; Snijder, Berend; Frappier-Brinton, Tristan; Isserlin, Ruth; Gyimesi, Gergely; Bai, Xiaoyun; Reithmeier, Reinhart A.; Hepworth, David; Hediger, Matthias A.; Edwards, Aled M.; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">478-487</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Solute carrier (SLC) membrane transport proteins control essential physiol. functions, including nutrient uptake, ion transport, and waste removal.  SLCs interact with several important drugs, and a quarter of the more than 400 SLC genes are assocd. with human diseases.  Yet, compared to other gene families of similar stature, SLCs are relatively understudied.  The time is right for a systematic attack on SLC structure, specificity, and function, taking into account kinship and expression, as well as the dependencies that arise from the common metabolic space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowMgFKDGzGgrVg90H21EOLACvtfcHk0lhXm3AHjexa6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jsr%252FP&md5=d159e524e5f2b713a1c512ffe633050e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.07.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.07.022%26sid%3Dliteratum%253Aachs%26aulast%3DCesar-Razquin%26aufirst%3DA.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DFrappier-Brinton%26aufirst%3DT.%26aulast%3DIsserlin%26aufirst%3DR.%26aulast%3DGyimesi%26aufirst%3DG.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DReithmeier%26aufirst%3DR.%2BA.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DEdwards%26aufirst%3DA.%2BM.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DA%2520call%2520for%2520systematic%2520research%2520on%2520solute%2520carriers%26jtitle%3DCell%26date%3D2015%26volume%3D162%26issue%3D3%26spage%3D478%26epage%3D487%26doi%3D10.1016%2Fj.cell.2015.07.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span> <span> </span><span class="NLM_article-title">SLC transporters as therapeutic targets: emerging opportunities</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">560</span>, <span class="refDoi">Â DOI: 10.1038/nrd4626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd4626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26111766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7nJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=543-560&issue=8&author=L.+Linauthor=S.+W.+Yeeauthor=R.+B.+Kimauthor=K.+M.+Giacomini&title=SLC+transporters+as+therapeutic+targets%3A+emerging+opportunities&doi=10.1038%2Fnrd4626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">SLC transporters as therapeutic targets: emerging opportunities</span></div><div class="casAuthors">Lin, Lawrence; Yee, Sook Wah; Kim, Richard B.; Giacomini, Kathleen M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">543-560</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Solute carrier (SLC) transporters - a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biol. membranes - have important roles in physiol. processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics.  Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities.  This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx70dg86WE57Vg90H21EOLACvtfcHk0lhOqTZMpoWq0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7nJ&md5=559132670a520a0dcccb1d858436599d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd4626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4626%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DL.%26aulast%3DYee%26aufirst%3DS.%2BW.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26atitle%3DSLC%2520transporters%2520as%2520therapeutic%2520targets%253A%2520emerging%2520opportunities%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D8%26spage%3D543%26epage%3D560%26doi%3D10.1038%2Fnrd4626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takanaga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruford, E. A.</span></span> <span> </span><span class="NLM_article-title">The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins</span>. <i>Pfluegers Arch.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">465</span>â <span class="NLM_lpage">468</span>, <span class="refDoi">Â DOI: 10.1007/s00424-003-1192-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00424-003-1192-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=14624363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVygt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2004&pages=465-468&issue=5&author=M.+A.+Hedigerauthor=M.+F.+Romeroauthor=J.+B.+Pengauthor=A.+Rolfsauthor=H.+Takanagaauthor=E.+A.+Bruford&title=The+ABCs+of+solute+carriers%3A+physiological%2C+pathological+and+therapeutic+implications+of+human+membrane+transport+proteins&doi=10.1007%2Fs00424-003-1192-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins Introduction</span></div><div class="casAuthors">Hediger, Matthias A.; Romero, Michael F.; Peng, Ji-Bin; Rolfs, Andreas; Takanaga, Hitomi; Bruford, Elspeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Pfluegers Archiv</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">465-468</span>CODEN:
                <span class="NLM_cas:coden">PFLABK</span>;
        ISSN:<span class="NLM_cas:issn">0031-6768</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The Human Genome Organization (HUGO) Nomenclature Committee Database provides a list of transporter families of the solute carrier (SLC) gene series.  Currently, it includes 43 families and 298 transporter genes.  This special issue features mini-reviews on each of these SLC families written by the experts in each field.  A WEB site has been established that gives the latest updates for the SLC families and their members as well as relevant links to gene databases and reviews in the literature.  A list of all currently known SLC families, a discussion of addnl. SLC families and family members as well as a brief summary of non-SLC transporter genes is included in this introduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWvcPuX4WTrVg90H21EOLACvtfcHk0lhOqTZMpoWq0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVygt70%253D&md5=7d979e32b9216f988ca3e2292078b5f8</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs00424-003-1192-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00424-003-1192-y%26sid%3Dliteratum%253Aachs%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DRomero%26aufirst%3DM.%2BF.%26aulast%3DPeng%26aufirst%3DJ.%2BB.%26aulast%3DRolfs%26aufirst%3DA.%26aulast%3DTakanaga%26aufirst%3DH.%26aulast%3DBruford%26aufirst%3DE.%2BA.%26atitle%3DThe%2520ABCs%2520of%2520solute%2520carriers%253A%2520physiological%252C%2520pathological%2520and%2520therapeutic%2520implications%2520of%2520human%2520membrane%2520transport%2520proteins%26jtitle%3DPfluegers%2520Arch.%26date%3D2004%26volume%3D447%26issue%3D5%26spage%3D465%26epage%3D468%26doi%3D10.1007%2Fs00424-003-1192-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruford, E. A.</span></span> <span> </span><span class="NLM_article-title">A review of the new HGNC gene family resource</span>. <i>Hum. Genomics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">6</span>, <span class="refDoi">Â DOI: 10.1186/s40246-016-0062-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1186%2Fs40246-016-0062-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26842383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslGktbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=6&author=K.+A.+Grayauthor=R.+L.+Sealauthor=S.+Tweedieauthor=M.+W.+Wrightauthor=E.+A.+Bruford&title=A+review+of+the+new+HGNC+gene+family+resource&doi=10.1186%2Fs40246-016-0062-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the new HGNC gene family resource</span></div><div class="casAuthors">Gray, Kristian A.; Seal, Ruth L.; Tweedie, Susan; Wright, Mathew W.; Bruford, Elspeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Human Genomics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6/1-6/9</span>CODEN:
                <span class="NLM_cas:coden">HGUEAT</span>;
        ISSN:<span class="NLM_cas:issn">1479-7364</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The HUGO Gene Nomenclature Committee (HGNC) approves unique gene symbols and names for human loci.  As well as naming genomic loci, we manually curate genes into family sets based on shared characteristics such as function, homol. or phenotype.  Each HGNC gene family has its own dedicated gene family report on our website, www.genenames.org.  We have recently redesigned these reports to support the visualisation and browsing of complex relationships between families and to provide extra curated information such as family descriptions, protein domain graphics and gene family aliases.  Here, we review how our gene families are curated and explain how to view, search and download the gene family data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3ujrY83-hBLVg90H21EOLACvtfcHk0lhOqTZMpoWq0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslGktbY%253D&md5=26da6deb0cb573a9b2c0dadaa676df0d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1186%2Fs40246-016-0062-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40246-016-0062-6%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DK.%2BA.%26aulast%3DSeal%26aufirst%3DR.%2BL.%26aulast%3DTweedie%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DM.%2BW.%26aulast%3DBruford%26aufirst%3DE.%2BA.%26atitle%3DA%2520review%2520of%2520the%2520new%2520HGNC%2520gene%2520family%2520resource%26jtitle%3DHum.%2520Genomics%26date%3D2016%26volume%3D10%26spage%3D6%26doi%3D10.1186%2Fs40246-016-0062-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perland, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span> <span> </span><span class="NLM_article-title">Classification systems of secondary active transporters</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">305</span>â <span class="NLM_lpage">315</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2016.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tips.2016.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27939446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFOis7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2017&pages=305-315&issue=3&author=E.+Perlandauthor=R.+Fredriksson&title=Classification+systems+of+secondary+active+transporters&doi=10.1016%2Fj.tips.2016.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Classification Systems of Secondary Active Transporters</span></div><div class="casAuthors">Perland, Emelie; Fredriksson, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-315</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Membrane-bound solute carrier (SLC) transporter proteins are vital to the human body, as they sustain homeostasis by moving sol. mol. as nutrients, drugs, and waste across lipid membranes.  Of the 430 identified secondary active transporters in humans, 30% are still orphans, and systematic research has been requested to elaborate on their possible involvement in diseases and their potential as drug targets.  To enable this, the various classification systems in use must be understood and used correctly.  In this review, we describe how various classification systems for human SLCs are constructed, and how they overlap and differ.  To facilitate communication between researchers and to avoid ambiguities, everyone must clearly state which classification system they are referring to when writing scientific articles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozhvKcW7vAPrVg90H21EOLACvtfcHk0lhOqTZMpoWq0A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFOis7rP&md5=e77548a64c08700c00b586821bc0e1b9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2016.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2016.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DPerland%26aufirst%3DE.%26aulast%3DFredriksson%26aufirst%3DR.%26atitle%3DClassification%2520systems%2520of%2520secondary%2520active%2520transporters%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2017%26volume%3D38%26issue%3D3%26spage%3D305%26epage%3D315%26doi%3D10.1016%2Fj.tips.2016.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoglund, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordstrom, K. J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span> <span> </span><span class="NLM_article-title">The solute carrier families have a remarkably long evolutionary history with the majority of the human families present before divergence of bilaterian species</span>. <i>Mol. Biol. Evol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1531</span>â <span class="NLM_lpage">1541</span>, <span class="refDoi">Â DOI: 10.1093/molbev/msq350</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Fmolbev%2Fmsq350" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21186191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC3M3ntlCksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=1531-1541&issue=4&author=P.+J.+Hoglundauthor=K.+J.+V.+Nordstromauthor=H.+B.+Schiothauthor=R.+Fredriksson&title=The+solute+carrier+families+have+a+remarkably+long+evolutionary+history+with+the+majority+of+the+human+families+present+before+divergence+of+bilaterian+species&doi=10.1093%2Fmolbev%2Fmsq350"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The solute carrier families have a remarkably long evolutionary history with the majority of the human families present before divergence of Bilaterian species</span></div><div class="casAuthors">Hoglund Par J; Nordstrom Karl J V; Schioth Helgi B; Fredriksson Robert</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology and evolution</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1531-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Solute Carriers (SLCs) are membrane proteins that regulate transport of many types of substances over the cell membrane.  The SLCs are found in at least 46 gene families in the human genome.  Here, we performed the first evolutionary analysis of the entire SLC family based on whole genome sequences.  We systematically mined and analyzed the genomes of 17 species to identify SLC genes.  In all, we identified 4,813 SLC sequences in these genomes, and we delineated the evolutionary history of each of the subgroups.  Moreover, we also identified ten new human sequences not previously classified as SLCs, which most likely belong to the SLC family.  We found that 43 of the 46 SLC families found in Homo sapiens were also found in Caenorhabditis elegans, whereas 42 of them were also found in insects.  Mammals have a higher number of SLC genes in most families, perhaps reflecting important roles for these in central nervous system functions.  This study provides a systematic analysis of the evolutionary history of the SLC families in Eukaryotes showing that the SLC superfamily is ancient with multiple branches that were present before early divergence of Bilateria.  The results provide foundation for overall classification of SLC genes and are valuable for annotation and prediction of substrates for the many SLCs that have not been tested in experimental transport assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiyBhdq98sQT0O18WR3iAofW6udTcc2eZ6qZiMjte0ULntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3ntlCksA%253D%253D&md5=7b48e5f85d54d5d23b9dd5c37bc737f9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1093%2Fmolbev%2Fmsq350&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmolbev%252Fmsq350%26sid%3Dliteratum%253Aachs%26aulast%3DHoglund%26aufirst%3DP.%2BJ.%26aulast%3DNordstrom%26aufirst%3DK.%2BJ.%2BV.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26aulast%3DFredriksson%26aufirst%3DR.%26atitle%3DThe%2520solute%2520carrier%2520families%2520have%2520a%2520remarkably%2520long%2520evolutionary%2520history%2520with%2520the%2520majority%2520of%2520the%2520human%2520families%2520present%2520before%2520divergence%2520of%2520bilaterian%2520species%26jtitle%3DMol.%2520Biol.%2520Evol.%26date%3D2011%26volume%3D28%26issue%3D4%26spage%3D1531%26epage%3D1541%26doi%3D10.1093%2Fmolbev%2Fmsq350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemencon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrier, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruford, E. A.</span></span> <span> </span><span class="NLM_article-title">The ABCs of membrane transporters in health and disease (SLC series): introduction</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">95</span>â <span class="NLM_lpage">107</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyktrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=95-107&issue=2%E2%80%933&author=M.+A.+Hedigerauthor=B.+Clemenconauthor=R.+E.+Burrierauthor=E.+A.+Bruford&title=The+ABCs+of+membrane+transporters+in+health+and+disease+%28SLC+series%29%3A+introduction&doi=10.1016%2Fj.mam.2012.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The ABCs of membrane transporters in health and disease (SLC series): Introduction</span></div><div class="casAuthors">Hediger, Matthias A.; Clemencon, Benjamin; Burrier, Robert E.; Bruford, Elspeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">95-107</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The field of transport biol. has steadily grown over the past decade and is now recognized as playing an important role in manifestation and treatment of disease.  The SLC (solute carrier) gene series has grown to now include 52 families and 395 transporter genes in the human genome.  A list of these genes can be found at the HUGO Gene Nomenclature Committee (HGNC) website (see www.genenames.org/genefamilies/SLC).  This special issue features mini-reviews for each of these SLC families written by the experts in each field.  The existing online resource for solute carriers, the Bioparadigms SLC Tables (www.bioparadigms.org), has been updated and significantly extended with addnl. information and cross-links to other relevant databases, and the nomenclature used in this database has been validated and approved by the HGNC.  In addn., the Bioparadigms SLC Tables functionality has been improved to allow easier access by the scientific community.  This introduction includes: an overview of all known SLC and "non-SLC" transporter genes; a list of transporters of water sol. vitamins; a summary of recent progress in the structure detn. of transporters (including GLUT1/SLC2A1); roles of transporters in human diseases and roles in drug approval and pharmaceutical perspectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK0fRstQGk7bVg90H21EOLACvtfcHk0lhVjJ7aIctuwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyktrk%253D&md5=5d559fd0aba51c721ec45abd5893d1eb</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DClemencon%26aufirst%3DB.%26aulast%3DBurrier%26aufirst%3DR.%2BE.%26aulast%3DBruford%26aufirst%3DE.%2BA.%26atitle%3DThe%2520ABCs%2520of%2520membrane%2520transporters%2520in%2520health%2520and%2520disease%2520%2528SLC%2520series%2529%253A%2520introduction%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D95%26epage%3D107%26doi%3D10.1016%2Fj.mam.2012.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span> <span> </span><span class="NLM_article-title">Mitochondrial transporters of the SLC25 family and associated diseases: a review</span>. <i>J. Inherited Metab. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>37</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">565</span>â <span class="NLM_lpage">575</span>, <span class="refDoi">Â DOI: 10.1007/s10545-014-9708-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs10545-014-9708-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24797559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVamu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2014&pages=565-575&issue=4&author=F.+Palmieri&title=Mitochondrial+transporters+of+the+SLC25+family+and+associated+diseases%3A+a+review&doi=10.1007%2Fs10545-014-9708-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mitochondrial transporters of the SLC25 family and associated diseases: a review</span></div><div class="casAuthors">Palmieri, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Inherited Metabolic Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">565-575</span>CODEN:
                <span class="NLM_cas:coden">JIMDDP</span>;
        ISSN:<span class="NLM_cas:issn">0141-8955</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  To date, 14 inherited diseases (including phenotypes) assocd. to mitochondrial transporters of the SLC25 family have been well characterized biochem. and genetically.  They are rare metabolic disorders caused by mutations in the SLC25 nuclear genes that encode mitochondrial carriers, a superfamily of 53 proteins in humans that shuttle a variety of solutes across the mitochondrial membrane.  Mitochondrial carriers vary considerably in the nature and size of the substrates they transport, the modes of transport and driving forces.  However, their substrate translocation mechanism at the mol. level is thought to be basically the same.  Herein, the main structural and functional properties of the SLC25 mitochondrial carriers and the known carrier-related diseases are presented.  Two of these disorders, ADP/ATP carrier deficiency and phosphate carrier deficiency, are caused by defects of the two mitochondrial carriers that provide mitochondria with ADP and phosphate, the substrates of oxidative phosphorylation; these disorders therefore are characterized by defective energy prodn. by mitochondria.  The mutations of SLC25 carrier genes involved in other cellular functions cause carnitine/acylcarnitine carrier deficiency, HHH syndrome, aspartate/glutamate isoform 1 and 2 deficiencies, congenital Amish microcephaly, neuropathy with bilateral striatal necrosis, congenital sideroblastic anemia, neonatal epileptic encephalopathy, and citrate carrier deficiency; these disorders are characterized by specific metabolic dysfunctions depending on the role of the defective carrier in intermediary metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXEveYUSt9-rVg90H21EOLACvtfcHk0lhVjJ7aIctuwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVamu7w%253D&md5=76c20c20b5ad26c8f1d2de1e626336e7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs10545-014-9708-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10545-014-9708-5%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DF.%26atitle%3DMitochondrial%2520transporters%2520of%2520the%2520SLC25%2520family%2520and%2520associated%2520diseases%253A%2520a%2520review%26jtitle%3DJ.%2520Inherited%2520Metab.%2520Dis.%26date%3D2014%26volume%3D37%26issue%3D4%26spage%3D565%26epage%3D575%26doi%3D10.1007%2Fs10545-014-9708-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Structure of the human LAT1â4F2hc heteromeric amino acid transporter complex</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>568</i></span> (<span class="NLM_issue">7750</span>),  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">130</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-1011-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-1011-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30867591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmslKhurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=568&publication_year=2019&pages=127-130&issue=7750&author=R.+Yanauthor=X.+Zhaoauthor=J.+Leiauthor=Q.+Zhou&title=Structure+of+the+human+LAT1%E2%80%934F2hc+heteromeric+amino+acid+transporter+complex&doi=10.1038%2Fs41586-019-1011-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex</span></div><div class="casAuthors">Yan, Renhong; Zhao, Xin; Lei, Jianlin; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">568</span>
        (<span class="NLM_cas:issue">7750</span>),
    <span class="NLM_cas:pages">127-130</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The L-type amino acid transporter 1 (LAT1; also known as SLC7A5) catalyzes the cross-membrane flux of large neutral amino acids in a sodium- and pH-independent manner.  LAT1, an antiporter of the amino acid-polyamine-organocation superfamily, also catalyzes the permeation of thyroid hormones, pharmaceutical drugs, and hormone precursors such as L-3,4-dihydroxyphenylalanine across membranes.  Overexpression of LAT1 has been obsd. in a wide range of tumor cells, and it is thus a potential target for anti-cancer drugs.  LAT1 forms a heteromeric amino acid transporter complex with 4F2 cell-surface antigen heavy chain (4F2hc; also known as SLC3A2)-a type II membrane glycoprotein that is essential for the stability of LAT1 and for its localization to the plasma membrane.  Despite extensive cell-based characterization of the LAT1-4F2hc complex and structural detn. of its homologs in bacteria, the interactions between LAT1 and 4F2hc and the working mechanism of the complex remain largely unknown.  Here we report the cryo-electron microscopy structures of human LAT1-4F2hc alone and in complex with the inhibitor 2-amino-2-norbornanecarboxylic acid at resolns. of 3.3 Ã and 3.5 Ã, resp.  LAT1 exhibits an inward open conformation.  Besides a disulfide bond assocn., LAT1 also interacts extensively with 4F2hc on the extracellular side, within the membrane, and on the intracellular side.  Biochem. anal. reveals that 4F2hc is essential for the transport activity of the complex.  Together, our characterizations shed light on the architecture of the LAT1-4F2hc complex, and provide insights into its function and the mechanisms through which it might be assocd. with disease.  LAT1 transporter complex 4F2hc human structure drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdBX0ZuozAAbVg90H21EOLACvtfcHk0lg0z5NEQgEnYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmslKhurc%253D&md5=21f3bbb22441cd49666914a98a3852b3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1011-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1011-z%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLei%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DStructure%2520of%2520the%2520human%2520LAT1%25E2%2580%25934F2hc%2520heteromeric%2520amino%2520acid%2520transporter%2520complex%26jtitle%3DNature%26date%3D2019%26volume%3D568%26issue%3D7750%26spage%3D127%26epage%3D130%26doi%3D10.1038%2Fs41586-019-1011-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajkhorshid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>569</i></span> (<span class="NLM_issue">7754</span>),  <span class="NLM_fpage">141</span>â <span class="NLM_lpage">145</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-1135-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-1135-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31019304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXosVSkurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=569&publication_year=2019&pages=141-145&issue=7754&author=J.+A.+Colemanauthor=D.+Yangauthor=Z.+Zhaoauthor=P.+C.+Wenauthor=C.+Yoshiokaauthor=E.+Tajkhorshidauthor=E.+Gouaux&title=Serotonin+transporter-ibogaine+complexes+illuminate+mechanisms+of+inhibition+and+transport&doi=10.1038%2Fs41586-019-1135-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport</span></div><div class="casAuthors">Coleman, Jonathan A.; Yang, Dongxue; Zhao, Zhiyu; Wen, Po-Chao; Yoshioka, Craig; Tajkhorshid, Emad; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">569</span>
        (<span class="NLM_cas:issue">7754</span>),
    <span class="NLM_cas:pages">141-145</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) regulates neurotransmitter homeostasis through the sodium- and chloride-dependent recycling of serotonin into presynaptic neurons1-3.  Major depression and anxiety disorders are treated using selective serotonin reuptake inhibitors-small mols. that competitively block substrate binding and thereby prolong neurotransmitter action2,4.  The dopamine and noradrenaline transporters, together with SERT, are members of the neurotransmitter sodium symporter (NSS) family.  The transport activities of NSSs can be inhibited or modulated by cocaine and amphetamines2,3, and genetic variants of NSSs are assocd. with several neuropsychiatric disorders including attention deficit hyperactivity disorder, autism and bipolar disorder2,5.  Studies of bacterial NSS homologues-including LeuT-have shown how their transmembrane helixes (TMs) undergo conformational changes during the transport cycle, exposing a central binding site to either side of the membrane1,6-12.  However, the conformational changes assocd. with transport in NSSs remain unknown.  To elucidate structure-based mechanisms for transport in SERT we investigated its complexes with ibogaine, a hallucinogenic natural product with psychoactive and anti-addictive properties13,14.  Notably, ibogaine is a non-competitive inhibitor of transport but displays competitive binding towards selective serotonin reuptake inhibitors15,16.  Here we report cryo-electron microscopy structures of SERT-ibogaine complexes captured in outward-open, occluded and inward-open conformations.  Ibogaine binds to the central binding site, and closure of the extracellular gate largely involves movements of TMs 1b and 6a.  Opening of the intracellular gate involves a hinge-like movement of TM1a and the partial unwinding of TM5, which together create a permeation pathway that enables substrate and ion diffusion to the cytoplasm.  These structures define the structural rearrangements that occur from the outward-open to inward-open conformations, and provide insight into the mechanism of neurotransmitter transport and ibogaine inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGl4bcGBU7V7Vg90H21EOLACvtfcHk0lg0z5NEQgEnYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXosVSkurw%253D&md5=c149b8cf3358fdbb655f9cd260d54a6a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1135-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1135-1%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWen%26aufirst%3DP.%2BC.%26aulast%3DYoshioka%26aufirst%3DC.%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DSerotonin%2520transporter-ibogaine%2520complexes%2520illuminate%2520mechanisms%2520of%2520inhibition%2520and%2520transport%26jtitle%3DNature%26date%3D2019%26volume%3D569%26issue%3D7754%26spage%3D141%26epage%3D145%26doi%3D10.1038%2Fs41586-019-1135-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garaeva, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oostergetel, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guskov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slotboom, D. J.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human neutral amino acid transporter ASCT2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">515</span>â <span class="NLM_lpage">521</span>, <span class="refDoi">Â DOI: 10.1038/s41594-018-0076-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-018-0076-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29872227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=515-521&issue=6&author=A.+A.+Garaevaauthor=G.+T.+Oostergetelauthor=C.+Gatiauthor=A.+Guskovauthor=C.+Paulinoauthor=D.+J.+Slotboom&title=Cryo-EM+structure+of+the+human+neutral+amino+acid+transporter+ASCT2&doi=10.1038%2Fs41594-018-0076-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the human neutral amino acid transporter ASCT2</span></div><div class="casAuthors">Garaeva, Alisa A.; Oostergetel, Gert T.; Gati, Cornelius; Guskov, Albert; Paulino, Cristina; Slotboom, Dirk J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">515-521</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Human ASCT2 belongs to the SLC1 family of secondary transporters and is specific for the transport of small neutral amino acids.  ASCT2 is upregulated in cancer cells and serves as the receptor for many retroviruses; hence, it has importance as a potential drug target.  Here we used single-particle cryo-EM to det. a structure of the functional and unmodified human ASCT2 at 3.85-Ã resoln.  ASCT2 forms a homotrimeric complex in which each subunit contains a transport and a scaffold domain.  Prominent extracellular extensions on the scaffold domain form the predicted docking site for retroviruses.  Relative to structures of other SLC1 members, ASCT2 is in the most extreme inward-oriented state, with the transport domain largely detached from the central scaffold domain on the cytoplasmic side.  This domain detachment may be required for substrate binding and release on the intracellular side of the membrane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeHykepTMB2rVg90H21EOLACvtfcHk0lg0z5NEQgEnYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKqu7fN&md5=c175f3ea45ca21f1b31e930497c4e7e1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0076-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0076-y%26sid%3Dliteratum%253Aachs%26aulast%3DGaraeva%26aufirst%3DA.%2BA.%26aulast%3DOostergetel%26aufirst%3DG.%2BT.%26aulast%3DGati%26aufirst%3DC.%26aulast%3DGuskov%26aufirst%3DA.%26aulast%3DPaulino%26aufirst%3DC.%26aulast%3DSlotboom%26aufirst%3DD.%2BJ.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520neutral%2520amino%2520acid%2520transporter%2520ASCT2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D6%26spage%3D515%26epage%3D521%26doi%3D10.1038%2Fs41594-018-0076-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abuladze, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsirulnikov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pushkin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurtz, I.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human SLC4A4 sodium-coupled acid-base transporter NBCe1</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">900</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-03271-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41467-018-03271-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29500354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1Mrnt1Kjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=900&author=K.+W.+Huynhauthor=J.+Jiangauthor=N.+Abuladzeauthor=K.+Tsirulnikovauthor=L.+Kaoauthor=X.+Shaoauthor=D.+Newmanauthor=R.+Azimovauthor=A.+Pushkinauthor=Z.+H.+Zhouauthor=I.+Kurtz&title=Cryo-EM+structure+of+the+human+SLC4A4+sodium-coupled+acid-base+transporter+NBCe1&doi=10.1038%2Fs41467-018-03271-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CryoEM structure of the human SLC4A4 sodium-coupled acid-base transporter NBCe1</span></div><div class="casAuthors">Huynh Kevin W; Abuladze Natalia; Tsirulnikov Kirill; Kao Liyo; Newman Debra; Azimov Rustam; Pushkin Alexander; Kurtz Ira; Huynh Kevin W; Jiang Jiansen; Zhou Z Hong; Jiang Jiansen; Zhou Z Hong; Shao Xuesi; Kurtz Ira</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">900</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Na(+)-coupled acid-base transporters play essential roles in human biology.  Their dysfunction has been linked to cancer, heart, and brain disease.  High-resolution structures of mammalian Na(+)-coupled acid-base transporters are not available.  The sodium-bicarbonate cotransporter NBCe1 functions in multiple organs and its mutations cause blindness, abnormal growth and blood chemistry, migraines, and impaired cognitive function.  Here, we have determined the structure of the membrane domain dimer of human NBCe1 at 3.9 ÃA resolution by cryo electron microscopy.  Our atomic model and functional mutagenesis revealed the ion accessibility pathway and the ion coordination site, the latter containing residues involved in human disease-causing mutations.  We identified a small number of residues within the ion coordination site whose modification transformed NBCe1 into an anion exchanger.  Our data suggest that symporters and exchangers utilize comparable transport machinery and that subtle differences in their substrate-binding regions have very significant effects on their transport mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRPzHSE9LOK2cRAV4D_Ins_fW6udTcc2eafYjgvTlK2U7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mrnt1Kjtg%253D%253D&md5=0f48a91d16682563ab6692f503ea5f7f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-03271-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-03271-3%26sid%3Dliteratum%253Aachs%26aulast%3DHuynh%26aufirst%3DK.%2BW.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DAbuladze%26aufirst%3DN.%26aulast%3DTsirulnikov%26aufirst%3DK.%26aulast%3DKao%26aufirst%3DL.%26aulast%3DShao%26aufirst%3DX.%26aulast%3DNewman%26aufirst%3DD.%26aulast%3DAzimov%26aufirst%3DR.%26aulast%3DPushkin%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DZ.%2BH.%26aulast%3DKurtz%26aufirst%3DI.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520SLC4A4%2520sodium-coupled%2520acid-base%2520transporter%2520NBCe1%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D900%26doi%3D10.1038%2Fs41467-018-03271-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garaeva, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guskov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slotboom, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulino, C.</span></span> <span> </span><span class="NLM_article-title">A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3427</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-11363-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41467-019-11363-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31366933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3MvjsVensg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=3427&author=A.+A.+Garaevaauthor=A.+Guskovauthor=D.+J.+Slotboomauthor=C.+Paulino&title=A+one-gate+elevator+mechanism+for+the+human+neutral+amino+acid+transporter+ASCT2&doi=10.1038%2Fs41467-019-11363-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">A one-gate elevator mechanism for the human neutral amino acid transporter ASCT2</span></div><div class="casAuthors">Garaeva Alisa A; Slotboom Dirk J; Paulino Cristina; Guskov Albert; Paulino Cristina; Slotboom Dirk J</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3427</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human Alanine Serine Cysteine Transporter 2 (ASCT2) is a neutral amino acid exchanger that belongs to the solute carrier family 1 (SLC1A).  SLC1A structures have revealed an elevator-type mechanism, in which the substrate is translocated across the cell membrane by a large displacement of the transport domain, whereas a small movement of hairpin 2 (HP2) gates the extracellular access to the substrate-binding site.  However, it has remained unclear how substrate binding and release is gated on the cytoplasmic side.  Here, we present an inward-open structure of the human ASCT2, revealing a hitherto elusive SLC1A conformation.  Strikingly, the same structural element (HP2) serves as a gate in the inward-facing as in the outward-facing state.  The structures reveal that SLC1A transporters work as one-gate elevators.  Unassigned densities near the gate and surrounding the scaffold domain, may represent potential allosteric binding sites, which could guide the design of lipidic-inhibitors for anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwPdPrOAUoabGbPKh4T9eAfW6udTcc2ebTLICMlXAkwrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvjsVensg%253D%253D&md5=bdb8e27fd66ac8d3a59fc28b3740d9d1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-11363-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-11363-x%26sid%3Dliteratum%253Aachs%26aulast%3DGaraeva%26aufirst%3DA.%2BA.%26aulast%3DGuskov%26aufirst%3DA.%26aulast%3DSlotboom%26aufirst%3DD.%2BJ.%26aulast%3DPaulino%26aufirst%3DC.%26atitle%3DA%2520one-gate%2520elevator%2520mechanism%2520for%2520the%2520human%2520neutral%2520amino%2520acid%2520transporter%2520ASCT2%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D3427%26doi%3D10.1038%2Fs41467-019-11363-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiriyasermkul, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohgaki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusakizako, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishitani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nureki, O.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">510</span>â <span class="NLM_lpage">517</span>, <span class="refDoi">Â DOI: 10.1038/s41594-019-0237-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-019-0237-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31160781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7nP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=510-517&issue=6&author=Y.+Leeauthor=P.+Wiriyasermkulauthor=C.+Jinauthor=L.+Quanauthor=R.+Ohgakiauthor=S.+Okudaauthor=T.+Kusakizakoauthor=T.+Nishizawaauthor=K.+Odaauthor=R.+Ishitaniauthor=T.+Yokoyamaauthor=T.+Nakaneauthor=M.+Shirouzuauthor=H.+Endouauthor=S.+Nagamoriauthor=Y.+Kanaiauthor=O.+Nureki&title=Cryo-EM+structure+of+the+human+L-type+amino+acid+transporter+1+in+complex+with+glycoprotein+CD98hc&doi=10.1038%2Fs41594-019-0237-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc</span></div><div class="casAuthors">Lee, Yongchan; Wiriyasermkul, Pattama; Jin, Chunhuan; Quan, Lili; Ohgaki, Ryuichi; Okuda, Suguru; Kusakizako, Tsukasa; Nishizawa, Tomohiro; Oda, Kazumasa; Ishitani, Ryuichiro; Yokoyama, Takeshi; Nakane, Takanori; Shirouzu, Mikako; Endou, Hitoshi; Nagamori, Shushi; Kanai, Yoshikatsu; Nureki, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">510-517</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The L-type amino acid transporter 1 (LAT1 or SLC7A5) transports large neutral amino acids across the membrane and is crucial for brain drug delivery and tumor growth.  LAT1 forms a disulfide-linked heterodimer with CD98 heavy chain (CD98hc, 4F2hc or SLC3A2), but the mechanism of assembly and amino acid transport are poorly understood.  Here we report the cryo-EM structure of the human LAT1-CD98hc heterodimer at 3.3-Ã resoln.  LAT1 features a canonical Leu T-fold and exhibits an unusual loop structure on transmembrane helix 6, creating an extended cavity that might accommodate bulky amino acids and drugs.  CD98hc engages with LAT1 through the extracellular, transmembrane and putative cholesterol-mediated interactions.  We also show that two anti-CD98 antibodies recognize distinct, multiple epitopes on CD98hc but not its glycans, explaining their robust reactivities.  These results reveal the principles of glycoprotein-solute carrier assembly and provide templates for improving preclin. drugs and antibodies targeting LAT1 or CD98hc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5dNxEDKM31rVg90H21EOLACvtfcHk0lgYANo-Ujf_KA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2it7nP&md5=76486ba3a84bf0b54eea6a43502cea2a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41594-019-0237-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-019-0237-7%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%26aulast%3DWiriyasermkul%26aufirst%3DP.%26aulast%3DJin%26aufirst%3DC.%26aulast%3DQuan%26aufirst%3DL.%26aulast%3DOhgaki%26aufirst%3DR.%26aulast%3DOkuda%26aufirst%3DS.%26aulast%3DKusakizako%26aufirst%3DT.%26aulast%3DNishizawa%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DIshitani%26aufirst%3DR.%26aulast%3DYokoyama%26aufirst%3DT.%26aulast%3DNakane%26aufirst%3DT.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DEndou%26aufirst%3DH.%26aulast%3DNagamori%26aufirst%3DS.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DNureki%26aufirst%3DO.%26atitle%3DCryo-EM%2520structure%2520of%2520the%2520human%2520L-type%2520amino%2520acid%2520transporter%25201%2520in%2520complex%2520with%2520glycoprotein%2520CD98hc%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D510%26epage%3D517%26doi%3D10.1038%2Fs41594-019-0237-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structures of the human cation-chloride cotransporter KCC1</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>366</i></span> (<span class="NLM_issue">6464</span>),  <span class="NLM_fpage">505</span>â <span class="NLM_lpage">508</span>, <span class="refDoi">Â DOI: 10.1126/science.aay3129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.aay3129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31649201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVemtrzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2019&pages=505-508&issue=6464&author=S.+Liuauthor=S.+Changauthor=B.+Hanauthor=L.+Xuauthor=M.+Zhangauthor=C.+Zhaoauthor=W.+Yangauthor=F.+Wangauthor=J.+Liauthor=E.+Delpireauthor=S.+Yeauthor=X.+C.+Baiauthor=J.+Guo&title=Cryo-EM+structures+of+the+human+cation-chloride+cotransporter+KCC1&doi=10.1126%2Fscience.aay3129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structures of the human cation-chloride cotransporter KCC1</span></div><div class="casAuthors">Liu, Si; Chang, Shenghai; Han, Binming; Xu, Lingyi; Zhang, Mingfeng; Zhao, Cheng; Yang, Wei; Wang, Feng; Li, Jingyuan; Delpire, Eric; Ye, Sheng; Bai, Xiao-chen; Guo, Jiangtao</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">6464</span>),
    <span class="NLM_cas:pages">505-508</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cation-chloride cotransporters move chloride and cations across the cell membrane and are important in regulating cell vol. and setting the chloride concn. inside the cell.  Mutations lead to serious diseases, such as epilepsy.  Liu et al. present the structure of the human potassium-chloride cotransporter KCC1, as detd. by Cryo-electron microscopy.  Based on the structure, functional studies, and mol. dynamics simulations, they propose an ion transport model.  The structure provides a framework for interpreting disease-related mutations in potassium-chloride cotransporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeP9poU5b_S7Vg90H21EOLACvtfcHk0lgYANo-Ujf_KA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVemtrzI&md5=34f810dba287470ec4913a8ab9e0b2f6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.aay3129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aay3129%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DDelpire%26aufirst%3DE.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DX.%2BC.%26aulast%3DGuo%26aufirst%3DJ.%26atitle%3DCryo-EM%2520structures%2520of%2520the%2520human%2520cation-chloride%2520cotransporter%2520KCC1%26jtitle%3DScience%26date%3D2019%26volume%3D366%26issue%3D6464%26spage%3D505%26epage%3D508%26doi%3D10.1126%2Fscience.aay3129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reithmeier, R. A. F.</span></span> <span> </span><span class="NLM_article-title">Structural biology of solute carrier (SLC) membrane transport proteins</span>. <i>Mol. Membr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">1â2</span>),  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">32</span>, <span class="refDoi">Â DOI: 10.1080/09687688.2018.1448123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1080%2F09687688.2018.1448123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29651895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1Omsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1-32&issue=1%E2%80%932&author=X.+Baiauthor=T.+F.+Moraesauthor=R.+A.+F.+Reithmeier&title=Structural+biology+of+solute+carrier+%28SLC%29+membrane+transport+proteins&doi=10.1080%2F09687688.2018.1448123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Structural biology of solute carrier (SLC) membrane transport proteins</span></div><div class="casAuthors">Bai, Xiaoyun; Moraes, Trevor F.; Reithmeier, Reinhart A. F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Membrane Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">1-32</span>CODEN:
                <span class="NLM_cas:coden">MMEBE7</span>;
        ISSN:<span class="NLM_cas:issn">0968-7688</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  The human solute carriers (SLCs) comprise over 400 different transporters, organized into 65 families (http://slc.bioparadigms.org/) based on their sequence homol. and transport function.  SLCs are responsible for transporting extraordinarily diverse solutes across biol. membranes, including inorg. ions, amino acids, lipids, sugars, neurotransmitters and drugs.  Most of these membrane proteins function as coupled symporters (co-transporters) utilizing downhill ion (H+ or Na+) gradients as the driving force for the transport of substrate against its concn. gradient into cells.  Other members work as antiporters (exchangers) that typically contain a single substrate-binding site with an alternating access mode of transport, while a few members exhibit channel-like properties.  Dysfunction of SLCs is correlated with numerous human diseases and therefore they are potential therapeutic drug targets.  In this review, we identified all of the SLC crystal structures that have been detd., most of which are from prokaryotic species.  We further sorted all the SLC structures into four main groups with different protein folds and further discuss the well-characterized MFS (major facilitator superfamily) and LeuT (leucine transporter) folds.  This review provides a systematic anal. of the structure, mol. basis of substrate recognition and mechanism of action in different SLC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAsFzTpIxkmbVg90H21EOLACvtfcHk0lhT_gPK3SlUyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1Omsr8%253D&md5=070a749c134430cd9edfe09d22c65112</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1080%2F09687688.2018.1448123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F09687688.2018.1448123%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DX.%26aulast%3DMoraes%26aufirst%3DT.%2BF.%26aulast%3DReithmeier%26aufirst%3DR.%2BA.%2BF.%26atitle%3DStructural%2520biology%2520of%2520solute%2520carrier%2520%2528SLC%2529%2520membrane%2520transport%2520proteins%26jtitle%3DMol.%2520Membr.%2520Biol.%26date%3D2017%26volume%3D34%26issue%3D1%25E2%2580%25932%26spage%3D1%26epage%3D32%26doi%3D10.1080%2F09687688.2018.1448123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ung, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">SLC transporters: structure, function, and drug discovery</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1069</span>â <span class="NLM_lpage">1081</span>, <span class="refDoi">Â DOI: 10.1039/C6MD00005C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1039%2FC6MD00005C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27672436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFGhtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1069-1081&issue=6&author=C.+Colasauthor=P.+M.+Ungauthor=A.+Schlessinger&title=SLC+transporters%3A+structure%2C+function%2C+and+drug+discovery&doi=10.1039%2FC6MD00005C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">SLC transporters: structure, function, and drug discovery</span></div><div class="casAuthors">Colas, Claire; Ung, Peter Man-Un; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1069-1081</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The human solute carrier (SLC) transporters are important targets for drug development.  Structure-based drug discovery for SLC transporters requires the description of their structure, dynamics, and mechanism of interaction with small mol. ligands and ions.  The recent detn. of at. structures of human SLC transporters and their homologs, combined with improved computational power and prediction methods, has led to an increased applicability of structure-based drug design methods for human SLC members.  In this review, we provide an overview of the SLC transporters' structures and transport mechanisms.  We then describe computational techniques, such as homol. modeling and virtual screening that are emerging as key tools to discover chem. probes for human SLC members.  We illustrate the utility of these methods by presenting case studies in which rational integration of computation and expt. was used to characterize SLC members that transport key nutrients and metabolites, including the amino acid transporters LAT-1 and ASCT2, the SLC13 family of citric acid cycle intermediates transporters, and the glucose transporter GLUT1.  We conclude with a brief discussion about future directions in structure-based drug discovery for the human SLC superfamily, one of the most structurally and functionally diverse protein families in human.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5sBwcRO3JnbVg90H21EOLACvtfcHk0lhT_gPK3SlUyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFGhtL4%253D&md5=3b31e4a50f1d25db9e6756163360e086</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1039%2FC6MD00005C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00005C%26sid%3Dliteratum%253Aachs%26aulast%3DColas%26aufirst%3DC.%26aulast%3DUng%26aufirst%3DP.%2BM.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DSLC%2520transporters%253A%2520structure%252C%2520function%252C%2520and%2520drug%2520discovery%26jtitle%3DMedChemComm%26date%3D2016%26volume%3D7%26issue%3D6%26spage%3D1069%26epage%3D1081%26doi%3D10.1039%2FC6MD00005C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drew, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boudker, O.</span></span> <span> </span><span class="NLM_article-title">Shared molecular mechanisms of membrane transporters</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">543</span>â <span class="NLM_lpage">572</span>, <span class="refDoi">Â DOI: 10.1146/annurev-biochem-060815-014520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1146%2Fannurev-biochem-060815-014520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27023848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XltFGrs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2016&pages=543-572&author=D.+Drewauthor=O.+Boudker&title=Shared+molecular+mechanisms+of+membrane+transporters&doi=10.1146%2Fannurev-biochem-060815-014520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Shared Molecular Mechanisms of Membrane Transporters</span></div><div class="casAuthors">Drew, David; Boudker, Olga</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">543-572</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The detn. of the crystal structures of small-mol. transporters has shed light on the conformational changes that take place during structural isomerization from outward- to inward-facing states.  Rather than using a simple rocking movement of two bundles around a central substrate-binding site, it has become clear that even the most simplistic transporters utilize rearrangements of nonrigid bodies.  In the most dramatic cases, one bundle is fixed while the other, structurally divergent, bundle carries the substrate some 18 Ã across the membrane, which in this review is termed an elevator alternating-access mechanism.  Here, we compare and contrast rocker-switch, rocking-bundle, and elevator alternating-access mechanisms to highlight shared features and novel refinements to the basic alternating-access model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojfB2giGzclrVg90H21EOLACvtfcHk0lhT_gPK3SlUyw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XltFGrs7s%253D&md5=5c586b058975893286ea63406126ef29</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-060815-014520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-060815-014520%26sid%3Dliteratum%253Aachs%26aulast%3DDrew%26aufirst%3DD.%26aulast%3DBoudker%26aufirst%3DO.%26atitle%3DShared%2520molecular%2520mechanisms%2520of%2520membrane%2520transporters%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2016%26volume%3D85%26spage%3D543%26epage%3D572%26doi%3D10.1146%2Fannurev-biochem-060815-014520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, N.</span></span> <span> </span><span class="NLM_article-title">Structural advances for the major facilitator superfamily (MFS) transporters</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">151</span>â <span class="NLM_lpage">159</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2013.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tibs.2013.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23403214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1yrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=151-159&issue=3&author=N.+Yan&title=Structural+advances+for+the+major+facilitator+superfamily+%28MFS%29+transporters&doi=10.1016%2Fj.tibs.2013.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural advances for the major facilitator superfamily (MFS) transporters</span></div><div class="casAuthors">Yan, Nieng</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The major facilitator superfamily (MFS) is one of the largest groups of secondary active transporters conserved from bacteria to humans.  MFS proteins selectively transport a wide spectrum of substrates across biomembranes and play a pivotal role in multiple physiol. processes.  Despite intense investigation, only seven MFS proteins from six subfamilies have been structurally elucidated.  These structures were captured in distinct states during a transport cycle involving alternating access to binding sites from either side of the membrane.  This review discusses recent progress in MFS structure anal. and focuses on the mol. basis for substrate binding, co-transport coupling, and alternating access.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOoE0sVI2ux7Vg90H21EOLACvtfcHk0ljoLYxAipUXGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1yrtL8%253D&md5=afedff31eec0011b04efd4a86127b1f2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2013.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2013.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DN.%26atitle%3DStructural%2520advances%2520for%2520the%2520major%2520facilitator%2520superfamily%2520%2528MFS%2529%2520transporters%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2013%26volume%3D38%26issue%3D3%26spage%3D151%26epage%3D159%26doi%3D10.1016%2Fj.tibs.2013.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, N.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human glucose transporter GLUT1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>510</i></span> (<span class="NLM_issue">7503</span>),  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">125</span>, <span class="refDoi">Â DOI: 10.1038/nature13306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature13306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24847886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitFGitL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=510&publication_year=2014&pages=121-125&issue=7503&author=D.+Dengauthor=C.+Xuauthor=P.+Sunauthor=J.+Wuauthor=C.+Yanauthor=M.+Huauthor=N.+Yan&title=Crystal+structure+of+the+human+glucose+transporter+GLUT1&doi=10.1038%2Fnature13306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human glucose transporter GLUT1</span></div><div class="casAuthors">Deng, Dong; Xu, Chao; Sun, Pengcheng; Wu, Jianping; Yan, Chuangye; Hu, Mingxu; Yan, Nieng</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">510</span>
        (<span class="NLM_cas:issue">7503</span>),
    <span class="NLM_cas:pages">121-125</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The glucose transporter GLUT1 catalyzes facilitative diffusion of glucose into erythrocytes and is responsible for glucose supply to the brain and other organs.  Dysfunctional mutations may lead to GLUT1 deficiency syndrome, whereas overexpression of GLUT1 is a prognostic indicator for cancer.  Despite decades of investigation, the structure of GLUT1 remains unknown.  Here we report the crystal structure of human GLUT1 at 3.2 Ã resoln.  The full-length protein, which has a canonical major facilitator superfamily fold, is captured in an inward-open conformation.  This structure allows accurate mapping and potential mechanistic interpretation of disease-assocd. mutations in GLUT1.  Structure-based anal. of these mutations provides an insight into the alternating access mechanism of GLUT1 and other members of the sugar porter subfamily.  Structural comparison of the uniporter GLUT1 with its bacterial homolog XylE, a proton-coupled xylose symporter, allows examn. of the transport mechanisms of both passive facilitators and active transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSeBmEBIMIurVg90H21EOLACvtfcHk0ljoLYxAipUXGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitFGitL8%253D&md5=b9426a934cddf7347fdc6c9073aa8636</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature13306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13306%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DN.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520glucose%2520transporter%2520GLUT1%26jtitle%3DNature%26date%3D2014%26volume%3D510%26issue%3D7503%26spage%3D121%26epage%3D125%26doi%3D10.1038%2Fnature13306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, N.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of ligand recognition and transport by glucose transporters</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>526</i></span> (<span class="NLM_issue">7573</span>),  <span class="NLM_fpage">391</span>â <span class="NLM_lpage">396</span>, <span class="refDoi">Â DOI: 10.1038/nature14655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature14655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26176916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyltLzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=526&publication_year=2015&pages=391-396&issue=7573&author=D.+Dengauthor=P.+Sunauthor=C.+Yanauthor=M.+Keauthor=X.+Jiangauthor=L.+Xiongauthor=W.+Renauthor=K.+Hirataauthor=M.+Yamamotoauthor=S.+Fanauthor=N.+Yan&title=Molecular+basis+of+ligand+recognition+and+transport+by+glucose+transporters&doi=10.1038%2Fnature14655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of ligand recognition and transport by glucose transporters</span></div><div class="casAuthors">Deng, Dong; Sun, Pengcheng; Yan, Chuangye; Ke, Meng; Jiang, Xin; Xiong, Lei; Ren, Wenlin; Hirata, Kunio; Yamamoto, Masaki; Fan, Shilong; Yan, Nieng</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">526</span>
        (<span class="NLM_cas:issue">7573</span>),
    <span class="NLM_cas:pages">391-396</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The major facilitator superfamily glucose transporters, exemplified by human GLUT1-4, have been central to the study of solute transport.  Using lipidic cubic phase crystn. and microfocus X-ray diffraction, we detd. the structure of human GLUT3 in complex with D-glucose at 1.5 Ã resoln. in an outward-occluded conformation.  The high-resoln. structure allows discrimination of both Î±- and Î²-anomers of D-glucose.  Two addnl. structures of GLUT3 bound to the exofacial inhibitor maltose were obtained at 2.6 Ã in the outward-open and 2.4 Ã in the outward-occluded states.  In all three structures, the ligands are predominantly coordinated by polar residues from the carboxy terminal domain.  Conformational transition from outward-open to outward-occluded entails a prominent local rearrangement of the extracellular part of transmembrane segment TM7.  Comparison of the outward-facing GLUT3 structures with the inward-open GLUT1 provides insights into the alternating access cycle for GLUTs, whereby the C-terminal domain provides the primary substrate-binding site and the amino-terminal domain undergoes rigid-body rotation with respect to the C-terminal domain.  Our studies provide an important framework for the mechanistic and kinetic understanding of GLUTs and shed light on structure-guided ligand design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3p8Y2gV917LVg90H21EOLACvtfcHk0ljoLYxAipUXGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyltLzO&md5=77ab999156155b38156394961682804d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature14655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14655%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DKe%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DYan%26aufirst%3DN.%26atitle%3DMolecular%2520basis%2520of%2520ligand%2520recognition%2520and%2520transport%2520by%2520glucose%2520transporters%26jtitle%3DNature%26date%3D2015%26volume%3D526%26issue%3D7573%26spage%3D391%26epage%3D396%26doi%3D10.1038%2Fnature14655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahar, I.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporters: structure, intrinsic dynamics and allosteric regulation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">545</span>â <span class="NLM_lpage">556</span>, <span class="refDoi">Â DOI: 10.1038/s41594-019-0253-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-019-0253-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31270469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamurrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=545-556&issue=7&author=M.+H.+Chengauthor=I.+Bahar&title=Monoamine+transporters%3A+structure%2C+intrinsic+dynamics+and+allosteric+regulation&doi=10.1038%2Fs41594-019-0253-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporters: structure, intrinsic dynamics and allosteric regulation</span></div><div class="casAuthors">Cheng, Mary Hongying; Bahar, Ivet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">545-556</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Monoamine transporters (MATs) regulate neurotransmission via the reuptake of dopamine, serotonin and norepinephrine from extra-neuronal regions and thus maintain neurotransmitter homeostasis.  As targets of a wide range of compds., including antidepressants, substances of abuse and drugs for neuropsychiatric and neurodegenerative disorders, their mechanism of action and their modulation by small mols. have long been of broad interest.  Recent advances in the structural characterization of dopamine and serotonin transporters have opened the way for structure-based modeling and simulations, which, together with exptl. data, now provide mechanistic understanding of their transport function and interactions.  Here we review recent progress in the elucidation of the structural dynamics of MATs and their conformational landscape and transitions, as well as allosteric regulation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoruK1kJTRahrVg90H21EOLACvtfcHk0ljoLYxAipUXGA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamurrN&md5=dd8add19bafb1252816b2b9f2ca3c207</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41594-019-0253-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-019-0253-7%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%2BH.%26aulast%3DBahar%26aufirst%3DI.%26atitle%3DMonoamine%2520transporters%253A%2520structure%252C%2520intrinsic%2520dynamics%2520and%2520allosteric%2520regulation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D7%26spage%3D545%26epage%3D556%26doi%3D10.1038%2Fs41594-019-0253-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kazmier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claxton, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHaourab, H. S.</span></span> <span> </span><span class="NLM_article-title">Alternating access mechanisms of LeuT-fold transporters: trailblazing towards the promised energy landscapes</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">100</span>â <span class="NLM_lpage">108</span>, <span class="refDoi">Â DOI: 10.1016/j.sbi.2016.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.sbi.2016.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28040635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFGis7%252FM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=100-108&author=K.+Kazmierauthor=D.+P.+Claxtonauthor=H.+S.+McHaourab&title=Alternating+access+mechanisms+of+LeuT-fold+transporters%3A+trailblazing+towards+the+promised+energy+landscapes&doi=10.1016%2Fj.sbi.2016.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Alternating access mechanisms of LeuT-fold transporters: trailblazing towards the promised energy landscapes</span></div><div class="casAuthors">Kazmier, Kelli; Claxton, Derek P.; Mchaourab, Hassane S.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">100-108</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Secondary active transporters couple the uphill translocation of substrates to electrochem. ion gradients.  Transporter conformational motion, generically referred to as alternating access, enables a central ligand binding site to change its orientation relative to the membrane.  Here we review themes of alternating access and the transduction of ion gradient energy to power this process in the LeuT-fold class of transporters where crystallog., computational and spectroscopic approaches have converged to yield detailed models of transport cycles.  Specifically, we compare findings for the Na+-coupled amino acid transporter LeuT and the Na+-coupled hydantoin transporter Mhp1.  Although these studies have illuminated multiple aspects of transporter structures and dynamics, a no. of questions remain unresolved that so far hinder understanding transport mechanisms in an energy landscape perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppHcxtGMp5PLVg90H21EOLACvtfcHk0lj8v7LYR4Vxvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFGis7%252FM&md5=d91709d4c68e4fcd6233b64d19e77ae7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2016.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DKazmier%26aufirst%3DK.%26aulast%3DClaxton%26aufirst%3DD.%2BP.%26aulast%3DMcHaourab%26aufirst%3DH.%2BS.%26atitle%3DAlternating%2520access%2520mechanisms%2520of%2520LeuT-fold%2520transporters%253A%2520trailblazing%2520towards%2520the%2520promised%2520energy%2520landscapes%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2017%26volume%3D45%26spage%3D100%26epage%3D108%26doi%3D10.1016%2Fj.sbi.2016.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postis, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, A.</span></span> <span> </span><span class="NLM_article-title">Transport mechanism of a glutamate transporter homologue GltPh</span>. <i>Biochem. Soc. Trans.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">898</span>â <span class="NLM_lpage">904</span>, <span class="refDoi">Â DOI: 10.1042/BST20160055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1042%2FBST20160055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27284058" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xps1WmtLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=898-904&issue=3&author=Y.+Jiauthor=V.+L.+Postisauthor=Y.+Wangauthor=M.+Bartlamauthor=A.+Goldman&title=Transport+mechanism+of+a+glutamate+transporter+homologue+GltPh&doi=10.1042%2FBST20160055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Transport mechanism of a glutamate transporter homologue GltPh</span></div><div class="casAuthors">Ji, Yurui; Postis, Vincent L. G.; Wang, Yingying; Bartlam, Mark; Goldman, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Society Transactions</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">898-904</span>CODEN:
                <span class="NLM_cas:coden">BCSTB5</span>;
        ISSN:<span class="NLM_cas:issn">0300-5127</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Glutamate transporters are responsible for uptake of the neurotransmitter glutamate in mammalian central nervous systems.  Their archaeal homolog GltPh, an aspartate transporter isolated from Pyrococcus horikoshii, has been the focus of extensive studies through crystallog., MD simulations and single-mol. FRET (smFRET).  Here, we summarize the recent research progress on GltPh, in the hope of gaining some insights into the transport mechanism of this aspartate transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPAGbGP2Xf_LVg90H21EOLACvtfcHk0lj8v7LYR4Vxvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xps1WmtLY%253D&md5=c96357a2a275e2e85341bd909a42a37f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1042%2FBST20160055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBST20160055%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DY.%26aulast%3DPostis%26aufirst%3DV.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DGoldman%26aufirst%3DA.%26atitle%3DTransport%2520mechanism%2520of%2520a%2520glutamate%2520transporter%2520homologue%2520GltPh%26jtitle%3DBiochem.%2520Soc.%2520Trans.%26date%3D2016%26volume%3D44%26issue%3D3%26spage%3D898%26epage%3D904%26doi%3D10.1042%2FBST20160055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Canul-Tec, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamot-Rooke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyes, N.</span></span> <span> </span><span class="NLM_article-title">Structure and allosteric inhibition of excitatory amino acid transporter 1</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>544</i></span> (<span class="NLM_issue">7651</span>),  <span class="NLM_fpage">446</span>â <span class="NLM_lpage">451</span>, <span class="refDoi">Â DOI: 10.1038/nature22064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature22064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28424515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtlalt7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=544&publication_year=2017&pages=446-451&issue=7651&author=J.+C.+Canul-Tecauthor=R.+Assalauthor=E.+Cirriauthor=P.+Legrandauthor=S.+Brierauthor=J.+Chamot-Rookeauthor=N.+Reyes&title=Structure+and+allosteric+inhibition+of+excitatory+amino+acid+transporter+1&doi=10.1038%2Fnature22064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and allosteric inhibition of excitatory amino acid transporter 1</span></div><div class="casAuthors">Canul-Tec, Juan C.; Assal, Reda; Cirri, Erica; Legrand, Pierre; Brier, Sebastien; Chamot-Rooke, Julia; Reyes, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">544</span>
        (<span class="NLM_cas:issue">7651</span>),
    <span class="NLM_cas:pages">446-451</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human members of the solute carrier 1 (SLC1) family of transporters take up excitatory neurotransmitters in the brain and amino acids in peripheral organs.  Dysregulation of the function of SLC1 transporters is assocd. with neurodegenerative disorders and cancer.  Here we present crystal structures of a thermostabilized human SLC1 transporter, the excitatory amino acid transporter 1 (EAAT1), with and without allosteric and competitive inhibitors bound.  The structures reveal architectural features of the human transporters, such as intra- and extracellular domains that have potential roles in transport function, regulation by lipids and post-translational modifications.  The coordination of the allosteric inhibitor in the structures and the change in the transporter dynamics measured by hydrogen-deuterium exchange mass spectrometry reveal a mechanism of inhibition, in which the transporter is locked in the outward-facing states of the transport cycle.  Our results provide insights into the mol. mechanisms underlying the function and pharmacol. of human SLC1 transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2niGusxCYIbVg90H21EOLACvtfcHk0lj8v7LYR4Vxvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtlalt7k%253D&md5=1107e965f53e44801b6f51152f29ba13</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnature22064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22064%26sid%3Dliteratum%253Aachs%26aulast%3DCanul-Tec%26aufirst%3DJ.%2BC.%26aulast%3DAssal%26aufirst%3DR.%26aulast%3DCirri%26aufirst%3DE.%26aulast%3DLegrand%26aufirst%3DP.%26aulast%3DBrier%26aufirst%3DS.%26aulast%3DChamot-Rooke%26aufirst%3DJ.%26aulast%3DReyes%26aufirst%3DN.%26atitle%3DStructure%2520and%2520allosteric%2520inhibition%2520of%2520excitatory%2520amino%2520acid%2520transporter%25201%26jtitle%3DNature%26date%3D2017%26volume%3D544%26issue%3D7651%26spage%3D446%26epage%3D451%26doi%3D10.1038%2Fnature22064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navale, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranjape, A. N.</span></span> <span> </span><span class="NLM_article-title">Glucose transporters: physiological and pathological roles</span>. <i>Biophys. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">5</span>â <span class="NLM_lpage">9</span>, <span class="refDoi">Â DOI: 10.1007/s12551-015-0186-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs12551-015-0186-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28510148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2isb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=5-9&issue=1&author=A.+M.+Navaleauthor=A.+N.+Paranjape&title=Glucose+transporters%3A+physiological+and+pathological+roles&doi=10.1007%2Fs12551-015-0186-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose transporters: physiological and pathological roles</span></div><div class="casAuthors">Navale, Archana M.; Paranjape, Archana N.</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-9</span>CODEN:
                <span class="NLM_cas:coden">BRIECG</span>;
        ISSN:<span class="NLM_cas:issn">1867-2450</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Glucose is a primary energy source for most cells and an important substrate for many biochem. reactions.  As glucose is a need of each and every cell of the body, so are the glucose transporters.  Consequently, all cells express these important proteins on their surface.  In recent years developments in genetics have shed new light on the types and physiol. of various glucose transporters, of which there are two main types-sodium-glucose linked transporters (SGLTs) and facilitated diffusion glucose transporters (GLUT)-which can be divided into many more subclasses.  Transporters differ in terms of their substrate specificity, distribution and regulatory mechanisms.  Glucose transporters have also received much attention as therapeutic targets for various diseases.  In this review, we attempt to present a simplified view of this complex topic which may be of interest to researchers involved in biochem. and pharmacol. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZHTI_CfH8WbVg90H21EOLACvtfcHk0lg9Iueu_6Sz2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2isb0%253D&md5=e328a4728ff6bca082764e1d06372066</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs12551-015-0186-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12551-015-0186-2%26sid%3Dliteratum%253Aachs%26aulast%3DNavale%26aufirst%3DA.%2BM.%26aulast%3DParanjape%26aufirst%3DA.%2BN.%26atitle%3DGlucose%2520transporters%253A%2520physiological%2520and%2520pathological%2520roles%26jtitle%3DBiophys.%2520Rev.%26date%3D2016%26volume%3D8%26issue%3D1%26spage%3D5%26epage%3D9%26doi%3D10.1007%2Fs12551-015-0186-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kasahara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkle, P. C.</span></span> <span> </span><span class="NLM_article-title">Reconstitution and purification of the D-glucose transporter from human erythrocytes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>252</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">7384</span>â <span class="NLM_lpage">7390</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=903365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaE2sXls1eit7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=1977&pages=7384-7390&issue=20&author=M.+Kasaharaauthor=P.+C.+Hinkle&title=Reconstitution+and+purification+of+the+D-glucose+transporter+from+human+erythrocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Reconstitution and purification of the D-glucose transporter from human erythrocytes</span></div><div class="casAuthors">Kasahara, Michihiro; Hinkle, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">252</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7384-90</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The D-glucose transporter from human erythrocytes was solubilized from washed membranes using Triton X 100.  After removal of the Triton X 100, the protein was incorporated into phospholipid vesicles by the sonication method of M. Kasahara and P. C. Hinkle (1976), but including a freeze-thaw step after adding the protein to the phospholipids.  The component catalyzing transport was purified from the Triton ext. by DEAE-cellulose chromatog.  The active fraction contained 1 major protein (96%) with apparent mol. wt. from Na dodecyl sulfate-polyacrylamide gel electrophoresis of 55,000.  The protein had a high lipid content and is probably a glycoprotein.  Antibody absorption expts. indicated that the protein is exposed to the inner face of the erythrocyte membrane.  D-glucose transport into liposomes reconstituted with the purified protein fraction was inhibited by Hg2+ or cytochalasin B, but not by phloretin or stilbestrol.  The specific activity of D-glucose transport was 85 nmol/min/mg of protein at 0.2 mM D-glucose, which is 10-fold higher than that of reconstituted liposomes with crude Triton ext.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjEDaKsQOX2bVg90H21EOLACvtfcHk0lg9Iueu_6Sz2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXls1eit7k%253D&md5=a7c100824a2c7c7ef92418d27dbe7ee0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKasahara%26aufirst%3DM.%26aulast%3DHinkle%26aufirst%3DP.%2BC.%26atitle%3DReconstitution%2520and%2520purification%2520of%2520the%2520D-glucose%2520transporter%2520from%2520human%2520erythrocytes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1977%26volume%3D252%26issue%3D20%26spage%3D7384%26epage%3D7390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueckler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panico, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blench, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allard, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienhard, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodish, H. F.</span></span> <span> </span><span class="NLM_article-title">Sequence and structure of a human glucose transporter</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>229</i></span> (<span class="NLM_issue">4717</span>),  <span class="NLM_fpage">941</span>â <span class="NLM_lpage">945</span>, <span class="refDoi">Â DOI: 10.1126/science.3839598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.3839598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=3839598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaL2MXlvFSkt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=229&publication_year=1985&pages=941-945&issue=4717&author=M.+Muecklerauthor=C.+Carusoauthor=S.+A.+Baldwinauthor=M.+Panicoauthor=I.+Blenchauthor=H.+R.+Morrisauthor=W.+J.+Allardauthor=G.+E.+Lienhardauthor=H.+F.+Lodish&title=Sequence+and+structure+of+a+human+glucose+transporter&doi=10.1126%2Fscience.3839598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence and structure of a human glucose transporter</span></div><div class="casAuthors">Mueckler, Mike; Caruso, Carla; Baldwin, Stephen A.; Panico, Maria; Blench, Ian; Morris, Howard R.; Allard, W. Jeffrey; Lienhard, Gustav E.; Lodish, Harvey F.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">229</span>
        (<span class="NLM_cas:issue">4717</span>),
    <span class="NLM_cas:pages">941-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The amino acid sequence of the glucose  [50-99-7] transport protein from human HepG2 hepatoma cells was deduced from anal. of a cDNA clone.  Structural anal. of the purified human erythrocyte glucose transport by fast atom bombardment mapping and gas-phase Edman degrdn. confirmed the identity of the clone and demonstrated that the HepG2 and erythrocyte transporters are highly homologous and may be identical.  The protein lacks a cleavable N-terminal signal sequence.  Anal. of the primary structure suggests the presence of 12 membrane-spanning domains.  Several of these may form amphipathic Î±-helices and contain abundant OH and amide side chains that could participate in glucose binding or line a transmembrane pore through which the sugar moves.  The N-terminus, C-terminus, and a highly hydrophilic domain in the center of the protein are all predicted to lie on the cytoplasmic face.  Species of mRNA homologous to HepG2 glucose transporter mRNA were detected in K562 leukemia cells, HT29 colon adenocarcinoma cells, and human kidney tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkan9yoEzSPrVg90H21EOLACvtfcHk0lg9Iueu_6Sz2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlvFSkt70%253D&md5=6ee2bbe2380641b3cc4bce47a611cdc0</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1126%2Fscience.3839598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3839598%26sid%3Dliteratum%253Aachs%26aulast%3DMueckler%26aufirst%3DM.%26aulast%3DCaruso%26aufirst%3DC.%26aulast%3DBaldwin%26aufirst%3DS.%2BA.%26aulast%3DPanico%26aufirst%3DM.%26aulast%3DBlench%26aufirst%3DI.%26aulast%3DMorris%26aufirst%3DH.%2BR.%26aulast%3DAllard%26aufirst%3DW.%2BJ.%26aulast%3DLienhard%26aufirst%3DG.%2BE.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DSequence%2520and%2520structure%2520of%2520a%2520human%2520glucose%2520transporter%26jtitle%3DScience%26date%3D1985%26volume%3D229%26issue%3D4717%26spage%3D941%26epage%3D945%26doi%3D10.1126%2Fscience.3839598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGraw, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span> <span> </span><span class="NLM_article-title">30 sweet years of GLUT4</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>294</i></span> (<span class="NLM_issue">30</span>),  <span class="NLM_fpage">11369</span>â <span class="NLM_lpage">11381</span>, <span class="refDoi">Â DOI: 10.1074/jbc.REV119.008351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.REV119.008351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31175156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVOgur%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2019&pages=11369-11381&issue=30&author=A.+Klipauthor=T.+E.+McGrawauthor=D.+E.+James&title=30+sweet+years+of+GLUT4&doi=10.1074%2Fjbc.REV119.008351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty sweet years of GLUT4</span></div><div class="casAuthors">Klip, Amira; McGraw, Timothy E.; James, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">11369-11382</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  A pivotal metabolic function of insulin is the stimulation of glucose uptake into muscle and adipose tissues.  The discovery of the insulin-responsive glucose transporter type 4 (GLUT4) protein in 1988 inspired its mol. cloning in the following year.  It also spurred numerous cellular mechanistic studies laying the foundations for how insulin regulates glucose uptake by muscle and fat cells.  Here, we reflect on the importance of the GLUT4 discovery and chronicle addnl. key findings made in the past 30 years.  That exocytosis of a multispanning membrane protein regulates cellular glucose transport illuminated a novel adaptation of the secretory pathway, which is to transiently modulate the protein compn. of the cellular plasma membrane.  GLUT4 controls glucose transport into fat and muscle tissues in response to insulin and also into muscle during exercise.  Thus, investigation of regulated GLUT4 trafficking provides a major means by which to map the essential signaling components that transmit the effects of insulin and exercise.  Manipulation of the expression of GLUT4 or GLUT4-regulating mols. in mice has revealed the impact of glucose uptake on whole-body metab.  Remaining gaps in our understanding of GLUT4 function and regulation are highlighted here, along with opportunities for future discoveries and for the development of therapeutic approaches to manage metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUEuNcY_josbVg90H21EOLACvtfcHk0lg9Iueu_6Sz2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVOgur%252FJ&md5=4d47e51735afa6837332b8aff4246aa7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1074%2Fjbc.REV119.008351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.REV119.008351%26sid%3Dliteratum%253Aachs%26aulast%3DKlip%26aufirst%3DA.%26aulast%3DMcGraw%26aufirst%3DT.%2BE.%26aulast%3DJames%26aufirst%3DD.%2BE.%26atitle%3D30%2520sweet%2520years%2520of%2520GLUT4%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2019%26volume%3D294%26issue%3D30%26spage%3D11369%26epage%3D11381%26doi%3D10.1074%2Fjbc.REV119.008351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mueckler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorens, B.</span></span> <span> </span><span class="NLM_article-title">The SLC2 (GLUT) family of membrane transporters</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">121</span>â <span class="NLM_lpage">138</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2juro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=121-138&issue=2%E2%80%933&author=M.+Muecklerauthor=B.+Thorens&title=The+SLC2+%28GLUT%29+family+of+membrane+transporters&doi=10.1016%2Fj.mam.2012.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC2 (GLUT) family of membrane transporters</span></div><div class="casAuthors">Mueckler, Mike; Thorens, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">121-138</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  GLUT proteins are encoded by the SLC2 genes and are members of the major facilitator superfamily of membrane transporters.  Fourteen GLUT proteins are expressed in the human and they are categorized into three classes based on sequence similarity.  All GLUTs appear to transport hexoses or polyols when expressed ectopically, but the primary physiol. substrates for several of the GLUTs remain uncertain.  GLUTs 1-5 are the most thoroughly studied and all have well established roles as glucose and/or fructose transporters in various tissues and cell types.  The GLUT proteins are comprised of â¼500 amino acid residues, possess a single N-linked oligosaccharide, and have 12 membrane-spanning domains.  In this review we briefly describe the major characteristics of the 14 GLUT family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl2JJBNd-e3LVg90H21EOLACvtfcHk0liViRfxNQXiYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2juro%253D&md5=67435eebb5f373cd6b5624b1e02ebcb7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DMueckler%26aufirst%3DM.%26aulast%3DThorens%26aufirst%3DB.%26atitle%3DThe%2520SLC2%2520%2528GLUT%2529%2520family%2520of%2520membrane%2520transporters%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D121%26epage%3D138%26doi%3D10.1016%2Fj.mam.2012.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirayama, B. A.</span></span> <span> </span><span class="NLM_article-title">Biology of human sodium glucose transporters</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">733</span>â <span class="NLM_lpage">794</span>, <span class="refDoi">Â DOI: 10.1152/physrev.00055.2009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fphysrev.00055.2009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21527736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2011&pages=733-794&issue=2&author=E.+M.+Wrightauthor=D.+D.+Looauthor=B.+A.+Hirayama&title=Biology+of+human+sodium+glucose+transporters&doi=10.1152%2Fphysrev.00055.2009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Biology of human sodium glucose transporters</span></div><div class="casAuthors">Wright, Ernest M.; Loo, Donald D. F.; Hirayama, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">733-794</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  There are two classes of glucose transporters involved in glucose homeostasis in the body, the facilitated transporters or uniporters (GLUTs) and the active transporters or symporters (SGLTs).  The energy for active glucose transport is provided by the sodium gradient across the cell membrane, the Na+ glucose cotransport hypothesis first proposed in 1960 by Crane.  Since the cloning of SGLT1 in 1987, there have been advances in the genetics, mol. biol., biochem., biophysics, and structure of SGLTs.  There are 12 members of the human SGLT (SLC5) gene family, including cotransporters for sugars, anions, vitamins, and short-chain fatty acids.  Here we give a personal review of these advances.  The SGLTs belong to a structural class of membrane proteins from unrelated gene families of antiporters and Na+ and H+ symporters.  This class shares a common at. architecture and a common transport mechanism.  SGLTs also function as water and urea channels, glucose sensors, and coupled-water and urea transporters.  We also discuss the physiol. and pathophysiol. of SGLTs, e.g., glucose galactose malabsorption and familial renal glycosuria, and briefly report on targeting of SGLTs for new therapies for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquMSW1jSySGbVg90H21EOLACvtfcHk0liViRfxNQXiYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1Cms7g%253D&md5=e3863e27fb78867488347b4289bc13e0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00055.2009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00055.2009%26sid%3Dliteratum%253Aachs%26aulast%3DWright%26aufirst%3DE.%2BM.%26aulast%3DLoo%26aufirst%3DD.%2BD.%26aulast%3DHirayama%26aufirst%3DB.%2BA.%26atitle%3DBiology%2520of%2520human%2520sodium%2520glucose%2520transporters%26jtitle%3DPhysiol.%2520Rev.%26date%3D2011%26volume%3D91%26issue%3D2%26spage%3D733%26epage%3D794%26doi%3D10.1152%2Fphysrev.00055.2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, B. C.</span></span> <span> </span><span class="NLM_article-title">The SLC37 family of sugar-phosphate/phosphate exchangers</span>. <i>Curr. Top. Membr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">357</span>â <span class="NLM_lpage">382</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-800223-0.00010-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FB978-0-12-800223-0.00010-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24745989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlymsLfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=357-382&author=J.+Y.+Chouauthor=B.+C.+Mansfield&title=The+SLC37+family+of+sugar-phosphate%2Fphosphate+exchangers&doi=10.1016%2FB978-0-12-800223-0.00010-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC37 family of sugar-phosphate/phosphate exchangers</span></div><div class="casAuthors">Chou, Janice Y.; Mansfield, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Membranes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">Exchangers</span>),
    <span class="NLM_cas:pages">357-382</span>CODEN:
                <span class="NLM_cas:coden">CTMEET</span>;
        ISSN:<span class="NLM_cas:issn">1063-5823</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The SLC37 family members are endoplasmic reticulum (ER)-assocd. sugar-phosphate/phosphate (Pi) exchangers.  Three of the four members, SLC37A1, SLC37A2, and SLC37A4, function as Pi-linked glucose-6-phosphate (G6P) antiporters catalyzing G6P:P, and Pi:Pi exchanges.  The activity of SLC37A3 is unknown.  SLC37A4, better known as the G6P transporter (G6PT), has been extensively characterized, functionally and structurally, and is the best characterized family member.  G6PT contains 10 transmembrane helixes with both N and C termini facing the cytoplasm.  The primary in vivo function of the G6PT protein is to translocate G6P from the cytoplasm into the ER lumen where it couples with either the liver/kidney/intestine-restricted glucose-6-phosphatase-Î± (G6Pase-Î± or G6PC) or the ubiquitously expressed G6Pase-Î² (or G6PC3) to hydrolyze G6P to glucose and Pi.  The G6PT/G6Pase-Î± complex maintains interprandial glucose homeostasis, and the G6PT/G6Pase-Î² complex maintains neutrophil energy homeostasis and functionality.  G6PT is highly selective for G6P and is competitively inhibited by cholorogenic acid and its derivs.  Neither SLC37A1 nor SLC37A2 can couple functionally with G6Pase-Î± or G6Pase-Î², and the antiporter activities of SLC37A1 or SLC37A2 are not inhibited by cholorogenic acid.  Deficiencies in G6PT cause glycogen storage disease type Ib (GSD-Ib), a metabolic and immune disorder.  To date, 91 sep. SLC37A4 mutations, including 39 missense mutations, have been identified in GSD-Ib patients.  Characterization of missense mutations has yielded valuable information on functionally important residues in the G6PT protein.  The biol. roles of the other SLC37 proteins remain to be detd. and deficiencies have not yet been correlated to diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprz6xKKGufkbVg90H21EOLACvtfcHk0liViRfxNQXiYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlymsLfM&md5=b488bb135a090e8d1ae0e8a5c5b1187e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800223-0.00010-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800223-0.00010-4%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DJ.%2BY.%26aulast%3DMansfield%26aufirst%3DB.%2BC.%26atitle%3DThe%2520SLC37%2520family%2520of%2520sugar-phosphate%252Fphosphate%2520exchangers%26jtitle%3DCurr.%2520Top.%2520Membr.%26date%3D2014%26volume%3D73%26spage%3D357%26epage%3D382%26doi%3D10.1016%2FB978-0-12-800223-0.00010-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gyimesi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span> <span> </span><span class="NLM_article-title">Amino acid transporters revisited: new views in health and disease</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>43</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">789</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2018.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tibs.2018.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30177408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2018&pages=752-789&issue=10&author=P.+Kandasamyauthor=G.+Gyimesiauthor=Y.+Kanaiauthor=M.+A.+Hediger&title=Amino+acid+transporters+revisited%3A+new+views+in+health+and+disease&doi=10.1016%2Fj.tibs.2018.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acid transporters revisited: New views in health and disease</span></div><div class="casAuthors">Kandasamy, Palanivel; Gyimesi, Gergely; Kanai, Yoshikatsu; Hediger, Matthias A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">752-789</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Amino acid transporters (AATs) are membrane-bound transport proteins that mediate transfer of amino acids into and out of cells or cellular organelles.  AATs have diverse functional roles ranging from neurotransmission to acid-base balance, intracellular energy metab., and anabolic and catabolic reactions.  In cancer cells and diabetes, dysregulation of AATs leads to metabolic reprogramming, which changes intracellular amino acid levels, contributing to the pathogenesis of cancer, obesity and diabetes.  Indeed, the neutral amino acid transporters (NATs) SLC7A5/LAT1 and SLC1A5/ASCT2 are likely involved in several human malignancies.  However, a clin. therapy that directly targets AATs has not yet been developed.  The purpose of this review is to highlight the structural and functional diversity of AATs, their diverse physiol. roles in different tissues and organs, their wide-ranging implications in human diseases and the emerging strategies and tools that will be necessary to target AATs therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5BHLRYRsmE7Vg90H21EOLACvtfcHk0li7d-xKwQiZbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsb7J&md5=ca03f1ef10cf9929ae6be316ecff547f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2018.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2018.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DKandasamy%26aufirst%3DP.%26aulast%3DGyimesi%26aufirst%3DG.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26atitle%3DAmino%2520acid%2520transporters%2520revisited%253A%2520new%2520views%2520in%2520health%2520and%2520disease%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2018%26volume%3D43%26issue%3D10%26spage%3D752%26epage%3D789%26doi%3D10.1016%2Fj.tibs.2018.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shigeri, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seal, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamoto, K.</span></span> <span> </span><span class="NLM_article-title">Molecular pharmacology of glutamate transporters, EAATs and VGLUTs</span>. <i>Brain Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">250</span>â <span class="NLM_lpage">265</span>, <span class="refDoi">Â DOI: 10.1016/j.brainresrev.2004.04.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.brainresrev.2004.04.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15210307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVCgsr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2004&pages=250-265&issue=3&author=Y.+Shigeriauthor=R.+P.+Sealauthor=K.+Shimamoto&title=Molecular+pharmacology+of+glutamate+transporters%2C+EAATs+and+VGLUTs&doi=10.1016%2Fj.brainresrev.2004.04.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular pharmacology of glutamate transporters, EAATs and VGLUTs</span></div><div class="casAuthors">Shigeri, Yasushi; Seal, Rebecca P.; Shimamoto, Keiko</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-265</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  L-Glutamate serves as a major excitatory neurotransmitter in the mammalian central nervous system (CNS) and is stored in synaptic vesicles by an uptake system that is dependent on the proton electrochem. gradient (VGLUTs).  Following its exocytotic release, glutamate activates fast-acting, excitatory ionotropic receptors and slower-acting metabotropic receptors to mediate neurotransmission.  Na+-dependent glutamate transporters (EAATs) located on the plasma membrane of neurons and glial cells rapidly terminate the action of glutamate and maintain its extracellular concn. below excitotoxic levels.  Thus far, 5 Na+-dependent glutamate transporters (EAATs 1-5) and 3 vesicular glutamate transporters (VGLUTs 1-3) have been identified.  Examn. of EAATs and VGLUTs in brain prepns. and by heterologous expression of the various cloned subtypes shows these 2 transporter families differ in many of their functional properties including substrate specificity and ion requirements.  Alterations in the function and/or expression of these carriers have been implicated in a range of psychiatric and neurol. disorders.  EAATs have been implicated in cerebral stroke, epilepsy, Alzheimer's disease, HIV-assocd. dementia, Huntington's disease, amyotrophic lateral sclerosis (ALS), and malignant glioma, while VGLUTs have been implicated in schizophrenia.  To examine the physiol. role of glutamate transporters in more detail, several classes of transportable and non-transportable inhibitors have been developed, many of which are derivs. of the natural amino acids, aspartate and glutamate.  This review summarizes the development of these indispensable pharmacol. tools, which have been crit. to our understanding of normal and abnormal synaptic transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN0PzoN_wZ07Vg90H21EOLACvtfcHk0li7d-xKwQiZbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVCgsr8%253D&md5=d1898c51836320739c1cc8acc4c99e7b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2004.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2004.04.004%26sid%3Dliteratum%253Aachs%26aulast%3DShigeri%26aufirst%3DY.%26aulast%3DSeal%26aufirst%3DR.%2BP.%26aulast%3DShimamoto%26aufirst%3DK.%26atitle%3DMolecular%2520pharmacology%2520of%2520glutamate%2520transporters%252C%2520EAATs%2520and%2520VGLUTs%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2004%26volume%3D45%26issue%3D3%26spage%3D250%26epage%3D265%26doi%3D10.1016%2Fj.brainresrev.2004.04.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fotiadis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacin, M.</span></span> <span> </span><span class="NLM_article-title">The SLC3 and SLC7 families of amino acid transporters</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">139</span>â <span class="NLM_lpage">158</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2js7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=139-158&issue=2%E2%80%933&author=D.+Fotiadisauthor=Y.+Kanaiauthor=M.+Palacin&title=The+SLC3+and+SLC7+families+of+amino+acid+transporters&doi=10.1016%2Fj.mam.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC3 and SLC7 families of amino acid transporters</span></div><div class="casAuthors">Fotiadis, Dimitrios; Kanai, Yoshikatsu; Palacin, Manuel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">139-158</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Amino acids are necessary for all living cells and organisms.  Specialized transporters mediate the transfer of amino acids across plasma membranes.  Malfunction of these proteins can affect whole-body homoeostasis giving raise to diverse human diseases.  Here, we review the main features of the SLC3 and SLC7 families of amino acid transporters.  The SLC7 family is divided into two subfamilies, the cationic amino acid transporters (CATs), and the L-type amino acid transporters (LATs).  The latter are the light or catalytic subunits of the heteromeric amino acid transporters (HATs), which are assocd. by a disulfide bridge with the heavy subunits 4F2hc or rBAT.  These two subunits are glycoproteins and form the SLC3 family.  Most CAT subfamily members were functionally characterized and shown to function as facilitated diffusers mediating the entry and efflux of cationic amino acids.  In certain cells, CATs play an important role in the delivery of L-arginine for the synthesis of nitric oxide.  HATs are mostly exchangers with a broad spectrum of substrates and are crucial in renal and intestinal re-absorption and cell redox balance.  Furthermore, the role of the HAT 4F2hc/LAT1 in tumor growth and the application of LAT1 inhibitors and PET tracers for redn. of tumor progression and imaging of tumors are discussed.  Finally, we describe the link between specific mutations in HATs and the primary inherited aminoacidurias, cystinuria and lysinuric protein intolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzCY992BVM0LVg90H21EOLACvtfcHk0li7d-xKwQiZbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2js7g%253D&md5=9a39bcc649b0b4bcf71cc83ad2d6c836</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DFotiadis%26aufirst%3DD.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DPalacin%26aufirst%3DM.%26atitle%3DThe%2520SLC3%2520and%2520SLC7%2520families%2520of%2520amino%2520acid%2520transporters%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D139%26epage%3D158%26doi%3D10.1016%2Fj.mam.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scalise, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluccio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Console, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pochini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Indiveri, C.</span></span> <span> </span><span class="NLM_article-title">The human SLC7A5 (LAT1): The intriguing histidine/large neutral amino acid transporter and its relevance to human health</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">243</span>, <span class="refDoi">Â DOI: 10.3389/fchem.2018.00243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffchem.2018.00243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29988369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFait7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=243&author=M.+Scaliseauthor=M.+Galluccioauthor=L.+Consoleauthor=L.+Pochiniauthor=C.+Indiveri&title=The+human+SLC7A5+%28LAT1%29%3A+The+intriguing+histidine%2Flarge+neutral+amino+acid+transporter+and+its+relevance+to+human+health&doi=10.3389%2Ffchem.2018.00243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The human SLC7A5 (LAT1): the intriguing histidine/large neutral amino acid transporter and its relevance to human health</span></div><div class="casAuthors">Scalise, Mariafrancesca; Galluccio, Michele; Console, Lara; Pochini, Lorena; Indiveri, Cesare</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243/1-243/12</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">SLC7A5, known as LAT1, belongs to the APC superfamily and forms a heterodimeric amino acid transporter interacting with the glycoprotein CD98 (SLC3A2) through a conserved disulfide.  The complex is responsible for uptake of essential amino acids in crucial body districts such as placenta and blood brain barrier.  LAT1/CD98 heterodimer has been studied over the years to unravel the transport mechanism and the role of each subunit.  Studies conducted in intact cells demonstrated that LAT1/CD98 mediates a Na+ and pH independent antiport of amino acids.  Some novel insights into the function of LAT1 derived from studies conducted in proteoliposomes reconstituted with the recombinant human LAT1.  Using this exptl. tool, it has been demonstrated that the preferred substrate is histidine and that CD98 is not required for transport being, plausibly, involved in routing LAT1 to the plasma membrane.  Since a 3D structure of LAT1 is not available, homol. models have been built on the basis of the AdiC transporter from E.coli.  Crucial residues for substrate recognition and gating have been identified using a combined approach of bioinformatics and site-directed mutagenesis coupled to functional assays.  Over the years, the interest around LAT1 increased because this transporter is involved in important human diseases such as neurol. disorders and cancer.  Therefore, LAT1 became an important pharmacol. target together with other nutrient membrane transporters.  Moving from knowledge on structure/function relationships, two cysteine residues, lying on the substrate binding site, have been exploited for designing thiol reacting covalent inhibitors.  Some lead compds. have been characterized whose efficacy has been tested in a cancer cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreoyv-71qXBbVg90H21EOLACvtfcHk0li7d-xKwQiZbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFait7%252FF&md5=fe939bf29b7965b1b2cbe1805e492be0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00243%26sid%3Dliteratum%253Aachs%26aulast%3DScalise%26aufirst%3DM.%26aulast%3DGalluccio%26aufirst%3DM.%26aulast%3DConsole%26aufirst%3DL.%26aulast%3DPochini%26aufirst%3DL.%26aulast%3DIndiveri%26aufirst%3DC.%26atitle%3DThe%2520human%2520SLC7A5%2520%2528LAT1%2529%253A%2520The%2520intriguing%2520histidine%252Flarge%2520neutral%2520amino%2520acid%2520transporter%2520and%2520its%2520relevance%2520to%2520human%2520health%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D243%26doi%3D10.3389%2Ffchem.2018.00243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natale, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. A.</span></span> <span> </span><span class="NLM_article-title">System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>165</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">20</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1111/j.1476-5381.2011.01480.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fj.1476-5381.2011.01480.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21564084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLjM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2012&pages=20-34&issue=1&author=R.+J.+Bridgesauthor=N.+R.+Nataleauthor=S.+A.+Patel&title=System+xc-+cystine%2Fglutamate+antiporter%3A+an+update+on+molecular+pharmacology+and+roles+within+the+CNS&doi=10.1111%2Fj.1476-5381.2011.01480.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS</span></div><div class="casAuthors">Bridges, Richard J.; Natale, Nicholas R.; Patel, Sarjubhai A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-34</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">System xc- is an amino acid antiporter that typically mediates the exchange of extracellular L-cystine and intracellular L-glutamate across the cellular plasma membrane.  Studied in a variety of cell types, the import of L-cystine through this transporter is crit. to glutathione prodn. and oxidative protection.  The exchange-mediated export of L-glutamate takes on added significance within the CNS, as it represents a non-vesicular route of release through which this excitatory neurotransmitter can participate in either neuronal signalling or excitotoxic pathol.  When both the import of L-cystine and the export of L-glutamate are taken into consideration, system xc- has now been linked to a wide range of CNS functions, including oxidative protection, the operation of the blood-brain barrier, neurotransmitter release, synaptic organization, viral pathol., drug addiction, chemosensitivity and chemoresistance, and brain tumor growth.  The ability to selectively manipulate system xc-, delineate its function, probe its structure and evaluate it as a therapeutic target is closely linked to understanding its pharmacol. and the subsequent development of selective inhibitors and substrates.  Towards that goal, this review will examine the current status of our understanding of system xc- pharmacol. and the structure-activity relationships that have guided the development of an initial pharmacophore model, including the presence of lipophilic domains adjacent to the substrate binding site.  A special emphasis is placed on the roles of system xc- within the CNS, as it is these actions that are among the most exciting as potential long-range therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkHeqBt_KsJLVg90H21EOLACvtfcHk0lhrvMIOJXgqzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1yksLjM&md5=ed3ade4d1aee288820b85fb2fdf7c573</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01480.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01480.x%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DR.%2BJ.%26aulast%3DNatale%26aufirst%3DN.%2BR.%26aulast%3DPatel%26aufirst%3DS.%2BA.%26atitle%3DSystem%2520xc-%2520cystine%252Fglutamate%2520antiporter%253A%2520an%2520update%2520on%2520molecular%2520pharmacology%2520and%2520roles%2520within%2520the%2520CNS%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D165%26issue%3D1%26spage%3D20%26epage%3D34%26doi%3D10.1111%2Fj.1476-5381.2011.01480.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friesema, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Docter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moerings, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verrey, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenning, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennemann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visser, T. J.</span></span> <span> </span><span class="NLM_article-title">Thyroid hormone transport by the heterodimeric human system L amino acid transporter</span>. <i>Endocrinology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>142</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4339</span>â <span class="NLM_lpage">4438</span>, <span class="refDoi">Â DOI: 10.1210/endo.142.10.8418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1210%2Fendo.142.10.8418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11564694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnt1ertL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2001&pages=4339-4438&issue=10&author=E.+C.+Friesemaauthor=R.+Docterauthor=E.+P.+Moeringsauthor=F.+Verreyauthor=E.+P.+Krenningauthor=G.+Hennemannauthor=T.+J.+Visser&title=Thyroid+hormone+transport+by+the+heterodimeric+human+system+L+amino+acid+transporter&doi=10.1210%2Fendo.142.10.8418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Thyroid hormone transport by the heterodimeric human system L-amino acid transporter</span></div><div class="casAuthors">Friesema, Edith C. H.; Docter, Roel; Moerings, Ellis P. C. M.; Verrey, Francois; Krenning, Eric P.; Hennemann, Georg; Visser, Theo J.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrinology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4339-4348</span>CODEN:
                <span class="NLM_cas:coden">ENDOAO</span>;
        ISSN:<span class="NLM_cas:issn">0013-7227</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Transport of thyroid hormone across the cell membrane is required for thyroid hormone action and metab.  The authors have investigated the possible transport of iodothyronines by the human system L-amino acid transporter, a protein consisting of the human 4F2 heavy chain and the human LAT1 light chain.  Xenopus oocytes were injected with the cRNAs coding for human 4F2 heavy chain and/or human LAT1 light chain, and after 2 d were incubated at 25Â° with 0.01-10 Î¼M [125I]T4, [125I]T3, [125I]rT3, or [125I]3,3'-diiodothyronine or with 10-100 Î¼M [3H]arginine, [3H]leucine, [3H]phenylalanine, [3H]tyrosine, or [3H]tryptophan.  Injection of human 4F2 heavy chain cRNA alone stimulated the uptake of leucine and arginine due to dimerization of human 4F2 heavy chain with an endogenous Xenopus light chain, but did not affect the uptake of other ligands.  Injection of human LAT1 light chain cRNA alone did not stimulate the uptake of any ligand.  Coinjection of cRNAs for human 4F2 heavy chain and human LAT1 light chain stimulated the uptake of phenylalanine > tyrosine > leucine > tryptophan (100 Î¼M) and of 3,3'-diiodothyronine > rT3 â¼ T3 > T4 (10 nM), which in all cases was Na+ independent.  Satn. anal. provided apparent Michaelis const. (Km) values of 7.9 Î¼M for T4, 0.8 Î¼M for T3, 12.5 Î¼M for rT3, 7.9 Î¼M for 3,3'-diiodothyronine, 46 Î¼M for leucine, and 19 Î¼M for tryptophan.  Uptake of leucine, tyrosine, and tryptophan (10 Î¼M) was inhibited by the different iodothyronines (10 Î¼M), in particular T3.  Vice versa, uptake of 0.1 Î¼M T3 was almost completely blocked by coincubation with 100 Î¼M leucine, tryptophan, tyrosine, or phenylalanine.  The authors' results demonstrate stereospecific Na+-independent transport of iodothyronines by the human heterodimeric system L-amino acid transporter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhpkVGbyImrVg90H21EOLACvtfcHk0lhrvMIOJXgqzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnt1ertL4%253D&md5=c1073ef8ec3599165c7a34da7fefc690</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1210%2Fendo.142.10.8418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fendo.142.10.8418%26sid%3Dliteratum%253Aachs%26aulast%3DFriesema%26aufirst%3DE.%2BC.%26aulast%3DDocter%26aufirst%3DR.%26aulast%3DMoerings%26aufirst%3DE.%2BP.%26aulast%3DVerrey%26aufirst%3DF.%26aulast%3DKrenning%26aufirst%3DE.%2BP.%26aulast%3DHennemann%26aufirst%3DG.%26aulast%3DVisser%26aufirst%3DT.%2BJ.%26atitle%3DThyroid%2520hormone%2520transport%2520by%2520the%2520heterodimeric%2520human%2520system%2520L%2520amino%2520acid%2520transporter%26jtitle%3DEndocrinology%26date%3D2001%26volume%3D142%26issue%3D10%26spage%3D4339%26epage%3D4438%26doi%3D10.1210%2Fendo.142.10.8418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhutia, Y. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Amino acid transporters in cancer and their relevance to â³glutamine addictionâ³: novel targets for the design of a new class of anticancer drugs</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1782</span>â <span class="NLM_lpage">1788</span>, <span class="refDoi">Â DOI: 10.1158/0008-5472.CAN-14-3745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1158%2F0008-5472.CAN-14-3745" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25855379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsFemu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=1782-1788&issue=9&author=Y.+D.+Bhutiaauthor=E.+Babuauthor=S.+Ramachandranauthor=V.+Ganapathy&title=Amino+acid+transporters+in+cancer+and+their+relevance+to+%E2%80%B3glutamine+addiction%E2%80%B3%3A+novel+targets+for+the+design+of+a+new+class+of+anticancer+drugs&doi=10.1158%2F0008-5472.CAN-14-3745"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Amino Acid Transporters in Cancer and Their Relevance to "Glutamine Addiction": Novel Targets for the Design of a New Class of Anticancer Drugs</span></div><div class="casAuthors">Bhutia, Yangzom D.; Babu, Ellappan; Ramachandran, Sabarish; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1782-1788</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tumor cells have an increased demand for amino acids because of their rapid proliferation rate.  In addn. to their need in protein synthesis, several amino acids have other roles in supporting cancer growth.  There are approx. two-dozen amino acid transporters in humans, and tumor cells must upregulate one or more of these transporters to satisfy their demand for amino acids.  If the transporters that specifically serve this purpose in tumor cells are identified, they can be targeted for the development of a brand new class of anticancer drugs; the logical basis of such a strategy would be to starve the tumor cells of an important class of nutrients.  To date, four amino acid transporters have been found to be expressed at high levels in cancer: SLC1A5, SLC7A5, SLC7A11, and SLC6A14.  Their induction occurs in a cancer type-specific manner with a direct or indirect involvement of the oncogene c-Myc.  Further, these transporters are functionally coupled, thus maximizing their ability to promote cancer growth and chemoresistance.  Progress has been made in preclin. studies, exploiting these transporters as drug targets in cancer therapy.  These transporters also show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents.  Cancer Res; 75(9); 1782-8. Â©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHCUEzyXW3qLVg90H21EOLACvtfcHk0lhrvMIOJXgqzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsFemu7Y%253D&md5=f15ce2573ab5ae5fb4ed7a048da69f38</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-3745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-3745%26sid%3Dliteratum%253Aachs%26aulast%3DBhutia%26aufirst%3DY.%2BD.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DAmino%2520acid%2520transporters%2520in%2520cancer%2520and%2520their%2520relevance%2520to%2520%25E2%2580%25B3glutamine%2520addiction%25E2%2580%25B3%253A%2520novel%2520targets%2520for%2520the%2520design%2520of%2520a%2520new%2520class%2520of%2520anticancer%2520drugs%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26issue%3D9%26spage%3D1782%26epage%3D1788%26doi%3D10.1158%2F0008-5472.CAN-14-3745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span> <span> </span><span class="NLM_article-title">Amino acid transporters as disease modifiers and drug targets</span>. <i>Slas Discov</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">303</span>â <span class="NLM_lpage">320</span>, <span class="refDoi">Â DOI: 10.1177/2472555218755629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1177%2F2472555218755629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29557284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1yisbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=303-320&issue=4&author=S.+Broer&title=Amino+acid+transporters+as+disease+modifiers+and+drug+targets&doi=10.1177%2F2472555218755629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Amino Acid Transporters as Disease Modifiers and Drug Targets</span></div><div class="casAuthors">Broer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">SLAS Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">303-320</span>CODEN:
                <span class="NLM_cas:coden">SDLIBT</span>;
        ISSN:<span class="NLM_cas:issn">2472-5560</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Amino acids perform a variety of functions in cells and organisms, particularly in the synthesis of proteins, as energy metabolites, neurotransmitters, and precursors for many other mols.  Amino acid transport plays a key role in all these functions.  Inhibition of amino acid transport is pursued as a therapeutic strategy in several areas, such as diabetes and related metabolic disorders, neurol. disorders, cancer, and stem cell biol.  The role of amino acid transporters in these disorders and processes is well established, but the implementation of amino acid transporters as drug targets is still in its infancy.  This is at least in part due to the underdeveloped pharmacol. of this group of membrane proteins.  Recent advances in structural biol., membrane protein expression, and inhibitor screening methodol. will see an increased no. of improved and selective inhibitors of amino acid transporters that can serve as tool compds. for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX0fAODZizB7Vg90H21EOLACvtfcHk0lhiAdpZkq9ynA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1yisbc%253D&md5=e6ccf34920a48643a07ad307a9f6b6f0</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1177%2F2472555218755629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555218755629%26sid%3Dliteratum%253Aachs%26aulast%3DBroer%26aufirst%3DS.%26atitle%3DAmino%2520acid%2520transporters%2520as%2520disease%2520modifiers%2520and%2520drug%2520targets%26jtitle%3DSlas%2520Discov%26date%3D2018%26volume%3D23%26issue%3D4%26spage%3D303%26epage%3D320%26doi%3D10.1177%2F2472555218755629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kristensen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromgaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gether, U.</span></span> <span> </span><span class="NLM_article-title">SLC6 neurotransmitter transporters: structure, function, and regulation</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">585</span>â <span class="NLM_lpage">640</span>, <span class="refDoi">Â DOI: 10.1124/pr.108.000869</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fpr.108.000869" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21752877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtb3O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=585-640&issue=3&author=A.+S.+Kristensenauthor=J.+Andersenauthor=T.+N.+Jorgensenauthor=L.+Sorensenauthor=J.+Eriksenauthor=C.+J.+Lolandauthor=K.+Stromgaardauthor=U.+Gether&title=SLC6+neurotransmitter+transporters%3A+structure%2C+function%2C+and+regulation&doi=10.1124%2Fpr.108.000869"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6 neurotransmitter transporters: structure, function, and regulation</span></div><div class="casAuthors">Kristensen, Anders S.; Andersen, Jacob; Joergensen, Trine N.; Soerensen, Lena; Eriksen, Jacob; Loland, Claus J.; Stroemgaard, Kristian; Gether, Ulrik</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">585-640</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The neurotransmitter transporters (NTTs) belonging to the solute carrier 6 (SLC6) gene family (also referred to as the neurotransmitter-sodium-symporter family or Na+/Cl--dependent transporters) comprise a group of nine sodium- and chloride-dependent plasma membrane transporters for the monoamine neurotransmitters serotonin (5-hydroxytryptamine), dopamine, and norepinephrine, and the amino acid neurotransmitters GABA and glycine.  The SLC6 NTTs are widely expressed in the mammalian brain and play an essential role in regulating neurotransmitter signaling and homeostasis by mediating uptake of released neurotransmitters from the extracellular space into neurons and glial cells.  The transporters are targets for a wide range of therapeutic drugs used in treatment of psychiatric diseases, including major depression, anxiety disorders, attention deficit hyperactivity disorder and epilepsy.  Furthermore, psychostimulants such as cocaine and amphetamines have the SLC6 NTTs as primary targets.  Beginning with the detn. of a high-resoln. structure of a prokaryotic homolog of the mammalian SLC6 transporters in 2005, the understanding of the mol. structure, function, and pharmacol. of these proteins has advanced rapidly.  Furthermore, intensive efforts have been directed toward understanding the mol. and cellular mechanisms involved in regulation of the activity of this important class of transporters, leading to new methodol. developments and important insights.  This review provides an update of these advances and their implications for the current understanding of the SLC6 NTTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa7rqrgWDrurVg90H21EOLACvtfcHk0lhiAdpZkq9ynA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtb3O&md5=354a72260448d8ec68cb8b5e0e3c45d4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fpr.108.000869&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.108.000869%26sid%3Dliteratum%253Aachs%26aulast%3DKristensen%26aufirst%3DA.%2BS.%26aulast%3DAndersen%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DT.%2BN.%26aulast%3DSorensen%26aufirst%3DL.%26aulast%3DEriksen%26aufirst%3DJ.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DStromgaard%26aufirst%3DK.%26aulast%3DGether%26aufirst%3DU.%26atitle%3DSLC6%2520neurotransmitter%2520transporters%253A%2520structure%252C%2520function%252C%2520and%2520regulation%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26issue%3D3%26spage%3D585%26epage%3D640%26doi%3D10.1124%2Fpr.108.000869" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pramod, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, L. K.</span></span> <span> </span><span class="NLM_article-title">SLC6 transporters: structure, function, regulation, disease association and therapeutics</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">197</span>â <span class="NLM_lpage">219</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=197-219&issue=2%E2%80%933&author=A.+B.+Pramodauthor=J.+Fosterauthor=L.+Carvelliauthor=L.+K.+Henry&title=SLC6+transporters%3A+structure%2C+function%2C+regulation%2C+disease+association+and+therapeutics&doi=10.1016%2Fj.mam.2012.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6 transporters: Structure, function, regulation, disease association and therapeutics</span></div><div class="casAuthors">Pramod, Akula Bala; Foster, James; Carvelli, Lucia; Henry, L. Keith</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">197-219</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The SLC6 family of secondary active transporters are integral membrane solute carrier proteins characterized by the Na+-dependent translocation of small amino acid or amino acid-like substrates.  SLC6 transporters, which include the serotonin, dopamine, norepinephrine, GABA, taurine, creatine, as well as amino acid transporters, are assocd. with a no. of human diseases and disorders making this family a crit. target for therapeutic development.  In addn., several members of this family are directly involved in the action of drugs of abuse such as cocaine, amphetamines, and ecstasy.  Recent advances providing structural insight into this family have vastly accelerated our ability to study these proteins and their involvement in complex biol. processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAzktUjNxilrVg90H21EOLACvtfcHk0lhiAdpZkq9ynA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jurg%253D&md5=4a6f7cbd7781c11178de3d6b8e2516be</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DPramod%26aufirst%3DA.%2BB.%26aulast%3DFoster%26aufirst%3DJ.%26aulast%3DCarvelli%26aufirst%3DL.%26aulast%3DHenry%26aufirst%3DL.%2BK.%26atitle%3DSLC6%2520transporters%253A%2520structure%252C%2520function%252C%2520regulation%252C%2520disease%2520association%2520and%2520therapeutics%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D197%26epage%3D219%26doi%3D10.1016%2Fj.mam.2012.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quick, M. W.</span></span> <span> </span><span class="NLM_article-title">Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6</span>. <i>Pfluegers Arch.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">519</span>â <span class="NLM_lpage">531</span>, <span class="refDoi">Â DOI: 10.1007/s00424-003-1064-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00424-003-1064-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12719981" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVygs7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2004&pages=519-531&issue=5&author=N.+H.+Chenauthor=M.+E.+Reithauthor=M.+W.+Quick&title=Synaptic+uptake+and+beyond%3A+the+sodium-+and+chloride-dependent+neurotransmitter+transporter+family+SLC6&doi=10.1007%2Fs00424-003-1064-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6</span></div><div class="casAuthors">Chen, Nian-Hang; Reith, Maarten E. A.; Quick, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Pfluegers Archiv</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-531</span>CODEN:
                <span class="NLM_cas:coden">PFLABK</span>;
        ISSN:<span class="NLM_cas:issn">0031-6768</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  The SLC6 family is a diverse set of transporters that mediate solute translocation across cell plasma membranes by coupling solute transport to the cotransport of sodium and chloride down their electrochem. gradients.  These transporters probably have 12 transmembrane domains, with cytoplasmic N- and C-terminal tails, and at least some may function as homo-oligomers.  Family members include the transporters for the inhibitory neurotransmitters GABA and glycine, the aminergic transmitters norepinephrine, serotonin, and dopamine, the osmolytes betaine and taurine, the amino acid proline, and the metabolic compd. creatine.  In addn., this family includes a system B0+ cationic and neutral amino acid transporter, and two transporters for which the solutes are unknown.  In general, SLC6 transporters act to regulate the level of extracellular solute concns.  In the central and the peripheral nervous system, these transporters can regulate signaling among neurons, are the sites of action of various drugs of abuse, and naturally occurring mutations in several of these proteins are assocd. with a variety of neurol. disorders.  For example, transgenic animals lacking specific aminergic transporters show profoundly disturbed behavioral phenotypes and probably represent excellent systems for investigating psychiatric disease.  SLC6 transporters are also found in many non-neural tissues, including kidney, intestine, and testis, consistent with their diverse physiol. roles.  Transporters in this family represent attractive therapeutic targets because they are subject to multiple forms of regulation by many different signaling cascades, and because a no. of pharmacol. agents have been identified that act specifically on these proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqN0HkC6ZQG77Vg90H21EOLACvtfcHk0lhiAdpZkq9ynA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVygs7o%253D&md5=a1f3ae53461103ce9f2d7435c014022a</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs00424-003-1064-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00424-003-1064-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%2BH.%26aulast%3DReith%26aufirst%3DM.%2BE.%26aulast%3DQuick%26aufirst%3DM.%2BW.%26atitle%3DSynaptic%2520uptake%2520and%2520beyond%253A%2520the%2520sodium-%2520and%2520chloride-dependent%2520neurotransmitter%2520transporter%2520family%2520SLC6%26jtitle%3DPfluegers%2520Arch.%26date%3D2004%26volume%3D447%26issue%3D5%26spage%3D519%26epage%3D531%26doi%3D10.1007%2Fs00424-003-1064-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scimemi, A.</span></span> <span> </span><span class="NLM_article-title">Structure, function, and plasticity of GABA transporters</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">161</span>, <span class="refDoi">Â DOI: 10.3389/fncel.2014.00161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffncel.2014.00161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24987330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGnurvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2014&pages=161&author=A.+Scimemi&title=Structure%2C+function%2C+and+plasticity+of+GABA+transporters&doi=10.3389%2Ffncel.2014.00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure, function, and plasticity of GABA transporters</span></div><div class="casAuthors">Scimemi, Annalisa</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">161/1-161/14</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  GABA transporters belong to a large family of neurotransmitter:sodium symporters.  They are widely expressed throughout the brain, with different levels of expression in different brain regions.  GABA transporters are present in neurons and in astrocytes and their activity is crucial to regulate the extracellular concn. of GABA under basal conditions and during ongoing synaptic events.  Numerous efforts have been devoted to det. the structural and functional properties of GABA transporters.  There is also evidence that the expression of GABA transporters on the cell membrane and their lateral mobility can be modulated by different intracellular signaling cascades.  The strength of individual synaptic contacts and the activity of entire neuronal networks may be finely tuned by altering the d., distribution and diffusion rate of GABA transporters within the cell membrane.  These findings are intriguing because they suggest the existence of complex regulatory systems that control the plasticity of GABAergic transmission in the brain.  Here we review the current knowledge on the structural and functional properties of GABA transporters and highlight the mol. mechanisms that alter the expression and mobility of GABA transporters at central synapses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcN1Rw0fET2LVg90H21EOLACvtfcHk0lhenKtLXs3vaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGnurvP&md5=e142869ea8efd357282a6fd212febedf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2014.00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2014.00161%26sid%3Dliteratum%253Aachs%26aulast%3DScimemi%26aufirst%3DA.%26atitle%3DStructure%252C%2520function%252C%2520and%2520plasticity%2520of%2520GABA%2520transporters%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2014%26volume%3D8%26spage%3D161%26doi%3D10.3389%2Ffncel.2014.00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Indiveri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobazzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonazzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giangregorio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infantino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Convertini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Console, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span> <span> </span><span class="NLM_article-title">The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">4â6</span>),  <span class="NLM_fpage">223</span>â <span class="NLM_lpage">233</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22020112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2rsL%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=223-233&issue=4%E2%80%936&author=C.+Indiveriauthor=V.+Iacobazziauthor=A.+Tonazziauthor=N.+Giangregorioauthor=V.+Infantinoauthor=P.+Convertiniauthor=L.+Consoleauthor=F.+Palmieri&title=The+mitochondrial+carnitine%2Facylcarnitine+carrier%3A+function%2C+structure+and+physiopathology&doi=10.1016%2Fj.mam.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology</span></div><div class="casAuthors">Indiveri, Cesare; Iacobazzi, Vito; Tonazzi, Annamaria; Giangregorio, Nicola; Infantino, Vittoria; Convertini, Paolo; Console, Lara; Palmieri, Ferdinando</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4-6</span>),
    <span class="NLM_cas:pages">223-233</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The carnitine/acylcarnitine carrier (CAC) is a transport protein of the inner mitochondrial membrane that belongs to the mitochondrial carrier protein family.  In its cytosolic conformation the carrier consists of a bundle of six transmembrane Î±-helixes, which delimit a water filled cavity opened towards the cytosol and closed towards the matrix by a network of interacting charged residues.  Most of the functional data on this transporter come from studies performed with the protein purified from rat liver mitochondria or recombinant proteins from different sources incorporated into phospholipid vesicles (liposomes).  The carnitine/acylcarnitine carrier transports carnitine and acylcarnitines with acyl chains of various lengths from 2 to 18 carbon atoms.  The mammalian transporter exhibits higher affinity for acylcarnitines with longer carbon chains.  The functional data indicate that CAC plays the important function of catalyzing transport of acylcarnitines into the mitochondria in exchange for intramitochondrial free carnitine.  This results in net transport of fatty acyl units into the mitochondrial matrix where they are oxidized by the Î²-oxidn. enzymes.  The essential role of the transporter in cell metab. is demonstrated by the fact that alterations of the human gene SLC25A20 coding for CAC are assocd. with a severe disease known as carnitine carrier deficiency.  This autosomal recessive disorder is characterized by life-threatening episodes of coma induced by fasting, cardiomyopathy, liver dysfunction, muscle weakness, respiratory distress and seizures.  Until now 35 different mutations of CAC gene have been identified in carnitine carrier deficient patients.  Some missense mutations concern residues of the signature motif present in all mitochondrial carriers.  Diagnosis of carnitine carrier deficiency requires biochem. and genetic tests; treatment is essentially limited to important dietetic measures.  Recently, a pharmacol. approach based on the use of statins and/or fibrates for the treatment of CAC-deficient patients with mild phenotype has been proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoy5f8AJp477Vg90H21EOLACvtfcHk0lhenKtLXs3vaw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2rsL%252FO&md5=431e35a560cf1ddf81647de62b92f4bf</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DIndiveri%26aufirst%3DC.%26aulast%3DIacobazzi%26aufirst%3DV.%26aulast%3DTonazzi%26aufirst%3DA.%26aulast%3DGiangregorio%26aufirst%3DN.%26aulast%3DInfantino%26aufirst%3DV.%26aulast%3DConvertini%26aufirst%3DP.%26aulast%3DConsole%26aufirst%3DL.%26aulast%3DPalmieri%26aufirst%3DF.%26atitle%3DThe%2520mitochondrial%2520carnitine%252Facylcarnitine%2520carrier%253A%2520function%252C%2520structure%2520and%2520physiopathology%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2011%26volume%3D32%26issue%3D4%25E2%2580%25936%26spage%3D223%26epage%3D233%26doi%3D10.1016%2Fj.mam.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepien, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torroni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, D. C.</span></span> <span> </span><span class="NLM_article-title">Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>267</i></span> (<span class="NLM_issue">21</span>),  <span class="NLM_fpage">14592</span>â <span class="NLM_lpage">14597</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1378836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK38Xlt1ymuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1992&pages=14592-14597&issue=21&author=G.+Stepienauthor=A.+Torroniauthor=A.+B.+Chungauthor=J.+A.+Hodgeauthor=D.+C.+Wallace&title=Differential+expression+of+adenine+nucleotide+translocator+isoforms+in+mammalian+tissues+and+during+muscle+cell+differentiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation</span></div><div class="casAuthors">Stepien, Georges; Torroni, Antonio; Chung, Andrew B.; Hodge, Judy A.; Wallace, Douglas C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">14592-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The adenine nucleotide translocator (ANT) catalyzes the exchange of ADP and ATP across the mitochondrial internal membrane.  Its 3 isoforms, ANT1, ANT2, and ANT3 are coded by differentially regulated nuclear genes.  The patterns of expression of these genes in human, bovine, and mouse tissue are similar.  ANT1 is highly expressed in heart and skeletal muscle and is induced during myoblast differentiation.  It is coordinately regulated with the nuclear gene for the mitochondrial ATP synthase Î² subunit, with which it shares the pos. muscle cis element, OXBOX.  ANT2 is either absent or weakly expressed in all tissues.  ANT3 is ubiquitously expressed in all tissues, and its transcript level is proportional to the level of oxidative metab.  The tissue-specific expression of the ANT gene family thus provides insight into the mol. basis of the differential reliance of mammalian tissues on oxidative phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhX6W_NrJ6KLVg90H21EOLACvtfcHk0ljeCYJRFii9sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xlt1ymuro%253D&md5=ab29cfead648041d2772bb26e673e5d5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStepien%26aufirst%3DG.%26aulast%3DTorroni%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DA.%2BB.%26aulast%3DHodge%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DD.%2BC.%26atitle%3DDifferential%2520expression%2520of%2520adenine%2520nucleotide%2520translocator%2520isoforms%2520in%2520mammalian%2520tissues%2520and%2520during%2520muscle%2520cell%2520differentiation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1992%26volume%3D267%26issue%3D21%26spage%3D14592%26epage%3D14597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedorenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lishko, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirichok, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>151</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">400</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2012.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2012.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23063128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2qtL7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2012&pages=400-413&issue=2&author=A.+Fedorenkoauthor=P.+V.+Lishkoauthor=Y.+Kirichok&title=Mechanism+of+fatty-acid-dependent+UCP1+uncoupling+in+brown+fat+mitochondria&doi=10.1016%2Fj.cell.2012.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of Fatty-Acid-Dependent UCP1 Uncoupling in Brown Fat Mitochondria</span></div><div class="casAuthors">Fedorenko, Andriy; Lishko, Polina V.; Kirichok, Yuriy</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">400-413</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mitochondrial uncoupling protein 1 (UCP1) is responsible for nonshivering thermogenesis in brown adipose tissue (BAT).  Upon activation by long-chain fatty acids (LCFAs), UCP1 increases the conductance of the inner mitochondrial membrane (IMM) to make BAT mitochondria generate heat rather than ATP.  Despite being a member of the family of mitochondrial anion carriers (SLC25), UCP1 is believed to transport H+ by an unusual mechanism that has long remained unresolved.  Here, we achieved direct patch-clamp measurements of UCP1 currents from the IMM of BAT mitochondria.  We show that UCP1 is an LCFA anion/H+ symporter.  However, the LCFA anions cannot dissoc. from UCP1 due to hydrophobic interactions established by their hydrophobic tails, and UCP1 effectively operates as an H+ carrier activated by LCFA.  A similar LCFA-dependent mechanism of transmembrane H+ transport may be employed by other SLC25 members and be responsible for mitochondrial uncoupling and regulation of metabolic efficiency in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrid7PUVLnEC7Vg90H21EOLACvtfcHk0ljeCYJRFii9sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2qtL7P&md5=0f2dbf775c28a5981e45da22104eca87</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DFedorenko%26aufirst%3DA.%26aulast%3DLishko%26aufirst%3DP.%2BV.%26aulast%3DKirichok%26aufirst%3DY.%26atitle%3DMechanism%2520of%2520fatty-acid-dependent%2520UCP1%2520uncoupling%2520in%2520brown%2520fat%2520mitochondria%26jtitle%3DCell%26date%3D2012%26volume%3D151%26issue%3D2%26spage%3D400%26epage%3D413%26doi%3D10.1016%2Fj.cell.2012.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonne, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler-Keylin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinoda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luijten, I. H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kajimura, S.</span></span> <span> </span><span class="NLM_article-title">ThermoMouse: an in vivo model to identify modulators of UCP1 expression in brown adipose tissue</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1584</span>â <span class="NLM_lpage">1593</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2014.10.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.celrep.2014.10.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25466254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2gs7%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1584-1593&issue=5&author=A.+Galmozziauthor=S.+B.+Sonneauthor=S.+Altshuler-Keylinauthor=Y.+Hasegawaauthor=K.+Shinodaauthor=I.+H.+N.+Luijtenauthor=J.+W.+Changauthor=L.+Z.+Sharpauthor=B.+F.+Cravattauthor=E.+Saezauthor=S.+Kajimura&title=ThermoMouse%3A+an+in+vivo+model+to+identify+modulators+of+UCP1+expression+in+brown+adipose+tissue&doi=10.1016%2Fj.celrep.2014.10.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">ThermoMouse: An In Vivo Model to Identify Modulators of UCP1 Expression in Brown Adipose Tissue</span></div><div class="casAuthors">Galmozzi, Andrea; Sonne, Si B.; Altshuler-Keylin, Svetlana; Hasegawa, Yutaka; Shinoda, Kosaku; Luijten, Ineke H. N.; Chang, Jae Won; Sharp, Louis Z.; Cravatt, Benjamin F.; Saez, Enrique; Kajimura, Shingo</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1584-1593</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Obesity develops when energy intake chronically exceeds energy expenditure.  Because brown adipose tissue (BAT) dissipates energy in the form of heat, increasing energy expenditure by augmenting BAT-mediated thermogenesis may represent an approach to counter obesity and its complications.  The ability of BAT to dissipate energy is dependent on expression of mitochondrial uncoupling protein 1 (UCP1).  To facilitate the identification of pharmacol. modulators of BAT UCP1 levels, which may have potential as antiobesity medications, we developed a transgenic model in which luciferase activity faithfully mimics endogenous UCP1 expression and its response to physiol. stimuli.  Phenotypic screening of a library using cells derived from this model yielded a small mol. that increases UCP1 expression in brown fat cells and mice.  Upon adrenergic stimulation, compd.-treated mice showed increased energy expenditure.  These tools offer an opportunity to identify pharmacol. modulators of UCP1 expression and uncover regulatory pathways that impact BAT-mediated thermogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFEGenyPvq5rVg90H21EOLACvtfcHk0ljeCYJRFii9sQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2gs7%252FE&md5=4fb09e6c83ab5a2da2e30d27f6e8e7ee</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2014.10.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2014.10.066%26sid%3Dliteratum%253Aachs%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DSonne%26aufirst%3DS.%2BB.%26aulast%3DAltshuler-Keylin%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DShinoda%26aufirst%3DK.%26aulast%3DLuijten%26aufirst%3DI.%2BH.%2BN.%26aulast%3DChang%26aufirst%3DJ.%2BW.%26aulast%3DSharp%26aufirst%3DL.%2BZ.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DKajimura%26aufirst%3DS.%26atitle%3DThermoMouse%253A%2520an%2520in%2520vivo%2520model%2520to%2520identify%2520modulators%2520of%2520UCP1%2520expression%2520in%2520brown%2520adipose%2520tissue%26jtitle%3DCell%2520Rep.%26date%3D2014%26volume%3D9%26issue%3D5%26spage%3D1584%26epage%3D1593%26doi%3D10.1016%2Fj.celrep.2014.10.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madejczyk, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballatori, N.</span></span> <span> </span><span class="NLM_article-title">The iron transporter ferroportin can also function as a manganese exporter</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1818</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">651</span>â <span class="NLM_lpage">657</span>, <span class="refDoi">Â DOI: 10.1016/j.bbamem.2011.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bbamem.2011.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFartbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1818&publication_year=2012&pages=651-657&issue=3&author=M.+S.+Madejczykauthor=N.+Ballatori&title=The+iron+transporter+ferroportin+can+also+function+as+a+manganese+exporter&doi=10.1016%2Fj.bbamem.2011.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The iron transporter ferroportin can also function as a manganese exporter</span></div><div class="casAuthors">Madejczyk, Michael S.; Ballatori, Nazzareno</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1818</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">651-657</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study examd. the hypothesis that the iron exporter ferroportin (FPN1/SLC40A1) can also mediate cellular export of the essential trace element manganese, using Xenopus laevis oocytes expressing human FPN1.  When compared to oocytes expressing only the divalent metal transporter-1 (DMT1/NRAMP2), 54Mn accumulation was lower in oocytes also expressing FPN1.  FPN1-expressing oocytes exported more 54Mn than control oocytes (26.6 Â± 0.6% vs. 7.1 Â± 0.5%, resp., over 4 h at pH 7.4 when preloaded with approx. 16 Î¼M 54Mn); however, there was no difference in 54Mn uptake between control and FPN1-expressing oocytes.  FPN1-mediated Mn export was concn. dependent and could be partially cis-inhibited by 100 Î¼M Fe, Co, and Ni, but not by Rb.  In addn., Mn export ability was significantly reduced when the extracellular pH was reduced from 7.4 to 5.5, and when Na+ was substituted with K+ in the incubation media.  These results indicate that Mn is a substrate for FPN1, and that this export process is inhibited by a low extracellular pH and by incubation in a high K+ medium, indicating the involvement of transmembrane ion gradients in FPN1-mediated transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI1RobrQmbJ7Vg90H21EOLACvtfcHk0ljYl18seAzv5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFartbk%253D&md5=b6eca99ba543e2de81fc68e6df23c7c0</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2011.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2011.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DMadejczyk%26aufirst%3DM.%2BS.%26aulast%3DBallatori%26aufirst%3DN.%26atitle%3DThe%2520iron%2520transporter%2520ferroportin%2520can%2520also%2520function%2520as%2520a%2520manganese%2520exporter%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2012%26volume%3D1818%26issue%3D3%26spage%3D651%26epage%3D657%26doi%3D10.1016%2Fj.bbamem.2011.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalbetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simonin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span> <span> </span><span class="NLM_article-title">Mammalian iron transporters: families SLC11 and SLC40</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">270</span>â <span class="NLM_lpage">287</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2013.01.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2013.01.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jtL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=270-287&issue=2%E2%80%933&author=N.+Montalbettiauthor=A.+Simoninauthor=G.+Kovacsauthor=M.+A.+Hediger&title=Mammalian+iron+transporters%3A+families+SLC11+and+SLC40&doi=10.1016%2Fj.mam.2013.01.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian iron transporters: Families SLC11 and SLC40</span></div><div class="casAuthors">Montalbetti, Nicolas; Simonin, Alexandre; Kovacs, Gergely; Hediger, Matthias A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">270-287</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This review is focused on the mammalian SLC11 and SLC40 families and their roles in iron homeostasis.  The SLC11 family is composed of two members, SLC11A1 and SLC11A2.  SLC11A1 is expressed in the lysosomal compartment of macrophages and in the tertiary granules of neutrophils, playing a key role in innate resistance against infection by intracellular microbes.  SLC11A2 is a key player in iron metab. and is ubiquitously expressed, most notably in the proximal duodenum, immature erythroid cells, brain, placenta and kidney.  Intestinal iron absorption is mediated by SLC11A2 at the apical membrane of enterocytes, followed by basolateral exit via SLC40A1.  To meet the daily requirement for iron, approx. 80% of the iron comes from the breakdown of Hb following macrophage phagocytosis of senescent erythrocytes (iron recycling).  Both SLC11A1 and SLC11A2 play an important role in macrophage iron recycling.  SLC11A2 also transports iron into the cytosol across the membrane of endocytotic vesicles of the transferrin receptor-cycle.  SLC40A1 is the sole member of the SLC40 family and is involved in the only cellular iron efflux mechanism described.  SLC40A1 is highly expressed in several tissues and cells that play a crit. role in body iron homeostasis.  The signaling pathways that regulate SLC11A2 and SLC40A1 expression at transcriptional, post-transcriptional and post-translational levels are discussed.  The roles of SLC11A2 and/or SLC40A1 in iron-assocd. disorders such as hemochromatosis, neurodegenerative diseases, and breast cancer are also summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9krct7mErb7Vg90H21EOLACvtfcHk0ljYl18seAzv5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jtL4%253D&md5=b17d4baaf3fadb6915ea4b6f5108647e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontalbetti%26aufirst%3DN.%26aulast%3DSimonin%26aufirst%3DA.%26aulast%3DKovacs%26aufirst%3DG.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26atitle%3DMammalian%2520iron%2520transporters%253A%2520families%2520SLC11%2520and%2520SLC40%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D270%26epage%3D287%26doi%3D10.1016%2Fj.mam.2013.01.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eide, D. J.</span></span> <span> </span><span class="NLM_article-title">Zinc transporters and the cellular trafficking of zinc</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1763</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">711</span>â <span class="NLM_lpage">722</span>, <span class="refDoi">Â DOI: 10.1016/j.bbamcr.2006.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bbamcr.2006.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=16675045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD28XotFGqu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1763&publication_year=2006&pages=711-722&issue=7&author=D.+J.+Eide&title=Zinc+transporters+and+the+cellular+trafficking+of+zinc&doi=10.1016%2Fj.bbamcr.2006.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc transporters and the cellular trafficking of zinc</span></div><div class="casAuthors">Eide, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1763</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">711-722</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Zinc is an essential nutrient for all organisms because this metal serves as a catalytic or structural cofactor for many different proteins.  Zinc-dependent proteins are found in the cytoplasm and within many organelles of the eukaryotic cell including the nucleus, the endoplasmic reticulum, Golgi, secretory vesicles, and mitochondria.  Thus, cells require zinc transport mechanisms to allow cells to efficiently accumulate the metal ion and distribute it within the cell.  Our current knowledge of these transport systems in eukaryotes is the focus of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWy56fsCOa5bVg90H21EOLACvtfcHk0ljYl18seAzv5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotFGqu7g%253D&md5=a0aff8021307e525093d9ba2fccf6350</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2006.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2006.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DD.%2BJ.%26atitle%3DZinc%2520transporters%2520and%2520the%2520cellular%2520trafficking%2520of%2520zinc%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2006%26volume%3D1763%26issue%3D7%26spage%3D711%26epage%3D722%26doi%3D10.1016%2Fj.bbamcr.2006.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petris, M. J.</span></span> <span> </span><span class="NLM_article-title">The SLC31 (Ctr) copper transporter family</span>. <i>Pfluegers Arch.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>447</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">752</span>â <span class="NLM_lpage">755</span>, <span class="refDoi">Â DOI: 10.1007/s00424-003-1092-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00424-003-1092-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12827356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVygsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2004&pages=752-755&issue=5&author=M.+J.+Petris&title=The+SLC31+%28Ctr%29+copper+transporter+family&doi=10.1007%2Fs00424-003-1092-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The SLC31 (Ctr) copper transporter family</span></div><div class="casAuthors">Petris, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Pfluegers Archiv</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">752-755</span>CODEN:
                <span class="NLM_cas:coden">PFLABK</span>;
        ISSN:<span class="NLM_cas:issn">0031-6768</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Copper is essential for many copper-dependent processes, including mitochondrial oxidative phosphorylation, free-radical detoxification, pigmentation, neurotransmitter synthesis, and iron metab.  The identification of proteins for high affinity copper uptake and export has greatly expanded our understanding of cellular copper homeostasis.  Copper export in human cells is mediated by the ATP7A and ATP7B P-type ATPases, which are, resp., affected in the genetic disorders of copper metab., Menkes disease and Wilson disease.  A different class of transporter known as the SLC31 or Ctr family of proteins mediates cellular copper uptake.  These high-affinity copper transporters exist in all eukaryotes and their discovery has provided new insights into how cells acquire and regulate this essential nutrient.  The following is a brief overview of the SLC31 copper transporter family with a focus on the human hCtr1 protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoob5ur56LA1bVg90H21EOLACvtfcHk0ljYl18seAzv5Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVygsbs%253D&md5=ca8058867568cd43ef00ebf23499b7b3</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1007%2Fs00424-003-1092-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00424-003-1092-1%26sid%3Dliteratum%253Aachs%26aulast%3DPetris%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520SLC31%2520%2528Ctr%2529%2520copper%2520transporter%2520family%26jtitle%3DPfluegers%2520Arch.%26date%3D2004%26volume%3D447%26issue%3D5%26spage%3D752%26epage%3D755%26doi%3D10.1007%2Fs00424-003-1092-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schweigel-Rontgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolisek, M.</span></span> <span> </span><span class="NLM_article-title">SLC41 transporters-molecular identification and functional role</span>. <i>Curr. Top. Membr.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">383</span>â <span class="NLM_lpage">410</span>, <span class="refDoi">Â DOI: 10.1016/B978-0-12-800223-0.00011-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FB978-0-12-800223-0.00011-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24745990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2cnltFajsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=383-410&author=M.+Schweigel-Rontgenauthor=M.+Kolisek&title=SLC41+transporters-molecular+identification+and+functional+role&doi=10.1016%2FB978-0-12-800223-0.00011-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">SLC41 transporters--molecular identification and functional role</span></div><div class="casAuthors">Schweigel-Rontgen Monika; Kolisek Martin</div><div class="citationInfo"><span class="NLM_cas:title">Current topics in membranes</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">383-410</span>
        ISSN:<span class="NLM_cas:issn">1063-5823</span>.
    </div><div class="casAbstract">The solute carrier family 41 (SLC41) encompasses three members A1, A2, and A3.  Based on their distant homology to the bacterial Mg2+ channel MgtE, all have been linked to Mg2+ transport.  There is only very limited knowledge on the molecular biology and exact functions of SLC41A2 and SLC41A3.  SLC41A1 is ubiquitously expressed and data on its functional and molecular properties, regulation, complex-forming ability, and spectrum of binding partners are available.  SLC41A1 was recently identified as being the Na+/Mg2+ exchanger (NME)-a predominant Mg2+ efflux system.  Mg2+-dependent and hormonal regulation of NME activity is now known to depend on the intracellular N terminus of SLC41A1 that is involved in Mg2+ sensing and contains phosphorylation sites for protein kinase (PK) A and PKC.  Data showing a link between SLC41A1 and human disorders such as Parkinson's disease, nephronophthisis (induced by the null mutation c.698G>T in renal SLC41A1), and preeclampsia make the protein a candidate therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjyOa2EH75A0EksK8CslK8fW6udTcc2eZ_4at8CQcVTrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnltFajsA%253D%253D&md5=6564cf6c16fa36094fe7710a745b8a32</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-800223-0.00011-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-800223-0.00011-6%26sid%3Dliteratum%253Aachs%26aulast%3DSchweigel-Rontgen%26aufirst%3DM.%26aulast%3DKolisek%26aufirst%3DM.%26atitle%3DSLC41%2520transporters-molecular%2520identification%2520and%2520functional%2520role%26jtitle%3DCurr.%2520Top.%2520Membr.%26date%3D2014%26volume%3D73%26spage%3D383%26epage%3D410%26doi%3D10.1016%2FB978-0-12-800223-0.00011-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrion, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faccenda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. A.</span></span> <span> </span><span class="NLM_article-title">The concise guide to pharmacology 2017/18: transporters</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">S360</span>â <span class="NLM_lpage">S446</span>, <span class="refDoi">Â DOI: 10.1111/bph.13883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fbph.13883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29055035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=S360-S446&author=S.+P.+Alexanderauthor=E.+Kellyauthor=N.+V.+Marrionauthor=J.+A.+Petersauthor=E.+Faccendaauthor=S.+D.+Hardingauthor=A.+J.+Pawsonauthor=J.+L.+Sharmanauthor=C.+Southanauthor=J.+A.+Davies&title=The+concise+guide+to+pharmacology+2017%2F18%3A+transporters&doi=10.1111%2Fbph.13883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters</span></div><div class="casAuthors">Alexander, Stephen P. H.; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena; Harding, Simon D.; Pawson, Adam J.; Sharman, Joanna L.; Southan, Christopher; Davies, Jamie A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">S1</span>),
    <span class="NLM_cas:pages">S360-S446</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Concise Guide to PHARMACOl. 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacol. (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacol.org), which provides more detailed views of target and ligand properties.  Although the Concise Guide represents approx. 400 pages, the material presented is substantially reduced compared to information and links presented on the website.  It provides a permanent, citable, point-in-time record that will survive database updates.  The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13883/full.  Transporters are one of the eight major pharmacol. targets into which the Guide is divided, with the others being: G protein-coupled receptors, ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors and enzymes.  These are presented with nomenclature guidance and summary information on the best available pharmacol. tools, alongside key refs. and suggestions for further reading.  The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels.  It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clin. Pharmacol. (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVLQ5zlSHuY7Vg90H21EOLACvtfcHk0liCAQt8FSCoAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs12ls7%252FL&md5=cd03a74d7c3f1c0c959211704ebe1cd2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1111%2Fbph.13883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13883%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DS.%2BP.%26aulast%3DKelly%26aufirst%3DE.%26aulast%3DMarrion%26aufirst%3DN.%2BV.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DFaccenda%26aufirst%3DE.%26aulast%3DHarding%26aufirst%3DS.%2BD.%26aulast%3DPawson%26aufirst%3DA.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BL.%26aulast%3DSouthan%26aufirst%3DC.%26aulast%3DDavies%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520concise%2520guide%2520to%2520pharmacology%25202017%252F18%253A%2520transporters%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2017%26volume%3D174%26spage%3DS360%26epage%3DS446%26doi%3D10.1111%2Fbph.13883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maret, W.</span></span> <span> </span><span class="NLM_article-title">Zinc in cellular regulation: the nature and significance of â³zinc signalsâ³</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2285</span>, <span class="refDoi">Â DOI: 10.3390/ijms18112285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3390%2Fijms18112285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOgu7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=2285&issue=11&author=W.+Maret&title=Zinc+in+cellular+regulation%3A+the+nature+and+significance+of+%E2%80%B3zinc+signals%E2%80%B3&doi=10.3390%2Fijms18112285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc in cellular regulation: the nature and significance of "zinc signals"</span></div><div class="casAuthors">Maret, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2285/1-2285/12</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In the last decade, we witnessed discoveries that established Zn2+ as a second major signalling metal ion in the transmission of information within cells and in communication between cells.  Together with Ca2+ and Mg2+, Zn2+ covers biol. regulation with redox-inert metal ions over many orders of magnitude in concns.  The regulatory functions of zinc ions, together with their functions as a cofactor in about three thousand zinc metalloproteins, impact virtually all aspects of cell biol.  This article attempts to define the regulatory functions of zinc ions, and focuses on the nature of zinc signals and zinc signalling in pathways where zinc ions are either extracellular stimuli or intracellular messengers.  These pathways interact with Ca2+, redox, and phosphorylation signalling.  The regulatory functions of zinc require a complex system of precise homeostatic control for transients, subcellular distribution and traffic, organellar homeostasis, and vesicular storage and exocytosis of zinc ions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1-5UXm4cj0bVg90H21EOLACvtfcHk0liCAQt8FSCoAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOgu7vK&md5=44287582ded0f3f7319b4326ad03f119</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.3390%2Fijms18112285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18112285%26sid%3Dliteratum%253Aachs%26aulast%3DMaret%26aufirst%3DW.%26atitle%3DZinc%2520in%2520cellular%2520regulation%253A%2520the%2520nature%2520and%2520significance%2520of%2520%25E2%2580%25B3zinc%2520signals%25E2%2580%25B3%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26issue%3D11%26spage%3D2285%26doi%3D10.3390%2Fijms18112285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzlau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâBrien, R. M.</span></span> <span> </span><span class="NLM_article-title">Zinc transporter 8 (ZnT8) and beta cell function</span>. <i>Trends Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">415</span>â <span class="NLM_lpage">424</span>, <span class="refDoi">Â DOI: 10.1016/j.tem.2014.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tem.2014.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24751356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsFCms7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2014&pages=415-424&issue=8&author=H.+W.+Davidsonauthor=J.+M.+Wenzlauauthor=R.+M.+O%E2%80%99Brien&title=Zinc+transporter+8+%28ZnT8%29+and+beta+cell+function&doi=10.1016%2Fj.tem.2014.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc transporter 8 (ZnT8) and Î² cell function</span></div><div class="casAuthors">Davidson, Howard W.; Wenzlau, Janet M.; O'Brien, Richard M.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Endocrinology and Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">415-424</span>CODEN:
                <span class="NLM_cas:coden">TENME4</span>;
        ISSN:<span class="NLM_cas:issn">1043-2760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human pancreatic Î² cells have exceptionally high zinc content.  In Î² cells the highest zinc concn. is in insulin secretory granules, from which it is cosecreted with the hormone.  Uptake of zinc into secretory granules is mainly mediated by zinc transporter 8 (ZnT8), the product of the SLC30A8 [solute carrier family 30 (zinc transporter), member 8] gene.  The minor alleles of several single-nucleotide polymorphisms (SNPs) in SLC30A8 are assocd. with decreased risk of type 2 diabetes (T2D), but the precise mechanisms underlying the protective effects remain uncertain.  In this article we review current knowledge of the role of ZnT8 in maintaining zinc homeostasis in Î² cells, its role in glucose metab. based on knockout mouse studies, and current theories regarding the link between ZnT8 function and T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcprSfV2FvIbVg90H21EOLACvtfcHk0liCAQt8FSCoAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsFCms7Y%253D&md5=24c8474701fe010bb771fd53f40c6501</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.tem.2014.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tem.2014.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DH.%2BW.%26aulast%3DWenzlau%26aufirst%3DJ.%2BM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DR.%2BM.%26atitle%3DZinc%2520transporter%25208%2520%2528ZnT8%2529%2520and%2520beta%2520cell%2520function%26jtitle%3DTrends%2520Endocrinol.%2520Metab.%26date%3D2014%26volume%3D25%26issue%3D8%26spage%3D415%26epage%3D424%26doi%3D10.1016%2Fj.tem.2014.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harland, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettifer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chichester, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willighagen, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evelo, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ecker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goble, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mons, B.</span></span> <span> </span><span class="NLM_article-title">Open PHACTS: semantic interoperability for drug discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">21â22</span>),  <span class="NLM_fpage">1188</span>â <span class="NLM_lpage">1198</span>, <span class="refDoi">Â DOI: 10.1016/j.drudis.2012.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.drudis.2012.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22683805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC38jgsVWqtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1188-1198&issue=21%E2%80%9322&author=A.+J.+Williamsauthor=L.+Harlandauthor=P.+Grothauthor=S.+Pettiferauthor=C.+Chichesterauthor=E.+L.+Willighagenauthor=C.+T.+Eveloauthor=N.+Blombergauthor=G.+Eckerauthor=C.+Gobleauthor=B.+Mons&title=Open+PHACTS%3A+semantic+interoperability+for+drug+discovery&doi=10.1016%2Fj.drudis.2012.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Open PHACTS: semantic interoperability for drug discovery</span></div><div class="casAuthors">Williams Antony J; Harland Lee; Groth Paul; Pettifer Stephen; Chichester Christine; Willighagen Egon L; Evelo Chris T; Blomberg Niklas; Ecker Gerhard; Goble Carole; Mons Barend</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">21-22</span>),
    <span class="NLM_cas:pages">1188-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Open PHACTS is a public-private partnership between academia, publishers, small and medium sized enterprises and pharmaceutical companies.  The goal of the project is to deliver and sustain an 'open pharmacological space' using and enhancing state-of-the-art semantic web standards and technologies.  It is focused on practical and robust applications to solve specific questions in drug discovery research.  OPS is intended to facilitate improvements in drug discovery in academia and industry and to support open innovation and in-house non-public drug discovery research.  This paper lays out the challenges and how the Open PHACTS project is hoping to address these challenges technically and socially.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgQwQiZHAzrVw2ofyr07jXfW6udTcc2eYtvhm358VIuLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jgsVWqtQ%253D%253D&md5=ae3584b34948d7f6e92aee3ef36cc6a8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DA.%2BJ.%26aulast%3DHarland%26aufirst%3DL.%26aulast%3DGroth%26aufirst%3DP.%26aulast%3DPettifer%26aufirst%3DS.%26aulast%3DChichester%26aufirst%3DC.%26aulast%3DWillighagen%26aufirst%3DE.%2BL.%26aulast%3DEvelo%26aufirst%3DC.%2BT.%26aulast%3DBlomberg%26aufirst%3DN.%26aulast%3DEcker%26aufirst%3DG.%26aulast%3DGoble%26aufirst%3DC.%26aulast%3DMons%26aufirst%3DB.%26atitle%3DOpen%2520PHACTS%253A%2520semantic%2520interoperability%2520for%2520drug%2520discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26issue%3D21%25E2%2580%259322%26spage%3D1188%26epage%3D1198%26doi%3D10.1016%2Fj.drudis.2012.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rask-Andersen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fredriksson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schioth, H. B.</span></span> <span> </span><span class="NLM_article-title">Solute carriers as drug targets: current use, clinical trials and prospective</span>. <i>Mol. Aspects Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">702</span>â <span class="NLM_lpage">710</span>, <span class="refDoi">Â DOI: 10.1016/j.mam.2012.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.mam.2012.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23506903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksV2jsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=702-710&issue=2%E2%80%933&author=M.+Rask-Andersenauthor=S.+Masuramauthor=R.+Fredrikssonauthor=H.+B.+Schioth&title=Solute+carriers+as+drug+targets%3A+current+use%2C+clinical+trials+and+prospective&doi=10.1016%2Fj.mam.2012.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Solute carriers as drug targets: Current use, clinical trials and prospective</span></div><div class="casAuthors">Rask-Andersen, Mathias; Masuram, Surendar; Fredriksson, Robert; Schioeth, Helgi B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">702-710</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Solute carriers (SLCs) comprise a large family of membrane transporters responsible for the transmembrane transport of a wide variety of substrates such as inorg. ions, amino acids, neurotransmitters and sugars.  Despite being the largest family of membrane transport proteins, SLCs have been relatively under-utilized as therapeutic drug targets by approved drugs.  In this paper, we aim to catalog therapeutic SLCs utilized by approved drugs or currently in clin. trials.  By mining information on clin. trials from the Centerwatch.com "drugs in clin. trials database" we were able to identify potentially novel SLC drug targets currently under development.  We also searched the literature for SLCs that have been discussed as future therapeutic drug targets.  We find SLCs to be utilized as therapeutic targets in treatment of a wide variety of diseases and disorders, such as major depression, ADHD, osteoporosis and hypertension.  Drugs targeting SLCs for treatment of diabetes, constipation and hypercholesterolemia are currently in clin. trials.  SLC drug targets have also been explored in clin. trials for cardioprotection after an ischemic event.  SLCs are of particular interest as targets in antineoplastic treatment and for the targeted transport of cytotoxic drugs into tumors, e.g. via the glucose transporters GLUT1-5 and SGLT1-3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDkN3N6VPYB7Vg90H21EOLACvtfcHk0lguVOdUu9flGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksV2jsrc%253D&md5=a3c4d6f2da377bcea88b644524edd530</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2012.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2012.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DRask-Andersen%26aufirst%3DM.%26aulast%3DMasuram%26aufirst%3DS.%26aulast%3DFredriksson%26aufirst%3DR.%26aulast%3DSchioth%26aufirst%3DH.%2BB.%26atitle%3DSolute%2520carriers%2520as%2520drug%2520targets%253A%2520current%2520use%252C%2520clinical%2520trials%2520and%2520prospective%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26issue%3D2%25E2%2580%25933%26spage%3D702%26epage%3D710%26doi%3D10.1016%2Fj.mam.2012.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nestler, E. J.</span></span> <span> </span><span class="NLM_article-title">The molecular neurobiology of depression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>455</i></span> (<span class="NLM_issue">7215</span>),  <span class="NLM_fpage">894</span>â <span class="NLM_lpage">902</span>, <span class="refDoi">Â DOI: 10.1038/nature07455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature07455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=18923511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=894-902&issue=7215&author=V.+Krishnanauthor=E.+J.+Nestler&title=The+molecular+neurobiology+of+depression&doi=10.1038%2Fnature07455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular neurobiology of depression</span></div><div class="casAuthors">Krishnan, Vaishnav; Nestler, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">894-902</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Unraveling the pathophysiol. of depression is a unique challenge.  Not only are depressive syndromes heterogeneous and their etiologies diverse, but symptoms such as guilt and suicidality are impossible to reproduce in animal models.  Nevertheless, other symptoms have been accurately modeled, and these, together with clin. data, are providing insight into the neurobiol. of depression.  Recent studies combining behavioral, mol. and electrophysiol. techniques reveal that certain aspects of depression result from maladaptive stress-induced neuroplastic changes in specific neural circuits.  They also show that understanding the mechanisms of resilience to stress offers a crucial new dimension for the development of fundamentally novel antidepressant treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHLnyp4sMWLVg90H21EOLACvtfcHk0lguVOdUu9flGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrE&md5=bed2e4ae1259f3670459ddaf2dbd3057</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fnature07455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07455%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26atitle%3DThe%2520molecular%2520neurobiology%2520of%2520depression%26jtitle%3DNature%26date%3D2008%26volume%3D455%26issue%3D7215%26spage%3D894%26epage%3D902%26doi%3D10.1038%2Fnature07455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarakad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez-Shahed, J.</span></span> <span> </span><span class="NLM_article-title">VMAT2 inhibitors in neuropsychiatric disorders</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1131</span>â <span class="NLM_lpage">1144</span>, <span class="refDoi">Â DOI: 10.1007/s40263-018-0580-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs40263-018-0580-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30306450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2qsrzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=1131-1144&issue=12&author=A.+Tarakadauthor=J.+Jimenez-Shahed&title=VMAT2+inhibitors+in+neuropsychiatric+disorders&doi=10.1007%2Fs40263-018-0580-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">VMAT2 Inhibitors in Neuropsychiatric Disorders</span></div><div class="casAuthors">Tarakad, Arjun; Jimenez-Shahed, Joohi</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1131-1144</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders.  Vesicular monoamine transporter 2 (VMAT2) inhibitors, which deplete dopamine at presynaptic striatal nerve terminals, are a class of drugs that have long been used to treat hyperkinetic movement disorders, but have recently gained more attention following their development for specific indications in the United States.  At present, there are three com. available VMAT2 inhibitors: tetrabenazine, deutetrabenazine, and valbenazine.  Pharmacokinetics, metab., and dosing vary significantly between the three drugs, and likely underlie the more favorable side effect profile of the newer agents (deutetrabenazine and valbenazine).  Tetrabenazine and deutetrabenazine have demonstrated safety and efficacy in the treatment of chorea assocd. with Huntington's disease, including in randomized controlled trials, although direct comparison studies are limited.  Both deutetrabenazine and valbenazine have demonstrated safety and efficacy in the treatment of tardive dyskinesia, with multiple double-blind, placebo-controlled trials, whereas tetrabenazine has been studied less rigorously.  There have been no blinded, prospective trials with tetrabenazine in Tourette's syndrome (TS); however, double-blind, placebo-controlled trials in TS are ongoing for both deutetrabenazine and valbenazine.  Given the favored side effect profile of newer VMAT2 inhibitors, clinicians should be aware of the distinctions between agents and become familiar with differences in their use, esp. as there is potential for their utilization to increase across the range of hyperkinetic movement disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrl38BcsTPsKbVg90H21EOLACvtfcHk0lgP4cEz5T427w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2qsrzO&md5=392d8e968bc87370060157b180035f8b</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs40263-018-0580-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-018-0580-y%26sid%3Dliteratum%253Aachs%26aulast%3DTarakad%26aufirst%3DA.%26aulast%3DJimenez-Shahed%26aufirst%3DJ.%26atitle%3DVMAT2%2520inhibitors%2520in%2520neuropsychiatric%2520disorders%26jtitle%3DCNS%2520Drugs%26date%3D2018%26volume%3D32%26issue%3D12%26spage%3D1131%26epage%3D1144%26doi%3D10.1007%2Fs40263-018-0580-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. L. G.</span></span> <span> </span><span class="NLM_article-title">Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">3489</span>â <span class="NLM_lpage">3506</span>, <span class="refDoi">Â DOI: 10.1007/s00018-015-1937-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00018-015-1937-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26033496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFejtbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=3489-3506&issue=18&author=K.+Takahashiauthor=J.+B.+Fosterauthor=C.+L.+G.+Lin&title=Glutamate+transporter+EAAT2%3A+regulation%2C+function%2C+and+potential+as+a+therapeutic+target+for+neurological+and+psychiatric+disease&doi=10.1007%2Fs00018-015-1937-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate transporter EAAT2- regulation, function, and potential as a therapeutic target for neurological and psychiatric disease</span></div><div class="casAuthors">Takahashi, Kou; Foster, Joshua B.; Lin, Chien-Liang Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3489-3506</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Glutamate is the predominant excitatory neurotransmitter in the central nervous system.  Excitatory amino acid transporter 2 (EAAT2) is primarily responsible for clearance of extracellular glutamate to prevent neuronal excitotoxicity and hyperexcitability.  EAAT2 plays a crit. role in regulation of synaptic activity and plasticity.  In addn., EAAT2 has been implicated in the pathogenesis of many central nervous system disorders.  In this review, we summarize current understanding of EAAT2, including structure, pharmacol., physiol., and functions, as well as disease relevancy, such as in stroke, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis, Alzheimer's disease, major depressive disorder, and addiction.  A large no. of studies have demonstrated that up-regulation of EAAT2 protein provides significant beneficial effects in many disease models suggesting EAAT2 activation is a promising therapeutic approach.  Several EAAT2 activators have been identified.  Further understanding of EAAT2 regulatory mechanisms could improve development of drug-like compds. that spatiotemporally regulate EAAT2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSDfRKc3x_9LVg90H21EOLACvtfcHk0lgP4cEz5T427w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFejtbg%253D&md5=b4635bb27ff03306fd4fb3a1a87ebceb</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-1937-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-1937-8%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DFoster%26aufirst%3DJ.%2BB.%26aulast%3DLin%26aufirst%3DC.%2BL.%2BG.%26atitle%3DGlutamate%2520transporter%2520EAAT2%253A%2520regulation%252C%2520function%252C%2520and%2520potential%2520as%2520a%2520therapeutic%2520target%2520for%2520neurological%2520and%2520psychiatric%2520disease%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26issue%3D18%26spage%3D3489%26epage%3D3506%26doi%3D10.1007%2Fs00018-015-1937-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kegelman, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dash, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barral, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedvat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span> <span> </span><span class="NLM_article-title">Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>226</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2484</span>â <span class="NLM_lpage">2493</span>, <span class="refDoi">Â DOI: 10.1002/jcp.22609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fjcp.22609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21792905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpt1Clt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=226&publication_year=2011&pages=2484-2493&issue=10&author=K.+Kimauthor=S.+G.+Leeauthor=T.+P.+Kegelmanauthor=Z.+Z.+Suauthor=S.+K.+Dasauthor=R.+Dashauthor=S.+Dasguptaauthor=P.+M.+Barralauthor=M.+Hedvatauthor=P.+Diazauthor=J.+C.+Reedauthor=J.+L.+Stebbinsauthor=M.+Pellecchiaauthor=D.+Sarkarauthor=P.+B.+Fisher&title=Role+of+excitatory+amino+acid+transporter-2+%28EAAT2%29+and+glutamate+in+neurodegeneration%3A+opportunities+for+developing+novel+therapeutics&doi=10.1002%2Fjcp.22609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Excitatory Amino Acid Transporter-2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics</span></div><div class="casAuthors">Kim, Keetae; Lee, Seok-Geun; Kegelman, Timothy P.; Su, Zhao-Zhong; Das, Swadesh K.; Dash, Rupesh; Dasgupta, Santanu; Barral, Paola M.; Hedvat, Michael; Diaz, Paul; Reed, John C.; Stebbins, John L.; Pellecchia, Maurizio; Sarkar, Devanand; Fisher, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">226</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2484-2493</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Glutamate is an essential excitatory neurotransmitter regulating brain functions.  Excitatory amino acid transporter (EAAT)-2 is one of the major glutamate transporters expressed predominantly in astroglial cells and is responsible for 90% of total glutamate uptake.  Glutamate transporters tightly regulate glutamate concn. in the synaptic cleft.  Dysfunction of EAAT2 and accumulation of excessive extracellular glutamate has been implicated in the development of several neurodegenerative diseases including Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis.  Anal. of the 2.5 kb human EAAT2 promoter showed that NF-ÎºB is an important regulator of EAAT2 expression in astrocytes.  Screening of approx. 1,040 FDA-approved compds. and nutritionals led to the discovery that many Î²-lactam antibiotics are transcriptional activators of EAAT2 resulting in increased EAAT2 protein levels.  Treatment of animals with ceftriaxone (CEF), a Î²-lactam antibiotic, led to an increase of EAAT2 expression and glutamate transport activity in the brain.  CEF has neuroprotective effects in both in vitro and in vivo models based on its ability to inhibit neuronal cell death by preventing glutamate excitotoxicity.  CEF increases EAAT2 transcription in primary human fetal astrocytes through the NF-ÎºB signaling pathway.  The NF-ÎºB binding site at -272 position was crit. in CEF-mediated EAAT2 protein induction.  These studies emphasize the importance of transcriptional regulation in controlling glutamate levels in the brain.  They also emphasize the potential utility of the EAAT2 promoter for developing both low and high throughput screening assays to identify novel small mol. regulators of glutamate transport with potential to ameliorate pathol. changes occurring during and causing neurodegeneration.  J. Cell. Physiol. 226: 2484-2493, 2011. Â© 2010 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDdoPAeaC_5rVg90H21EOLACvtfcHk0lgP4cEz5T427w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpt1Clt7g%253D&md5=4e837820dbfe500409a6178a229a8464</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fjcp.22609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.22609%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DS.%2BG.%26aulast%3DKegelman%26aufirst%3DT.%2BP.%26aulast%3DSu%26aufirst%3DZ.%2BZ.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DDash%26aufirst%3DR.%26aulast%3DDasgupta%26aufirst%3DS.%26aulast%3DBarral%26aufirst%3DP.%2BM.%26aulast%3DHedvat%26aufirst%3DM.%26aulast%3DDiaz%26aufirst%3DP.%26aulast%3DReed%26aufirst%3DJ.%2BC.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPellecchia%26aufirst%3DM.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26atitle%3DRole%2520of%2520excitatory%2520amino%2520acid%2520transporter-2%2520%2528EAAT2%2529%2520and%2520glutamate%2520in%2520neurodegeneration%253A%2520opportunities%2520for%2520developing%2520novel%2520therapeutics%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2011%26volume%3D226%26issue%3D10%26spage%3D2484%26epage%3D2493%26doi%3D10.1002%2Fjcp.22609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Javitt, D. C.</span></span> <span> </span><span class="NLM_article-title">Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions</span>. <i>Int. Rev. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">69</span>â <span class="NLM_lpage">108</span>, <span class="refDoi">Â DOI: 10.1016/S0074-7742(06)78003-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0074-7742%2806%2978003-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17349858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Gmt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2007&pages=69-108&author=D.+C.+Javitt&title=Glutamate+and+schizophrenia%3A+phencyclidine%2C+N-methyl-D-aspartate+receptors%2C+and+dopamine-glutamate+interactions&doi=10.1016%2FS0074-7742%2806%2978003-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions</span></div><div class="casAuthors">Javitt, Daniel C.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">Integrating the Neurobiology of Schizophrenia</span>),
    <span class="NLM_cas:pages">69-108,, 1 plate</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide.  As of yet, neurochem. mechanisms underlying schizophrenia remain unknown.  To date, the most widely considered neurochem. hypothesis of schizophrenia is the dopamine hypothesis, which postulates that symptoms of schizophrenia may result from excess dopaminergic neurotransmission particularly in striatal brain regions, along with dopaminergic deficits in prefrontal brain regions.  Alternative neurochem. models of schizophrenia, however, have been proposed involving glutamatergic mechanisms in general and N-methyl-D-aspartate (NMDA) receptors in particular.  A potential role for glutamatergic mechanisms in schizophrenia was first proposed â¼15 years ago based on the observation that the psychotomimetic agents phencyclidine (PCP) and ketamine induce psychotic symptoms and neurocognitive disturbances similar to those of schizophrenia by blocking neurotransmission at NMDA-type glutamate receptors.  Since that time, significant addnl. evidence has accumulated supporting a role for NMDA hypofunction in the pathophysiol. of schizophrenia.  Clin. challenge studies with PCP and ketamine have confirmed the close resemblance between NMDA antagonist-induced symptoms and neurocognitive deficits and those obsd. in schizophrenia, and suggest that NMDA dysfunction may lead to secondary dopaminergic dysregulation in striatal and prefrontal brain regions.  As compared to dopaminergic agents, NMDA antagonists induce neg. and cognitive symptoms of schizophrenia, as well as pos. symptoms.  Treatment studies with NMDA modulators, such as glycine, D-serine, and glycine transport inhibitors (GTIs), have yielded encouraging findings, although results remain controversial.  Finally, genetic linkage and in vivo neurochem. studies in schizophrenia highlight potential etiol. mechanisms giving rise to glutamatergic/NMDA dysfunction in schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ZhuFfD0tJ7Vg90H21EOLACvtfcHk0lheoTUpw2Pfwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Gmt74%253D&md5=dd081e288a66cdc6e3a98d0cfb49fa50</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2FS0074-7742%2806%2978003-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0074-7742%252806%252978003-5%26sid%3Dliteratum%253Aachs%26aulast%3DJavitt%26aufirst%3DD.%2BC.%26atitle%3DGlutamate%2520and%2520schizophrenia%253A%2520phencyclidine%252C%2520N-methyl-D-aspartate%2520receptors%252C%2520and%2520dopamine-glutamate%2520interactions%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2007%26volume%3D78%26spage%3D69%26epage%3D108%26doi%3D10.1016%2FS0074-7742%2806%2978003-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, R. A.</span>; <span class="NLM_string-name">Dawson, L. A.</span></span>, <span> </span><span class="NLM_article-title">GlyT-1 Inhibitors: From Hits to Clinical Candidates</span>. In  <i>Small Molecule Therapeutics for Schizophrenia</i>, <span class="NLM_contrib-group"><span class="NLM_string-name">Celanire, S.</span>, <span class="NLM_string-name">Poli, S.</span></span>, Eds.; <span class="NLM_publisher-name">Springer International Publishing</span>: <span class="NLM_publisher-loc">Cham</span>, <span class="NLM_year">2015</span>; pp  <span class="NLM_fpage">51</span>â <span class="NLM_lpage">99</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=51-99&author=R.+A.+Porter&author=L.+A.+Dawsonauthor=S.+Celanire&author=S.+Poli&title=Small+Molecule+Therapeutics+for+Schizophrenia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DR.%2BA.%26atitle%3DGlyT-1%2520Inhibitors%253A%2520From%2520Hits%2520to%2520Clinical%2520Candidates%26btitle%3DSmall%2520Molecule%2520Therapeutics%2520for%2520Schizophrenia%26aulast%3DCelanire%26aufirst%3DS.%26pub%3DSpringer%2520International%2520Publishing%26date%3D2015%26spage%3D51%26epage%3D99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tillman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. W.</span></span> <span> </span><span class="NLM_article-title">Crossing the chloride channel: the current and potential therapeutic value of the neuronal K+-Cl- cotransporter KCC2</span>. <i>BioMed Res. Int.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2019</i></span>,  <span class="NLM_fpage">8941046</span>, <span class="refDoi">Â DOI: 10.1155/2019/8941046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1155%2F2019%2F8941046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31240228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3MzgvVChsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2019&publication_year=2019&pages=8941046&author=L.+Tillmanauthor=J.+W.+Zhang&title=Crossing+the+chloride+channel%3A+the+current+and+potential+therapeutic+value+of+the+neuronal+K%2B-Cl-+cotransporter+KCC2&doi=10.1155%2F2019%2F8941046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Crossing the Chloride Channel: The Current and Potential Therapeutic Value of the Neuronal K(+)-Cl(-) Cotransporter KCC2</span></div><div class="casAuthors">Tillman Luke; Zhang Jinwei</div><div class="citationInfo"><span class="NLM_cas:title">BioMed research international</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">2019</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">8941046</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chloride (Cl(-)) homeostasis is an essential process involved in neuronal signalling and cell survival.  Inadequate regulation of intracellular Cl(-) interferes with synaptic signalling and is implicated in several neurological diseases.  The main inhibitory neurotransmitter of the central nervous system is Î³-aminobutyric acid (GABA).  GABA hyperpolarises the membrane potential by activating Cl(-) permeable GABAA receptor channels (GABAAR).  This process is reliant on Cl(-) extruder K(+)-Cl(-) cotransporter 2 (KCC2), which generates the neuron's inward, hyperpolarising Cl(-) gradient.  KCC2 is encoded by the fifth member of the solute carrier 12 family (SLC12A5) and has remained a poorly understood component in the development and severity of many neurological diseases for many years.  Recent advancements in next-generation sequencing and specific gene targeting, however, have indicated that loss of KCC2 activity is involved in a number of diseases including epilepsy and schizophrenia.  It has also been implicated in neuropathic pain following spinal cord injury.  Any variant of SLC12A5 that negatively regulates the transporter's expression may, therefore, be implicated in neurological disease.  A recent whole exome study has discovered several causative mutations in patients with epilepsy.  Here, we discuss the implications of KCC2 in neurological disease and consider the evolving evidence for KCC2's potential as a therapeutic target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTygwrSuFoU5WtyewyzkyLfW6udTcc2eaveIxa39jrILntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzgvVChsA%253D%253D&md5=bceb220afddc338ce01be9bf93e01415</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1155%2F2019%2F8941046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2019%252F8941046%26sid%3Dliteratum%253Aachs%26aulast%3DTillman%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%2BW.%26atitle%3DCrossing%2520the%2520chloride%2520channel%253A%2520the%2520current%2520and%2520potential%2520therapeutic%2520value%2520of%2520the%2520neuronal%2520K%252B-Cl-%2520cotransporter%2520KCC2%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2019%26volume%3D2019%26spage%3D8941046%26doi%3D10.1155%2F2019%2F8941046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camargo, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockenhauer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleta, R.</span></span> <span> </span><span class="NLM_article-title">Aminoacidurias: clinical and molecular aspects</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">918</span>â <span class="NLM_lpage">925</span>, <span class="refDoi">Â DOI: 10.1038/sj.ki.5002790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fsj.ki.5002790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=18200002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVWmt7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=918-925&issue=8&author=S.+M.+Camargoauthor=D.+Bockenhauerauthor=R.+Kleta&title=Aminoacidurias%3A+clinical+and+molecular+aspects&doi=10.1038%2Fsj.ki.5002790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoacidurias: Clinical and molecular aspects</span></div><div class="casAuthors">Camargo, S. M. R.; Bockenhauer, D.; Kleta, R.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">918-925</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inherited aminoacidurias are caused by defective amino-acid transport through renal (reabsorption) and in many cases also small intestinal epithelia (absorption).  Recently, many of the genes causing this abnormal transport have been molecularly identified.  In this review, we summarize the latest findings in the clin. and mol. aspects concerning the principal aminoacidurias, cystinuria, lysinuric protein intolerance, Hartnup disorder, iminoglycinuria, and dicarboxylic aminoaciduria.  Signs, symptoms, diagnosis, treatment, causative or candidate genes, functional characterization of the encoded transporters, and animal models are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmAYl1-I6pObVg90H21EOLACvtfcHk0lheoTUpw2Pfwg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVWmt7g%253D&md5=0ddb2b94f84836fc9bb5fdc1efe16423</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5002790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5002790%26sid%3Dliteratum%253Aachs%26aulast%3DCamargo%26aufirst%3DS.%2BM.%26aulast%3DBockenhauer%26aufirst%3DD.%26aulast%3DKleta%26aufirst%3DR.%26atitle%3DAminoacidurias%253A%2520clinical%2520and%2520molecular%2520aspects%26jtitle%3DKidney%2520Int.%26date%3D2008%26volume%3D73%26issue%3D8%26spage%3D918%26epage%3D925%26doi%3D10.1038%2Fsj.ki.5002790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feliubadalo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbones, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chillaron, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorzano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, V.</span></span> <span> </span><span class="NLM_article-title">SLC7A9-deficient mice develop cystinuria non-i and cystine urolithiasis</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2097</span>â <span class="NLM_lpage">2108</span>, <span class="refDoi">Â DOI: 10.1093/hmg/ddg228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Fhmg%2Fddg228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12915471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnsV2ntbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2003&pages=2097-2108&issue=17&author=L.+Feliubadaloauthor=M.+L.+Arbonesauthor=S.+Manasauthor=J.+Chillaronauthor=J.+Visaauthor=M.+Rodesauthor=F.+Rousaudauthor=A.+Zorzanoauthor=M.+Palacinauthor=V.+Nunes&title=SLC7A9-deficient+mice+develop+cystinuria+non-i+and+cystine+urolithiasis&doi=10.1093%2Fhmg%2Fddg228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Slc7a9-deficient mice develop cystinuria non-I and cystine urolithiasis</span></div><div class="casAuthors">Feliubadalo, Lidia; Arbones, Maria Lourdes; Manas, Sandra; Chillaron, Josep; Visa, Joana; Rodes, Margot; Rousaud, Ferran; Zorzano, Antonio; Palacin, Manuel; Nunes, Virginia</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2097-2108</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Cystinuria is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids that results in urolithiasis of cystine.  Cystinuria is caused by defects in the amino acid transport system b0,+ (i.e. the rBAT/b0,+ AT heteromeric complex).  Mutations in SLC3A1, encoding rBAT, cause cystinuria type A, characterized by a silent phenotype in heterozygotes (phenotype I).  Mutations in SLC7A9, encoding b0,+ AT, cause cystinuria type B, in which heterozygotes in most cases hyperexcrete cystine and dibasic amino acids (phenotype non-I).  To facilitate in vivo investigation of b0,+ AT in cystinuria, Slc7a9 knockout mice have been generated.  Expression of b0,+ AT protein is completely abolished in the kidney of Slc7a9-/- mice ("Stones").  In contrast, Stones expressed significant amts. of rBAT protein, which is covalently linked to unidentified light subunit(s).  Stones mice present a dramatic hyperexcretion of cystine and dibasic amino acids, while Slc7a9+/- mice show moderate but significant hyperexcretion of these amino acids (phenotype non-I).  Forty-two per cent of Stones mice develop cystine calculi in the urinary system.  Calculi develop during the first month of life and grow throughout the life span of the animals.  Histopathol. in kidney reveals typical changes for urolithiasis (tubular and pelvic dilatation, tubular necrosis, tubular hyaline droplets and chronic interstitial nephritis).  The fact that some Stones mice, generated in a mixed genetic background, develop cystine calculi from an early age, while others do not develop them in their first year of life, suggests the involvement of modifier genes in the lithiasis phenotype.  Thus, Stones provide a valid model of cystinuria which can be used in the study of genetic, pharmacol. and environmental factors involved in cystine urolithiasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP9HcLSyQrWbVg90H21EOLACvtfcHk0lizvsejTWeBJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnsV2ntbo%253D&md5=d8d289e95f5ab1093c5d535179ca132f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddg228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddg228%26sid%3Dliteratum%253Aachs%26aulast%3DFeliubadalo%26aufirst%3DL.%26aulast%3DArbones%26aufirst%3DM.%2BL.%26aulast%3DManas%26aufirst%3DS.%26aulast%3DChillaron%26aufirst%3DJ.%26aulast%3DVisa%26aufirst%3DJ.%26aulast%3DRodes%26aufirst%3DM.%26aulast%3DRousaud%26aufirst%3DF.%26aulast%3DZorzano%26aufirst%3DA.%26aulast%3DPalacin%26aufirst%3DM.%26aulast%3DNunes%26aufirst%3DV.%26atitle%3DSLC7A9-deficient%2520mice%2520develop%2520cystinuria%2520non-i%2520and%2520cystine%2520urolithiasis%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2003%26volume%3D12%26issue%3D17%26spage%3D2097%26epage%3D2108%26doi%3D10.1093%2Fhmg%2Fddg228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouffard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiermonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilliard, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalikin, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makalowska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morton, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petty, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesecker, L. G.</span></span> <span> </span><span class="NLM_article-title">Mutant deoxynucleotide carrier is associated with congenital microcephaly</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">175</span>â <span class="NLM_lpage">179</span>, <span class="refDoi">Â DOI: 10.1038/ng948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fng948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12185364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1ajs70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=175-179&issue=1&author=M.+J.+Rosenbergauthor=R.+Agarwalaauthor=G.+Bouffardauthor=J.+Davisauthor=G.+Fiermonteauthor=M.+S.+Hilliardauthor=T.+Kochauthor=L.+M.+Kalikinauthor=I.+Makalowskaauthor=D.+H.+Mortonauthor=E.+M.+Pettyauthor=J.+L.+Weberauthor=F.+Palmieriauthor=R.+I.+Kelleyauthor=A.+A.+Schafferauthor=L.+G.+Biesecker&title=Mutant+deoxynucleotide+carrier+is+associated+with+congenital+microcephaly&doi=10.1038%2Fng948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant deoxynucleotide carrier is associated with congenital microcephaly</span></div><div class="casAuthors">Rosenberg, Marjorie J.; Agarwala, Richa; Bouffard, Gerard; Davis, Joie; Fiermonte, Giuseppe; Hilliard, Mark S.; Koch, Thorsten; Kalikin, Linda M.; Makalowska, Izabela; Morton, D. Holmes; Petty, Elizabeth M.; Weber, James L.; Palmieri, Ferdinando; Kelley, Richard I.; Schaeffer, Alejandro A.; Biesecker, Leslie G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-179</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The disorder Amish microcephaly (MCPHA) is characterized by severe congenital microcephaly, elevated levels of Î±-ketoglutarate in the urine and premature death.  The disorder is inherited in an autosomal recessive pattern and has been obsd. only in Old Order Amish families whose ancestors lived in Lancaster County, Pennsylvania.  Here the authors show, by using a genealogy database and automated pedigree software, that 23 nuclear families affected with MCPHA are connected to a single ancestral couple.  Through a whole-genome scan, fine mapping and haplotype anal., the authors localized the gene affected in MCPHA to a region of 3 cM, or 2 Mb, on chromosome 17q25.  The authors constructed a map of contiguous genomic clones spanning this region.  One of the genes in this region, SLC25A19, which encodes a nuclear mitochondrial deoxynucleotide carrier (DNC), contains a substitution that segregates with the disease in affected individuals and alters an amino acid that is highly conserved in similar proteins.  Functional anal. shows that the mutant DNC protein lacks the normal transport activity, implying that failed deoxynucleotide transport across the inner mitochondrial membrane causes MCPHA.  These data indicate that mitochondrial deoxynucleotide transport may be essential for prenatal brain growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnW7rF-OfndrVg90H21EOLACvtfcHk0lizvsejTWeBJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1ajs70%253D&md5=065e61fe41acb1fee84e3df2ef3d2656</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1038%2Fng948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng948%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DM.%2BJ.%26aulast%3DAgarwala%26aufirst%3DR.%26aulast%3DBouffard%26aufirst%3DG.%26aulast%3DDavis%26aufirst%3DJ.%26aulast%3DFiermonte%26aufirst%3DG.%26aulast%3DHilliard%26aufirst%3DM.%2BS.%26aulast%3DKoch%26aufirst%3DT.%26aulast%3DKalikin%26aufirst%3DL.%2BM.%26aulast%3DMakalowska%26aufirst%3DI.%26aulast%3DMorton%26aufirst%3DD.%2BH.%26aulast%3DPetty%26aufirst%3DE.%2BM.%26aulast%3DWeber%26aufirst%3DJ.%2BL.%26aulast%3DPalmieri%26aufirst%3DF.%26aulast%3DKelley%26aufirst%3DR.%2BI.%26aulast%3DSchaffer%26aufirst%3DA.%2BA.%26aulast%3DBiesecker%26aufirst%3DL.%2BG.%26atitle%3DMutant%2520deoxynucleotide%2520carrier%2520is%2520associated%2520with%2520congenital%2520microcephaly%26jtitle%3DNat.%2520Genet.%26date%3D2002%26volume%3D32%26issue%3D1%26spage%3D175%26epage%3D179%26doi%3D10.1038%2Fng948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindhurst, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiermonte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Struys, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Leonardis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartzberg, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castegna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biesecker, L. G.</span></span> <span> </span><span class="NLM_article-title">Knockout of SLC25A19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span> (<span class="NLM_issue">43</span>),  <span class="NLM_fpage">15927</span>â <span class="NLM_lpage">15932</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0607661103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.0607661103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17035501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFymurfO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=15927-15932&issue=43&author=M.+J.+Lindhurstauthor=G.+Fiermonteauthor=S.+Songauthor=E.+Struysauthor=F.+De+Leonardisauthor=P.+L.+Schwartzbergauthor=A.+Chenauthor=A.+Castegnaauthor=N.+Verhoevenauthor=C.+K.+Mathewsauthor=F.+Palmieriauthor=L.+G.+Biesecker&title=Knockout+of+SLC25A19+causes+mitochondrial+thiamine+pyrophosphate+depletion%2C+embryonic+lethality%2C+CNS+malformations%2C+and+anemia&doi=10.1073%2Fpnas.0607661103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Knockout of SLc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia</span></div><div class="casAuthors">Lindhurst, Marjorie J.; Fiermonte, Giuseppe; Song, Shiwei; Struys, Eduard; De Leonardis, Francesco; Schwartzberg, Pamela L.; Chen, Amy; Castegna, Alessandra; Verhoeven, Nanda; Mathews, Christopher K.; Palmieri, Ferdinando; Biesecker, Leslie G.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">15927-15932</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">SLC25A19 mutations cause Amish lethal microcephaly (MCPHA), which markedly retards brain development and leads to Î±-ketoglutaric aciduria.  Previous data suggested that SLC25A19, also called DNC, is a mitochondrial deoxyribonucleotide transporter.  We generated a knockout mouse model of SLc25a19.  These animals had 100% prenatal lethality by embryonic day 12.  Affected embryos at embryonic day 10.5 have a neural-tube closure defect with ruffling of the neural fold ridges, a yolk sac erythropoietic failure, and elevated a-ketoglutarate in the amniotic fluid.  We found that these animals have normal mitochondrial ribo- and deoxyribonucleoside triphosphate levels, suggesting that transport of these mols. is not the primary role of SLC25A19.  We identified thiamine pyrophosphate (ThPP) transport as a candidate function of SLC25A19 through homol. searching and confirmed it by transport assays of the recombinant reconstituted protein.  The mitochondria of 51c25a1-/1 and MCPHA cells have undetectable and markedly reduced ThPP content, resp.  The redn. of ThPP levels causes dysfunction of the Î±-ketoglutarate dehydrogenase complex, which explains the high levels of this org. acid in MCPHA and suggests that mitochondrial ThPP transport is important for CNS development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeGKeUDEIW97Vg90H21EOLACvtfcHk0lizvsejTWeBJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFymurfO&md5=455daa1bdcb8abc75cec8fb2b325d62e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0607661103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0607661103%26sid%3Dliteratum%253Aachs%26aulast%3DLindhurst%26aufirst%3DM.%2BJ.%26aulast%3DFiermonte%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DS.%26aulast%3DStruys%26aufirst%3DE.%26aulast%3DDe%2BLeonardis%26aufirst%3DF.%26aulast%3DSchwartzberg%26aufirst%3DP.%2BL.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DCastegna%26aufirst%3DA.%26aulast%3DVerhoeven%26aufirst%3DN.%26aulast%3DMathews%26aufirst%3DC.%2BK.%26aulast%3DPalmieri%26aufirst%3DF.%26aulast%3DBiesecker%26aufirst%3DL.%2BG.%26atitle%3DKnockout%2520of%2520SLC25A19%2520causes%2520mitochondrial%2520thiamine%2520pyrophosphate%2520depletion%252C%2520embryonic%2520lethality%252C%2520CNS%2520malformations%252C%2520and%2520anemia%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26issue%3D43%26spage%3D15927%26epage%3D15932%26doi%3D10.1073%2Fpnas.0607661103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galuska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rincon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornholm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krook, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallberg-Henriksson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zierath, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holman, G. D.</span></span> <span> </span><span class="NLM_article-title">Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">647</span>â <span class="NLM_lpage">654</span>, <span class="refDoi">Â DOI: 10.2337/diabetes.49.4.647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2337%2Fdiabetes.49.4.647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10871204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFylsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2000&pages=647-654&issue=4&author=J.+W.+Ryderauthor=J.+Yangauthor=D.+Galuskaauthor=J.+Rinconauthor=M.+Bjornholmauthor=A.+Krookauthor=S.+Lundauthor=O.+Pedersenauthor=H.+Wallberg-Henrikssonauthor=J.+R.+Zierathauthor=G.+D.+Holman&title=Use+of+a+novel+impermeable+biotinylated+photolabeling+reagent+to+assess+insulin-+and+hypoxia-stimulated+cell+surface+GLUT4+content+in+skeletal+muscle+from+type+2+diabetic+patients&doi=10.2337%2Fdiabetes.49.4.647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a novel impermeable biotinylated photolabeling reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients</span></div><div class="casAuthors">Ryder, Jeffrey W.; Yang, Jing; Galuska, Dana; Rincon, Jorge; Bjornholm, Marie; Krook, Anna; Lund, Sten; Pedersen, Oluf; Wallberg-Henriksson, Harriet; Zierath, Juleen R.; Holman, Geoffrey D.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">647-654</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">Cell surface GLUT4 levels in skeletal muscle from nine type 2 diabetic subjects and nine healthy control subjects have been assessed by a new technique that involves the use of a biotinylated photo-affinity label.  A profound impairment in GLUT4 translocation to the skeletal muscle cell surface in response to insulin was obsd. in type 2 diabetic patients.  Levels of insulin-stimulated cell surface GLUT4 above basal in type 2 diabetic patients were only â¼10% of those obsd. in healthy subjects.  The magnitude of the defect in GLUT4 translocation in type 2 diabetic patients was greater than that obsd. for glucose transport activity, which was â¼50% of that in healthy subjects.  Reduced GLUT4 translocation is therefore a major contributor to the impaired glucose transport activity in skeletal muscle from type 2 diabetic subjects.  When a marked impairment in GLUT4 translocation occurs, the contribution of other transporters to transport activity becomes apparent.  In response to hypoxia, marked redns. in skeletal muscle cell surface GLUT4 levels were also obsd. in type 2 diabetic patients.  Therefore, a defect in a common late stage in signal transduction and/or a direct impairment in the GLUT4 translocation process accounts for reduced glucose transport in type 2 diabetic patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5K0u2Njim9rVg90H21EOLACvtfcHk0litEdXQXM1KOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFylsbw%253D&md5=4926551052cef030ed85e3910af565fa</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.49.4.647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.49.4.647%26sid%3Dliteratum%253Aachs%26aulast%3DRyder%26aufirst%3DJ.%2BW.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGaluska%26aufirst%3DD.%26aulast%3DRincon%26aufirst%3DJ.%26aulast%3DBjornholm%26aufirst%3DM.%26aulast%3DKrook%26aufirst%3DA.%26aulast%3DLund%26aufirst%3DS.%26aulast%3DPedersen%26aufirst%3DO.%26aulast%3DWallberg-Henriksson%26aufirst%3DH.%26aulast%3DZierath%26aufirst%3DJ.%2BR.%26aulast%3DHolman%26aufirst%3DG.%2BD.%26atitle%3DUse%2520of%2520a%2520novel%2520impermeable%2520biotinylated%2520photolabeling%2520reagent%2520to%2520assess%2520insulin-%2520and%2520hypoxia-stimulated%2520cell%2520surface%2520GLUT4%2520content%2520in%2520skeletal%2520muscle%2520from%2520type%25202%2520diabetic%2520patients%26jtitle%3DDiabetes%26date%3D2000%26volume%3D49%26issue%3D4%26spage%3D647%26epage%3D654%26doi%3D10.2337%2Fdiabetes.49.4.647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroyanagi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuzono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">1785</span>â <span class="NLM_lpage">1790</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2019.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2019.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31101471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvVGjtb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=1785-1790&issue=14&author=T.+Tsujiauthor=M.+Yamaguchiauthor=J.+Kuroyanagiauthor=S.+Furuzonoauthor=M.+Konishiauthor=K.+Terayamaauthor=J.+Tanakaauthor=M.+Saitoauthor=Y.+Kobayashi&title=Discovery+of+novel+pyridazine+derivatives+as+glucose+transporter+type+4+%28GLUT4%29+translocation+activators&doi=10.1016%2Fj.bmcl.2019.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators</span></div><div class="casAuthors">Tsuji, Takashi; Yamaguchi, Mitsuhiro; Kuroyanagi, Junichi; Furuzono, Shinji; Konishi, Masahiro; Terayama, Koji; Tanaka, Jun; Saito, Motoko; Kobayashi, Yoshiyuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1785-1790</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Fused pyridazines such as I were prepd. as glucose transporter type 4 (GLUT4) translocation activators for potential use in the treatment of type 2 diabetes; their structure-activity relationships were detd.  I lowered blood glucose levels in severely diabetic mice (10-wk aged db/db mice) after oral dosing even at 10 mg/kg; the pharmacokinetics (Cmax, AUC) of I in mice was detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFtpEOLNFBFbVg90H21EOLACvtfcHk0litEdXQXM1KOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvVGjtb4%253D&md5=43c6debc12b869f9157e1f46e4aea01c</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DTsuji%26aufirst%3DT.%26aulast%3DYamaguchi%26aufirst%3DM.%26aulast%3DKuroyanagi%26aufirst%3DJ.%26aulast%3DFuruzono%26aufirst%3DS.%26aulast%3DKonishi%26aufirst%3DM.%26aulast%3DTerayama%26aufirst%3DK.%26aulast%3DTanaka%26aufirst%3DJ.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520novel%2520pyridazine%2520derivatives%2520as%2520glucose%2520transporter%2520type%25204%2520%2528GLUT4%2529%2520translocation%2520activators%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26issue%3D14%26spage%3D1785%26epage%3D1790%26doi%3D10.1016%2Fj.bmcl.2019.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajeev, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, J. P. H.</span></span> <span> </span><span class="NLM_article-title">A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors</span>. <i>Diabetes, Obes. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">9</span>â <span class="NLM_lpage">18</span>, <span class="refDoi">Â DOI: 10.1111/dom.13650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fdom.13650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31081592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsFWiurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=9-18&author=E.+Brownauthor=S.+P.+Rajeevauthor=D.+J.+Cuthbertsonauthor=J.+P.+H.+Wilding&title=A+review+of+the+mechanism+of+action%2C+metabolic+profile+and+haemodynamic+effects+of+sodium-glucose+co-transporter-2+inhibitors&doi=10.1111%2Fdom.13650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors</span></div><div class="casAuthors">Brown, Emily; Rajeev, Surya P.; Cuthbertson, Daniel J.; Wilding, John P. H.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">S2</span>),
    <span class="NLM_cas:pages">9-18</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Inhibition of glucose transport in the kidney, to produce glucosuria and thus directly lower blood glucose seems a remarkably simple way to treat diabetes (type 1 or type 2).  The development of sodium-glucose co-transporter-2 (SGLT2) inhibitors and their subsequent clin. development has on one hand shown this to be true, but at another level has helped reveal a complex web of interacting effects starting in the kidney and modulating multiple metabolic pathways in a variety of other organs.  These underlie the now clear benefits of this class of drugs in the management of type 2 diabetes from glucose lowering, wt. loss and blood pressure redn. through to the redns. in cardiovascular and renal complications obsd. in long-term outcomes trials.  They also explain some of the adverse effects that have emerged, including the risk of diabetic ketoacidosis.  This review describes the effects of SGLT2 inhibition in relation to this complex physiol., and shows how this can favorably alter the pathophysiol. of type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuhyP9kd2nBbVg90H21EOLACvtfcHk0litEdXQXM1KOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsFWiurs%253D&md5=da83e388ab48406551ea865a65164b19</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1111%2Fdom.13650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.13650%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%26aulast%3DRajeev%26aufirst%3DS.%2BP.%26aulast%3DCuthbertson%26aufirst%3DD.%2BJ.%26aulast%3DWilding%26aufirst%3DJ.%2BP.%2BH.%26atitle%3DA%2520review%2520of%2520the%2520mechanism%2520of%2520action%252C%2520metabolic%2520profile%2520and%2520haemodynamic%2520effects%2520of%2520sodium-glucose%2520co-transporter-2%2520inhibitors%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2019%26volume%3D21%26spage%3D9%26epage%3D18%26doi%3D10.1111%2Fdom.13650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rusu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercader, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenen, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gymrek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartigan, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Grotthuss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanillas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spooner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deik, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. C.Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centeno-Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerrweck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, S. B.R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lander, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, M. C.Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shriner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielinski, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanek, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nalls, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen-Torvik, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenknecht, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snively, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudgal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langefeld, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keene, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mychaleckyj, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raffel, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodarzi, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y-D I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couper, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerwinkle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeyemo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doumatey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zonderman, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igo, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedor, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabagambe, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siscovick, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsueh, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielak, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Province, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottinger, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blot, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacheco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loos, R. J.F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borecki, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyser, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Psaty, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fornage, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, W.H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sale, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rotimi, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercader, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huerta-Chagoya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Ortiz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Macias, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtt, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar-Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tusie-Luna, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altshuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Hernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Centeno-Cruz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barajas-Olmos, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zerrweck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras-Cubas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendoza-Caamal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revilla-Monsalve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islas-Andrade, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soberon, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orozco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Villalpando, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Villalpando, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Marchand, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monroe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolonel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arellano-Campos, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ordonez-Sanchez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura-Kato, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Guillen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruz-Bautista, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Hernandez, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvirde, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeda-Valdes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, M. L.</span></span> <span> </span><span class="NLM_article-title">Type 2 diabetes variants disrupt function of SLC16A11 through two distinct mechanisms</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">199</span>â <span class="NLM_lpage">212</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2017.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28666119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsb7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2017&pages=199-212&author=V.+Rusuauthor=E.+Hochauthor=J.+M.+Mercaderauthor=D.+E.+Tenenauthor=M.+Gymrekauthor=C.+R.+Hartiganauthor=M.+DeRanauthor=M.+von+Grotthussauthor=P.+Fontanillasauthor=A.+Spoonerauthor=G.+Guzmanauthor=A.+A.+Deikauthor=K.+A.+Pierceauthor=C.+Dennisauthor=C.+B.+Clishauthor=S.+A.+Carrauthor=B.+K.+Wagnerauthor=M.+Schenoneauthor=M.+C.Y.+Ngauthor=B.+H.+Chenauthor=F.+Centeno-Cruzauthor=C.+Zerrweckauthor=L.+Orozcoauthor=D.+M.+Altshulerauthor=S.+L.+Schreiberauthor=J.+C.+Florezauthor=S.+B.R.+Jacobsauthor=E.+S.+Landerauthor=M.+C.Y.+Ngauthor=D.+Shrinerauthor=B.+H.+Chenauthor=J.+Liauthor=W.-M.+Chenauthor=X.+Guoauthor=J.+Liuauthor=S.+J.+Bielinskiauthor=L.+R.+Yanekauthor=M.+A.+Nallsauthor=M.+E.+Comeauauthor=L.+J.+Rasmussen-Torvikauthor=R.+A.+Jensenauthor=D.+S.+Evansauthor=Y.+V.+Sunauthor=P.+Anauthor=S.+R.+Patelauthor=Y.+Luauthor=J.+Longauthor=L.+L.+Armstrongauthor=L.+Wagenknechtauthor=L.+Yangauthor=B.+M.+Snivelyauthor=N.+D.+Palmerauthor=P.+Mudgalauthor=C.+D.+Langefeldauthor=K.+L.+Keeneauthor=B.+I.+Freedmanauthor=J.+C.+Mychaleckyjauthor=U.+Nayakauthor=L.+J.+Raffelauthor=M.+O.+Goodarziauthor=Y-D+I.+Chenauthor=H.+A.+Taylorauthor=A.+Correaauthor=M.+Simsauthor=D.+Couperauthor=J.+S.+Pankowauthor=E.+Boerwinkleauthor=A.+Adeyemoauthor=A.+Doumateyauthor=G.+Chenauthor=R.+A.+Mathiasauthor=D.+Vaidyaauthor=A.+B.+Singletonauthor=A.+B.+Zondermanauthor=R.+P.+Igoauthor=J.+R.+Sedorauthor=E.+K.+Kabagambeauthor=D.+S.+Siscovickauthor=B.+McKnightauthor=K.+Riceauthor=Y.+Liuauthor=W.-C.+Hsuehauthor=W.+Zhaoauthor=L.+F.+Bielakauthor=A.+Krajaauthor=M.+A.+Provinceauthor=E.+P.+Bottingerauthor=O.+Gottesmanauthor=Q.+Caiauthor=W.+Zhengauthor=W.+J.+Blotauthor=W.+L.+Loweauthor=J.+A.+Pachecoauthor=D.+C.+Crawfordauthor=E.+Grundbergauthor=S.+S.+Richauthor=M.+G.+Hayesauthor=X.-O.+Shuauthor=R.+J.F.+Loosauthor=I.+B.+Boreckiauthor=P.+A.+Peyserauthor=S.+R.+Cummingsauthor=B.+M.+Psatyauthor=M.+Fornageauthor=S.+K.+Iyengarauthor=M.+K.+Evansauthor=D.+M.+Beckerauthor=W.H.+L.+Kaoauthor=J.+G.+Wilsonauthor=J.+I.+Rotterauthor=M.+M.+Saleauthor=S.+Liuauthor=C.+N.+Rotimiauthor=D.+W.+Bowdenauthor=J.+M.+Mercaderauthor=A.+Huerta-Chagoyaauthor=H.+Garcia-Ortizauthor=H.+Moreno-Maciasauthor=A.+Manningauthor=L.+Caulkinsauthor=N.+P.+Burttauthor=J.+Flannickauthor=N.+Pattersonauthor=C.+A.+Aguilar-Salinasauthor=T.+Tusie-Lunaauthor=D.+Altshulerauthor=J.+C.+Florezauthor=A.+Martinez-Hernandezauthor=F.+Centeno-Cruzauthor=F.+M.+Barajas-Olmosauthor=C.+Zerrweckauthor=C.+Contreras-Cubasauthor=E.+Mendoza-Caamalauthor=C.+Revilla-Monsalveauthor=S.+Islas-Andradeauthor=E.+Cordovaauthor=X.+Soberonauthor=L.+Orozcoauthor=C.+Gonzalez-Villalpandoauthor=M.+E.+Gonzalez-Villalpandoauthor=C.+A.+Haimanauthor=L.+Wilkensauthor=L.+Le+Marchandauthor=K.+Monroeauthor=L.+Kolonelauthor=O.+Arellano-Camposauthor=M.+L.+Ordonez-Sanchezauthor=M.+Rodriguez-Torresauthor=Y.+Segura-Katoauthor=R.+Rodriguez-Guillenauthor=I.+Cruz-Bautistaauthor=L.+L.+Munoz-Hernandezauthor=T.+Saenzauthor=D.+Gomezauthor=U.+Alvirdeauthor=P.+Almeda-Valdesauthor=M.+L.+Cortes&title=Type+2+diabetes+variants+disrupt+function+of+SLC16A11+through+two+distinct+mechanisms&doi=10.1016%2Fj.cell.2017.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms</span></div><div class="casAuthors">Rusu, Victor; Hoch, Eitan; Mercader, Josep M.; Tenen, Danielle E.; Gymrek, Melissa; Hartigan, Christina R.; DeRan, Michael; von Grotthuss, Marcin; Fontanillas, Pierre; Spooner, Alexandra; Guzman, Gaelen; Deik, Amy A.; Pierce, Kerry A.; Dennis, Courtney; Clish, Clary B.; Carr, Steven A.; Wagner, Bridget K.; Schenone, Monica; Ng, Maggie C. Y.; Chen, Brian H.; Centeno-Cruz, Federico; Zerrweck, Carlos; Orozco, Lorena; Altshuler, David M.; Schreiber, Stuart L.; Florez, Jose C.; Jacobs, Suzanne B. R.; Lander, Eric S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">199-212.e20</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Type 2 diabetes (T2D) affects Latinos at twice the rate seen in populations of European descent.  We recently identified a risk haplotype spanning SLC16A11 that explains â¼20% of the increased T2D prevalence in Mexico.  Here, through genetic fine-mapping, we define a set of tightly linked variants likely to contain the causal allele(s).  We show that variants on the T2D-assocd. haplotype have two distinct effects: (1) decreasing SLC16A11 expression in liver and (2) disrupting a key interaction with basigin, thereby reducing cell-surface localization.  Both independent mechanisms reduce SLC16A11 function and suggest SLC16A11 is the causal gene at this locus.  To gain insight into how SLC16A11 disruption impacts T2D risk, we demonstrate that SLC16A11 is a proton-coupled monocarboxylate transporter and that genetic perturbation of SLC16A11 induces changes in fatty acid and lipid metab. that are assocd. with increased T2D risk.  Our findings suggest that increasing SLC16A11 function could be therapeutically beneficial for T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW0nTWwH_PrLVg90H21EOLACvtfcHk0lhdeFVX2U4wJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFSqsb7N&md5=9e78f244ed37f88a8ebc9c5b2ad7a204</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DRusu%26aufirst%3DV.%26aulast%3DHoch%26aufirst%3DE.%26aulast%3DMercader%26aufirst%3DJ.%2BM.%26aulast%3DTenen%26aufirst%3DD.%2BE.%26aulast%3DGymrek%26aufirst%3DM.%26aulast%3DHartigan%26aufirst%3DC.%2BR.%26aulast%3DDeRan%26aufirst%3DM.%26aulast%3Dvon%2BGrotthuss%26aufirst%3DM.%26aulast%3DFontanillas%26aufirst%3DP.%26aulast%3DSpooner%26aufirst%3DA.%26aulast%3DGuzman%26aufirst%3DG.%26aulast%3DDeik%26aufirst%3DA.%2BA.%26aulast%3DPierce%26aufirst%3DK.%2BA.%26aulast%3DDennis%26aufirst%3DC.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DWagner%26aufirst%3DB.%2BK.%26aulast%3DSchenone%26aufirst%3DM.%26aulast%3DNg%26aufirst%3DM.%2BC.Y.%26aulast%3DChen%26aufirst%3DB.%2BH.%26aulast%3DCenteno-Cruz%26aufirst%3DF.%26aulast%3DZerrweck%26aufirst%3DC.%26aulast%3DOrozco%26aufirst%3DL.%26aulast%3DAltshuler%26aufirst%3DD.%2BM.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DFlorez%26aufirst%3DJ.%2BC.%26aulast%3DJacobs%26aufirst%3DS.%2BB.R.%26aulast%3DLander%26aufirst%3DE.%2BS.%26aulast%3DNg%26aufirst%3DM.%2BC.Y.%26aulast%3DShriner%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DB.%2BH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DW.-M.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DBielinski%26aufirst%3DS.%2BJ.%26aulast%3DYanek%26aufirst%3DL.%2BR.%26aulast%3DNalls%26aufirst%3DM.%2BA.%26aulast%3DComeau%26aufirst%3DM.%2BE.%26aulast%3DRasmussen-Torvik%26aufirst%3DL.%2BJ.%26aulast%3DJensen%26aufirst%3DR.%2BA.%26aulast%3DEvans%26aufirst%3DD.%2BS.%26aulast%3DSun%26aufirst%3DY.%2BV.%26aulast%3DAn%26aufirst%3DP.%26aulast%3DPatel%26aufirst%3DS.%2BR.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DJ.%26aulast%3DArmstrong%26aufirst%3DL.%2BL.%26aulast%3DWagenknecht%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DSnively%26aufirst%3DB.%2BM.%26aulast%3DPalmer%26aufirst%3DN.%2BD.%26aulast%3DMudgal%26aufirst%3DP.%26aulast%3DLangefeld%26aufirst%3DC.%2BD.%26aulast%3DKeene%26aufirst%3DK.%2BL.%26aulast%3DFreedman%26aufirst%3DB.%2BI.%26aulast%3DMychaleckyj%26aufirst%3DJ.%2BC.%26aulast%3DNayak%26aufirst%3DU.%26aulast%3DRaffel%26aufirst%3DL.%2BJ.%26aulast%3DGoodarzi%26aufirst%3DM.%2BO.%26aulast%3DChen%26aufirst%3DY-D%2BI.%26aulast%3DTaylor%26aufirst%3DH.%2BA.%26aulast%3DCorrea%26aufirst%3DA.%26aulast%3DSims%26aufirst%3DM.%26aulast%3DCouper%26aufirst%3DD.%26aulast%3DPankow%26aufirst%3DJ.%2BS.%26aulast%3DBoerwinkle%26aufirst%3DE.%26aulast%3DAdeyemo%26aufirst%3DA.%26aulast%3DDoumatey%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMathias%26aufirst%3DR.%2BA.%26aulast%3DVaidya%26aufirst%3DD.%26aulast%3DSingleton%26aufirst%3DA.%2BB.%26aulast%3DZonderman%26aufirst%3DA.%2BB.%26aulast%3DIgo%26aufirst%3DR.%2BP.%26aulast%3DSedor%26aufirst%3DJ.%2BR.%26aulast%3DKabagambe%26aufirst%3DE.%2BK.%26aulast%3DSiscovick%26aufirst%3DD.%2BS.%26aulast%3DMcKnight%26aufirst%3DB.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHsueh%26aufirst%3DW.-C.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DBielak%26aufirst%3DL.%2BF.%26aulast%3DKraja%26aufirst%3DA.%26aulast%3DProvince%26aufirst%3DM.%2BA.%26aulast%3DBottinger%26aufirst%3DE.%2BP.%26aulast%3DGottesman%26aufirst%3DO.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DBlot%26aufirst%3DW.%2BJ.%26aulast%3DLowe%26aufirst%3DW.%2BL.%26aulast%3DPacheco%26aufirst%3DJ.%2BA.%26aulast%3DCrawford%26aufirst%3DD.%2BC.%26aulast%3DGrundberg%26aufirst%3DE.%26aulast%3DRich%26aufirst%3DS.%2BS.%26aulast%3DHayes%26aufirst%3DM.%2BG.%26aulast%3DShu%26aufirst%3DX.-O.%26aulast%3DLoos%26aufirst%3DR.%2BJ.F.%26aulast%3DBorecki%26aufirst%3DI.%2BB.%26aulast%3DPeyser%26aufirst%3DP.%2BA.%26aulast%3DCummings%26aufirst%3DS.%2BR.%26aulast%3DPsaty%26aufirst%3DB.%2BM.%26aulast%3DFornage%26aufirst%3DM.%26aulast%3DIyengar%26aufirst%3DS.%2BK.%26aulast%3DEvans%26aufirst%3DM.%2BK.%26aulast%3DBecker%26aufirst%3DD.%2BM.%26aulast%3DKao%26aufirst%3DW.H.%2BL.%26aulast%3DWilson%26aufirst%3DJ.%2BG.%26aulast%3DRotter%26aufirst%3DJ.%2BI.%26aulast%3DSale%26aufirst%3DM.%2BM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRotimi%26aufirst%3DC.%2BN.%26aulast%3DBowden%26aufirst%3DD.%2BW.%26aulast%3DMercader%26aufirst%3DJ.%2BM.%26aulast%3DHuerta-Chagoya%26aufirst%3DA.%26aulast%3DGarcia-Ortiz%26aufirst%3DH.%26aulast%3DMoreno-Macias%26aufirst%3DH.%26aulast%3DManning%26aufirst%3DA.%26aulast%3DCaulkins%26aufirst%3DL.%26aulast%3DBurtt%26aufirst%3DN.%2BP.%26aulast%3DFlannick%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DN.%26aulast%3DAguilar-Salinas%26aufirst%3DC.%2BA.%26aulast%3DTusie-Luna%26aufirst%3DT.%26aulast%3DAltshuler%26aufirst%3DD.%26aulast%3DFlorez%26aufirst%3DJ.%2BC.%26aulast%3DMartinez-Hernandez%26aufirst%3DA.%26aulast%3DCenteno-Cruz%26aufirst%3DF.%26aulast%3DBarajas-Olmos%26aufirst%3DF.%2BM.%26aulast%3DZerrweck%26aufirst%3DC.%26aulast%3DContreras-Cubas%26aufirst%3DC.%26aulast%3DMendoza-Caamal%26aufirst%3DE.%26aulast%3DRevilla-Monsalve%26aufirst%3DC.%26aulast%3DIslas-Andrade%26aufirst%3DS.%26aulast%3DCordova%26aufirst%3DE.%26aulast%3DSoberon%26aufirst%3DX.%26aulast%3DOrozco%26aufirst%3DL.%26aulast%3DGonzalez-Villalpando%26aufirst%3DC.%26aulast%3DGonzalez-Villalpando%26aufirst%3DM.%2BE.%26aulast%3DHaiman%26aufirst%3DC.%2BA.%26aulast%3DWilkens%26aufirst%3DL.%26aulast%3DLe%2BMarchand%26aufirst%3DL.%26aulast%3DMonroe%26aufirst%3DK.%26aulast%3DKolonel%26aufirst%3DL.%26aulast%3DArellano-Campos%26aufirst%3DO.%26aulast%3DOrdonez-Sanchez%26aufirst%3DM.%2BL.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DSegura-Kato%26aufirst%3DY.%26aulast%3DRodriguez-Guillen%26aufirst%3DR.%26aulast%3DCruz-Bautista%26aufirst%3DI.%26aulast%3DMunoz-Hernandez%26aufirst%3DL.%2BL.%26aulast%3DSaenz%26aufirst%3DT.%26aulast%3DGomez%26aufirst%3DD.%26aulast%3DAlvirde%26aufirst%3DU.%26aulast%3DAlmeda-Valdes%26aufirst%3DP.%26aulast%3DCortes%26aufirst%3DM.%2BL.%26atitle%3DType%25202%2520diabetes%2520variants%2520disrupt%2520function%2520of%2520SLC16A11%2520through%2520two%2520distinct%2520mechanisms%26jtitle%3DCell%26date%3D2017%26volume%3D170%26spage%3D199%26epage%3D212%26doi%3D10.1016%2Fj.cell.2017.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Orlov, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltsova, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapilevich, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusakova, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dulin, N. O.</span></span> <span> </span><span class="NLM_article-title">NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension</span>. <i>Genes Dis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">186</span>â <span class="NLM_lpage">196</span>, <span class="refDoi">Â DOI: 10.1016/j.gendis.2015.02.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.gendis.2015.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26114157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtFKrur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=186-196&issue=2&author=S.+N.+Orlovauthor=S.+V.+Koltsovaauthor=L.+V.+Kapilevichauthor=S.+V.+Gusakovaauthor=N.+O.+Dulin&title=NKCC1+and+NKCC2%3A+The+pathogenetic+role+of+cation-chloride+cotransporters+in+hypertension&doi=10.1016%2Fj.gendis.2015.02.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">NKCC1 and NKCC2: The pathogenetic role of cation-chloride cotransporters in hypertension</span></div><div class="casAuthors">Orlov, Sergei N.; Koltsova, Svetlana V.; Kapilevich, Leonid V.; Gusakova, Svetlana V.; Dulin, Nickolai O.</div><div class="citationInfo"><span class="NLM_cas:title">Genes and Diseases</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-196</span>CODEN:
                <span class="NLM_cas:coden">GDEIAV</span>;
        ISSN:<span class="NLM_cas:issn">2352-3042</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This review summarizes the data on the functional significance of ubiquitous (NKCC1) and renal-specific (NKCC2) isoforms of electroneutral sodium, potassium and chloride cotransporters.  These carriers contribute to the pathogenesis of hypertension via regulation of intracellular chloride concn. in vascular smooth muscle and neuronal cells and via sensing chloride concn. in the renal tubular fluid, resp.  Both NKCC1 and NKCC2 are inhibited by furosemide and other high-ceiling diuretics widely used for attenuation of extracellular fluid vol.  However, the chronic usage of these compds. for the treatment of hypertension and other vol.-expanded disorders may have diverse side-effects due to suppression of myogenic response in microcirculatory beds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorW1zx-rv8bLVg90H21EOLACvtfcHk0lih4DeC9wR8AA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtFKrur8%253D&md5=f5bd38fd2477cbaec53730f37b2ec1c4</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.gendis.2015.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gendis.2015.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DOrlov%26aufirst%3DS.%2BN.%26aulast%3DKoltsova%26aufirst%3DS.%2BV.%26aulast%3DKapilevich%26aufirst%3DL.%2BV.%26aulast%3DGusakova%26aufirst%3DS.%2BV.%26aulast%3DDulin%26aufirst%3DN.%2BO.%26atitle%3DNKCC1%2520and%2520NKCC2%253A%2520The%2520pathogenetic%2520role%2520of%2520cation-chloride%2520cotransporters%2520in%2520hypertension%26jtitle%3DGenes%2520Dis%26date%3D2015%26volume%3D2%26issue%3D2%26spage%3D186%26epage%3D196%26doi%3D10.1016%2Fj.gendis.2015.02.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miner, J. N.</span></span> <span> </span><span class="NLM_article-title">Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">665</span>, <span class="refDoi">Â DOI: 10.1038/s41598-017-00706-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41598-017-00706-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28386072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1cvlsVymsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=665&author=P.+K.+Tanauthor=S.+Liuauthor=E.+Gunicauthor=J.+N.+Miner&title=Discovery+and+characterization+of+verinurad%2C+a+potent+and+specific+inhibitor+of+URAT1+for+the+treatment+of+hyperuricemia+and+gout&doi=10.1038%2Fs41598-017-00706-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout</span></div><div class="casAuthors">Tan Philip K; Liu Sha; Miner Jeffrey N; Gunic Esmir</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">665</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1.  Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy.  Verinurad specifically inhibits URAT1 with a potency of 25 nM.  High affinity inhibition of uric acid transport requires URAT1 residues Cys-32, Ser-35, Phe-365 and Ile-481.  Unlike other available uricosuric agents, the requirement for Cys-32 is unique to verinurad.  Two of these residues, Ser-35 and Phe-365, are also important for urate transport kinetics.  A URAT1 binding assay using radiolabeled verinurad revealed that distinct URAT1 inhibitors benzbromarone, sulfinpyrazone and probenecid all inhibit verinurad binding via a competitive mechanism.  However, mutations made within the predicted transporter substrate channel differentially altered the potency for individual URAT1 inhibitors.  Overall, our results suggest that URAT1 inhibitors bind to a common site in the core of the transporter and sterically hinder the transit of uric acid through the substrate channel, albeit with vastly different potencies and with differential interactions with specific URAT1 amino acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSR5U-7IZ-EeOb6AVA-44PTfW6udTcc2ebb8SeBvNiCvrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvlsVymsA%253D%253D&md5=94bb439f7fa518dbff9b2e312d50074b</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-00706-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-00706-7%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DP.%2BK.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DGunic%26aufirst%3DE.%26aulast%3DMiner%26aufirst%3DJ.%2BN.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520verinurad%252C%2520a%2520potent%2520and%2520specific%2520inhibitor%2520of%2520URAT1%2520for%2520the%2520treatment%2520of%2520hyperuricemia%2520and%2520gout%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D665%26doi%3D10.1038%2Fs41598-017-00706-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Dury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, H.-U.</span></span> <span> </span><span class="NLM_article-title">Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">931</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.00931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffphar.2018.00931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30186169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVartrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=931&author=S.+Al-Duryauthor=H.-U.+Marschall&title=Ileal+bile+acid+transporter+inhibition+for+the+treatment+of+chronic+constipation%2C+cholestatic+pruritus%2C+and+NASH&doi=10.3389%2Ffphar.2018.00931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH</span></div><div class="casAuthors">Al-Dury, Samer; Marschall, Hanns-Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">931/1-931/8</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Bile acids are synthesized from cholesterol in the liver, excreted with bile into the duodenum, almost completely taken up again in the distal ileum and finally returned to the liver with portal blood in a process termed enterohepatic circulation.  Bile acid synthesis, excretion, and reuptake are tightly regulated.  The apical sodium-dependent bile acid transporter [ASBT; also known as ileal bile acid transporter (IBAT) and SLC10A2] is pivotal for the almost complete reabsorption of conjugated bile acids in the ileum.  Dysfunctional IBAT may be the cause of bile acid diarrhea.  Pharmacol. IBAT inhibition results in an increased bile acid load in the colon and subsequently a lower bile acid pool, which is assocd. with improved liver histol. in animal models of cholestatic liver disease and non-alc. steatohepatitis (NASH).  In humans, IBAT inhibitors have been tested in clin. trials with widely different indications: in patients with idiopathic chronic constipation, an increased no. of bowel movements was obsd.  In adult and pediatric cholestatic liver diseases with pruritus, various IBAT inhibitors showed potential to improve itching.  Adverse events of IBAT inhibitors, based on their mode of action, are abdominal pain and diarrhea which might patients to withdraw from study medications.  So far, no data are available of a study of IBAT inhibitors in patients with NASH.  In this review we summarize the preclin. and most recent clin. studies with various IBAT inhibitors and discuss the difficulties that should be addressed in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8e8NYHl9dubVg90H21EOLACvtfcHk0lgQgxmYeoKQdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVartrk%253D&md5=066fd4a7da22b886f98d35823f3a54a0</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00931%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Dury%26aufirst%3DS.%26aulast%3DMarschall%26aufirst%3DH.-U.%26atitle%3DIleal%2520bile%2520acid%2520transporter%2520inhibition%2520for%2520the%2520treatment%2520of%2520chronic%2520constipation%252C%2520cholestatic%2520pruritus%252C%2520and%2520NASH%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D931%26doi%3D10.3389%2Ffphar.2018.00931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Willmes, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurzbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heifetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helfand, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkenfeld, A. L.</span></span> <span> </span><span class="NLM_article-title">The longevity gene INDY (Iâm Not Dead Yet) in metabolic control: potential as pharmacological target</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">11</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2017.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.pharmthera.2017.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28987323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVygu73E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2018&pages=1-11&author=D.+M.+Willmesauthor=A.+Kurzbachauthor=C.+Henkeauthor=T.+Schumannauthor=G.+Zahnauthor=A.+Heifetzauthor=J.+Jordanauthor=S.+L.+Helfandauthor=A.+L.+Birkenfeld&title=The+longevity+gene+INDY+%28I%E2%80%99m+Not+Dead+Yet%29+in+metabolic+control%3A+potential+as+pharmacological+target&doi=10.1016%2Fj.pharmthera.2017.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">The longevity gene INDY (I'm Not Dead Yet) in metabolic control: Potential as pharmacological target</span></div><div class="casAuthors">Willmes, Diana M.; Kurzbach, Anica; Henke, Christine; Schumann, Tina; Zahn, Grit; Heifetz, Alexander; Jordan, Jens; Helfand, Stephen L.; Birkenfeld, Andreas L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The regulation of metabolic processes by the Indy (I'm Not Dead Yet) (SLC13A5/NaCT) gene was revealed through studies in Drosophila melanogaster and Caenorhabditis elegans.  Reducing the expression of Indy in these species extended their life span by a mechanism resembling caloric restriction, without reducing food intake.  In D. melanogaster, mutating the Indy gene reduced body fat content, insulin-like proteins and reactive oxygen species prodn.  Subsequent studies indicated that Indy encodes a citrate transporter located on the cell plasma membrane.  The transporter is highly expressed in the mammalian liver.  We generated a mammalian knock out model deleting the mammalian homolog mIndy (SLC13A5).  The knock out animals were protected from HFD induced obesity, fatty liver and insulin resistance.  Moreover, we have shown that inducible and liver selective knock down of mIndy protects against the development of fatty liver and insulin resistance and that obese humans with type 2 diabetes and non-alc. fatty liver disease have increased levels of mIndy.  Therefore, the transporter mINDY (NaCT) has been proposed to be an 'ideal target for the treatment of metabolic disease'.  A small mol. inhibitor of the mINDY transporter has been generated, normalizing glucose levels and reducing fatty liver in a model of diet induced obese mice.  Taken together, studies from lower organisms, mammals and humans suggest that mINDY (NaCT) is an attractive target for the treatment of metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGSuu3ENLlo7Vg90H21EOLACvtfcHk0lgQgxmYeoKQdA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVygu73E&md5=ac9c4b9b44b0985b9ac700902d49e170</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DWillmes%26aufirst%3DD.%2BM.%26aulast%3DKurzbach%26aufirst%3DA.%26aulast%3DHenke%26aufirst%3DC.%26aulast%3DSchumann%26aufirst%3DT.%26aulast%3DZahn%26aufirst%3DG.%26aulast%3DHeifetz%26aufirst%3DA.%26aulast%3DJordan%26aufirst%3DJ.%26aulast%3DHelfand%26aufirst%3DS.%2BL.%26aulast%3DBirkenfeld%26aufirst%3DA.%2BL.%26atitle%3DThe%2520longevity%2520gene%2520INDY%2520%2528I%25E2%2580%2599m%2520Not%2520Dead%2520Yet%2529%2520in%2520metabolic%2520control%253A%2520potential%2520as%2520pharmacological%2520target%26jtitle%3DPharmacol.%2520Ther.%26date%3D2018%26volume%3D185%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.pharmthera.2017.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maratou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atanur, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotroneo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chabosseau, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponsa-Cobas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frid, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldashev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutter, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aitman, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkins, M. R.</span></span> <span> </span><span class="NLM_article-title">The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>524</i></span> (<span class="NLM_issue">7565</span>),  <span class="NLM_fpage">356</span>â <span class="NLM_lpage">360</span>, <span class="refDoi">Â DOI: 10.1038/nature14620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature14620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26258299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=524&publication_year=2015&pages=356-360&issue=7565&author=L.+Zhaoauthor=E.+Oliverauthor=K.+Maratouauthor=S.+S.+Atanurauthor=O.+D.+Duboisauthor=E.+Cotroneoauthor=C.+N.+Chenauthor=L.+Wangauthor=C.+Arceauthor=P.+L.+Chabosseauauthor=J.+Ponsa-Cobasauthor=M.+G.+Fridauthor=B.+Moyonauthor=Z.+Websterauthor=A.+Aldashevauthor=J.+Ferrerauthor=G.+A.+Rutterauthor=K.+R.+Stenmarkauthor=T.+J.+Aitmanauthor=M.+R.+Wilkins&title=The+zinc+transporter+ZIP12+regulates+the+pulmonary+vascular+response+to+chronic+hypoxia&doi=10.1038%2Fnature14620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia</span></div><div class="casAuthors">Zhao, Lan; Oliver, Eduardo; Maratou, Klio; Atanur, Santosh S.; Dubois, Olivier D.; Cotroneo, Emanuele; Chen, Chien-Nien; Wang, Lei; Arce, Cristina; Chabosseau, Pauline L.; Ponsa-Cobas, Joan; Frid, Maria G.; Moyon, Benjamin; Webster, Zoe; Aldashev, Almaz; Ferrer, Jorge; Rutter, Guy A.; Stenmark, Kurt R.; Aitman, Timothy J.; Wilkins, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">524</span>
        (<span class="NLM_cas:issue">7565</span>),
    <span class="NLM_cas:pages">356-360</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The typical response of the adult mammalian pulmonary circulation to a low oxygen environment is vasoconstriction and structural remodelling of pulmonary arterioles, leading to chronic elevation of pulmonary artery pressure (pulmonary hypertension) and right ventricular hypertrophy.  Some mammals, however, exhibit genetic resistance to hypoxia-induced pulmonary hypertension.  We used a congenic breeding program and comparative genomics to exploit this variation in the rat and identified the gene Slc39a12 as a major regulator of hypoxia-induced pulmonary vascular remodelling.  Slc39a12 encodes the zinc transporter ZIP12.  Here we report that ZIP12 expression is increased in many cell types, including endothelial, smooth muscle and interstitial cells, in the remodelled pulmonary arterioles of rats, cows and humans susceptible to hypoxia-induced pulmonary hypertension.  We show that ZIP12 expression in pulmonary vascular smooth muscle cells is hypoxia dependent and that targeted inhibition of ZIP12 inhibits the rise in intracellular labile zinc in hypoxia-exposed pulmonary vascular smooth muscle cells and their proliferation in culture.  We demonstrate that genetic disruption of ZIP12 expression attenuates the development of pulmonary hypertension in rats housed in a hypoxic atm.  This new and unexpected insight into the fundamental role of a zinc transporter in mammalian pulmonary vascular homeostasis suggests a new drug target for the pharmacol. management of pulmonary hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohKfta06gnfLVg90H21EOLACvtfcHk0ljZvKyz0OymVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12jtb%252FO&md5=d1f204ffbb9e3f697da9a86b01d96bfa</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fnature14620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14620%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DOliver%26aufirst%3DE.%26aulast%3DMaratou%26aufirst%3DK.%26aulast%3DAtanur%26aufirst%3DS.%2BS.%26aulast%3DDubois%26aufirst%3DO.%2BD.%26aulast%3DCotroneo%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DC.%2BN.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DArce%26aufirst%3DC.%26aulast%3DChabosseau%26aufirst%3DP.%2BL.%26aulast%3DPonsa-Cobas%26aufirst%3DJ.%26aulast%3DFrid%26aufirst%3DM.%2BG.%26aulast%3DMoyon%26aufirst%3DB.%26aulast%3DWebster%26aufirst%3DZ.%26aulast%3DAldashev%26aufirst%3DA.%26aulast%3DFerrer%26aufirst%3DJ.%26aulast%3DRutter%26aufirst%3DG.%2BA.%26aulast%3DStenmark%26aufirst%3DK.%2BR.%26aulast%3DAitman%26aufirst%3DT.%2BJ.%26aulast%3DWilkins%26aufirst%3DM.%2BR.%26atitle%3DThe%2520zinc%2520transporter%2520ZIP12%2520regulates%2520the%2520pulmonary%2520vascular%2520response%2520to%2520chronic%2520hypoxia%26jtitle%3DNature%26date%3D2015%26volume%3D524%26issue%3D7565%26spage%3D356%26epage%3D360%26doi%3D10.1038%2Fnature14620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adekola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmugam, M.</span></span> <span> </span><span class="NLM_article-title">Glucose transporters in cancer metabolism</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">650</span>â <span class="NLM_lpage">654</span>, <span class="refDoi">Â DOI: 10.1097/CCO.0b013e328356da72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1097%2FCCO.0b013e328356da72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22913968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCltr%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=650-654&issue=6&author=K.+Adekolaauthor=S.+T.+Rosenauthor=M.+Shanmugam&title=Glucose+transporters+in+cancer+metabolism&doi=10.1097%2FCCO.0b013e328356da72"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose transporters in cancer metabolism</span></div><div class="casAuthors">Adekola, Kehinde; Rosen, Steven T.; Shanmugam, Mala</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">650-654</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: Transformed cells exhibit a high rate of glucose consumption beyond that necessary for ATP synthesis.  Glucose aids in the generation of biomass and regulates cellular signaling crit. for oncogenic progression.  A key rate-limiting step in glucose utilization is the transport of glucose across the plasma membrane.  This review will highlight key glucose transporters (GLUTs) and current therapies targeting this class of proteins.  Recent findings: GLUTs, enabling the facilitative entry of glucose into a cell, are increasingly found to be deregulated in cancer.  Although cancer-specific expression patterns for GLUTs are being identified, comprehensive analyses substantiating a role for individual GLUTs are still required.  Studies defining GLUTs as being rate-limiting in specific tumor contexts, the identification of GLUT1 inhibitors via synthetic lethality screens, novel engagement of the insulin-responsive GLUT4 in myeloma and identification of GLUT9 being a urate transporter, are key advances underscoring the need for continued investigation of this large and enigmatic class of proteins.  Summary: Tumor cells exhibit elevated levels of glucose uptake, a phenomenon that has been capitalized upon for the prognostic and diagnostic imaging of a wide range of cancers using radio-labeled glucose analogs.  We have, however, not yet been able to target glucose entry in a tumor cell-specific manner for therapy.  GLUTs have been identified as rate-limiting in specific tumor contexts.  The identification and targeting of tumor-specific GLUTs provide a promising approach to block glucose-regulated metab. and signaling more comprehensively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGmT18-me7D7Vg90H21EOLACvtfcHk0ljZvKyz0OymVQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCltr%252FL&md5=5ad6bc3f29caf6f7bb508123dcb256f1</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1097%2FCCO.0b013e328356da72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0b013e328356da72%26sid%3Dliteratum%253Aachs%26aulast%3DAdekola%26aufirst%3DK.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DShanmugam%26aufirst%3DM.%26atitle%3DGlucose%2520transporters%2520in%2520cancer%2520metabolism%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2012%26volume%3D24%26issue%3D6%26spage%3D650%26epage%3D654%26doi%3D10.1097%2FCCO.0b013e328356da72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wise, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. B.</span></span> <span> </span><span class="NLM_article-title">Glutamine addiction: a new therapeutic target in cancer</span>. <i>Trends Biochem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">433</span>, <span class="refDoi">Â DOI: 10.1016/j.tibs.2010.05.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tibs.2010.05.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20570523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=427-433&issue=8&author=D.+R.+Wiseauthor=C.+B.+Thompson&title=Glutamine+addiction%3A+a+new+therapeutic+target+in+cancer&doi=10.1016%2Fj.tibs.2010.05.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamine addiction: A new therapeutic target in cancer</span></div><div class="casAuthors">Wise, David R.; Thompson, Craig B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">427-433</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Most cancers depend on a high rate of aerobic glycolysis for their continued growth and survival.  Paradoxically, some cancer cell lines also display addiction to glutamine despite the fact that glutamine is a nonessential amino acid that can be synthesized from glucose.  The high rate of glutamine uptake exhibited by glutamine-dependent cells does not appear to result solely from its role as a nitrogen donor in nucleotide and amino acid biosynthesis.  Instead, glutamine plays a required role in the uptake of essential amino acids and in maintaining activation of TOR (target of rapamycin) kinase.  Moreover, in many cancer cells, glutamine is the primary mitochondrial substrate and is required for maintenance of mitochondrial membrane potential and integrity and for support of the NADPH prodn. needed for redox control and macromol. synthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Gv_LsNdulLVg90H21EOLACvtfcHk0ljXLrAKUH229Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKqs7s%253D&md5=915fa51996bc1c9b3ec3970b2dae7163</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2010.05.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2010.05.003%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DD.%2BR.%26aulast%3DThompson%26aufirst%3DC.%2BB.%26atitle%3DGlutamine%2520addiction%253A%2520a%2520new%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2010%26volume%3D35%26issue%3D8%26spage%3D427%26epage%3D433%26doi%3D10.1016%2Fj.tibs.2010.05.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altman, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stine, Z. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, C. V.</span></span> <span> </span><span class="NLM_article-title">From Krebs to clinic: glutamine metabolism to cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">619</span>â <span class="NLM_lpage">634</span>, <span class="refDoi">Â DOI: 10.1038/nrc.2016.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrc.2016.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27492215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=619-634&issue=10&author=B.+J.+Altmanauthor=Z.+E.+Stineauthor=C.+V.+Dang&title=From+Krebs+to+clinic%3A+glutamine+metabolism+to+cancer+therapy&doi=10.1038%2Fnrc.2016.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">From Krebs to clinic: glutamine metabolism to cancer therapy</span></div><div class="casAuthors">Altman, Brian J.; Stine, Zachary E.; Dang, Chi V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">619-634</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The resurgence of research into cancer metab. has recently broadened interests beyond glucose and the Warburg effect to other nutrients, including glutamine.  Because oncogenic alterations of metab. render cancer cells addicted to nutrients, pathways involved in glycolysis or glutaminolysis could be exploited for therapeutic purposes.  In this Review, we provide an updated overview of glutamine metab. and its involvement in tumorigenesis in vitro and in vivo, and explore the recent potential applications of basic science discoveries in the clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2GDHcwHXcnLVg90H21EOLACvtfcHk0ljXLrAKUH229Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurbI&md5=00b34261d90a91151a3e833605c4aaec</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.71%26sid%3Dliteratum%253Aachs%26aulast%3DAltman%26aufirst%3DB.%2BJ.%26aulast%3DStine%26aufirst%3DZ.%2BE.%26aulast%3DDang%26aufirst%3DC.%2BV.%26atitle%3DFrom%2520Krebs%2520to%2520clinic%253A%2520glutamine%2520metabolism%2520to%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26issue%3D10%26spage%3D619%26epage%3D634%26doi%3D10.1038%2Fnrc.2016.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Geldermalsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoeng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beith, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selinger, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâToole, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasko, J. E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J.</span></span> <span> </span><span class="NLM_article-title">ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">3201</span>â <span class="NLM_lpage">3208</span>, <span class="refDoi">Â DOI: 10.1038/onc.2015.381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fonc.2015.381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26455325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1eks73J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2016&pages=3201-3208&issue=24&author=M.+van%0AGeldermalsenauthor=Q.+Wangauthor=R.+Nagarajahauthor=A.+D.+Marshallauthor=A.+Thoengauthor=D.+Gaoauthor=W.+Ritchieauthor=Y.+Fengauthor=C.+G.+Baileyauthor=N.+Dengauthor=K.+Harveyauthor=J.+M.+Beithauthor=C.+I.+Selingerauthor=S.+A.+O%E2%80%99Tooleauthor=J.+E.+J.+Raskoauthor=J.+Holst&title=ASCT2%2FSLC1A5+controls+glutamine+uptake+and+tumour+growth+in+triple-negative+basal-like+breast+cancer&doi=10.1038%2Fonc.2015.381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">ASCT2/SLC1A5 controls glutamine uptake and tumor growth in triple-negative basal-like breast cancer</span></div><div class="casAuthors">van Geldermalsen, M.; Wang, Q.; Nagarajah, R.; Marshall, A. D.; Thoeng, A.; Gao, D.; Ritchie, W.; Feng, Y.; Bailey, C. G.; Deng, N.; Harvey, K.; Beith, J. M.; Selinger, C. I.; O'Toole, S. A.; Rasko, J. E. J.; Holst, J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3201-3208</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alanine, serine, cysteine-preferring transporter 2 (ASCT2; SLC1A5) mediates uptake of glutamine, a conditionally essential amino acid in rapidly proliferating tumor cells.  Uptake of glutamine and subsequent glutaminolysis is crit. for activation of the mTORC1 nutrient-sensing pathway, which regulates cell growth and protein translation in cancer cells.  This is of particular interest in breast cancer, as glutamine dependence is increased in high-risk breast cancer subtypes.  Pharmacol. inhibitors of ASCT2-mediated transport significantly reduced glutamine uptake in human breast cancer cell lines, leading to the suppression of mTORC1 signaling, cell growth and cell cycle progression.  Notably, these effects were subtype-dependent, with ASCT2 transport crit. only for triple-neg. (TN) basal-like breast cancer cell growth compared with minimal effects in luminal breast cancer cells.  Both stable and inducible shRNA-mediated ASCT2 knockdown confirmed that inhibiting ASCT2 function was sufficient to prevent cellular proliferation and induce rapid cell death in TN basal-like breast cancer cells, but not in luminal cells.  Using a bioluminescent orthotopic xenograft mouse model, ASCT2 expression was then shown to be necessary for both successful engraftment and growth of HCC1806 TN breast cancer cells in vivo.  Lower tumoral expression of ASCT2 conferred a significant survival advantage in xenografted mice.  These responses remained intact in primary breast cancers, where gene expression anal. showed high expression of ASCT2 and glutamine metab.-related genes, including GLUL and GLS, in a cohort of 90 TN breast cancer patients, as well as correlations with the transcriptional regulators, MYC and ATF4.  This study provides preclin. evidence for the feasibility of novel therapies exploiting ASCT2 transporter activity in breast cancer, particularly in the high-risk basal-like subgroup of TN breast cancer where there is not only high expression of ASCT2, but also a marked reliance on its activity for sustained cellular proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-no_vuezZeLVg90H21EOLACvtfcHk0ljXLrAKUH229Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1eks73J&md5=9f79dc0c47998d477eb1debe4ad3303a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fonc.2015.381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2015.381%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BGeldermalsen%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DNagarajah%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DA.%2BD.%26aulast%3DThoeng%26aufirst%3DA.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DRitchie%26aufirst%3DW.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBailey%26aufirst%3DC.%2BG.%26aulast%3DDeng%26aufirst%3DN.%26aulast%3DHarvey%26aufirst%3DK.%26aulast%3DBeith%26aufirst%3DJ.%2BM.%26aulast%3DSelinger%26aufirst%3DC.%2BI.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DS.%2BA.%26aulast%3DRasko%26aufirst%3DJ.%2BE.%2BJ.%26aulast%3DHolst%26aufirst%3DJ.%26atitle%3DASCT2%252FSLC1A5%2520controls%2520glutamine%2520uptake%2520and%2520tumour%2520growth%2520in%2520triple-negative%2520basal-like%2520breast%2520cancer%26jtitle%3DOncogene%26date%3D2016%26volume%3D35%26issue%3D24%26spage%3D3201%26epage%3D3208%26doi%3D10.1038%2Fonc.2015.381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicklin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triantafellow, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyfeler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKeigan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L. O.</span></span> <span> </span><span class="NLM_article-title">Bidirectional transport of amino acids regulates mTOR and autophagy</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">521</span>â <span class="NLM_lpage">534</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2008.11.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2008.11.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19203585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltFSnsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=521-534&issue=3&author=P.+Nicklinauthor=P.+Bergmanauthor=B.+L.+Zhangauthor=E.+Triantafellowauthor=H.+Wangauthor=B.+Nyfelerauthor=H.+D.+Yangauthor=M.+Hildauthor=C.+Kungauthor=C.+Wilsonauthor=V.+E.+Myerauthor=J.+P.+MacKeiganauthor=J.+A.+Porterauthor=Y.+K.+Wangauthor=L.+C.+Cantleyauthor=P.+M.+Finanauthor=L.+O.+Murphy&title=Bidirectional+transport+of+amino+acids+regulates+mTOR+and+autophagy&doi=10.1016%2Fj.cell.2008.11.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Bidirectional transport of amino acids regulates mTOR and autophagy</span></div><div class="casAuthors">Nicklin, Paul; Bergman, Philip; Zhang, Bailin; Triantafellow, Ellen; Wang, Henry; Nyfeler, Beat; Yang, Haidi; Hild, Marc; Kung, Charles; Wilson, Christopher; Myer, Vic E.; MacKeigan, Jeffrey P.; Porter, Jeffrey A.; Karen Wang, Y.; Cantley, Lewis C.; Finan, Peter M.; Murphy, Leon O.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">521-534</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Amino acids are required for activation of the mammalian target of rapamycin (mTOR) kinase which regulates protein translation, cell growth, and autophagy.  Cell surface transporters that allow amino acids to enter the cell and signal to mTOR are unknown.  We show that cellular uptake of L-glutamine and its subsequent rapid efflux in the presence of essential amino acids (EAA) is the rate-limiting step that activates mTOR.  L-Glutamine uptake is regulated by SLC1A5 and loss of SLC1A5 function inhibits cell growth and activates autophagy.  The mol. basis for L-glutamine sensitivity is due to SLC7A5/SLC3A2, a bidirectional transporter that regulates the simultaneous efflux of L-glutamine out of cells and transport of L-leucine/EAA into cells.  Certain tumor cell lines with high basal cellular levels of L-glutamine bypass the need for L-glutamine uptake and are primed for mTOR activation.  Thus, L-glutamine flux regulates mTOR, translation and autophagy to coordinate cell growth and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou-WsQFP-BcbVg90H21EOLACvtfcHk0litkoiuAss-Mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltFSnsrc%253D&md5=bc244efe138359f3090f6fcebe2134cd</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2008.11.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2008.11.044%26sid%3Dliteratum%253Aachs%26aulast%3DNicklin%26aufirst%3DP.%26aulast%3DBergman%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DB.%2BL.%26aulast%3DTriantafellow%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DNyfeler%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BD.%26aulast%3DHild%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DMyer%26aufirst%3DV.%2BE.%26aulast%3DMacKeigan%26aufirst%3DJ.%2BP.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%2BK.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DMurphy%26aufirst%3DL.%2BO.%26atitle%3DBidirectional%2520transport%2520of%2520amino%2520acids%2520regulates%2520mTOR%2520and%2520autophagy%26jtitle%3DCell%26date%3D2009%26volume%3D136%26issue%3D3%26spage%3D521%26epage%3D534%26doi%3D10.1016%2Fj.cell.2008.11.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppula, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, B.</span></span> <span> </span><span class="NLM_article-title">The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span> (<span class="NLM_issue">34</span>),  <span class="NLM_fpage">14240</span>â <span class="NLM_lpage">14249</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M117.798405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M117.798405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28630042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtl2iurzF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=14240-14249&issue=34&author=P.+Koppulaauthor=Y.+Zhangauthor=J.+Shiauthor=W.+Liauthor=B.+Gan&title=The+glutamate%2Fcystine+antiporter+SLC7A11%2FxCT+enhances+cancer+cell+dependency+on+glucose+by+exporting+glutamate&doi=10.1074%2Fjbc.M117.798405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate</span></div><div class="casAuthors">Koppula, Pranavi; Zhang, Yilei; Shi, Jiejun; Li, Wei; Gan, Boyi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">14240-14249</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Cancer cells with specific genetic alterations may be highly dependent on certain nutrients for survival, which can inform therapeutic strategies to target these cancer-specific metabolic vulnerabilities.  The glutamate/cystine antiporter solute carrier family 7 member 11 (SLC7A11, also called xCT) is overexpressed in several cancers.  Contrasting the established pro-survival roles of SLC7A11 under other stress conditions, here we report the unexpected finding that SLC7A11 overexpression enhances cancer cell dependence on glucose and renders cancer cells more sensitive to glucose starvation-induced cell death and, conversely, that SLC7A11 deficiency by either knockdown or pharmacol. inhibition promotes cancer cell survival upon glucose starvation.  We further show that glucose starvation induces SLC7A11 expression through ATF4 and NRF2 transcription factors and, correspondingly, that ATF4 or NRF2 deficiency also renders cancer cells more resistant to glucose starvation.  Finally, we show that SLC7A11 overexpression decreases whereas SLC7A11 deficiency increases intracellular glutamate levels because of SLC7A11-mediated glutamate export and that supplementation of Î±-ketoglutarate, a key downstream metabolite of glutamate, fully restores survival in SLC7A11-overexpressing cells under glucose starvation.  Together, our results support the notion that both glucose and glutamate have important roles in maintaining cancer cell survival and uncover a previously unappreciated role of SLC7A11 to promote cancer cell dependence on glucose.  Our study therefore informs therapeutic strategies to target the metabolic vulnerability in tumors with high SLC7A11 expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJkn9sw8AinbVg90H21EOLACvtfcHk0litkoiuAss-Mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtl2iurzF&md5=df0b727df322afb7ea0b95cc6d159b40</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.798405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.798405%26sid%3Dliteratum%253Aachs%26aulast%3DKoppula%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DGan%26aufirst%3DB.%26atitle%3DThe%2520glutamate%252Fcystine%2520antiporter%2520SLC7A11%252FxCT%2520enhances%2520cancer%2520cell%2520dependency%2520on%2520glucose%2520by%2520exporting%2520glutamate%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26issue%3D34%26spage%3D14240%26epage%3D14249%26doi%3D10.1074%2Fjbc.M117.798405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karunakaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coothankandaswamy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elangovan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy-Thandavan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnanaprakasam, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoenlein, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangaraju, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">SLC6A14 (ATB(0,+)) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span> (<span class="NLM_issue">36</span>),  <span class="NLM_fpage">31830</span>â <span class="NLM_lpage">31838</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M111.229518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M111.229518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21771784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=31830-31838&issue=36&author=S.+Karunakaranauthor=S.+Ramachandranauthor=V.+Coothankandaswamyauthor=S.+Elangovanauthor=E.+Babuauthor=S.+Periyasamy-Thandavanauthor=A.+Guravauthor=J.+P.+Gnanaprakasamauthor=N.+Singhauthor=P.+V.+Schoenleinauthor=P.+D.+Prasadauthor=M.+Thangarajuauthor=V.+Ganapathy&title=SLC6A14+%28ATB%280%2C%2B%29%29+protein%2C+a+highly+concentrative+and+broad+specific+amino+acid+transporter%2C+is+a+novel+and+effective+drug+target+for+treatment+of+estrogen+receptor-positive+breast+cancer&doi=10.1074%2Fjbc.M111.229518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer</span></div><div class="casAuthors">Karunakaran, Senthil; Ramachandran, Sabarish; Coothankandaswamy, Veena; Elangovan, Selvakumar; Babu, Ellappan; Periyasamy-Thandavan, Sudharsan; Gurav, Ashish; Gnanaprakasam, Jaya P.; Singh, Nagendra; Schoenlein, Patricia V.; Prasad, Puttur D.; Thangaraju, Muthusamy; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">31830-31838</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">SLC6A14, also known as ATB0,+, is an amino acid transporter with unique characteristics.  It transports 18 of the 20 proteinogenic amino acids.  However, this transporter is expressed only at low levels in normal tissues.  Here, we show that the transporter is up-regulated specifically in estrogen receptor (ER)-pos. breast cancer, demonstrable with primary human breast cancer tissues and human breast cancer cell lines.  SLC6A14 is an estrogen/ER target.  The transport features of SLC6A14 include concentrative transport of leucine (an activator of mTOR), glutamine (an essential amino acid for nucleotide biosynthesis and substrate for glutaminolysis), and arginine (an essential amino acid for tumor cells), suggesting that ER-pos. breast cancer cells up-regulate SLC6A14 to meet their increased demand for these amino acids.  Consequently, treatment of ER-pos. breast cancer cells in vitro with Î±-methyl-DL-tryptophan (Î±-MT), a selective blocker of SLC6A14, induces amino acid deprivation, inhibits mTOR, and activates autophagy.  Prolongation of the treatment with Î±-MT causes apoptosis.  Addn. of an autophagy inhibitor (3-methyladenine) during Î±-MT treatment also induces apoptosis.  These effects of Î±-MT are specific to ER-pos. breast cancer cells, which express the transporter.  The ability of Î±-MT to cause amino acid deprivation is significantly attenuated in MCF-7 cells, an ER-pos. breast cancer cell line, when SLC6A14 is silenced with shRNA.  In mouse xenograft studies, Î±-MT by itself is able to reduce the growth of the ER-pos. ZR-75-1 breast cancer cells.  These studies identify SLC6A14 as a novel and effective drug target for the treatment of ER-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfDE1psCVVsrVg90H21EOLACvtfcHk0litkoiuAss-Mg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFaiurzO&md5=046c74001108f451cd741e46d2ab5ec8</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.229518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.229518%26sid%3Dliteratum%253Aachs%26aulast%3DKarunakaran%26aufirst%3DS.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DCoothankandaswamy%26aufirst%3DV.%26aulast%3DElangovan%26aufirst%3DS.%26aulast%3DBabu%26aufirst%3DE.%26aulast%3DPeriyasamy-Thandavan%26aufirst%3DS.%26aulast%3DGurav%26aufirst%3DA.%26aulast%3DGnanaprakasam%26aufirst%3DJ.%2BP.%26aulast%3DSingh%26aufirst%3DN.%26aulast%3DSchoenlein%26aufirst%3DP.%2BV.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DThangaraju%26aufirst%3DM.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DSLC6A14%2520%2528ATB%25280%252C%252B%2529%2529%2520protein%252C%2520a%2520highly%2520concentrative%2520and%2520broad%2520specific%2520amino%2520acid%2520transporter%252C%2520is%2520a%2520novel%2520and%2520effective%2520drug%2520target%2520for%2520treatment%2520of%2520estrogen%2520receptor-positive%2520breast%2520cancer%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26issue%3D36%26spage%3D31830%26epage%3D31838%26doi%3D10.1074%2Fjbc.M111.229518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahimi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span> <span> </span><span class="NLM_article-title">Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">13194</span>â <span class="NLM_lpage">13205</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M115.700534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M115.700534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27129276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=13194-13205&issue=25&author=A.+Broerauthor=F.+Rahimiauthor=S.+Broer&title=Deletion+of+amino+acid+transporter+ASCT2+%28SLC1A5%29+reveals+an+essential+role+for+transporters+SNAT1+%28SLC38A1%29+and+SNAT2+%28SLC38A2%29+to+sustain+glutaminolysis+in+cancer+cells&doi=10.1074%2Fjbc.M115.700534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells</span></div><div class="casAuthors">Broer, Angelika; Rahimi, Farid; Broer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">13194-13205</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Many cancer cells depend on glutamine as they use the glutaminolysis pathway to generate building blocks and energy for anabolic purposes.  As a result, glutamine transporters are essential for cancer growth and are potential targets for cancer chemotherapy with ASCT2 (SLC1A5) being investigated most intensively.  Here we show that HeLa epithelial cervical cancer cells and 143B osteosarcoma cells express a set of glutamine transporters including SNAT1 (SLC38A1), SNAT2 (SLC38A2), SNAT4 (SLC38A4), LAT1 (SLC7A5), and ASCT2 (SLC1A5).  Net glutamine uptake did not depend on ASCT2 but required expression of SNAT1 and SNAT2.  Deletion of ASCT2 did not reduce cell growth but caused an amino acid starvation response and up-regulation of SNAT1 to replace ASCT2 functionally.  Silencing of GCN2 in the ASCT2(-/-) background reduced cell growth, showing that a combined targeted approach would inhibit growth of glutamine-dependent cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT3LAc1IdgBLVg90H21EOLACvtfcHk0lhr2cO3TzyhTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksLvE&md5=efe20f840b3c528ec6ce07791ab4849b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.700534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.700534%26sid%3Dliteratum%253Aachs%26aulast%3DBroer%26aufirst%3DA.%26aulast%3DRahimi%26aufirst%3DF.%26aulast%3DBroer%26aufirst%3DS.%26atitle%3DDeletion%2520of%2520amino%2520acid%2520transporter%2520ASCT2%2520%2528SLC1A5%2529%2520reveals%2520an%2520essential%2520role%2520for%2520transporters%2520SNAT1%2520%2528SLC38A1%2529%2520and%2520SNAT2%2520%2528SLC38A2%2529%2520to%2520sustain%2520glutaminolysis%2520in%2520cancer%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26issue%3D25%26spage%3D13194%26epage%3D13205%26doi%3D10.1074%2Fjbc.M115.700534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watrous, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAurelio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, D. C.</span></span> <span> </span><span class="NLM_article-title">The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">15074</span>, <span class="refDoi">Â DOI: 10.1038/ncomms15074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fncomms15074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28429737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1cvpvVChtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=15074&author=C.+S.+Shinauthor=P.+Mishraauthor=J.+D.+Watrousauthor=V.+Carelliauthor=M.+D%E2%80%99Aurelioauthor=M.+Jainauthor=D.+C.+Chan&title=The+glutamate%2Fcystine+xCT+antiporter+antagonizes+glutamine+metabolism+and+reduces+nutrient+flexibility&doi=10.1038%2Fncomms15074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility</span></div><div class="casAuthors">Shin Chun-Shik; Mishra Prashant; Chan David C; Mishra Prashant; Watrous Jeramie D; Jain Mohit; Carelli Valerio; Carelli Valerio; D'Aurelio Marilena</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15074</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As noted by Warburg, many cancer cells depend on the consumption of glucose.  We performed a genetic screen to identify factors responsible for glucose addiction and recovered the two subunits of the xCT antiporter (system xc(-)), which plays an antioxidant role by exporting glutamate for cystine.  Disruption of the xCT antiporter greatly improves cell viability after glucose withdrawal, because conservation of glutamate enables cells to maintain mitochondrial respiration.  In some breast cancer cells, xCT antiporter expression is upregulated through the antioxidant transcription factor Nrf2 and contributes to their requirement for glucose as a carbon source.  In cells carrying patient-derived mitochondrial DNA mutations, the xCT antiporter is upregulated and its inhibition improves mitochondrial function and cell viability.  Therefore, although upregulation of the xCT antiporter promotes antioxidant defence, it antagonizes glutamine metabolism and restricts nutrient flexibility.  In cells with mitochondrial dysfunction, the potential utility of xCT antiporter inhibition should be further tested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQRClV9KJBGDkcLvDNbOD4DfW6udTcc2eau6VWO63qV5bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvpvVChtg%253D%253D&md5=4745c5aa46dac5683db415920a023c3f</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fncomms15074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms15074%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DC.%2BS.%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DWatrous%26aufirst%3DJ.%2BD.%26aulast%3DCarelli%26aufirst%3DV.%26aulast%3DD%25E2%2580%2599Aurelio%26aufirst%3DM.%26aulast%3DJain%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DD.%2BC.%26atitle%3DThe%2520glutamate%252Fcystine%2520xCT%2520antiporter%2520antagonizes%2520glutamine%2520metabolism%2520and%2520reduces%2520nutrient%2520flexibility%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15074%26doi%3D10.1038%2Fncomms15074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardie, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Geldermalsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadowski, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreuder, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagarajah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metierre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleave, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasko, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J.</span></span> <span> </span><span class="NLM_article-title">Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development</span>. <i>J. Pathol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>236</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">278</span>â <span class="NLM_lpage">289</span>, <span class="refDoi">Â DOI: 10.1002/path.4518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fpath.4518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25693838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpslOksb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=2015&pages=278-289&issue=3&author=Q.+Wangauthor=R.+A.+Hardieauthor=A.+J.+Hoyauthor=M.+van+Geldermalsenauthor=D.+Gaoauthor=L.+Fazliauthor=M.+C.+Sadowskiauthor=S.+Balabanauthor=M.+Schreuderauthor=R.+Nagarajahauthor=J.+J.+Wongauthor=C.+Metierreauthor=N.+Pinelloauthor=N.+J.+Otteauthor=M.+L.+Lehmanauthor=M.+Gleaveauthor=C.+C.+Nelsonauthor=C.+G.+Baileyauthor=W.+Ritchieauthor=J.+E.+Raskoauthor=J.+Holst&title=Targeting+ASCT2-mediated+glutamine+uptake+blocks+prostate+cancer+growth+and+tumour+development&doi=10.1002%2Fpath.4518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development</span></div><div class="casAuthors">Wang, Qian; Hardie, Rae-Anne; Hoy, Andrew J.; van Geldermalsen, Michelle; Gao, Dadi; Fazli, Ladan; Sadowski, Martin C.; Balaban, Seher; Schreuder, Mark; Nagarajah, Rajini; Wong, Justin J.-L.; Metierre, Cynthia; Pinello, Natalia; Otte, Nicholas J.; Lehman, Melanie L.; Gleave, Martin; Nelson, Colleen C.; Bailey, Charles G.; Ritchie, William; Rasko, John E. J.; Holst, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">236</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">278-289</span>CODEN:
                <span class="NLM_cas:coden">JPTLAS</span>;
        ISSN:<span class="NLM_cas:issn">1096-9896</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Glutamine is conditionally essential in cancer cells, being utilized as a carbon and nitrogen source for macromol. prodn., as well as for anaplerotic reactions fuelling the tricarboxylic acid (TCA) cycle.  In this study, we demonstrated that the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer patient samples.  Using LNCaP and PC-3 prostate cancer cell lines, we showed that chem. or shRNA-mediated inhibition of ASCT2 function in vitro decreases glutamine uptake, cell cycle progression through E2F transcription factors, mTORC1 pathway activation and cell growth.  Chem. inhibition also reduces basal oxygen consumption and fatty acid synthesis, showing that downstream metabolic function is reliant on ASCT2-mediated glutamine uptake.  Furthermore, shRNA knockdown of ASCT2 in PC-3 cell xenografts significantly inhibits tumor growth and metastasis in vivo, assocd. with the down-regulation of E2F cell cycle pathway proteins.  In conclusion, ASCT2-mediated glutamine uptake is essential for multiple pathways regulating the cell cycle and cell growth, and is therefore a putative therapeutic target in prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowVIpseGk9_rVg90H21EOLACvtfcHk0lhr2cO3TzyhTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpslOksb8%253D&md5=71c4189e331afdca39ff610f8fa5b5ae</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fpath.4518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.4518%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHardie%26aufirst%3DR.%2BA.%26aulast%3DHoy%26aufirst%3DA.%2BJ.%26aulast%3Dvan%2BGeldermalsen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DFazli%26aufirst%3DL.%26aulast%3DSadowski%26aufirst%3DM.%2BC.%26aulast%3DBalaban%26aufirst%3DS.%26aulast%3DSchreuder%26aufirst%3DM.%26aulast%3DNagarajah%26aufirst%3DR.%26aulast%3DWong%26aufirst%3DJ.%2BJ.%26aulast%3DMetierre%26aufirst%3DC.%26aulast%3DPinello%26aufirst%3DN.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DLehman%26aufirst%3DM.%2BL.%26aulast%3DGleave%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DC.%2BC.%26aulast%3DBailey%26aufirst%3DC.%2BG.%26aulast%3DRitchie%26aufirst%3DW.%26aulast%3DRasko%26aufirst%3DJ.%2BE.%26aulast%3DHolst%26aufirst%3DJ.%26atitle%3DTargeting%2520ASCT2-mediated%2520glutamine%2520uptake%2520blocks%2520prostate%2520cancer%2520growth%2520and%2520tumour%2520development%26jtitle%3DJ.%2520Pathol%26date%3D2015%26volume%3D236%26issue%3D3%26spage%3D278%26epage%3D289%26doi%3D10.1002%2Fpath.4518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleveland, J. L.</span></span> <span> </span><span class="NLM_article-title">Targeting lactate metabolism for cancer therapeutics</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">3685</span>â <span class="NLM_lpage">3692</span>, <span class="refDoi">Â DOI: 10.1172/JCI69741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1172%2FJCI69741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23999443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=3685-3692&issue=9&author=J.+R.+Dohertyauthor=J.+L.+Cleveland&title=Targeting+lactate+metabolism+for+cancer+therapeutics&doi=10.1172%2FJCI69741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting lactate metabolism for cancer therapeutics</span></div><div class="casAuthors">Doherty, Joanne R.; Cleveland, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3685-3692</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Lactate, once considered a waste product of glycolysis, has emerged as a crit. regulator of cancer development, maintenance, and metastasis.  Indeed, tumor lactate levels correlate with increased metastasis, tumor recurrence, and poor outcome.  Lactate mediates cancer cell intrinsic effects on metab. and has addnl. non-tumor cell autonomous effects that drive tumorigenesis.  Tumor cells can metabolize lactate as an energy source and shuttle lactate to neighboring cancer cells, adjacent stroma, and vascular endothelial cells, which induces metabolic reprogramming.  Lactate also plays roles in promoting tumor inflammation and in functioning as a signaling mol. that stimulates tumor angiogenesis.  Here we review the mechanisms of lactate prodn. and transport and highlight emerging evidence indicating that targeting lactate metab. is a promising approach for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFmg5ARs0RTbVg90H21EOLACvtfcHk0liQXmWry3slBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVenu7bE&md5=aace1060fc624a520881b8e341ef33fe</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1172%2FJCI69741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI69741%26sid%3Dliteratum%253Aachs%26aulast%3DDoherty%26aufirst%3DJ.%2BR.%26aulast%3DCleveland%26aufirst%3DJ.%2BL.%26atitle%3DTargeting%2520lactate%2520metabolism%2520for%2520cancer%2520therapeutics%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26issue%3D9%26spage%3D3685%26epage%3D3692%26doi%3D10.1172%2FJCI69741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espindola Camacho, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mah, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maresh, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alavi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagryanova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krotee, P. A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behbahan, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvath, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chia, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellinghoff, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubinett, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdistani, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodglick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braas, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christofk, H. R.</span></span> <span> </span><span class="NLM_article-title">MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1590</span>â <span class="NLM_lpage">1601</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2016.01.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.celrep.2016.01.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26876179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFOht7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=1590-1601&issue=7&author=C.+S.+Hongauthor=N.+A.+Grahamauthor=W.+Guauthor=C.+Espindola+Camachoauthor=V.+Mahauthor=E.+L.+Mareshauthor=M.+Alaviauthor=L.+Bagryanovaauthor=P.+A.+L.+Kroteeauthor=B.+K.+Gardnerauthor=I.+S.+Behbahanauthor=S.+Horvathauthor=D.+Chiaauthor=I.+K.+Mellinghoffauthor=S.+A.+Hurvitzauthor=S.+M.+Dubinettauthor=S.+E.+Critchlowauthor=S.+K.+Kurdistaniauthor=L.+Goodglickauthor=D.+Braasauthor=T.+G.+Graeberauthor=H.+R.+Christofk&title=MCT1+modulates+cancer+cell+pyruvate+export+and+growth+of+tumors+that+co-express+MCT1+and+MCT4&doi=10.1016%2Fj.celrep.2016.01.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4</span></div><div class="casAuthors">Hong, Candice Sun; Graham, Nicholas A.; Gu, Wen; Espindola Camacho, Carolina; Mah, Vei; Maresh, Erin L.; Alavi, Mohammed; Bagryanova, Lora; Krotee, Pascal A. L.; Gardner, Brian K.; Behbahan, Iman Saramipoor; Horvath, Steve; Chia, David; Mellinghoff, Ingo K.; Hurvitz, Sara A.; Dubinett, Steven M.; Critchlow, Susan E.; Kurdistani, Siavash K.; Goodglick, Lee; Braas, Daniel; Graeber, Thomas G.; Christofk, Heather R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1590-1601</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Monocarboxylate transporter 1 (MCT1) inhibition is thought to block tumor growth through disruption of lactate transport and glycolysis.  Here, we show MCT1 inhibition impairs proliferation of glycolytic breast cancer cells co-expressing MCT1 and MCT4 via disruption of pyruvate rather than lactate export.  MCT1 expression is elevated in glycolytic breast tumors, and high MCT1 expression predicts poor prognosis in breast and lung cancer patients.  Acute MCT1 inhibition reduces pyruvate export but does not consistently alter lactate transport or glycolytic flux in breast cancer cells that co-express MCT1 and MCT4.  Despite the lack of glycolysis impairment, MCT1 loss-of-function decreases breast cancer cell proliferation and blocks growth of mammary fat pad xenograft tumors.  Our data suggest MCT1 expression is elevated in glycolytic cancers to promote pyruvate export that when inhibited, enhances oxidative metab. and reduces proliferation.  This study presents an alternative mol. consequence of MCT1 inhibitors, further supporting their use as anti-cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriOSyxhbJmb7Vg90H21EOLACvtfcHk0liQXmWry3slBQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFOht7o%253D&md5=2d8a976ab178e2aaa41f387a6773c18c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.01.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.01.057%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DC.%2BS.%26aulast%3DGraham%26aufirst%3DN.%2BA.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DEspindola%2BCamacho%26aufirst%3DC.%26aulast%3DMah%26aufirst%3DV.%26aulast%3DMaresh%26aufirst%3DE.%2BL.%26aulast%3DAlavi%26aufirst%3DM.%26aulast%3DBagryanova%26aufirst%3DL.%26aulast%3DKrotee%26aufirst%3DP.%2BA.%2BL.%26aulast%3DGardner%26aufirst%3DB.%2BK.%26aulast%3DBehbahan%26aufirst%3DI.%2BS.%26aulast%3DHorvath%26aufirst%3DS.%26aulast%3DChia%26aufirst%3DD.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DDubinett%26aufirst%3DS.%2BM.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DKurdistani%26aufirst%3DS.%2BK.%26aulast%3DGoodglick%26aufirst%3DL.%26aulast%3DBraas%26aufirst%3DD.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DChristofk%26aufirst%3DH.%2BR.%26atitle%3DMCT1%2520modulates%2520cancer%2520cell%2520pyruvate%2520export%2520and%2520growth%2520of%2520tumors%2520that%2520co-express%2520MCT1%2520and%2520MCT4%26jtitle%3DCell%2520Rep.%26date%3D2016%26volume%3D14%26issue%3D7%26spage%3D1590%26epage%3D1601%26doi%3D10.1016%2Fj.celrep.2016.01.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghergurovich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morscher, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esparza, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanxiang
Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span> <span> </span><span class="NLM_article-title">Glucose feeds the TCA cycle via circulating lactate</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>551</i></span>,  <span class="NLM_fpage">115</span>â <span class="NLM_lpage">118</span>, <span class="refDoi">Â DOI: 10.1038/nature24057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature24057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29045397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1M7itVeitA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=551&publication_year=2017&pages=115-118&author=S.+Huiauthor=J.+M.+Ghergurovichauthor=R.+J.+Morscherauthor=C.+Jangauthor=X.+Tengauthor=W.+Luauthor=L.+A.+Esparzaauthor=T.+Reyaauthor=L.+Zhanauthor=J.+Yanxiang%0AGuoauthor=E.+Whiteauthor=J.+D.+Rabinowitz&title=Glucose+feeds+the+TCA+cycle+via+circulating+lactate&doi=10.1038%2Fnature24057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Glucose feeds the TCA cycle via circulating lactate</span></div><div class="casAuthors">Hui Sheng; Ghergurovich Jonathan M; Morscher Raphael J; Jang Cholsoon; Teng Xin; Lu Wenyun; Rabinowitz Joshua D; Hui Sheng; Morscher Raphael J; Jang Cholsoon; Teng Xin; Lu Wenyun; Rabinowitz Joshua D; Ghergurovich Jonathan M; Esparza Lourdes A; Reya Tannishtha; Le Zhan; Yanxiang Guo Jessie; White Eileen; Rabinowitz Joshua D; Le Zhan; White Eileen; Yanxiang Guo Jessie; Yanxiang Guo Jessie</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">551</span>
        (<span class="NLM_cas:issue">7678</span>),
    <span class="NLM_cas:pages">115-118</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mammalian tissues are fuelled by circulating nutrients, including glucose, amino acids, and various intermediary metabolites.  Under aerobic conditions, glucose is generally assumed to be burned fully by tissues via the tricarboxylic acid cycle (TCA cycle) to carbon dioxide.  Alternatively, glucose can be catabolized anaerobically via glycolysis to lactate, which is itself also a potential nutrient for tissues and tumours.  The quantitative relevance of circulating lactate or other metabolic intermediates as fuels remains unclear.  Here we systematically examine the fluxes of circulating metabolites in mice, and find that lactate can be a primary source of carbon for the TCA cycle and thus of energy.  Intravenous infusions of (13)C-labelled nutrients reveal that, on a molar basis, the circulatory turnover flux of lactate is the highest of all metabolites and exceeds that of glucose by 1.1-fold in fed mice and 2.5-fold in fasting mice; lactate is made primarily from glucose but also from other sources.  In both fed and fasted mice, (13)C-lactate extensively labels TCA cycle intermediates in all tissues.  Quantitative analysis reveals that during the fasted state, the contribution of glucose to tissue TCA metabolism is primarily indirect (via circulating lactate) in all tissues except the brain.  In genetically engineered lung and pancreatic cancer tumours in fasted mice, the contribution of circulating lactate to TCA cycle intermediates exceeds that of glucose, with glutamine making a larger contribution than lactate in pancreatic cancer.  Thus, glycolysis and the TCA cycle are uncoupled at the level of lactate, which is a primary circulating TCA substrate in most tissues and tumours.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRg5xRraXiXr7BItaL1WaVAfW6udTcc2ebuK387t63vnrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7itVeitA%253D%253D&md5=52d11bb82116a571b4bf551ecd2c4690</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fnature24057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature24057%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DS.%26aulast%3DGhergurovich%26aufirst%3DJ.%2BM.%26aulast%3DMorscher%26aufirst%3DR.%2BJ.%26aulast%3DJang%26aufirst%3DC.%26aulast%3DTeng%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DEsparza%26aufirst%3DL.%2BA.%26aulast%3DReya%26aufirst%3DT.%26aulast%3DZhan%26aufirst%3DL.%26aulast%3DYanxiang%2BGuo%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DE.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26atitle%3DGlucose%2520feeds%2520the%2520TCA%2520cycle%2520via%2520circulating%2520lactate%26jtitle%3DNature%26date%3D2017%26volume%3D551%26spage%3D115%26epage%3D118%26doi%3D10.1038%2Fnature24057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faubert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharias, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, Q. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doucette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burguete, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butt, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrealba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenkinski, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malloy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wachsmann, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kernstine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBerardinis, R. J.</span></span> <span> </span><span class="NLM_article-title">Lactate metabolism in human lung tumors</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>171</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">358</span>â <span class="NLM_lpage">371</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2017.09.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2017.09.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28985563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2017&pages=358-371&issue=2&author=B.+Faubertauthor=K.+Y.+Liauthor=L.+Caiauthor=C.+T.+Hensleyauthor=J.+Kimauthor=L.+G.+Zachariasauthor=C.+Yangauthor=Q.+N.+Doauthor=S.+Doucetteauthor=D.+Burgueteauthor=H.+Liauthor=G.+Huetauthor=Q.+Yuanauthor=T.+Wigalauthor=Y.+Buttauthor=M.+Niauthor=J.+Torrealbaauthor=D.+Oliverauthor=R.+E.+Lenkinskiauthor=C.+R.+Malloyauthor=J.+W.+Wachsmannauthor=J.+D.+Youngauthor=K.+Kernstineauthor=R.+J.+DeBerardinis&title=Lactate+metabolism+in+human+lung+tumors&doi=10.1016%2Fj.cell.2017.09.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lactate Metabolism in Human Lung Tumors</span></div><div class="casAuthors">Faubert, Brandon; Li, Kevin Y.; Cai, Ling; Hensley, Christopher T.; Kim, Jiyeon; Zacharias, Lauren G.; Yang, Chendong; Do, Quyen N.; Doucette, Sarah; Burguete, Daniel; Li, Hong; Huet, Giselle; Yuan, Qing; Wigal, Trevor; Butt, Yasmeen; Ni, Min; Torrealba, Jose; Oliver, Dwight; Lenkinski, Robert E.; Malloy, Craig R.; Wachsmann, Jason W.; Young, Jamey D.; Kernstine, Kemp; De Berardinis, Ralph J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">358-371.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cancer cells consume glucose and secrete lactate in culture.  It is unknown whether lactate contributes to energy metab. in living tumors.  We previously reported that human non-small-cell lung cancers (NSCLCs) oxidize glucose in the tricarboxylic acid (TCA) cycle.  Here, we show that lactate is also a TCA cycle carbon source for NSCLC.  In human NSCLC, evidence of lactate utilization was most apparent in tumors with high 18fluorodeoxyglucose uptake and aggressive oncol. behavior.  Infusing human NSCLC patients with 13C-lactate revealed extensive labeling of TCA cycle metabolites.  In mice, deleting monocarboxylate transporter-1 (MCT1) from tumor cells eliminated lactate-dependent metabolite labeling, confirming tumor-cell-autonomous lactate uptake.  Strikingly, directly comparing lactate and glucose metab. in vivo indicated that lactate's contribution to the TCA cycle predominates.  The data indicate that tumors, including bona fide human NSCLC, can use lactate as a fuel in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFvHZlHeZHzrVg90H21EOLACvtfcHk0lgPLsFBnWFFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1WqsrfJ&md5=efdddf0b938cd359030d28964f642873</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.09.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.09.019%26sid%3Dliteratum%253Aachs%26aulast%3DFaubert%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DK.%2BY.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DHensley%26aufirst%3DC.%2BT.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DZacharias%26aufirst%3DL.%2BG.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DDo%26aufirst%3DQ.%2BN.%26aulast%3DDoucette%26aufirst%3DS.%26aulast%3DBurguete%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuet%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DQ.%26aulast%3DWigal%26aufirst%3DT.%26aulast%3DButt%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DTorrealba%26aufirst%3DJ.%26aulast%3DOliver%26aufirst%3DD.%26aulast%3DLenkinski%26aufirst%3DR.%2BE.%26aulast%3DMalloy%26aufirst%3DC.%2BR.%26aulast%3DWachsmann%26aufirst%3DJ.%2BW.%26aulast%3DYoung%26aufirst%3DJ.%2BD.%26aulast%3DKernstine%26aufirst%3DK.%26aulast%3DDeBerardinis%26aufirst%3DR.%2BJ.%26atitle%3DLactate%2520metabolism%2520in%2520human%2520lung%2520tumors%26jtitle%3DCell%26date%3D2017%26volume%3D171%26issue%3D2%26spage%3D358%26epage%3D371%26doi%3D10.1016%2Fj.cell.2017.09.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elia, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stegen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broekaert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doglioni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gorsel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escalona-Noguero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrekens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verfaillie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verbeken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmeliet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fendt, S. M.</span></span> <span> </span><span class="NLM_article-title">Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>568</i></span> (<span class="NLM_issue">7750</span>),  <span class="NLM_fpage">117</span>â <span class="NLM_lpage">121</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-0977-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-0977-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30814728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmsVyqtbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=568&publication_year=2019&pages=117-121&issue=7750&author=I.+Eliaauthor=M.+Rossiauthor=S.+Stegenauthor=D.+Broekaertauthor=G.+Doglioniauthor=M.+van+Gorselauthor=R.+Boonauthor=C.+Escalona-Nogueroauthor=S.+Torrekensauthor=C.+Verfaillieauthor=E.+Verbekenauthor=G.+Carmelietauthor=S.+M.+Fendt&title=Breast+cancer+cells+rely+on+environmental+pyruvate+to+shape+the+metastatic+niche&doi=10.1038%2Fs41586-019-0977-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</span></div><div class="casAuthors">Elia, Ilaria; Rossi, Matteo; Stegen, Steve; Broekaert, Dorien; Doglioni, Ginevra; van Gorsel, Marit; Boon, Ruben; Escalona-Noguero, Carmen; Torrekens, Sophie; Verfaillie, Catherine; Verbeken, Erik; Carmeliet, Geert; Fendt, Sarah-Maria</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">568</span>
        (<span class="NLM_cas:issue">7750</span>),
    <span class="NLM_cas:pages">117-121</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The extracellular matrix is a major component of the local environment - i.e., the niche - that dets. cell behavior.  During metastatic growth, cancer cells shape the extracellular matrix of the metastatic niche by hydroxylating collagen to promote their own metastatic growth.  However, only particular nutrients might support the ability of cancer cells to hydroxylate collagen, because nutrients dictate which enzymic reactions are active in cancer cells.  Here we show that breast cancer cells rely on the nutrient pyruvate to drive collagen-based remodelling of the extracellular matrix in the lung metastatic niche.  Specifically, we discovered that pyruvate uptake induces the prodn. of Î±-ketoglutarate.  This metabolite in turn activates collagen hydroxylation by increasing the activity of the enzyme collagen prolyl-4-hydroxylase (P4HA).  Inhibition of pyruvate metab. was sufficient to impair collagen hydroxylation and consequently the growth of breast-cancer-derived lung metastases in different mouse models.  In summary, we provide a mechanistic understanding of the link between collagen remodelling and the nutrient environment in the metastatic niche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT_tkXiytetbVg90H21EOLACvtfcHk0lgPLsFBnWFFhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmsVyqtbY%253D&md5=522f26dd89ea6261a38d79a88b9934ca</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-0977-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-0977-x%26sid%3Dliteratum%253Aachs%26aulast%3DElia%26aufirst%3DI.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DStegen%26aufirst%3DS.%26aulast%3DBroekaert%26aufirst%3DD.%26aulast%3DDoglioni%26aufirst%3DG.%26aulast%3Dvan%2BGorsel%26aufirst%3DM.%26aulast%3DBoon%26aufirst%3DR.%26aulast%3DEscalona-Noguero%26aufirst%3DC.%26aulast%3DTorrekens%26aufirst%3DS.%26aulast%3DVerfaillie%26aufirst%3DC.%26aulast%3DVerbeken%26aufirst%3DE.%26aulast%3DCarmeliet%26aufirst%3DG.%26aulast%3DFendt%26aufirst%3DS.%2BM.%26atitle%3DBreast%2520cancer%2520cells%2520rely%2520on%2520environmental%2520pyruvate%2520to%2520shape%2520the%2520metastatic%2520niche%26jtitle%3DNature%26date%3D2019%26volume%3D568%26issue%3D7750%26spage%3D117%26epage%3D121%26doi%3D10.1038%2Fs41586-019-0977-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bafaro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dempski, R. E.</span></span> <span> </span><span class="NLM_article-title">The emerging role of zinc transporters in cellular homeostasis and cancer</span>. <i>Signal. Transduct. Target Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">17029</span>, <span class="refDoi">Â DOI: 10.1038/sigtrans.2017.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fsigtrans.2017.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29218234" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=17029&author=E.+Bafaroauthor=Y.+Liuauthor=Y.+Xuauthor=R.+E.+Dempski&title=The+emerging+role+of+zinc+transporters+in+cellular+homeostasis+and+cancer&doi=10.1038%2Fsigtrans.2017.29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2017.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2017.29%26sid%3Dliteratum%253Aachs%26aulast%3DBafaro%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDempski%26aufirst%3DR.%2BE.%26atitle%3DThe%2520emerging%2520role%2520of%2520zinc%2520transporters%2520in%2520cellular%2520homeostasis%2520and%2520cancer%26jtitle%3DSignal.%2520Transduct.%2520Target%2520Ther.%26date%3D2017%26volume%3D2%26spage%3D17029%26doi%3D10.1038%2Fsigtrans.2017.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoene, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, K. Y.</span></span> <span> </span><span class="NLM_article-title">Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells</span>. <i>Am. J. Physiol Cell Physiol</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>297</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">C1188</span>â <span class="NLM_lpage">1199</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00042.2009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpcell.00042.2009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19657064" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=297&publication_year=2009&pages=C1188-1199&issue=5&author=C.+T.+Hanauthor=N.+W.+Schoeneauthor=K.+Y.+Lei&title=Influence+of+zinc+deficiency+on+Akt-Mdm2-p53+and+Akt-p21+signaling+axes+in+normal+and+malignant+human+prostate+cells&doi=10.1152%2Fajpcell.00042.2009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00042.2009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00042.2009%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DC.%2BT.%26aulast%3DSchoene%26aufirst%3DN.%2BW.%26aulast%3DLei%26aufirst%3DK.%2BY.%26atitle%3DInfluence%2520of%2520zinc%2520deficiency%2520on%2520Akt-Mdm2-p53%2520and%2520Akt-p21%2520signaling%2520axes%2520in%2520normal%2520and%2520malignant%2520human%2520prostate%2520cells%26jtitle%3DAm.%2520J.%2520Physiol%2520Cell%2520Physiol%26date%3D2009%26volume%3D297%26issue%3D5%26spage%3DC1188%26epage%3D1199%26doi%3D10.1152%2Fajpcell.00042.2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">855</span>â <span class="NLM_lpage">867</span>, <span class="refDoi">Â DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&issue=6&author=P.+T.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0ljzyeKZ4fn5aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26issue%3D6%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brady, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turski, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobbs, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiele, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Counter, C. M.</span></span> <span> </span><span class="NLM_article-title">Copper is required for oncogenic BRAF signaling and tumorigenesis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span> (<span class="NLM_issue">7501</span>),  <span class="NLM_fpage">492</span>â <span class="NLM_lpage">496</span>, <span class="refDoi">Â DOI: 10.1038/nature13180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature13180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24717435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotlymsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=492-496&issue=7501&author=D.+C.+Bradyauthor=M.+S.+Croweauthor=M.+L.+Turskiauthor=G.+A.+Hobbsauthor=X.+Yaoauthor=A.+Chaikuadauthor=S.+Knappauthor=K.+Xiaoauthor=S.+L.+Campbellauthor=D.+J.+Thieleauthor=C.+M.+Counter&title=Copper+is+required+for+oncogenic+BRAF+signaling+and+tumorigenesis&doi=10.1038%2Fnature13180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Copper is required for oncogenic BRAF signalling and tumorigenesis</span></div><div class="casAuthors">Brady, Donita C.; Crowe, Matthew S.; Turski, Michelle L.; Hobbs, G. Aaron; Yao, Xiaojie; Chaikuad, Apirat; Knapp, Stefan; Xiao, Kunhong; Campbell, Sharon L.; Thiele, Dennis J.; Counter, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7501</span>),
    <span class="NLM_cas:pages">492-496</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The BRAF kinase is mutated, typically Val 600âGlu (V600E), to induce an active oncogenic state in a large fraction of melanomas, thyroid cancers, hairy cell leukemias and, to a smaller extent, a wide spectrum of other cancers.  BRAFV600E phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer.  Targeting MEK1/2 is proving to be an important therapeutic strategy, given that a MEK1/2 inhibitor provides a survival advantage in metastatic melanoma, an effect that is increased when administered together with a BRAFV600E inhibitor.  We previously found that copper (Cu) influx enhances MEK1 phosphorylation of ERK1/2 through a Cu-MEK1 interaction.  Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAFV600E-driven signaling and tumorigenesis in mice and human cell settings.  Conversely, a MEK1-MEK5 chimera that phosphorylated ERK1/2 independently of Cu or an active ERK2 restored the tumor growth of murine cells lacking Ctr1.  Cu chelators used in the treatment of Wilson disease decreased tumor growth of human or murine cells transformed by BRAFV600E or engineered to be resistant to BRAF inhibition.  Taken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers contg. the BRAFV600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFwn_1AXDxbVg90H21EOLACvtfcHk0ljzyeKZ4fn5aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotlymsbo%253D&md5=e9514d73a334e9636f500763a78fa5bb</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnature13180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13180%26sid%3Dliteratum%253Aachs%26aulast%3DBrady%26aufirst%3DD.%2BC.%26aulast%3DCrowe%26aufirst%3DM.%2BS.%26aulast%3DTurski%26aufirst%3DM.%2BL.%26aulast%3DHobbs%26aufirst%3DG.%2BA.%26aulast%3DYao%26aufirst%3DX.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DK.%26aulast%3DCampbell%26aufirst%3DS.%2BL.%26aulast%3DThiele%26aufirst%3DD.%2BJ.%26aulast%3DCounter%26aufirst%3DC.%2BM.%26atitle%3DCopper%2520is%2520required%2520for%2520oncogenic%2520BRAF%2520signaling%2520and%2520tumorigenesis%26jtitle%3DNature%26date%3D2014%26volume%3D509%26issue%3D7501%26spage%3D492%26epage%3D496%26doi%3D10.1038%2Fnature13180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theofilopoulos, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccala, R.</span></span> <span> </span><span class="NLM_article-title">The multiple pathways to autoimmunity</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">716</span>â <span class="NLM_lpage">724</span>, <span class="refDoi">Â DOI: 10.1038/ni.3731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fni.3731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28632714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWls7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=716-724&issue=7&author=A.+N.+Theofilopoulosauthor=D.+H.+Konoauthor=R.+Baccala&title=The+multiple+pathways+to+autoimmunity&doi=10.1038%2Fni.3731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">The multiple pathways to autoimmunity</span></div><div class="casAuthors">Theofilopoulos, Argyrios N.; Kono, Dwight H.; Baccala, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">716-724</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Efforts to understand autoimmunity have been pursued relentlessly for several decades.  It has become apparent that the immune system evolved multiple mechanisms for controlling self-reactivity, and defects in one or more of these mechanisms can lead to a breakdown of tolerance.  Among the multitude of lesions assocd. with disease, the most common seem to affect peripheral tolerance rather than central tolerance.  The initial trigger for both systemic autoimmune disorders and organ-specific autoimmune disorders probably involves the recognition of self or foreign mols., esp. nucleic acids, by innate sensors.  Such recognition, in turn, triggers inflammatory responses and the engagement of previously quiescent autoreactive T cells and B cells.  Here we summarize the most prominent autoimmune pathways and identify key issues that require resoln. for full understanding of pathogenic autoimmunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr53DAy516zrLVg90H21EOLACvtfcHk0ljzyeKZ4fn5aQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWls7zF&md5=e352c17c1fd221b5892ac4c93d9d0130</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fni.3731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni.3731%26sid%3Dliteratum%253Aachs%26aulast%3DTheofilopoulos%26aufirst%3DA.%2BN.%26aulast%3DKono%26aufirst%3DD.%2BH.%26aulast%3DBaccala%26aufirst%3DR.%26atitle%3DThe%2520multiple%2520pathways%2520to%2520autoimmunity%26jtitle%3DNat.%2520Immunol.%26date%3D2017%26volume%3D18%26issue%3D7%26spage%3D716%26epage%3D724%26doi%3D10.1038%2Fni.3731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baccala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Quintial, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasius, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rimann, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutler, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theofilopoulos, A. N.</span></span> <span> </span><span class="NLM_article-title">Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">2940</span>â <span class="NLM_lpage">2945</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1222798110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.1222798110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23382217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVyqtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=2940-2945&issue=8&author=R.+Baccalaauthor=R.+Gonzalez-Quintialauthor=A.+L.+Blasiusauthor=I.+Rimannauthor=K.+Ozatoauthor=D.+H.+Konoauthor=B.+Beutlerauthor=A.+N.+Theofilopoulos&title=Essential+requirement+for+IRF8+and+SLC15A4+implicates+plasmacytoid+dendritic+cells+in+the+pathogenesis+of+lupus&doi=10.1073%2Fpnas.1222798110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Essential requirement for IRF8 and SLC15A4 implicates plasmacytoid dendritic cells in the pathogenesis of lupus</span></div><div class="casAuthors">Baccala, Oberto; Gonzalez-Quintial, Rosana; Blasius, Amanda L.; Rimann, Ivo; Ozato, Keiko; Kono, Dwight H.; Beutler, Bruce; Theofilopoulos, Argyrios N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2940-2945, S2940/1-S2940/4</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In vitro evidence suggests that plasmacytoid dendritic cells (pDCs) are intimately involved in the pathogenesis of lupus.  However, it remains to be detd. whether these cells are required in vivo for disease development and whether their contribution is restricted to hyperprodn. of type I IFNs.  To address these issues, we created lupus-predisposed mice lacking the IFN regulatory factor 8 (IRF8) or carrying a mutation that impairs the peptide/histidine transporter solute carrier family 15, member 4 (SLC15A4).  IRFS-deficient NZB mice, lacking pDCs, showed almost complete absence of anti-nuclear, anti-chromatin, and anti-erythrocyte autoantibodies, along with reduced kidney disease.  These effects were obsd. despite normal B-cell responses to Toll-like receptor (TLR) 7 and TLR9 stimuli and intact humoral responses to conventional T-dependent and -independent antigens.  Moreover, Slc1Sa4 mutant 0578176-Falpr in which pDCs are present but unable to produce type I IFNs in response to endosomal TLR ligands, also showed an absence of autoantibodies, reduced lymphadenopathy and splenomegaly, and extended survival.  Taken together, our results demonstrate that pDCs and the prodn. of type I IFNs by these cells are crit. contributors to the pathogenesis of lupus-like autoimmunity in these models.  Thus, IRF8 and SLC15A4 may provide important targets for therapeutic intervention in human lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OkV7hXLrh7Vg90H21EOLACvtfcHk0ljuJmwiE0zshg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVyqtLg%253D&md5=b3db2d5641c0dd28dea536bb6c835abc</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1222798110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1222798110%26sid%3Dliteratum%253Aachs%26aulast%3DBaccala%26aufirst%3DR.%26aulast%3DGonzalez-Quintial%26aufirst%3DR.%26aulast%3DBlasius%26aufirst%3DA.%2BL.%26aulast%3DRimann%26aufirst%3DI.%26aulast%3DOzato%26aufirst%3DK.%26aulast%3DKono%26aufirst%3DD.%2BH.%26aulast%3DBeutler%26aufirst%3DB.%26aulast%3DTheofilopoulos%26aufirst%3DA.%2BN.%26atitle%3DEssential%2520requirement%2520for%2520IRF8%2520and%2520SLC15A4%2520implicates%2520plasmacytoid%2520dendritic%2520cells%2520in%2520the%2520pathogenesis%2520of%2520lupus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26issue%3D8%26spage%3D2940%26epage%3D2945%26doi%3D10.1073%2Fpnas.1222798110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakalarski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Maziere, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlatter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span> <span> </span><span class="NLM_article-title">Endosomes are specialized platforms for bacterial sensing and NOD2 signalling</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>509</i></span> (<span class="NLM_issue">7499</span>),  <span class="NLM_fpage">240</span>â <span class="NLM_lpage">244</span>, <span class="refDoi">Â DOI: 10.1038/nature13133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature13133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24695226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Wqsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=509&publication_year=2014&pages=240-244&issue=7499&author=N.+Nakamuraauthor=J.+R.+Lillauthor=Q.+Phungauthor=Z.+Jiangauthor=C.+Bakalarskiauthor=A.+de+Maziereauthor=J.+Klumpermanauthor=M.+Schlatterauthor=L.+Delamarreauthor=I.+Mellman&title=Endosomes+are+specialized+platforms+for+bacterial+sensing+and+NOD2+signalling&doi=10.1038%2Fnature13133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Endosomes are specialized platforms for bacterial sensing and NOD2 signalling</span></div><div class="casAuthors">Nakamura, Norihiro; Lill, Jennie R.; Phung, Qui; Jiang, Zhaoshi; Bakalarski, Corey; de Maziere, Ann; Klumperman, Judith; Schlatter, Megan; Delamarre, Lelia; Mellman, Ira</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">509</span>
        (<span class="NLM_cas:issue">7499</span>),
    <span class="NLM_cas:pages">240-244</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detection of microbial pathogens involves the recognition of conserved microbial components by host cell sensors such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs).  TLRs are membrane receptors that survey the extracellular environment for microbial infections, whereas NLRs are cytosolic complexes that detect microbial products that reach the cytosol.  Upon detection, both sensor classes trigger innate inflammatory responses and allow the engagement of adaptive immunity.  Endo-lysosomes are the entry sites for a variety of pathogens, and therefore the sites at which the immune system first senses their presence.  Pathogens internalized by endocytosis are well known to activate TLRs 3 and 7-9 that are localized to endocytic compartments and detect ligands present in the endosomal lumen.  Internalized pathogens also activate sensors in the cytosol such as NOD1 and NOD2 (ref. 2), indicating that endosomes also provide for the translocation of bacterial components across the endosomal membrane.  Despite the fact that NOD2 is well understood to have a key role in regulating innate immune responses and that mutations at the NOD2 locus are a common risk factor in inflammatory bowel disease and possibly other chronic inflammatory states, little is known about how its ligands escape from endosomes.  Here we show that two endo-lysosomal peptide transporters, SLC15A3 and SLC15A4, are preferentially expressed by dendritic cells, esp. after TLR stimulation.  The transporters mediate the egress of bacterially derived components, such as the NOD2 cognate ligand muramyl dipeptide (MDP), and are selectively required for NOD2 responses to endosomally derived MDP.  Enhanced expression of the transporters also generates endosomal membrane tubules characteristic of dendritic cells, which further enhanced the NOD2-dependent response to MDP.  Finally, sensing required the recruitment of NOD2 and its effector kinase RIPK2 to the endosomal membrane, possibly by forming a complex with SLC15A3 or SLC15A4.  Thus, dendritic cell endosomes are specialized platforms for both the lumenal and cytosolic sensing of pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoppdcGuBL0_bVg90H21EOLACvtfcHk0ljuJmwiE0zshg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Wqsrw%253D&md5=dd38ce753d9529651acea52f83a753b1</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fnature13133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13133%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DN.%26aulast%3DLill%26aufirst%3DJ.%2BR.%26aulast%3DPhung%26aufirst%3DQ.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DBakalarski%26aufirst%3DC.%26aulast%3Dde%2BMaziere%26aufirst%3DA.%26aulast%3DKlumperman%26aufirst%3DJ.%26aulast%3DSchlatter%26aufirst%3DM.%26aulast%3DDelamarre%26aufirst%3DL.%26aulast%3DMellman%26aufirst%3DI.%26atitle%3DEndosomes%2520are%2520specialized%2520platforms%2520for%2520bacterial%2520sensing%2520and%2520NOD2%2520signalling%26jtitle%3DNature%26date%3D2014%26volume%3D509%26issue%3D7499%26spage%3D240%26epage%3D244%26doi%3D10.1038%2Fnature13133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span> <span> </span><span class="NLM_article-title">Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">770</span>, <span class="refDoi">Â DOI: 10.1038/s41419-018-0809-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41419-018-0809-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29991810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FmslSktw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=770&author=F.+Songauthor=Y.+Yiauthor=C.+Liauthor=Y.+Huauthor=J.+Wangauthor=D.+E.+Smithauthor=H.+Jiang&title=Regulation+and+biological+role+of+the+peptide%2Fhistidine+transporter+SLC15A3+in+Toll-like+receptor-mediated+inflammatory+responses+in+macrophage&doi=10.1038%2Fs41419-018-0809-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and biological role of the peptide/histidine transporter SLC15A3 in Toll-like receptor-mediated inflammatory responses in macrophage</span></div><div class="casAuthors">Song Feifeng; Yi Yaodong; Li Cui; Jiang Huidi; Hu Yongjun; Smith David E; Wang Jinhai</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">770</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The peptide/histidine transporter SLC15A3 is responsible for transporting histidine, certain dipeptide and peptidomimetics from inside the lysosome to cytosol.  Previous studies have indicated that SLC15A3 transcripts are mainly expressed in the lymphatic system, however, its regulation and biological role in innate immune responses and inflammatory diseases are as yet unknown.  In this study, mouse peritoneal macrophages (PMs), mouse bone marrow-derived macrophages (BMDMs), the human acute monocytic leukemia cell line THP-1 and the human lung epithelial carcinoma cell line A549 were used to investigate the regulation and biological role of SLC15A3 in TLR-mediated inflammatory responses.  Our results showed that SLC15A3 was upregulated by TLR2, TLR4, TLR7 and TLR9 ligands in macrophages at both the mRNA and protein levels via activation of NF-ÎºB (nuclear factor-kappa-B), MAPK (mitogen-activated protein kinase) and IRF3 (interferon regulatory factor 3).  Furthermore, knockdown or overexpression of SLC15A3 influenced the TLR4-triggered expression of proinflammatory cytokines.  A reporter gene assay showed that the SLC15A3 promotor contained potential NF-ÎºB binding sites, which were reasonable for regulating SLC15A3 by TLR-activation through NF-ÎºB signaling.  Additionally, SLC15A3 expression was increased and positively related to inflammation in mice with bacterial peritonitis.  The collective findings suggest that SLC15A3 is regulated by various TLRs, and that it plays an important role in regulating TLR4-mediated inflammatory responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJU6z_OohDxfx2phytoz6_fW6udTcc2eaxl7xeXid22rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FmslSktw%253D%253D&md5=d0b6becff64c3926b196b4e5d2ff1ce0</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0809-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0809-1%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DF.%26aulast%3DYi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DD.%2BE.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DRegulation%2520and%2520biological%2520role%2520of%2520the%2520peptide%252Fhistidine%2520transporter%2520SLC15A3%2520in%2520Toll-like%2520receptor-mediated%2520inflammatory%2520responses%2520in%2520macrophage%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D770%26doi%3D10.1038%2Fs41419-018-0809-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peltekova, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wintle, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amos, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Oene, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St George-Hyslop, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siminovitch, K. A.</span></span> <span> </span><span class="NLM_article-title">Functional variants of OCTN cation transporter genes are associated with Crohn disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">471</span>â <span class="NLM_lpage">475</span>, <span class="refDoi">Â DOI: 10.1038/ng1339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fng1339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15107849" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSntrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=471-475&author=V.+D.+Peltekovaauthor=R.+F.+Wintleauthor=L.+A.+Rubinauthor=C.+I.+Amosauthor=Q.+Q.+Huangauthor=X.+J.+Guauthor=B.+Newmanauthor=M.+Van+Oeneauthor=D.+Cesconauthor=G.+Greenbergauthor=A.+M.+Griffithsauthor=P.+H.+St+George-Hyslopauthor=K.+A.+Siminovitch&title=Functional+variants+of+OCTN+cation+transporter+genes+are+associated+with+Crohn+disease&doi=10.1038%2Fng1339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Functional variants of OCTN cation transporter genes are associated with Crohn disease</span></div><div class="casAuthors">Peltekova, Vanya D.; Wintle, Richard F.; Rubin, Laurence A.; Amos, Christopher I.; Huang, Qiqing; Gu, Xiangjun; Newman, Bill; Van Oene, Mark; Cescon, David; Greenberg, Gordon; Griffiths, Anne M.; St. George-Hyslop, Peter H.; Siminovitch, Katherine A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-475</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Crohn disease is a chronic, inflammatory disease of the gastrointestinal tract.  A locus of â¼250 kb at 5q31 (IBD5) was previously assocd. with susceptibility to Crohn disease, as indicated by increased prevalence of a risk haplotype of 11 single-nucleotide polymorphisms among individuals with Crohn disease, but the pathogenic lesion in the region has not yet been identified.  We report here that two variants in the org. cation transporter cluster at 5q31 (a missense substitution in SLC22A4 and a GâC transversion in the SLC22A5 promoter) form a haplotype assocd. with susceptibility to Crohn disease.  These variants alter transcription and transporter functions of the org. cation transporters and interact with variants in another gene assocd. with Crohn disease, CARD15, to increase risk of Crohn disease.  These results suggest that SLC22A4, SLC22A5 and CARD15 act in a common pathogenic pathway to cause Crohn disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowLMxh8RtbV7Vg90H21EOLACvtfcHk0lh8wARa74FH_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSntrg%253D&md5=4c6bd30ff5675377797905d36c9e50a9</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1038%2Fng1339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1339%26sid%3Dliteratum%253Aachs%26aulast%3DPeltekova%26aufirst%3DV.%2BD.%26aulast%3DWintle%26aufirst%3DR.%2BF.%26aulast%3DRubin%26aufirst%3DL.%2BA.%26aulast%3DAmos%26aufirst%3DC.%2BI.%26aulast%3DHuang%26aufirst%3DQ.%2BQ.%26aulast%3DGu%26aufirst%3DX.%2BJ.%26aulast%3DNewman%26aufirst%3DB.%26aulast%3DVan%2BOene%26aufirst%3DM.%26aulast%3DCescon%26aufirst%3DD.%26aulast%3DGreenberg%26aufirst%3DG.%26aulast%3DGriffiths%26aufirst%3DA.%2BM.%26aulast%3DSt%2BGeorge-Hyslop%26aufirst%3DP.%2BH.%26aulast%3DSiminovitch%26aufirst%3DK.%2BA.%26atitle%3DFunctional%2520variants%2520of%2520OCTN%2520cation%2520transporter%2520genes%2520are%2520associated%2520with%2520Crohn%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D471%26epage%3D475%26doi%3D10.1038%2Fng1339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekhawat, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boriack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasad, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganapathy, V.</span></span> <span> </span><span class="NLM_article-title">Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2(â/â)) mice</span>. <i>Mol. Genet. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>92</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">324</span>, <span class="refDoi">Â DOI: 10.1016/j.ymgme.2007.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.ymgme.2007.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17884651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1WltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2007&pages=315-324&issue=4&author=P.+S.+Shekhawatauthor=S.+R.+Srinivasauthor=D.+Maternauthor=M.+J.+Bennettauthor=R.+Boriackauthor=V.+Georgeauthor=H.+Xuauthor=P.+D.+Prasadauthor=P.+Roonauthor=V.+Ganapathy&title=Spontaneous+development+of+intestinal+and+colonic+atrophy+and+inflammation+in+the+carnitine-deficient+jvs+%28OCTN2%28%E2%88%92%2F%E2%88%92%29%29+mice&doi=10.1016%2Fj.ymgme.2007.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Spontaneous development of intestinal and colonic atrophy and inflammation in the carnitine-deficient jvs (OCTN2-/-) mice</span></div><div class="casAuthors">Shekhawat, Prem S.; Srinivas, Sonne R.; Matern, Dietrich; Bennett, Michael J.; Boriack, Richard; George, Varghese; Xu, Hongyan; Prasad, Puttur D.; Roon, Penny; Ganapathy, Vadivel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Genetics and Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-324</span>CODEN:
                <span class="NLM_cas:coden">MGMEFF</span>;
        ISSN:<span class="NLM_cas:issn">1096-7192</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Carnitine is essential for transport of long-chain fatty acids into mitochondria for their subsequent Î²-oxidn., but its role in the gastrointestinal tract was not well described.  Recently several genetic epidemiol. studies have shown strong assocn. between mutations in carnitine transporter genes OCTN1 and OCTN2 and a propensity to develop Crohn's disease.  This study aims to investigate role of carnitine and Î²-oxidn. in the GI tract.  The authors have studied the gastrointestinal tract effects of carnitine deficiency in a mouse model with loss-of-function mutation in the OCTN2 carnitine transporter.  Juvenile visceral steatosis (OCTN2-/-) mouse spontaneously develops intestinal villous atrophy, breakdown and inflammation with intense lymphocytic and macrophage infiltration, leading to ulcer formation and gut perforation.  There is increased apoptosis of jvs (OCTN2-/-) gut epithelial cells.  The authors obsd. an up-regulation of heat shock factor-1 (HSF-1) and several heat shock proteins (HSPs) which are known to regulate OCTN2 gene expression.  Intestinal and colonic epithelial cells in wild type mice showed high expression and activity of the enzymes of Î²-oxidn. pathway.  These studies provide evidence of an obligatory role for carnitine in the maintenance of normal intestinal and colonic structure and morphol.  Fatty acid oxidn., a metabolic pathway regulated by carnitine-dependent entry of long-chain fatty acids into mitochondrial matrix, is likely essential for normal gut function.  The authors' studies suggest that carnitine supplementation, as a means of boosting fatty acid oxidn., may be therapeutically beneficial in patients with inflammation of the intestinal tract.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy69j9_oGADbVg90H21EOLACvtfcHk0lh8wARa74FH_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1WltA%253D%253D&md5=9cb7593fdfadfbad17278cd9ecfac3ca</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ymgme.2007.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ymgme.2007.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DShekhawat%26aufirst%3DP.%2BS.%26aulast%3DSrinivas%26aufirst%3DS.%2BR.%26aulast%3DMatern%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DBoriack%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DV.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DPrasad%26aufirst%3DP.%2BD.%26aulast%3DRoon%26aufirst%3DP.%26aulast%3DGanapathy%26aufirst%3DV.%26atitle%3DSpontaneous%2520development%2520of%2520intestinal%2520and%2520colonic%2520atrophy%2520and%2520inflammation%2520in%2520the%2520carnitine-deficient%2520jvs%2520%2528OCTN2%2528%25E2%2588%2592%252F%25E2%2588%2592%2529%2529%2520mice%26jtitle%3DMol.%2520Genet.%2520Metab.%26date%3D2007%26volume%3D92%26issue%3D4%26spage%3D315%26epage%3D324%26doi%3D10.1016%2Fj.ymgme.2007.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rotter, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakir, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainin, N.</span></span> <span> </span><span class="NLM_article-title">Role of L-alanine in the response of human lymphocytes to PHA and Con A</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1726</span>â <span class="NLM_lpage">1731</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=573302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaE1MXmtV2it7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=1979&pages=1726-1731&issue=4&author=V.+Rotterauthor=Y.+Yakirauthor=N.+Trainin&title=Role+of+L-alanine+in+the+response+of+human+lymphocytes+to+PHA+and+Con+A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Role of L-alanine in the response of human lymphocytes to PHA and Con A</span></div><div class="casAuthors">Rotter, Varda; Yakir, Yeshayahu; Trainin, Nathan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1726-31</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    </div><div class="casAbstract">L-Alanine was responsible for the plasma-restoring activity of a crude thymus ext. in the response of umbilical cord lymphocytes to phytohemagglutinin and concanavalin A.  The impaired allogeneic response of umbilical cord lymphocytes in dialyzed plasma was also restored by L-alanine.  Thus, L-alanine is essential for lymphocyte allogeneic or mitogenic stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJzSPAQElCjrVg90H21EOLACvtfcHk0lh8wARa74FH_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXmtV2it7c%253D&md5=b68c0f3fda3fee9d0885f1c2e50ee536</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRotter%26aufirst%3DV.%26aulast%3DYakir%26aufirst%3DY.%26aulast%3DTrainin%26aufirst%3DN.%26atitle%3DRole%2520of%2520L-alanine%2520in%2520the%2520response%2520of%2520human%2520lymphocytes%2520to%2520PHA%2520and%2520Con%2520A%26jtitle%3DJ.%2520Immunol.%26date%3D1979%26volume%3D123%26issue%3D4%26spage%3D1726%26epage%3D1731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ron-Harel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghergurovich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Notarangelo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubosaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haigis, M. C.</span></span> <span> </span><span class="NLM_article-title">T cell activation depends on extracellular alanine</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3011</span>â <span class="NLM_lpage">3021</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2019.08.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.celrep.2019.08.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31533027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWktLrP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2019&pages=3011-3021&issue=12&author=N.+Ron-Harelauthor=J.+M.+Ghergurovichauthor=G.+Notarangeloauthor=M.+W.+LaFleurauthor=Y.+Tsubosakaauthor=A.+H.+Sharpeauthor=J.+D.+Rabinowitzauthor=M.+C.+Haigis&title=T+cell+activation+depends+on+extracellular+alanine&doi=10.1016%2Fj.celrep.2019.08.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">T Cell Activation Depends on Extracellular Alanine</span></div><div class="casAuthors">Ron-Harel, Noga; Ghergurovich, Jonathan M.; Notarangelo, Giulia; LaFleur, Martin W.; Tsubosaka, Yoshiki; Sharpe, Arlene H.; Rabinowitz, Joshua D.; Haigis, Marcia C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3011-3021.e4</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">T cell stimulation is metabolically demanding.  To exit quiescence, T cells rely on environmental nutrients, including glucose and the amino acids glutamine, leucine, serine, and arginine.  The expression of transporters for these nutrients is tightly regulated and required for T cell activation.  In contrast to these amino acids, which are essential or require multi-step biosynthesis, alanine can be made from pyruvate by a single transamination.  Here, we show that extracellular alanine is nevertheless required for efficient exit from quiescence during naive T cell activation and memory T cell restimulation.  Alanine deprivation leads to metabolic and functional impairments.  Mechanistically, this vulnerability reflects the low expression of alanine aminotransferase, the enzyme required for interconverting pyruvate and alanine, whereas activated T cells instead induce alanine transporters.  Stable isotope tracing reveals that alanine is not catabolized but instead supports protein synthesis.  Thus, T cells depend on exogenous alanine for protein synthesis and normal activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoD3RKbs2lUIbVg90H21EOLACvtfcHk0lj54iaq8uexGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWktLrP&md5=975467884a99eb75b4b05b40563496fb</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2019.08.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2019.08.034%26sid%3Dliteratum%253Aachs%26aulast%3DRon-Harel%26aufirst%3DN.%26aulast%3DGhergurovich%26aufirst%3DJ.%2BM.%26aulast%3DNotarangelo%26aufirst%3DG.%26aulast%3DLaFleur%26aufirst%3DM.%2BW.%26aulast%3DTsubosaka%26aufirst%3DY.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DRabinowitz%26aufirst%3DJ.%2BD.%26aulast%3DHaigis%26aufirst%3DM.%2BC.%26atitle%3DT%2520cell%2520activation%2520depends%2520on%2520extracellular%2520alanine%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D28%26issue%3D12%26spage%3D3011%26epage%3D3021%26doi%3D10.1016%2Fj.celrep.2019.08.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matheson, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wals, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapiteanu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weekes, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinelt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antrobus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clish, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neil, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, P. J.</span></span> <span> </span><span class="NLM_article-title">Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">409</span>â <span class="NLM_lpage">423</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2015.09.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.chom.2015.09.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26439863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SqsLzJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2015&pages=409-423&issue=4&author=N.+J.+Mathesonauthor=J.+Sumnerauthor=K.+Walsauthor=R.+Rapiteanuauthor=M.+P.+Weekesauthor=R.+Viganauthor=J.+Weineltauthor=M.+Schindlerauthor=R.+Antrobusauthor=A.+S.+Costaauthor=C.+Frezzaauthor=C.+B.+Clishauthor=S.+J.+Neilauthor=P.+J.+Lehner&title=Cell+surface+proteomic+map+of+HIV+infection+reveals+antagonism+of+amino+acid+metabolism+by+Vpu+and+Nef&doi=10.1016%2Fj.chom.2015.09.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef</span></div><div class="casAuthors">Matheson, Nicholas J.; Sumner, Jonathan; Wals, Kim; Rapiteanu, Radu; Weekes, Michael P.; Vigan, Raphael; Weinelt, Julia; Schindler, Michael; Antrobus, Robin; Costa, Ana S. H.; Frezza, Christian; Clish, Clary B.; Neil, Stuart J. D.; Lehner, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">409-423</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Crit. cell surface immunoreceptors downregulated during HIV infection have previously been identified using non-systematic, candidate approaches.  To gain a comprehensive, unbiased overview of how HIV infection remodels the T cell surface, we took a distinct, systems-level, quant. proteomic approach. >100 plasma membrane proteins, many without characterized immune functions, were downregulated during HIV infection.  Host factors targeted by the viral accessory proteins Vpu or Nef included the amino acid transporter SNAT1 and the serine carriers SERINC3/5.  We focused on SNAT1, a Î²-TrCP-dependent Vpu substrate.  SNAT1 antagonism was acquired by Vpu variants from the lineage of SIVcpz/HIV-1 viruses responsible for pandemic AIDS.  We found marked SNAT1 induction in activated primary human CD4+ T cells, and used Consumption and Release (CoRe) metabolomics to identify alanine as an endogenous SNAT1 substrate required for T cell mitogenesis.  Downregulation of SNAT1 therefore defines a unique paradigm of HIV interference with immunometabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCRR3G4C4N9bVg90H21EOLACvtfcHk0lj54iaq8uexGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SqsLzJ&md5=ce53b41dc5992aa615ee19d377e31ca6</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2015.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2015.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DMatheson%26aufirst%3DN.%2BJ.%26aulast%3DSumner%26aufirst%3DJ.%26aulast%3DWals%26aufirst%3DK.%26aulast%3DRapiteanu%26aufirst%3DR.%26aulast%3DWeekes%26aufirst%3DM.%2BP.%26aulast%3DVigan%26aufirst%3DR.%26aulast%3DWeinelt%26aufirst%3DJ.%26aulast%3DSchindler%26aufirst%3DM.%26aulast%3DAntrobus%26aufirst%3DR.%26aulast%3DCosta%26aufirst%3DA.%2BS.%26aulast%3DFrezza%26aufirst%3DC.%26aulast%3DClish%26aufirst%3DC.%2BB.%26aulast%3DNeil%26aufirst%3DS.%2BJ.%26aulast%3DLehner%26aufirst%3DP.%2BJ.%26atitle%3DCell%2520surface%2520proteomic%2520map%2520of%2520HIV%2520infection%2520reveals%2520antagonism%2520of%2520amino%2520acid%2520metabolism%2520by%2520Vpu%2520and%2520Nef%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2015%26volume%3D18%26issue%3D4%26spage%3D409%26epage%3D423%26doi%3D10.1016%2Fj.chom.2015.09.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaratne, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K. E.</span></span> <span> </span><span class="NLM_article-title">The role of ion transporters in the pathophysiology of infectious diarrhea</span>. <i>Cell Mol. Gastroenterol Hepatol</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>â <span class="NLM_lpage">45</span>, <span class="refDoi">Â DOI: 10.1016/j.jcmgh.2018.02.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.jcmgh.2018.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29928670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1MbpvFaqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=33-45&issue=1&author=S.+Dasauthor=R.+Jayaratneauthor=K.+E.+Barrett&title=The+role+of+ion+transporters+in+the+pathophysiology+of+infectious+diarrhea&doi=10.1016%2Fj.jcmgh.2018.02.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Ion Transporters in the Pathophysiology of Infectious Diarrhea</span></div><div class="casAuthors">Das Soumita; Jayaratne Rashini; Barrett Kim E</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular gastroenterology and hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33-45</span>
        ISSN:<span class="NLM_cas:issn">2352-345X</span>.
    </div><div class="casAbstract">Every year, enteric infections and associated diarrhea kill millions of people.  The situation is compounded by increases in the number of enteric pathogens that are acquiring resistance to antibiotics, as well as (hitherto) a relative paucity of information on host molecular targets that may contribute to diarrhea.  Many forms of diarrheal disease depend on the dysregulation of intestinal ion transporters, and an associated imbalance between secretory and absorptive functions of the intestinal epithelium.  A number of major transporters have been implicated in the pathogenesis of diarrheal diseases and thus an understanding of their expression, localization, and regulation after infection with various bacteria, viruses, and protozoa likely will prove critical in designing new therapies.  This article surveys our understanding of transporters that are modulated by specific pathogens and the mechanism(s) involved, thereby illuminating targets that might be exploited for new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTU2_b4Qx962a91pGlMMoT5fW6udTcc2eYfZaUn_vQztLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbpvFaqsQ%253D%253D&md5=98e87eab395154f187e9a221a41d4b5e</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.jcmgh.2018.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcmgh.2018.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DS.%26aulast%3DJayaratne%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DK.%2BE.%26atitle%3DThe%2520role%2520of%2520ion%2520transporters%2520in%2520the%2520pathophysiology%2520of%2520infectious%2520diarrhea%26jtitle%3DCell%2520Mol.%2520Gastroenterol%2520Hepatol%26date%3D2018%26volume%3D6%26issue%3D1%26spage%3D33%26epage%3D45%26doi%3D10.1016%2Fj.jcmgh.2018.02.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gujral, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priyamvada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrefai, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudeja, P. K.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of DRA recycling in intestinal epithelial cells: effect of enteropathogenic E. coli</span>. <i>Am. J. Physiol Cell Physiol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>309</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">C835</span>â <span class="NLM_lpage">846</span>, <span class="refDoi">Â DOI: 10.1152/ajpcell.00107.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpcell.00107.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26447204" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=309&publication_year=2015&pages=C835-846&issue=12&author=T.+Gujralauthor=A.+Kumarauthor=S.+Priyamvadaauthor=S.+Saksenaauthor=R.+K.+Gillauthor=K.+Hodgesauthor=W.+A.+Alrefaiauthor=G.+A.+Hechtauthor=P.+K.+Dudeja&title=Mechanisms+of+DRA+recycling+in+intestinal+epithelial+cells%3A+effect+of+enteropathogenic+E.+coli&doi=10.1152%2Fajpcell.00107.2015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00107.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00107.2015%26sid%3Dliteratum%253Aachs%26aulast%3DGujral%26aufirst%3DT.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DPriyamvada%26aufirst%3DS.%26aulast%3DSaksena%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DHodges%26aufirst%3DK.%26aulast%3DAlrefai%26aufirst%3DW.%2BA.%26aulast%3DHecht%26aufirst%3DG.%2BA.%26aulast%3DDudeja%26aufirst%3DP.%2BK.%26atitle%3DMechanisms%2520of%2520DRA%2520recycling%2520in%2520intestinal%2520epithelial%2520cells%253A%2520effect%2520of%2520enteropathogenic%2520E.%2520coli%26jtitle%3DAm.%2520J.%2520Physiol%2520Cell%2520Physiol%26date%3D2015%26volume%3D309%26issue%3D12%26spage%3DC835%26epage%3D846%26doi%3D10.1152%2Fajpcell.00107.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laiko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murtazina, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malyukova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boedeker, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutsal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâMalley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovbasnjuk, O.</span></span> <span> </span><span class="NLM_article-title">Shiga toxin 1 interaction with enterocytes causes apical protein mistargeting through the depletion of intracellular galectin-3</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">657</span>â <span class="NLM_lpage">666</span>, <span class="refDoi">Â DOI: 10.1016/j.yexcr.2009.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.yexcr.2009.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19744479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCmt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2010&pages=657-666&author=M.+Laikoauthor=R.+Murtazinaauthor=I.+Malyukovaauthor=C.+R.+Zhuauthor=E.+C.+Boedekerauthor=O.+Gutsalauthor=R.+O%E2%80%99Malleyauthor=R.+N.+Coleauthor=P.+I.+Tarrauthor=K.+F.+Murrayauthor=A.+Kaneauthor=M.+Donowitzauthor=O.+Kovbasnjuk&title=Shiga+toxin+1+interaction+with+enterocytes+causes+apical+protein+mistargeting+through+the+depletion+of+intracellular+galectin-3&doi=10.1016%2Fj.yexcr.2009.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Shiga toxin 1 interaction with enterocytes causes apical protein mistargeting through the depletion of intracellular galectin-3</span></div><div class="casAuthors">Laiko, Marina; Murtazina, Rakhilya; Malyukova, Irina; Zhu, Chengru; Boedeker, Edgar C.; Gutsal, Oksana; O'Malley, Robert; Cole, Robert N.; Tarr, Phillip I.; Murray, Karen F.; Kane, Anne; Donowitz, Mark; Kovbasnjuk, Olga</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-666</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Shiga toxins (Stx) 1 and 2 are responsible for intestinal and systemic sequelae of infection by enterohemorrhagic Escherichia coli (EHEC).  However, the mechanisms through which enterocytes are damaged remain unclear.  While secondary damage from ischemia and inflammation are postulated mechanisms for all intestinal effects, little evidence excludes roles for more primary toxin effects on intestinal epithelial cells.  We now document direct pathol. effects of Stx on intestinal epithelial cells.  We study a well-characterized rabbit model of EHEC infection, intestinal tissue and stool samples from EHEC-infected patients, and T84 intestinal epithelial cells treated with Stx1.  Toxin uptake by intestinal epithelial cells in vitro and in vivo causes galectin-3 depletion from enterocytes by increasing the apical galectin-3 secretion.  This Shiga toxin-mediated galectin-3 depletion impairs trafficking of several brush border structural proteins and transporters, including villin, dipeptidyl peptidase IV, and the sodium-proton exchanger 2, a major colonic sodium absorptive protein.  The mistargeting of proteins responsible for the absorptive function might be a key event in Stx1-induced diarrhea.  These observations provide new evidence that human enterocytes are directly damaged by Stx1.  Conceivably, depletion of galectin-3 from enterocytes and subsequent apical protein mistargeting might even provide a means whereby other pathogens might alter intestinal epithelial absorption and produce diarrhea.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhbliVqfBUzbVg90H21EOLACvtfcHk0ljkBtTXYiUtmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCmt7o%253D&md5=c861bbc8dd78ff4771ec2bc757073489</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2009.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2009.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DLaiko%26aufirst%3DM.%26aulast%3DMurtazina%26aufirst%3DR.%26aulast%3DMalyukova%26aufirst%3DI.%26aulast%3DZhu%26aufirst%3DC.%2BR.%26aulast%3DBoedeker%26aufirst%3DE.%2BC.%26aulast%3DGutsal%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DR.%26aulast%3DCole%26aufirst%3DR.%2BN.%26aulast%3DTarr%26aufirst%3DP.%2BI.%26aulast%3DMurray%26aufirst%3DK.%2BF.%26aulast%3DKane%26aufirst%3DA.%26aulast%3DDonowitz%26aufirst%3DM.%26aulast%3DKovbasnjuk%26aufirst%3DO.%26atitle%3DShiga%2520toxin%25201%2520interaction%2520with%2520enterocytes%2520causes%2520apical%2520protein%2520mistargeting%2520through%2520the%2520depletion%2520of%2520intracellular%2520galectin-3%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2010%26volume%3D316%26spage%3D657%26epage%3D666%26doi%3D10.1016%2Fj.yexcr.2009.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeruva, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamprecht, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jonge, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogema, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. C.</span></span> <span> </span><span class="NLM_article-title">Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">649</span>â <span class="NLM_lpage">658</span>, <span class="refDoi">Â DOI: 10.1053/j.gastro.2009.09.055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1053%2Fj.gastro.2009.09.055" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19800338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVCns7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2010&pages=649-658&issue=2&author=S.+Linauthor=S.+Yeruvaauthor=P.+Heauthor=A.+K.+Singhauthor=H.+Zhangauthor=M.+Chenauthor=G.+Lamprechtauthor=H.+R.+de+Jongeauthor=M.+Tseauthor=M.+Donowitzauthor=B.+M.+Hogemaauthor=J.+Chunauthor=U.+Seidlerauthor=C.+C.+Yun&title=Lysophosphatidic+acid+stimulates+the+intestinal+brush+border+Na%28%2B%29%2FH%28%2B%29+exchanger+3+and+fluid+absorption+via+LPA%285%29+and+NHERF2&doi=10.1053%2Fj.gastro.2009.09.055"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Lysophosphatidic acid stimulates the intestinal brush border Na+/H+ exchanger 3 and fluid absorption via LPA5 and NHERF2</span></div><div class="casAuthors">Lin, Songbai; Yeruva, Sunil; He, Peijian; Singh, Anurag Kumar; Zhang, Huanchun; Chen, Mingmin; Lamprecht, Georg; de Jonge, Hugo R.; Tse, Ming; Donowitz, Mark; Hogema, Boris M.; Chun, Jerold; Seidler, Ursula; Yun, C. Chris</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">649-658</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background & Aims: Diarrhea results from reduced net fluid and salt absorption caused by an imbalance in intestinal absorption and secretion.  The bulk of sodium and water absorption in the intestine is mediated by Na+/H+ exchanger 3 (NHE3), located in the luminal membrane of enterocytes.  We investigated the effect of lysophosphatidic acid (LPA) on Na+/H+ exchanger activity and Na+-dependent fluid absorption in the intestine.  Methods: We analyzed the effects of LPA on fluid absorption in intestines of wild-type mice and mice deficient in Na+/H+ exchanger regulatory factor 2 (NHERF2; Nherf2-/-), or LPA2 (Lpa2-/-).  Roles of LPA5 and NHERF2 were detd. by anal. of heterologous expression.  Results: Under basal conditions, LPA increased fluid absorption in an NHE3-dependent manner and restored the net fluid loss in a mouse model of acute diarrhea.  Expression of the LPA receptor LPA5 was necessary for LPA-induced stimulation of NHE3 activity in colonic epithelial cells.  Stimulation of NHE3 by the LPA-LPA5 signaling required coexpression of NHERF2, which interacted with LPA5.  LPA-mediated intestinal fluid absorption was impaired in Nherf2-/- mice, demonstrating the requirement for NHERF2 in LPA5 activity.  However, fluid absorption was unaltered in Lpa2-/- mice.  LPA stimulated NHE3 and fluid absorption in part by increasing NHE3 protein abundance at the brush border membrane of intestinal epithelial cells.  Conclusions: LPA is a potent stimulant of NHE3 and fluid absorption in the intestine, signaling through LPA5.  Regulation by LPA5 depends on its interaction with NHERF2.  LPA might be useful in the treatment of certain diarrheal diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojl5tXr1pzqbVg90H21EOLACvtfcHk0ljkBtTXYiUtmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVCns7w%253D&md5=99cef518c40f1ddd437b35540fbd0033</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2009.09.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2009.09.055%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DS.%26aulast%3DYeruva%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%2BK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLamprecht%26aufirst%3DG.%26aulast%3Dde%2BJonge%26aufirst%3DH.%2BR.%26aulast%3DTse%26aufirst%3DM.%26aulast%3DDonowitz%26aufirst%3DM.%26aulast%3DHogema%26aufirst%3DB.%2BM.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DSeidler%26aufirst%3DU.%26aulast%3DYun%26aufirst%3DC.%2BC.%26atitle%3DLysophosphatidic%2520acid%2520stimulates%2520the%2520intestinal%2520brush%2520border%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%25203%2520and%2520fluid%2520absorption%2520via%2520LPA%25285%2529%2520and%2520NHERF2%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26issue%3D2%26spage%3D649%26epage%3D658%26doi%3D10.1053%2Fj.gastro.2009.09.055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anbazhagan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priyamvada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gujral, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrefai, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borthakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudeja, P. K.</span></span> <span> </span><span class="NLM_article-title">Lactobacillus acidophilus counteracts inhibition of NHE3 and DRA expression and alleviates diarrheal phenotype in mice infected with Citrobacter rodentium</span>. <i>Am. J. Physiol Gastrointest Liver Physiol</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>311</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">G817</span>â <span class="NLM_lpage">G826</span>, <span class="refDoi">Â DOI: 10.1152/ajpgi.00173.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpgi.00173.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27634011" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2016&pages=G817-G826&issue=5&author=A.+Kumarauthor=A.+N.+Anbazhaganauthor=H.+Coffingauthor=I.+Chatterjeeauthor=S.+Priyamvadaauthor=T.+Gujralauthor=S.+Saksenaauthor=R.+K.+Gillauthor=W.+A.+Alrefaiauthor=A.+Borthakurauthor=P.+K.+Dudeja&title=Lactobacillus+acidophilus+counteracts+inhibition+of+NHE3+and+DRA+expression+and+alleviates+diarrheal+phenotype+in+mice+infected+with+Citrobacter+rodentium&doi=10.1152%2Fajpgi.00173.2016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1152%2Fajpgi.00173.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpgi.00173.2016%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DAnbazhagan%26aufirst%3DA.%2BN.%26aulast%3DCoffing%26aufirst%3DH.%26aulast%3DChatterjee%26aufirst%3DI.%26aulast%3DPriyamvada%26aufirst%3DS.%26aulast%3DGujral%26aufirst%3DT.%26aulast%3DSaksena%26aufirst%3DS.%26aulast%3DGill%26aufirst%3DR.%2BK.%26aulast%3DAlrefai%26aufirst%3DW.%2BA.%26aulast%3DBorthakur%26aufirst%3DA.%26aulast%3DDudeja%26aufirst%3DP.%2BK.%26atitle%3DLactobacillus%2520acidophilus%2520counteracts%2520inhibition%2520of%2520NHE3%2520and%2520DRA%2520expression%2520and%2520alleviates%2520diarrheal%2520phenotype%2520in%2520mice%2520infected%2520with%2520Citrobacter%2520rodentium%26jtitle%3DAm.%2520J.%2520Physiol%2520Gastrointest%2520Liver%2520Physiol%26date%3D2016%26volume%3D311%26issue%3D5%26spage%3DG817%26epage%3DG826%26doi%3D10.1152%2Fajpgi.00173.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donadi, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologa, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">A comprehensive map of molecular drug targets</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">19</span>â <span class="NLM_lpage">34</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd.2016.230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27910877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=19-34&issue=1&author=R.+Santosauthor=O.+Ursuauthor=A.+Gaultonauthor=A.+P.+Bentoauthor=R.+S.+Donadiauthor=C.+G.+Bologaauthor=A.+Karlssonauthor=B.+Al-Lazikaniauthor=A.+Herseyauthor=T.+I.+Opreaauthor=J.+P.+Overington&title=A+comprehensive+map+of+molecular+drug+targets&doi=10.1038%2Fnrd.2016.230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive map of molecular drug targets</span></div><div class="casAuthors">Santos, Rita; Ursu, Oleg; Gaulton, Anna; Bento, A. Patricia; Donadi, Ramesh S.; Bologa, Cristian G.; Karlsson, Anneli; Al-Lazikani, Bissan; Hersey, Anne; Oprea, Tudor I.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-34</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The success of mechanism-based drug discovery depends on the definition of the drug target.  This definition becomes even more important as we try to link drug response to genetic variation, understand stratified clin. efficacy and safety, rationalize the differences between drugs in the same therapeutic class and predict drug utility in patient subgroups.  However, drug targets are often poorly defined in the literature, both for launched drugs and for potential therapeutic agents in discovery and development.  Here, we present an updated comprehensive map of mol. targets of approved drugs.  We curate a total of 893 human and pathogen-derived biomols. through which 1,578 US FDA-approved drugs act.  These biomols. include 667 human-genome-derived proteins targeted by drugs for human disease.  Anal. of these drug targets indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms, particularly in oncol.  We explore the relationships between bioactivity class and clin. success, as well as the presence of orthologues between human and animal models and between pathogen and human genomes.  Through the collaboration of three independent teams, we highlight some of the ongoing challenges in accurately defining the targets of mol. therapeutics and present conventions for deconvoluting the complexities of mol. pharmacol. and drug efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTfWwWkoZnbrVg90H21EOLACvtfcHk0lhxTT5uUmbOPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSms7rK&md5=7437d4b678ac75dac0a5e3248df98761</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.230%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DR.%26aulast%3DUrsu%26aufirst%3DO.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DDonadi%26aufirst%3DR.%2BS.%26aulast%3DBologa%26aufirst%3DC.%2BG.%26aulast%3DKarlsson%26aufirst%3DA.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DA%2520comprehensive%2520map%2520of%2520molecular%2520drug%2520targets%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D1%26spage%3D19%26epage%3D34%26doi%3D10.1038%2Fnrd.2016.230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillhouse, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. H.</span></span> <span> </span><span class="NLM_article-title">A brief history of the development of antidepressant drugs: from monoamines to glutamate</span>. <i>Exp. Clin. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">21</span>, <span class="refDoi">Â DOI: 10.1037/a0038550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1037%2Fa0038550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25643025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltlyhsbg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1-21&issue=1&author=T.+M.+Hillhouseauthor=J.+H.+Porter&title=A+brief+history+of+the+development+of+antidepressant+drugs%3A+from+monoamines+to+glutamate&doi=10.1037%2Fa0038550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">A brief history of the development of antidepressant drugs: from monoamines to glutamate</span></div><div class="casAuthors">Hillhouse, Todd M.; Porter, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">ECLPES</span>;
        ISSN:<span class="NLM_cas:issn">1936-2293</span>.
    
            (<span class="NLM_cas:orgname">American Psychological Association</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that is the most common mood disorder in the United States.  It has been almost 50 years since the monoamine hypothesis of depression was articulated, and just over 50 years since the first pharmacol. treatment for MDD was discovered.  Several monoamine-based pharmacol. drug classes have been developed and approved for the treatment of MDD; however, remission rates are low (often less than 60%) and there is a delayed onset before remission of depressive symptoms is achieved.  As a result of a "proof-of-concept" study in 2000 with the noncompetitive NMDA antagonist ketamine, a no. of studies have examd. the glutamatergic systems as viable targets for the treatment of MDD.  This review will provide a brief history on the development of clin. available antidepressant drugs, and then review the possible role of glutamatergic systems in the pathophysiol. of MDD.  Specifically, the glutamatergic review will focus on the N-methyl-D-aspartate (NMDA) receptor and the efficacy of drugs that target the NMDA receptor for the treatment of MDD.  The noncompetitive NMDA receptor antagonist ketamine, which has consistently produced rapid and sustained antidepressant effects in MDD patients in a no. of clin. studies, has shown the most promise as a novel glutamatergic-based treatment for MDD.  However, compds. that target other glutamatergic mechanisms, such as GLYX-13 (a glycine-site partial agonist at NMDA receptors) appear promising in early clin. trials.  Thus, the clin. findings to date are encouraging and support the continued search for and the development of novel compds. that target glutamatergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVRSP4bo13rVg90H21EOLACvtfcHk0lhxTT5uUmbOPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltlyhsbg%253D&md5=d2c0f346f720c66bbdb9d29429b42f5c</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1037%2Fa0038550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252Fa0038550%26sid%3Dliteratum%253Aachs%26aulast%3DHillhouse%26aufirst%3DT.%2BM.%26aulast%3DPorter%26aufirst%3DJ.%2BH.%26atitle%3DA%2520brief%2520history%2520of%2520the%2520development%2520of%2520antidepressant%2520drugs%253A%2520from%2520monoamines%2520to%2520glutamate%26jtitle%3DExp.%2520Clin.%2520Psychopharmacol.%26date%3D2015%26volume%3D23%26issue%3D1%26spage%3D1%26epage%3D21%26doi%3D10.1037%2Fa0038550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tatsumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richelson, E.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profile of antidepressants and related compounds at human monoamine transporters</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>340</i></span> (<span class="NLM_issue">2â3</span>),  <span class="NLM_fpage">249</span>â <span class="NLM_lpage">258</span>, <span class="refDoi">Â DOI: 10.1016/S0014-2999(97)01393-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0014-2999%2897%2901393-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9537821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2sXotVyjsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=340&publication_year=1997&pages=249-258&issue=2%E2%80%933&author=M.+Tatsumiauthor=K.+Groshanauthor=R.+D.+Blakelyauthor=E.+Richelson&title=Pharmacological+profile+of+antidepressants+and+related+compounds+at+human+monoamine+transporters&doi=10.1016%2FS0014-2999%2897%2901393-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of antidepressants and related compounds at human monoamine transporters</span></div><div class="casAuthors">Tatsumi, Masahiko; Groshan, Karen; Blakely, Randy D.; Richelson, Elliott</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">340</span>
        (<span class="NLM_cas:issue">2/3</span>),
    <span class="NLM_cas:pages">249-258</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Using radioligand binding assays, we detd. the equil. dissocn. consts. (KD's) for 37 antidepressants, three of their metabolites (desmethylcitalopram, desmethylsertraline, and norfluoxetine), some mood stabilizers, and assorted other compds. (some antiepileptics, Ca2+ channel antagonists, benzodiazepines, psychostimulants, antihistamines, and monoamines) for the human serotonin, norepinephrine, and dopamine transporters.  Among the compds. that we tested, mazindol was the most potent at the human norepinephrine and dopamine transporters with KD's of 0.45Â±0.03 nM and 8.1Â±0.4 nM, resp.  Sertraline (KD=25Â±2 nM) and nomifensine (56Â±3 nM) were the two most potent antidepressants at the human dopamine transporter.  We showed significant correlations for antidepressant affinities at binding to serotonin (R=0.93), norepinephrine (R=0.97), and dopamine (R=0.87) transporters in comparison to their resp. values for inhibiting uptake of monoamines into rat brain synaptosomes.  These data are useful in predicting some possible adverse effects and drug-drug interactions of antidepressants and related compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpHZLfaFAMerVg90H21EOLACvtfcHk0lhxTT5uUmbOPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVyjsbo%253D&md5=0aa5f4372309c8f244f960897362aa2a</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901393-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901393-9%26sid%3Dliteratum%253Aachs%26aulast%3DTatsumi%26aufirst%3DM.%26aulast%3DGroshan%26aufirst%3DK.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26aulast%3DRichelson%26aufirst%3DE.%26atitle%3DPharmacological%2520profile%2520of%2520antidepressants%2520and%2520related%2520compounds%2520at%2520human%2520monoamine%2520transporters%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D340%26issue%3D2%25E2%2580%25933%26spage%3D249%26epage%3D258%26doi%3D10.1016%2FS0014-2999%2897%2901393-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamba, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyanoshita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lytton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hediger, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brenner, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebert, S. C.</span></span> <span> </span><span class="NLM_article-title">Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2749</span>â <span class="NLM_lpage">2753</span>, <span class="refDoi">Â DOI: 10.1073/pnas.90.7.2749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.90.7.2749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8464884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK3sXksVels7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=2749-2753&issue=7&author=G.+Gambaauthor=S.+N.+Saltzbergauthor=M.+Lombardiauthor=A.+Miyanoshitaauthor=J.+Lyttonauthor=M.+A.+Hedigerauthor=B.+M.+Brennerauthor=S.+C.+Hebert&title=Primary+structure+and+functional+expression+of+a+cDNA+encoding+the+thiazide-sensitive%2C+electroneutral+sodium-chloride+cotransporter&doi=10.1073%2Fpnas.90.7.2749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Primary structure and functional expression of a cDNA encoding the thiazide-sensitive, electroneutral sodium-chloride cotransporter</span></div><div class="casAuthors">Gamba, Gerardo; Saltzberg, Samuel N.; Lombardi, Michael; Miyanoshita, Akihiko; Lytton, Jonathan; Hediger, Matthias A.; Brenner, Barry M.; Hebert, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2749-53</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Electroneutral Na+:Cl- cotransport systems are involved in a no. of important physiol. processes including salt absorption and secretion by epithelia and cell vol. regulation.  One group of Na+:Cl- cotransporters is specifically inhibited by the benzothiadiazine (thiazide) class of diuretic agents and can be distinguished from Na+:K+:2Cl- cotransporters based on a lack of K+ requirement and insensitivity to sulfamoylbenzoic acid diuretics like bumetanide.  The isolation of a cDNA encoding a thiazide-sensitive, electroneutral sodium-chloride cotransporter from the winter flounder urinary bladder using an expression cloning strategy is reported here.  The pharmacol. and kinetic characteristics of the cloned cotransporter are consistent with the properties of native thiazide-sensitive sodium-chloride cotransporters in teleost urinary bladder and mammalian renal distal tubule epithelia.  The nucleotide sequence predicts a protein of 1023 amino acids (112 kDa) with 12 putative membrane-spanning regions, which is not related to other previously cloned sodium or chloride transporters.  Northern hybridization shows two different gene products: a 3.7-kb mRNA localized only to the urinary bladder and a 3.0-kb mRNA present in several nonbladder/kidney tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGiIVaH4HPW7Vg90H21EOLACvtfcHk0liKnisPDytU8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXksVels7Y%253D&md5=15e400762c2f3d153883f32aa6245f9a</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.7.2749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.7.2749%26sid%3Dliteratum%253Aachs%26aulast%3DGamba%26aufirst%3DG.%26aulast%3DSaltzberg%26aufirst%3DS.%2BN.%26aulast%3DLombardi%26aufirst%3DM.%26aulast%3DMiyanoshita%26aufirst%3DA.%26aulast%3DLytton%26aufirst%3DJ.%26aulast%3DHediger%26aufirst%3DM.%2BA.%26aulast%3DBrenner%26aufirst%3DB.%2BM.%26aulast%3DHebert%26aufirst%3DS.%2BC.%26atitle%3DPrimary%2520structure%2520and%2520functional%2520expression%2520of%2520a%2520cDNA%2520encoding%2520the%2520thiazide-sensitive%252C%2520electroneutral%2520sodium-chloride%2520cotransporter%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1993%26volume%3D90%26issue%3D7%26spage%3D2749%26epage%3D2753%26doi%3D10.1073%2Fpnas.90.7.2749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lytle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, E.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbush, B.,  3rd</span></span> <span> </span><span class="NLM_article-title">Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2201</span>â <span class="NLM_lpage">2205</span>, <span class="refDoi">Â DOI: 10.1073/pnas.91.6.2201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.91.6.2201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8134373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2cXjtFOqt78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=1994&pages=2201-2205&issue=6&author=J.+C.+Xuauthor=C.+Lytleauthor=T.+T.+Zhuauthor=J.+A.+Payneauthor=E.+Benzauthor=B.+Forbush&title=Molecular+cloning+and+functional+expression+of+the+bumetanide-sensitive+Na-K-Cl+cotransporter&doi=10.1073%2Fpnas.91.6.2201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter</span></div><div class="casAuthors">Xu, Jian Chao; Lytle, Christian; Zhu, Tracey T.; Payne, John A.; Benz, Edward, Jr.; Forbush, Bliss, III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2201-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">By mediating the coupled movement of Na, K, and Cl ions across the plasma membrane of most animal cells, the bumetanide-sensitive Na-K-Cl cotransporter (NKCC) plays a vital role in the regulation of ionic balance and cell vol.  The transporter is a central element in the process of vectorial salt transport in secretory and absorptive epithelia.  A cDNA encoding a Na-K-Cl cotransport protein was isolated from a shark rectal gland library by screening with monoclonal antibodies to the native shark cotransporter.  The 1191-residue protein predicted from the cDNA sequence has 12 putative transmembrane domains flanked by large cytoplasmic N and C termini.  Regulatory phosphoacceptor residues in isolated peptides are identified as Thr-189 and Thr-1114 in the predicted sequence.  Northern blot anal. identified a 7.4-kb mRNA in rectal gland and most other shark tissues; a 5.2-kb mRNA was restricted to shark kidney.  Homol. with an uncharacterized gene from Caenorhabditis elegans and with the thiazide-sensitive Na-Cl cotransporter of flounder urinary bladder was found over most of the coding region; shorter stretches of homol. were found with a C. elegans cDNA and with an uncharacterized gene of cyanobacterium.  Human HEK-293 cells have been stably transfected with the shark cDNA and shown to express Na-K-Cl cotransport activity with the bumetanide sensitivity of the shark protein.  The expressed transporter is functionally quiescent in the host cells and can be activated by depleting the cells of chloride.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUXRH86GV2V7Vg90H21EOLACvtfcHk0liKnisPDytU8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXjtFOqt78%253D&md5=9d10163f151cb950440a9c4f57dc5996</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1073%2Fpnas.91.6.2201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.91.6.2201%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%2BC.%26aulast%3DLytle%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DT.%2BT.%26aulast%3DPayne%26aufirst%3DJ.%2BA.%26aulast%3DBenz%26aufirst%3DE.%26aulast%3DForbush%26aufirst%3DB.%26atitle%3DMolecular%2520cloning%2520and%2520functional%2520expression%2520of%2520the%2520bumetanide-sensitive%2520Na-K-Cl%2520cotransporter%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1994%26volume%3D91%26issue%3D6%26spage%3D2201%26epage%3D2205%26doi%3D10.1073%2Fpnas.91.6.2201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miner, P. B.</span></span> <span> </span><span class="NLM_article-title">Elobixibat, the first-in-class ileal bile acid transporter inhibitor, for the treatment of chronic idiopathic constipation</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1381</span>â <span class="NLM_lpage">1388</span>, <span class="refDoi">Â DOI: 10.1080/14656566.2018.1508450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1080%2F14656566.2018.1508450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30129377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1381-1388&issue=12&author=P.+B.+Miner&title=Elobixibat%2C+the+first-in-class+ileal+bile+acid+transporter+inhibitor%2C+for+the+treatment+of+chronic+idiopathic+constipation&doi=10.1080%2F14656566.2018.1508450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Elobixibat, the first-in-class Ileal Bile Acid Transporter inhibitor, for the treatment of Chronic Idiopathic Constipation</span></div><div class="casAuthors">Miner, Philip B. Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1381-1388</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Elobixibat is the first in class ileal bile acid transporter (IBAT) inhibitor.  IBAT inhibitors block ileal absorption of bile acids by: (1) interrupting the enterohepatic circulation of bile resulting in a fall in serum cholesterol and (2) increasing the delivery of bile acids into the colon.  Increasing colonic bile acids causes mucosal fluid secretion and enhances colonic motor activity.  Changes in colonic physiol. may be useful in treating constipation.  In this review, the author reviews the prevalence and medical cost of Chronic Idiopathic Constipation (CIC) and the heterogeneity of the CIC patient population as a complicating factor in drug development and clin. care.  And also reviews the history of Bile Acid cathartics and the complex pharmacophysiol. of bile therapy with fluid and electrolyte shifts, colonic motor function changes and mucosal immunol. activation.  Finally, the author reviews elobixabat development and the clin. trials that demonstrate improvement in constipation.  The early phases of elobixibat development provide confirmation of high IBAT binding affinity which translates into the expected inhibition of enterohepatic bile acid circulation and enhanced delivery of ileal bile acids to the colon assocd. with expected physiol. changes.  Elobixibat as a treatment of CIC appears promising.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6CcsditpIz7Vg90H21EOLACvtfcHk0liKnisPDytU8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKqtLfF&md5=5ba00fab2446a3a735368df82bb5429a</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1508450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1508450%26sid%3Dliteratum%253Aachs%26aulast%3DMiner%26aufirst%3DP.%2BB.%26atitle%3DElobixibat%252C%2520the%2520first-in-class%2520ileal%2520bile%2520acid%2520transporter%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520idiopathic%2520constipation%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26issue%3D12%26spage%3D1381%26epage%3D1388%26doi%3D10.1080%2F14656566.2018.1508450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgkinson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonaka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priest, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bishop, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Critchlow, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackhall, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, C. J.</span></span> <span> </span><span class="NLM_article-title">Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">926</span>â <span class="NLM_lpage">937</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-13-2270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1158%2F1078-0432.CCR-13-2270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24277449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=926-937&issue=4&author=R.+Polanskiauthor=C.+L.+Hodgkinsonauthor=A.+Fusiauthor=D.+Nonakaauthor=L.+Priestauthor=P.+Kellyauthor=F.+Trapaniauthor=P.+W.+Bishopauthor=A.+Whiteauthor=S.+E.+Critchlowauthor=P.+D.+Smithauthor=F.+Blackhallauthor=C.+Diveauthor=C.+J.+Morrow&title=Activity+of+the+monocarboxylate+transporter+1+inhibitor+AZD3965+in+small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-13-2270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer</span></div><div class="casAuthors">Polanski, Radoslaw; Hodgkinson, Cassandra L.; Fusi, Alberto; Nonaka, Daisuke; Priest, Lynsey; Kelly, Paul; Trapani, Francesca; Bishop, Paul W.; White, Anne; Critchlow, Susan E.; Smith, Paul D.; Blackhall, Fiona; Dive, Caroline; Morrow, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">926-937</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom.  AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis.  We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clin. testing in this disease and putative predictive biomarkers for trial use.  Exptl. Design: AZD3965 sensitivity was detd. for seven SCLC cell lines, in normoxia and hypoxia, and for a tumor xenograft model.  Proof of mechanism was sought via changes in intracellular/tumor lactate.  Expression of MCT1 and related transporter MCT4 was assessed by Western blot anal.  Drug resistance was investigated via MCT4 siRNAi and overexpression.  The expression and clin. significance of MCT1 and MCT4 were explored in a tissue microarray (TMA) from 78 patients with SCLC.  Results: AZD3965 sensitivity varied in vitro and was highest in hypoxia.  Resistance in hypoxia was assocd. with increased MCT4 expression.  In vivo, AZD3965 reduced tumor growth and increased intratumor lactate.  In the TMA, high MCT1 expression was assocd. with worse prognosis (P = 0.014).  MCT1 and hypoxia marker CA IX expression in the absence of MCT4 was obsd. in 21% of SCLC tumors.  Conclusions: This study provides a rationale to test AZD3965 in patients with SCLC.  Our results suggest that patients with tumors expressing MCT1 and lacking in MCT4 are most likely to respond.  Clin Cancer Res; 20(4); 926-37. 2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSspebNlIjdbVg90H21EOLACvtfcHk0liChHXQuKnzXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejtLo%253D&md5=9609fad6b0c2e5b4ebc9d2465743f6bb</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-2270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-2270%26sid%3Dliteratum%253Aachs%26aulast%3DPolanski%26aufirst%3DR.%26aulast%3DHodgkinson%26aufirst%3DC.%2BL.%26aulast%3DFusi%26aufirst%3DA.%26aulast%3DNonaka%26aufirst%3DD.%26aulast%3DPriest%26aufirst%3DL.%26aulast%3DKelly%26aufirst%3DP.%26aulast%3DTrapani%26aufirst%3DF.%26aulast%3DBishop%26aufirst%3DP.%2BW.%26aulast%3DWhite%26aufirst%3DA.%26aulast%3DCritchlow%26aufirst%3DS.%2BE.%26aulast%3DSmith%26aufirst%3DP.%2BD.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DDive%26aufirst%3DC.%26aulast%3DMorrow%26aufirst%3DC.%2BJ.%26atitle%3DActivity%2520of%2520the%2520monocarboxylate%2520transporter%25201%2520inhibitor%2520AZD3965%2520in%2520small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26issue%3D4%26spage%3D926%26epage%3D937%26doi%3D10.1158%2F1078-0432.CCR-13-2270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Cruz, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. E.</span></span> <span> </span><span class="NLM_article-title">Cellular uptake of MCT1 inhibitors AR-C155858 and AZD3965 and their effects on MCT-mediated transport of L-lactate in murine 4T1 breast tumor cancer cells</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">13</span>, <span class="refDoi">Â DOI: 10.1208/s12248-018-0279-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1208%2Fs12248-018-0279-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30617815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3cnovVymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2019&pages=13&author=X.+Guanauthor=V.+Rodriguez-Cruzauthor=M.+E.+Morris&title=Cellular+uptake+of+MCT1+inhibitors+AR-C155858+and+AZD3965+and+their+effects+on+MCT-mediated+transport+of+L-lactate+in+murine+4T1+breast+tumor+cancer+cells&doi=10.1208%2Fs12248-018-0279-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells</span></div><div class="casAuthors">Guan Xiaowen; Rodriguez-Cruz Vivian; Morris Marilyn E</div><div class="citationInfo"><span class="NLM_cas:title">The AAPS journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">13</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AR-C155858 and AZD3965, pyrrole pyrimidine derivatives, represent potent monocarboxylate transporter 1 (MCT1) inhibitors, with potential immunomodulatory and chemotherapeutic properties.  Currently, there is limited information on the inhibitory properties of this new class of MCT1 inhibitors.  The purpose of this study was to characterize the concentration- and time-dependent inhibition of L-lactate transport and the membrane permeability properties of AR-C155858 and AZD3965 in the murine 4T1 breast tumor cells that express MCT1.  Our results demonstrated time-dependent inhibition of L-lactate uptake by AR-C155858 and AZD3965 with maximal inhibition occurring after a 5-min pre-incubation period and prolonged inhibition.  Following removal of AR-C155858 or AZD3965 from the incubation buffer, inhibition of L-lactate uptake was only fully reversed after 3 and 12 h, respectively, indicating that these inhibitors are slowly reversible.  The uptake of AR-C155858 was concentration-dependent in 4T1 cells, whereas the uptake of AZD3965 exhibited no concentration dependence over the range of concentrations examined.  The uptake kinetics of AR-C155858 was best fitted to a Michaelis-Menten equation with a diffusional clearance component, P (Km = 0.399 Â± 0.067 Î¼M, Vmax = 4.79 Â± 0.58 pmol/mg/min, and P = 0.330 Â± 0.088 Î¼L/mg/min).  AR-C155858 uptake, but not AZD3965 uptake, was significantly inhibited by alpha-cyano-4-hydroxycinnamic acid, a known nonspecific inhibitor of MCTs 1, 2, and 4.  AR-C155858 demonstrated a trend toward higher uptake at lower pH, a characteristic of proton-dependent MCT1.  These findings provide evidence that AR-C155858 and AZD3965 exert slowly reversible inhibition of MCT1-mediated L-lactate uptake in 4T1 cells, with AR-C155858 representing a potential substrate of MCT1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGRzsabYqKBGxpATR2EQURfW6udTcc2eaUYlsf7M-ndbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnovVymuw%253D%253D&md5=a71fe4cd8bd0e400f5314eee18f3fa94</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1208%2Fs12248-018-0279-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-018-0279-5%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DRodriguez-Cruz%26aufirst%3DV.%26aulast%3DMorris%26aufirst%3DM.%2BE.%26atitle%3DCellular%2520uptake%2520of%2520MCT1%2520inhibitors%2520AR-C155858%2520and%2520AZD3965%2520and%2520their%2520effects%2520on%2520MCT-mediated%2520transport%2520of%2520L-lactate%2520in%2520murine%25204T1%2520breast%2520tumor%2520cancer%2520cells%26jtitle%3DAAPS%2520J.%26date%3D2019%26volume%3D21%26spage%3D13%26doi%3D10.1208%2Fs12248-018-0279-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrington, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callies, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McColm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbury, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyas, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truhlar, S. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benschop, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witcher, D. R.</span></span> <span> </span><span class="NLM_article-title">Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>85</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">935</span>â <span class="NLM_lpage">948</span>, <span class="refDoi">Â DOI: 10.1111/bcp.13877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fbcp.13877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30677788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXot1amsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2019&pages=935-948&issue=5&author=M.+Sheetzauthor=P.+Barringtonauthor=S.+Calliesauthor=P.+H.+Bergauthor=J.+McColmauthor=T.+Marburyauthor=B.+Deckerauthor=G.+L.+Dyasauthor=S.+M.+E.+Truhlarauthor=R.+Benschopauthor=D.+Leungauthor=J.+Bergauthor=D.+R.+Witcher&title=Targeting+the+hepcidin-ferroportin+pathway+in+anaemia+of+chronic+kidney+disease&doi=10.1111%2Fbcp.13877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease</span></div><div class="casAuthors">Sheetz, Matthew; Barrington, Philip; Callies, Sophie; Berg, Paul H.; McColm, Juliet; Marbury, Thomas; Decker, Brian; Dyas, Gregory L.; Truhlar, Stephanie M. E.; Benschop, Robert; Leung, Donmienne; Berg, Jolene; Witcher, Derrick R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">935-948</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease (CKD) have been assocd. with cardiovascular adverse events.  Hepcidin prodn., controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin.  High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anemia in CKD patients.  To investigate alternative therapies to erythropoiesis-stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin resp., were tested in CKD patients.  Methods : Preclin. in vitro/vivo data and clin. data in healthy subjects and CKD patients were used to illustrate the translation of pharmacol. properties of LY3113593 and LY2928057, highlighting the novelty of targeting these nodes within the hepcidin-ferroportin pathway.  Results : LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux, leading to increased serum iron and transferrin satn. levels and increased hepcidin in monkeys and humans.  In CKD patients, LY2928057 led to slower Hb decline and redn. in ferritin (compared to placebo).  Serum iron increase was (mean [90% confidence interval]) 1.98 [1.46-2.68] and 1.36 [1.22-1.51] fold-relative to baseline following LY2928057 600 mg and LY311593 150 mg resp. in CKD patients.  LY3113593 specifically blocked BMP6 binding to its receptor and produced increases in iron and transferrin satn. and decreases in hepcidin preclinically and clin.  In CKD patients, LY3113593 produced an increase in Hb and redn. in ferritin (compared to placebo).  Conclusion : LY3113593 and LY2928057 pharmacol. effects (serum iron and ferritin) were translated from preclin.-to-clin. development.  Such interventions may lead to new CKD anemia treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTgEW1JOMNDrVg90H21EOLACvtfcHk0liChHXQuKnzXg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXot1amsbw%253D&md5=3467865b463c2619e22d92705a078ba3</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13877%26sid%3Dliteratum%253Aachs%26aulast%3DSheetz%26aufirst%3DM.%26aulast%3DBarrington%26aufirst%3DP.%26aulast%3DCallies%26aufirst%3DS.%26aulast%3DBerg%26aufirst%3DP.%2BH.%26aulast%3DMcColm%26aufirst%3DJ.%26aulast%3DMarbury%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DB.%26aulast%3DDyas%26aufirst%3DG.%2BL.%26aulast%3DTruhlar%26aufirst%3DS.%2BM.%2BE.%26aulast%3DBenschop%26aufirst%3DR.%26aulast%3DLeung%26aufirst%3DD.%26aulast%3DBerg%26aufirst%3DJ.%26aulast%3DWitcher%26aufirst%3DD.%2BR.%26atitle%3DTargeting%2520the%2520hepcidin-ferroportin%2520pathway%2520in%2520anaemia%2520of%2520chronic%2520kidney%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D85%26issue%3D5%26spage%3D935%26epage%3D948%26doi%3D10.1111%2Fbcp.13877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McHugh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danila, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathkopf, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slovin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonarakis, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. J.</span></span> <span> </span><span class="NLM_article-title">A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1052</span>â <span class="NLM_lpage">1060</span>, <span class="refDoi">Â DOI: 10.1007/s10637-019-00731-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs10637-019-00731-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30725389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrt7bI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=1052-1060&author=D.+McHughauthor=M.+Eisenbergerauthor=E.+I.+Heathauthor=J.+Bruceauthor=D.+C.+Danilaauthor=D.+E.+Rathkopfauthor=J.+Feldmanauthor=S.+F.+Slovinauthor=B.+Anandauthor=R.+Chuauthor=J.+Lackeyauthor=L.+Reynoauthor=E.+S.+Antonarakisauthor=M.+J.+Morris&title=A+phase+I+study+of+the+antibody+drug+conjugate+ASG-5ME%2C+an+SLC44A4-targeting+antibody+carrying+auristatin+E%2C+in+metastatic+castration-resistant+prostate+cancer&doi=10.1007%2Fs10637-019-00731-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer</span></div><div class="casAuthors">McHugh, Deaglan; Eisenberger, Mario; Heath, Elisabeth I.; Bruce, Justine; Danila, Daniel C.; Rathkopf, Dana E.; Feldman, Jarett; Slovin, Susan F.; Anand, Banmeet; Chu, Rong; Lackey, Jacqueline; Reyno, Leonard; Antonarakis, Emmanuel S.; Morris, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1052-1060</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The primary objective of this phase I study was to det. max. tolerated dose (MTD) and recommended phase II dose.  Secondary objectives were safety, antitumor activity, pharmacokinetic properties, immunogenicity, and the detection of SLC44A4 on circulating tumor cells.  Patients (pts) were treated among 7 dose levels every 21 days.  A dose expansion phase enrolled 20 addnl. pts. at the MTD.  Twenty-six and 20 pts. were treated in dose escalation and dose expansion cohorts resp.  The MTD was 2.7 mg/kg.  Dose-limiting toxicities occurred in 4 pts.: grade 3 fatigue (n = 1); grade 3 abdominal pain, diarrhea and fatigue (n = 1); grade 4 neutropenia and hyponatremia and grade 3 maculopapular rash, constipation and hypoxia (n = 1); grade 3 troponin elevation without cardiac sequelae (n = 1).  Fatigue and diarrhea were the most prevalent adverse events (AEs) across all cycles.  Two grade 5 AEs occurred in the dose expansion cohort, each after 1 dose: 1 pt. developed grade 3 hyperglycemia, renal insufficiency and leukopenia; 1 pt. developed grade 3 hyperglycemia complicated by bacteremia.  Free MMAE levels did not accumulate with repeat dosing.  Of evaluable pts., 52% had either stable disease or a partial response.  Some toxicities were potentially related to on-target effects on normal tissue expressing the SLC44A4 protein.  However, other toxicities were consistent with studies of previous MMAE-contg. ADCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphkoY7dWx0rLVg90H21EOLACvtfcHk0ljHkt74U3rvBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrt7bI&md5=bf9ec283a033f9a1969353cf563b57b6</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1007%2Fs10637-019-00731-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-019-00731-5%26sid%3Dliteratum%253Aachs%26aulast%3DMcHugh%26aufirst%3DD.%26aulast%3DEisenberger%26aufirst%3DM.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBruce%26aufirst%3DJ.%26aulast%3DDanila%26aufirst%3DD.%2BC.%26aulast%3DRathkopf%26aufirst%3DD.%2BE.%26aulast%3DFeldman%26aufirst%3DJ.%26aulast%3DSlovin%26aufirst%3DS.%2BF.%26aulast%3DAnand%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DR.%26aulast%3DLackey%26aufirst%3DJ.%26aulast%3DReyno%26aufirst%3DL.%26aulast%3DAntonarakis%26aufirst%3DE.%2BS.%26aulast%3DMorris%26aufirst%3DM.%2BJ.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520the%2520antibody%2520drug%2520conjugate%2520ASG-5ME%252C%2520an%2520SLC44A4-targeting%2520antibody%2520carrying%2520auristatin%2520E%252C%2520in%2520metastatic%2520castration-resistant%2520prostate%2520cancer%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2019%26volume%3D37%26spage%3D1052%26epage%3D1060%26doi%3D10.1007%2Fs10637-019-00731-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nigam, S. K.</span></span> <span> </span><span class="NLM_article-title">What do drug transporters really do?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">29</span>â <span class="NLM_lpage">44</span>, <span class="refDoi">Â DOI: 10.1038/nrd4461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd4461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25475361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClu7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=29-44&issue=1&author=S.+K.+Nigam&title=What+do+drug+transporters+really+do%3F&doi=10.1038%2Fnrd4461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">What do drug transporters really do?</span></div><div class="casAuthors">Nigam, Sanjay K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-44</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Potential drug-drug interactions mediated by the ATP-binding cassette (ABC) transporter and solute carrier (SLC) transporter families are of clin. and regulatory concern.  However, the endogenous functions of these drug transporters are not well understood.  Discussed here is evidence for the roles of ABC and SLC transporters in the handling of diverse substrates, including metabolites, antioxidants, signaling mols., hormones, nutrients, and neurotransmitters.  It is suggested that these transporters may be part of a larger system of remote communication ('remote sensing and signaling') between cells, organs, body fluid compartments, and perhaps even sep. organisms.  This broader view may help to clarify disease mechanisms, drug-metabolite interactions, and drug effects relevant to diabetes, chronic kidney disease, metabolic syndrome, hypertension, gout, liver disease, neuropsychiatric disorders, inflammatory syndromes, and organ injury, as well as prenatal and postnatal development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeezdvl3p-z7Vg90H21EOLACvtfcHk0ljHkt74U3rvBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClu7rN&md5=41debd2dfed0f0c0282be88583c1b0a6</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fnrd4461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4461%26sid%3Dliteratum%253Aachs%26aulast%3DNigam%26aufirst%3DS.%2BK.%26atitle%3DWhat%2520do%2520drug%2520transporters%2520really%2520do%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D1%26spage%3D29%26epage%3D44%26doi%3D10.1038%2Fnrd4461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fahrmayr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fromm, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konig, J.</span></span> <span> </span><span class="NLM_article-title">Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">380</span>â <span class="NLM_lpage">401</span>, <span class="refDoi">Â DOI: 10.3109/03602530903491683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3109%2F03602530903491683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20100011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2010&pages=380-401&issue=3&author=C.+Fahrmayrauthor=M.+F.+Frommauthor=J.+Konig&title=Hepatic+OATP+and+OCT+uptake+transporters%3A+their+role+for+drug-drug+interactions+and+pharmacogenetic+aspects&doi=10.3109%2F03602530903491683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects</span></div><div class="casAuthors">Fahrmayr, Christina; Fromm, Martin F.; Koenig, Joerg</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">380-401</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Uptake transporters in the basolateral membrane of hepatocytes are important for the hepatobiliary elimination of drugs.  Further, since drug-metabolizing enzymes are located intracellularly, uptake into hepatocytes is a prerequisite for their subsequent metab.  Therefore, alteration of uptake transporter function (e.g., by concomitantly administered drugs or due to functional consequences of genetic variations, leading to reduced transport function) may result in a change in drug pharmacokinetics.  In this review, we focus on the hepatocellularly expressed members of the OATP and OCT family, their impact on transport-mediated drug-drug interactions, and on the functional consequences of variations in genes encoding these transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohkKPXsJ_nkLVg90H21EOLACvtfcHk0liLBwkGdPBGhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlSmt7s%253D&md5=3ef70a9fdaf699f3261b26d0f02b1406</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.3109%2F03602530903491683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F03602530903491683%26sid%3Dliteratum%253Aachs%26aulast%3DFahrmayr%26aufirst%3DC.%26aulast%3DFromm%26aufirst%3DM.%2BF.%26aulast%3DKonig%26aufirst%3DJ.%26atitle%3DHepatic%2520OATP%2520and%2520OCT%2520uptake%2520transporters%253A%2520their%2520role%2520for%2520drug-drug%2520interactions%2520and%2520pharmacogenetic%2520aspects%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2010%26volume%3D42%26issue%3D3%26spage%3D380%26epage%3D401%26doi%3D10.3109%2F03602530903491683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rizwan, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burckhardt, G.</span></span> <span> </span><span class="NLM_article-title">Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">450</span>â <span class="NLM_lpage">470</span>, <span class="refDoi">Â DOI: 10.1007/s11095-006-9181-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs11095-006-9181-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17245646" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhslWisr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2007&pages=450-470&issue=3&author=A.+N.+Rizwanauthor=G.+Burckhardt&title=Organic+anion+transporters+of+the+SLC22+family%3A+biopharmaceutical%2C+physiological%2C+and+pathological+roles&doi=10.1007%2Fs11095-006-9181-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Organic Anion Transporters of the SLC22 Family: Biopharmaceutical, Physiological, and Pathological Roles</span></div><div class="casAuthors">Rizwan, Ahsan N.; Burckhardt, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">450-470</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The human org. anion transporters OAT1, OAT2, OAT3, OAT4 and URAT1 belong to a family of poly-specific transporters mainly located in kidneys.  Selected OATs occur also in liver, placenta, and brain.  OATs interact with endogenous metabolic end products such as urate and acidic neurotransmitter metabolites, as well as with a multitude of widely used drugs, including antibiotics, antihypertensives, antivirals, anti-inflammatory drugs, diuretics and uricosurics.  Thereby, OATs play an important role in renal drug elimination and have an impact on pharmacokinetics.  In this review the authors focus on the interaction of human OATs with drugs.  The authors report the affinities of human OATs for drug classes and compare the putative importance of individual OATs for renal drug excretion.  The role of OATs as sites of drug-drug interaction and mediators cell toxicity, their gender-dependent regulation in health and diseased states, and the possible impact of single nucleotide polymorphisms are also dealt with.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIQcFgXPgVbbVg90H21EOLACvtfcHk0liLBwkGdPBGhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhslWisr4%253D&md5=40ecfcb70a2c404fd2710a2da1810e3f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs11095-006-9181-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-006-9181-4%26sid%3Dliteratum%253Aachs%26aulast%3DRizwan%26aufirst%3DA.%2BN.%26aulast%3DBurckhardt%26aufirst%3DG.%26atitle%3DOrganic%2520anion%2520transporters%2520of%2520the%2520SLC22%2520family%253A%2520biopharmaceutical%252C%2520physiological%252C%2520and%2520pathological%2520roles%26jtitle%3DPharm.%2520Res.%26date%3D2007%26volume%3D24%26issue%3D3%26spage%3D450%26epage%3D470%26doi%3D10.1007%2Fs11095-006-9181-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lier, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roubert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haboubi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohring, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durrenberger, F.</span></span> <span> </span><span class="NLM_article-title">Oral ferroportin inhibitor VIT-2763: first-in-human, phase 1 study in healthy volunteers</span>. <i>Am. J. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi">Â DOI: 10.1002/ajh.25670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fajh.25670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31674058" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=F.+Richardauthor=J.+J.+van+Lierauthor=B.+Roubertauthor=T.+Haboubiauthor=U.+M.+Gohringauthor=F.+Durrenberger&title=Oral+ferroportin+inhibitor+VIT-2763%3A+first-in-human%2C+phase+1+study+in+healthy+volunteers&doi=10.1002%2Fajh.25670"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1002%2Fajh.25670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajh.25670%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DF.%26aulast%3Dvan%2BLier%26aufirst%3DJ.%2BJ.%26aulast%3DRoubert%26aufirst%3DB.%26aulast%3DHaboubi%26aufirst%3DT.%26aulast%3DGohring%26aufirst%3DU.%2BM.%26aulast%3DDurrenberger%26aufirst%3DF.%26atitle%3DOral%2520ferroportin%2520inhibitor%2520VIT-2763%253A%2520first-in-human%252C%2520phase%25201%2520study%2520in%2520healthy%2520volunteers%26jtitle%3DAm.%2520J.%2520Hematol.%26date%3D2019%26doi%3D10.1002%2Fajh.25670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Visentin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kullak-Ublick, G. A.</span></span> <span> </span><span class="NLM_article-title">Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>355</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">145</span>â <span class="NLM_lpage">151</span>, <span class="refDoi">Â DOI: 10.1124/jpet.115.227546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fjpet.115.227546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26330539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhslamsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2015&pages=145-151&issue=2&author=M.+Visentinauthor=B.+Stiegerauthor=M.+Merzauthor=G.+A.+Kullak-Ublick&title=Octreotide+inhibits+the+bilirubin+carriers+organic+anion+transporting+polypeptides+1B1+and+1B3+and+the+multidrug+resistance-associated+protein+2&doi=10.1124%2Fjpet.115.227546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2</span></div><div class="casAuthors">Visentin, Michele; Stieger, Bruno; Merz, Michael; Kullak-Ublick, Gerd A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The somatostatin analog octreotide can lead to hyperbilirubinemia without evidence of liver injury.  Here we investigate whether octreotide inhibits the main sinusoidal/canalicular bilirubin carriers and whether it is a transport substrate.  Octreotide showed the most potent inhibitory effect toward OATP1B1-mediated transport and weaker inhibition for OATP1B3- and MRP2-mediated transport.  Octreotide had no effect on OATP2B1-mediated transport.  Octreotide inhibited [3H]estradiol-17-Î²-glucuronide (E17Î²G) influx mediated by OATP1B1, 1B3, and multidrug resistance-assocd. protein 2 (MRP2) in a concn.-dependent manner, and the IC50 values were computed to be 23 Î¼M (95% confidence interval [CI] 18-29), 68 Î¼M (95% CI 50-91), and 116.6 Î¼M (95% CI 74.5-182.4), resp.  The interaction between octreotide and OATP1B1 was further studied.  Inhibition of [3H]E17Î²G OATP1B1-mediated transport was purely competitive with no changes in max. transport capacity (Vmax) and a twofold Km increase when the influx kinetics of [3H]E17Î²G were measured in the presence of octreotide (8.8 Â± 3.1 vs. 4.4 Â± 1.2 Î¼M, P = 0.03).  The inhibition const. (Ki) of octreotide for the transport of [3H]E17Î²G was calcd. at 33.5 Â± 5.5 Î¼M.  Uptake of radiolabeled octreotide by OATP1B1-CHO cells was higher than in wild-type CHO cells and nonlabeled octreotide at the extracellular compartment was able to trans-stimulate the OATP1B1-mediated efflux of intracellular [3H]E17Î²G, suggesting that octreotide is a substrate of OATP1B1.  In summary, this study shows interaction of octreotide on the human hepatocellular bilirubin transporters OATP1B1, OATP1B3, and MRP2, notably OATP1B1.  These findings are in line with the clin. observation that a fraction of patients under treatment with octreotide exhibit hyperbilirubinemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEjLsy1D61J7Vg90H21EOLACvtfcHk0liLBwkGdPBGhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhslamsrg%253D&md5=dbe35dfc2b95cc861ce8d76be91cf4d3</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.227546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.227546%26sid%3Dliteratum%253Aachs%26aulast%3DVisentin%26aufirst%3DM.%26aulast%3DStieger%26aufirst%3DB.%26aulast%3DMerz%26aufirst%3DM.%26aulast%3DKullak-Ublick%26aufirst%3DG.%2BA.%26atitle%3DOctreotide%2520inhibits%2520the%2520bilirubin%2520carriers%2520organic%2520anion%2520transporting%2520polypeptides%25201B1%2520and%25201B3%2520and%2520the%2520multidrug%2520resistance-associated%2520protein%25202%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D355%26issue%3D2%26spage%3D145%26epage%3D151%26doi%3D10.1124%2Fjpet.115.227546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonezawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inui, K.</span></span> <span> </span><span class="NLM_article-title">Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>80</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1762</span>â <span class="NLM_lpage">1767</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2010.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bcp.2010.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20813096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlSmsbfP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2010&pages=1762-1767&issue=11&author=T.+Nakamuraauthor=A.+Yonezawaauthor=S.+Hashimotoauthor=T.+Katsuraauthor=K.+Inui&title=Disruption+of+multidrug+and+toxin+extrusion+MATE1+potentiates+cisplatin-induced+nephrotoxicity&doi=10.1016%2Fj.bcp.2010.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity</span></div><div class="casAuthors">Nakamura, Takanori; Yonezawa, Atsushi; Hashimoto, Shinya; Katsura, Toshiya; Inui, Ken-ichi</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1762-1767</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug and toxin extrusion 1 (MATE1/SLC47A1) is expressed in the brush-border membrane of renal proximal tubules and mediates the efflux of cationic drugs.  In the present study, the role of MATE1 in the nephrotoxicity of cisplatin was investigated in vivo and in vitro.  Cisplatin (15 mg/kg) was administered i.p. to wild-type (Mate1(+/+)) and Mate1 knockout (Mate1(-/-)) mice.  Lifespan was significantly shorter in Mate1(-/-) mice than Mate1(+/+) mice.  Three days after the administration of cisplatin, plasma creatinine and blood urea nitrogen (BUN) levels were increased in both Mate1(+/+) and Mate1(-/-) mice compared with vehicle-treated controls, and creatinine clearance was decreased.  Moreover, a significant rise in creatinine and BUN levels was obsd. in cisplatin-treated Mate1(-/-) mice in comparison to Mate1(+/+) mice.  A pharmacokinetic anal. revealed the plasma concn. and renal accumulation of cisplatin to be higher in Mate1(-/-) mice than Mate1(+/+) mice 1 h after a single i.v. administration of cisplatin (0.5 mg/kg).  Furthermore, the combination of a selective MATE inhibitor, pyrimethamine, with cisplatin also elevated creatinine and BUN levels compared to cisplatin alone.  In expts. in vitro, the cellular uptake of cisplatin was stimulated by the expression of mouse MATE1 as well as org. cation transporters OCT1 and OCT2.  In conclusion, MATE1 mediates the efflux of cisplatin and is involved in cisplatin-induced nephrotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHzSPRW77TrVg90H21EOLACvtfcHk0lj29RqwYxV8lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlSmsbfP&md5=6dfaa19521622cf8425fe87bfbbc8094</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2010.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2010.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DYonezawa%26aufirst%3DA.%26aulast%3DHashimoto%26aufirst%3DS.%26aulast%3DKatsura%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DK.%26atitle%3DDisruption%2520of%2520multidrug%2520and%2520toxin%2520extrusion%2520MATE1%2520potentiates%2520cisplatin-induced%2520nephrotoxicity%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2010%26volume%3D80%26issue%3D11%26spage%3D1762%26epage%3D1767%26doi%3D10.1016%2Fj.bcp.2010.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cundy, K. C.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">127</span>â <span class="NLM_lpage">143</span>, <span class="refDoi">Â DOI: 10.2165/00003088-199936020-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2165%2F00003088-199936020-00004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10092959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1MXitFCntLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1999&pages=127-143&issue=2&author=K.+C.+Cundy&title=Clinical+pharmacokinetics+of+the+antiviral+nucleotide+analogues+cidofovir+and+adefovir&doi=10.2165%2F00003088-199936020-00004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir</span></div><div class="casAuthors">Cundy, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-143</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review with 63 refs. Cidofovir and adefovir are members of a new class of antiviral compds.  They are acyclic phosphonate analogs of deoxynucleoside monophosphates.  Both compds. undergo intracellular activation to form diphosphates that are potent inhibitors of viral DNA polymerases.  Cidofovir has broad-spectrum antiviral activity against herpesviruses, papillomaviruses and poxviruses, whereas adefovir has potent activity against retroviruses and certain DNA viruses, including herpesviruses and hepadnaviruses.  I.v. cidofovir is approved for treatment of cytomegalovirus retinitis in patients with AIDS.  Cidofovir and adefovir are dianionic at physiol. pH and have low oral bioavailability in animals and humans.  After i.v. administration to HIV-infected patients, the pharmacokinetics of both drugs are independent of dose and are consistent with preclin. data.  Systemic exposure is proportional to the i.v. dose, and both drugs are cleared by the kidneys and excreted extensively as unchanged drug in the urine.  Intracellular activation of a small fraction (<10%) of the dose by cellular kinases leads to prolonged antiviral effects that are not easily predicted from conventional pharmacokinetic studies.  The rate of elimination of cidofovir and adefovir from serum may not reflect the true duration of action of these drugs, since the antiviral effect is dependent on concns. of the active phosphorylated metabolites that are present within cells.  For both drugs, >90% of an i.v. dose is recovered unchanged in the urine over 24 h.  Metab. does not contribute significantly to the total clearance of either drug.  Concomitant oral probenecid decreases both the renal clearance of cidofovir and the incidence of nephrotoxicity, presumably by blocking its active tubular secretion.  This is the basis of the clin. use of concomitant probenecid as a nephroprotectant during cidofovir therapy.  S.c. administration produces exposure equiv. to that following i.v. administration.  Drug- interaction studies with cidofovir are ongoing, but there is no evidence of an interaction between zidovudine and either cidofovir or adefovir.  Clearance of cidofovir in patients with renal impairment showed a linear relationship to creatinine clearance.  The low oral bioavailability of adefovir has led to the development of an oral prodrug, adefovir dipivoxil, currently in development for the treatment of HIV and hepatitis B infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6qJXBxXebNLVg90H21EOLACvtfcHk0lj29RqwYxV8lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitFCntLs%253D&md5=04b0ffcafdb4a1d9faf74ee58ffe0feb</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.2165%2F00003088-199936020-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-199936020-00004%26sid%3Dliteratum%253Aachs%26aulast%3DCundy%26aufirst%3DK.%2BC.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520the%2520antiviral%2520nucleotide%2520analogues%2520cidofovir%2520and%2520adefovir%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D1999%26volume%3D36%26issue%3D2%26spage%3D127%26epage%3D143%26doi%3D10.2165%2F00003088-199936020-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakanishi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leibach, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span> <span> </span><span class="NLM_article-title">Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>250</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">246</span>â <span class="NLM_lpage">251</span>, <span class="refDoi">Â DOI: 10.1006/bbrc.1998.9298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1006%2Fbbrc.1998.9298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9753615" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1cXmt1ygsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=250&publication_year=1998&pages=246-251&issue=2&author=P.+V.+Balimaneauthor=I.+Tamaiauthor=A.+Guoauthor=T.+Nakanishiauthor=H.+Kitadaauthor=F.+H.+Leibachauthor=A.+Tsujiauthor=P.+J.+Sinko&title=Direct+evidence+for+peptide+transporter+%28PepT1%29-mediated+uptake+of+a+nonpeptide+prodrug%2C+valacyclovir&doi=10.1006%2Fbbrc.1998.9298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir</span></div><div class="casAuthors">Balimane, Praveen V.; Tamai, Ikumi; Guo, Ailan; Nakanishi, Takeo; Kitada, Hideyuki; Leibach, Frederick H.; Tsuji, Akira; Sinko, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">250</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">246-251</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Xenopus laevis oocytes were used as a gene expression system to characterize the carrier-mediated transport of valacyclovir (vacv), the L-valine ester prodrug of the acyclic nucleoside acyclovir (acv).  A significant increase in the uptake of [3H]vacv by Xenopus laevis oocytes injected with human intestinal peptide transporter (hPepT1) cRNA compared to the uptake by water injected oocytes indicated that vacv was translocated by hPepT1.  Vacv uptake was concn. dependent, saturable (Km = 5.94Â±1.91mM and Jmax = 1.68Â±0.25 nmoles/h/oocyte), pH dependent, and inhibited by various known substrates of hPepT1 but not by acv, valine or pentaglycine.  Vacv also inhibited the uptake of 14C-glycylsarcosine, a known substrate of hPepT1, in a concn.-dependent manner (Ki = 4.08Â±1.02mM).  These results demonstrate that human intestinal peptide transporter hPepT1 has broad specificity since it recognizes vacv as a substrate even though it lacks a typical peptide bond.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI2khMq3L7ZbVg90H21EOLACvtfcHk0lj29RqwYxV8lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmt1ygsbc%253D&md5=eed4e80e2285a3ab9e519ffb99aab29c</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1998.9298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1998.9298%26sid%3Dliteratum%253Aachs%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DTamai%26aufirst%3DI.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DNakanishi%26aufirst%3DT.%26aulast%3DKitada%26aufirst%3DH.%26aulast%3DLeibach%26aufirst%3DF.%2BH.%26aulast%3DTsuji%26aufirst%3DA.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DDirect%2520evidence%2520for%2520peptide%2520transporter%2520%2528PepT1%2529-mediated%2520uptake%2520of%2520a%2520nonpeptide%2520prodrug%252C%2520valacyclovir%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1998%26volume%3D250%26issue%3D2%26spage%3D246%26epage%3D251%26doi%3D10.1006%2Fbbrc.1998.9298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aouida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramotar, D.</span></span> <span> </span><span class="NLM_article-title">A new twist in cellular resistance to the anticancer drug bleomycin-A5</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">595</span>â <span class="NLM_lpage">602</span>, <span class="refDoi">Â DOI: 10.2174/138920010792927307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2174%2F138920010792927307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20812903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=595-602&issue=7&author=M.+Aouidaauthor=D.+Ramotar&title=A+new+twist+in+cellular+resistance+to+the+anticancer+drug+bleomycin-A5&doi=10.2174%2F138920010792927307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">A new twist in cellular resistance to the anticancer drug bleomycin-A5</span></div><div class="casAuthors">Aouida, Mustapha; Ramotar, Dindial</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">595-602</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Bleomycin is a potent chemotherapeutic agent that can mediate cell killing by attacking the DNA.  It is used in combination with other antineoplastic agents to effectively treat lymphomas, testicular carcinomas and squamous cell carcinomas of the cervix, head and neck.  However, resistance to bleomycin remains a persistent limitation in exploiting the full therapeutic benefit of the drug for other types of cancers.  Herein, we review recent findings frm both yeast and human cells showing that uptake of bleomycin-A5 is a key mechanism that limits toxicity of the drug.  We also discuss how the mammalian transporter hCT2 (SLC22A16) could be used to predict the outcome of tumor responses towards bleomycin therapy, and highlight the importance of further exploring this permease with respect to its regulation and pharmacol. substrates for treating a wide range of cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrButD5pmCYarVg90H21EOLACvtfcHk0lj29RqwYxV8lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrF&md5=4f4e992fb25bb454ad3caaec80d7258b</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.2174%2F138920010792927307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920010792927307%26sid%3Dliteratum%253Aachs%26aulast%3DAouida%26aufirst%3DM.%26aulast%3DRamotar%26aufirst%3DD.%26atitle%3DA%2520new%2520twist%2520in%2520cellular%2520resistance%2520to%2520the%2520anticancer%2520drug%2520bleomycin-A5%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2010%26volume%3D11%26issue%3D7%26spage%3D595%26epage%3D602%26doi%3D10.2174%2F138920010792927307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayor-Ruiz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomen, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trefzer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandasamy, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gridling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klampfl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kralovics, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Capetillo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummelkamp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">768</span>â <span class="NLM_lpage">773</span>, <span class="refDoi">Â DOI: 10.1038/nchembio.1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnchembio.1590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25064833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ait7bO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=768-773&issue=9&author=G.+E.+Winterauthor=B.+Radicauthor=C.+Mayor-Ruizauthor=V.+A.+Blomenauthor=C.+Trefzerauthor=R.+K.+Kandasamyauthor=K.+V.+M.+Huberauthor=M.+Gridlingauthor=D.+Chenauthor=T.+Klampflauthor=R.+Kralovicsauthor=S.+Kubicekauthor=O.+Fernandez-Capetilloauthor=T.+R.+Brummelkampauthor=G.+Superti-Furga&title=The+solute+carrier+SLC35F2+enables+YM155-mediated+DNA+damage+toxicity&doi=10.1038%2Fnchembio.1590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity</span></div><div class="casAuthors">Winter, Georg E.; Radic, Branka; Mayor-Ruiz, Cristina; Blomen, Vincent A.; Trefzer, Claudia; Kandasamy, Richard K.; Huber, Kilian V. M.; Gridling, Manuela; Chen, Doris; Klampfl, Thorsten; Kralovics, Robert; Kubicek, Stefan; Fernandez-Capetillo, Oscar; Brummelkamp, Thijn R.; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">768-773</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genotoxic chemotherapy is the most common cancer treatment strategy.  However, its untargeted generic DNA-damaging nature and assocd. systemic cytotoxicity greatly limit its therapeutic applications.  Here, the authors used a haploid genetic screen in human cells to discover an abs. dependency of the clin. evaluated anticancer compd. YM155 on solute carrier family member 35 F2 (SLC35F2), an uncharacterized member of the solute carrier protein family that is highly expressed in a variety of human cancers.  YM155 generated DNA damage through intercalation, which was contingent on the expression of SLC35F2 and its drug-importing activity.  SLC35F2 expression and YM155 sensitivity correlated across a panel of cancer cell lines, and targeted genome editing verified SLC35F2 as the main determinant of YM155-mediated DNA damage toxicity in vitro and in vivo.  These findings suggest a new route to targeted DNA damage by exploiting tumor and patient-specific import of YM155.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGoPhFyyw9DrVg90H21EOLACvtfcHk0lgqiKJ0xwnkXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ait7bO&md5=e3d936a3d37c869cda174c8ef47ad150</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1590%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DG.%2BE.%26aulast%3DRadic%26aufirst%3DB.%26aulast%3DMayor-Ruiz%26aufirst%3DC.%26aulast%3DBlomen%26aufirst%3DV.%2BA.%26aulast%3DTrefzer%26aufirst%3DC.%26aulast%3DKandasamy%26aufirst%3DR.%2BK.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DGridling%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DKlampfl%26aufirst%3DT.%26aulast%3DKralovics%26aufirst%3DR.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DFernandez-Capetillo%26aufirst%3DO.%26aulast%3DBrummelkamp%26aufirst%3DT.%2BR.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520solute%2520carrier%2520SLC35F2%2520enables%2520YM155-mediated%2520DNA%2520damage%2520toxicity%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D9%26spage%3D768%26epage%3D773%26doi%3D10.1038%2Fnchembio.1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stensbol, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">912</span>â <span class="NLM_lpage">915</span>, <span class="refDoi">Â DOI: 10.1021/jm8013458</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8013458" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSqs78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=912-915&issue=4&author=A.+A.+Jensenauthor=M.+N.+Erichsenauthor=C.+W.+Nielsenauthor=T.+B.+Stensbolauthor=J.+Kehlerauthor=L.+Bunch&title=Discovery+of+the+first+selective+inhibitor+of+excitatory+amino+acid+transporter+subtype+1&doi=10.1021%2Fjm8013458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First Selective Inhibitor of Excitatory Amino Acid Transporter Subtype 1</span></div><div class="casAuthors">Jensen, Anders A.; Erichsen, Mette N.; Nielsen, Christina W.; Stensboel, Tine B.; Kehler, Jan; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">912-915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of the first class of subtype-selective inhibitors of the human excitatory amino acid transporter subtype 1 (EAAT1) and its rat orthologue GLAST is reported.  An opening structure-activity relationship of 25 analogs is presented that addresses the influence of substitutions at the 4- and 7-positions of the parental skeleton 2-amino-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile.  The most potent analog 10 displays high nanomolar inhibitory activity at EAAT1 and a >400-fold selectivity over EAAT2 and EAAT3, making it a highly valuable pharmacol. tool.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVu7PAOshxerVg90H21EOLACvtfcHk0lgqiKJ0xwnkXQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSqs78%253D&md5=7036a6fe617a9908a36fda6a87400e2c</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm8013458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8013458%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DErichsen%26aufirst%3DM.%2BN.%26aulast%3DNielsen%26aufirst%3DC.%2BW.%26aulast%3DStensbol%26aufirst%3DT.%2BB.%26aulast%3DKehler%26aufirst%3DJ.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520the%2520first%2520selective%2520inhibitor%2520of%2520excitatory%2520amino%2520acid%2520transporter%2520subtype%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26issue%3D4%26spage%3D912%26epage%3D915%26doi%3D10.1021%2Fjm8013458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strobel, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mseeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopinathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlins, D. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LX2761, a sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor restricted to the intestinal lumen, for the treatment of diabetes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">710</span>â <span class="NLM_lpage">721</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01541</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01541" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=710-721&issue=2&author=N.+C.+Goodwinauthor=Z.+M.+Dingauthor=B.+A.+Harrisonauthor=E.+D.+Strobelauthor=A.+L.+Harrisauthor=M.+Smithauthor=A.+Y.+Thompsonauthor=W.+Xiongauthor=F.+Mseehauthor=D.+J.+Bruceauthor=D.+Diazauthor=S.+Gopinathanauthor=L.+Liauthor=E.+O%E2%80%99Neillauthor=M.+Thielauthor=A.+G.+Wilsonauthor=K.+G.+Carsonauthor=D.+R.+Powellauthor=D.+B.+Rawlins&title=Discovery+of+LX2761%2C+a+sodium-dependent+glucose+cotransporter+1+%28SGLT1%29+inhibitor+restricted+to+the+intestinal+lumen%2C+for+the+treatment+of+diabetes&doi=10.1021%2Facs.jmedchem.6b01541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes</span></div><div class="casAuthors">Goodwin, Nicole C.; Ding, Zhi-Ming; Harrison, Bryce A.; Strobel, Eric D.; Harris, Angela L.; Smith, Melinda; Thompson, Andrea Y.; Xiong, Wendy; Mseeh, Faika; Bruce, Debra J.; Diaz, Damaris; Gopinathan, Suma; Li, Ling; O'Neill, Emily; Thiel, Mary; Wilson, Alan G. E.; Carson, Kenneth G.; Powell, David R.; Rawlins, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">710-721</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The increasing no. of people afflicted with diabetes throughout the world is a major health issue.  Inhibitors of the sodium-dependent glucose cotransporters (SGLT) have appeared as viable therapeutics to control blood glucose levels in diabetic patients.  Herein the authors report the discovery of LX2761, a locally-acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_jImP-MX5y7Vg90H21EOLACvtfcHk0lgdjUrW1WU3JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yqtA%253D%253D&md5=d07c28561e0bb9be4320391a94020d5c</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01541%26sid%3Dliteratum%253Aachs%26aulast%3DGoodwin%26aufirst%3DN.%2BC.%26aulast%3DDing%26aufirst%3DZ.%2BM.%26aulast%3DHarrison%26aufirst%3DB.%2BA.%26aulast%3DStrobel%26aufirst%3DE.%2BD.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26aulast%3DSmith%26aufirst%3DM.%26aulast%3DThompson%26aufirst%3DA.%2BY.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DMseeh%26aufirst%3DF.%26aulast%3DBruce%26aufirst%3DD.%2BJ.%26aulast%3DDiaz%26aufirst%3DD.%26aulast%3DGopinathan%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DE.%26aulast%3DThiel%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DA.%2BG.%26aulast%3DCarson%26aufirst%3DK.%2BG.%26aulast%3DPowell%26aufirst%3DD.%2BR.%26aulast%3DRawlins%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520LX2761%252C%2520a%2520sodium-dependent%2520glucose%2520cotransporter%25201%2520%2528SGLT1%2529%2520inhibitor%2520restricted%2520to%2520the%2520intestinal%2520lumen%252C%2520for%2520the%2520treatment%2520of%2520diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26issue%3D2%26spage%3D710%26epage%3D721%26doi%3D10.1021%2Facs.jmedchem.6b01541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slack, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakare, O. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzynski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slusher, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellenberger, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loland, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, A. H.</span></span> <span> </span><span class="NLM_article-title">Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues as atypical dopamine transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">10676</span>â <span class="NLM_lpage">10691</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10676-10691&issue=23&author=J.+Caoauthor=R.+D.+Slackauthor=O.+M.+Bakareauthor=C.+Burzynskiauthor=R.+Raisauthor=B.+S.+Slusherauthor=T.+Kopajticauthor=A.+Bonifaziauthor=M.+P.+Ellenbergerauthor=H.+Yanoauthor=Y.+Heauthor=G.+H.+Biauthor=Z.+X.+Xiauthor=C.+J.+Lolandauthor=A.+H.+Newman&title=Novel+and+high+affinity+2-%5B%28diphenylmethyl%29sulfinyl%5Dacetamide+%28modafinil%29+analogues+as+atypical+dopamine+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.6b01373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors</span></div><div class="casAuthors">Cao, Jianjing; Slack, Rachel D.; Bakare, Oluyomi M.; Burzynski, Caitlin; Rais, Rana; Slusher, Barbara S.; Kopajtic, Theresa; Bonifazi, Alessandro; Ellenberger, Michael P.; Yano, Hideaki; He, Yi; Bi, Guo-Hua; Xi, Zheng-Xiong; Loland, Claus J.; Newman, Amy Hauck</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10676-10691</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of pharmacotherapeutic treatments of psychostimulant abuse has remained a challenge, despite significant efforts made toward relevant mechanistic targets, such as the dopamine transporter (DAT).  The atypical DAT inhibitors have received attention due to their promising pharmacol. profiles in animal models of cocaine and methamphetamine abuse.  Herein the authors report a series of modafinil analogs that have an atypical DAT inhibitor profile.  The authors extended SAR by chem. manipulating the oxidn. states of the sulfoxide and the amide functional groups, halogenating the Ph rings, and/or functionalizing the terminal nitrogen with substituted piperazines, resulting in several novel leads such as 1-(4-(2-((bis(4-fluorophenyl)methyl)sulfinyl)ethyl)piperazin-1-yl)-3-phenylpropan-2-ol (compd. 11b), which demonstrated high DAT affinity (Ki = 2.5 nM) and selectivity without producing concomitant locomotor stimulation in mice, as compared to cocaine.  These results are consistent with an atypical DAT inhibitor profile and suggest that 11b may be a potential lead for development as a psychostimulant abuse medication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL0BwESHNuRbVg90H21EOLACvtfcHk0lgdjUrW1WU3JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelu7bP&md5=e912f256c764249ad606d83ac9c570fb</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01373%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSlack%26aufirst%3DR.%2BD.%26aulast%3DBakare%26aufirst%3DO.%2BM.%26aulast%3DBurzynski%26aufirst%3DC.%26aulast%3DRais%26aufirst%3DR.%26aulast%3DSlusher%26aufirst%3DB.%2BS.%26aulast%3DKopajtic%26aufirst%3DT.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DEllenberger%26aufirst%3DM.%2BP.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DG.%2BH.%26aulast%3DXi%26aufirst%3DZ.%2BX.%26aulast%3DLoland%26aufirst%3DC.%2BJ.%26aulast%3DNewman%26aufirst%3DA.%2BH.%26atitle%3DNovel%2520and%2520high%2520affinity%25202-%255B%2528diphenylmethyl%2529sulfinyl%255Dacetamide%2520%2528modafinil%2529%2520analogues%2520as%2520atypical%2520dopamine%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26issue%3D23%26spage%3D10676%26epage%3D10691%26doi%3D10.1021%2Facs.jmedchem.6b01373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tremont, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Both, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeller, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziej, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischke, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollefson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, D. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (Part 1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5837</span>â <span class="NLM_lpage">5852</span>, <span class="refDoi">Â DOI: 10.1021/jm040215+</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040215%2B" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVChtrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5837-5852&issue=18&author=S.+J.+Tremontauthor=L.+F.+Leeauthor=H.+C.+Huangauthor=B.+T.+Kellerauthor=S.+C.+Banerjeeauthor=S.+R.+Bothauthor=A.+J.+Carpenterauthor=C.+C.+Wangauthor=D.+J.+Garlandauthor=W.+Huangauthor=C.+Jonesauthor=K.+J.+Koellerauthor=S.+A.+Kolodziejauthor=J.+Liauthor=R.+E.+Manningauthor=M.+W.+Mahoneyauthor=R.+E.+Millerauthor=D.+A.+Mischkeauthor=N.+P.+Rathauthor=T.+Fletcherauthor=E.+J.+Reinhardauthor=M.+B.+Tollefsonauthor=W.+F.+Vernierauthor=G.+M.+Wagnerauthor=S.+R.+Rappauthor=J.+Beaudryauthor=K.+Glennauthor=K.+Reginaauthor=J.+R.+Schuhauthor=M.+E.+Smithauthor=J.+S.+Trivediauthor=D.+B.+Reitz&title=Discovery+of+potent%2C+nonsystemic+apical+sodium-codependent+bile+acid+transporter+inhibitors+%28Part+1%29&doi=10.1021%2Fjm040215%2B"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Nonsystemic Apical Sodium-Codependent Bile Acid Transporter Inhibitors (Part 1)</span></div><div class="casAuthors">Tremont, Samuel J.; Lee, Len F.; Huang, Horng-Chih; Keller, Bradley T.; Banerjee, Shyamal C.; Both, Scott R.; Carpenter, Andrew J.; Wang, Ching-Cheng; Garland, Danny J.; Huang, Wei; Jones, Claude; Koeller, Kevin J.; Kolodziej, Steve A.; Li, James; Manning, Robert E.; Mahoney, Matthew W.; Miller, Raymond E.; Mischke, Deborah A.; Rath, Nigam P.; Fletcher, Theresa; Reinhard, Emily J.; Tollefson, Michael B.; Vernier, William F.; Wagner, Grace M.; Rapp, Steve R.; Beaudry, Judy; Glenn, Kevin; Regina, Karen; Schuh, Joe R.; Smith, Mark E.; Trivedi, Jay S.; Reitz, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5837-5852</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Elevated plasma levels of low-d. lipoprotein (LDL) cholesterol are a major risk factor for atherosclerosis leading to coronary artery disease (CAD), which remains the main cause of mortality in Western society.  By preventing the reabsorption of bile acids, a minimally absorbed apical sodium-codependent bile acid transporter (ASBT) inhibitor would lower the serum cholesterol without the potential systemic side effects of an absorbed drug.  A series of novel benzothiepins (3R,3R'-2,3,4,5-tetrahydro-5-aryl-1-benzothiepin-4-ol 1,1-dioxides) I (R1 = H, 7-Me, 7-H2N, 7-MeS, 7-Br, 7-Ph, 8-OH, 9-F, etc.; R2 = Ph, 4-FC6H4, 4-MeOC6H4, etc.; R3 = R4 = Me, Et, n-Pr, n-Bu, n-pentyl; R3 = Et, R4 = Bu) was synthesized and tested for their ability to inhibit the apical sodium dependent bile acid transport (ASBT)-mediated uptake of [14C]taurocholate in H14 cells.  A 3R,4R,5R/3S,4S,5S racemate was found to have greater potency than the other three possible racemates.  Addn. of electron-donating groups such as a dimethylamino substituent at the 7 position greatly enhanced potency, and incorporation of a long-chain quaternary ammonium substituent on the 5-Ph ring was useful in minimizing systemic exposure of this locally active ASBT inhibitor while also increasing water soly. and maintaining potency.  The reported results describe the synthesis and SAR development of this benzothiepin class of ASBT inhibitors resulting in an 6000-fold improvement in ASBT inhibition with desired minimal systemic exposure of this locally acting drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0bgwePkZi7Vg90H21EOLACvtfcHk0lgdjUrW1WU3JA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVChtrk%253D&md5=e730b5e2d4c63e6717c85bca8192c800</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Fjm040215%2B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040215%252B%26sid%3Dliteratum%253Aachs%26aulast%3DTremont%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BF.%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DKeller%26aufirst%3DB.%2BT.%26aulast%3DBanerjee%26aufirst%3DS.%2BC.%26aulast%3DBoth%26aufirst%3DS.%2BR.%26aulast%3DCarpenter%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DGarland%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKoeller%26aufirst%3DK.%2BJ.%26aulast%3DKolodziej%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DR.%2BE.%26aulast%3DMahoney%26aufirst%3DM.%2BW.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRath%26aufirst%3DN.%2BP.%26aulast%3DFletcher%26aufirst%3DT.%26aulast%3DReinhard%26aufirst%3DE.%2BJ.%26aulast%3DTollefson%26aufirst%3DM.%2BB.%26aulast%3DVernier%26aufirst%3DW.%2BF.%26aulast%3DWagner%26aufirst%3DG.%2BM.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DBeaudry%26aufirst%3DJ.%26aulast%3DGlenn%26aufirst%3DK.%26aulast%3DRegina%26aufirst%3DK.%26aulast%3DSchuh%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%26aulast%3DTrivedi%26aufirst%3DJ.%2BS.%26aulast%3DReitz%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520potent%252C%2520nonsystemic%2520apical%2520sodium-codependent%2520bile%2520acid%2520transporter%2520inhibitors%2520%2528Part%25201%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D18%26spage%3D5837%26epage%3D5852%26doi%3D10.1021%2Fjm040215%2B" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, P. C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, R. W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoi, M. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwan, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, G. P. H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human equilibrative nucleoside transporters by 4((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-y1)-1,3,5-triazin-2-amine</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>791</i></span>,  <span class="NLM_fpage">544</span>â <span class="NLM_lpage">551</span>, <span class="refDoi">Â DOI: 10.1016/j.ejphar.2016.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.ejphar.2016.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27388143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyrurrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=791&publication_year=2016&pages=544-551&author=P.+C.+T.+Tangauthor=C.+Yangauthor=R.+W.+S.+Liauthor=S.+M.+Y.+Leeauthor=M.+P.+M.+Hoiauthor=S.+W.+Chanauthor=Y.+W.+Kwanauthor=C.+M.+Tseauthor=G.+P.+H.+Leung&title=Inhibition+of+human+equilibrative+nucleoside+transporters+by+4%28%284-%282-fluorophenyl%29piperazin-1-yl%29methyl%29-6-imino-N-%28naphthalen-2-y1%29-1%2C3%2C5-triazin-2-amine&doi=10.1016%2Fj.ejphar.2016.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human equilibrative nucleoside transporters by 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine</span></div><div class="casAuthors">Tang, Philip C. T.; Yang, Cui; Li, Rachel Wai-Sum; Lee, Simon Ming-Yuen; Hoi, Maggie Pui-man; Chan, Shun-Wan; Kwan, Yiu-Wa; Tse, Chung-Ming; Leung, George Pak-Heng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">791</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">544-551</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Equilibrative nucleoside transporters (ENTs) play a crucial role in the transport of nucleoside and nucleoside analogs, which are important for nucleotide synthesis and chemotherapy.  In addn., ENTs regulate extracellular adenosine levels in the vicinity of its receptors and hence influence adenosine-related functions.  The clin. applications of ENT inhibitors in the treatment of cardiovascular diseases and cancer therapy have been explored in numerous studies.  However, all ENT inhibitors to date are selective for ENT1 but not ENT2.  In the present study, we investigated the novel compd. 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) as an inhibitor of ENT1 and ENT2.  Nucleoside transporter-deficient PK15NTD cells stably expressing ENT1 and ENT2 showed that FPMINT inhibited [3H]uridine and [3H]adenosine transport through both ENT1 and ENT2 in a concn.-dependent manner.  The IC50 value of FPMINT for ENT2 was 5-10-fold less than for ENT1, and FPMINT could not be displaced with excess washing.  Kinetic studies revealed that FPMINT reduced Vmax of [3H]uridine transport in ENT1 and ENT2 without affecting KM.  Therefore, we conclude that FPMINT inhibits ENTs in an irreversible and non-competitive manner.  Although already selective for ENT2 over ENT1, further modification of the chem. structure of FPMINT may lead to even better ENT2-selective inhibitors of potential clin., physiol. and pharmacol. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-nWSJEs3jwbVg90H21EOLACvtfcHk0lhCLlytyNlHAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyrurrK&md5=e53131e025f9a337b8041befc5808d1e</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2016.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2016.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DP.%2BC.%2BT.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DR.%2BW.%2BS.%26aulast%3DLee%26aufirst%3DS.%2BM.%2BY.%26aulast%3DHoi%26aufirst%3DM.%2BP.%2BM.%26aulast%3DChan%26aufirst%3DS.%2BW.%26aulast%3DKwan%26aufirst%3DY.%2BW.%26aulast%3DTse%26aufirst%3DC.%2BM.%26aulast%3DLeung%26aufirst%3DG.%2BP.%2BH.%26atitle%3DInhibition%2520of%2520human%2520equilibrative%2520nucleoside%2520transporters%2520by%25204%2528%25284-%25282-fluorophenyl%2529piperazin-1-yl%2529methyl%2529-6-imino-N-%2528naphthalen-2-y1%2529-1%252C3%252C5-triazin-2-amine%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D791%26spage%3D544%26epage%3D551%26doi%3D10.1016%2Fj.ejphar.2016.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentzien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyer, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lombaert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haist, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplita, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmazyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemper, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirrane, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madwed, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mainolfi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraja, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleymanzadeh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swinamer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eldrup, A. B.</span></span> <span> </span><span class="NLM_article-title">Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">16</span>),  <span class="NLM_fpage">7114</span>â <span class="NLM_lpage">7140</span>, <span class="refDoi">Â DOI: 10.1021/jm300601d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300601d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7zJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7114-7140&issue=16&author=J.+D.+Huberauthor=J.+Bentzienauthor=S.+J.+Boyerauthor=J.+Burkeauthor=S.+De+Lombaertauthor=C.+Eickmeierauthor=X.+Guoauthor=J.+V.+Haistauthor=E.+R.+Hickeyauthor=P.+Kaplitaauthor=M.+Karmazynauthor=R.+Kemperauthor=C.+A.+Kennedyauthor=T.+Kirraneauthor=J.+B.+Madwedauthor=E.+Mainolfiauthor=N.+Nagarajaauthor=F.+Soleymanzadehauthor=A.+Swinamerauthor=A.+B.+Eldrup&title=Identification+of+a+potent+sodium+hydrogen+exchanger+isoform+1+%28NHE1%29+inhibitor+with+a+suitable+profile+for+chronic+dosing+and+demonstrated+cardioprotective+effects+in+a+preclinical+model+of+myocardial+infarction+in+the+rat&doi=10.1021%2Fjm300601d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Potent Sodium Hydrogen Exchanger Isoform 1 (NHE1) Inhibitor with a Suitable Profile for Chronic Dosing and Demonstrated Cardioprotective Effects in a Preclinical Model of Myocardial Infarction in the Rat</span></div><div class="casAuthors">Huber, John D.; Bentzien, Jorg; Boyer, Stephen J.; Burke, Jennifer; De Lombaert, Stephane; Eickmeier, Christian; Guo, Xin; Haist, James V.; Hickey, Eugene R.; Kaplita, Paul; Karmazyn, Morris; Kemper, Raymond; Kennedy, Charles A.; Kirrane, Thomas; Madwed, Jeffrey B.; Mainolfi, Elizabeth; Nagaraja, Nelamangara; Soleymanzadeh, Fariba; Swinamer, Alan; Eldrup, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7114-7140</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation.  During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular processes, leading to myocardial stunning, arrhythmias, and ultimately cell damage and death.  The role of NHE1 in cardiac injury has prompted interest in the development of NHE1 inhibitors for the treatment of heart failure.  This report outlines our efforts to identify a compd. suitable for once daily, oral administration with low drug-drug interaction potential starting from NHE1 inhibitor sabiporide.  Substitution of a piperidine for the piperazine of sabiporide followed by replacement of the pyrrole moiety and subsequent optimization to improve potency and eliminate off-target activities resulted in the identification of N-[4-(1-acetyl-piperidin-4-yl)-3-trifluoromethylbenzoyl]guanidine (I).  Pharmacol. evaluation of I revealed a remarkable ability to prevent ischemic damage in an ex vivo model of ischemia reperfusion injury in isolated rat hearts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL--7k8Ug8F7Vg90H21EOLACvtfcHk0lhCLlytyNlHAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGhs7zJ&md5=bb7ec3a582e03d620e226fb150800cb2</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fjm300601d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300601d%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DJ.%2BD.%26aulast%3DBentzien%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DS.%2BJ.%26aulast%3DBurke%26aufirst%3DJ.%26aulast%3DDe%2BLombaert%26aufirst%3DS.%26aulast%3DEickmeier%26aufirst%3DC.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DHaist%26aufirst%3DJ.%2BV.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DKaplita%26aufirst%3DP.%26aulast%3DKarmazyn%26aufirst%3DM.%26aulast%3DKemper%26aufirst%3DR.%26aulast%3DKennedy%26aufirst%3DC.%2BA.%26aulast%3DKirrane%26aufirst%3DT.%26aulast%3DMadwed%26aufirst%3DJ.%2BB.%26aulast%3DMainolfi%26aufirst%3DE.%26aulast%3DNagaraja%26aufirst%3DN.%26aulast%3DSoleymanzadeh%26aufirst%3DF.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DEldrup%26aufirst%3DA.%2BB.%26atitle%3DIdentification%2520of%2520a%2520potent%2520sodium%2520hydrogen%2520exchanger%2520isoform%25201%2520%2528NHE1%2529%2520inhibitor%2520with%2520a%2520suitable%2520profile%2520for%2520chronic%2520dosing%2520and%2520demonstrated%2520cardioprotective%2520effects%2520in%2520a%2520preclinical%2520model%2520of%2520myocardial%2520infarction%2520in%2520the%2520rat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D16%26spage%3D7114%26epage%3D7140%26doi%3D10.1021%2Fjm300601d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruggiero, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivy, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmstrand, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ennis, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blakely, R. D.</span></span> <span> </span><span class="NLM_article-title">Nonoisotopic assay for the presynaptic choline transporter reveals capacity for allosteric modulation of choline uptake</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">767</span>â <span class="NLM_lpage">781</span>, <span class="refDoi">Â DOI: 10.1021/cn3000718</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn3000718" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVKltb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=767-781&issue=10&author=A.+M.+Ruggieroauthor=J.+Wrightauthor=S.+M.+Fergusonauthor=M.+Lewisauthor=K.+S.+Emersonauthor=H.+Iwamotoauthor=M.+T.+Ivyauthor=E.+C.+Holmstrandauthor=E.+A.+Ennisauthor=C.+D.+Weaverauthor=R.+D.+Blakely&title=Nonoisotopic+assay+for+the+presynaptic+choline+transporter+reveals+capacity+for+allosteric+modulation+of+choline+uptake&doi=10.1021%2Fcn3000718"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Nonoisotopic Assay for the Presynaptic Choline Transporter Reveals Capacity for Allosteric Modulation of Choline Uptake</span></div><div class="casAuthors">Ruggiero, Alicia M.; Wright, Jane; Ferguson, Shawn M.; Lewis, Michelle; Emerson, Katie S.; Iwamoto, Hideki; Ivy, Michael T.; Holmstrand, Ericka C.; Ennis, Elizabeth. A.; Weaver, C. David; Blakely, Randy D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">767-781</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Current therapies to enhance CNS cholinergic function rely primarily on extracellular acetylcholinesterase (AChE) inhibition, a pharmacotherapeutic strategy that produces dose-limiting side effects.  The Na+-dependent, high-affinity choline transporter (CHT) is an unexplored target for cholinergic medication development.  Although functional at the plasma membrane, CHT at steady-state is localized to synaptic vesicles such that vesicular fusion can support a biosynthetic response to neuronal excitation.  To identify allosteric potentiators of CHT activity, the authors mapped endocytic sequences in the C-terminus of human CHT, identifying transporter mutants that exhibit significantly increased transport function.  A stable HEK-293 cell line was generated from one of these mutants (CHT LV-AA) and used to establish a high-throughput screen (HTS) compatible assay based on the electrogenic nature of the transporter.  The authors established that the addn. of choline to these cells, at concns. appropriate for high-affinity choline transport at presynaptic terminals, generates a hemicholinium-3 (HC-3)-sensitive, membrane depolarization that can be used for the screening of CHT inhibitors and activators.  Using this assay, the authors discovered that staurosporine increased CHT LV-AA choline uptake activity, an effect mediated by a decrease in choline Km with no change in Vmax.  As staurosporine did not change surface levels of CHT, nor inhibit HC-3 binding, the authors propose that its action is directly or indirectly allosteric in nature.  Surprisingly, staurosporine reduced choline-induced membrane depolarization, suggesting that increased substrate coupling to ion gradients, arising at the expense of nonstoichiometric ion flow, accompanies a shift of CHT to a higher-affinity state.  The authors' findings provide a new approach for the identification of CHT modulators that is compatible with high-throughput screening approaches and presents a novel model by which small mols. can enhance substrate flux through enhanced gradient coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrELuyUK7m6sbVg90H21EOLACvtfcHk0lg0SLhZA6DgQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVKltb8%253D&md5=4f8022c6b7b76e2aed0a9b71e597f462</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1021%2Fcn3000718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn3000718%26sid%3Dliteratum%253Aachs%26aulast%3DRuggiero%26aufirst%3DA.%2BM.%26aulast%3DWright%26aufirst%3DJ.%26aulast%3DFerguson%26aufirst%3DS.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DEmerson%26aufirst%3DK.%2BS.%26aulast%3DIwamoto%26aufirst%3DH.%26aulast%3DIvy%26aufirst%3DM.%2BT.%26aulast%3DHolmstrand%26aufirst%3DE.%2BC.%26aulast%3DEnnis%26aufirst%3DE.%2BA.%26aulast%3DWeaver%26aufirst%3DC.%2BD.%26aulast%3DBlakely%26aufirst%3DR.%2BD.%26atitle%3DNonoisotopic%2520assay%2520for%2520the%2520presynaptic%2520choline%2520transporter%2520reveals%2520capacity%2520for%2520allosteric%2520modulation%2520of%2520choline%2520uptake%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26issue%3D10%26spage%3D767%26epage%3D781%26doi%3D10.1021%2Fcn3000718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sindelar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wanner, K. T.</span></span> <span> </span><span class="NLM_article-title">Library screening by means of mass spectrometry (MS) binding assays-exemplarily demonstrated for a pseudostatic library addressing gamma-aminobutyric acid (GABA) transporter 1 (GAT1)</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1678</span>â <span class="NLM_lpage">1690</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201200201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201200201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22689508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xot1Khu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1678-1690&issue=9&author=M.+Sindelarauthor=K.+T.+Wanner&title=Library+screening+by+means+of+mass+spectrometry+%28MS%29+binding+assays-exemplarily+demonstrated+for+a+pseudostatic+library+addressing+gamma-aminobutyric+acid+%28GABA%29+transporter+1+%28GAT1%29&doi=10.1002%2Fcmdc.201200201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Library Screening by Means of Mass Spectrometry (MS) Binding Assays-Exemplarily Demonstrated for a Pseudostatic Library Addressing Î³-Aminobutyric Acid (GABA) Transporter 1 (GAT1)</span></div><div class="casAuthors">Sindelar, Miriam; Wanner, Klaus T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1678-1690, S1678/1-S1678/7</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In the present study, the application of mass spectrometry (MS) binding assays as a tool for library screening is reported.  For library generation, dynamic combinatorial chem. (DCC) was used.  These libraries can be screened by MS binding assays when appropriate measures are taken to render the libraries pseudostatic.  That way, the efficiency of MS binding assays to det. ligand binding in compd. screening with the ease of library generation by DCC is combined.  The feasibility of this approach is shown for Î³-aminobutyric acid (GABA) transporter 1 (GAT1) as a target, representing the most important subtype of the GABA transporters.  For the screening, hydrazone libraries were employed that were generated in the presence of the target by reacting various sets of aldehydes with a hydrazine deriv. that is delineated from piperidine-3-carboxylic acid (nipecotic acid), a common fragment of known GAT1 inhibitors.  To ensure that the library generated is pseudostatic, a large excess of the nipecotic acid deriv. is employed.  As the library is generated in a buffer system suitable for binding and the target is already present, the mixts. can be directly analyzed by MS binding assays-the process of library generation and screening thus becoming simple to perform.  The binding affinities of the hits identified by deconvolution were confirmed in conventional competitive MS binding assays performed with single compds. obtained by sep. synthesis.  In this way, two nipecotic acid derivs. exhibiting a biaryl moiety, 1-{2-[2'-(1,1'-biphenyl-2-ylmethylidene)hydrazine]ethyl}piperidine-3-carboxylic acid and 1-(2-{2'-[1-(2-thiophenylphenyl)methylidene]hydrazine}ethyl)piperidine-3-carboxylic acid, were potent GAT1 ligands exhibiting pKi values of 6.186Â±0.028 and 6.229Â±0.039, resp.  This method enables screening of libraries, whether generated by conventional chem. or DCC, and is applicable to all kinds of targets including membrane-bound targets such as G protein coupled receptors (GPCRs), ion channels and transporters.  As such, this strategy displays high potential in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnSKnSrfzoNbVg90H21EOLACvtfcHk0lg0SLhZA6DgQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xot1Khu7c%253D&md5=98216d9b84dca9be3dd0b34fe4602461</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201200201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201200201%26sid%3Dliteratum%253Aachs%26aulast%3DSindelar%26aufirst%3DM.%26aulast%3DWanner%26aufirst%3DK.%2BT.%26atitle%3DLibrary%2520screening%2520by%2520means%2520of%2520mass%2520spectrometry%2520%2528MS%2529%2520binding%2520assays-exemplarily%2520demonstrated%2520for%2520a%2520pseudostatic%2520library%2520addressing%2520gamma-aminobutyric%2520acid%2520%2528GABA%2529%2520transporter%25201%2520%2528GAT1%2529%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26issue%3D9%26spage%3D1678%26epage%3D1690%26doi%3D10.1002%2Fcmdc.201200201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joslyn, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallaro, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narvaiza, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Ligand and target discovery by fragment-based screening in human cells</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">527</span>â <span class="NLM_lpage">541</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2016.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2016.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28111073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=527-541&issue=3&author=C.+G.+Parkerauthor=A.+Galmozziauthor=Y.+J.+Wangauthor=B.+E.+Correiaauthor=K.+Sasakiauthor=C.+M.+Joslynauthor=A.+S.+Kimauthor=C.+L.+Cavallaroauthor=R.+M.+Lawrenceauthor=S.+R.+Johnsonauthor=I.+Narvaizaauthor=E.+Saezauthor=B.+F.+Cravatt&title=Ligand+and+target+discovery+by+fragment-based+screening+in+human+cells&doi=10.1016%2Fj.cell.2016.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand and Target Discovery by Fragment-Based Screening in Human Cells</span></div><div class="casAuthors">Parker, Christopher G.; Galmozzi, Andrea; Wang, Yujia; Correia, Bruno E.; Sasaki, Kenji; Joslyn, Christopher M.; Kim, Arthur S.; Cavallaro, Cullen L.; Lawrence, R. Michael; Johnson, Stephen R.; Narvaiza, Inigo; Saez, Enrique; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">527-541.e29</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in the synthesis and screening of small-mol. libraries have accelerated the discovery of chem. probes for studying biol. processes.  Still, only a small fraction of the human proteome has chem. ligands.  Here, we describe a platform that marries fragment-based ligand discovery with quant. chem. proteomics to map thousands of reversible small mol.-protein interactions directly in human cells, many of which can be site-specifically detd.  We show that fragment hits can be advanced to furnish selective ligands that affect the activity of proteins heretofore lacking chem. probes.  We further combine fragment-based chem. proteomics with phenotypic screening to identify small mols. that promote adipocyte differentiation by engaging the poorly characterized membrane protein PGRMC2.  Fragment-based screening in human cells thus provides an extensive proteome-wide map of protein ligandability and facilitates the coordinated discovery of bioactive small mols. and their mol. targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPk-YJwFlDwbVg90H21EOLACvtfcHk0lg0SLhZA6DgQA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVeiu7Y%253D&md5=835264291015037ab9b7e446992caba3</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2016.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2016.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DCorreia%26aufirst%3DB.%2BE.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DJoslyn%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DA.%2BS.%26aulast%3DCavallaro%26aufirst%3DC.%2BL.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DNarvaiza%26aufirst%3DI.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DLigand%2520and%2520target%2520discovery%2520by%2520fragment-based%2520screening%2520in%2520human%2520cells%26jtitle%3DCell%26date%3D2017%26volume%3D168%26issue%3D3%26spage%3D527%26epage%3D541%26doi%3D10.1016%2Fj.cell.2016.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuttruff, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galmozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermanson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKerrall, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josyln, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norremark, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunstl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baran, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Chemical proteomics identifies SLC25A20 as a functional target of the ingenol class of actinic keratosis drugs</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1276</span>â <span class="NLM_lpage">1285</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.7b00420</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00420" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWnsrfM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1276-1285&issue=12&author=C.+G.+Parkerauthor=C.+A.+Kuttruffauthor=A.+Galmozziauthor=L.+Jorgensenauthor=C.+H.+Yehauthor=D.+J.+Hermansonauthor=Y.+J.+Wangauthor=M.+Artolaauthor=S.+J.+McKerrallauthor=C.+M.+Josylnauthor=B.+Norremarkauthor=G.+Dunstlauthor=J.+Feldingauthor=E.+Saezauthor=P.+S.+Baranauthor=B.+F.+Cravatt&title=Chemical+proteomics+identifies+SLC25A20+as+a+functional+target+of+the+ingenol+class+of+actinic+keratosis+drugs&doi=10.1021%2Facscentsci.7b00420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs</span></div><div class="casAuthors">Parker, Christopher G.; Kuttruff, Christian A.; Galmozzi, Andrea; Joergensen, Lars; Yeh, Chien-Hung; Hermanson, Daniel J.; Wang, Yujia; Artola, Marta; McKerrall, Steven J.; Josyln, Christopher M.; Noerremark, Bjarne; Dunstl, Georg; Felding, Jakob; Saez, Enrique; Baran, Phil S.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1276-1285</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The diterpenoid ester ingenol mebutate (IngMeb) is the active ingredient in the topical drug Picato, a first-in-class treatment for the precancerous skin condition actinic keratosis.  IngMeb is proposed to exert its therapeutic effects through a dual mode of action involving (i) induction of cell death that is assocd. with mitochondrial dysfunction followed by (ii) stimulation of a local inflammatory response, at least partially driven by protein kinase C (PKC) activation.  Although this therapeutic model has been well characterized, the complete set of mol. targets responsible for mediating IngMeb activity remains ill-defined.  Here, the authors have synthesized a photoreactive, clickable analog of IngMeb and used this probe in quant. proteomic expts. to map several protein targets of IngMeb in human cancer cell lines and primary human keratinocytes.  Prominent among these targets was the mitochondrial carnitine-acylcarnitine translocase SLC25A20, which the authors proceed to show is inhibited in cells by IngMeb and the more stable analog ingenol disoxate (IngDsx), but not by the canonical PKC agonist 12-O-tetradecanoylphorbal-13-acetate (TPA).  SLC25A20 blockade by IngMeb and IngDsx leads to a buildup of cellular acylcarnitines and blockade of fatty acid oxidn. (FAO), pointing to a possible mechanism for IngMeb-mediated perturbations in mitochondrial function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvBH7tPLoN-bVg90H21EOLACvtfcHk0li3Z7-ovblRBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWnsrfM&md5=af15c86bf1f8ac2de2bfded316e58ad3</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00420%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DKuttruff%26aufirst%3DC.%2BA.%26aulast%3DGalmozzi%26aufirst%3DA.%26aulast%3DJorgensen%26aufirst%3DL.%26aulast%3DYeh%26aufirst%3DC.%2BH.%26aulast%3DHermanson%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DY.%2BJ.%26aulast%3DArtola%26aufirst%3DM.%26aulast%3DMcKerrall%26aufirst%3DS.%2BJ.%26aulast%3DJosyln%26aufirst%3DC.%2BM.%26aulast%3DNorremark%26aufirst%3DB.%26aulast%3DDunstl%26aufirst%3DG.%26aulast%3DFelding%26aufirst%3DJ.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DBaran%26aufirst%3DP.%2BS.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DChemical%2520proteomics%2520identifies%2520SLC25A20%2520as%2520a%2520functional%2520target%2520of%2520the%2520ingenol%2520class%2520of%2520actinic%2520keratosis%2520drugs%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2017%26volume%3D3%26issue%3D12%26spage%3D1276%26epage%3D1285%26doi%3D10.1021%2Facscentsci.7b00420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, F. B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franken, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savitski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dovega, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaeger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuster, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nordlund, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span> <span> </span><span class="NLM_article-title">Tracking cancer drugs in living cells by thermal profiling of the proteome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">6205</span>),  <span class="NLM_fpage">1255784</span>, <span class="refDoi">Â DOI: 10.1126/science.1255784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1255784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25278616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2014&pages=1255784&issue=6205&author=M.+M.+Savitskiauthor=F.+B.+M.+Reinhardauthor=H.+Frankenauthor=T.+Wernerauthor=M.+F.+Savitskiauthor=D.+Eberhardauthor=D.+M.+Molinaauthor=R.+Jafariauthor=R.+B.+Dovegaauthor=S.+Klaegerauthor=B.+Kusterauthor=P.+Nordlundauthor=M.+Bantscheffauthor=G.+Drewes&title=Tracking+cancer+drugs+in+living+cells+by+thermal+profiling+of+the+proteome&doi=10.1126%2Fscience.1255784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Tracking cancer drugs in living cells by thermal profiling of the proteome</span></div><div class="casAuthors">Savitski Mikhail M; Reinhard Friedrich B M; Franken Holger; Werner Thilo; Savitski Maria Falth; Eberhard Dirk; Bantscheff Marcus; Drewes Gerard; Martinez Molina Daniel; Jafari Rozbeh; Dovega Rebecca Bakszt; Klaeger Susan; Kuster Bernhard; Nordlund Par</div><div class="citationInfo"><span class="NLM_cas:title">Science (New York, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">6205</span>),
    <span class="NLM_cas:pages">1255784</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The thermal stability of proteins can be used to assess ligand binding in living cells.  We have generalized this concept by determining the thermal profiles of more than 7000 proteins in human cells by means of mass spectrometry.  Monitoring the effects of small-molecule ligands on the profiles delineated more than 50 targets for the kinase inhibitor staurosporine.  We identified the heme biosynthesis enzyme ferrochelatase as a target of kinase inhibitors and suggest that its inhibition causes the phototoxicity observed with vemurafenib and alectinib.  Thermal shifts were also observed for downstream effectors of drug treatment.  In live cells, dasatinib induced shifts in BCR-ABL pathway proteins, including CRK/CRKL.  Thermal proteome profiling provides an unbiased measure of drug-target engagement and facilitates identification of markers for drug efficacy and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0ur3d8ba-Bu2mnZh2OgS0fW6udTcc2eY-_HlMxneDFrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ntVKgsg%253D%253D&md5=493a89ad107e656e0f0786ff5c8e5f63</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1126%2Fscience.1255784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1255784%26sid%3Dliteratum%253Aachs%26aulast%3DSavitski%26aufirst%3DM.%2BM.%26aulast%3DReinhard%26aufirst%3DF.%2BB.%2BM.%26aulast%3DFranken%26aufirst%3DH.%26aulast%3DWerner%26aufirst%3DT.%26aulast%3DSavitski%26aufirst%3DM.%2BF.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DD.%2BM.%26aulast%3DJafari%26aufirst%3DR.%26aulast%3DDovega%26aufirst%3DR.%2BB.%26aulast%3DKlaeger%26aufirst%3DS.%26aulast%3DKuster%26aufirst%3DB.%26aulast%3DNordlund%26aufirst%3DP.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26atitle%3DTracking%2520cancer%2520drugs%2520in%2520living%2520cells%2520by%2520thermal%2520profiling%2520of%2520the%2520proteome%26jtitle%3DScience%26date%3D2014%26volume%3D346%26issue%3D6205%26spage%3D1255784%26doi%3D10.1126%2Fscience.1255784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olek, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, C. S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colinge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1055</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1038/nmeth.3590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnmeth.3590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26389571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFersL%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=1055-1057&issue=11&author=K.+V.+M.+Huberauthor=K.+M.+Olekauthor=A.+C.+Mullerauthor=C.+S.+H.+Tanauthor=K.+L.+Bennettauthor=J.+Colingeauthor=G.+Superti-Furga&title=Proteome-wide+drug+and+metabolite+interaction+mapping+by+thermal-stability+profiling&doi=10.1038%2Fnmeth.3590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Proteome-wide drug and metabolite interaction mapping by thermal-stability profiling</span></div><div class="casAuthors">Huber, Kilian V. M.; Olek, Karin M.; Mueller, Andre C.; Tan, Chris Soon Heng; Bennett, Keiryn L.; Colinge, Jacques; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1055-1057</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Thermal stabilization of proteins after ligand binding provides an efficient means to assess the binding of small mols. to proteins.  We show here that in combination with quant. mass spectrometry, the approach allows for the systematic survey of protein engagement by cellular metabolites and drugs.  We profiled the targets of the drugs methotrexate and (S)-crizotinib and the metabolite 2'3'-cGAMP in intact cells and identified the 2'3'-cGAMP cognate transmembrane receptor STING, involved in immune signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrow66ugdg1oLVg90H21EOLACvtfcHk0li3Z7-ovblRBA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFersL%252FI&md5=619a2c08c4f151f4e3ab8bd8fc45c2b6</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3590%26sid%3Dliteratum%253Aachs%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DOlek%26aufirst%3DK.%2BM.%26aulast%3DMuller%26aufirst%3DA.%2BC.%26aulast%3DTan%26aufirst%3DC.%2BS.%2BH.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DProteome-wide%2520drug%2520and%2520metabolite%2520interaction%2520mapping%2520by%2520thermal-stability%2520profiling%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26issue%3D11%26spage%3D1055%26epage%3D1057%26doi%3D10.1038%2Fnmeth.3590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Detection of chemical engagement of solute carrier proteins by a cellular thermal shift assay</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1480</span>â <span class="NLM_lpage">1486</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.8b00270</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00270" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVCksrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=1480-1486&issue=6&author=M.+Hashimotoauthor=E.+Girardiauthor=R.+Eichnerauthor=G.+Superti-Furga&title=Detection+of+chemical+engagement+of+solute+carrier+proteins+by+a+cellular+thermal+shift+assay&doi=10.1021%2Facschembio.8b00270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of Chemical Engagement of Solute Carrier Proteins by a Cellular Thermal Shift Assay</span></div><div class="casAuthors">Hashimoto, Mari; Girardi, Enrico; Eichner, Ruth; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1480-1486</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Solute carriers (SLCs) are transmembrane proteins that transport various nutrients, metabolites, and drugs across cellular membranes.  Despite the relevance of SLCs to cell homeostasis, metab., and disease states, for the majority of SLCs the authors lack exptl. evidence regarding the nature of the cognate ligands, whether endobiotic or xenobiotic.  Moreover, even for the roughly 20 SLCs for which inhibitors have been characterized, engagement assays in cells are limited to the accessibility of radiolabeled or fluorescent probes.  The cellular thermal shift assay (CETSA) has been introduced as a powerful method to assess target engagement by monitoring ligand-induced changes in the thermal stability of cellular proteins.  The authors addressed the question of whether CETSA could be modified to become routinely applicable to membrane transporters such as SLCs.  The authors used SLC16A1 (MCT1) and SLC1A2 (EAAT2) as targets to establish robust conditions by which chem. engagement of SLCs can be detected.  Using immunoblotting, the authors demonstrate that treatment with the SLC16A1 inhibitors AZD3965 and AR-C155858 stabilized endogenous SLC16A1 in HEK293 cell lysates as well as intact cells.  In addn., the high-affinity ligand of SLC16A1, L-lactate, and the low-affinity ligand, formate, resulted in strong and weak stabilization of SLC16A1, resp.  Moreover, the authors obsd. stabilization of SLC1A2 upon treatment with the selective inhibitor WAY-213613.  The authors propose that the exptl. approach presented here should be generally and easily applicable for monitoring the engagement of chem. ligands by SLCs in cellular settings and thus assisting in their deorphanization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEpqIcKteWbVg90H21EOLACvtfcHk0lg0_7wzGwnYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVCksrjP&md5=06a1a4f91a1ffa3de49b59ce6f95fb1c</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00270%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DM.%26aulast%3DGirardi%26aufirst%3DE.%26aulast%3DEichner%26aufirst%3DR.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DDetection%2520of%2520chemical%2520engagement%2520of%2520solute%2520carrier%2520proteins%2520by%2520a%2520cellular%2520thermal%2520shift%2520assay%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26issue%3D6%26spage%3D1480%26epage%3D1486%26doi%3D10.1021%2Facschembio.8b00270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Earl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Ezetimibe</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">97</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1038/nrd1015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd1015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12572539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot12ltQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=97-98&issue=2&author=J.+Earlauthor=P.+Kirkpatrick&title=Ezetimibe&doi=10.1038%2Fnrd1015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Fresh from the pipeline: Ezetimibe</span></div><div class="casAuthors">Earl, John; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-98</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ezetimibe (Zetia), the first in a new class of agents that inhibit cholesterol absorption in the intestine, was approved by the FDA in Oct. 2002 for the redn. of cholesterol levels in patients with hypercholesterolemia.  What impact is it likely to have on the multi-billion-dollar market for cholesterol-lowering drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon7pUdtXVW1bVg90H21EOLACvtfcHk0lg0_7wzGwnYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot12ltQ%253D%253D&md5=39ef80f0d152e413fcfb579adcdced41</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fnrd1015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1015%26sid%3Dliteratum%253Aachs%26aulast%3DEarl%26aufirst%3DJ.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DEzetimibe%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26issue%3D2%26spage%3D97%26epage%3D98%26doi%3D10.1038%2Fnrd1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzloff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S. P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golovko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgolo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, M. P.</span></span> <span> </span><span class="NLM_article-title">Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>303</i></span> (<span class="NLM_issue">5661</span>),  <span class="NLM_fpage">1201</span>â <span class="NLM_lpage">1204</span>, <span class="refDoi">Â DOI: 10.1126/science.1093131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1093131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=14976318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVWgtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2004&pages=1201-1204&issue=5661&author=S.+W.+Altmannauthor=H.+R.+Davisauthor=L.+J.+Zhuauthor=X.+R.+Yaoauthor=L.+M.+Hoosauthor=G.+Tetzloffauthor=S.+P.+N.+Iyerauthor=M.+Maguireauthor=A.+Golovkoauthor=M.+Zengauthor=L.+Q.+Wangauthor=N.+Murgoloauthor=M.+P.+Graziano&title=Niemann-Pick+C1+like+1+protein+is+critical+for+intestinal+cholesterol+absorption&doi=10.1126%2Fscience.1093131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption</span></div><div class="casAuthors">Altmann, Scott W.; Davis, Harry R., Jr.; Zhu, Li-ji; Yao, Xiaorui; Hoos, Lizbeth M.; Tetzloff, Glen; Iyer, Sai Prasad N.; Maguire, Maureen; Golovko, Andrei; Zeng, Ming; Wang, Luquan; Murgolo, Nicholas; Graziano, Michael P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">5661</span>),
    <span class="NLM_cas:pages">1201-1204</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dietary cholesterol consumption and intestinal cholesterol absorption contribute to plasma cholesterol levels, a risk factor for coronary heart disease.  The mol. mechanism of sterol uptake from the lumen of the small intestine is poorly defined.  We show that Niemann-Pick C1 Like 1 (NPC1L1) protein plays a crit. role in the absorption of intestinal cholesterol.  NPC1L1 expression is enriched in the small intestine and is in the brush border membrane of enterocytes.  Although otherwise phenotypically normal, NPC1L1-deficient mice exhibit a substantial redn. in absorbed cholesterol, which is unaffected by dietary supplementation of bile acids.  Ezetimibe, a drug that inhibits cholesterol absorption, had no effect in NPC1L1 knockout mice, suggesting that NPC1L1 resides in an ezetimibe-sensitive pathway responsible for intestinal cholesterol absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk89QuURahR7Vg90H21EOLACvtfcHk0lg0_7wzGwnYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVWgtbc%253D&md5=d845c6a42d62bd3e9bcb783612c043f0</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1126%2Fscience.1093131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1093131%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DS.%2BW.%26aulast%3DDavis%26aufirst%3DH.%2BR.%26aulast%3DZhu%26aufirst%3DL.%2BJ.%26aulast%3DYao%26aufirst%3DX.%2BR.%26aulast%3DHoos%26aufirst%3DL.%2BM.%26aulast%3DTetzloff%26aufirst%3DG.%26aulast%3DIyer%26aufirst%3DS.%2BP.%2BN.%26aulast%3DMaguire%26aufirst%3DM.%26aulast%3DGolovko%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%2BQ.%26aulast%3DMurgolo%26aufirst%3DN.%26aulast%3DGraziano%26aufirst%3DM.%2BP.%26atitle%3DNiemann-Pick%2520C1%2520like%25201%2520protein%2520is%2520critical%2520for%2520intestinal%2520cholesterol%2520absorption%26jtitle%3DScience%26date%3D2004%26volume%3D303%26issue%3D5661%26spage%3D1201%26epage%3D1204%26doi%3D10.1126%2Fscience.1093131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B. L.</span></span> <span> </span><span class="NLM_article-title">The clathrin adaptor proteins ARH, Dab2, and Numb play distinct roles in Niemann-Pick C1-Like 1 versus low density lipoprotein receptor-mediated cholesterol uptake</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>289</i></span> (<span class="NLM_issue">48</span>),  <span class="NLM_fpage">33689</span>â <span class="NLM_lpage">33700</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M114.593764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1074%2Fjbc.M114.593764" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25331956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsbnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2014&pages=33689-33700&issue=48&author=J.+Weiauthor=Z.+Y.+Fuauthor=P.+S.+Liauthor=H.+H.+Miaoauthor=B.+L.+Liauthor=Y.+T.+Maauthor=B.+L.+Song&title=The+clathrin+adaptor+proteins+ARH%2C+Dab2%2C+and+Numb+play+distinct+roles+in+Niemann-Pick+C1-Like+1+versus+low+density+lipoprotein+receptor-mediated+cholesterol+uptake&doi=10.1074%2Fjbc.M114.593764"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">The Clathrin Adaptor Proteins ARH, Dab2, and Numb Play Distinct Roles in Niemann-Pick C1-Like 1 Versus Low Density Lipoprotein Receptor-mediated Cholesterol Uptake</span></div><div class="casAuthors">Wei, Jian; Fu, Zhen-Yan; Li, Pei-Shan; Miao, Hong-Hua; Li, Bo-Liang; Ma, Yi-Tong; Song, Bao-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">33689-33700</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The uptake of circulating low d. lipoproteins (LDL) is mediated by LDL receptor (LDLR) through clathrin-dependent endocytosis.  At the early stage of this process, adaptor proteins ARH and Dab2 specifically bind the endocytic signal motif in LDLR and recruit clathrin/AP2 to initiate internalization.  On the other hand, intestinal cholesterol is absorbed by Niemann-Pick C1-Like 1 (NPC1L1) through clathrin-dependent endocytosis.  Another adaptor protein, Numb recognizes the endocytic motif in NPC1L1 C terminus and couples NPC1L1 to endocytic machinery.  The ARH, Dab2, and Numb proteins contain a homogeneous phosphotyrosine binding (PTB) domain that directly binds endocytic motifs.  Because ARH, Dab2, and Numb are all PTB domain family members, the emerging mystery is whether these adaptors act complementally in LDLR and NPC1L1 endocytosis.  Here, we found that ARH and Dab2 did not bind NPC1L1 and were not required for NPC1L1 internalization.  Similarly, Numb lacked the ability to interact with the LDLR C terminus and was dispensable for LDL uptake.  Only the Numb isoforms with shorter PTB domain could facilitate NPC1L1 endocytosis.  Besides the reported function in intestinal cholesterol absorption, Numb also mediated cholesterol reabsorption from bile in liver.  We further identified a Numb variant with G595D substitution in humans of low blood LDL-cholesterol.  The G595D substitution impaired NPC1L1 internalization and cholesterol reabsorption, due to attenuating affinity of Numb to clathrin/AP2.  These results demonstrate that Numb specifically regulates NPC1L1-mediated cholesterol absorption both in human intestine and liver, distinct from ARH and Dab2, which selectively participate in LDLR-mediated LDL uptake.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMiWfmDyFEG7Vg90H21EOLACvtfcHk0lg0_7wzGwnYYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2rsbnN&md5=bd0b283b3a495568add306eebfcb813a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M114.593764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M114.593764%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DFu%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DP.%2BS.%26aulast%3DMiao%26aufirst%3DH.%2BH.%26aulast%3DLi%26aufirst%3DB.%2BL.%26aulast%3DMa%26aufirst%3DY.%2BT.%26aulast%3DSong%26aufirst%3DB.%2BL.%26atitle%3DThe%2520clathrin%2520adaptor%2520proteins%2520ARH%252C%2520Dab2%252C%2520and%2520Numb%2520play%2520distinct%2520roles%2520in%2520Niemann-Pick%2520C1-Like%25201%2520versus%2520low%2520density%2520lipoprotein%2520receptor-mediated%2520cholesterol%2520uptake%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2014%26volume%3D289%26issue%3D48%26spage%3D33689%26epage%3D33700%26doi%3D10.1074%2Fjbc.M114.593764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Irizarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blacklow, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span> <span> </span><span class="NLM_article-title">Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>306</i></span> (<span class="NLM_issue">5694</span>),  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1126/science.1102160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1102160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15472075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotFWnsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2004&pages=269-271&issue=5694&author=A.+P.+Wengauthor=A.+A.+Ferrandoauthor=W.+Leeauthor=J.+P.+Morrisauthor=L.+B.+Silvermanauthor=C.+Sanchez-Irizarryauthor=S.+C.+Blacklowauthor=A.+T.+Lookauthor=J.+C.+Aster&title=Activating+mutations+of+NOTCH1+in+human+T+cell+acute+lymphoblastic+leukemia&doi=10.1126%2Fscience.1102160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia</span></div><div class="casAuthors">Weng, Andrew P.; Ferrando, Adolfo A.; Lee, Woojoong; Morris, John P., IV; Silverman, Lewis B.; Sanchez-Irizarry, Cheryll; Blacklow, Stephen C.; Look, A. Thomas; Aster, Jon C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">5694</span>),
    <span class="NLM_cas:pages">269-271</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Very rare cases of human T cell acute lymphoblastic leukemia (T-ALL) harbor chromosomal translocations that involve NOTCH1, a gene encoding a transmembrane receptor that regulates normal T cell development.  Here, we report that more than 50% of human T-ALLs, including tumors from all major mol. oncogenic subtypes, have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1.  These findings greatly expand the role of activated NOTCH1 in the mol. pathogenesis of human T-ALL and provide a strong rationale for targeted therapies that interfere with NOTCH signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsYJ5knLWfRbVg90H21EOLACvtfcHk0li0eUpkJ1WK1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotFWnsbo%253D&md5=e538239c4757048377f5173543e67639</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1126%2Fscience.1102160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1102160%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DA.%2BP.%26aulast%3DFerrando%26aufirst%3DA.%2BA.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DMorris%26aufirst%3DJ.%2BP.%26aulast%3DSilverman%26aufirst%3DL.%2BB.%26aulast%3DSanchez-Irizarry%26aufirst%3DC.%26aulast%3DBlacklow%26aufirst%3DS.%2BC.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26atitle%3DActivating%2520mutations%2520of%2520NOTCH1%2520in%2520human%2520T%2520cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DScience%26date%3D2004%26volume%3D306%26issue%3D5694%26spage%3D269%26epage%3D271%26doi%3D10.1126%2Fscience.1102160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nolin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gans, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llamas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi-Elias, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loureiro, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schirle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuierer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beibel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sigoillot, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reece-Hoyes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weihofen, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyskiewicz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepfner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dogra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canham, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boynton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antczak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushell, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a ZIP7 inhibitor from a NOTCH pathway screen</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">179</span>â <span class="NLM_lpage">188</span>, <span class="refDoi">Â DOI: 10.1038/s41589-018-0200-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41589-018-0200-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30643281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFSgu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=179-188&issue=2&author=E.+Nolinauthor=S.+Gansauthor=L.+Llamasauthor=S.+Bandyopadhyayauthor=S.+M.+Brittainauthor=P.+Bernasconi-Eliasauthor=K.+P.+Carterauthor=J.+J.+Loureiroauthor=J.+R.+Thomasauthor=M.+Schirleauthor=Y.+Yangauthor=N.+Guoauthor=G.+Romaauthor=S.+Schuiererauthor=M.+Beibelauthor=A.+Lindemanauthor=F.+Sigoillotauthor=A.+Chenauthor=K.+X.+Xieauthor=S.+Hoauthor=J.+Reece-Hoyesauthor=W.+A.+Weihofenauthor=K.+Tyskiewiczauthor=D.+Hoepfnerauthor=R.+I.+McDonaldauthor=N.+Guthrieauthor=A.+Dograauthor=H.+B.+Guoauthor=J.+Shaoauthor=J.+Dingauthor=S.+M.+Canhamauthor=G.+Boyntonauthor=E.+L.+Georgeauthor=Z.+B.+Kangauthor=C.+Antczakauthor=J.+A.+Porterauthor=O.+Wallaceauthor=J.+A.+Tallaricoauthor=A.+E.+Palmerauthor=J.+L.+Jenkinsauthor=R.+K.+Jainauthor=S.+M.+Bushellauthor=C.+Fryer&title=Discovery+of+a+ZIP7+inhibitor+from+a+NOTCH+pathway+screen&doi=10.1038%2Fs41589-018-0200-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a ZIP7 inhibitor from a Notch pathway screen</span></div><div class="casAuthors">Nolin, Erin; Gans, Sara; Llamas, Luis; Bandyopadhyay, Somnath; Brittain, Scott M.; Bernasconi-Elias, Paula; Carter, Kyle P.; Loureiro, Joseph J.; Thomas, Jason R.; Schirle, Markus; Yang, Yi; Guo, Ning; Roma, Guglielmo; Schuierer, Sven; Beibel, Martin; Lindeman, Alicia; Sigoillot, Frederic; Chen, Amy; Xie, Kevin X.; Ho, Samuel; Reece-Hoyes, John; Weihofen, Wilhelm A.; Tyskiewicz, Kayla; Hoepfner, Dominic; McDonald, Richard I.; Guthrie, Nicolette; Dogra, Abhishek; Guo, Haibing; Shao, Jian; Ding, Jian; Canham, Stephen M.; Boynton, Geoff; George, Elizabeth L.; Kang, Zhao B.; Antczak, Christophe; Porter, Jeffery A.; Wallace, Owen; Tallarico, John A.; Palmer, Amy E.; Jenkins, Jeremy L.; Jain, Rishi K.; Bushell, Simon M.; Fryer, Christy J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The identification of activating mutations in NOTCH1 in 50% of T cell acute lymphoblastic leukemia has generated interest in elucidating how these mutations contribute to oncogenic transformation and in targeting the pathway.  A phenotypic screen identified compds. that interfere with trafficking of Notch and induce apoptosis via an endoplasmic reticulum (ER) stress mechanism.  Target identification approaches revealed a role for SLC39A7 (ZIP7), a zinc transport family member, in governing Notch trafficking and signaling.  Generation and sequencing of a compd.-resistant cell line identified a V430E mutation in ZIP7 that confers transferable resistance to the compd. NVS-ZP7-4.  NVS-ZP7-4 altered zinc in the ER, and an analog of the compd. photoaffinity labeled ZIP7 in cells, suggesting a direct interaction between the compd. and ZIP7.  NVS-ZP7-4 is the first reported chem. tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra24KMO8msebVg90H21EOLACvtfcHk0li0eUpkJ1WK1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFSgu78%253D&md5=fa168063f96b38f489b69f8418358149</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fs41589-018-0200-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-018-0200-7%26sid%3Dliteratum%253Aachs%26aulast%3DNolin%26aufirst%3DE.%26aulast%3DGans%26aufirst%3DS.%26aulast%3DLlamas%26aufirst%3DL.%26aulast%3DBandyopadhyay%26aufirst%3DS.%26aulast%3DBrittain%26aufirst%3DS.%2BM.%26aulast%3DBernasconi-Elias%26aufirst%3DP.%26aulast%3DCarter%26aufirst%3DK.%2BP.%26aulast%3DLoureiro%26aufirst%3DJ.%2BJ.%26aulast%3DThomas%26aufirst%3DJ.%2BR.%26aulast%3DSchirle%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGuo%26aufirst%3DN.%26aulast%3DRoma%26aufirst%3DG.%26aulast%3DSchuierer%26aufirst%3DS.%26aulast%3DBeibel%26aufirst%3DM.%26aulast%3DLindeman%26aufirst%3DA.%26aulast%3DSigoillot%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DXie%26aufirst%3DK.%2BX.%26aulast%3DHo%26aufirst%3DS.%26aulast%3DReece-Hoyes%26aufirst%3DJ.%26aulast%3DWeihofen%26aufirst%3DW.%2BA.%26aulast%3DTyskiewicz%26aufirst%3DK.%26aulast%3DHoepfner%26aufirst%3DD.%26aulast%3DMcDonald%26aufirst%3DR.%2BI.%26aulast%3DGuthrie%26aufirst%3DN.%26aulast%3DDogra%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%2BB.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DCanham%26aufirst%3DS.%2BM.%26aulast%3DBoynton%26aufirst%3DG.%26aulast%3DGeorge%26aufirst%3DE.%2BL.%26aulast%3DKang%26aufirst%3DZ.%2BB.%26aulast%3DAntczak%26aufirst%3DC.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DTallarico%26aufirst%3DJ.%2BA.%26aulast%3DPalmer%26aufirst%3DA.%2BE.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DJain%26aufirst%3DR.%2BK.%26aulast%3DBushell%26aufirst%3DS.%2BM.%26aulast%3DFryer%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520ZIP7%2520inhibitor%2520from%2520a%2520NOTCH%2520pathway%2520screen%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26issue%3D2%26spage%3D179%26epage%3D188%26doi%3D10.1038%2Fs41589-018-0200-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garibsingh, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">Advances and challenges in rational drug design for SLCs</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">790</span>â <span class="NLM_lpage">800</span>, <span class="refDoi">Â DOI: 10.1016/j.tips.2019.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.tips.2019.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31519459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12rt7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=790-800&issue=10&author=R.+A.+Garibsinghauthor=A.+Schlessinger&title=Advances+and+challenges+in+rational+drug+design+for+SLCs&doi=10.1016%2Fj.tips.2019.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Advances and Challenges in Rational Drug Design for SLCs</span></div><div class="casAuthors">Garibsingh, Rachel-Ann A.; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-800</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  There are over 420 human solute carrier (SLC) transporters from 65 families that are expressed ubiquitously in the body.  The SLCs mediate the movement of ions, drugs, and metabolites across membranes and their dysfunction has been assocd. with a variety of diseases, such as diabetes, cancer, and central nervous system (CNS) disorders.  Thus, SLCs are emerging as important targets for therapeutic intervention.  Recent technol. advances in exptl. and computational biol. allow better characterization of SLC pharmacol.  Here we describe recent approaches to modulate SLC transporter function, with an emphasis on the use of computational approaches and computer-aided drug design (CADD) to study nutrient transporters.  Finally, we discuss future perspectives in the rational design of SLC drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYk4nUrMsR7Vg90H21EOLACvtfcHk0lhc1h8nL7uwFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12rt7vK&md5=419fe074bf6001b78a0d111505ee2446</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DGaribsingh%26aufirst%3DR.%2BA.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DAdvances%2520and%2520challenges%2520in%2520rational%2520drug%2520design%2520for%2520SLCs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26issue%3D10%26spage%3D790%26epage%3D800%26doi%3D10.1016%2Fj.tips.2019.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahlke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">116</span>â <span class="NLM_lpage">123</span>, <span class="refDoi">Â DOI: 10.1016/j.coph.2014.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.coph.2014.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25466154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCktbvF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2015&pages=116-123&author=A.+A.+Jensenauthor=C.+Fahlkeauthor=W.+E.+Bjorn-Yoshimotoauthor=L.+Bunch&title=Excitatory+amino+acid+transporters%3A+recent+insights+into+molecular+mechanisms%2C+novel+modes+of+modulation+and+new+therapeutic+possibilities&doi=10.1016%2Fj.coph.2014.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities</span></div><div class="casAuthors">Jensen, Anders A.; Fahlke, Christoph; Bjoern-Yoshimoto, Walden E.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116-123</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The five excitatory amino acid transporters (EAAT1-5) mediating the synaptic uptake of the major excitatory neurotransmitter glutamate are differently expressed throughout the CNS and at the synaptic level.  Although EAATs are crucial for normal excitatory neurotransmission, explorations into the physiol. functions mediated by the different transporter subtypes and their resp. therapeutic potential have so far been sparse, in no small part due to the limited selection of pharmacol. tools available.  In the present update, we outline important new insights into the mol. compns. of EAATs and their intricate transport process, the novel approaches to pharmacol. modulation of the transporters that have emerged, and interesting new perspectives in EAAT as drug targets proposed in recent years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHCPIMplW6KLVg90H21EOLACvtfcHk0lhc1h8nL7uwFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCktbvF&md5=4619d6aebdc64cfd77a44bae4379eb53</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2014.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2014.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DFahlke%26aufirst%3DC.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DExcitatory%2520amino%2520acid%2520transporters%253A%2520recent%2520insights%2520into%2520molecular%2520mechanisms%252C%2520novel%2520modes%2520of%2520modulation%2520and%2520new%2520therapeutic%2520possibilities%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D20%26spage%3D116%26epage%3D123%26doi%3D10.1016%2Fj.coph.2014.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yumoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeri, Y.</span></span> <span> </span><span class="NLM_article-title">Characterization of novel L-threo-beta-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>65</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1008</span>â <span class="NLM_lpage">1015</span>, <span class="refDoi">Â DOI: 10.1124/mol.65.4.1008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fmol.65.4.1008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15044631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFaltbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2004&pages=1008-1015&issue=4&author=K.+Shimamotoauthor=R.+Sakaiauthor=K.+Takaokaauthor=N.+Yumotoauthor=T.+Nakajimaauthor=S.+G.+Amaraauthor=Y.+Shigeri&title=Characterization+of+novel+L-threo-beta-benzyloxyaspartate+derivatives%2C+potent+blockers+of+the+glutamate+transporters&doi=10.1124%2Fmol.65.4.1008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of novel L-threo-Î²-benzyloxyaspartate derivatives, potent blockers of the glutamate transporters</span></div><div class="casAuthors">Shimamoto, Keiko; Sakai, Ryuichi; Takaoka, Kiyo; Yumoto, Noboru; Nakajima, Terumi; Amara, Susan G.; Shigeri, Yasushi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1008-1015</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Nontransportable blockers of the glutamate transporters are important tools for investigating mechanisms of synaptic transmission.  DL-threo-Î²-Benzyloxyaspartate (DL-TBOA) is a potent blocker of all subtypes of the excitatory amino acid transporters (EAATs).  We characterized novel L-TBOA analogs possessing a substituent on their resp. benzene rings.  The analogs significantly inhibited labeled glutamate uptake, the most potent of which was (2S,3S)-3-{3-[4-(trifluoromethyl)benzoylamino]benzyloxy}aspartate (TFB-TBOA).  In an uptake assay using cells transiently expressing EAATs, the IC50 values of TFB-TBOA for EAAT1, EAAT2, and EAAT3 were 22, 17, and 300 nM, resp.  TFB-TBOA was significantly more potent at inhibiting EAAT1 and EAAT2 compared with L-TBOA (IC50 values for EAAT1-3 were 33, 6.2, and 15 Î¼M, resp.).  Electrophysiol. analyses revealed that TBOA analogs block the transport-assocd. currents in all five EAAT subtypes and also block leak currents in EAAT5.  The rank order of the analogs for potencies at inhibiting substrate-induced currents was identical to that obsd. in the uptake assay.  However, the kinetics of TFB-TBOA differed from the kinetics of L-TBOA, probably because of the strong binding affinity.  Notably, TFB-TBOA did not affect other representative neurotransmitter transporters or receptors, including ionotropic and metabotropic glutamate receptors, indicating that it is highly selective for EAATs.  Moreover, intracerebroventricular administration of the TBOA analogs induced severe convulsive behaviors in mice, probably because of the accumulation of glutamate.  Taken together, these findings indicate that novel TBOA analogs, esp. TFB-TBOA, should serve as useful tools for elucidating the physiol. roles of the glutamate transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2c5VUbloVLLVg90H21EOLACvtfcHk0lhc1h8nL7uwFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFaltbo%253D&md5=48cc0d672b697001a4161172920406e8</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1124%2Fmol.65.4.1008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.65.4.1008%26sid%3Dliteratum%253Aachs%26aulast%3DShimamoto%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DR.%26aulast%3DTakaoka%26aufirst%3DK.%26aulast%3DYumoto%26aufirst%3DN.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DAmara%26aufirst%3DS.%2BG.%26aulast%3DShigeri%26aufirst%3DY.%26atitle%3DCharacterization%2520of%2520novel%2520L-threo-beta-benzyloxyaspartate%2520derivatives%252C%2520potent%2520blockers%2520of%2520the%2520glutamate%2520transporters%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D65%26issue%3D4%26spage%3D1008%26epage%3D1015%26doi%3D10.1124%2Fmol.65.4.1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepper, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poelarends, G. J.</span></span> <span> </span><span class="NLM_article-title">Chemoenzymatic synthesis and pharmacological characterization of functionalized aspartate analogues as novel excitatory amino acid transporter inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7741</span>â <span class="NLM_lpage">7753</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00700</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00700" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlantb3E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7741-7753&issue=17&author=H.+G.+Fuauthor=J.+L.+Zhangauthor=P.+G.+Tepperauthor=L.+Bunchauthor=A.+A.+Jensenauthor=G.+J.+Poelarends&title=Chemoenzymatic+synthesis+and+pharmacological+characterization+of+functionalized+aspartate+analogues+as+novel+excitatory+amino+acid+transporter+inhibitors&doi=10.1021%2Facs.jmedchem.8b00700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoenzymatic Synthesis and Pharmacological Characterization of Functionalized Aspartate Analogues As Novel Excitatory Amino Acid Transporter Inhibitors</span></div><div class="casAuthors">Fu, Haigen; Zhang, Jielin; Tepper, Pieter G.; Bunch, Lennart; Jensen, Anders A.; Poelarends, Gerrit J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7741-7753</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aspartate (Asp) derivs. are privileged compds. for investigating the roles governed by excitatory amino acid transporters (EAATs) in glutamatergic neurotransmission.  Here, we report the synthesis of various Asp derivs. with (cyclo)alkyloxy and (hetero)aryloxy substituents at C-3.  Their pharmacol. properties were characterized at the EAAT1-4 subtypes.  The L-threo-3-substituted Asp derivs. (I) (R1 = cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-thiophenyl, 3-thiophenyl, 2-furanyl, 3-furanyl, propargyl) were non-substrate inhibitors, exhibiting pan activity at EAAT1-4 with IC50 values ranging from 0.49 to 15 Î¼M.  Comparisons between (DL-threo)- and (DL-erythro)-Asp analogs I (R1 = cyclopropyl, 3-thiophenyl, propargyl) confirmed that the threo configuration is crucial for the EAAT1-4 inhibitory activities.  Analogs I (R1 = cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl) of L-TFB-TBOA I (R1 = cyclopropyl) were shown to be potent EAAT1-4 inhibitors, with IC50 values ranging from 5-530 nM.  Hybridization of the nonselective EAAT inhibitor L-TBOA with EAAT2-selective inhibitor WAY-213613 or EAAT3-preferring inhibitor NBI-59159 yielded compds. (II)(R2 = III and IV) resp., which were non-selective EAAT inhibitors displaying considerably lower IC50 values at EAAT1-4 (11-140 nM) than those displayed by the resp. parent mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKgfCBuGDnErVg90H21EOLACvtfcHk0lj5b9yU51IbAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlantb3E&md5=7cc9859a2743c381856009492c23de2c</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00700%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DH.%2BG.%26aulast%3DZhang%26aufirst%3DJ.%2BL.%26aulast%3DTepper%26aufirst%3DP.%2BG.%26aulast%3DBunch%26aufirst%3DL.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DPoelarends%26aufirst%3DG.%2BJ.%26atitle%3DChemoenzymatic%2520synthesis%2520and%2520pharmacological%2520characterization%2520of%2520functionalized%2520aspartate%2520analogues%2520as%2520novel%2520excitatory%2520amino%2520acid%2520transporter%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D17%26spage%3D7741%26epage%3D7753%26doi%3D10.1021%2Facs.jmedchem.8b00700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. H. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haym, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahamsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storgaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">New insight into the structure-activity relationships of the selective excitatory amino acid transporter subtype1 (EAAT1) inhibitors UCPH-101 and UCPH-102</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">382</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201500525" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26757239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOmsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=382-402&issue=4&author=S.+W.+Hansenauthor=M.+N.+Erichsenauthor=T.+H.+V.+Huynhauthor=J.+A.+Ruizauthor=I.+Haymauthor=W.+E.+Bjorn-Yoshimotoauthor=B.+Abrahamsenauthor=J.+Hansenauthor=M.+Storgaardauthor=A.+L.+Eriksenauthor=A.+A.+Jensenauthor=L.+Bunch&title=New+insight+into+the+structure-activity+relationships+of+the+selective+excitatory+amino+acid+transporter+subtype1+%28EAAT1%29+inhibitors+UCPH-101+and+UCPH-102&doi=10.1002%2Fcmdc.201500525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">New Insight into the Structure-Activity Relationships of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitors UCPH-101 and UCPH-102</span></div><div class="casAuthors">Hansen, Stinne W.; Erichsen, Mette N.; Huynh, Tri H. V.; Ruiz, Josep A.; Haym, Isabell; Bjorn-Yoshimoto, Walden E.; Abrahamsen, Bjarke; Hansen, Jeanette; Storgaard, Morten; Eriksen, Anette L.; Jensen, Anders A.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">382-402</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In the present study, the authors made further investigations on the structure-activity requirements of the selective excitatory amino acid transporter 1 (EAAT1) inhibitor, (UCPH-101), by exploring 15 different substituents (R1) at the 7-position in combination with eight different substituents (R2) at the 4-position.  Among the 63 new analogs synthesized, the authors identified a no. of compds. that unexpectedly displayed inhibitory activities at EAAT1 in light of understanding the structure-activity relationship (SAR) of this inhibitor class extd. from previous studies.  Moreover, the nature of the R1 and R2 substituents were obsd. to contribute to the functional properties of the various analogs in additive and nonadditive ways.  Finally, sepn. of the four stereoisomers of analog I was carried out, and in agreement with a study of a related scaffold, the R configuration at C4 was found to be mandatory for inhibitory activity, while both the C7 diastereomers were found to be active as EAAT1 inhibitors.  A study of the stereochem. stability of the four pure stereoisomers I-A-D showed that epimerization takes places at C7 via a ring-opening, C-C bond rotation, ring-closing mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfOLZ4EMNW9bVg90H21EOLACvtfcHk0lj5b9yU51IbAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOmsw%253D%253D&md5=b3bef8333896eda1a6790c07bb40f8c3</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500525%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DS.%2BW.%26aulast%3DErichsen%26aufirst%3DM.%2BN.%26aulast%3DHuynh%26aufirst%3DT.%2BH.%2BV.%26aulast%3DRuiz%26aufirst%3DJ.%2BA.%26aulast%3DHaym%26aufirst%3DI.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DAbrahamsen%26aufirst%3DB.%26aulast%3DHansen%26aufirst%3DJ.%26aulast%3DStorgaard%26aufirst%3DM.%26aulast%3DEriksen%26aufirst%3DA.%2BL.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DNew%2520insight%2520into%2520the%2520structure-activity%2520relationships%2520of%2520the%2520selective%2520excitatory%2520amino%2520acid%2520transporter%2520subtype1%2520%2528EAAT1%2529%2520inhibitors%2520UCPH-101%2520and%2520UCPH-102%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D382%26epage%3D402%26doi%3D10.1002%2Fcmdc.201500525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haym, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gynther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjorn-Yoshimoto, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrahamsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastlund, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundgaard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksen, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunch, L.</span></span> <span> </span><span class="NLM_article-title">Bioavailability studies and in vitro profiling of the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-102</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">403</span>â <span class="NLM_lpage">419</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201500527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201500527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26797816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFWitbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=403-419&issue=4&author=I.+Haymauthor=T.+H.+Huynhauthor=S.+W.+Hansenauthor=M.+H.+Pedersenauthor=J.+A.+Ruizauthor=M.+N.+Erichsenauthor=M.+Gyntherauthor=W.+E.+Bjorn-Yoshimotoauthor=B.+Abrahamsenauthor=J.+F.+Bastlundauthor=C.+Bundgaardauthor=A.+L.+Eriksenauthor=A.+A.+Jensenauthor=L.+Bunch&title=Bioavailability+studies+and+in+vitro+profiling+of+the+selective+excitatory+amino+acid+transporter+subtype+1+%28EAAT1%29+inhibitor+UCPH-102&doi=10.1002%2Fcmdc.201500527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Bioavailability Studies and in vitro Profiling of the Selective Excitatory Amino Acid Transporter Subtype 1 (EAAT1) Inhibitor UCPH-102</span></div><div class="casAuthors">Haym, Isabell; Huynh, Tri H. V.; Hansen, Stinne W.; Pedersen, Martin H. F.; Ruiz, Josep A.; Erichsen, Mette N.; Gynther, Mikko; Bjorn-Yoshimoto, Walden E.; Abrahamsen, Bjarke; Bastlund, Jesper F.; Bundgaard, Christoffer; Eriksen, Anette L.; Jensen, Anders A.; Bunch, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">403-419</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Although the selective excitatory amino acid transporter subtype 1 (EAAT1) inhibitor UCPH-101 has become a std. pharmacol. tool compd. for in vitro and ex vivo studies in the EAAT research field, its inability to penetrate the blood-brain barrier makes it unsuitable for in vivo studies.  In the present study, per os (p.o.) administration (40 mg kg-1) of the closely related analog UCPH-102 in rats yielded resp. plasma and brain concns. of 10.5 and 6.67 Î¼m after 1 h.  Three analog series were designed and synthesized to improve the bioavailability profile of UCPH-102, but none displayed substantially improved properties in this respect.  In vitro profiling of UCPH-102 (10 Î¼m) at 51 central nervous system targets in radioligand binding assays strongly suggests that the compd. is completely selective for EAAT1.  Finally, in a rodent locomotor model, p.o. administration of UCPH-102 (20 mg kg-1) did not induce acute effects or any visible changes in behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3bgLF5KR1jLVg90H21EOLACvtfcHk0lj5b9yU51IbAg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFWitbY%253D&md5=1486540624603e2c18d5127eea3a6124</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500527%26sid%3Dliteratum%253Aachs%26aulast%3DHaym%26aufirst%3DI.%26aulast%3DHuynh%26aufirst%3DT.%2BH.%26aulast%3DHansen%26aufirst%3DS.%2BW.%26aulast%3DPedersen%26aufirst%3DM.%2BH.%26aulast%3DRuiz%26aufirst%3DJ.%2BA.%26aulast%3DErichsen%26aufirst%3DM.%2BN.%26aulast%3DGynther%26aufirst%3DM.%26aulast%3DBjorn-Yoshimoto%26aufirst%3DW.%2BE.%26aulast%3DAbrahamsen%26aufirst%3DB.%26aulast%3DBastlund%26aufirst%3DJ.%2BF.%26aulast%3DBundgaard%26aufirst%3DC.%26aulast%3DEriksen%26aufirst%3DA.%2BL.%26aulast%3DJensen%26aufirst%3DA.%2BA.%26aulast%3DBunch%26aufirst%3DL.%26atitle%3DBioavailability%2520studies%2520and%2520in%2520vitro%2520profiling%2520of%2520the%2520selective%2520excitatory%2520amino%2520acid%2520transporter%2520subtype%25201%2520%2528EAAT1%2529%2520inhibitor%2520UCPH-102%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D4%26spage%3D403%26epage%3D419%26doi%3D10.1002%2Fcmdc.201500527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Vivo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalski, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechner, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ognyanov, V. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tham, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klitenick, M. A.</span></span> <span> </span><span class="NLM_article-title">ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1414</span>â <span class="NLM_lpage">1420</span>, <span class="refDoi">Â DOI: 10.1124/mol.60.6.1414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fmol.60.6.1414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11723250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovVOitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=1414-1420&issue=6&author=B.+N.+Atkinsonauthor=S.+C.+Bellauthor=M.+De+Vivoauthor=L.+R.+Kowalskiauthor=S.+M.+Lechnerauthor=V.+I.+Ognyanovauthor=C.+S.+Thamauthor=C.+Tsaiauthor=J.+Jiaauthor=D.+Ashtonauthor=M.+A.+Klitenick&title=ALX+5407%3A+a+potent%2C+selective+inhibitor+of+the+hGlyT1+glycine+transporter&doi=10.1124%2Fmol.60.6.1414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter</span></div><div class="casAuthors">Atkinson, B. N.; Bell, S. C.; De Vivo, M.; Kowalski, L. R.; Lechner, S. M.; Ognyanov, V. I.; Tham, C.-S.; Tsai, C.; Jia, J.; Ashton, D.; Klitenick, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1414-1420</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">High-affinity glycine transport in neurons and glial cells is a primary means of inactivating synaptic glycine.  We have synthesized a potent selective inhibitor of glycine transporter 1 (GlyT1), and characterized its activity using a quail fibroblast cell line (QT6).  The glycine transporters GlyT1A, GlyT1B, GlyT1C, and GlyT2 were stably expressed in QT6 cells.  The transporters expressed in these cells exhibited appropriate characteristics as described previously for these genes: Na+/Cl- dependence, appropriate Km values for glycine uptake, and appropriate pharmacol., as defined in part by the ability of N-Me glycine (sarcosine) to competitively inhibit glycine transport.  Furthermore, the characteristics of the transporters in the cell lines recapitulate the characteristics of glycine transporters obsd. in tissue prepns.  We developed a sarcosine deriv., (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (ALX 5407), and examd. its activity against the cloned glycine transporters.  ALX 5407 completely inhibited glycine transport in the GlyT1 cells, with an IC50 value of 3 nM, but had little or no activity at the human GlyT2 transporter, at other binding sites for glycine, or at other neurotransmitter transporters.  The inhibition of glycine transport was essentially irreversible.  ALX 5407 represents a novel tool in the investigation of N-methyl-D-aspartate-receptor function.  This class of drug may lead to novel therapies in the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpa7gbKMbogbbVg90H21EOLACvtfcHk0ljkmtjFs0DnEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovVOitb8%253D&md5=f7b88d389e78e8bdae009cd3d81de6c9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fmol.60.6.1414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.60.6.1414%26sid%3Dliteratum%253Aachs%26aulast%3DAtkinson%26aufirst%3DB.%2BN.%26aulast%3DBell%26aufirst%3DS.%2BC.%26aulast%3DDe%2BVivo%26aufirst%3DM.%26aulast%3DKowalski%26aufirst%3DL.%2BR.%26aulast%3DLechner%26aufirst%3DS.%2BM.%26aulast%3DOgnyanov%26aufirst%3DV.%2BI.%26aulast%3DTham%26aufirst%3DC.%2BS.%26aulast%3DTsai%26aufirst%3DC.%26aulast%3DJia%26aufirst%3DJ.%26aulast%3DAshton%26aufirst%3DD.%26aulast%3DKlitenick%26aufirst%3DM.%2BA.%26atitle%3DALX%25205407%253A%2520a%2520potent%252C%2520selective%2520inhibitor%2520of%2520the%2520hGlyT1%2520glycine%2520transporter%26jtitle%3DMol.%2520Pharmacol.%26date%3D2001%26volume%3D60%26issue%3D6%26spage%3D1414%26epage%3D1420%26doi%3D10.1124%2Fmol.60.6.1414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlyle, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGarry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rae, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span> <span> </span><span class="NLM_article-title">Discovery and SAR of org 24598-a selective glycine uptake inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">2007</span>â <span class="NLM_lpage">2009</span>, <span class="refDoi">Â DOI: 10.1016/S0960-894X(01)00355-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0960-894X%2801%2900355-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11454468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltVWqtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2007-2009&issue=15&author=A.+Brownauthor=I.+Carlyleauthor=J.+Clarkauthor=W.+Hamiltonauthor=S.+Gibsonauthor=G.+McGarryauthor=S.+McEachenauthor=D.+Raeauthor=S.+Thornauthor=G.+Walker&title=Discovery+and+SAR+of+org+24598-a+selective+glycine+uptake+inhibitor&doi=10.1016%2FS0960-894X%2801%2900355-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and SAR of Org 24598-A Selective Glycine Uptake Inhibitor</span></div><div class="casAuthors">Brown, A.; Carlyle, I.; Clark, J.; Hamilton, W.; Gibson, S.; McGarry, G.; McEachen, S.; Rae, D.; Thorn, S.; Walker, G.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2007-2009</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The authors describe the discovery of a series of selective GlyT-1b inhibitors, by application of solid-phase chem. and library design.  Specifically the discovery of Org 24598, one of the first potent and selective inhibitors of the glycine transporter is discussed.  In vitro structure-activity relationships (SARs) data for interaction of a ligand with this system is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoapnLrELt37bVg90H21EOLACvtfcHk0ljkmtjFs0DnEQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltVWqtrY%253D&md5=4e06a1947df00eda93404605167f1ccb</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900355-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900355-9%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%26aulast%3DCarlyle%26aufirst%3DI.%26aulast%3DClark%26aufirst%3DJ.%26aulast%3DHamilton%26aufirst%3DW.%26aulast%3DGibson%26aufirst%3DS.%26aulast%3DMcGarry%26aufirst%3DG.%26aulast%3DMcEachen%26aufirst%3DS.%26aulast%3DRae%26aufirst%3DD.%26aulast%3DThorn%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DG.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520org%252024598-a%2520selective%2520glycine%2520uptake%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D15%26spage%3D2007%26epage%3D2009%26doi%3D10.1016%2FS0960-894X%2801%2900355-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schipper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marston, H. M.</span></span> <span> </span><span class="NLM_article-title">Effect of the selective glycine re-uptake (GlyT-1) inhibitor Org 25935 on glycine levels in CSF and dialysates</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">S497</span>â <span class="NLM_lpage">S498</span>, <span class="refDoi">Â DOI: 10.1016/S0924-977X(07)70764-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0924-977X%2807%2970764-2" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=S497-S498&author=N.+Andrewsauthor=J.+Geauthor=G.+Walkerauthor=J.+Schipperauthor=H.+M.+Marston&title=Effect+of+the+selective+glycine+re-uptake+%28GlyT-1%29+inhibitor+Org+25935+on+glycine+levels+in+CSF+and+dialysates&doi=10.1016%2FS0924-977X%2807%2970764-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2FS0924-977X%2807%2970764-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-977X%252807%252970764-2%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DN.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DG.%26aulast%3DSchipper%26aufirst%3DJ.%26aulast%3DMarston%26aufirst%3DH.%2BM.%26atitle%3DEffect%2520of%2520the%2520selective%2520glycine%2520re-uptake%2520%2528GlyT-1%2529%2520inhibitor%2520Org%252025935%2520on%2520glycine%2520levels%2520in%2520CSF%2520and%2520dialysates%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D2007%26volume%3D17%26spage%3DS497%26epage%3DS498%26doi%3D10.1016%2FS0924-977X%2807%2970764-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunayevich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marder, S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia</span>. <i>Schizophr Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">90</span>â <span class="NLM_lpage">97</span>, <span class="refDoi">Â DOI: 10.1016/j.schres.2016.10.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.schres.2016.10.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27789188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2sngsVOhug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2017&pages=90-97&author=E.+Dunayevichauthor=R.+W.+Buchananauthor=C.+Y.+Chenauthor=J.+Yangauthor=J.+Nilsenauthor=J.+M.+Dietrichauthor=H.+Sunauthor=S.+Marder&title=Efficacy+and+safety+of+the+glycine+transporter+type-1+inhibitor+AMG+747+for+the+treatment+of+negative+symptoms+associated+with+schizophrenia&doi=10.1016%2Fj.schres.2016.10.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia</span></div><div class="casAuthors">Dunayevich Eduardo; Buchanan Robert W; Chen Chao-Yin; Yang Jun; Nilsen Jon; Dietrich Julie M; Sun Hong; Marder Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Schizophrenia research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine the safety and efficacy of AMG 747, an oral inhibitor of glycine transporter type-1 (GlyT1), as an add-on to antipsychotic therapy in clinically stable people with schizophrenia with enduring negative symptoms.  METHOD:  Analysis of pooled data from two phase 2 studies.  Adults diagnosed with schizophrenia stabilized on antipsychotic medication randomized (2:2:2:3) to orally receive daily AMG 747 (5mg, 15mg, or 40mg) or placebo.  Primary endpoint was Negative Symptom Assessment (NSA)-16 total score change from baseline to week 12.  RESULTS:  Studies were terminated early after a report of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) in one participant (40-mg AMG 747).  At termination, 232 participants had enrolled and 153 completed 12weeks of treatment.  At week 12, change from baseline NSA-16 total score showed no differences between groups.  Mean decrease in Positive and Negative Syndrome Scale (PANSS) Negative Symptom Factor Score (NSFS) and NSA-16 global score were greater with 15-mg AMG 747 than placebo (p<0.05).  Changes in PANSS-Positive Symptom Factor Scale were not significantly different for any group.  Changes in patient-reported outcomes (Sheehan Disability Scale and Quality of Life Enjoyment and Satisfaction Questionnaire) showed trends consistent with greater efficacy of 15-mg AMG 747 compared with placebo (pâ¤0.1).  Adverse event rates were similar among all groups, with no clear differences observed.  CONCLUSIONS:  Significant treatment effects of 15-mg AMG 747, but not higher or lower doses, were observed on secondary endpoints but not on the primary outcome.  These results replicate previous reports of an inverted-U dose response curve and suggest further evaluation of GlyT1 inhibitors in schizophrenia negative symptoms is warranted.  TRIAL REGISTRATION:  Clinicaltrials.govNCT01568216 (https://clinicaltrials.gov/ct2/show/NCT01568216) and NCT01568229 (https://clinicaltrials.gov/ct2/show/NCT01568229?term=NCT01568229&rank=1); EudraCT number 2011-004844-23 and 2011-004845-42.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpl0hAmcYkA0cLvDNbOD4DfW6udTcc2eZF60oRNKV8P7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sngsVOhug%253D%253D&md5=57bc1aa2a1f7c1efbc396235dbe527a6</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1016%2Fj.schres.2016.10.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.schres.2016.10.027%26sid%3Dliteratum%253Aachs%26aulast%3DDunayevich%26aufirst%3DE.%26aulast%3DBuchanan%26aufirst%3DR.%2BW.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNilsen%26aufirst%3DJ.%26aulast%3DDietrich%26aufirst%3DJ.%2BM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DMarder%26aufirst%3DS.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520the%2520glycine%2520transporter%2520type-1%2520inhibitor%2520AMG%2520747%2520for%2520the%2520treatment%2520of%2520negative%2520symptoms%2520associated%2520with%2520schizophrenia%26jtitle%3DSchizophr%2520Res.%26date%3D2017%26volume%3D182%26spage%3D90%26epage%3D97%26doi%3D10.1016%2Fj.schres.2016.10.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borroni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koerner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umbricht, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberati, D.</span></span> <span> </span><span class="NLM_article-title">Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient</span>. <i>Chimia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">477</span>â <span class="NLM_lpage">484</span>, <span class="refDoi">Â DOI: 10.2533/chimia.2018.477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2533%2Fchimia.2018.477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30158010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVShsb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=477-484&issue=7&author=E.+Pinardauthor=E.+Borroniauthor=A.+Koernerauthor=D.+Umbrichtauthor=D.+Alberati&title=Glycine+transporter+type+I+%28GlyT1%29+inhibitor%2C+bitopertin%3A+a+journey+from+lab+to+patient&doi=10.2533%2Fchimia.2018.477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient</span></div><div class="casAuthors">Pinard, Emmanuel; Borroni, Edilio; Koerner, Annette; Umbricht, Daniel; Alberati, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Chimia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">477-484</span>CODEN:
                <span class="NLM_cas:coden">CHIMAD</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Swiss Chemical Society</span>)
        </div><div class="casAbstract">Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical companies and academic institutions primarily as a potential new approach to treat schizophrenia, a severe and chronic mental illness.  More recently, preclin. results have suggested that this approach could also have therapeutic potential for CNS disorders beyond schizophrenia as well as for non-CNS indications.  Over the past 17 years, Roche has been a key player in the GlyT1 field with the discovery and development of bitopertin, the most advanced GlyT1 inhibitor to date and the only one which completed Phase III clin. studies for schizophrenia.  In this article, we relate the eventful journey of the discovery and development of bitopertin, from project initiation in 2001 to its evaluation today in patients suffering from beta-thalassemia, a monogenic hereditary haematol. disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7gCBfO1rCa7Vg90H21EOLACvtfcHk0ljAl5suVo4Qbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVShsb%252FE&md5=12bdce99341fb48ee481354999e1a5fd</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.2533%2Fchimia.2018.477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2533%252Fchimia.2018.477%26sid%3Dliteratum%253Aachs%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DBorroni%26aufirst%3DE.%26aulast%3DKoerner%26aufirst%3DA.%26aulast%3DUmbricht%26aufirst%3DD.%26aulast%3DAlberati%26aufirst%3DD.%26atitle%3DGlycine%2520transporter%2520type%2520I%2520%2528GlyT1%2529%2520inhibitor%252C%2520bitopertin%253A%2520a%2520journey%2520from%2520lab%2520to%2520patient%26jtitle%3DChimia%26date%3D2018%26volume%3D72%26issue%3D7%26spage%3D477%26epage%3D484%26doi%3D10.2533%2Fchimia.2018.477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peakman, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strick, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebel, L.</span></span> <span> </span><span class="NLM_article-title">A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1675</span>â <span class="NLM_lpage">1678</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2006.12.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2006.12.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17257843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1yrsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=1675-1678&issue=6&author=J.+Loweauthor=S.+Drozdaauthor=W.+Qianauthor=M.+C.+Peakmanauthor=J.+Liuauthor=J.+Gibbsauthor=J.+Harmsauthor=C.+Schmidtauthor=K.+Fisherauthor=C.+Strickauthor=A.+Schmidtauthor=M.+Vanaseauthor=L.+Lebel&title=A+novel%2C+non-substrate-based+series+of+glycine+type+1+transporter+inhibitors+derived+from+high-throughput+screening&doi=10.1016%2Fj.bmcl.2006.12.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening</span></div><div class="casAuthors">Lowe, J.; Drozda, S.; Qian, W.; Peakman, M.-C.; Liu, J.; Gibbs, J.; Harms, J.; Schmidt, C.; Fisher, K.; Strick, C.; Schmidt, A.; Vanase, M.; Lebel, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1675-1678</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Aryloxadiazoles (and a pyridine) with piperidine- or piperazine-substituted indane or tetralin moieties such as I are prepd. as selective inhibitors of the glycine type 1 transporter for use as potential antischizophrenic agents; their inhibition of glycine type 1 and glycine type 2 transporters, 5-HT1B receptors, and cytochrome P450 2D6 (CYP2D6) and their binding to the potassium channel HERG are detd. as well as their half-lives in human microsomes.  I inhibits the glycine type 1 transporter with a Ki value of 15.9 nM while inhibiting the corresponding type 2 transporter with a Ki value of 319 nM; I inhibits 96% of CYP2D6 activity at a concn. of 1.5 Î¼M and has a human microsomal half-life of 22 min. while displacing dofetillide from HERG with a Ki value of 271 nM.  The four stereoisomers of I differ little in their inhibition of the glycine type 1 transporter and in their binding to HERG.  Selective inhibition of the glycine type 1 transporter by some of the compds. is found; attempts to decrease the inhibition of CYP2D6, the binding to HERG, and the degrdn. by human microsomes by the compds. did not succeed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeJwwmheK9oLVg90H21EOLACvtfcHk0ljAl5suVo4Qbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1yrsLc%253D&md5=5d09da74ffc4d0f869fd97e65aa29fe6</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.12.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.12.109%26sid%3Dliteratum%253Aachs%26aulast%3DLowe%26aufirst%3DJ.%26aulast%3DDrozda%26aufirst%3DS.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DPeakman%26aufirst%3DM.%2BC.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DGibbs%26aufirst%3DJ.%26aulast%3DHarms%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DC.%26aulast%3DFisher%26aufirst%3DK.%26aulast%3DStrick%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DA.%26aulast%3DVanase%26aufirst%3DM.%26aulast%3DLebel%26aufirst%3DL.%26atitle%3DA%2520novel%252C%2520non-substrate-based%2520series%2520of%2520glycine%2520type%25201%2520transporter%2520inhibitors%2520derived%2520from%2520high-throughput%2520screening%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26issue%3D6%26spage%3D1675%26epage%3D1678%26doi%3D10.1016%2Fj.bmcl.2006.12.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DâSouza, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driesen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannesen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bielen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbuto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâSouza, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naganawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâSouza, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabulsi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driesen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suckow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannesen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelernter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, B.</span></span> <span> </span><span class="NLM_article-title">Dose-related target occupancy and effects on circuitry, behavior, and neuroplasticity of the glycine transporter-1 inhibitor PF-03463275 in healthy and schizophrenia subjects</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">413</span>â <span class="NLM_lpage">421</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2017.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.biopsych.2017.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29499855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkt1Gns7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=413-421&issue=6&author=D.+C.+D%E2%80%99Souzaauthor=R.+E.+Carsonauthor=N.+Driesenauthor=J.+Johannesenauthor=M.+Ranganathanauthor=J.+H.+Krystalauthor=K.-H.+Ahnauthor=K.+Bielenauthor=M.+Carbutoauthor=E.+Deasoauthor=D.+C.+D%E2%80%99Souzaauthor=M.+Ranganathanauthor=M.+Naganawaauthor=M.+Ranganathanauthor=D.+C.+D%E2%80%99Souzaauthor=N.+Nabulsiauthor=M.-Q.+Zhengauthor=S.-f.+Linauthor=Y.+Huangauthor=R.+E.+Carsonauthor=N.+Driesenauthor=K.-H.+Ahnauthor=P.+T.+Morganauthor=R.+Suckowauthor=G.+Heauthor=G.+McCarthyauthor=J.+H.+Krystalauthor=J.+Johannesenauthor=J.+Kenneyauthor=J.+Gelernterauthor=R.+Gueorguievaauthor=B.+Pittman&title=Dose-related+target+occupancy+and+effects+on+circuitry%2C+behavior%2C+and+neuroplasticity+of+the+glycine+transporter-1+inhibitor+PF-03463275+in+healthy+and+schizophrenia+subjects&doi=10.1016%2Fj.biopsych.2017.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects</span></div><div class="casAuthors">D'Souza, Deepak Cyril; Carson, Richard E.; Driesen, Naomi; Johannesen, Jason; Ranganathan, Mohini; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">413-421</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Glycine transporter-1 (GlyT1) inhibitors may ameliorate cognitive impairments assocd. with schizophrenia.  The dose-related occupancy and target engagement of the GlyT1 inhibitor PF-03463275 were studied to inform optimal dose selection for a clin. trial for cognitive impairments assocd. with schizophrenia.  In substudy 1, the effects of PF-03463275 (10, 20, and 40 mg twice a day) on occupancy of GlyT1 were tested using positron emission tomog. and 18F-MK-6577, and visual long-term potentiation (LTP) in schizophrenia patients (SZs) and healthy control subjects.  Furthermore, the capacity of PF-03463275 to attenuate ketamine-induced disruption of working memory-related activation of a "working memory" circuit was tested only in healthy control subjects using functional magnetic resonance imaging.  Subsequently, the effects of PF-03463275 (60 mg twice a day) on occupancy of GlyT1 and long-term potentiation were examd. only in SZs (substudy 2).  PF-03463275 at 10, 20, 40, and 60 mg twice a day produced â¼44%, 61%, 76%, and 83% GlyT1 occupancy, resp., in SZs with higher ligand binding to GlyT1 in subcortical vs. cortical regions.  PF-03463275 did not attenuate any ketamine-induced effects but did improve working memory accuracy in healthy control subjects.  PF-03463275 increased long-term potentiation only in SZs with peak effects at 40 mg twice a day (â¼75% GlyT1 occupancy) and with a profile suggestive of an inverted U dose response.  PF-03463275 was well-tolerated.  The dose-related GlyT1 occupancy of PF-03463275 is linear.  While PF-03463275 did not show evidence of facilitating N-methyl-D-aspartate receptor function in the ketamine assay, it enhanced neuroplasticity in SZs.  These findings provide support for a clin. trial to test the ability of PF-03463275 to enhance cognitive remediation toward addressing cognitive impairments assocd. with schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEEhrKOulSj7Vg90H21EOLACvtfcHk0ljAl5suVo4Qbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkt1Gns7g%253D&md5=e44174bf6bb9cc6e17f7e992beb84622</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DDriesen%26aufirst%3DN.%26aulast%3DJohannesen%26aufirst%3DJ.%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26aulast%3DAhn%26aufirst%3DK.-H.%26aulast%3DBielen%26aufirst%3DK.%26aulast%3DCarbuto%26aufirst%3DM.%26aulast%3DDeaso%26aufirst%3DE.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DNaganawa%26aufirst%3DM.%26aulast%3DRanganathan%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Souza%26aufirst%3DD.%2BC.%26aulast%3DNabulsi%26aufirst%3DN.%26aulast%3DZheng%26aufirst%3DM.-Q.%26aulast%3DLin%26aufirst%3DS.-f.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCarson%26aufirst%3DR.%2BE.%26aulast%3DDriesen%26aufirst%3DN.%26aulast%3DAhn%26aufirst%3DK.-H.%26aulast%3DMorgan%26aufirst%3DP.%2BT.%26aulast%3DSuckow%26aufirst%3DR.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DMcCarthy%26aufirst%3DG.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26aulast%3DJohannesen%26aufirst%3DJ.%26aulast%3DKenney%26aufirst%3DJ.%26aulast%3DGelernter%26aufirst%3DJ.%26aulast%3DGueorguieva%26aufirst%3DR.%26aulast%3DPittman%26aufirst%3DB.%26atitle%3DDose-related%2520target%2520occupancy%2520and%2520effects%2520on%2520circuitry%252C%2520behavior%252C%2520and%2520neuroplasticity%2520of%2520the%2520glycine%2520transporter-1%2520inhibitor%2520PF-03463275%2520in%2520healthy%2520and%2520schizophrenia%2520subjects%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26issue%3D6%26spage%3D413%26epage%3D421%26doi%3D10.1016%2Fj.biopsych.2017.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dohi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morioka, N.</span></span> <span> </span><span class="NLM_article-title">Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>123</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">54</span>â <span class="NLM_lpage">79</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2009.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.pharmthera.2009.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=19393690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1MXms1ahsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2009&pages=54-79&issue=1&author=T.+Dohiauthor=K.+Moritaauthor=T.+Kitayamaauthor=N.+Motoyamaauthor=N.+Morioka&title=Glycine+transporter+inhibitors+as+a+novel+drug+discovery+strategy+for+neuropathic+pain&doi=10.1016%2Fj.pharmthera.2009.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain</span></div><div class="casAuthors">Dohi, Toshihiro; Morita, Katsuya; Kitayama, Tomoya; Motoyama, Naoyo; Morioka, Norimitsu</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">54-79</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Injury to peripheral or spinal nerves following either trauma or disease has several consequences including the development of neuropathic pain.  This syndrome is often refractory against conventional analgesics; and thus, novel medicaments are desired for its treatment.  Recent studies have emphasized that dysfunction of inhibitory neuronal regulation of pain signal transduction may be relevant to the development of neuropathic pain.  Glycinergic neurons are localized in specific brain regions and the spinal cord, where they play an important role in the prevention of pathol. pain symptoms.  Thus, an enhancement of glycinergic control in the spinal cord is a promising strategy for pain relief from neuropathic pain.  Glycine transporter (GlyT) 1 and GlyT2, which are located in glial cells and neurons, resp. play important roles by clearing synaptically released glycine or supplying glycine to glycinergic neurons to regulate glycinergic neurotransmission.  Thus, an inhibition of GlyTs could be used to modify pain signal transmission in the spinal cord.  Recently developed specific inhibitors of GlyTs have made this possibility a reality.  Both GlyT1 and GlyT2 inhibitors produced potential anti-nociceptive effect in various neuropathic pain models, chronic and acute inflammatory models in animals.  Their anti-allodynia effects are mediated by the inhibition of GlyTs following activation of spinal glycine receptor Î±3.  These results established GlyTs as target mols. for medicaments for neuropathic pain.  Moreover, the phase-dependent anti-allodynia effects of GlyT inhibitors have provided important information on effective therapeutic strategies and also understanding the underlying mol. mechanisms of the development of neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAkxcSLELFbbVg90H21EOLACvtfcHk0lhoU_tE_85G5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXms1ahsbw%253D&md5=962c43949acb185c71037acd12855c2b</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DDohi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DK.%26aulast%3DKitayama%26aufirst%3DT.%26aulast%3DMotoyama%26aufirst%3DN.%26aulast%3DMorioka%26aufirst%3DN.%26atitle%3DGlycine%2520transporter%2520inhibitors%2520as%2520a%2520novel%2520drug%2520discovery%2520strategy%2520for%2520neuropathic%2520pain%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D123%26issue%3D1%26spage%3D54%26epage%3D79%26doi%3D10.1016%2Fj.pharmthera.2009.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caulfield, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collie, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickins, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epemolu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaram, H.</span></span> <span> </span><span class="NLM_article-title">The first potent and selective inhibitors of the glycine transporter type 2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2679</span>â <span class="NLM_lpage">2682</span>, <span class="refDoi">Â DOI: 10.1021/jm0011272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0011272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltlClsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2679-2682&issue=17&author=W.+L.+Caulfieldauthor=I.+T.+Collieauthor=R.+S.+Dickinsauthor=O.+Epemoluauthor=R.+McGuireauthor=D.+R.+Hillauthor=G.+McVeyauthor=J.+R.+Morphyauthor=Z.+Rankovicauthor=H.+Sundaram&title=The+first+potent+and+selective+inhibitors+of+the+glycine+transporter+type+2&doi=10.1021%2Fjm0011272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">The first potent and selective inhibitors of the glycine transporter type 2</span></div><div class="casAuthors">Caulfield, Wilson L.; Collie, Iain T.; Dickins, Rachel S.; Epemolu, Ola; McGuire, Ross; Hill, David R.; McVey, Gillian; Morphy, J. Richard; Rankovic, Zoran; Sundaram, Hardy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2679-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Glycine is one of the major inhibitory neurotransmitters in the spinal cord and brain stem of vertebrates.  The inhibitory actions of glycine are mediated by the strychnine-sensitive glycine receptor, a ligand-gated chloride channel distributed throughout the spinal cord and brain stem.  Glycine is also known to potentiate the action of glutamate acting as an essential co-agonist on postsynaptic N-methyl-d-aspartate (NMDA) receptors.  Synaptic levels of glycine are believed to be controlled by high-affinity glycine transporters.  These transporters are members of a large family of sodium/chloride-dependent transporters, which are composed of single oligomeric proteins contg. 12 hydrophobic membrane-spanning domains.  There is evidence that glycine-mediated inhibition produces muscle relaxation and blockade of this inhibition produces convulsions.  Therefore, we postulated that modulators of endogenous levels of glycine might provide skeletal muscle relaxation.  A significant amt. of data has accumulated over recent years, indicating that glycine also has an important role in the modulation of nociceptive pathways.  Thus, it was anticipated that an increase in synaptic levels of endogenous glycine by a selective inhibition of the GlyT-2 transporter in the spinal cord may offer a unique approach for developing a novel muscle relaxant, anesthetic, and/or analgesic reagent, suitable for use during surgical anesthesia.  Due to the discrete localization of both ssGlyR and the GlyT-2 transporter within the spinal cord and brain stem, a glycine modulator might not be expected to lead to serious CNS side effects that are characteristic for currently used Î¼-opioid analgesics.  Since testing of this hypothesis has been hampered by the lack of a suitable GlyT-2 inhibitor, we sought a potent and selective inhibitor of the transporter that would enable us to conduct proof-of-principle studies.  In summary, high-throughput screening of Organon's compd. collection provided an attractive drug-like GlyT-2 inhibitor suitable for high-throughput synthesis.  A detailed study of the SAR and rapid hit optimization were achieved through synthesis of a soln.-phase 2D library.  This led to identification of 4-benzyloxy-3,5-dimethoxy-N-[(1-dimethylaminocyclopentyl)methyl]benzamide, the first potent and selective GlyT-2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpVNVN55SHKrVg90H21EOLACvtfcHk0lhoU_tE_85G5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltlClsrg%253D&md5=25df8d1d93a08022c361df0e0031414c</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm0011272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0011272%26sid%3Dliteratum%253Aachs%26aulast%3DCaulfield%26aufirst%3DW.%2BL.%26aulast%3DCollie%26aufirst%3DI.%2BT.%26aulast%3DDickins%26aufirst%3DR.%2BS.%26aulast%3DEpemolu%26aufirst%3DO.%26aulast%3DMcGuire%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DD.%2BR.%26aulast%3DMcVey%26aufirst%3DG.%26aulast%3DMorphy%26aufirst%3DJ.%2BR.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DSundaram%26aufirst%3DH.%26atitle%3DThe%2520first%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520glycine%2520transporter%2520type%25202%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26issue%3D17%26spage%3D2679%26epage%3D2682%26doi%3D10.1021%2Fjm0011272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mingorance-Le Meur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghisdal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Perren, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Declercq, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Famelart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Asperen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jnoff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courade, J. P.</span></span> <span> </span><span class="NLM_article-title">Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1053</span>â <span class="NLM_lpage">1063</span>, <span class="refDoi">Â DOI: 10.1111/bph.12343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fbph.12343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23962079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1SlurfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=1053-1063&issue=5&author=A.+Mingorance-Le+Meurauthor=P.+Ghisdalauthor=B.+Mullierauthor=P.+De+Ronauthor=P.+Downeyauthor=C.+Van+Der+Perrenauthor=V.+Declercqauthor=S.+Cornelisauthor=M.+Famelartauthor=J.+Van+Asperenauthor=E.+Jnoffauthor=J.+P.+Courade&title=Reversible+inhibition+of+the+glycine+transporter+GlyT2+circumvents+acute+toxicity+while+preserving+efficacy+in+the+treatment+of+pain&doi=10.1111%2Fbph.12343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain</span></div><div class="casAuthors">Mingorance-Le Meur, A.; Ghisdal, P.; Mullier, B.; De Ron, P.; Downey, P.; Van Der Perren, C.; Declercq, V.; Cornelis, S.; Famelart, M.; Van Asperen, J.; Jnoff, E.; Courade, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1053-1063</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Available medications for chronic pain provide only partial relief and often cause unacceptable side effects.  There is therefore a need for novel mol. targets to develop new therapeutics with improved efficacy and tolerability.  Despite encouraging efficacy data in rodents with inhibitors of the neuronal glycine transporter-2 (GlyT2), there are also some reports of toxicity and their development was discontinued.  Exptl. Approach : In order to clarify the possibility of targeting GlyT2 for the treatment of pain, we have used an integrated approach comprising in vitro pharmacol., selectivity, bioavailability, in vivo efficacy and safety assessment to analyze the properties and efficacy of ALX-1393 and Org-25543, the two published GlyT2 inhibitors from which in vivo data are available.  Key Results : We report that these compds. have a different set of undesirable properties that limit their usefulness as pharmacol. tools.  Importantly, we discover that inhibitors of GlyT2 can exert an apparent reversible or irreversible inhibition of the transporter and describe a new class of reversible GlyT2 inhibitors that preserves efficacy while avoiding acute toxicity.  Conclusions and Implications : Our pharmacol. comparison of two closely related GlyT2 inhibitors with different modes of inhibition provides important insights into their safety and efficacy profiles, uncovering that in the presence of a GlyT2 mechanism-based toxicity, reversible inhibitors might allow a tolerable balance between efficacy and toxicity.  These findings shed light into the drawbacks assocd. with the early GlyT2 inhibitors and describe a new mechanism that might serve as the starting point for new drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqu9AgzGlvlLVg90H21EOLACvtfcHk0lhoU_tE_85G5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1SlurfL&md5=73c0b4d4dd102b75e02b2272f6b00283</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1111%2Fbph.12343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12343%26sid%3Dliteratum%253Aachs%26aulast%3DMingorance-Le%2BMeur%26aufirst%3DA.%26aulast%3DGhisdal%26aufirst%3DP.%26aulast%3DMullier%26aufirst%3DB.%26aulast%3DDe%2BRon%26aufirst%3DP.%26aulast%3DDowney%26aufirst%3DP.%26aulast%3DVan%2BDer%2BPerren%26aufirst%3DC.%26aulast%3DDeclercq%26aufirst%3DV.%26aulast%3DCornelis%26aufirst%3DS.%26aulast%3DFamelart%26aufirst%3DM.%26aulast%3DVan%2BAsperen%26aufirst%3DJ.%26aulast%3DJnoff%26aufirst%3DE.%26aulast%3DCourade%26aufirst%3DJ.%2BP.%26atitle%3DReversible%2520inhibition%2520of%2520the%2520glycine%2520transporter%2520GlyT2%2520circumvents%2520acute%2520toxicity%2520while%2520preserving%2520efficacy%2520in%2520the%2520treatment%2520of%2520pain%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D170%26issue%3D5%26spage%3D1053%26epage%3D1063%26doi%3D10.1111%2Fbph.12343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haranishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, T.</span></span> <span> </span><span class="NLM_article-title">The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>110</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">615</span>â <span class="NLM_lpage">621</span>, <span class="refDoi">Â DOI: 10.1213/ANE.0b013e3181c7ebbb</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1213%2FANE.0b013e3181c7ebbb" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=20081141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252Fjt1Cltw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2010&pages=615-621&issue=2&author=Y.+Haranishiauthor=K.+Haraauthor=T.+Teradaauthor=S.+Nakamuraauthor=T.+Sata&title=The+antinociceptive+effect+of+intrathecal+administration+of+glycine+transporter-2+inhibitor+ALX1393+in+a+rat+acute+pain+model&doi=10.1213%2FANE.0b013e3181c7ebbb"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model</span></div><div class="casAuthors">Haranishi Yasunori; Hara Koji; Terada Tadanori; Nakamura Seiya; Sata Takeyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia and analgesia</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">615-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Glycinergic neurons in the spinal dorsal horn have been implicated in the inhibition of spinal pain processing in peripheral inflammation and chronic pain states.  Neuronal isoform glycine transporter-2 (GlyT2) reuptakes presynaptically released glycine and regulates the glycinergic neurotransmission.  In this study, we examined whether a selective GlyT2 inhibitor, ALX1393, elicits an antinociceptive effect in a rat acute pain model.  METHODS:  Male Sprague-Dawley rats were implanted with a catheter intrathecally.  The effects of intrathecal administration of ALX1393 (4, 20, or 40 microg) on thermal, mechanical, and chemical nociception were evaluated by tail flick, hot plate, paw pressure, and formalin tests.  Furthermore, to explore whether ALX1393 affects motor function, a rotarod test was performed.  RESULTS:  ALX1393 exhibited antinociceptive effects on the thermal and mechanical stimulations in a dose-dependent manner.  The maximal effect of ALX1393 was observed at 15 min after administration, and a significant effect lasted for about 60 min.  These antinociceptive effects were reversed completely by strychnine injected immediately after the administration of ALX1393.  In the formalin test, ALX1393 inhibited pain behaviors in a dose-dependent manner, both in the early and late phases, although the influence was greater in the late phase.  In contrast to antinociceptive action, ALX1393 did not affect motor function up to 40 microg.  CONCLUSIONS:  This study demonstrates the antinociceptive action of ALX1393 on acute pain.  These findings suggest that the inhibitory neurotransmitter transporters are promising targets for the treatment of acute pain and that the selective inhibitor of GlyT2 could be a novel therapeutic drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScnwYgIQdufuvW160gIxP_fW6udTcc2eZ5XQUbVS7M_7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252Fjt1Cltw%253D%253D&md5=a34ae7550e9ba9b1e5a763c694888fd3</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1213%2FANE.0b013e3181c7ebbb&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252FANE.0b013e3181c7ebbb%26sid%3Dliteratum%253Aachs%26aulast%3DHaranishi%26aufirst%3DY.%26aulast%3DHara%26aufirst%3DK.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DSata%26aufirst%3DT.%26atitle%3DThe%2520antinociceptive%2520effect%2520of%2520intrathecal%2520administration%2520of%2520glycine%2520transporter-2%2520inhibitor%2520ALX1393%2520in%2520a%2520rat%2520acute%2520pain%2520model%26jtitle%3DAnesth.%2520Analg.%26date%3D2010%26volume%3D110%26issue%3D2%26spage%3D615%26epage%3D621%26doi%3D10.1213%2FANE.0b013e3181c7ebbb" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osanai-Sasakawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sumitomo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomura-Suruki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imaizumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poh, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kono, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, R.</span></span> <span> </span><span class="NLM_article-title">An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models</span>. <i>Am. J. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1499</span>â <span class="NLM_lpage">1513</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30210919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKmu7nL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1499-1513&issue=8&author=A.+Osanai-Sasakawaauthor=K.+Hosomiauthor=Y.+Sumitomoauthor=T.+Takizawaauthor=S.+Tomura-Surukiauthor=M.+Imaizumiauthor=N.+Kasaiauthor=T.+W.+Pohauthor=K.+Yamanoauthor=W.+P.+Yongauthor=K.+Konoauthor=S.+Nakamuraauthor=T.+Ishiiauthor=R.+Nakai&title=An+anti-ASCT2+monoclonal+antibody+suppresses+gastric+cancer+growth+by+inducing+oxidative+stress+and+antibody+dependent+cellular+toxicity+in+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models</span></div><div class="casAuthors">Osanai-Sasakawa, Aya; Hosomi, Kenta; Sumitomo, Yoshiki; Takizawa, Takuya; Tomura-Suruki, Shiho; Imaizumi, Minami; Kasai, Noriyuki; Poh, Tze Wei; Yamano, Kazuya; Yong, Wei Peng; Kono, Koji; Nakamura, Satoshi; Ishii, Toshihiko; Nakai, Ryuichiro</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1499-1513</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Glutamine is a major nutrient for cancer cells during rapid proliferation.  Alanine-serine-cysteine (ASC) transporter 2 (ASCT2; SLC1A5) mediates glutamine uptake in a variety of cancer cells.  We previously reported that KM8094, a novel anti-ASCT2 humanized monoclonal antibody, possesses anti-tumor efficacy in gastric cancer patient-derived xenografts.  The aim of this study was to investigate the mol. mechanism underlying the effect of KM8094 and to further substantiate the preclin. feasibility of using KM8094 as a potential therapeutic agent against gastric cancer.  First, ASCT2 was found to be highly expressed in cancer tissues derived from gastric cancer patients by an immunohistochem. anal.  Next, we performed in vitro studies using multiple gastric cancer cell lines and obsd. that several gastric cancer cells expressing ASCT2 showed glutamine-dependent cell growth, which was repressed by KM8094.  We found that KM8094 inhibited the glutamine uptake, leading to the redn. of glutathione (GSH) level and the elevation of oxidative stress.  KM8094 suppressed the cell cycle progression and increased the apoptosis.  Furthermore, KM8094 exerted antibody dependent cellular cytotoxicity (ADCC) against human gastric cancer cells in vitro.  Finally, in vivo studies revealed that KM8094 suppressed tumor growth in several gastric cancer xenografts.  This effect was enhanced by docetaxel, one of the agents commonly used in gastric cancer therapy.  Thus, our findings suggest that KM8094 is a potential new therapeutic agent for gastric cancer expressing ASCT2, which blocks the cellular glutamine metab. and possesses ADCC activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSIRGLTft4bVg90H21EOLACvtfcHk0liGxMm6h5OUUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKmu7nL&md5=f3aa44164ca980f4c978be31eca69b2e</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOsanai-Sasakawa%26aufirst%3DA.%26aulast%3DHosomi%26aufirst%3DK.%26aulast%3DSumitomo%26aufirst%3DY.%26aulast%3DTakizawa%26aufirst%3DT.%26aulast%3DTomura-Suruki%26aufirst%3DS.%26aulast%3DImaizumi%26aufirst%3DM.%26aulast%3DKasai%26aufirst%3DN.%26aulast%3DPoh%26aufirst%3DT.%2BW.%26aulast%3DYamano%26aufirst%3DK.%26aulast%3DYong%26aufirst%3DW.%2BP.%26aulast%3DKono%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DT.%26aulast%3DNakai%26aufirst%3DR.%26atitle%3DAn%2520anti-ASCT2%2520monoclonal%2520antibody%2520suppresses%2520gastric%2520cancer%2520growth%2520by%2520inducing%2520oxidative%2520stress%2520and%2520antibody%2520dependent%2520cellular%2520toxicity%2520in%2520preclinical%2520models%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2018%26volume%3D8%26issue%3D8%26spage%3D1499%26epage%3D1513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esslinger, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cybulski, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhoderick, J. F.</span></span> <span> </span><span class="NLM_article-title">N-gamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>13</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">1111</span>â <span class="NLM_lpage">1118</span>, <span class="refDoi">Â DOI: 10.1016/j.bmc.2004.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmc.2004.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15670919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFWgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2005&pages=1111-1118&issue=4&author=C.+S.+Esslingerauthor=K.+A.+Cybulskiauthor=J.+F.+Rhoderick&title=N-gamma-aryl+glutamine+analogues+as+probes+of+the+ASCT2+neutral+amino+acid+transporter+binding+site&doi=10.1016%2Fj.bmc.2004.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">NÎ³-Aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site</span></div><div class="casAuthors">Esslinger, C. Sean; Cybulski, Kimberly A.; Rhoderick, Joseph F.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1111-1118</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Analogs of L-glutamine were designed and synthesized to test a hydrogen-bond hypothesis between ligand and neutral amino acid transporter ASCT2.  The key design feature contains a substituted Ph ring on the amide nitrogen that contains electron withdrawing and electron donating groups that alter the pKa of the amide NH.  Through this study a preliminary binding site map has been developed, and a potent com. available competitive inhibitor of the ASCT2 transporter has been identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp35ku5ItCIXrVg90H21EOLACvtfcHk0liGxMm6h5OUUA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFWgtw%253D%253D&md5=ba6ab757e14e18c4b5abbcbfffe98eb7</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DEsslinger%26aufirst%3DC.%2BS.%26aulast%3DCybulski%26aufirst%3DK.%2BA.%26aulast%3DRhoderick%26aufirst%3DJ.%2BF.%26atitle%3DN-gamma-aryl%2520glutamine%2520analogues%2520as%2520probes%2520of%2520the%2520ASCT2%2520neutral%2520amino%2520acid%2520transporter%2520binding%2520site%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2005%26volume%3D13%26issue%3D4%26spage%3D1111%26epage%3D1118%26doi%3D10.1016%2Fj.bmc.2004.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saleh, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span> <span> </span><span class="NLM_article-title">2-Substituted N gamma-glutamylanilides as novel probes of ASCT2 with improved potency</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">113</span>â <span class="NLM_lpage">116</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2014.10.098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2014.10.098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25435145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGitLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=113-116&issue=1&author=M.+L.+Schulteauthor=E.+S.+Dawsonauthor=S.+A.+Salehauthor=M.+L.+Cuthbertsonauthor=H.+C.+Manning&title=2-Substituted+N+gamma-glutamylanilides+as+novel+probes+of+ASCT2+with+improved+potency&doi=10.1016%2Fj.bmcl.2014.10.098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">2-Substituted NÎ³-glutamylanilides as novel probes of ASCT2 with improved potency</span></div><div class="casAuthors">Schulte, Michael L.; Dawson, Eric S.; Saleh, Sam A.; Cuthbertson, Madison L.; Manning, H. Charles</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-116</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the discovery and structure-activity relationships (SAR) of 2-substituted glutamylanilides as novel probes of the steric environment comprising the amino acid binding domain of alanine-serine-cysteine transporter subtype 2 (ASCT2).  Focused library development led to three novel, highly potent ASCT2 inhibitors, with N-(2-(morpholinomethyl)phenyl)-L-glutamine exhibiting the greatest potency in a live-cell glutamine uptake assay.  This level of potency represents a three-fold improvement over the most potent, previously reported inhibitor in this series, GPNA.  Furthermore, this and other compds. in the series exhibit tractable chem. properties for further development as potential therapeutic leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDrPfsuvI6VbVg90H21EOLACvtfcHk0lj5TE2qH_o6Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGitLzP&md5=8be732f1654803cd62a665bc18cdce36</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.10.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.10.098%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DM.%2BL.%26aulast%3DDawson%26aufirst%3DE.%2BS.%26aulast%3DSaleh%26aufirst%3DS.%2BA.%26aulast%3DCuthbertson%26aufirst%3DM.%2BL.%26aulast%3DManning%26aufirst%3DH.%2BC.%26atitle%3D2-Substituted%2520N%2520gamma-glutamylanilides%2520as%2520novel%2520probes%2520of%2520ASCT2%2520with%2520improved%2520potency%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D1%26spage%3D113%26epage%3D116%26doi%3D10.1016%2Fj.bmcl.2014.10.098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schulte, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khodadadi, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuthbertson, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, H. C.</span></span> <span> </span><span class="NLM_article-title">2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: a novel scaffold for inhibition of ASCT2-mediated glutamine transport</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1044</span>â <span class="NLM_lpage">1047</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2015.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2015.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26750251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XpsVGr" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1044-1047&issue=3&author=M.+L.+Schulteauthor=A.+B.+Khodadadiauthor=M.+L.+Cuthbertsonauthor=J.+A.+Smithauthor=H.+C.+Manning&title=2-Amino-4-bis%28aryloxybenzyl%29aminobutanoic+acids%3A+a+novel+scaffold+for+inhibition+of+ASCT2-mediated+glutamine+transport&doi=10.1016%2Fj.bmcl.2015.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">2-Amino-4-bis(aryloxybenzyl)aminobutanoic acids: A novel scaffold for inhibition of ASCT2-mediated glutamine transport</span></div><div class="casAuthors">Schulte, Michael L.; Khodadadi, Alexandra B.; Cuthbertson, Madison L.; Smith, Jarrod A.; Manning, H. Charles</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1044-1047</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the discovery of 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids as novel inhibitors of ASCT2(SLC1A5)-mediated glutamine accumulation in mammalian cells.  Focused library development led to two novel ASCT2 inhibitors that exhibit significantly improved potency compared with prior art in C6 (rat) and HEK293 (human) cells.  The potency of leads reported here represents a 40-fold improvement over our most potent, previously reported inhibitor and represents, to our knowledge, the most potent pharmacol. inhibitors of ASCT2-mediated glutamine accumulation in live cells.  These and other compds. in this novel series exhibit tractable chem. properties for further development as potential therapeutic leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq536mhHh5MXbVg90H21EOLACvtfcHk0lj5TE2qH_o6Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpsVGr&md5=d6a393c6948b0fec0d7b490d244a7d14</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DSchulte%26aufirst%3DM.%2BL.%26aulast%3DKhodadadi%26aufirst%3DA.%2BB.%26aulast%3DCuthbertson%26aufirst%3DM.%2BL.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DManning%26aufirst%3DH.%2BC.%26atitle%3D2-Amino-4-bis%2528aryloxybenzyl%2529aminobutanoic%2520acids%253A%2520a%2520novel%2520scaffold%2520for%2520inhibition%2520of%2520ASCT2-mediated%2520glutamine%2520transport%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D3%26spage%3D1044%26epage%3D1047%26doi%3D10.1016%2Fj.bmcl.2015.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Broer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairweather, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broer, S.</span></span> <span> </span><span class="NLM_article-title">Disruption of amino acid homeostasis by novel ASCT2 inhibitors involves multiple targets</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">785</span>, <span class="refDoi">Â DOI: 10.3389/fphar.2018.00785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3389%2Ffphar.2018.00785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30072900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXis1ertbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=785&author=A.+Broerauthor=S.+Fairweatherauthor=S.+Broer&title=Disruption+of+amino+acid+homeostasis+by+novel+ASCT2+inhibitors+involves+multiple+targets&doi=10.3389%2Ffphar.2018.00785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Disruption of amino acid homeostasis by novel ASCT2 inhibitors involves multiple targets</span></div><div class="casAuthors">Broer, Angelika; Fairweather, Stephen; Broer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">785/1-785/11</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The glutamine transporter ASCT2 (SLC1A5) is actively investigated as an oncol. target, but the field lacks efficient ASCT2 inhibitors.  A new group of ASCT2 inhibitors, 2-amino-4-bis(aryloxybenzyl)aminobutanoic acids (AABA), were developed recently and shown to suppress tumor growth in preclin. in vivo models.  To test its specificity, we deleted ASCT2 in two human cancer cell lines.  Surprisingly, growth of parental and ASCT2-knockout cells was equally sensitive to AABA compds.  AABA compds. inhibited glutamine transport in cells lacking ASCT2, but not in parental cells.  Deletion of ASCT2 and amino acid (AA) depletion induced expression of SNAT2 (SLC38A2), the activity of which was inhibited by AABA compds.  They also potently inhibited isoleucine uptake via LAT1 (SLC7A5), a transporter that is upregulated in cancer cells together with ASCT2.  Inhibition of SNAT2 and LAT1 was confirmed by recombinant expression in Xenopus laevis oocytes.  The reported redn. of tumor growth in preclin. models may be explained by a significant disruption of AA homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8y0sCAGi7A7Vg90H21EOLACvtfcHk0lj5TE2qH_o6Pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXis1ertbw%253D&md5=5b3b18bfe87c063be793152df7e51a38</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00785%26sid%3Dliteratum%253Aachs%26aulast%3DBroer%26aufirst%3DA.%26aulast%3DFairweather%26aufirst%3DS.%26aulast%3DBroer%26aufirst%3DS.%26atitle%3DDisruption%2520of%2520amino%2520acid%2520homeostasis%2520by%2520novel%2520ASCT2%2520inhibitors%2520involves%2520multiple%2520targets%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D785%26doi%3D10.3389%2Ffphar.2018.00785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gameiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shere, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonomi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span> <span> </span><span class="NLM_article-title">Ligand discovery for the alanine-serine-cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">e1004477</span>, <span class="refDoi">Â DOI: 10.1371/journal.pcbi.1004477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1371%2Fjournal.pcbi.1004477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26444490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XotVelsbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=e1004477&issue=10&author=C.+Colasauthor=C.+Grewerauthor=N.+J.+Otteauthor=A.+Gameiroauthor=T.+Albersauthor=K.+Singhauthor=H.+Shereauthor=M.+Bonomiauthor=J.+Holstauthor=A.+Schlessinger&title=Ligand+discovery+for+the+alanine-serine-cysteine+transporter+%28ASCT2%2C+SLC1A5%29+from+homology+modeling+and+virtual+screening&doi=10.1371%2Fjournal.pcbi.1004477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand discovery for the alanine-serine- cysteine transporter (ASCT2, SLC1A5) from homology modeling and virtual screening</span></div><div class="casAuthors">Colas, Claire; Grewer, Christof; Otte, Nicholas James; Gameiro, Armanda; Albers, Thomas; Singh, Kurnvir; Shere, Helen; Bonomi, Massimiliano; Holst, Jeff; Schlessinger, Avner</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1004477/1-e1004477/22</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The Alanine-Serine-Cysteine transporter ASCT2 (SLC1A5) is a membrane protein that transports neutral amino acids into cells in exchange for outward movement of intracellular amino acids.  ASCT2 is highly expressed in peripheral tissues such as the lung and intestines where it contributes to the homeostasis of intracellular concns. of neutral amino acids.  ASCT2 also plays an important role in the development of a variety of cancers such as melanoma by transporting amino acid nutrients such as glutamine into the proliferating tumors.  Therefore, ASCT2 is a key drug target with potentially great pharmacol. importance.  Here, we identify seven ASCT2 ligands by computational modeling and exptl. testing.  In particular, we construct homol. models based on crystallog. structures of the aspartate transporter GltPh in two different conformations.  Optimization of the models' binding sites for protein-ligand complementarity reveals new putative pockets that can be targeted via structure-based drug design.  Virtual screening of drugs, metabolites, fragments- like, and lead-like mols. from the ZINC database, followed by exptl. testing of 14 top hits with functional measurements using electrophysiol. methods reveals seven ligands, including five activators and two inhibitors.  For example, aminooxetane-3- carboxylate is a more efficient activator than any other known ASCT2 natural or unnatural substrate.  Furthermore, two of the hits inhibited ASCT2 mediated glutamine uptake and proliferation of a melanoma cancer cell line.  Our results improve our understanding of how substrate specificity is detd. in amino acid transporters, as well as provide novel scaffolds for developing chem. tools targeting ASCT2, an emerging therapeutic target for cancer and neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotIg3GUAwXMLVg90H21EOLACvtfcHk0ljOwA-gccNygw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XotVelsbk%253D&md5=85170aa0e74b109de3e1f283b1a6d816</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1004477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1004477%26sid%3Dliteratum%253Aachs%26aulast%3DColas%26aufirst%3DC.%26aulast%3DGrewer%26aufirst%3DC.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DGameiro%26aufirst%3DA.%26aulast%3DAlbers%26aufirst%3DT.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DShere%26aufirst%3DH.%26aulast%3DBonomi%26aufirst%3DM.%26aulast%3DHolst%26aufirst%3DJ.%26aulast%3DSchlessinger%26aufirst%3DA.%26atitle%3DLigand%2520discovery%2520for%2520the%2520alanine-serine-cysteine%2520transporter%2520%2528ASCT2%252C%2520SLC1A5%2529%2520from%2520homology%2520modeling%2520and%2520virtual%2520screening%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2015%26volume%3D11%26issue%3D10%26spage%3De1004477%26doi%3D10.1371%2Fjournal.pcbi.1004477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gameiro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewer, C.</span></span> <span> </span><span class="NLM_article-title">Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">398</span>â <span class="NLM_lpage">402</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.12.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2016.12.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28057420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGkuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=398-402&issue=3&author=K.+Singhauthor=R.+Tanuiauthor=A.+Gameiroauthor=G.+Eisenbergauthor=C.+Colasauthor=A.+Schlessingerauthor=C.+Grewer&title=Structure+activity+relationships+of+benzylproline-derived+inhibitors+of+the+glutamine+transporter+ASCT2&doi=10.1016%2Fj.bmcl.2016.12.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2</span></div><div class="casAuthors">Singh, Kurnvir; Tanui, Rose; Gameiro, Armanda; Eisenberg, Gilad; Colas, Claire; Schlessinger, Avner; Grewer, Christof</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">398-402</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The glutamine transporter ASCT2 has been identified as a promising target to inhibit rapid growth of cancer cells.  However, ASCT2 pharmacol. is not well established.  The authors performed a systematic structure activity anal. of a series of substituted benzylproline derivs.  Substitutions on the Ph ring resulted in compds. with characteristics of ASCT2 inhibitors.  Apparent binding affinity increased with increasing hydrophobicity of the side chain.  In contrast, interaction of the ASCT2 binding site with specific positions on the Ph ring was not obsd.  The most potent compd. inhibits the ASCT2 anion conductance with a Ki of 3 Î¼M, which is in the same range as that of more bulky and higher mol. wt. inhibitors recently reported by others.  The exptl. results are consistent with computational anal. based on docking of the inhibitors against an ASCT2 homol. model.  The benzylproline scaffold provides a valuable tool for further improving binding potency of future ASCT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo78M_phvAZbVg90H21EOLACvtfcHk0ljOwA-gccNygw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGkuw%253D%253D&md5=96407ed37caa7d14526d272edb3e8d41</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.12.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.12.063%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DTanui%26aufirst%3DR.%26aulast%3DGameiro%26aufirst%3DA.%26aulast%3DEisenberg%26aufirst%3DG.%26aulast%3DColas%26aufirst%3DC.%26aulast%3DSchlessinger%26aufirst%3DA.%26aulast%3DGrewer%26aufirst%3DC.%26atitle%3DStructure%2520activity%2520relationships%2520of%2520benzylproline-derived%2520inhibitors%2520of%2520the%2520glutamine%2520transporter%2520ASCT2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26issue%3D3%26spage%3D398%26epage%3D402%26doi%3D10.1016%2Fj.bmcl.2016.12.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Son, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Leucine signals to mTORC1 via its metabolite acetyl-coenzyme A</span>. <i>Cell Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">192</span>â <span class="NLM_lpage">201</span>, <span class="refDoi">Â DOI: 10.1016/j.cmet.2018.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cmet.2018.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30197302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7nN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=192-201&issue=1&author=S.+M.+Sonauthor=S.+J.+Parkauthor=H.+Leeauthor=F.+Siddiqiauthor=J.+E.+Leeauthor=F.+M.+Menziesauthor=D.+C.+Rubinsztein&title=Leucine+signals+to+mTORC1+via+its+metabolite+acetyl-coenzyme+A&doi=10.1016%2Fj.cmet.2018.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A</span></div><div class="casAuthors">Son, Sung Min; Park, So Jung; Lee, Huikyong; Siddiqi, Farah; Lee, Jong Eun; Menzies, Fiona M.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Metabolism</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">192-201.e7</span>CODEN:
                <span class="NLM_cas:coden">CMEEB5</span>;
        ISSN:<span class="NLM_cas:issn">1550-4131</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is a master regulator of cell growth and metab.  Leucine (Leu) activates mTORC1 and many have tried to identify the mechanisms whereby cells sense Leu in this context.  Here we describe that the Leu metabolite acetyl-CoA (AcCoA) pos. regulates mTORC1 activity by EP300-mediated acetylation of the mTORC1 regulator, Raptor, at K1097.  Leu metab. and consequent mTORC1 activity are regulated by intermediary enzymes.  As AcCoA is a Leu metabolite, this process directly correlates with Leu abundance, and does not require Leu sensing via intermediary proteins, as has been described previously.  Importantly, we describe that this pathway regulates mTORC1 in a cell-type-specific manner.  Finally, we obsd. decreased acetylated Raptor, and inhibited mTORC1 and EP300 activity in fasted mice tissues.  These results provide a direct mechanism for mTORC1 regulation by Leu metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8c-YTdEjqnbVg90H21EOLACvtfcHk0ljOwA-gccNygw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Kkt7nN&md5=fad5d32f5d03e129634c89da99bc9444</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.cmet.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cmet.2018.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DSon%26aufirst%3DS.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSiddiqi%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DJ.%2BE.%26aulast%3DMenzies%26aufirst%3DF.%2BM.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DLeucine%2520signals%2520to%2520mTORC1%2520via%2520its%2520metabolite%2520acetyl-coenzyme%2520A%26jtitle%3DCell%2520Metab.%26date%3D2019%26volume%3D29%26issue%3D1%26spage%3D192%26epage%3D201%26doi%3D10.1016%2Fj.cmet.2018.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engleman, E. A.</span></span> <span> </span><span class="NLM_article-title">Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">411</span>â <span class="NLM_lpage">441</span>, <span class="refDoi">Â DOI: 10.1016/0024-3205(95)00209-O</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2F0024-3205%2895%2900209-O" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=7623609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2MXmsFOiurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1995&pages=411-441&issue=5&author=D.+T.+Wongauthor=F.+P.+Bymasterauthor=E.+A.+Engleman&title=Prozac+%28fluoxetine%2C+Lilly+110140%29%2C+the+first+selective+serotonin+uptake+inhibitor+and+an+antidepressant+drug%3A+twenty+years+since+its+first+publication&doi=10.1016%2F0024-3205%2895%2900209-O"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication</span></div><div class="casAuthors">Wong, David T.; Bymaster, Frank P.; Engleman, Eric A.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">411-41</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 325 refs. of discovery of the selective 5-HT uptake inhibitor, fluoxetine, and of the scientific research performed on fluoxetine in the 20 yr since the first publication.  The historical background of the proposed involvement of 5-HT in psychiatric disorders and the activity of tricyclic antidepressants in depression is reviewed.  The effects of fluoxetine in various in vitro assays and in animal studies including receptor down-regulation, neurochem. and behavioral models are summarized.  In addn., the clin. effectiveness of fluoxetine in depression and obsessive compulsive disorders and its potential use in other disorders are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscSsLvemfnbVg90H21EOLACvtfcHk0ljOwA-gccNygw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmsFOiurs%253D&md5=a189792f11d27491df125afde67630d2</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2895%2900209-O&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252895%252900209-O%26sid%3Dliteratum%253Aachs%26aulast%3DWong%26aufirst%3DD.%2BT.%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DEngleman%26aufirst%3DE.%2BA.%26atitle%3DProzac%2520%2528fluoxetine%252C%2520Lilly%2520110140%2529%252C%2520the%2520first%2520selective%2520serotonin%2520uptake%2520inhibitor%2520and%2520an%2520antidepressant%2520drug%253A%2520twenty%2520years%2520since%2520its%2520first%2520publication%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D57%26issue%3D5%26spage%3D411%26epage%3D441%26doi%3D10.1016%2F0024-3205%2895%2900209-O" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owens, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plott, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemeroff, C. B.</span></span> <span> </span><span class="NLM_article-title">Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1305</span>â <span class="NLM_lpage">1322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9400006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1cXis1GmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=1305-1322&issue=3&author=M.+J.+Owensauthor=W.+N.+Morganauthor=S.+J.+Plottauthor=C.+B.+Nemeroff&title=Neurotransmitter+receptor+and+transporter+binding+profile+of+antidepressants+and+their+metabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites</span></div><div class="casAuthors">Owens, Michael J.; Morgan, W. Neal; Plott, Susan J.; Nemeroff, Charles B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1305-1322</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Several new antidepressants that inhibit the serotonin (SERT) and norepinephrine transporters (NET) have been introduced into clin. practice the past several years.  This report focuses on the further pharmacol. characterization of nefazodone and its metabolites within the serotonergic and noradrenergic systems, in comparison with other antidepressants.  By use of radioligand binding assays, we measured the affinity (Ki) of 13 antidepressants and 6 metabolites for the rat and human SERT and NET.  The Ki values for eight of the antidepressants and three metabolites were also detd. for the rat 5-HT1A, 5-HT2A and muscarinic cholinergic receptors, the guinea pig histamine1 receptor and the human alpha-1 and alpha-2 receptors.  These data are useful for predicting side effect profiles and the potential for pharmacodynamic drug-drug interactions of antidepressants.  Of particular interest were the findings that paroxetine, generally thought of as a selective SERT antagonist, possesses moderately high affinity for the NET and that venlafaxine, which has been described as a "dual uptake inhibitor", possesses weak affinity for the NET.  We obsd. significant correlations in SERT (r = 0.965) or NET (r = 0.983) affinity between rat and human transporters.  Significant correlations were also obsd. between muscarinic cholinergic and NET affinity.  There are several significant correlations between affinities for the 5-HT1A, 5-HT2A, histamine1, alpha-1 and alpha-2 receptors.  These novel findings, not widely described previously, suggest that many of the, individual drugs studied in these expts. possess some structural characteristic that dets. affinity for several G protein-coupled, but not muscarinic, receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGradn8u7KxbQrVg90H21EOLACvtfcHk0lhroSiNBYv3Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXis1GmtQ%253D%253D&md5=fa8d12aed5de3875493c77cd9a869933</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOwens%26aufirst%3DM.%2BJ.%26aulast%3DMorgan%26aufirst%3DW.%2BN.%26aulast%3DPlott%26aufirst%3DS.%2BJ.%26aulast%3DNemeroff%26aufirst%3DC.%2BB.%26atitle%3DNeurotransmitter%2520receptor%2520and%2520transporter%2520binding%2520profile%2520of%2520antidepressants%2520and%2520their%2520metabolites%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26issue%3D3%26spage%3D1305%26epage%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindmarch, I.</span></span> <span> </span><span class="NLM_article-title">Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors</span>. <i>Acta Psychiatr. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>101</i></span> (<span class="NLM_issue">s403</span>),  <span class="NLM_fpage">17</span>â <span class="NLM_lpage">25</span>, <span class="refDoi">Â DOI: 10.1111/j.1600-0447.2000.tb10944.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1111%2Fj.1600-0447.2000.tb10944.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2000&pages=17-25&issue=s403&author=S.+Perettiauthor=R.+Judgeauthor=I.+Hindmarch&title=Safety+and+tolerability+considerations%3A+tricyclic+antidepressants+vs.+selective+serotonin+reuptake+inhibitors&doi=10.1111%2Fj.1600-0447.2000.tb10944.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0447.2000.tb10944.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0447.2000.tb10944.x%26sid%3Dliteratum%253Aachs%26aulast%3DPeretti%26aufirst%3DS.%26aulast%3DJudge%26aufirst%3DR.%26aulast%3DHindmarch%26aufirst%3DI.%26atitle%3DSafety%2520and%2520tolerability%2520considerations%253A%2520tricyclic%2520antidepressants%2520vs.%2520selective%2520serotonin%2520reuptake%2520inhibitors%26jtitle%3DActa%2520Psychiatr.%2520Scand.%26date%3D2000%26volume%3D101%26issue%3Ds403%26spage%3D17%26epage%3D25%26doi%3D10.1111%2Fj.1600-0447.2000.tb10944.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Comley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salinas, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slifstein, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennacef, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shotbolt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Aart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iavarone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomeni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laruelle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunn, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiner, E. A.</span></span> <span> </span><span class="NLM_article-title">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">311</span>â <span class="NLM_lpage">317</span>, <span class="refDoi">Â DOI: 10.1124/jpet.112.202895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1124%2Fjpet.112.202895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23685546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=311-317&issue=2&author=R.+A.+Comleyauthor=C.+A.+Salinasauthor=M.+Slifsteinauthor=M.+Petroneauthor=C.+Marzanoauthor=I.+Bennacefauthor=P.+Shotboltauthor=J.+Van+der+Aartauthor=M.+Neveauthor=L.+Iavaroneauthor=R.+Gomeniauthor=M.+Laruelleauthor=F.+A.+Grayauthor=R.+N.+Gunnauthor=E.+A.+Rabiner&title=Monoamine+transporter+occupancy+of+a+novel+triple+reuptake+inhibitor+in+baboons+and+humans+using+positron+emission+tomography&doi=10.1124%2Fjpet.112.202895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography</span></div><div class="casAuthors">Comley, Robert A.; Salinas, Cristian A.; Slifstein, Mark; Petrone, Marcella; Marzano, Carmine; Bennacef, Idriss; Shotbolt, Paul; Van der Aart, Jasper; Neve, Marta; Iavarone, Laura; Gomeni, Roberto; Laruelle, Marc; Gray, Frank A.; Gunn, Roger N.; Rabiner, Eugenii A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">311-317</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The selection of a therapeutically meaningful dose of a novel pharmaceutical is a crucial step in drug development.  Positron emission tomog. (PET) allows the in vivo estn. of the relationship between the plasma concn. of a drug and its target occupancy, optimizing dose selection and reducing the time and cost of early development.  Triple reuptake inhibitors (TRIs), also referred to as serotonin-norepinephrine-dopamine reuptake inhibitors, enhance monoaminergic neurotransmission by blocking the action of the monoamine transporters, raising extracellular concns. of those neurotransmitters.  GSK1360707 [(1R,6S)-1-(3,4-dichlorophenyl)-6-(methoxymethyl)-4-azabicyclo[4.1.0]heptane] is a novel TRI that until recently was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.  We present the results of an in vivo assessment of the relationship between plasma exposure and transporter blockade (occupancy).  Studies were performed in baboons (Papio anubis) to det. the relationship between plasma concn. and occupancy of brain serotonin reuptake transporter (SERT), dopamine reuptake transporter (DAT), and norepinephrine uptake transporter (NET) using the radioligands [11C]DASB [(N,N-dimethyl-2-(2-amino-4-cyanophenylthio) benzylamine], [11C]PE2I [N-(3-iodoprop-2E-enyl)-2Î²-carbomethoxy-3Î²-(4-methylphenyl)nortropane], and [11C]2-[(2-methoxyphenoxy)phenylmethyl]morpholine (also known as [11C]MRB) and in humans using [11C]DASB and [11C]PE2I.  In P. anubis, plasma concns. resulting in half-maximal occupancy at SERT, DAT, and NET were 15.16, 15.56, and 0.97 ng/mL, resp.  In humans, the corresponding values for SERT and DAT were 6.80 and 18.00 ng/mL.  GSK1360707 dose-dependently blocked the signal of SERT-, DAT-, and NET-selective PET ligands, confirming its penetration across the blood-brain barrier and blockade of all three monoamine transporters in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOk3b2TA00rVg90H21EOLACvtfcHk0lhroSiNBYv3Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbfE&md5=b92262955a074c2d981015dc436127bb</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.202895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.202895%26sid%3Dliteratum%253Aachs%26aulast%3DComley%26aufirst%3DR.%2BA.%26aulast%3DSalinas%26aufirst%3DC.%2BA.%26aulast%3DSlifstein%26aufirst%3DM.%26aulast%3DPetrone%26aufirst%3DM.%26aulast%3DMarzano%26aufirst%3DC.%26aulast%3DBennacef%26aufirst%3DI.%26aulast%3DShotbolt%26aufirst%3DP.%26aulast%3DVan%2Bder%2BAart%26aufirst%3DJ.%26aulast%3DNeve%26aufirst%3DM.%26aulast%3DIavarone%26aufirst%3DL.%26aulast%3DGomeni%26aufirst%3DR.%26aulast%3DLaruelle%26aufirst%3DM.%26aulast%3DGray%26aufirst%3DF.%2BA.%26aulast%3DGunn%26aufirst%3DR.%2BN.%26aulast%3DRabiner%26aufirst%3DE.%2BA.%26atitle%3DMonoamine%2520transporter%2520occupancy%2520of%2520a%2520novel%2520triple%2520reuptake%2520inhibitor%2520in%2520baboons%2520and%2520humans%2520using%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26issue%3D2%26spage%3D311%26epage%3D317%26doi%3D10.1124%2Fjpet.112.202895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bymaster, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreshfield-Ahmad, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Threlkeld, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemrick-Luecke, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, D. T.</span></span> <span> </span><span class="NLM_article-title">Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">871</span>â <span class="NLM_lpage">880</span>, <span class="refDoi">Â DOI: 10.1016/S0893-133X(01)00298-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0893-133X%2801%2900298-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11750180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1antLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2001&pages=871-880&issue=6&author=F.+P.+Bymasterauthor=L.+J.+Dreshfield-Ahmadauthor=P.+G.+Threlkeldauthor=J.+L.+Shawauthor=L.+Thompsonauthor=D.+L.+Nelsonauthor=S.+K.+Hemrick-Lueckeauthor=D.+T.+Wong&title=Comparative+affinity+of+duloxetine+and+venlafaxine+for+serotonin+and+norepinephrine+transporters+in+vitro+and+in+vivo%2C+human+serotonin+receptor+subtypes%2C+and+other+neuronal+receptors&doi=10.1016%2FS0893-133X%2801%2900298-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors</span></div><div class="casAuthors">Bymaster, Frank P.; Dreshfield-Ahmad, Laura J.; Threlkeld, Penny G.; Shaw, Janice L.; Thompson, Linda; Nelson, David L.; Hemrick-Luecke, Susan K.; Wong, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">871-880</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The blockade of serotonin (5-HT) and norepinephrine (NE) transporters in vitro and in vivo by the dual 5-HT/NE reuptake inhibitors duloxetine and venlafaxine was compared.  Duloxetine inhibited binding to the human NE and 5-HT transporters with Ki values of 7.5 and 0.8 nM, resp., and with a Ki ratio of 9.  Venlafaxine inhibited binding to the human NE and 5-HT transporters with Ki values of 2480 and 82 nM, resp., and with a Ki ratio of 30.  Duloxetine inhibited ex vivo binding to rat 5-HT transporters and NE transporters with ED50 values of 0.03 and 0.7 mg/kg, resp., whereas venlafaxine had ED50 values of 2 and 54 mg/kg, resp.  The depletion of rat brain 5-HT by p-chloramphetamine and depletion of rat hypothalamic NE by 6-hydroxydopamine was blocked by duloxetine with ED50 values of 2.3 and 12 mg/kg, resp.  Venlafaxine had ED50 values of 5.9 and 94 mg/kg for blocking p-chloramphetamine- and 6-hydroxydopamine-induced monoamine depletion, resp.  Thus, duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFiyEG228XhLVg90H21EOLACvtfcHk0lhagqcBhfbw8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1antLo%253D&md5=5e394cdee917e0189acf774233617e60</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1016%2FS0893-133X%2801%2900298-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0893-133X%252801%252900298-6%26sid%3Dliteratum%253Aachs%26aulast%3DBymaster%26aufirst%3DF.%2BP.%26aulast%3DDreshfield-Ahmad%26aufirst%3DL.%2BJ.%26aulast%3DThrelkeld%26aufirst%3DP.%2BG.%26aulast%3DShaw%26aufirst%3DJ.%2BL.%26aulast%3DThompson%26aufirst%3DL.%26aulast%3DNelson%26aufirst%3DD.%2BL.%26aulast%3DHemrick-Luecke%26aufirst%3DS.%2BK.%26aulast%3DWong%26aufirst%3DD.%2BT.%26atitle%3DComparative%2520affinity%2520of%2520duloxetine%2520and%2520venlafaxine%2520for%2520serotonin%2520and%2520norepinephrine%2520transporters%2520in%2520vitro%2520and%2520in%2520vivo%252C%2520human%2520serotonin%2520receptor%2520subtypes%252C%2520and%2520other%2520neuronal%2520receptors%26jtitle%3DNeuropsychopharmacology%26date%3D2001%26volume%3D25%26issue%3D6%26spage%3D871%26epage%3D880%26doi%3D10.1016%2FS0893-133X%2801%2900298-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papakostas, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R. C.</span></span> <span> </span><span class="NLM_article-title">Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1217</span>â <span class="NLM_lpage">1227</span>, <span class="refDoi">Â DOI: 10.1016/j.biopsych.2007.03.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.biopsych.2007.03.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17588546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ymu7jI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=1217-1227&issue=11&author=G.+I.+Papakostasauthor=M.+E.+Thaseauthor=M.+Favaauthor=J.+C.+Nelsonauthor=R.+C.+Shelton&title=Are+antidepressant+drugs+that+combine+serotonergic+and+noradrenergic+mechanisms+of+action+more+effective+than+the+selective+serotonin+reuptake+inhibitors+in+treating+major+depressive+disorder%3F+A+meta-analysis+of+studies+of+newer+agents&doi=10.1016%2Fj.biopsych.2007.03.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents</span></div><div class="casAuthors">Papakostas, George I.; Thase, Michael E.; Fava, Maurizio; Nelson, J. Craig; Shelton, Richard C.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1217-1227</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Recent studies suggest that the treatment of major depressive disorder (MDD) with newer antidepressant drugs that simultaneously enhance norepinephrine and serotonin neurotransmission might result in higher response and remission rates than the selective serotonin reuptake inhibitors (SSRIs).  The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs.  Methods: Medline/Pubmed, EMBase, clin. trial registries, program syllabi from major psychiatric meetings held since 1995, and documents from relevant pharmaceutical companies were searched for double-blind, randomized trials comparing a newer serotonergic-noradrenergic antidepressant drug (venlafaxine, duloxetine, milnacipran, mirtazapine, mianserin, or moclobemide) with an SSRI for MDD.  Results: Ninety-three trials (n = 17,036) were combined using a random-effects model.  Treatment with serotonergic + noradrenergic antidepressant drugs was more likely to result in clin. response than the SSRIs (risk ratio [RR] = 1.059; response rates 63.6% vs. 59.3%; p = .003).  There was no evidence for heterogeneity among studies combined (p = 1.0).  Excluding each individual agent did not significantly alter the pooled RR.  With the exception of duloxetine (.985), RRs for response for each individual serotonergic + noradrenergic antidepressant drug were within the 95% confidence interval of the pooled RR (1.019-1.101).  Conclusions: Serotonergic-noradrenergic antidepressant drugs seem to have a modest efficacy advantage compared with SSRIs in MDD.  With the No. Needed to Treat (NNT) statistic as one indicator of clin. significance, nearly 24 patients would need to be treated with dual-action antidepressant drugs instead of SSRIs in order to obtain one addnl. responder.  This difference falls well below the mark of NNT = 10 suggested by the United Kingdom's National Institute of Clin. Excellence but nonetheless might be of public health relevance given the large no. of depressed patients treated with SSRI /serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant drugs.  Further research is needed to examine whether larger differences between classes of antidepressant drugs might exist in specific MDD sub-populations or for specific MDD symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFTcv5V6MlT7Vg90H21EOLACvtfcHk0lhagqcBhfbw8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ymu7jI&md5=4c4bd9fe021e6fab91cb3a18b779c4e5</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.03.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.03.027%26sid%3Dliteratum%253Aachs%26aulast%3DPapakostas%26aufirst%3DG.%2BI.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DFava%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DJ.%2BC.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26atitle%3DAre%2520antidepressant%2520drugs%2520that%2520combine%2520serotonergic%2520and%2520noradrenergic%2520mechanisms%2520of%2520action%2520more%2520effective%2520than%2520the%2520selective%2520serotonin%2520reuptake%2520inhibitors%2520in%2520treating%2520major%2520depressive%2520disorder%253F%2520A%2520meta-analysis%2520of%2520studies%2520of%2520newer%2520agents%26jtitle%3DBiol.%2520Psychiatry%26date%3D2007%26volume%3D62%26issue%3D11%26spage%3D1217%26epage%3D1227%26doi%3D10.1016%2Fj.biopsych.2007.03.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morabito, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muscatello, M. R.</span></span> <span> </span><span class="NLM_article-title">The role of levomilnacipran in the management of major depressive disorder: a comprehensive review</span>. <i>Current Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">191</span>â <span class="NLM_lpage">199</span>, <span class="refDoi">Â DOI: 10.2174/1570159X14666151117122458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2174%2F1570159X14666151117122458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26572745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsVGntbY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=191-199&issue=2&author=A.+Brunoauthor=P.+Morabitoauthor=E.+Spinaauthor=M.+R.+Muscatello&title=The+role+of+levomilnacipran+in+the+management+of+major+depressive+disorder%3A+a+comprehensive+review&doi=10.2174%2F1570159X14666151117122458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review</span></div><div class="casAuthors">Bruno, Antonio; Morabito, Paolo; Spina, Edoardo; Muscatello, Maria Rosaria</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">191-199</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Levomilnacipran, the more active enantiomer of the serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in the US for the treatment of major depressive disorder (MDD).  The drug was developed as an extended release (ER) capsule formulation to allow for once-daily administration, thereby improving patient adherence.  This agent differs from other available SNRIs in having a greater potency for inhibition of norepinephrine relative to serotonin reuptake.  The efficacy of levomilnacipran ER has been evaluated in seven randomized, double-blind clin. trials (one Phase II and four Phase III trials, and two long-term efficacy studies).  These studies documented that levomilnacipran is generally more effective than placebo for the treatment of MDD in the short-term, whereas no firm evidence exists on long-term efficacy for relapse prevention.  Preliminary evidence suggests that levomilnacipran ER may be effective in improving not only depressive symptoms but also symptoms related to functioning (social life, work, and family life).  Short-and longer-term studies found that the rate of withdrawal from levomilnacipran therapy due to adverse events was rather low.  Moreover the drug appeared to be generally well tolerated.  The most common adverse effects included nausea, hyperhidrosis, constipation, tachycardia, palpitations, erectile dysfunction and ejaculation disorder.  As hypertension or orthostatic hypotension may occur in a few patients, the cardiovascular safety of levomilnacipran needs to be more extensively investigated esp. on long-term treatment.  Addnl. active comparator trials evaluating efficacy, tolerability and cost-effectiveness are required to better define the role of levomilnacipran ER in the treatment of MDD in relation to currently available antidepressants including other SNRIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSH4IjUxNj7Vg90H21EOLACvtfcHk0lhagqcBhfbw8A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsVGntbY%253D&md5=c29309495b78cedbc3cad6eb1e0d8da7</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.2174%2F1570159X14666151117122458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1570159X14666151117122458%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DMorabito%26aufirst%3DP.%26aulast%3DSpina%26aufirst%3DE.%26aulast%3DMuscatello%26aufirst%3DM.%2BR.%26atitle%3DThe%2520role%2520of%2520levomilnacipran%2520in%2520the%2520management%2520of%2520major%2520depressive%2520disorder%253A%2520a%2520comprehensive%2520review%26jtitle%3DCurrent%2520Neuropharmacology%26date%3D2016%26volume%3D14%26issue%3D2%26spage%3D191%26epage%3D199%26doi%3D10.2174%2F1570159X14666151117122458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradko, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haight, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modell, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rockett, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Learned-Coughlin, S.</span></span> <span> </span><span class="NLM_article-title">A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor</span>. <i>Prim. Care Companion J. Clin. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">159</span>â <span class="NLM_lpage">166</span>, <span class="refDoi">Â DOI: 10.4088/PCC.v06n0403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.4088%2FPCC.v06n0403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15361919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC2sbnvFaqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=159-166&issue=4&author=S.+M.+Stahlauthor=J.+F.+Pradkoauthor=B.+R.+Haightauthor=J.+G.+Modellauthor=C.+B.+Rockettauthor=S.+Learned-Coughlin&title=A+review+of+the+neuropharmacology+of+bupropion%2C+a+dual+norepinephrine+and+dopamine+reuptake+inhibitor&doi=10.4088%2FPCC.v06n0403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor</span></div><div class="casAuthors">Stahl Stephen M.; Pradko James F.; Haight Barbara R.; Modell Jack G.; Rockett Carol B.; Learned-Coughlin Susan</div><div class="citationInfo"><span class="NLM_cas:title">Primary care companion to the Journal of clinical psychiatry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">159-166</span>
        ISSN:<span class="NLM_cas:issn">1523-5998</span>.
    </div><div class="casAbstract">BACKGROUND: The neurochemical and biological effects of antidepressant medications have become better defined over the last decade.  When the anti-depressant bupropion was introduced in the United States in 1989, the specific pharmacologic basis of its clinical effects was uncertain.  Research conducted over the past decade has significantly advanced the understanding of the neuropharmacology of bupropion and has demonstrated a novel mechanism of antidepressant activity.  This article discusses the mechanism of action of bupropion and relates the drug's neuropharmacologic effects to its clinical efficacy and tolerability profiles.  DATA SOURCES: Data were obtained via the MEDLINE database in an English-language search spanning the period 1965 to May 2002 and using the search terms bupropion, bupropion SR, and antidepressants, as well as from the manufacturer's bupropion databases.  CONCLUSIONS: The preclinical and clinical data show that bupropion acts via dual inhibition of norepinephrine and dopamine reuptake and is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors.  Dual norepinephrine and dopamine reuptake inhibition is associated with a unique clinical profile.  Bupropion has demonstrated efficacy comparable to that of other antidepressants.  However, because bupropion is a selective norepinephrine and dopamine reuptake inhibitor with no serotonergic activity, common antidepressant-associated side effects, such as sexual dysfunction, weight gain, and sedation, are not associated with bupropion therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-_ZTfnJrdW_6AExegM5LLfW6udTcc2eYmaG7IMJVYO7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbnvFaqsw%253D%253D&md5=58cacfbd299dd471fb1d5a09f17c0fd6</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.4088%2FPCC.v06n0403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.v06n0403%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DS.%2BM.%26aulast%3DPradko%26aufirst%3DJ.%2BF.%26aulast%3DHaight%26aufirst%3DB.%2BR.%26aulast%3DModell%26aufirst%3DJ.%2BG.%26aulast%3DRockett%26aufirst%3DC.%2BB.%26aulast%3DLearned-Coughlin%26aufirst%3DS.%26atitle%3DA%2520review%2520of%2520the%2520neuropharmacology%2520of%2520bupropion%252C%2520a%2520dual%2520norepinephrine%2520and%2520dopamine%2520reuptake%2520inhibitor%26jtitle%3DPrim.%2520Care%2520Companion%2520J.%2520Clin.%2520Psychiatry%26date%3D2004%26volume%3D6%26issue%3D4%26spage%3D159%26epage%3D166%26doi%3D10.4088%2FPCC.v06n0403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glase, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barta, N. S.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5550</span>â <span class="NLM_lpage">5553</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.09.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2008.09.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=18805691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs73L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5550-5553&issue=20&author=W.+J.+Xuauthor=D.+L.+Grayauthor=S.+A.+Glaseauthor=N.+S.+Barta&title=Design+and+synthesis+of+reboxetine+analogs+morpholine+derivatives+as+selective+norepinephrine+reuptake+inhibitors&doi=10.1016%2Fj.bmcl.2008.09.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors</span></div><div class="casAuthors">Xu, Wenjian; Gray, David L.; Glase, Shelly A.; Barta, Nancy S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5550-5553</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">As part of a discovery effort aimed at identifying novel norepinephrine reuptake inhibitors (NRIs), a no. of substituted morpholines were designed and synthesized.  The target compds. contain vicinal stereogenic centers, and the program was greatly facilitated by the adoption of efficient synthetic routes which allowed for the late stage incorporation of structural and physicochem. diversity into the targets.  Structure-activity relationships were developed by optimizing individual ring components of the structure for NRI potency and for selectivity against other monoamine reuptake transporters.  Several novel morpholine derivs. with a potent and selective NRI profile are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplQjUTJkL2frVg90H21EOLACvtfcHk0lhedBEHKmCmZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Cqs73L&md5=97804088401d35c78cdd0acad155888d</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.09.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.09.007%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%2BJ.%26aulast%3DGray%26aufirst%3DD.%2BL.%26aulast%3DGlase%26aufirst%3DS.%2BA.%26aulast%3DBarta%26aufirst%3DN.%2BS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520reboxetine%2520analogs%2520morpholine%2520derivatives%2520as%2520selective%2520norepinephrine%2520reuptake%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26issue%3D20%26spage%3D5550%26epage%3D5553%26doi%3D10.1016%2Fj.bmcl.2008.09.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blough, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partilla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span>. <i>Drug Alcohol Depend.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">19</span>, <span class="refDoi">Â DOI: 10.1016/j.drugalcdep.2014.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.drugalcdep.2014.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25548026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2015&pages=1-19&author=M.+E.+A.+Reithauthor=B.+E.+Bloughauthor=W.+M.+C.+Hongauthor=K.+T.+Jonesauthor=K.+C.+Schmittauthor=M.+H.+Baumannauthor=J.+S.+Partillaauthor=R.+B.+Rothmanauthor=J.+L.+Katz&title=Behavioral%2C+biological%2C+and+chemical+perspectives+on+atypical+agents+targeting+the+dopamine+transporter&doi=10.1016%2Fj.drugalcdep.2014.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter</span></div><div class="casAuthors">Reith, Maarten E. A.; Blough, Bruce E.; Hong, Weimin C.; Jones, Kymry T.; Schmitt, Kyle C.; Baumann, Michael H.; Partilla, John S.; Rothman, Richard B.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Drug and Alcohol Dependence</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-19</span>CODEN:
                <span class="NLM_cas:coden">DADEDV</span>;
        ISSN:<span class="NLM_cas:issn">0376-8716</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Treatment of stimulant-use disorders remains a formidable challenge, and the dopamine transporter (DAT) remains a potential target for antagonist or agonist-like substitution therapies, so this review focuses on DAT ligands, such as benztropine, GBR 12909, modafinil, and DAT substrates derived from phenethylamine or cathinone that have atypical DAT-inhibitor effects, either in vitro or in vivo.  The compds. are described from a mol. mechanistic, behavioral, and medicinal-chem. perspective.Possible mechanisms for atypicality at the mol. level can be deduced from the conformational cycle for substrate translocation.  For each conformation, a crystal structure of a bacterial homolog is available, with a possible role of cholesterol, which is also present in the crystal of Drosophila DAT.  Although there is a direct relationship between behavioral potencies of most DAT inhibitors and their DAT affinities, a no. of compds. bind to the DAT and inhibit dopamine uptake but do not share cocaine-like effects.  Such atypical behavior, depending on the compd., may be related to slow DAT assocn., combined sigma-receptor actions, or bias for cytosol-facing DAT.  Some structures are sterically small enough to serve as DAT substrates but large enough to also inhibit transport.  Such compds. may display partial DA releasing effects, and may be combined with release or uptake inhibition at other monoamine transporters.  Mechanisms of atypical DAT inhibitors may serve as targets for the development of treatments for stimulant abuse.  These mechanisms are novel and their further exploration may produce compds. with unique therapeutic potential as treatments for stimulant abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGsfVrk5h43rVg90H21EOLACvtfcHk0lhedBEHKmCmZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Oqs74%253D&md5=d6f46c4fd505810f64eafc748702d299</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.drugalcdep.2014.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drugalcdep.2014.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DReith%26aufirst%3DM.%2BE.%2BA.%26aulast%3DBlough%26aufirst%3DB.%2BE.%26aulast%3DHong%26aufirst%3DW.%2BM.%2BC.%26aulast%3DJones%26aufirst%3DK.%2BT.%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DBaumann%26aufirst%3DM.%2BH.%26aulast%3DPartilla%26aufirst%3DJ.%2BS.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DBehavioral%252C%2520biological%252C%2520and%2520chemical%2520perspectives%2520on%2520atypical%2520agents%2520targeting%2520the%2520dopamine%2520transporter%26jtitle%3DDrug%2520Alcohol%2520Depend.%26date%3D2015%26volume%3D147%26spage%3D1%26epage%3D19%26doi%3D10.1016%2Fj.drugalcdep.2014.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cetin, M.</span></span> <span> </span><span class="NLM_article-title">Triple reuptake inhibitors (TRIs): do they promise us a rose garden?</span>. <i>Psychiat Clin Psych</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">119</span>â <span class="NLM_lpage">122</span>, <span class="refDoi">Â DOI: 10.1080/24750573.2018.1443386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1080%2F24750573.2018.1443386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt12isbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=119-122&issue=2&author=S.+Koseauthor=M.+Cetin&title=Triple+reuptake+inhibitors+%28TRIs%29%3A+do+they+promise+us+a+rose+garden%3F&doi=10.1080%2F24750573.2018.1443386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Triple reuptake inhibitors (TRIs): do they promise us a rose garden?</span></div><div class="casAuthors">Kose, Samet; Cetin, Mesut</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and Clinical Psychopharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-122</span>CODEN:
                <span class="NLM_cas:coden">PCPSC6</span>;
        ISSN:<span class="NLM_cas:issn">2475-0581</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPo_iFHjGTpbVg90H21EOLACvtfcHk0lhedBEHKmCmZw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt12isbk%253D&md5=f68227c50a6eacb71f0937055ae4fba5</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1080%2F24750573.2018.1443386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F24750573.2018.1443386%26sid%3Dliteratum%253Aachs%26aulast%3DKose%26aufirst%3DS.%26aulast%3DCetin%26aufirst%3DM.%26atitle%3DTriple%2520reuptake%2520inhibitors%2520%2528TRIs%2529%253A%2520do%2520they%2520promise%2520us%2520a%2520rose%2520garden%253F%26jtitle%3DPsychiat%2520Clin%2520Psych%26date%3D2018%26volume%3D28%26issue%3D2%26spage%3D119%26epage%3D122%26doi%3D10.1080%2F24750573.2018.1443386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">X-ray structures and mechanism of the human serotonin transporter</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span> (<span class="NLM_issue">7599</span>),  <span class="NLM_fpage">334</span>â <span class="NLM_lpage">339</span>, <span class="refDoi">Â DOI: 10.1038/nature17629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature17629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27049939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=334-339&issue=7599&author=J.+A.+Colemanauthor=E.+M.+Greenauthor=E.+Gouaux&title=X-ray+structures+and+mechanism+of+the+human+serotonin+transporter&doi=10.1038%2Fnature17629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray structures and mechanism of the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Green, Evan M.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7599</span>),
    <span class="NLM_cas:pages">334-339</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The serotonin transporter (SERT) terminates serotonergic signaling through the sodium- and chloride-dependent reuptake of neurotransmitter into presynaptic neurons.  SERT is a target for antidepressant and psychostimulant drugs, which block reuptake and prolong neurotransmitter signaling.  Here the authors report x-ray crystallog. structures of human SERT at 3.15 Ã resoln. bound to the antidepressants (S)-citalopram or paroxetine.  Antidepressants lock SERT in an outward-open conformation by lodging in the central binding site, located between transmembrane helixes 1, 3, 6, 8 and 10, directly blocking serotonin binding.  The authors further identify the location of an allosteric site in the complex as residing at the periphery of the extracellular vestibule, interposed between extracellular loops 4 and 6 and transmembrane helixes 1, 6, 10 and 11.  Occupancy of the allosteric site sterically hinders ligand unbinding from the central site, providing an explanation for the action of (S)-citalopram as an allosteric ligand.  These structures define the mechanism of antidepressant action in SERT, and provide blueprints for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYAxl5tROCorVg90H21EOLACvtfcHk0lh-WbKsBbblvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gtrY%253D&md5=e4fa11a1e5abdd7b39f44375506aa249</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1038%2Fnature17629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17629%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGreen%26aufirst%3DE.%2BM.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DX-ray%2520structures%2520and%2520mechanism%2520of%2520the%2520human%2520serotonin%2520transporter%26jtitle%3DNature%26date%3D2016%26volume%3D532%26issue%3D7599%26spage%3D334%26epage%3D339%26doi%3D10.1038%2Fnature17629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for recognition of diverse antidepressants by the human serotonin transporter</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">170</span>â <span class="NLM_lpage">175</span>, <span class="refDoi">Â DOI: 10.1038/s41594-018-0026-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41594-018-0026-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29379174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlCqu7jN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=170-175&issue=2&author=J.+A.+Colemanauthor=E.+Gouaux&title=Structural+basis+for+recognition+of+diverse+antidepressants+by+the+human+serotonin+transporter&doi=10.1038%2Fs41594-018-0026-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for recognition of diverse antidepressants by the human serotonin transporter</span></div><div class="casAuthors">Coleman, Jonathan A.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">170-175</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Selective serotonin reuptake inhibitors are clin. prescribed antidepressants that act by increasing the local concns. of neurotransmitters at synapses and in extracellular spaces via blockade of the serotonin transporter.  Here we report X-ray structures of engineered thermostable variants of the human serotonin transporter bound to the antidepressants sertraline, fluvoxamine, and paroxetine.  The drugs prevent serotonin binding by occupying the central substrate-binding site and stabilizing the transporter in an outward-open conformation.  These structures explain how residues within the central site orchestrate binding of chem. diverse inhibitors and mediate transporter drug selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwSIgd0WTZL7Vg90H21EOLACvtfcHk0lh-WbKsBbblvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlCqu7jN&md5=1ea0418315d7c7a134ddef48e36c6d07</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0026-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0026-8%26sid%3Dliteratum%253Aachs%26aulast%3DColeman%26aufirst%3DJ.%2BA.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DStructural%2520basis%2520for%2520recognition%2520of%2520diverse%2520antidepressants%2520by%2520the%2520human%2520serotonin%2520transporter%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D170%26epage%3D175%26doi%3D10.1038%2Fs41594-018-0026-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiden, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, B. J.</span></span> <span> </span><span class="NLM_article-title">Expression cloning of a reserpine-sensitive vesicular monoamine transporter</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">22</span>),  <span class="NLM_fpage">10993</span>â <span class="NLM_lpage">10997</span>, <span class="refDoi">Â DOI: 10.1073/pnas.89.22.10993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.89.22.10993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1438304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK3sXkvV2ht7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=1992&pages=10993-10997&issue=22&author=J.+D.+Ericksonauthor=L.+E.+Eidenauthor=B.+J.+Hoffman&title=Expression+cloning+of+a+reserpine-sensitive+vesicular+monoamine+transporter&doi=10.1073%2Fpnas.89.22.10993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Expression cloning of a reserpine-sensitive vesicular monoamine transporter</span></div><div class="casAuthors">Erickson, Jeffrey D.; Eiden, Lee E.; Hoffman, Beth J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10993-7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A cDNA for a rat vesicular monoamine transporter, designated MAT, was isolated by expression cloning in a mammalian cell line (CV-1).  The cDNA sequence predicts a protein of 515 amino acids with 12 putative membrane-spanning domains.  The characteristics of [3H]serotonin accumulation by CV-1 cells expressing the cDNA clone suggested sequestration by an intracellular compartment.  In cells permeabilized with digitonin, uptake was ATP dependent with an apparent Km of 1.3 Î¼M.  Uptake was abolished by the proton-translocating ionophore carbonylcyanide p-trifluoromethoxyphenylhydrazone and with tri-(n-butyl)tin, an inhibitor of the vacuolar H+-ATPase.  The rank order of potency to inhibit uptake was reserpine > tetrabenazine > serotonin > dopamine > norepinephrine > epinephrine.  Direct comparison of [3H]monoamine uptake indicated that serotonin was the preferred substrate.  Photolabeling of membranes prepd. form CV-1 cells expressing MAT with 7-azido-8-[125I]iodoketanserin revealed a predominant tetrabenazine-sensitive photolabeled glycoprotein with an apparent mol. mass of â75 kDa.  The mRNA that encodes MAT was present specifically in monoamine-contg. cells of the locus coeruleus, substantia nigra, and raphe nucleus of rat brain, each of which expresses a unique plasma membrane reuptake transporter.  The MAT cDNA clone defines a vesicular monoamine transporter representing a distinct class of neurotransmitter transport mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5IYDWkYJGhrVg90H21EOLACvtfcHk0lh-WbKsBbblvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvV2ht7o%253D&md5=ff81153925159172ceb476d60bf1eeac</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1073%2Fpnas.89.22.10993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.89.22.10993%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DJ.%2BD.%26aulast%3DEiden%26aufirst%3DL.%2BE.%26aulast%3DHoffman%26aufirst%3DB.%2BJ.%26atitle%3DExpression%2520cloning%2520of%2520a%2520reserpine-sensitive%2520vesicular%2520monoamine%2520transporter%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1992%26volume%3D89%26issue%3D22%26spage%3D10993%26epage%3D10997%26doi%3D10.1073%2Fpnas.89.22.10993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, R. H.</span></span> <span> </span><span class="NLM_article-title">The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>269</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">7231</span>â <span class="NLM_lpage">7237</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8125935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK2cXitV2htrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=7231-7237&issue=10&author=D.+Peterauthor=J.+Jimenezauthor=Y.+Liuauthor=J.+Kimauthor=R.+H.+Edwards&title=The+chromaffin+granule+and+synaptic+vesicle+amine+transporters+differ+in+substrate+recognition+and+sensitivity+to+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors</span></div><div class="casAuthors">Peter, Doris; Jimenez, Juan; Liu, Yongjian; Kim, Jung; Edwards, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">7231-7</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Classical studies using bovine chromaffin granules have defined the physiol. and pharmacol. properties of the vesicular amine transporter that packages monoamine transmitters into intracellular vesicles for subsequent regulated release.  The recent isolation of two distinct but closely related cDNA clones encoding vesicular amine transport suggests that the activity expressed in the brain (synaptic vesicle amine transporter or SVAT) may differ significantly from the previously described adrenal gland activity (chromaffin granule amine transporter or CGAT).  A direct comparison of the two transporters now shows that SVAT has a higher affinity than CGAT for monoamine substrates, in particular for histamine.  In addn., SVAT shows approx. 10-fold greater sensitivity to tetrabenazine than CGAT.  [3H]Dihydrotetrabenazine shows no detectable binding to CGAT but does bind to SVAT, accounting for the differential sensitivity.  Furthermore, methamphetamine preferentially inhibits transport by SVAT relative to CGAT, apparently by competing at the site of amine recognition rather than by disrupting the vesicular pH gradient.  These previously unsuspected differences in the storage of monoamine transmitter in the central nervous system and the adrenal gland may help to account for several classic pharmacol. observations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKKuFUbOWyY7Vg90H21EOLACvtfcHk0lh-WbKsBbblvg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXitV2htrY%253D&md5=a8b0b97f74061b1c2e00922aff725e11</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPeter%26aufirst%3DD.%26aulast%3DJimenez%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DEdwards%26aufirst%3DR.%2BH.%26atitle%3DThe%2520chromaffin%2520granule%2520and%2520synaptic%2520vesicle%2520amine%2520transporters%2520differ%2520in%2520substrate%2520recognition%2520and%2520sensitivity%2520to%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26issue%3D10%26spage%3D7231%26epage%3D7237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWitt, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maryanoff, B. E.</span></span> <span> </span><span class="NLM_article-title">Deuterated drug molecules: focus on FDA-approved deutetrabenazine</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">472</span>â <span class="NLM_lpage">473</span>, <span class="refDoi">Â DOI: 10.1021/acs.biochem.7b00765</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.7b00765" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=472-473&issue=5&author=S.+H.+DeWittauthor=B.+E.+Maryanoff&title=Deuterated+drug+molecules%3A+focus+on+FDA-approved+deutetrabenazine&doi=10.1021%2Facs.biochem.7b00765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Deuterated Drug Molecules: Focus on FDA-Approved Deutetrabenazine</span></div><div class="casAuthors">DeWitt, Sheila H.; Maryanoff, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">472-473</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The approval of Austedo (deutetrabenazine) as a new chem. entity (NCE) via the 505(b)(2) regulatory pathway established an important milestone for the development and marketing of deuterated drugs.  Its notable introduction into clin. medicine could well be the harbinger of a new era for the utility of deuterium-substituted drug mols.  This point of view is further supported by the sizable collection of other deuterated mols. that are currently in clin. trials, some of which will hopefully emerge successful for the benefit of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQcRjVCOoN5bVg90H21EOLACvtfcHk0ljvqBEnoBsZOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVaksLbL&md5=a1aecdd9f8b539b9e3988d8b135d881a</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.7b00765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.7b00765%26sid%3Dliteratum%253Aachs%26aulast%3DDeWitt%26aufirst%3DS.%2BH.%26aulast%3DMaryanoff%26aufirst%3DB.%2BE.%26atitle%3DDeuterated%2520drug%2520molecules%253A%2520focus%2520on%2520FDA-approved%2520deutetrabenazine%26jtitle%3DBiochemistry%26date%3D2018%26volume%3D57%26issue%3D5%26spage%3D472%26epage%3D473%26doi%3D10.1021%2Facs.biochem.7b00765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harriott, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozigian, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grigoriadis, D. E.</span></span> <span> </span><span class="NLM_article-title">VMAT2 inhibitors and the path to ingrezza (valbenazine)</span>. <i>Prog. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">87</span>â <span class="NLM_lpage">111</span>, <span class="refDoi">Â DOI: 10.1016/bs.pmch.2017.12.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fbs.pmch.2017.12.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29680151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BC1MjltFOgtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=87-111&issue=1&author=N.+D.+Harriottauthor=J.+P.+Williamsauthor=E.+B.+Smithauthor=H.+P.+Bozigianauthor=D.+E.+Grigoriadis&title=VMAT2+inhibitors+and+the+path+to+ingrezza+%28valbenazine%29&doi=10.1016%2Fbs.pmch.2017.12.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)</span></div><div class="casAuthors">Harriott Nicole D; Williams John P; Smith Evan B; Bozigian Haig P; Grigoriadis Dimitri E</div><div class="citationInfo"><span class="NLM_cas:title">Progress in medicinal chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-111</span>
        ISSN:<span class="NLM_cas:issn">0079-6468</span>.
    </div><div class="casAbstract">The dopaminergic system plays a key role in the central nervous system, regulating executive function, arousal, reward, and motor control.  Dysregulation of this critical monoaminergic system has been associated with diseases of the central nervous system including schizophrenia, Parkinson's disease, and disorders such as attention deficit hyperactivity disorders and addiction.  Drugs that modify the dopaminergic system by modulating the activity of dopamine have been successful in demonstrating clinical efficacy by providing treatments for these diseases.  Specifically, antipsychotics, both typical and atypical, while acting on a number of monoaminergic systems in the brain, primarily target the dopamine system via inhibition of postsynaptic dopamine receptors.  The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent release of dopamine and other monoamines from neuronal vesicles into the synapse.  Despite acting on opposing sides of the synapse, both antipsychotics and VMAT2 inhibitors act to decrease the activity of central dopaminergic systems.  Tardive dyskinesia is a disorder characterized by involuntary repetitive movements and thought to be a result of a hyperdopaminergic state precipitated by the use of antipsychotics.  Valbenazine (NBI-98854), a novel compound that selectively inhibits VMAT2 through an active metabolite, has been developed for the treatment of tardive dyskinesia and is the first drug approved for the treatment of this disorder.  This chapter describes the process leading to the discovery of valbenazine, its pharmacological characteristics, along with preclinical and clinical evidence of its efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZ9pfcWWVZ5sSzjBFCN0BJfW6udTcc2ebKJhz16fcfSLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjltFOgtw%253D%253D&md5=dec4e8c08f90ec962a10204bb8f32da7</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fbs.pmch.2017.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.pmch.2017.12.002%26sid%3Dliteratum%253Aachs%26aulast%3DHarriott%26aufirst%3DN.%2BD.%26aulast%3DWilliams%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26aulast%3DBozigian%26aufirst%3DH.%2BP.%26aulast%3DGrigoriadis%26aufirst%3DD.%2BE.%26atitle%3DVMAT2%2520inhibitors%2520and%2520the%2520path%2520to%2520ingrezza%2520%2528valbenazine%2529%26jtitle%3DProg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D57%26issue%3D1%26spage%3D87%26epage%3D111%26doi%3D10.1016%2Fbs.pmch.2017.12.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dwoskin, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crooks, P. A.</span></span> <span> </span><span class="NLM_article-title">A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>63</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1016/S0006-2952(01)00899-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2FS0006-2952%2801%2900899-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11841781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtF2js7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2002&pages=89-98&issue=2&author=L.+P.+Dwoskinauthor=P.+A.+Crooks&title=A+novel+mechanism+of+action+and+potential+use+for+lobeline+as+a+treatment+for+psychostimulant+abuse&doi=10.1016%2FS0006-2952%2801%2900899-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse</span></div><div class="casAuthors">Dwoskin, Linda P.; Crooks, Peter A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Lobeline, an alkaloidal constituent of Lobelia inflata LINN., has a long history of therapeutic usage ranging from emetic and respiratory stimulant to tobacco smoking cessation agent.  Although classified as both an agonist and an antagonist at nicotinic receptors, lobeline has no structural resemblance to nicotine, and structure-function relationships do not suggest a common pharmacophore.  Lobeline inhibits nicotine-evoked dopamine release and [3H]nicotine binding, thus acting as a potent antagonist at both Î±3Î²2* and Î±4Î²2* neuronal nicotinic receptor subtypes.  However, lobeline does not release dopamine from its presynaptic terminal, but appears to induce the metab. of dopamine intraneuronally.  Reevaluation of the mechanism by which lobeline alters dopamine function reveals that its primary mechanism is inhibition of dopamine uptake and promotion of dopamine release from the storage vesicles within the presynaptic terminal, via an interaction with the tetrabenazine-binding site on the vesicular monoamine transporter (VMAT2).  Thus, lobeline appears to perturb the fundamental mechanisms of dopamine storage and release.  Based on its neurochem. mechanism, the ability of lobeline to functionally antagonize the neurochem. and behavioral effects of the psychostimulants amphetamine and methamphetamine was examd.  Lobeline was found to inhibit the amphetamine-induced release of dopamine in vitro, and amphetamine-induced hyperactivity, drug discrimination, and self-administration.  However, lobeline does not support self-administration in rats, suggesting a lack of addiction liability.  Thus, lobeline may reduce the abuse liability of these psychostimulants.  The development of lobeline and lobeline analogs with targeted selectivity at VMAT2 represents a novel class of therapeutic agents having good potential as efficacious treatments for methamphetamine abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS8SVN_Ah01bVg90H21EOLACvtfcHk0ljvqBEnoBsZOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtF2js7s%253D&md5=fb59db7757c56baa802bf94df924f673</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2801%2900899-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252801%252900899-1%26sid%3Dliteratum%253Aachs%26aulast%3DDwoskin%26aufirst%3DL.%2BP.%26aulast%3DCrooks%26aufirst%3DP.%2BA.%26atitle%3DA%2520novel%2520mechanism%2520of%2520action%2520and%2520potential%2520use%2520for%2520lobeline%2520as%2520a%2520treatment%2520for%2520psychostimulant%2520abuse%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2002%26volume%3D63%26issue%3D2%26spage%3D89%26epage%3D98%26doi%3D10.1016%2FS0006-2952%2801%2900899-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mantle, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, N. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of monoamine-oxidase by amphetamine and related compounds</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">2073</span>â <span class="NLM_lpage">2077</span>, <span class="refDoi">Â DOI: 10.1016/0006-2952(76)90432-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2F0006-2952%2876%2990432-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=985546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaE2sXisFymuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1976&pages=2073-2077&issue=18&author=T.+J.+Mantleauthor=K.+F.+Tiptonauthor=N.+J.+Garrett&title=Inhibition+of+monoamine-oxidase+by+amphetamine+and+related+compounds&doi=10.1016%2F0006-2952%2876%2990432-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of monoamine oxidase by amphetamine and related compounds</span></div><div class="casAuthors">Mantle, Timothy J.; Tipton, Keith F.; Garrett, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2073-7</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Dl-Î±-methylbenzylamine-HCl [13437-79-1] (0.1, 1, or 10mM), dl-Î±-methyltryptamine-HCl [879-36-7], and d- [51-63-8] and l-amphetamine sulfate [51-62-7] (0-1.0mM) competitively inhibited the oxidn. of benzylamine-HCl [3287-99-8], tyramine-HCl [60-19-5], and serotonin creatinine sulfate [971-74-4] by partially purified, sol. or membrane-bound rat liver monoamine oxidase (I) [9001-66-5].  Serotonin oxidn. was more potently inhibited than benzylamine oxidn, Î±-methyltryptamine being the most and Î±-methylbenzylamine the least selective.  The kinetics of inhibition of tyramine oxidn. suggested it was acted on by 2 enzyme species with different inhibitor sensitivities.  The substrate selectivity of the inhibitors towards the sol. enzyme was abolished by treatment with the chaotropic agent, Na perchlorate.  The significance of I inhibition in the pharmacol. action of amphetamine is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF9wuUKrYGaLVg90H21EOLACvtfcHk0lgxwJjV2TDCaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXisFymuw%253D%253D&md5=b5cc73d9b6373f5bcb643cd3b71405fa</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2876%2990432-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252876%252990432-9%26sid%3Dliteratum%253Aachs%26aulast%3DMantle%26aufirst%3DT.%2BJ.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26aulast%3DGarrett%26aufirst%3DN.%2BJ.%26atitle%3DInhibition%2520of%2520monoamine-oxidase%2520by%2520amphetamine%2520and%2520related%2520compounds%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1976%26volume%3D25%26issue%3D18%26spage%3D2073%26epage%3D2077%26doi%3D10.1016%2F0006-2952%2876%2990432-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chasis, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jolliffe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, H. W.</span></span> <span> </span><span class="NLM_article-title">The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1933</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1083</span>â <span class="NLM_lpage">1090</span>, <span class="refDoi">Â DOI: 10.1172/JCI100559</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1172%2FJCI100559" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=16694183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaA2cXhsVGltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1933&pages=1083-1090&issue=6&author=H.+Chasisauthor=N.+Jolliffeauthor=H.+W.+Smith&title=The+action+of+phlorizin+on+the+excretion+of+glucose%2C+xylose%2C+sucrose%2C+creatinine+and+urea+by+man&doi=10.1172%2FJCI100559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man</span></div><div class="casAuthors">Chasis, Herbert; Jolliffe, Norman; Smith, Homer W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1933</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1083-90</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    </div><div class="casAbstract">The min. requirement of phlorizin by man for complete phlorizinization, i. e., raising of the glucose clearance to xylose clearance, is 10-20 mg. per kg.  A dose of 65 mg. did not raise the glucose clearance above that for xylose, and one of 59.4 mg. did not cause deviation between the xylose and sucrose clearances.  With the largest dose given there was no significant depressive action on the ratio creatinine:xylose clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOgugOsK5o7Vg90H21EOLACvtfcHk0lgxwJjV2TDCaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2cXhsVGltg%253D%253D&md5=0d80d580fc08681f0ecbe3663e2bfa52</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1172%2FJCI100559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI100559%26sid%3Dliteratum%253Aachs%26aulast%3DChasis%26aufirst%3DH.%26aulast%3DJolliffe%26aufirst%3DN.%26aulast%3DSmith%26aufirst%3DH.%2BW.%26atitle%3DThe%2520action%2520of%2520phlorizin%2520on%2520the%2520excretion%2520of%2520glucose%252C%2520xylose%252C%2520sucrose%252C%2520creatinine%2520and%2520urea%2520by%2520man%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1933%26volume%3D12%26issue%3D6%26spage%3D1083%26epage%3D1090%26doi%3D10.1172%2FJCI100559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oku, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishihara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuronuma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsujihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endou, H.</span></span> <span> </span><span class="NLM_article-title">T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes</span>. <i>Diabetes</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1794</span>â <span class="NLM_lpage">1800</span>, <span class="refDoi">Â DOI: 10.2337/diabetes.48.9.1794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.2337%2Fdiabetes.48.9.1794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10480610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVaitLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1999&pages=1794-1800&issue=9&author=A.+Okuauthor=K.+Uetaauthor=K.+Arakawaauthor=T.+Ishiharaauthor=M.+Nawanoauthor=Y.+Kuronumaauthor=M.+Matsumotoauthor=A.+Saitoauthor=K.+Tsujiharaauthor=M.+Anaiauthor=T.+Asanoauthor=Y.+Kanaiauthor=H.+Endou&title=T-1095%2C+an+inhibitor+of+renal+Na%2B-glucose+cotransporters%2C+may+provide+a+novel+approach+to+treating+diabetes&doi=10.2337%2Fdiabetes.48.9.1794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes</span></div><div class="casAuthors">Oku, Akira; Ueta, Kiichiro; Arakawa, Kenji; Ishihara, Tomomi; Nawano, Masao; Kuronuma, Yasuo; Matsumoto, Mamoru; Saito, Akira; Tsujihara, Kenji; Anai, Motonobu; Asano, Tomoichiro; Kanai, Yoshikatsu; Endou, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1794-1800</span>CODEN:
                <span class="NLM_cas:coden">DIAEAZ</span>;
        ISSN:<span class="NLM_cas:issn">0012-1797</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association</span>)
        </div><div class="casAbstract">T-1095A and T-1095 are synthetic agents derived from phlorizin, a specific inhibitor of Na+-glucose cotransporters (SGLTs).  Unlike phlorizin, T-1095 is absorbed into the circulation via oral administration, is metabolized to the active form, T-1095A, and suppresses the activity of SGLTs in the kidney.  Orally administered T-1095 increases urinary glucose excretion in diabetic animals, thereby decreasing blood glucose levels.  Indeed, the postprandial hyperglycemia after a meal load was shown to be suppressed by this compd. in streptozotocin (STZ)-induced diabetic rats.  With longterm T-1095 treatment, both blood glucose and HbA1c levels were reduced in STZ-induced diabetic rats and yellow KK mice.  In addn., there was amelioration of abnormal carbohydrate metab., i.e., hyperinsulinemia and hypertriglyceridemia, and of the development of microalbuminuria, in yellow KK mice.  Thus, T-1095 may be a useful antidiabetic drug, providing a novel therapeutic approach for diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKtVa6y9Aet7Vg90H21EOLACvtfcHk0lgxwJjV2TDCaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVaitLk%253D&md5=16ec9fefe5fbb3f3bc7e8fedd4815916</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.48.9.1794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.48.9.1794%26sid%3Dliteratum%253Aachs%26aulast%3DOku%26aufirst%3DA.%26aulast%3DUeta%26aufirst%3DK.%26aulast%3DArakawa%26aufirst%3DK.%26aulast%3DIshihara%26aufirst%3DT.%26aulast%3DNawano%26aufirst%3DM.%26aulast%3DKuronuma%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DM.%26aulast%3DSaito%26aufirst%3DA.%26aulast%3DTsujihara%26aufirst%3DK.%26aulast%3DAnai%26aufirst%3DM.%26aulast%3DAsano%26aufirst%3DT.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DEndou%26aufirst%3DH.%26atitle%3DT-1095%252C%2520an%2520inhibitor%2520of%2520renal%2520Na%252B-glucose%2520cotransporters%252C%2520may%2520provide%2520a%2520novel%2520approach%2520to%2520treating%2520diabetes%26jtitle%3DDiabetes%26date%3D1999%26volume%3D48%26issue%3D9%26spage%3D1794%26epage%3D1800%26doi%3D10.2337%2Fdiabetes.48.9.1794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C. I.</span></span> <span> </span><span class="NLM_article-title">Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1136</span>, <span class="refDoi">Â DOI: 10.3390/molecules21091136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3390%2Fmolecules21091136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKis7rO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1136&issue=9&author=C.+I.+Choi&title=Sodium-glucose+cotransporter+2+%28SGLT2%29+inhibitors+from+natural+products%3A+discovery+of+next-generation+antihyperglycemic+agents&doi=10.3390%2Fmolecules21091136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents</span></div><div class="casAuthors">Choi, Chang-Ik</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1136/1-1136/12</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Diabetes mellitus is a chronic condition assocd. with the metabolic impairment of insulin actions, leading to the development of life-threatening complications.  Although many kinds of oral antihyperglycemic agents with different therapeutic mechanisms have been marketed, their undesirable adverse effects, such as hypoglycemia, wt. gain, and hepato-renal toxicity, have increased demand for the discovery of novel, safer antidiabetic drugs.  Since the important roles of the sodium-glucose cotransporter 2 (SGLT2) for glucose homeostasis in the kidney were recently elucidated, pharmacol. inhibition of SGLT2 has been considered a promising therapeutic target for the treatment of type 2 diabetes.  Since the discovery of the first natural SGLT2 inhibitor, phlorizin, several synthetic glucoside analogs have been developed and introduced into the market.  Furthermore, many efforts to find new active constituents with SGLT2 inhibition from natural products are still ongoing.  This review introduces the history of research on the development of early-generation SGLT2 inhibitors, and recent progress on the discovery of novel candidates for SGLT2 inhibitor from several natural products that are widely used in traditional herbal medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCiOqML4-LirVg90H21EOLACvtfcHk0lgxwJjV2TDCaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKis7rO&md5=68a60f0c2c669cf328bf9a123491f6c6</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.3390%2Fmolecules21091136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules21091136%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DC.%2BI.%26atitle%3DSodium-glucose%2520cotransporter%25202%2520%2528SGLT2%2529%2520inhibitors%2520from%2520natural%2520products%253A%2520discovery%2520of%2520next-generation%2520antihyperglycemic%2520agents%26jtitle%3DMolecules%26date%3D2016%26volume%3D21%26issue%3D9%26spage%3D1136%26doi%3D10.3390%2Fmolecules21091136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Sotagliflozin: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1023</span>â <span class="NLM_lpage">1029</span>, <span class="refDoi">Â DOI: 10.1007/s40265-019-01146-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs40265-019-01146-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31172412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWlt7fI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1023-1029&issue=9&author=A.+Markhamauthor=S.+J.+Keam&title=Sotagliflozin%3A+first+global+approval&doi=10.1007%2Fs40265-019-01146-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Sotagliflozin: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1023-1029</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Sotagliflozin (Zynquista) is a dual inhibitor of sodium-glucose co-transporters (SGLT) 1 and 2 being developed by Lexicon Pharmaceuticals and Sanofi as a treatment for type 1 (T1DM) and type 2 diabetes mellitus (T2DM).  The drug has a dual action, blunting and delaying absorption of glucose from the gastrointestinal tract and the reabsorption of glucose in the proximal tubule of the kidney, resp.  In the phase III inTandem clin. trial program in patients with T1DM, sotagliflozin as an adjunct to optimized insulin therapy produced a clin. meaningful redn. in HbA1c levels, but was assocd. with a higher incidence of diabetic ketoacidosis than placebo.  Sotagliflozin was recently approved for use as an adjunct to insulin in T1DM in the EU.  However, the FDA Endocrinol. and Metabolic Drugs Advisory Committee was divided, citing concerns regarding diabetic ketoacidosis, leading the FDA to issue an Complete Response Letter for this indication in the USA.  This article summarizes the milestones in the development of sotagliflozin leading to this first approval in the EU as an adjunct to insulin in patients with T1DM with a body mass index â¥ 27 kg/m2 who have failed to achieve adequate glycemic control despite optimal insulin therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqA4Ji2ApgWrVg90H21EOLACvtfcHk0lgDyAYgP9ll0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWlt7fI&md5=b3980fb997c5f7f33e25a2816b9f0c3a</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01146-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01146-5%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DSotagliflozin%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26issue%3D9%26spage%3D1023%26epage%3D1029%26doi%3D10.1007%2Fs40265-019-01146-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ooi, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomperts, B. N.</span></span> <span> </span><span class="NLM_article-title">Molecular pathways: targeting cellular energy metabolism in cancer via inhibition of SLC2A1 and LDHA</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2440</span>â <span class="NLM_lpage">2444</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.CCR-14-1209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1158%2F1078-0432.CCR-14-1209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=25838393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1aktLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2440-2444&issue=11&author=A.+T.+Ooiauthor=B.+N.+Gomperts&title=Molecular+pathways%3A+targeting+cellular+energy+metabolism+in+cancer+via+inhibition+of+SLC2A1+and+LDHA&doi=10.1158%2F1078-0432.CCR-14-1209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA</span></div><div class="casAuthors">Ooi, Aik T.; Gomperts, Brigitte N.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2440-2444</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reprogramming of cellular energy metab. is widely accepted to be one of the main hallmarks of cancer.  The aberrant expression pattern of key regulators in the glycolysis pathway in cancer cells corroborates with the hypothesis that most cancer cells utilize aerobic glycolysis as their main ATP prodn. method instead of mitochondrial oxidative phosphorylation.  Overexpression of SLC2A1 and LDHA, both important regulators of the glycolysis pathway, was detected in the premalignant lesions and tumors of lung cancer patients, suggesting the involvement of these proteins in early carcinogenesis and tumor progression in cancer.  Preclin. studies demonstrated that inhibiting SLC2A1 or LDHA led to diminished tumor growth in vitro and in vivo.  SLC2A1 and LDHA inhibitors, when administered in combination with other chemotherapeutic agents, showed synergistic antitumor effects by resensitizing chemoresistant cancer cells to the chemotherapies.  These results indicate that disrupting SLC2A1, LDHA, or other regulators in cancer cell energetics is a very promising approach for new targeted therapies.  Clin Cancer Res; 21(11); 2440-4. cpr2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnAZlM7OEMh7Vg90H21EOLACvtfcHk0lgDyAYgP9ll0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1aktLc%253D&md5=59d9fc4a918571c1be9d2036a1597805</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1209%26sid%3Dliteratum%253Aachs%26aulast%3DOoi%26aufirst%3DA.%2BT.%26aulast%3DGomperts%26aufirst%3DB.%2BN.%26atitle%3DMolecular%2520pathways%253A%2520targeting%2520cellular%2520energy%2520metabolism%2520in%2520cancer%2520via%2520inhibition%2520of%2520SLC2A1%2520and%2520LDHA%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26issue%3D11%26spage%3D2440%26epage%3D2444%26doi%3D10.1158%2F1078-0432.CCR-14-1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siebeneicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleve, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehwinkel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, B.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2261</span>â <span class="NLM_lpage">2271</span>, <span class="refDoi">Â DOI: 10.1002/cmdc.201600276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fcmdc.201600276" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27552707" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyktr3L" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2261-2271&issue=20&author=H.+Siebeneicherauthor=A.+Cleveauthor=H.+Rehwinkelauthor=R.+Neuhausauthor=I.+Heislerauthor=T.+Mullerauthor=M.+Bauserauthor=B.+Buchmann&title=Identification+and+optimization+of+the+first+highly+selective+GLUT1+inhibitor+BAY-876&doi=10.1002%2Fcmdc.201600276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876</span></div><div class="casAuthors">Siebeneicher, Holger; Cleve, Arwed; Rehwinkel, Hartmut; Neuhaus, Roland; Heisler, Iring; Mueller, Thomas; Bauser, Marcus; Buchmann, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2261-2271</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Despite the long-known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only few endeavors have been undertaken to find a GLUT1-selective small-mol. inhibitor.  Because other transporters of the GLUT1 family are involved in crucial processes, these transporters should not be addressed by such an inhibitor.  A high-throughput screen against a library of â¼3 million compds. was performed to find a small mol. with this challenging potency and selectivity profile.  The N-(1H-pyrazol-4-yl)quinoline-4-carboxamides were identified as an excellent starting point for further compd. optimization.  After extensive structure-activity relationship explorations, single-digit nanomolar inhibitors with a selectivity factor of >100 against GLUT2, GLUT3, and GLUT4 were obtained.  The most promising compd., BAY-876 [N4-[1-(4-cyanobenzyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide], showed good metabolic stability in vitro and high oral bioavailability in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFnF7Pnmxup7Vg90H21EOLACvtfcHk0lgDyAYgP9ll0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyktr3L&md5=bcad707900882f937d137dc3925862a7</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600276%26sid%3Dliteratum%253Aachs%26aulast%3DSiebeneicher%26aufirst%3DH.%26aulast%3DCleve%26aufirst%3DA.%26aulast%3DRehwinkel%26aufirst%3DH.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DT.%26aulast%3DBauser%26aufirst%3DM.%26aulast%3DBuchmann%26aufirst%3DB.%26atitle%3DIdentification%2520and%2520optimization%2520of%2520the%2520first%2520highly%2520selective%2520GLUT1%2520inhibitor%2520BAY-876%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26issue%3D20%26spage%3D2261%26epage%3D2271%26doi%3D10.1002%2Fcmdc.201600276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idowu, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Temkin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X. J.</span></span> <span> </span><span class="NLM_article-title">Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">33</span>, <span class="refDoi">Â DOI: 10.3390/cancers11010033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.3390%2Fcancers11010033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=33&issue=1&author=Y.+B.+Maauthor=W.+Wangauthor=M.+O.+Idowuauthor=U.+Ohauthor=X.+Y.+Wangauthor=S.+M.+Temkinauthor=X.+J.+Fang&title=Ovarian+cancer+relies+on+glucose+transporter+1+to+fuel+glycolysis+and+growth%3A+anti-tumor+activity+of+BAY-876&doi=10.3390%2Fcancers11010033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876</span></div><div class="casAuthors">Ma, Yibao; Wang, Wei; Idowu, Michael O.; Oh, Unsong; Wang, Xiang-Yang; Temkin, Sarah M.; Fang, Xianjun</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The recent progresses in understanding of cancer glycolytic phenotype have offered new strategies to manage ovarian cancer and other malignancies.  However, therapeutic targeting of glycolysis to treat cancer remains unsuccessful due to complex mechanisms of tumor glycolysis and the lack of selective, potent and safe glycolytic inhibitors.  Recently, BAY-876 was identified as a new-generation inhibitor of glucose transporter 1 (GLUT1), a GLUT isoform commonly overexpressed but functionally poorly defined in ovarian cancer.  Notably, BAY-876 has not been evaluated in any cell or preclin. animal models since its discovery.  We herein took advantage of BAY-876 and mol. approaches to study GLUT1 regulation, targetability, and functional relevance to cancer glycolysis.  The anti-tumor activity of BAY-876 was evaluated with ovarian cancer cell line- and patient-derived xenograft (PDX) models.  Our results show that inhibition of GLUT1 is sufficient to block basal and stress-regulated glycolysis, and anchorage-dependent and independent growth of ovarian cancer cells.  BAY-876 dramatically inhibits tumorigenicity of both cell line-derived xenografts and PDXs.  These studies provide direct evidence that GLUT1 is causally linked to the glycolytic phenotype in ovarian cancer.  BAY-876 is a potent blocker of GLUT1 activity, glycolytic metab. and ovarian cancer growth, holding promise as a novel glycolysis-targeted anti-cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfLuPYZrtc5LVg90H21EOLACvtfcHk0liBC7AlnYVy2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKgsL%252FK&md5=d1a3f34ef50838e475009a2de554bb7e</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.3390%2Fcancers11010033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11010033%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DY.%2BB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DIdowu%26aufirst%3DM.%2BO.%26aulast%3DOh%26aufirst%3DU.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DTemkin%26aufirst%3DS.%2BM.%26aulast%3DFang%26aufirst%3DX.%2BJ.%26atitle%3DOvarian%2520cancer%2520relies%2520on%2520glucose%2520transporter%25201%2520to%2520fuel%2520glycolysis%2520and%2520growth%253A%2520anti-tumor%2520activity%2520of%2520BAY-876%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26issue%3D1%26spage%3D33%26doi%3D10.3390%2Fcancers11010033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siebeneicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuhaus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehwinkel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zorn, L.</span></span> <span> </span><span class="NLM_article-title">Identification of novel GLUT inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1732</span>â <span class="NLM_lpage">1737</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.02.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bmcl.2016.02.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26949183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1akt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1732-1737&issue=7&author=H.+Siebeneicherauthor=M.+Bauserauthor=B.+Buchmannauthor=I.+Heislerauthor=T.+Mullerauthor=R.+Neuhausauthor=H.+Rehwinkelauthor=J.+Telserauthor=L.+Zorn&title=Identification+of+novel+GLUT+inhibitors&doi=10.1016%2Fj.bmcl.2016.02.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of novel GLUT inhibitors</span></div><div class="casAuthors">Siebeneicher, Holger; Bauser, Marcus; Buchmann, Bernd; Heisler, Iring; Mueller, Thomas; Neuhaus, Roland; Rehwinkel, Hartmut; Telser, Joachim; Zorn, Ludwig</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1732-1737</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The compd. class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS (high-throughput screening) as very potent inhibitors of facilitated glucose transporter 1 (GLUT1).  Extensive structure-activity relationship studies (SAR) of each ring system of the mol. framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine).  The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvoI6G3pWwZrVg90H21EOLACvtfcHk0liBC7AlnYVy2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1akt70%253D&md5=79f2a3d68a3e38656b0b3ed4c99bd636</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.050%26sid%3Dliteratum%253Aachs%26aulast%3DSiebeneicher%26aufirst%3DH.%26aulast%3DBauser%26aufirst%3DM.%26aulast%3DBuchmann%26aufirst%3DB.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DT.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DRehwinkel%26aufirst%3DH.%26aulast%3DTelser%26aufirst%3DJ.%26aulast%3DZorn%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520novel%2520GLUT%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26issue%3D7%26spage%3D1732%26epage%3D1737%26doi%3D10.1016%2Fj.bmcl.2016.02.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kapoor, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finer-Moore, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caboni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waight, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillig, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebeneicher, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">4711</span>â <span class="NLM_lpage">4716</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1603735113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.1603735113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27078104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XlvV2nsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=4711-4716&issue=17&author=K.+Kapoorauthor=J.+S.+Finer-Mooreauthor=B.+P.+Pedersenauthor=L.+Caboniauthor=A.+Waightauthor=R.+C.+Hilligauthor=P.+Bringmannauthor=I.+Heislerauthor=T.+Mullerauthor=H.+Siebeneicherauthor=R.+M.+Stroud&title=Mechanism+of+inhibition+of+human+glucose+transporter+GLUT1+is+conserved+between+cytochalasin+B+and+phenylalanine+amides&doi=10.1073%2Fpnas.1603735113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides</span></div><div class="casAuthors">Kapoor, Khyati; Finer-Moore, Janet S.; Pedersen, Bjoern P.; Caboni, Laura; Waight, Andrew; Hillig, Roman C.; Bringmann, Peter; Heisler, Iring; Muller, Thomas; Siebeneicher, Holger; Stroud, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4711-4716</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Cancerous cells have an acutely increased demand for energy, leading to increased levels of human glucose transporter 1 (hGLUT1).  This up-regulation suggests hGLUT1 as a target for therapeutic inhibitors addressing a multitude of cancer types.  Here, the authors present three inhibitor-bound, inward-open structures of WT-hGLUT1 crystd. with three different inhibitors: cytochalasin B, a nine-membered bicyclic ring fused to a 14-membered macrocycle, which has been described extensively in the literature of hGLUTs, and two previously undescribed Phe amide-derived inhibitors.  Despite very different chem. backbones, all three compds. bind in the central cavity of the inward-open state of hGLUT1, and all binding sites overlap the glucose-binding site.  The inhibitory action of the compds. was detd. for hGLUT family members, hGLUT1-4, using cell-based assays, and compared with homol. models for these hGLUT members.  This comparison uncovered a probable basis for the obsd. differences in inhibition between family members.  The authors pinpoint regions of the hGLUT proteins that can be targeted to achieve isoform selectivity, and show that these same regions are used for inhibitors with very distinct structural backbones.  The inhibitor cocomplex structures of hGLUT1 provide an important structural insight for the design of more selective inhibitors for hGLUTs and hGLUT1 in particular.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopyfWMOg2jvLVg90H21EOLACvtfcHk0liBC7AlnYVy2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlvV2nsLw%253D&md5=473eb5209694681cf2df4be5603aaabc</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1603735113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1603735113%26sid%3Dliteratum%253Aachs%26aulast%3DKapoor%26aufirst%3DK.%26aulast%3DFiner-Moore%26aufirst%3DJ.%2BS.%26aulast%3DPedersen%26aufirst%3DB.%2BP.%26aulast%3DCaboni%26aufirst%3DL.%26aulast%3DWaight%26aufirst%3DA.%26aulast%3DHillig%26aufirst%3DR.%2BC.%26aulast%3DBringmann%26aufirst%3DP.%26aulast%3DHeisler%26aufirst%3DI.%26aulast%3DMuller%26aufirst%3DT.%26aulast%3DSiebeneicher%26aufirst%3DH.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26atitle%3DMechanism%2520of%2520inhibition%2520of%2520human%2520glucose%2520transporter%2520GLUT1%2520is%2520conserved%2520between%2520cytochalasin%2520B%2520and%2520phenylalanine%2520amides%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26issue%3D17%26spage%3D4711%26epage%3D4716%26doi%3D10.1073%2Fpnas.1603735113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petrecca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atanasiu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinstein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrier, A.</span></span> <span> </span><span class="NLM_article-title">Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>276</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">H709</span>â <span class="NLM_lpage">717</span>, <span class="refDoi">Â DOI: 10.1152/ajpheart.1999.276.2.H709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpheart.1999.276.2.H709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=9950874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlCktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=1999&pages=H709-717&issue=2&author=K.+Petreccaauthor=R.+Atanasiuauthor=S.+Grinsteinauthor=J.+Orlowskiauthor=A.+Shrier&title=Subcellular+localization+of+the+Na%2B%2FH%2B+exchanger+NHE1+in+rat+myocardium&doi=10.1152%2Fajpheart.1999.276.2.H709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Subcellular localization of the Na+/H+ exchanger NHE1 in rat myocardium</span></div><div class="casAuthors">Petrecca, Kevin; Atanasiu, Roxana; Grinstein, Sergio; Orlowski, John; Shrier, Alvin</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">2, Pt. 2</span>),
    <span class="NLM_cas:pages">H709-H717</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">The Na+/H+ exchanger NHE1 isoform is an integral component of cardiac intracellular pH homeostasis that is critically important for myocardial contractility.  To gain further insight into its physiol. significance, the authors detd. its cellular distribution in adult rat heart by using immunohistochem. and confocal microscopy.  NHE1 was localized predominantly at the intercalated disk regions in close proximity to the gap junction protein, connexin 43 (Cx43), of atrial and ventricular muscle cells.  Significant labeling of NHE1 was also obsd. along the transverse tubular systems, but not the lateral sarcolemmal membranes, of both cell types.  In contrast, the (Na+,K+)-ATPase Î±1 subunit was readily labeled by a specific mouse monoclonal antibody (McK1) along the entire ventricular sarcolemma and intercalated disks and, to a lesser extent, in the transverse tubules.  These results indicate that NHE1 has a distinct distribution in heart and may fulfill specialized roles by selectively regulating the pH microenvironment of pH-sensitive proteins at the intercalated disks (e.g., Cx43) and near the cytosolic surface of sarcoplasmic reticulum cisternae (e.g., ryanodine receptor), thereby influencing impulse conduction and excitation-contraction coupling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgzM6kR1g6a7Vg90H21EOLACvtfcHk0lgP0kTrW4Ssow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlCktLg%253D&md5=b31d256d3f2503f05ab37a792566573d</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.1999.276.2.H709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.1999.276.2.H709%26sid%3Dliteratum%253Aachs%26aulast%3DPetrecca%26aufirst%3DK.%26aulast%3DAtanasiu%26aufirst%3DR.%26aulast%3DGrinstein%26aufirst%3DS.%26aulast%3DOrlowski%26aufirst%3DJ.%26aulast%3DShrier%26aufirst%3DA.%26atitle%3DSubcellular%2520localization%2520of%2520the%2520Na%252B%252FH%252B%2520exchanger%2520NHE1%2520in%2520rat%2520myocardium%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1999%26volume%3D276%26issue%3D2%26spage%3DH709%26epage%3D717%26doi%3D10.1152%2Fajpheart.1999.276.2.H709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karmazyn, M.</span></span> <span> </span><span class="NLM_article-title">Amiloride enhances postischemic ventricular recovery: possible role of Na+-H+ exchange</span>. <i>Am. J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>255</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">H608</span>â <span class="NLM_lpage">H615</span>, <span class="refDoi">Â DOI: 10.1152/ajpheart.1988.255.3.H608</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1152%2Fajpheart.1988.255.3.H608" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=2843057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaL1cXls1eiu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=255&publication_year=1988&pages=H608-H615&issue=3&author=M.+Karmazyn&title=Amiloride+enhances+postischemic+ventricular+recovery%3A+possible+role+of+Na%2B-H%2B+exchange&doi=10.1152%2Fajpheart.1988.255.3.H608"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Amiloride enhances postischemic ventricular recovery:  possible role of sodium-proton exchange</span></div><div class="casAuthors">Karmazyn, Morris</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Physiology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">255</span>
        (<span class="NLM_cas:issue">3, Pt. 2</span>),
    <span class="NLM_cas:pages">H608-H615</span>CODEN:
                <span class="NLM_cas:coden">AJPHAP</span>;
        ISSN:<span class="NLM_cas:issn">0002-9513</span>.
    </div><div class="casAbstract">The effect of amiloride (40 Î¼g/mL) was studied in the isolated rat heart subjected to low-flow ischemia followed by reperfusion.  Reperfusion after 30 min of ischemia produced recoveries of force, rate of force development (+dF/dt), and rate of relaxation (-dF/dt) of 42, 82, and 71%, resp., in control hearts.  Amiloride did not enhance the max. degree of recovery, although, when present during ischemia, it markedly shortened the time required for peak recovery.  Reperfusion after 60 min of ischemia resulted in 18, 43, and 34% recovery of force, +dF/dt, and -dF/dt, resp.  Amiloride enhanced recovery to a max. of 39, 88, and 78% for force, +dF/dt, and -dF/dt, resp.  The improved contractile recovery was accompanied by substantial redns. in the release of creatine kinase and 6-ketoprostaglandin F1Î±.  Coronary perfusion pressure and resting tension were generally unaffected by amiloride, although there was a moderate tendency to attenuate these parameters after reperfusion.  The salutary effects of amiloride were dependent on the drug's presence during ischemia, with max. protection when it was administered during both ischemia and reperfusion and no benefit when added only at the time of reperfusion.  Because of amiloride's well-documented property in inhibiting Na+-H+ exchange, it is possible that this process plays an important role in modulating the cardiac response to reperfusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNYJHJhRIbnbVg90H21EOLACvtfcHk0lgP0kTrW4Ssow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXls1eiu7c%253D&md5=b87f4354c954c7339dd1c1fa945dbb53</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1152%2Fajpheart.1988.255.3.H608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpheart.1988.255.3.H608%26sid%3Dliteratum%253Aachs%26aulast%3DKarmazyn%26aufirst%3DM.%26atitle%3DAmiloride%2520enhances%2520postischemic%2520ventricular%2520recovery%253A%2520possible%2520role%2520of%2520Na%252B-H%252B%2520exchange%26jtitle%3DAm.%2520J.%2520Physiol.%26date%3D1988%26volume%3D255%26issue%3D3%26spage%3DH608%26epage%3DH615%26doi%3D10.1152%2Fajpheart.1988.255.3.H608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harguindey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arranz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polo Orozco, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardone, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reshkin, S. J.</span></span> <span> </span><span class="NLM_article-title">Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs - an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research</span>. <i>J. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">282</span>, <span class="refDoi">Â DOI: 10.1186/1479-5876-11-282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1186%2F1479-5876-11-282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=24195657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislOrtro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=282&author=S.+Harguindeyauthor=J.+L.+Arranzauthor=J.+D.+Polo+Orozcoauthor=C.+Rauchauthor=S.+Faisauthor=R.+A.+Cardoneauthor=S.+J.+Reshkin&title=Cariporide+and+other+new+and+powerful+NHE1+inhibitors+as+potentially+selective+anticancer+drugs+-+an+integral+molecular%2Fbiochemical%2Fmetabolic%2Fclinical+approach+after+one+hundred+years+of+cancer+research&doi=10.1186%2F1479-5876-11-282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Cariporide and other new and powerful NHE1 inhibitors as potentially selective anticancer drugs - an integral molecular/biochemical/metabolic/clinical approach after one hundred years of cancer research</span></div><div class="casAuthors">Harguindey, Salvador; Arranz, Jose Luis; Orozco, Julian David Polo; Rauch, Cyril; Fais, Stefano; Cardone, Rosa Angela; Reshkin, Stephan J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Translational Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">282/1-282/17, 17 pp.</span>CODEN:
                <span class="NLM_cas:coden">JTMOBV</span>;
        ISSN:<span class="NLM_cas:issn">1479-5876</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years an increasing no. of publications have emphasized the growing importance of hydrogen ion dynamics in modern cancer research, from etiopathogenesis and treatment.  A proton [H+]-related mechanism underlying the initiation and progression of the neoplastic process has been recently described by different research groups as a new paradigm in which all cancer cells and tissues, regardless of their origin and genetic background, have a pivotal energetic and homeostatic disturbance of their metab. that is completely different from all normal tissues: an aberrant regulation of hydrogen ion dynamics leading to a reversal of the pH gradient in cancer cells and tissues (âpHi/âpHe, or "proton reversal").  Tumor cells survive their hostile microenvironment due to membrane-bound proton pumps and transporters, and their main defensive strategy is to never allow internal acidification because that could lead to their death through apoptosis.  In this context, one of the primary and best studied regulators of both pHi and pHe in tumors is the Na+/H+ exchanger isoform 1 (NHE1).  An elevated NHE1 activity can be correlated with both an increase in cell pH and a decrease in the extracellular pH of tumors, and such proton reversal is assocd. with the origin, local growth, activation and further progression of the metastatic process.  Consequently, NHE1 pharmaceutical inhibition by new and potent NHE1 inhibitors represents a potential and highly selective target in anticancer therapy.  Cariporide, being one of the better studied specific and powerful NHE1 inhibitors, has proven to be well tolerated by humans in the cardiol. context, however some side-effects, mainly related to drug accumulation and cerebrovascular complications were reported.  Thus, cariporide could become a new, slightly toxic and effective anticancer agent in different human malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr5c_Sda6F1LVg90H21EOLACvtfcHk0lgP0kTrW4Ssow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislOrtro%253D&md5=f0faba61fdae83c1481ba3fe1dc8b382</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1186%2F1479-5876-11-282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1479-5876-11-282%26sid%3Dliteratum%253Aachs%26aulast%3DHarguindey%26aufirst%3DS.%26aulast%3DArranz%26aufirst%3DJ.%2BL.%26aulast%3DPolo%2BOrozco%26aufirst%3DJ.%2BD.%26aulast%3DRauch%26aufirst%3DC.%26aulast%3DFais%26aufirst%3DS.%26aulast%3DCardone%26aufirst%3DR.%2BA.%26aulast%3DReshkin%26aufirst%3DS.%2BJ.%26atitle%3DCariporide%2520and%2520other%2520new%2520and%2520powerful%2520NHE1%2520inhibitors%2520as%2520potentially%2520selective%2520anticancer%2520drugs%2520-%2520an%2520integral%2520molecular%252Fbiochemical%252Fmetabolic%252Fclinical%2520approach%2520after%2520one%2520hundred%2520years%2520of%2520cancer%2520research%26jtitle%3DJ.%2520Transl.%2520Med.%26date%3D2013%26volume%3D11%26spage%3D282%26doi%3D10.1186%2F1479-5876-11-282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karmazyn, M.</span></span> <span> </span><span class="NLM_article-title">NHE-1: still a viable therapeutic target</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">77</span>â <span class="NLM_lpage">82</span>, <span class="refDoi">Â DOI: 10.1016/j.yjmcc.2013.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.yjmcc.2013.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23429008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVOjsbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=77-82&author=M.+Karmazyn&title=NHE-1%3A+still+a+viable+therapeutic+target&doi=10.1016%2Fj.yjmcc.2013.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">NHE-1: Still a viable therapeutic target</span></div><div class="casAuthors">Karmazyn, Morris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">77-82</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The concept of NaH exchange (NHE) involvement in cardiac pathol. has been espoused for decades and supported by a plethora of exptl. studies demonstrating salutary effects of NHE inhibition in protecting the myocardium against ischemic and reperfusion injury as well as attenuating myocardial remodelling and heart failure.  NHE is actually a family of sodium and proton transporting proteins of which 10 isoforms have been identified.  Myocardial NHE is represented primarily by the ubiquitous NHE-1 subtype which is expressed in most tissues.  The robust pos. results seen with NHE-1 inhibitors in exptl. studies have led to relatively rapid development of these pharmacol. agents for clin. assessment esp. as potential cardioprotective therapies.  Yet clin. studies have revealed, at best, inconsistent results as evidenced by poor efficacy and serious side effects, the latter revealed with the use of the NHE-1 inhibitor cariporide in high-risk patients undergoing coronary artery bypass grafting and evidenced by an increased incidence of cerebrovascular events of thromboembolic origin.  The lack of success in clin. trials coupled with potential for toxicity has had a neg. impact on development of cardiac therapeutic agents which have been developed based on the concept of NHE-1 inhibition.  Whether this response is justified is open for discussion although a close scrutiny of clin. trial outcomes suggests that it may not be and that NHE-1 inhibition, if applied appropriately continues to represent an effective, if not the most effective approach for myocardial salvage following ischemic insult.  Moreover, in addn. to its cardioprotective effects, emerging evidence further suggests that NHE-1 inhibition is an effective strategy to minimize myocardial remodelling as well as a potentially effective strategy to improve efficacy of resuscitation following cardiac arrest.  Thus, NHE-1 inhibition continues to represent a potentially highly effective therapeutic approach for the treatment of heart disease.  This article is part of a Special Issue entitled "Na+ Regulation in Cardiac Myocytes".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriJ-lt41Mnu7Vg90H21EOLACvtfcHk0lhy5m845w7SoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVOjsbc%253D&md5=0b7503b3b998c76153d8c7807103624b</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2013.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2013.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DKarmazyn%26aufirst%3DM.%26atitle%3DNHE-1%253A%2520still%2520a%2520viable%2520therapeutic%2520target%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2013%26volume%3D61%26spage%3D77%26epage%3D82%26doi%3D10.1016%2Fj.yjmcc.2013.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amith, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fliegel, L.</span></span> <span> </span><span class="NLM_article-title">KR-33028, a potent inhibitor of the Na(+)/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">31</span>â <span class="NLM_lpage">39</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2016.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.bcp.2016.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27521504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2016&pages=31-39&author=S.+R.+Amithauthor=J.+M.+Wilkinsonauthor=L.+Fliegel&title=KR-33028%2C+a+potent+inhibitor+of+the+Na%28%2B%29%2FH%28%2B%29+exchanger+NHE1%2C+suppresses+metastatic+potential+of+triple-negative+breast+cancer+cells&doi=10.1016%2Fj.bcp.2016.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">KR-33028, a potent inhibitor of the Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells</span></div><div class="casAuthors">Amith, Schammim Ray; Wilkinson, Jodi Marie; Fliegel, Larry</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hyper-activation of the Na+/H+ exchanger NHE1 occurs at the onset of oncogenic transformation and plays a crit. role in breast cancer carcinogenesis.  Dysregulation of NHE1 activity results in intracellular alkalinization and the acidification of the extracellular tumor microenvironment that promotes metastasis.  Hence, the use of chem. inhibitors of NHE1 as chemotherapeutic agents is an alluring prospect.  We previously demonstrated that two structurally different NHE1 inhibitors, EMD87580 [(2-methyl-4,5-di-(methylsulfonyl)-benzoyl)-guanidine], and HMA [5-(N,N-hexamethylene)-amiloride], were effective as co-adjuvants to potentiate paclitaxel-mediated cytotoxic chemotherapy in triple-neg. breast cancer (TNBC) cells.  Both these drugs, however, had reduced or minimal anti-cancer effects when used alone.  Here, we tested KR-33028 (4-cyano (benzo[b]thiophene-2-carbonyl)guanidine), a potent and selective inhibitor of NHE1, to det. its efficacy in inhibition of metastatic potential of TNBC cells.  In highly invasive MDA-MB-231, moderately invasive MDA-MB-468, and lowly invasive Hs578T TNBC cells, KR-33028 considerably reduced rates of cell migration and anchorage-independent colony growth.  Invasion of MDA-MB-231 and MDA-MB-468 cells through extracellular matrix was also dramatically decreased in response to KR-33028.  We further tested the effect of KR-33028 on MDA-MB-231 cells lacking NHE1 expression (231koNHE1); no differences were obsd. between untreated control and KR-33028-treated 231koNHE1 cells.  Taken together, our results highlight the in vitro efficacy of KR-33028-mediated NHE1 inhibition on limiting cellular functions that are predictive of metastasis in vivo.  We suggest that targeting NHE1 in the development of novel chemotherapeutics could be highly effective in combating triple-neg. breast cancer and that KR-33028 is potentially useful in prevention of metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5F9yBhpgG87Vg90H21EOLACvtfcHk0lhy5m845w7SoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleisr3F&md5=12416b156b9e1e32cfdc604327c4112c</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAmith%26aufirst%3DS.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%2BM.%26aulast%3DFliegel%26aufirst%3DL.%26atitle%3DKR-33028%252C%2520a%2520potent%2520inhibitor%2520of%2520the%2520Na%2528%252B%2529%252FH%2528%252B%2529%2520exchanger%2520NHE1%252C%2520suppresses%2520metastatic%2520potential%2520of%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D118%26spage%3D31%26epage%3D39%26doi%3D10.1016%2Fj.bcp.2016.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hropot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juretschke, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwark, J. R.</span></span> <span> </span><span class="NLM_article-title">S3226, a novel NHE3 inhibitor, attenuates ischemia-induced acute renal failure in rats</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>60</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">2283</span>â <span class="NLM_lpage">2289</span>, <span class="refDoi">Â DOI: 10.1046/j.1523-1755.2001.00058.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1046%2Fj.1523-1755.2001.00058.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=11737601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3MXpt1KjsL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2001&pages=2283-2289&issue=6&author=M.+Hropotauthor=H.+P.+Juretschkeauthor=K.+H.+Langerauthor=J.+R.+Schwark&title=S3226%2C+a+novel+NHE3+inhibitor%2C+attenuates+ischemia-induced+acute+renal+failure+in+rats&doi=10.1046%2Fj.1523-1755.2001.00058.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">S3226, a novel NHE3 inhibitor, attenuates ischemia-induced acute renal failure in rats</span></div><div class="casAuthors">Hropot, Max; Juretschke, Hans-Paul; Langer, Karl Heinz; Schwark, Jan-Robert</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2283-2289</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">Acute renal failure (ARF) remains a major problem in clin. nephrol. characterized by sudden loss of the kidney function due to ischemia, trauma, and/or nephrotoxic drugs.  The current therapy of ARF is symptomatic with mortality rates exceeding 50%.  The aim of this study was to investigate the effects of an i.v. infusion of S3226 (3-[2-(3-guanidino-2-methyl-3-oxopropenyl)-5-methylphenyl]-N-isopropylidene-2-methylacrylamide dihydrochloride), a selective Na+/H+ exchange subtype 3 (NHE3) blocker, in ischemia-induced ARF in rats.  In a second series of expts. cytosolic pH (pHi) changes in the kidney during ARF were continuously measured by NMR spectroscopy (MRS).  ARF was induced by bilateral occlusion of renal arteries for 40 min in three groups of anesthetized Wistar rats.  Control rats (N = 12) were infused with saline (6.25 mL/kg over 30 min) before occlusion and the compd. groups (each N = 12) were infused with S3226 at a dose of 20 mg/kg over 30 min either before initiation of ischemia or immediately after release of clamps.  Plasma creatinine (PCr), creatinine clearance (CCr), urine vol., sodium, and potassium excretion were detd. up to seven days after release of clamps.  In the second series of expts. in anesthetized rats the left kidney was exposed by flank incision and fixed in a non-magnetic device.  An inflatable cuff was positioned around the pedicle to induce ischemia without removing animals from the magnet.  A double-tuned 1H-31P home-built surface coil was placed above the exposed kidney for the detection of pHi.  At day 1 after ischemia CCr in the control group was significantly lower as compared to S3226-treated animals (control 0.30Â±0.05 vs. before 0.90Â±0.26 and reperfusion 0.83Â±0.15 mL/min/kg, resp.).  PCr increased from 18Â±0.1 Î¼mol/L before occlusion to 245Â±7 Î¼mol/L in the control.  The increase in PCr was significantly lower in the S3226 treated groups on days 1, 2, and 3 post-infusion.  Fractional sodium excretion decreased significantly from 8.17% in the control to 1.42% and 1.88% in the treated groups.  Renal pHi was significantly decreased by 0.15 units vs. control during reperfusion.  Histol. examn. of the kidneys on day 7 revealed pronounced redn. of tubular necrosis, dilatation, protein casts and cellular infiltration.  These results demonstrate that an i.v. administration of S3226 acutely improves GFR and kidney function and structure in both treated groups.  In addn., in a sep. set of studies S3226 significantly decreased post-occlusion renal pHi values.  Thus, the inhibition of NHE3 with S3226 may be beneficial in treatment of ischemic ARF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2cDF05pnp8bVg90H21EOLACvtfcHk0lhy5m845w7SoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXpt1KjsL0%253D&md5=7781a921802834fc30b89057881971d5</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.2001.00058.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.2001.00058.x%26sid%3Dliteratum%253Aachs%26aulast%3DHropot%26aufirst%3DM.%26aulast%3DJuretschke%26aufirst%3DH.%2BP.%26aulast%3DLanger%26aufirst%3DK.%2BH.%26aulast%3DSchwark%26aufirst%3DJ.%2BR.%26atitle%3DS3226%252C%2520a%2520novel%2520NHE3%2520inhibitor%252C%2520attenuates%2520ischemia-induced%2520acute%2520renal%2520failure%2520in%2520rats%26jtitle%3DKidney%2520Int.%26date%3D2001%26volume%3D60%26issue%3D6%26spage%3D2283%26epage%3D2289%26doi%3D10.1046%2Fj.1523-1755.2001.00058.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo-McCoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minassian, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jafri, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumaraswamy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozuka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâNeill, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greasley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson-Rylander, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrendt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stromstedt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryden-Bergsten, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopfel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor Arroyo, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernando, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, J. S.</span></span> <span> </span><span class="NLM_article-title">Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">456</span>),  <span class="NLM_fpage">eaam6474</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aam6474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscitranslmed.aam6474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=30158152" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=eaam6474&issue=456&author=A.+J.+Kingauthor=M.+Siegelauthor=Y.+Heauthor=B.+Nieauthor=J.+Wangauthor=S.+Koo-McCoyauthor=N.+A.+Minassianauthor=Q.+Jafriauthor=D.+Panauthor=J.+Kohlerauthor=P.+Kumaraswamyauthor=K.+Kozukaauthor=J.+G.+Lewisauthor=D.+Dragoliauthor=D.+P.+Rosenbaumauthor=D.+O%E2%80%99Neillauthor=A.+Plainauthor=P.+J.+Greasleyauthor=A.+C.+Jonsson-Rylanderauthor=D.+Karlssonauthor=M.+Behrendtauthor=M.+Stromstedtauthor=T.+Ryden-Bergstenauthor=T.+Knopfelauthor=E.+M.+Pastor+Arroyoauthor=N.+Hernandoauthor=J.+Marksauthor=M.+Donowitzauthor=C.+A.+Wagnerauthor=R.+T.+Alexanderauthor=J.+S.+Caldwell&title=Inhibition+of+sodium%2Fhydrogen+exchanger+3+in+the+gastrointestinal+tract+by+tenapanor+reduces+paracellular+phosphate+permeability&doi=10.1126%2Fscitranslmed.aam6474"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aam6474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aam6474%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DSiegel%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DNie%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DKoo-McCoy%26aufirst%3DS.%26aulast%3DMinassian%26aufirst%3DN.%2BA.%26aulast%3DJafri%26aufirst%3DQ.%26aulast%3DPan%26aufirst%3DD.%26aulast%3DKohler%26aufirst%3DJ.%26aulast%3DKumaraswamy%26aufirst%3DP.%26aulast%3DKozuka%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DJ.%2BG.%26aulast%3DDragoli%26aufirst%3DD.%26aulast%3DRosenbaum%26aufirst%3DD.%2BP.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DD.%26aulast%3DPlain%26aufirst%3DA.%26aulast%3DGreasley%26aufirst%3DP.%2BJ.%26aulast%3DJonsson-Rylander%26aufirst%3DA.%2BC.%26aulast%3DKarlsson%26aufirst%3DD.%26aulast%3DBehrendt%26aufirst%3DM.%26aulast%3DStromstedt%26aufirst%3DM.%26aulast%3DRyden-Bergsten%26aufirst%3DT.%26aulast%3DKnopfel%26aufirst%3DT.%26aulast%3DPastor%2BArroyo%26aufirst%3DE.%2BM.%26aulast%3DHernando%26aufirst%3DN.%26aulast%3DMarks%26aufirst%3DJ.%26aulast%3DDonowitz%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DC.%2BA.%26aulast%3DAlexander%26aufirst%3DR.%2BT.%26aulast%3DCaldwell%26aufirst%3DJ.%2BS.%26atitle%3DInhibition%2520of%2520sodium%252Fhydrogen%2520exchanger%25203%2520in%2520the%2520gastrointestinal%2520tract%2520by%2520tenapanor%2520reduces%2520paracellular%2520phosphate%2520permeability%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2018%26volume%3D10%26issue%3D456%26spage%3Deaam6474%26doi%3D10.1126%2Fscitranslmed.aam6474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremont, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Both, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garland, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeller, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolodziej, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischke, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rath, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhard, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tollefson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, D. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent, nonsystemic apical sodium-codependent bile acid transporter inhibitors (part 2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span> (<span class="NLM_issue">18</span>),  <span class="NLM_fpage">5853</span>â <span class="NLM_lpage">5868</span>, <span class="refDoi">Â DOI: 10.1021/jm0402162</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0402162" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVChtrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5853-5868&issue=18&author=H.+C.+Huangauthor=S.+J.+Tremontauthor=L.+F.+Leeauthor=B.+T.+Kellerauthor=A.+J.+Carpenterauthor=C.+C.+Wangauthor=S.+C.+Banerjeeauthor=S.+R.+Bothauthor=T.+Fletcherauthor=D.+J.+Garlandauthor=W.+Huangauthor=C.+Jonesauthor=K.+J.+Koellerauthor=S.+A.+Kolodziejauthor=J.+Liauthor=R.+E.+Manningauthor=M.+W.+Mahoneyauthor=R.+E.+Millerauthor=D.+A.+Mischkeauthor=N.+P.+Rathauthor=E.+J.+Reinhardauthor=M.+B.+Tollefsonauthor=W.+F.+Vernierauthor=G.+M.+Wagnerauthor=S.+R.+Rappauthor=J.+Beaudryauthor=K.+Glennauthor=K.+Reginaauthor=J.+R.+Schuhauthor=M.+E.+Smithauthor=J.+S.+Trivediauthor=D.+B.+Reitz&title=Discovery+of+potent%2C+nonsystemic+apical+sodium-codependent+bile+acid+transporter+inhibitors+%28part+2%29&doi=10.1021%2Fjm0402162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent, Nonsystemic Apical Sodium-Codependent Bile Acid Transporter Inhibitors (Part 2)</span></div><div class="casAuthors">Huang, Horng-Chih; Tremont, Samuel J.; Lee, Len F.; Keller, Bradley T.; Carpenter, Andrew J.; Wang, Ching-Cheng; Banerjee, Shyamal C.; Both, Scott R.; Fletcher, Theresa; Garland, Danny J.; Huang, Wei; Jones, Claude; Koeller, Kevin J.; Kolodziej, Steve A.; Li, James; Manning, Robert E.; Mahoney, Matthew W.; Miller, Raymond E.; Mischke, Deborah A.; Rath, Nigam P.; Reinhard, Emily J.; Tollefson, Michael B.; Vernier, William F.; Wagner, Grace M.; Rapp, Steve R.; Beaudry, Judy; Glenn, Kevin; Regina, Karen; Schuh, Joe R.; Smith, Mark E.; Trivedi, Jay S.; Reitz, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5853-5868</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the primary site for active bile acid reabsorption is via apical sodium-codependent bile acid transporter (ASBT), which is localized on the luminal surface of the distal ileum, a nonsystemic inhibitor would be desirable to minimize or eliminate potential systemic side effects of an absorbed drug.  To ensure bioequivalency and product stability, it was also essential that a nonhygroscopic inhibitor in its most stable cryst. form was identified.  A series of benzothiepins I [R = Ph, 4-HOC6H4, 4-(Me2NCH2CH2)C6H4, 1-naphthyl, 2-thienyl, 3-pyridyl, etc.] was prepd. to refine the structure-activity relationship of the substituted Ph ring at the 5-position of benzothiepin ring and to identify potent, cryst., nonhygroscopic, and efficacious ASBT inhibitors with low systemic exposure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzy0VNrbGYxLVg90H21EOLACvtfcHk0lgEPuZvdCshlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVChtrY%253D&md5=beeef9fb2676b3e2e7787b6dfbc75f7a</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1021%2Fjm0402162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0402162%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BC.%26aulast%3DTremont%26aufirst%3DS.%2BJ.%26aulast%3DLee%26aufirst%3DL.%2BF.%26aulast%3DKeller%26aufirst%3DB.%2BT.%26aulast%3DCarpenter%26aufirst%3DA.%2BJ.%26aulast%3DWang%26aufirst%3DC.%2BC.%26aulast%3DBanerjee%26aufirst%3DS.%2BC.%26aulast%3DBoth%26aufirst%3DS.%2BR.%26aulast%3DFletcher%26aufirst%3DT.%26aulast%3DGarland%26aufirst%3DD.%2BJ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKoeller%26aufirst%3DK.%2BJ.%26aulast%3DKolodziej%26aufirst%3DS.%2BA.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DR.%2BE.%26aulast%3DMahoney%26aufirst%3DM.%2BW.%26aulast%3DMiller%26aufirst%3DR.%2BE.%26aulast%3DMischke%26aufirst%3DD.%2BA.%26aulast%3DRath%26aufirst%3DN.%2BP.%26aulast%3DReinhard%26aufirst%3DE.%2BJ.%26aulast%3DTollefson%26aufirst%3DM.%2BB.%26aulast%3DVernier%26aufirst%3DW.%2BF.%26aulast%3DWagner%26aufirst%3DG.%2BM.%26aulast%3DRapp%26aufirst%3DS.%2BR.%26aulast%3DBeaudry%26aufirst%3DJ.%26aulast%3DGlenn%26aufirst%3DK.%26aulast%3DRegina%26aufirst%3DK.%26aulast%3DSchuh%26aufirst%3DJ.%2BR.%26aulast%3DSmith%26aufirst%3DM.%2BE.%26aulast%3DTrivedi%26aufirst%3DJ.%2BS.%26aulast%3DReitz%26aufirst%3DD.%2BB.%26atitle%3DDiscovery%2520of%2520potent%252C%2520nonsystemic%2520apical%2520sodium-codependent%2520bile%2520acid%2520transporter%2520inhibitors%2520%2528part%25202%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26issue%3D18%26spage%3D5853%26epage%3D5868%26doi%3D10.1021%2Fjm0402162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mells, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setchell, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amanso, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karpen, S. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">357</span>),  <span class="NLM_fpage">357ra122</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aaf4823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscitranslmed.aaf4823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27655848" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=357ra122&issue=357&author=A.+Raoauthor=A.+Kostersauthor=J.+E.+Mellsauthor=W.+Zhangauthor=K.+D.+Setchellauthor=A.+M.+Amansoauthor=G.+M.+Wynnauthor=T.+Xuauthor=B.+T.+Kellerauthor=H.+Yinauthor=S.+Bantonauthor=D.+P.+Jonesauthor=H.+Wuauthor=P.+A.+Dawsonauthor=S.+J.+Karpen&title=Inhibition+of+ileal+bile+acid+uptake+protects+against+nonalcoholic+fatty+liver+disease+in+high-fat+diet-fed+mice&doi=10.1126%2Fscitranslmed.aaf4823"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aaf4823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aaf4823%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DA.%26aulast%3DKosters%26aufirst%3DA.%26aulast%3DMells%26aufirst%3DJ.%2BE.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSetchell%26aufirst%3DK.%2BD.%26aulast%3DAmanso%26aufirst%3DA.%2BM.%26aulast%3DWynn%26aufirst%3DG.%2BM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DKeller%26aufirst%3DB.%2BT.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DBanton%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DD.%2BP.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDawson%26aufirst%3DP.%2BA.%26aulast%3DKarpen%26aufirst%3DS.%2BJ.%26atitle%3DInhibition%2520of%2520ileal%2520bile%2520acid%2520uptake%2520protects%2520against%2520nonalcoholic%2520fatty%2520liver%2520disease%2520in%2520high-fat%2520diet-fed%2520mice%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26issue%3D357%26spage%3D357ra122%26doi%3D10.1126%2Fscitranslmed.aaf4823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, S. R.</span></span> <span> </span><span class="NLM_article-title">Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">14</span>â <span class="NLM_lpage">23</span>, <span class="refDoi">Â DOI: 10.1016/j.amjcard.2005.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.amjcard.2005.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFGmurs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2005&pages=14-23&author=S.+R.+Goldsmith&title=Current+treatments+and+novel+pharmacologic+treatments+for+hyponatremia+in+congestive+heart+failure&doi=10.1016%2Fj.amjcard.2005.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure</span></div><div class="casAuthors">Goldsmith, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">9A</span>),
    <span class="NLM_cas:pages">14B-23B</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Hyponatremia in congestive heart failure (CHF) is assocd. with increased morbidity and mortality, underlining the importance of adequate assessment and treatment of this electrolyte imbalance in patients with CHF.  Current treatment options for hyponatremia in CHF include hypertonic saline soln., loop diuretics, fluid restriction, and other pharmacol. agents, such as demeclocycline, lithium carbonate, and urea.  Hypertonic saline soln. must be administered with extreme caution because excessively slow or rapid sodium correction can lead to severe neurol. adverse effects.  Loop diuretics are useful for reducing the water retention caused by CHF.  However, the potent diuresis induced by agents such as furosemide results in loss of sodium and other essential electrolytes, which may exacerbate hyponatremia.  Fluid restriction is only moderately effective and often difficult to implement in the hospital setting.  Agents such as demeclocycline and lithium have potentially serious renal and cardiovascular side effects.  The arginine vasopressin (AVP) receptor antagonists are a promising new class of aquaretic agents that increase free-water excretion while maintaining levels of sodium and other essential electrolytes.  Tolvaptan (OPC-41061), lixivaptan (VPA-985), and conivaptan (YM-087) are currently under development for the treatment of hyponatremia.  Although tolvaptan and lixivaptan are selective for the vasopressin-2 (V2) receptor responsible for the antidiuretic actions of AVP, conivaptan demonstrates activity at both the V2 receptor and the V1a receptor responsible for the vasoconstricting properties of AVP.  This dual receptor activity may be particularly useful in patients with CHF.  These patients may benefit from the increased cardiac output, reduced total peripheral resistance, and reduced mean arterial blood pressure that results from V1a receptor blockade as well as the reduced congestion, reduced cardiac preload, and increased sodium concns. induced by V2 receptor antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrkyMd35k0gLVg90H21EOLACvtfcHk0lgEPuZvdCshlg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFGmurs%253D&md5=ed2bbacb19e2ae395fc45b477f77b1a6</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2005.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2005.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DGoldsmith%26aufirst%3DS.%2BR.%26atitle%3DCurrent%2520treatments%2520and%2520novel%2520pharmacologic%2520treatments%2520for%2520hyponatremia%2520in%2520congestive%2520heart%2520failure%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2005%26volume%3D95%26spage%3D14%26epage%3D23%26doi%3D10.1016%2Fj.amjcard.2005.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phuan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">5942</span>â <span class="NLM_lpage">5950</span>, <span class="refDoi">Â DOI: 10.1021/jm300491y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300491y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1Snur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5942-5950&issue=12&author=M.+O.+Andersonauthor=J.+Zhangauthor=Y.+Liuauthor=C.+Yaoauthor=P.+W.+Phuanauthor=A.+S.+Verkman&title=Nanomolar+potency+and+metabolically+stable+inhibitors+of+kidney+urea+transporter+UT-B&doi=10.1021%2Fjm300491y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomolar Potency and Metabolically Stable Inhibitors of Kidney Urea Transporter UT-B</span></div><div class="casAuthors">Anderson, Marc O.; Zhang, Jicheng; Liu, Yan; Yao, Chenjuan; Phuan, Puay-Wah; Verkman, A. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5942-5950</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea transporters, which include UT-B in kidney microvessels, are potential targets for development of drugs with a novel diuretic ('urearetic') mechanism.  We recently identified, by high-throughput screening, a triazolothienopyrimidine UT-B inhibitor, 1, that selectively and reversibly inhibited urea transport with IC50 = 25.1 nM and reduced urinary concn. in mice (Yao et al. J. Am. Soc. Nephrol., in press).  Here, we analyzed com. available analogs of (I) to establish a structure-activity series and synthesized a targeted library of 11 analogs to identify potent, metabolically stable UT-B inhibitors.  The best compd., {3-[4-(1,1-difluoroethyl)benzenesulfonyl]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl}thiophen-2-ylmethylamine, (II), had IC50 of 23 and 15 nM for inhibition of urea transport by mouse and human UT-B, resp., and â¼40-fold improved in vitro metabolic stability compared to I.  In mice, II accumulated in kidney and urine and reduced max. urinary concn.  Triazolothienopyrimidine may be useful for therapy of diuretic-refractory edema in heart and liver failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPSG5UZkS2D7Vg90H21EOLACvtfcHk0lgPjjMXbMxmaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1Snur4%253D&md5=a1140ee5f316022648a8140fbd6607df</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Fjm300491y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300491y%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DM.%2BO.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DC.%26aulast%3DPhuan%26aufirst%3DP.%2BW.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DNanomolar%2520potency%2520and%2520metabolically%2520stable%2520inhibitors%2520of%2520kidney%2520urea%2520transporter%2520UT-B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D12%26spage%3D5942%26epage%3D5950%26doi%3D10.1021%2Fjm300491y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cil, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diez-Cecilia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verkman, A. S.</span></span> <span> </span><span class="NLM_article-title">Nanomolar-potency 1,2,4-triazoloquinoxaline inhibitors of the kidney urea transporter UT-A1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3209</span>â <span class="NLM_lpage">3217</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00343</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00343" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFCntrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3209-3217&issue=7&author=S.+Leeauthor=O.+Cilauthor=E.+Diez-Ceciliaauthor=M.+O.+Andersonauthor=A.+S.+Verkman&title=Nanomolar-potency+1%2C2%2C4-triazoloquinoxaline+inhibitors+of+the+kidney+urea+transporter+UT-A1&doi=10.1021%2Facs.jmedchem.8b00343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Nanomolar-Potency 1,2,4-Triazoloquinoxaline Inhibitors of the Kidney Urea Transporter UT-A1</span></div><div class="casAuthors">Lee, Sujin; Cil, Onur; Diez-Cecilia, Elena; Anderson, Marc O.; Verkman, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3209-3217</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Urea transporter A (UT-A) isoforms encoded by the Slc14a2 gene are expressed in kidney tubule epithelial cells, where they facilitate urinary concn.  UT-A1 inhibition is predicted to produce a unique salt-sparing diuretic action in edema and hyponatremia.  Here we report the discovery of 1,2,4-triazoloquinoxalines and the anal. of 37 synthesized analogs.  The most potent compd., 8ay, contg. 1,2,4-triazolo[4,3-a]quinoxaline-substituted benzenesulfonamide linked by an aryl ether, rapidly and reversibly inhibited UT-A1 urea transport by a noncompetitive mechanism with IC50 â 150 nM; the IC50 was â¼2 Î¼M for the related urea transporter UT-B encoded by the Slc14a1 gene.  Mol. modeling suggested a putative binding site on the UT-A1 cytoplasmic domain.  In vitro metab. showing quinoxaline ring oxidn. prompted the synthesis of metabolically stable 7,8-difluoroquinoxaline analog 8bl, which when administered to rats produced marked diuresis and reduced urinary osmolality. 8bl has substantially improved UT-A1 inhibition potency and metabolic stability compared with prior compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox0SlHYp1XHrVg90H21EOLACvtfcHk0lgPjjMXbMxmaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFCntrs%253D&md5=665fb027518f2ce8e7db3d20a0873523</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00343%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%26aulast%3DCil%26aufirst%3DO.%26aulast%3DDiez-Cecilia%26aufirst%3DE.%26aulast%3DAnderson%26aufirst%3DM.%2BO.%26aulast%3DVerkman%26aufirst%3DA.%2BS.%26atitle%3DNanomolar-potency%25201%252C2%252C4-triazoloquinoxaline%2520inhibitors%2520of%2520the%2520kidney%2520urea%2520transporter%2520UT-A1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D7%26spage%3D3209%26epage%3D3217%26doi%3D10.1021%2Facs.jmedchem.8b00343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anzai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutabha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amonpatumrat-Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, H.</span></span> <span> </span><span class="NLM_article-title">Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies</span>. <i>Clin. Exp. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">89</span>â <span class="NLM_lpage">95</span>, <span class="refDoi">Â DOI: 10.1007/s10157-011-0532-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs10157-011-0532-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=22038265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFGmsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=89-95&issue=1&author=N.+Anzaiauthor=P.+Jutabhaauthor=S.+Amonpatumrat-Takahashiauthor=H.+Sakurai&title=Recent+advances+in+renal+urate+transport%3A+characterization+of+candidate+transporters+indicated+by+genome-wide+association+studies&doi=10.1007%2Fs10157-011-0532-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide associated studies</span></div><div class="casAuthors">Anzai, Naohiko; Jutabha, Promsuk; Amonpatumrat-Takahashi, Sirirat; Sakurai, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Nephrology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-95</span>CODEN:
                <span class="NLM_cas:coden">CENPFV</span>;
        ISSN:<span class="NLM_cas:issn">1342-1751</span>.
    
            (<span class="NLM_cas:orgname">Japanese Society of Nephrology</span>)
        </div><div class="casAbstract">A review.  Humans have higher serum uric acid levels than other mammalian species owing to the genetic silencing of the hepatic enzyme uricase that metabolizes uric acid into allantoin.  Urate (the ionized form of uric acid) is generated from purine metab. and it may provide antioxidant defense in the human body.  Despite its potential advantage, sustained hyperuricemia has pathogenetic causes in gout and renal diseases, and putative roles in hypertension and cardiovascular diseases.  Since the kidney plays a dominant role in maintaining plasma urate levels through the excretion process, it is important to understand the mol. mechanism of renal urate handling.  Although the mol. identification of a kidney-specific urate/anion exchanger URAT1 in 2002 paved the way for successive identification of several urate transport-related proteins, the entire picture of effective renal urate handling in humans has not yet been clarified.  Recently, several genome-wide assocn. studies identified a substantial assocn. between uric acid concn. and single nucleotide polymorphisms in at least ten genetic loci including eight transporter-coding genes.  In 2008, we functionally characterized the facilitatory glucose transporter family member SLC2A9 (GLUT9), one of the candidate genes for urate handling, as a voltage-driven urate transporter URATv1 at the basolateral side of renal proximal tubules that comprises the main route of the urate reabsorption pathway, in tandem with URAT1 at the apical side.  In this review, recent findings concerning these candidate mols. are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpywqSn8IxMg7Vg90H21EOLACvtfcHk0lgPjjMXbMxmaQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFGmsLw%253D&md5=36da5733dd8a6b861ffb70a53acf37b7</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1007%2Fs10157-011-0532-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10157-011-0532-z%26sid%3Dliteratum%253Aachs%26aulast%3DAnzai%26aufirst%3DN.%26aulast%3DJutabha%26aufirst%3DP.%26aulast%3DAmonpatumrat-Takahashi%26aufirst%3DS.%26aulast%3DSakurai%26aufirst%3DH.%26atitle%3DRecent%2520advances%2520in%2520renal%2520urate%2520transport%253A%2520characterization%2520of%2520candidate%2520transporters%2520indicated%2520by%2520genome-wide%2520association%2520studies%26jtitle%3DClin.%2520Exp.%2520Nephrol.%26date%3D2012%26volume%3D16%26issue%3D1%26spage%3D89%26epage%3D95%26doi%3D10.1007%2Fs10157-011-0532-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chairoungdua, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shigeta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jutabha, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoyamada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekine, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimokata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niwa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endou, H.</span></span> <span> </span><span class="NLM_article-title">Molecular identification of a renal urate-anion exchanger that regulates blood urate levels</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">447</span>â <span class="NLM_lpage">452</span>, <span class="refDoi">Â DOI: 10.1038/nature742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12024214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=447-452&author=A.+Enomotoauthor=H.+Kimuraauthor=A.+Chairoungduaauthor=Y.+Shigetaauthor=P.+Jutabhaauthor=S.+H.+Chaauthor=M.+Hosoyamadaauthor=M.+Takedaauthor=T.+Sekineauthor=T.+Igarashiauthor=H.+Matsuoauthor=Y.+Kikuchiauthor=T.+Odaauthor=K.+Ichidaauthor=T.+Hosoyaauthor=K.+Shimokataauthor=T.+Niwaauthor=Y.+Kanaiauthor=H.+Endou&title=Molecular+identification+of+a+renal+urate-anion+exchanger+that+regulates+blood+urate+levels&doi=10.1038%2Fnature742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular identification of a renal urate-anion exchanger that regulates blood urate levels</span></div><div class="casAuthors">Enomoto, Atsushi; Kimura, Hiroaki; Chairoungdua, Arthit; Shigeta, Yasuhiro; Jutabha, Promsuk; Cha, Seok Ho; Hosoyamada, Makoto; Takeda, Michio; Sekine, Takashi; Igarashi, Takashi; Matsuo, Hirotaka; Kikuchi, Yuichi; Oda, Takashi; Ichida, Kimiyoshi; Hosoya, Tatsuo; Shimokata, Kaoru; Niwa, Toshimitsu; Kanai, Yoshikatsu; Endou, Hitoshi</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">447-452</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Urate, a naturally occurring product of purine metab., is a scavenger of biol. oxidants implicated in numerous disease processes, as demonstrated by its capacity of neuroprotection.  It is present at higher levels in human blood (200-500 Î¼M) than in other mammals, because humans have an effective renal urate resorption system, despite their evolutionary loss of hepatic uricase by mutational silencing.  The mol. basis for urate handling in the human kidney remains unclear because of difficulties in understanding diverse urate transport systems and species differences.  Here we identify the long-hypothesized urate transporter in the human kidney (URAT1, encoded by SLC22A12), a urate-anion exchanger regulating blood urate levels and targeted by uricosuric and antiuricosuric agents (which affect excretion of uric acid).  Moreover, we provide evidence that patients with idiopathic renal hypouricemia (lack of blood uric acid) have defects in SLC22A12.  Identification of URAT1 should provide insights into the nature of urate homeostasis, as well as lead to the development of better agents against hyperuricemia, a disadvantage concomitant with human evolution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyAZNPywCQaLVg90H21EOLACvtfcHk0ljH4YdGXhtEAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersrs%253D&md5=3d4b19696eef041d9da8269a94a49ac6</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1038%2Fnature742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature742%26sid%3Dliteratum%253Aachs%26aulast%3DEnomoto%26aufirst%3DA.%26aulast%3DKimura%26aufirst%3DH.%26aulast%3DChairoungdua%26aufirst%3DA.%26aulast%3DShigeta%26aufirst%3DY.%26aulast%3DJutabha%26aufirst%3DP.%26aulast%3DCha%26aufirst%3DS.%2BH.%26aulast%3DHosoyamada%26aufirst%3DM.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DSekine%26aufirst%3DT.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DMatsuo%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DY.%26aulast%3DOda%26aufirst%3DT.%26aulast%3DIchida%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DShimokata%26aufirst%3DK.%26aulast%3DNiwa%26aufirst%3DT.%26aulast%3DKanai%26aufirst%3DY.%26aulast%3DEndou%26aufirst%3DH.%26atitle%3DMolecular%2520identification%2520of%2520a%2520renal%2520urate-anion%2520exchanger%2520that%2520regulates%2520blood%2520urate%2520levels%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D447%26epage%3D452%26doi%3D10.1038%2Fnature742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref239"><div class="reference"><strong class="refLabel"><a href="#ref239" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit239"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milner, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyndman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iverson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanavati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagerty, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manhard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardet, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, L. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terkeltaub, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quart, B.</span></span> <span> </span><span class="NLM_article-title">Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">214</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1186%2Fs13075-016-1107-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref239/cit239&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27716403" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=214&issue=1&author=J.+N.+Milnerauthor=P.+K.+Tanauthor=D.+Hyndmanauthor=S.+Liuauthor=C.+Iversonauthor=P.+Nanavatiauthor=D.+T.+Hagertyauthor=K.+Manhardauthor=Z.+Shenauthor=J.+L.+Girardetauthor=L.+T.+Yehauthor=R.+Terkeltaubauthor=B.+Quart&title=Lesinurad%2C+a+novel%2C+oral+compound+for+gout%2C+acts+to+decrease+serum+uric+acid+through+inhibition+of+urate+transporters+in+the+kidney"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit239&amp;dbid=16384&amp;doi=10.1186%2Fs13075-016-1107-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-016-1107-x%26sid%3Dliteratum%253Aachs%26aulast%3DMilner%26aufirst%3DJ.%2BN.%26aulast%3DTan%26aufirst%3DP.%2BK.%26aulast%3DHyndman%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DIverson%26aufirst%3DC.%26aulast%3DNanavati%26aufirst%3DP.%26aulast%3DHagerty%26aufirst%3DD.%2BT.%26aulast%3DManhard%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DGirardet%26aufirst%3DJ.%2BL.%26aulast%3DYeh%26aufirst%3DL.%2BT.%26aulast%3DTerkeltaub%26aufirst%3DR.%26aulast%3DQuart%26aufirst%3DB.%26atitle%3DLesinurad%252C%2520a%2520novel%252C%2520oral%2520compound%2520for%2520gout%252C%2520acts%2520to%2520decrease%2520serum%2520uric%2520acid%2520through%2520inhibition%2520of%2520urate%2520transporters%2520in%2520the%2520kidney%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2016%26volume%3D18%26issue%3D1%26spage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiramoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, J.</span></span> <span> </span><span class="NLM_article-title">Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1602</span>â <span class="NLM_lpage">1610</span>, <span class="refDoi">Â DOI: 10.1093/rheumatology/key100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Frheumatology%2Fkey100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29868853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlWksbvL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1602-1610&issue=9&author=M.+Shiramotoauthor=S.+Liuauthor=Z.+C.+Shenauthor=X.+H.+Yanauthor=A.+Yamamotoauthor=M.+Gillenauthor=Y.+Itoauthor=J.+Hall&title=Verinurad+combined+with+febuxostat+in+Japanese+adults+with+gout+or+asymptomatic+hyperuricaemia%3A+a+phase+2a%2C+open-label+study&doi=10.1093%2Frheumatology%2Fkey100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study</span></div><div class="casAuthors">Shiramoto, Masanari; Liu, Sha; Shen, Zancong; Yan, Xiaohong; Yamamoto, Amy; Gillen, Michael; Ito, Yasushi; Hall, Jesse</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1602-1610</span>CODEN:
                <span class="NLM_cas:coden">RUMAFK</span>;
        ISSN:<span class="NLM_cas:issn">1462-0332</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives.  Verinurad (RDEA3170) is a high-affinity inhibitor of the URAT1 transporter in clin. development for treating gout and asymptomatic hyperuricemia.  The aim of this Phase 2a, randomized, open-label study was to investigate the multiple-dose pharmacodynamics, pharmacokinetics and safety of oral verinurad combined with febuxostat vs febuxostat alone and verinurad alone.  Japanese male subjects aged 21-65 years with gout (n = 37) or asymptomatic hyperuricemia (n = 35) and serum urate (sUA) â¥8 mg/dL were randomized to febuxostat (10, 20, 40 mg) in combination with verinurad (2.5-10 mg), verinurad alone (2.5-15 mg), febuxostat alone (10, 20, 40 mg) or benzbromarone alone (50 mg).  There were four treatment periods per cohort and each treatment period was 7 days.  Study drugs were administered once-daily after breakfast.  Plasma, serum and urine samples were measured at pre-set intervals on days-1, 7, 14, 21 and 28.  Verinurad combined with febuxostat decreased sUA in dose-dependent manner, providing greater sUA lowering than febuxostat alone at the same dose (P < 0.001).  Urinary uric acid excretion rate was increased by verinurad, reduced by febuxostat and comparable to baseline for verinurad combined with febuxostat.  Verinurad from 2.5 mg to 15 mg was well tolerated, with no withdrawals due to adverse events.  Lab. assessments showed no clin. meaningful changes during combination treatment.  Conclusion.  Verinurad combined with febuxostat decreased sUA dose-dependently while maintaining uric acid excretion similar to baseline.  All dose combinations of verinurad and febuxostat were generally well tolerated.  These data support continued investigation of oral verinurad in patients with gout.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4fFMzekvydLVg90H21EOLACvtfcHk0ljH4YdGXhtEAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlWksbvL&md5=21b2c58df0621579f2f85ae05bcce019</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2Fkey100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252Fkey100%26sid%3Dliteratum%253Aachs%26aulast%3DShiramoto%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DZ.%2BC.%26aulast%3DYan%26aufirst%3DX.%2BH.%26aulast%3DYamamoto%26aufirst%3DA.%26aulast%3DGillen%26aufirst%3DM.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DVerinurad%2520combined%2520with%2520febuxostat%2520in%2520Japanese%2520adults%2520with%2520gout%2520or%2520asymptomatic%2520hyperuricaemia%253A%2520a%2520phase%25202a%252C%2520open-label%2520study%26jtitle%3DRheumatology%26date%3D2018%26volume%3D57%26issue%3D9%26spage%3D1602%26epage%3D1610%26doi%3D10.1093%2Frheumatology%2Fkey100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filone, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ory, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>477</i></span> (<span class="NLM_issue">7364</span>),  <span class="NLM_fpage">344</span>â <span class="NLM_lpage">348</span>, <span class="refDoi">Â DOI: 10.1038/nature10380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnature10380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=21866101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=344-348&issue=7364&author=M.+Coteauthor=J.+Misasiauthor=T.+Renauthor=A.+Bruchezauthor=K.+Leeauthor=C.+M.+Filoneauthor=L.+Hensleyauthor=Q.+Liauthor=D.+Oryauthor=K.+Chandranauthor=J.+Cunningham&title=Small+molecule+inhibitors+reveal+Niemann-Pick+C1+is+essential+for+Ebola+virus+infection&doi=10.1038%2Fnature10380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span></div><div class="casAuthors">Cote, Marceline; Misasi, John; Ren, Tao; Bruchez, Anna; Lee, Kyung-Ae; Filone, Claire Marie; Hensley, Lisa; Li, Qi; Ory, Daniel; Chandran, Kartik; Cunningham, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">7364</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa.  The clin. symptoms are manifestations of the massive prodn. of pro-inflammatory cytokines in response to infection and in many outbreaks, mortality exceeds 75%.  The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV.  Here, the authors report the identification of a novel benzylpiperazine adamantane diamide-derived compd. that inhibits EboV infection.  Using mutant cell lines and informative derivs. of the lead compd., they show that the target of the inhibitor is the endosomal membrane protein Niemann-Pick C1 (NPC1).  They find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compds. interfere with GP binding to NPC1.  Combined with the results of previous studies on GP structure and function, these findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit.  Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH09MFk31Ol7Vg90H21EOLACvtfcHk0ljhn9sXGc8Pmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI&md5=99e7763b2b95af9d046992a9d36fd3a2</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1038%2Fnature10380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10380%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DM.%26aulast%3DMisasi%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DBruchez%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DFilone%26aufirst%3DC.%2BM.%26aulast%3DHensley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DOry%26aufirst%3DD.%26aulast%3DChandran%26aufirst%3DK.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520reveal%2520Niemann-Pick%2520C1%2520is%2520essential%2520for%2520Ebola%2520virus%2520infection%26jtitle%3DNature%26date%3D2011%26volume%3D477%26issue%3D7364%26spage%3D344%26epage%3D348%26doi%3D10.1038%2Fnature10380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. C.</span></span> <span> </span><span class="NLM_article-title">Structure of human Niemann-Pick C1 (NPC1) protein and NPC1-NPC2 complex</span>. <i>FASEB J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">629.2</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=629.2&author=X.+C.+Li&title=Structure+of+human+Niemann-Pick+C1+%28NPC1%29+protein+and+NPC1-NPC2+complex"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%2BC.%26atitle%3DStructure%2520of%2520human%2520Niemann-Pick%2520C1%2520%2528NPC1%2529%2520protein%2520and%2520NPC1-NPC2%2520complex%26jtitle%3DFASEB%2520J.%26date%3D2017%26volume%3D31%26spage%3D629.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevers, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloveva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dedic, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J. M.</span></span> <span> </span><span class="NLM_article-title">Identification of potent Ebola virus entry inhibitors with suitable properties for in vivo studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">6293</span>â <span class="NLM_lpage">6307</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00704</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00704" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsrbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6293-6307&issue=14&author=H.+Liuauthor=Y.+Tianauthor=K.+Leeauthor=P.+Krishnanauthor=M.+K.+Wangauthor=S.+Whelanauthor=E.+Meversauthor=V.+Solovevaauthor=B.+Dedicauthor=X.+Liuauthor=J.+M.+Cunningham&title=Identification+of+potent+Ebola+virus+entry+inhibitors+with+suitable+properties+for+in+vivo+studies&doi=10.1021%2Facs.jmedchem.8b00704"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Ebola Virus Entry Inhibitors with Suitable Properties for in Vivo Studies</span></div><div class="casAuthors">Liu, Hu; Tian, Ye; Lee, Kyungae; Krishnan, Pranav; Wang, May Kwang-Mei; Whelan, Sean; Mevers, Emily; Soloveva, Veronica; Dedic, Benjamin; Liu, Xinyong; Cunningham, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6293-6307</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Previous studies identified an adamantane dipeptide piperazine 3.47 that inhibits Ebola virus (EBOV) infection by targeting the essential receptor Niemann-Pick C1 (NPC1).  The physicochem. properties of 3.47 limit its potential for testing in vivo.  Optimization by improving potency, reducing hydrophobicity, and replacing labile moieties identified 3.47 derivs. with improved in vitro ADME properties that are also highly active against EBOV infection, including when tested in the presence of 50% normal human serum (NHS).  In addn., 3A4 was identified as the major cytochrome P 450 isoform that metabolizes these compds., and accordingly, mouse microsome stability was significantly improved when tested in the presence of the CYP3A4 inhibitor ritonavir that is approved for clin. use as a booster of anti-HIV drugs.  Oral administration of the EBOV inhibitors with ritonavir resulted in a pharmacokinetic profile that supports a b.i.d. dosing regimen for efficacy studies in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJSxVgYCh0kLVg90H21EOLACvtfcHk0ljhn9sXGc8Pmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFGgsrbM&md5=c25d32ae9dbbd336b1e7d60dbf4949ff</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00704%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DKrishnan%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DM.%2BK.%26aulast%3DWhelan%26aufirst%3DS.%26aulast%3DMevers%26aufirst%3DE.%26aulast%3DSoloveva%26aufirst%3DV.%26aulast%3DDedic%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCunningham%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520potent%2520Ebola%2520virus%2520entry%2520inhibitors%2520with%2520suitable%2520properties%2520for%2520in%2520vivo%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26issue%3D14%26spage%3D6293%26epage%3D6307%26doi%3D10.1021%2Facs.jmedchem.8b00704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Q. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abi-Mosleh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Brabander, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M. S.</span></span> <span> </span><span class="NLM_article-title">Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e12177</span>, <span class="refDoi">Â DOI: 10.7554/eLife.12177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.7554%2FeLife.12177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26646182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVCms7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=e12177&author=F.+R.+Luauthor=Q.+R.+Liangauthor=L.+Abi-Moslehauthor=A.+Dasauthor=J.+K.+De+Brabanderauthor=J.+L.+Goldsteinauthor=M.+S.+Brown&title=Identification+of+NPC1+as+the+target+of+U18666A%2C+an+inhibitor+of+lysosomal+cholesterol+export+and+Ebola+infection&doi=10.7554%2FeLife.12177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NPC1 as the target of U18666A, an inhibitor of lysosomal cholesterol export and Ebola infection</span></div><div class="casAuthors">Lu, Feiran; Liang, Qiren; Abi-Mosleh, Lina; Das, Akash; De Brabander, Jef K.; Goldstein, Joseph L.; Brown, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e12177/1-e12177/16</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Niemann-Pick C1 (NPC1) is a lysosomal membrane protein that exports cholesterol derived from receptor-mediated uptake of LDL, and it also mediates cellular entry of Ebola virus.  Cholesterol export is inhibited by nanomolar concns. of U18666A, a cationic sterol.  To identify the target of U18666A, we synthesized U-X, a U18666A deriv. with a benzophenone that permits UV-induced crosslinking.  When added to CHO cells, U-X crosslinked to NPC1.  Crosslinking was blocked by U18666A derivs. that block cholesterol export, but not derivs. lacking blocking activity.  Crosslinking was prevented by point mutation in the sterol-sensing domain (SSD) of NPC1, but not by point mutation in the N-terminal domain (NTD).  These data suggest that the SSD contains a U18666A-inhibitable site required for cholesterol export distinct from the cholesterol-binding site in the NTD.  Inasmuch as inhibition of Ebola requires 100-fold higher concns. of U18666A, the high affinity U16888A-binding site is likely not required for virus entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJQTKeiWz3U7Vg90H21EOLACvtfcHk0ljhn9sXGc8Pmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVCms7c%253D&md5=d008fe46541036d0f78a73b0aa6e433a</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.7554%2FeLife.12177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.12177%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DF.%2BR.%26aulast%3DLiang%26aufirst%3DQ.%2BR.%26aulast%3DAbi-Mosleh%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DDe%2BBrabander%26aufirst%3DJ.%2BK.%26aulast%3DGoldstein%26aufirst%3DJ.%2BL.%26aulast%3DBrown%26aufirst%3DM.%2BS.%26atitle%3DIdentification%2520of%2520NPC1%2520as%2520the%2520target%2520of%2520U18666A%252C%2520an%2520inhibitor%2520of%2520lysosomal%2520cholesterol%2520export%2520and%2520Ebola%2520infection%26jtitle%3DeLife%26date%3D2015%26volume%3D4%26spage%3De12177%26doi%3D10.7554%2FeLife.12177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. H.</span></span> <span> </span><span class="NLM_article-title">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">e00049</span>, <span class="refDoi">Â DOI: 10.7554/eLife.00049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.7554%2FeLife.00049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=23150796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2012&pages=e00049&author=H.+Yanauthor=G.+C.+Zhongauthor=G.+W.+Xuauthor=W.+H.+Heauthor=Z.+Y.+Jingauthor=Z.+C.+Gaoauthor=Y.+Huangauthor=Y.+H.+Qiauthor=B.+Pengauthor=H.+M.+Wangauthor=L.+R.+Fuauthor=M.+Songauthor=P.+Chenauthor=W.+Q.+Gaoauthor=B.+J.+Renauthor=Y.+Y.+Sunauthor=T.+Caiauthor=X.+F.+Fengauthor=J.+H.+Suiauthor=W.+H.+Li&title=Sodium+taurocholate+cotransporting+polypeptide+is+a+functional+receptor+for+human+hepatitis+B+and+D+virus&doi=10.7554%2FeLife.00049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus</span></div><div class="casAuthors">Yan, Huan; Zhong, Guocai; Xu, Guangwei; He, Wenhui; Jing, Zhiyi; Gao, Zhenchao; Huang, Yi; Qi, Yonghe; Peng, Bo; Wang, Haimin; Fu, Liran; Song, Mei; Chen, Pan; Gao, Wenqing; Ren, Bijie; Sun, Yinyan; Cai, Tao; Feng, Xiaofeng; Sui, Jianhua; Li, Wenhui</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e00049, 28 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Human hepatitis B virus (HBV) infection and HBV-related diseases remain a major public health problem.  Individuals coinfected with its satellite hepatitis D virus (HDV) have more severe disease.  Cellular entry of both viruses is mediated by HBV envelope proteins.  The pre-S1 domain of the large envelope protein is a key determinant for receptor(s) binding.  However, the identity of the receptor(s) is unknown.  Here, by using near zero distance photo-crosslinking and tandem affinity purifn., the authors revealed that the receptor-binding region of pre-S1 specifically interacts with sodium taurocholate cotransporting polypeptide (NTCP), a multiple transmembrane transporter predominantly expressed in the liver.  Silencing NTCP inhibited HBV and HDV infection, while exogenous NTCP expression rendered nonsusceptible hepatocarcinoma cells susceptible to these viral infections.  Moreover, replacing amino acids 157-165 of nonfunctional monkey NTCP with the human counterpart conferred its ability in supporting both viral infections.  The authors' results demonstrate that NTCP is a functional receptor for HBV and HDV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0tqZhmqs37Vg90H21EOLACvtfcHk0lgDxVGsKnzPmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht12ms7nK&md5=7380905d92bd82b9cf3407b7c113bdfb</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.7554%2FeLife.00049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.00049%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DG.%2BW.%26aulast%3DHe%26aufirst%3DW.%2BH.%26aulast%3DJing%26aufirst%3DZ.%2BY.%26aulast%3DGao%26aufirst%3DZ.%2BC.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DQi%26aufirst%3DY.%2BH.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DH.%2BM.%26aulast%3DFu%26aufirst%3DL.%2BR.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DW.%2BQ.%26aulast%3DRen%26aufirst%3DB.%2BJ.%26aulast%3DSun%26aufirst%3DY.%2BY.%26aulast%3DCai%26aufirst%3DT.%26aulast%3DFeng%26aufirst%3DX.%2BF.%26aulast%3DSui%26aufirst%3DJ.%2BH.%26aulast%3DLi%26aufirst%3DW.%2BH.%26atitle%3DSodium%2520taurocholate%2520cotransporting%2520polypeptide%2520is%2520a%2520functional%2520receptor%2520for%2520human%2520hepatitis%2520B%2520and%2520D%2520virus%26jtitle%3DeLife%26date%3D2012%26volume%3D1%26spage%3De00049%26doi%3D10.7554%2FeLife.00049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Passioura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saso, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogasawara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">De novo macrocyclic peptide inhibitors of hepatitis B virus cellular entry</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">906</span>â <span class="NLM_lpage">915</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2018.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.chembiol.2018.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=29779957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVemsL4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=906-915&issue=7&author=T.+Passiouraauthor=K.+Watashiauthor=K.+Fukanoauthor=S.+Shimuraauthor=W.+Sasoauthor=R.+Morishitaauthor=Y.+Ogasawaraauthor=Y.+Tanakaauthor=M.+Mizokamiauthor=C.+Sureauauthor=H.+Sugaauthor=T.+Wakita&title=De+novo+macrocyclic+peptide+inhibitors+of+hepatitis+B+virus+cellular+entry&doi=10.1016%2Fj.chembiol.2018.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry</span></div><div class="casAuthors">Passioura, Toby; Watashi, Koichi; Fukano, Kento; Shimura, Satomi; Saso, Wakana; Morishita, Ryo; Ogasawara, Yuki; Tanaka, Yasuhito; Mizokami, Masashi; Sureau, Camille; Suga, Hiroaki; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">906-915.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) constitutes a significant public health burden, and currently available treatment options are not generally curative, necessitating the development of new therapeutics.  Here we have applied random non-std. peptide integrated discovery (RaPID) screening to identify small macrocyclic peptide inhibitors of HBV entry that target the cell-surface receptor for HBV, sodium taurocholate cotransporting polypeptide (NTCP).  In addn. to their anti-HBV activity, these mols. also inhibit cellular entry by the related hepatitis D virus (HDV), and are active against diverse strains of HBV (including clin. relevant nucleos(t)ide analog-resistant and vaccine escaping strains).  Importantly, these macrocyclic peptides, in contrast to other NTCP-binding HBV entry inhibitors, exhibited no inhibition of NTCP-mediated bile acid uptake, making them appealing candidates for therapeutic development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxE9mDycbKobVg90H21EOLACvtfcHk0lgDxVGsKnzPmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVemsL4%253D&md5=abb5f4c3bae8a692b7153546e520f218</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPassioura%26aufirst%3DT.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DFukano%26aufirst%3DK.%26aulast%3DShimura%26aufirst%3DS.%26aulast%3DSaso%26aufirst%3DW.%26aulast%3DMorishita%26aufirst%3DR.%26aulast%3DOgasawara%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DSuga%26aufirst%3DH.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DDe%2520novo%2520macrocyclic%2520peptide%2520inhibitors%2520of%2520hepatitis%2520B%2520virus%2520cellular%2520entry%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D7%26spage%3D906%26epage%3D915%26doi%3D10.1016%2Fj.chembiol.2018.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamisuki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukuda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohtani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizokami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sureau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakita, T.</span></span> <span> </span><span class="NLM_article-title">A novel tricyclic polyketide, vanitaracin a, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">11945</span>â <span class="NLM_lpage">11953</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01855-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1128%2FJVI.01855-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26378168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFyiur0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=11945-11953&issue=23&author=M.+Kanekoauthor=K.+Watashiauthor=S.+Kamisukiauthor=H.+Matsunagaauthor=M.+Iwamotoauthor=F.+Kawaiauthor=H.+Ohashiauthor=S.+Tsukudaauthor=S.+Shimuraauthor=R.+Suzukiauthor=H.+Aizakiauthor=M.+Sugiyamaauthor=S.+Y.+Parkauthor=T.+Itoauthor=N.+Ohtaniauthor=F.+Sugawaraauthor=Y.+Tanakaauthor=M.+Mizokamiauthor=C.+Sureauauthor=T.+Wakita&title=A+novel+tricyclic+polyketide%2C+vanitaracin+a%2C+specifically+inhibits+the+entry+of+hepatitis+B+and+D+viruses+by+targeting+sodium+taurocholate+cotransporting+polypeptide&doi=10.1128%2FJVI.01855-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">A novel tricyclic polyketide, vanitaracin A, specifically inhibits the entry of hepatitis B and D viruses by targeting sodium taurocholate cotransporting polypeptide</span></div><div class="casAuthors">Kaneko, Manabu; Watashi, Koichi; Kamisuki, Shinji; Matsunaga, Hiroki; Iwamoto, Masashi; Kawai, Fumihiro; Ohashi, Hirofumi; Tsukuda, Senko; Shimura, Satomi; Suzuki, Ryosuke; Aizaki, Hideki; Sugiyama, Masaya; Park, Sam-Yong; Ito, Takayoshi; Ohtani, Naoko; Sugawara, Fumio; Tanaka, Yasuhito; Mizokami, Masashi; Sureau, Camille; Wakita, Takaji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11945-11953</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Anti-hepatitis B virus (HBV) drugs are currently limited to nucleos(t)ide analogs (NAs) and interferons.  A challenge of drug development is the identification of small mols. that suppress HBV infection from new chem. sources.  Here, from a fungus-derived secondary metabolite library, we identify a structurally novel tricyclic polyketide, named vanitaracin A, which specifically inhibits HBV infection.  Vanitaracin A inhibited the viral entry process with a submicromolar 50% inhibitory concn. (IC50) (IC50 = 0.61 Â± 0.23 Î¼M), without evident cytotoxicity (50% cytotoxic concn. of >256 Î¼M; selectivity index value of >419) in primary human hepatocytes.  Vanitaracin A did not affect the HBV replication process.  This compd. was found to directly interact with the HBV entry receptor sodium taurocholate cotransporting polypeptide (NTCP) and impaired its bile acid transport activity.  Consistent with this NTCP targeting, antiviral activity of vanitaracin A was obsd. with hepatitis D virus (HDV) but not hepatitis C virus.  Importantly, vanitaracin A inhibited infection by all HBV genotypes tested (genotypes A to D) and clin. relevant NA-resistant HBV isolate.  Thus, we identified a fungal metabolite, vanitaracin A, which was a potent, well-tolerated, and broadly active inhibitor of HBV and HDV entry.  This compd., or its related analogs, could be part of an antiviral strategy for preventing reinfection with HBV, including clin. relevant nucleos(t)ide analog-resistant virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiy8gZypawebVg90H21EOLACvtfcHk0lgDxVGsKnzPmQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFyiur0%253D&md5=a474e23328a4f350415610cb08697512</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1128%2FJVI.01855-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01855-15%26sid%3Dliteratum%253Aachs%26aulast%3DKaneko%26aufirst%3DM.%26aulast%3DWatashi%26aufirst%3DK.%26aulast%3DKamisuki%26aufirst%3DS.%26aulast%3DMatsunaga%26aufirst%3DH.%26aulast%3DIwamoto%26aufirst%3DM.%26aulast%3DKawai%26aufirst%3DF.%26aulast%3DOhashi%26aufirst%3DH.%26aulast%3DTsukuda%26aufirst%3DS.%26aulast%3DShimura%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DAizaki%26aufirst%3DH.%26aulast%3DSugiyama%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DS.%2BY.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DOhtani%26aufirst%3DN.%26aulast%3DSugawara%26aufirst%3DF.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DMizokami%26aufirst%3DM.%26aulast%3DSureau%26aufirst%3DC.%26aulast%3DWakita%26aufirst%3DT.%26atitle%3DA%2520novel%2520tricyclic%2520polyketide%252C%2520vanitaracin%2520a%252C%2520specifically%2520inhibits%2520the%2520entry%2520of%2520hepatitis%2520B%2520and%2520D%2520viruses%2520by%2520targeting%2520sodium%2520taurocholate%2520cotransporting%2520polypeptide%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26issue%3D23%26spage%3D11945%26epage%3D11953%26doi%3D10.1128%2FJVI.01855-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knight, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Chemical genetics: where genetics and pharmacology meet</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">425</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2007.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.cell.2007.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=17289560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Wlt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=425-430&issue=3&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Chemical+genetics%3A+where+genetics+and+pharmacology+meet&doi=10.1016%2Fj.cell.2007.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics: where genetics and pharmacology meet</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">425-430</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Genetics and pharmacol. can elicit surprisingly different phenotypes despite targeting the same protein.  This Essay explores these unexpected differences and their implications for biol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq056BEgxFUHrVg90H21EOLACvtfcHk0ljeY6eghdRdqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Wlt74%253D&md5=8b5d8733dc3b3f699907709cd0ba6f62</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DChemical%2520genetics%253A%2520where%2520genetics%2520and%2520pharmacology%2520meet%26jtitle%3DCell%26date%3D2007%26volume%3D128%26issue%3D3%26spage%3D425%26epage%3D430%26doi%3D10.1016%2Fj.cell.2007.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&issue=2&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljeY6eghdRdqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D2%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belshaw, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crabtree, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">4604</span>â <span class="NLM_lpage">4607</span>, <span class="refDoi">Â DOI: 10.1073/pnas.93.10.4604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1073%2Fpnas.93.10.4604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=8643450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADyaK28XjtVKmu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=4604-4607&issue=10&author=P.+J.+Belshawauthor=S.+N.+Hoauthor=G.+R.+Crabtreeauthor=S.+L.+Schreiber&title=Controlling+protein+association+and+subcellular+localization+with+a+synthetic+ligand+that+induces+heterodimerization+of+proteins&doi=10.1073%2Fpnas.93.10.4604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins</span></div><div class="casAuthors">Belshaw, Peter J.; Ho, Steffan N.; Crabtree, Gerald R.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4604-4607</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Extracellular growth and differentiation factors induce changes in gene expression in the nucleus by initiating a series of protein assocns. that alter the subcellular localization of intracellular signaling proteins.  Initial events involve receptor homo- or heterodimerization and subsequent recruitment of cytosolic signaling proteins to the inner leaflet of the plasma membrane.  Intermediate events involve the translocation of proteins into the nucleus.  Late events involve the recruitment of transcriptional activators to the vicinity of specific genes in the nucleus, resulting in increased gene transcription.  The ability to induce signals at each of these three phases of signaling pathways is illustrated by the use of a heterodimeric chem. inducer of dimerization that causes a proximal relation between two different target proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSpwL7vAnV27Vg90H21EOLACvtfcHk0ljeY6eghdRdqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtVKmu70%253D&md5=1af6cf4a977b80807c763f0cc07f76dc</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.10.4604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.10.4604%26sid%3Dliteratum%253Aachs%26aulast%3DBelshaw%26aufirst%3DP.%2BJ.%26aulast%3DHo%26aufirst%3DS.%2BN.%26aulast%3DCrabtree%26aufirst%3DG.%2BR.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DControlling%2520protein%2520association%2520and%2520subcellular%2520localization%2520with%2520a%2520synthetic%2520ligand%2520that%2520induces%2520heterodimerization%2520of%2520proteins%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26issue%3D10%26spage%3D4604%26epage%3D4607%26doi%3D10.1073%2Fpnas.93.10.4604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taurino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussolati, O.</span></span> <span> </span><span class="NLM_article-title">GPNA inhibits the sodium-independent transport system L for neutral amino acids</span>. <i>Amino Acids</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1365</span>â <span class="NLM_lpage">1372</span>, <span class="refDoi">Â DOI: 10.1007/s00726-017-2436-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1007%2Fs00726-017-2436-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28516268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnvFGru78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=1365-1372&issue=8&author=M.+Chiuauthor=C.+Sabinoauthor=G.+Taurinoauthor=M.+G.+Bianchiauthor=R.+Andreoliauthor=N.+Giulianiauthor=O.+Bussolati&title=GPNA+inhibits+the+sodium-independent+transport+system+L+for+neutral+amino+acids&doi=10.1007%2Fs00726-017-2436-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">GPNA inhibits the sodium-independent transport system L for neutral amino acids</span></div><div class="casAuthors">Chiu, Martina; Sabino, Cosimo; Taurino, Giuseppe; Bianchi, Massimiliano G.; Andreoli, Roberta; Giuliani, Nicola; Bussolati, Ovidio</div><div class="citationInfo"><span class="NLM_cas:title">Amino Acids</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1365-1372</span>CODEN:
                <span class="NLM_cas:coden">AACIE6</span>;
        ISSN:<span class="NLM_cas:issn">0939-4451</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag GmbH</span>)
        </div><div class="casAbstract">L-Î³-Glutamyl-p-nitroanilide (GPNA) is widely used to inhibit the glutamine transporter ASCT2, although it is known that it also inhibits other sodium-dependent amino acid transporters.  In a panel of human cancer cell lines, which express the system L transporters LAT1 and LAT2, GPNA inhibits the sodium-independent influx of leucine and glutamine.  The kinetics of the effect suggests that GPNA is a low affinity, competitive inhibitor of system L transporters.  In Hs683 human oligodendroglioma cells, the incubation in the presence of GPNA, but not ASCT2 silencing, lowers the cell content of leucine.  Under the same conditions the activity of mTORC1 is inhibited.  Decreased cell content of branched chain amino acids and mTORC1 inhibition are obsd. in most of the other cell lines upon incubation with GPNA.  It is concluded that GPNA hinders the uptake of essential amino acids through system L transporters and lowers their cell content.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq52nlDMnvrbVg90H21EOLACvtfcHk0lg4jLbF2I6qvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnvFGru78%253D&md5=3598df6817c38f0e0baf8ff85fd6c360</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1007%2Fs00726-017-2436-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00726-017-2436-z%26sid%3Dliteratum%253Aachs%26aulast%3DChiu%26aufirst%3DM.%26aulast%3DSabino%26aufirst%3DC.%26aulast%3DTaurino%26aufirst%3DG.%26aulast%3DBianchi%26aufirst%3DM.%2BG.%26aulast%3DAndreoli%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DN.%26aulast%3DBussolati%26aufirst%3DO.%26atitle%3DGPNA%2520inhibits%2520the%2520sodium-independent%2520transport%2520system%2520L%2520for%2520neutral%2520amino%2520acids%26jtitle%3DAmino%2520Acids%26date%3D2017%26volume%3D49%26issue%3D8%26spage%3D1365%26epage%3D1372%26doi%3D10.1007%2Fs00726-017-2436-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">231</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McAlister, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nusinow, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedrychowski, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuhr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttlin, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span> <span> </span><span class="NLM_article-title">MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>86</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">7150</span>â <span class="NLM_lpage">7158</span>, <span class="refDoi">Â DOI: 10.1021/ac502040v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac502040v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1Kmur8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=7150-7158&issue=14&author=G.+C.+McAlisterauthor=D.+P.+Nusinowauthor=M.+P.+Jedrychowskiauthor=M.+Wuhrauthor=E.+L.+Huttlinauthor=B.+K.+Ericksonauthor=R.+Radauthor=W.+Haasauthor=S.+P.+Gygi&title=MultiNotch+MS3+enables+accurate%2C+sensitive%2C+and+multiplexed+detection+of+differential+expression+across+cancer+cell+line+proteomes&doi=10.1021%2Fac502040v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes</span></div><div class="casAuthors">McAlister, Graeme C.; Nusinow, David P.; Jedrychowski, Mark P.; Wuhr, Martin; Huttlin, Edward L.; Erickson, Brian K.; Rad, Ramin; Haas, Wilhelm; Gygi, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">7150-7158</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multiplexed quantitation via isobaric chem. tags (e.g., tandem mass tags (TMT) and isobaric tags for relative and abs. quantitation (iTRAQ)) has the potential to revolutionize quant. proteomics.  However, until recently the utility of these tags was questionable due to reporter ion ratio distortion resulting from fragmentation of coisolated interfering species.  These interfering signals can be negated through addnl. gas-phase manipulations (e.g., MS/MS/MS (MS3) and proton-transfer reactions (PTR)).  These methods, however, have a significant sensitivity penalty.  Using isolation waveforms with multiple frequency notches (i.e., synchronous precursor selection, SPS), the authors coisolated and cofragmented multiple MS2 fragment ions, thereby increasing the no. of reporter ions in the MS3 spectrum 10-fold over the std. MS3 method (i.e., MultiNotch MS3).  By increasing the reporter ion signals, this method improves the dynamic range of reporter ion quantitation, reduces reporter ion signal variance, and ultimately produces more high-quality quant. measurements.  To demonstrate utility, the authors analyzed biol. triplicates of eight colon cancer cell lines using the MultiNotch MS3 method.  Across all the replicates the authors quantified 8378 proteins in union and 6168 proteins in common.  Taking into account that each of these quantified proteins contains eight distinct cell-line measurements, this data set encompasses 174,704 quant. ratios each measured in triplicate across the biol. replicates.  Herein, the MultiNotch MS3 method uniquely combines multiplexing capacity with quant. sensitivity and accuracy, drastically increasing the informational value obtainable from proteomic expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonIBGSGUtKzbVg90H21EOLACvtfcHk0lg4jLbF2I6qvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1Kmur8%253D&md5=bda847612d4a16030b7921bc8ae6f5c6</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1021%2Fac502040v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac502040v%26sid%3Dliteratum%253Aachs%26aulast%3DMcAlister%26aufirst%3DG.%2BC.%26aulast%3DNusinow%26aufirst%3DD.%2BP.%26aulast%3DJedrychowski%26aufirst%3DM.%2BP.%26aulast%3DWuhr%26aufirst%3DM.%26aulast%3DHuttlin%26aufirst%3DE.%2BL.%26aulast%3DErickson%26aufirst%3DB.%2BK.%26aulast%3DRad%26aufirst%3DR.%26aulast%3DHaas%26aufirst%3DW.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26atitle%3DMultiNotch%2520MS3%2520enables%2520accurate%252C%2520sensitive%252C%2520and%2520multiplexed%2520detection%2520of%2520differential%2520expression%2520across%2520cancer%2520cell%2520line%2520proteomes%26jtitle%3DAnal.%2520Chem.%26date%3D2014%26volume%3D86%26issue%3D14%26spage%3D7150%26epage%3D7158%26doi%3D10.1021%2Fac502040v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref231"><div class="reference"><strong class="refLabel"><a href="#ref231" class="rightTabRefNumLink">232</a></strong><div class="NLM_citation" id="rightTab-cit231"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kienle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, C.</span></span> <span> </span><span class="NLM_article-title">Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>75</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1895</span>â <span class="NLM_lpage">1904</span>, <span class="refDoi">Â DOI: 10.1021/ac0262560</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac0262560" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref231/cit231&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhslSmtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2003&pages=1895-1904&issue=8&author=A.+Thompsonauthor=J.+Schaferauthor=K.+Kuhnauthor=S.+Kienleauthor=J.+Schwarzauthor=G.+Schmidtauthor=T.+Neumannauthor=C.+Hamon&title=Tandem+mass+tags%3A+a+novel+quantification+strategy+for+comparative+analysis+of+complex+protein+mixtures+by+MS%2FMS&doi=10.1021%2Fac0262560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit231R"><div class="casContent"><span class="casTitleNuber">231</span><div class="casTitle"><span class="NLM_cas:atitle">Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS</span></div><div class="casAuthors">Thompson, Andrew; Schaefer, Juergen; Kuhn, Karsten; Kienle, Stefan; Schwarz, Josef; Schmidt, Guenter; Neumann, Thomas; Hamon, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1895-1904</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel MS/MS-based anal. strategy using isotopomer labels, referred to as "tandem mass tags" (TMTs), for the accurate quantification of peptides and proteins is described.  The new tags are designed to ensure that identical peptides labeled with different TMTs exactly comigrate in all sepns.  The tags require novel methods of quantification anal. using tandem mass spectrometry.  The new tags and anal. methods allow peptides from different samples to be identified by their relative abundance with greater ease and accuracy than other methods.  The new TMTs permit simultaneous detn. of both the identity and relative abundances of peptide pairs using a collision induced dissocn. (CID)-based anal. method.  Relative abundance measurements made in the MS/MS mode using the new tags are accurate and sensitive.  Compared to MS-mode measurements, a very high signal-to-noise ratio is achieved with MS/MS based detection.  The new tags should be applicable to a wide variety of peptide isolation methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZtFmu3650nbVg90H21EOLACvtfcHk0lg4jLbF2I6qvQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhslSmtbw%253D&md5=6d73dfc7a2af2f2e2bf4c429ae3881bc</span></div><a href="/servlet/linkout?suffix=cit231&amp;dbid=16384&amp;doi=10.1021%2Fac0262560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac0262560%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%26aulast%3DSchafer%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DK.%26aulast%3DKienle%26aufirst%3DS.%26aulast%3DSchwarz%26aufirst%3DJ.%26aulast%3DSchmidt%26aufirst%3DG.%26aulast%3DNeumann%26aufirst%3DT.%26aulast%3DHamon%26aufirst%3DC.%26atitle%3DTandem%2520mass%2520tags%253A%2520a%2520novel%2520quantification%2520strategy%2520for%2520comparative%2520analysis%2520of%2520complex%2520protein%2520mixtures%2520by%2520MS%252FMS%26jtitle%3DAnal.%2520Chem.%26date%3D2003%26volume%3D75%26issue%3D8%26spage%3D1895%26epage%3D1904%26doi%3D10.1021%2Fac0262560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref232"><div class="reference"><strong class="refLabel"><a href="#ref232" class="rightTabRefNumLink">233</a></strong><div class="NLM_citation" id="rightTab-cit232"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tian, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Multiplexed thiol reactivity profiling for target discovery of electrophilic natural products</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1416</span>â <span class="NLM_lpage">1427</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.08.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.chembiol.2017.08.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=28988947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref232/cit232&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aitrrL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1416-1427&issue=11&author=C.+Tianauthor=R.+Sunauthor=K.+Liuauthor=L.+Fuauthor=X.+Liuauthor=W.+Zhouauthor=Y.+Yangauthor=J.+Yang&title=Multiplexed+thiol+reactivity+profiling+for+target+discovery+of+electrophilic+natural+products&doi=10.1016%2Fj.chembiol.2017.08.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit232R"><div class="casContent"><span class="casTitleNuber">232</span><div class="casTitle"><span class="NLM_cas:atitle">Multiplexed Thiol Reactivity Profiling for Target Discovery of Electrophilic Natural Products</span></div><div class="casAuthors">Tian, Caiping; Sun, Rui; Liu, Keke; Fu, Ling; Liu, Xiaoyu; Zhou, Wanqi; Yang, Yong; Yang, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1416-1427.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Electrophilic groups, such as Michael acceptors, expoxides, are common motifs in natural products (NPs).  Electrophilic NPs can act through covalent modification of cysteinyl thiols on functional proteins, and exhibit potent cytotoxicity and anti-inflammatory/cancer activities.  Here we describe a new chemoproteomic strategy, termed multiplexed thiol reactivity profiling (MTRP), and its use in target discovery of electrophilic NPs.  We demonstrate the utility of MTRP by identifying cellular targets of gambogic acid, an electrophilic NP that is currently under evaluation in clin. trials as anticancer agent.  Moreover, MTRP enables simultaneous comparison of seven structurally diversified Î±,Î²-unsatd. Î³-lactones, which provides insights into the relative proteomic reactivity and target preference of diverse structural scaffolds coupled to a common electrophilic motif and reveals various potential druggable targets with liganded cysteines.  We anticipate that this new method for thiol reactivity profiling in a multiplexed manner will find broad application in redox biol. and drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8SRVKEa8-2bVg90H21EOLACvtfcHk0ljyVwJIZ6HOeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aitrrL&md5=c5f482f57b0b6e63a61f73eb4789e1ce</span></div><a href="/servlet/linkout?suffix=cit232&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.022%26sid%3Dliteratum%253Aachs%26aulast%3DTian%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DMultiplexed%2520thiol%2520reactivity%2520profiling%2520for%2520target%2520discovery%2520of%2520electrophilic%2520natural%2520products%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D1416%26epage%3D1427%26doi%3D10.1016%2Fj.chembiol.2017.08.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref233"><div class="reference"><strong class="refLabel"><a href="#ref233" class="rightTabRefNumLink">234</a></strong><div class="NLM_citation" id="rightTab-cit233"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remsberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalocsay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gygi, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cravatt, B. F.</span></span> <span> </span><span class="NLM_article-title">Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs</span>. <i>Nat. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1113</span>â <span class="NLM_lpage">1123</span>, <span class="refDoi">Â DOI: 10.1038/s41557-019-0351-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41557-019-0351-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31659311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref233/cit233&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1113-1123&author=Y.+Wangauthor=M.+M.+Dixauthor=G.+Biancoauthor=J.+R.+Remsbergauthor=H.-Y.+Leeauthor=M.+Kalocsayauthor=S.+P.+Gygiauthor=S.+Forliauthor=G.+Viteauthor=R.+M.+Lawrenceauthor=C.+G.+Parkerauthor=B.+F.+Cravatt&title=Expedited+mapping+of+the+ligandable+proteome+using+fully+functionalized+enantiomeric+probe+pairs&doi=10.1038%2Fs41557-019-0351-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit233R"><div class="casContent"><span class="casTitleNuber">233</span><div class="casTitle"><span class="NLM_cas:atitle">Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs</span></div><div class="casAuthors">Wang, Yujia; Dix, Melissa M.; Bianco, Giulia; Remsberg, Jarrett R.; Lee, Hsin-Yu; Kalocsay, Marian; Gygi, Steven P.; Forli, Stefano; Vite, Gregory; Lawrence, R. Michael; Parker, Christopher G.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1113-1123</span>CODEN:
                <span class="NLM_cas:coden">NCAHBB</span>;
        ISSN:<span class="NLM_cas:issn">1755-4330</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A fundamental challenge in chem. biol. and medicine is to understand and expand the fraction of the human proteome that can be targeted by small mols.  We recently described a strategy that integrates fragment-based ligand discovery with chem. proteomics to furnish global portraits of reversible small-mol./protein interactions in human cells.  Excavating clear structure-activity relationships from these 'ligandability' maps, however, was confounded by the distinct physicochem. properties and corresponding overall protein-binding potential of individual fragments.  Here, we describe a compelling soln. to this problem by introducing a next-generation set of fully functionalized fragments differing only in abs. stereochem.  Using these enantiomeric probe pairs, or 'enantioprobes', we identify numerous stereoselective protein-fragment interactions in cells and show that these interactions occur at functional sites on proteins from diverse classes.  Our findings thus indicate that incorporating chirality into fully functionalized fragment libraries provides a robust and streamlined method to discover ligandable proteins in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfe1dis0v5rVg90H21EOLACvtfcHk0ljyVwJIZ6HOeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrt7rN&md5=f84988523b6c03c9fa616ccd684f9d6d</span></div><a href="/servlet/linkout?suffix=cit233&amp;dbid=16384&amp;doi=10.1038%2Fs41557-019-0351-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41557-019-0351-5%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DBianco%26aufirst%3DG.%26aulast%3DRemsberg%26aufirst%3DJ.%2BR.%26aulast%3DLee%26aufirst%3DH.-Y.%26aulast%3DKalocsay%26aufirst%3DM.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DForli%26aufirst%3DS.%26aulast%3DVite%26aufirst%3DG.%26aulast%3DLawrence%26aufirst%3DR.%2BM.%26aulast%3DParker%26aufirst%3DC.%2BG.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DExpedited%2520mapping%2520of%2520the%2520ligandable%2520proteome%2520using%2520fully%2520functionalized%2520enantiomeric%2520probe%2520pairs%26jtitle%3DNat.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D1113%26epage%3D1123%26doi%3D10.1038%2Fs41557-019-0351-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref234"><div class="reference"><strong class="refLabel"><a href="#ref234" class="rightTabRefNumLink">235</a></strong><div class="NLM_citation" id="rightTab-cit234"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordova, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">SLC19A1 is an importer of the immunotransmitter cGAMP</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">372</span>â <span class="NLM_lpage">381</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2019.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1016%2Fj.molcel.2019.05.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31126740" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref234/cit234&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2019&pages=372-381&author=C.+Ritchieauthor=A.+F.+Cordovaauthor=G.+T.+Hessauthor=M.+C.+Bassikauthor=L.+Li&title=SLC19A1+is+an+importer+of+the+immunotransmitter+cGAMP&doi=10.1016%2Fj.molcel.2019.05.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit234R"><div class="casContent"><span class="casTitleNuber">234</span><div class="casTitle"><span class="NLM_cas:atitle">SLC19A1 Is an Importer of the Immunotransmitter cGAMP</span></div><div class="casAuthors">Ritchie, Christopher; Cordova, Anthony F.; Hess, Gaelen T.; Bassik, Michael C.; Li, Lingyin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">372-381.e5</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">2'3'-cyclic-GMP-AMP (cGAMP) is a second messenger that activates the antiviral stimulator of interferon genes (STING) pathway.  We recently identified a novel role for cGAMP as a sol., extracellular immunotransmitter that is produced and secreted by cancer cells.  Secreted cGAMP is then sensed by host cells, eliciting an antitumoral immune response.  Due to the antitumoral effects of cGAMP, other CDN-based STING agonists are currently under investigation in clin. trials for metastatic solid tumors.  However, it is unknown how cGAMP and other CDNs cross the cell membrane to activate intracellular STING.  Using a genome-wide CRISPR screen, we identified SLC19A1 as the first known importer of cGAMP and other CDNs, including the investigational new drug 2'3'-bisphosphosphothioate-cyclic-di-AMP (2'3'-CDAS).  These discoveries will provide insight into cGAMP's role as an immunotransmitter and aid in the development of more targeted CDN-based cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyOzQ3QS5zDbVg90H21EOLACvtfcHk0ljyVwJIZ6HOeg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVSqurnJ&md5=c018cb15cd2b8b138ecd61d147d32138</span></div><a href="/servlet/linkout?suffix=cit234&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2019.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2019.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DC.%26aulast%3DCordova%26aufirst%3DA.%2BF.%26aulast%3DHess%26aufirst%3DG.%2BT.%26aulast%3DBassik%26aufirst%3DM.%2BC.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DSLC19A1%2520is%2520an%2520importer%2520of%2520the%2520immunotransmitter%2520cGAMP%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D75%26spage%3D372%26epage%3D381%26doi%3D10.1016%2Fj.molcel.2019.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref235"><div class="reference"><strong class="refLabel"><a href="#ref235" class="rightTabRefNumLink">236</a></strong><div class="NLM_citation" id="rightTab-cit235"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luteijn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaver, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garelis, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWhirter, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katibah, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodward, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raulet, D. H.</span></span> <span> </span><span class="NLM_article-title">SLC19A1 transports immunoreactive cyclic dinucleotides</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>573</i></span> (<span class="NLM_issue">7774</span>),  <span class="NLM_fpage">434</span>â <span class="NLM_lpage">438</span>, <span class="refDoi">Â DOI: 10.1038/s41586-019-1553-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41586-019-1553-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31511694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref235/cit235&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslKhsrzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=573&publication_year=2019&pages=434-438&issue=7774&author=R.+D.+Luteijnauthor=S.+A.+Zaverauthor=B.+G.+Gowenauthor=S.+K.+Wymanauthor=N.+E.+Garelisauthor=L.+Oniaauthor=S.+M.+McWhirterauthor=G.+E.+Katibahauthor=J.+E.+Cornauthor=J.+J.+Woodwardauthor=D.+H.+Raulet&title=SLC19A1+transports+immunoreactive+cyclic+dinucleotides&doi=10.1038%2Fs41586-019-1553-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit235R"><div class="casContent"><span class="casTitleNuber">235</span><div class="casTitle"><span class="NLM_cas:atitle">SLC19A1 transports immunoreactive cyclic dinucleotides</span></div><div class="casAuthors">Luteijn, Rutger D.; Zaver, Shivam A.; Gowen, Benjamin G.; Wyman, Stacia K.; Garelis, Nick E.; Onia, Liberty; McWhirter, Sarah M.; Katibah, George E.; Corn, Jacob E.; Woodward, Joshua J.; Raulet, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">573</span>
        (<span class="NLM_cas:issue">7774</span>),
    <span class="NLM_cas:pages">434-438</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The accumulation of DNA in the cytosol serves as a key immunostimulatory signal assocd. with infections, cancer and genomic damage.  Cytosolic DNA triggers immune responses by activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway.  The binding of DNA to cGAS activates its enzymic activity, leading to the synthesis of a second messenger, cyclic guanosine monophosphate-adenosine monophosphate (2'3'-cGAMP).  This cyclic dinucleotide (CDN) activates STING, which in turn activates the transcription factors interferon regulatory factor 3 (IRF3) and nuclear factor Îº-light-chain-enhancer of activated B cells (NF-ÎºB), promoting the transcription of genes encoding type I interferons and other cytokines and mediators that stimulate a broader immune response.  Exogenous 2'3'-cGAMP produced by malignant cells and other CDNs, including those produced by bacteria and synthetic CDNs used in cancer immunotherapy, must traverse the cell membrane to activate STING in target cells.  How these charged CDNs pass through the lipid bilayer is unknown.  Here we used a genome-wide CRISPR-interference screen to identify the reduced folate carrier SLC19A1, a folate-org. phosphate antiporter, as the major transporter of CDNs.  Depleting SLC19A1 in human cells inhibits CDN uptake and functional responses, and overexpressing SLC19A1 increases both uptake and functional responses.  In human cell lines and primary cells ex vivo, CDN uptake is inhibited by folates as well as two medications approved for treatment of inflammatory diseases, sulfasalazine and the antifolate methotrexate.  The identification of SLC19A1 as the major transporter of CDNs into cells has implications for the immunotherapeutic treatment of cancer, host responsiveness to CDN-producing pathogenic microorganisms and-potentially-for some inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBWRAJX5Hmb7Vg90H21EOLACvtfcHk0liaULvjx3vypA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslKhsrzP&md5=df739b1bb167208e3640651ee4d03a58</span></div><a href="/servlet/linkout?suffix=cit235&amp;dbid=16384&amp;doi=10.1038%2Fs41586-019-1553-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-019-1553-0%26sid%3Dliteratum%253Aachs%26aulast%3DLuteijn%26aufirst%3DR.%2BD.%26aulast%3DZaver%26aufirst%3DS.%2BA.%26aulast%3DGowen%26aufirst%3DB.%2BG.%26aulast%3DWyman%26aufirst%3DS.%2BK.%26aulast%3DGarelis%26aufirst%3DN.%2BE.%26aulast%3DOnia%26aufirst%3DL.%26aulast%3DMcWhirter%26aufirst%3DS.%2BM.%26aulast%3DKatibah%26aufirst%3DG.%2BE.%26aulast%3DCorn%26aufirst%3DJ.%2BE.%26aulast%3DWoodward%26aufirst%3DJ.%2BJ.%26aulast%3DRaulet%26aufirst%3DD.%2BH.%26atitle%3DSLC19A1%2520transports%2520immunoreactive%2520cyclic%2520dinucleotides%26jtitle%3DNature%26date%3D2019%26volume%3D573%26issue%3D7774%26spage%3D434%26epage%3D438%26doi%3D10.1038%2Fs41586-019-1553-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref236"><div class="reference"><strong class="refLabel"><a href="#ref236" class="rightTabRefNumLink">237</a></strong><div class="NLM_citation" id="rightTab-cit236"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moskovskich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldmann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kartnig, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiume, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">10471</span>, <span class="refDoi">Â DOI: 10.1038/s41598-019-46952-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fs41598-019-46952-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=31320712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref236/cit236&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A280%3ADC%252BB3MzovVeqtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=10471&author=A.+Moskovskichauthor=U.+Goldmannauthor=F.+Kartnigauthor=S.+Lindingerauthor=J.+Koneckaauthor=G.+Fiumeauthor=E.+Girardiauthor=G.+Superti-Furga&title=The+transporters+SLC35A1+and+SLC30A1+play+opposite+roles+in+cell+survival+upon+VSV+virus+infection&doi=10.1038%2Fs41598-019-46952-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit236R"><div class="casContent"><span class="casTitleNuber">236</span><div class="casTitle"><span class="NLM_cas:atitle">The transporters SLC35A1 and SLC30A1 play opposite roles in cell survival upon VSV virus infection</span></div><div class="casAuthors">Moskovskich Anna; Goldmann Ulrich; Kartnig Felix; Lindinger Sabrina; Konecka Justyna; Fiume Giuseppe; Girardi Enrico; Superti-Furga Giulio; Superti-Furga Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10471</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Host factor requirements for different classes of viruses have not been fully unraveled.  Replication of the viral genome and synthesis of viral proteins within the human host cell are associated with an increased demand for nutrients and specific metabolites.  With more than 400 acknowledged members to date in humans, solute carriers (SLCs) represent the largest family of transmembrane proteins dedicated to the transport of ions and small molecules such as amino acids, sugars and nucleotides.  Consistent with their impact on cellular metabolism, several SLCs have been implicated as host factors affecting the viral life cycle and the cellular response to infection.  In this study, we aimed at characterizing the role of host SLCs in cell survival upon viral infection by performing unbiased genetic screens using a focused CRISPR knockout library.  Genetic screens with the cytolytic vesicular stomatitis virus (VSV) showed that the loss of two SLCs genes, encoding the sialic acid transporter SLC35A1/CST and the zinc transporter SLC30A1/ZnT1, affected cell survival upon infection.  Further characterization of these genes suggests a role for both of these transporters in the apoptotic response induced by VSV, offering new insights into the cellular response to oncolytic virus infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTfuXnPZcPYSsK3uFsUIZtkfW6udTcc2eajkGNyrSn20Lntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzovVeqtw%253D%253D&md5=41f6db78279a18fe6339dd5c5ee06571</span></div><a href="/servlet/linkout?suffix=cit236&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-46952-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-46952-9%26sid%3Dliteratum%253Aachs%26aulast%3DMoskovskich%26aufirst%3DA.%26aulast%3DGoldmann%26aufirst%3DU.%26aulast%3DKartnig%26aufirst%3DF.%26aulast%3DLindinger%26aufirst%3DS.%26aulast%3DKonecka%26aufirst%3DJ.%26aulast%3DFiume%26aufirst%3DG.%26aulast%3DGirardi%26aufirst%3DE.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520transporters%2520SLC35A1%2520and%2520SLC30A1%2520play%2520opposite%2520roles%2520in%2520cell%2520survival%2520upon%2520VSV%2520virus%2520infection%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D10471%26doi%3D10.1038%2Fs41598-019-46952-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref237"><div class="reference"><strong class="refLabel"><a href="#ref237" class="rightTabRefNumLink">238</a></strong><div class="NLM_citation" id="rightTab-cit237"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanisevic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siuzdak, G.</span></span> <span> </span><span class="NLM_article-title">Metabolomics: beyond biomarkers and towards mechanisms</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">451</span>â <span class="NLM_lpage">459</span>, <span class="refDoi">Â DOI: 10.1038/nrm.2016.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1038%2Fnrm.2016.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=26979502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref237/cit237&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC28XktlCnsrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=451-459&issue=7&author=C.+H.+Johnsonauthor=J.+Ivanisevicauthor=G.+Siuzdak&title=Metabolomics%3A+beyond+biomarkers+and+towards+mechanisms&doi=10.1038%2Fnrm.2016.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit237R"><div class="casContent"><span class="casTitleNuber">237</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolomics: beyond biomarkers and towards mechanisms</span></div><div class="casAuthors">Johnson, Caroline H.; Ivanisevic, Julijana; Siuzdak, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">451-459</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Metabolomics, which is the profiling of metabolites in biofluids, cells and tissues, is routinely applied as a tool for biomarker discovery.  Owing to innovative developments in informatics and anal. technologies, and the integration of orthogonal biol. approaches, it is now possible to expand metabolomic analyses to understand the systems-level effects of metabolites.  Moreover, because of the inherent sensitivity of metabolomics, subtle alterations in biol. pathways can be detected to provide insight into the mechanisms that underlie various physiol. conditions and aberrant processes, including diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrESvDJCSJiw7Vg90H21EOLACvtfcHk0liaULvjx3vypA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktlCnsrY%253D&md5=a162bf9977253b31ca956f27a99ef2b1</span></div><a href="/servlet/linkout?suffix=cit237&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2016.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2016.25%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DC.%2BH.%26aulast%3DIvanisevic%26aufirst%3DJ.%26aulast%3DSiuzdak%26aufirst%3DG.%26atitle%3DMetabolomics%253A%2520beyond%2520biomarkers%2520and%2520towards%2520mechanisms%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2016%26volume%3D17%26issue%3D7%26spage%3D451%26epage%3D459%26doi%3D10.1038%2Fnrm.2016.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref240"><div class="reference"><strong class="refLabel"><a href="#ref240" class="rightTabRefNumLink">239</a></strong><div class="NLM_citation" id="rightTab-cit240"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudarsanam, S.</span></span> <span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span> (<span class="NLM_issue">5600</span>),  <span class="NLM_fpage">1912</span>â <span class="NLM_lpage">1934</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref240/cit240&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&issue=5600&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit240R"><div class="casContent"><span class="casTitleNuber">240</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0liaULvjx3vypA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit240&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26issue%3D5600%26spage%3D1912%26epage%3D1934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref241"><div class="reference"><strong class="refLabel"><a href="#ref241" class="rightTabRefNumLink">240</a></strong><div class="NLM_citation" id="rightTab-cit241"><span><span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-Silva, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">EspaÃ±ol, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada, V.</span></span> <span> </span><span class="NLM_article-title">The degradome database: expanding roles of mammalian proteases in life and disease</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">351</span>â <span class="NLM_lpage">355</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1093%2Fnar%2Fgkv1201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref241/cit241&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrvP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=351-355&issue=1&author=J.+G.+P%C3%A9rez-Silvaauthor=Y.+Espa%C3%B1olauthor=G.+Velascoauthor=V.+Quesada&title=The+degradome+database%3A+expanding+roles+of+mammalian+proteases+in+life+and+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit241R"><div class="casContent"><span class="casTitleNuber">241</span><div class="casTitle"><span class="NLM_cas:atitle">The Degradome database: expanding roles of mammalian proteases in life and disease</span></div><div class="casAuthors">Perez-Silva, Jose G.; Espanol, Yaiza; Velasco, Gloria; Quesada, Victor</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D351-D355</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Since the definition of the degradome as the complete repertoire of proteases in a given organism, the combined effort of numerous labs. has greatly expanded our knowledge of its roles in biol. and pathol.  Once the genomic sequences of several important model organisms were made available, we presented the Degradome database contg. the curated sets of known protease genes in human, chimpanzee, mouse and rat.  Here, we describe the updated Degradome database, featuring 81 new protease genes and 7 new protease families.  Notably, in this short time span, the no. of known hereditary diseases caused by mutations in protease genes has increased from 77 to 119.  This increase reflects the growing interest on the roles of the degradome in multiple diseases, including cancer and aging.  Finally, we have leveraged the widespread adoption of new webtools to provide interactive graphic views that show information about proteases in the global context of the degradome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZefQmIYrGg7Vg90H21EOLACvtfcHk0lh6d5j-JNM02g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrvP&md5=e1fce13cc5838391d45b7d563eadcacd</span></div><a href="/servlet/linkout?suffix=cit241&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv1201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv1201%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Silva%26aufirst%3DJ.%2BG.%26aulast%3DEspa%25C3%25B1ol%26aufirst%3DY.%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DQuesada%26aufirst%3DV.%26atitle%3DThe%2520degradome%2520database%253A%2520expanding%2520roles%2520of%2520mammalian%2520proteases%2520in%2520life%2520and%2520disease%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26issue%3D1%26spage%3D351%26epage%3D355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref238"><div class="reference"><strong class="refLabel"><a href="#ref238" class="rightTabRefNumLink">241</a></strong><div class="NLM_citation" id="rightTab-cit238"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goddard, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenblatt, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrin, T. E.</span></span> <span> </span><span class="NLM_article-title">UCSF Chimera--a visualization system for exploratory research and analysis</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">1605</span>â <span class="NLM_lpage">1612</span>, <span class="refDoi">Â DOI: 10.1002/jcc.20084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=10.1002%2Fjcc.20084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=15264254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref238/cit238&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=1605-1612&issue=13&author=E.+F.+Pettersenauthor=T.+D.+Goddardauthor=C.+C.+Huangauthor=G.+S.+Couchauthor=D.+M.+Greenblattauthor=E.+C.+Mengauthor=T.+E.+Ferrin&title=UCSF+Chimera%2D%2Da+visualization+system+for+exploratory+research+and+analysis&doi=10.1002%2Fjcc.20084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit238R"><div class="casContent"><span class="casTitleNuber">238</span><div class="casTitle"><span class="NLM_cas:atitle">UCSF Chimera-A visualization system for exploratory research and analysis</span></div><div class="casAuthors">Pettersen, Eric F.; Goddard, Thomas D.; Huang, Conrad C.; Couch, Gregory S.; Greenblatt, Daniel M.; Meng, Elaine C.; Ferrin, Thomas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1605-1612</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed.  Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality.  This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features.  Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale mol. assemblies such as viral coats, and Collab., which allows researchers to share a Chimera session interactively despite being at sep. locales.  Other extensions include Multalign Viewer, for showing multiple sequence alignments and assocd. structures; ViewDock, for screening docked ligand orientations; Movie, for replaying mol. dynamics trajectories; and Vol. Viewer, for display and anal. of volumetric data.  A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions.  Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmD4M5S0cPbVg90H21EOLACvtfcHk0lh6d5j-JNM02g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvVOhsbs%253D&md5=944b175f440c1ff323705987cf937ee7</span></div><a href="/servlet/linkout?suffix=cit238&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20084%26sid%3Dliteratum%253Aachs%26aulast%3DPettersen%26aufirst%3DE.%2BF.%26aulast%3DGoddard%26aufirst%3DT.%2BD.%26aulast%3DHuang%26aufirst%3DC.%2BC.%26aulast%3DCouch%26aufirst%3DG.%2BS.%26aulast%3DGreenblatt%26aufirst%3DD.%2BM.%26aulast%3DMeng%26aufirst%3DE.%2BC.%26aulast%3DFerrin%26aufirst%3DT.%2BE.%26atitle%3DUCSF%2520Chimera--a%2520visualization%2520system%2520for%2520exploratory%2520research%2520and%2520analysis%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2004%26volume%3D25%26issue%3D13%26spage%3D1605%26epage%3D1612%26doi%3D10.1002%2Fjcc.20084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZWC','PDB','4ZWC'); return false;">PDB: 4ZWC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PYP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4PYP','PDB','4PYP'); return false;">PDB: 4PYP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZY','PDB','6DZY'); return false;">PDB: 6DZY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DZZ','PDB','6DZZ'); return false;">PDB: 6DZZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LLU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5LLU','PDB','5LLU'); return false;">PDB: 5LLU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GCT','PDB','6GCT'); return false;">PDB: 6GCT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MJU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MJU','PDB','5MJU'); return false;">PDB: 5MJU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5I73','PDB','5I73'); return false;">PDB: 5I73</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EQG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EQG','PDB','5EQG'); return false;">PDB: 5EQG</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01237&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01237%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01237" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                12MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799188ae9f43c52","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
